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Natural products are a constant source of potentially active compounds for the treatment 
of various disorders. The Middle East and tropical regions are believed to have the richest 
supplies of natural products in the world. Plant derived secondary metabolites have been 
used by humans to treat acute infections, health disorders and chronic illness for tens 
of thousands of years. Only during the last 100 years have natural products been largely 
replaced by synthetic drugs. Estimates of 200 000 natural products in plant species have 
been revised upward as mass spectrometry techniques have developed. For developing 
countries the identification and use of endogenous medicinal plants as cures against 
cancers has become attractive. Books on drug discovery will play vital role in the new era 
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1. Introduction
Dietary habits are an important modifiable environmental factor influencing human health
and disease. Epidemiologic evidence suggests that regular consumption of fruits and vege‐
tables may reduce risk of some diseases, including cancer [1]. These properties have been
attributed to foods that are rich sources of numerous bioactive compounds such as phyto‐
chemicals [2]. Modifying the intake of specific foods and/or their bioactive components
seems to be a prudent, noninvasive, and cost-effective strategy for preventing some diseases
in people who appear to be “healthy” [3]. As will be discussed in this chapter, potential
problems occur when patients taking medicines regularly also consume certain fruits or
vegetables.
Thousands of drugs are commercially available and a great percentage of the population
takes at least one pharmacologically active agent on a regular basis. Given this magnitude of
use and variability in individual nutritional status, dietary habits and food composition,
there is a high potential for drug-nutrient interactions. However, there is a relatively short
list of documented fruit-drug or vegetable-drug interactions, necessitating further and ex‐
tensive clinical evaluation. Healthcare providers, such as physicians, pharmacists, nurses,
and dietitians, have to be aware of important food-drug interactions in order to optimize the
therapeutic efficacy of prescribed and over-the-counter drugs. Here, we review some of the
most widely consumed fruits and vegetables to inform healthcare providers of possible nu‐
trient-drug interactions and their potential clinical significance.
There are numerous patients who encounter increased risks of adverse events associated
with drug-nutrient interactions. These include elderly patients, patients with cancer and/ or
© 2013 Rodríguez-Fragoso and Reyes-Esparza; licensee InTech. This is an open access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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malnutrition, gastrointestinal tract dysfunctions, acquired immunodeficiency syndrome and
chronic diseases that require the use of multiple drugs, as well as those receiving enteral nu‐
trition or transplants. Therefore, the main reason for devoting a major review to nutrient-
drug interactions is the enormous importance of fruits and vegetables used for their
beneficial effects as nutrients and as components in folk medicine. There are currently few
studies that combine a nutrient-based and detailed pharmacological approach [4], or studies
that systematically explore the risk and benefits of fruit and vegetables [5-7].
2. Food-drug interactions
A drug-nutrient interaction is defined as the result of a physical, chemical, physiological, or
pathophysiological relationship between a drug and a nutrient [8,9]. An interaction is con‐
sidered significant from a clinical perspective if it alters the therapeutic response. Food-drug
interactions can result in two main clinical effects: the decreased bioavailability of a drug,
which predisposes to treatment failure, or an increased bioavailability, which increases the
risk of adverse events and may even precipitate toxicities (See Figure 1) [4, 10,11].
Figure 1. Drug-fruit/vegetable interaction and effects on bioavailability of drugs. During the consumption of drugs
with fruits or vegetables the ADME properties of drug (Absorption, Distribution, Metabolism and Excretion) can be
modified by drug-phytochemical interaction. As a result of this interaction can be increased or decreased plasma con‐
centrations of a drug which can lead to the presence of adverse events or treatment failure.
Drug Discovery2
Nutritional status and diet can affect drug action by altering metabolism and function. In
addition, various dietary components can have pharmacological activity under certain cir‐
cumstances [12]. For healthy-treatment intervention, it is necessary to understand how these
drug-food interactions can induce a beneficial result or lead to detrimental therapeutic con‐
ditions (less therapeutic action or more toxicity). Drug-drug interactions are widely recog‐
nized and evaluated as part of the drug-approval process, whether pharmaceutical,
pharmacokinetic, or pharmacodynamic in nature. Equal attention must be paid to food-drug
interactions (Figure 2).
Figure 2. Bioassay models for studying drug-phytochemical interaction.
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There are four types of accepted drug-food interactions based on their nature and mecha‐
nisms.
• Type I are ex vivo bioinactivations, which refer to interactions between the drug and the
nutritional element or formulation through biochemical or physical reactions, such as hy‐
drolysis, oxidation, neutralization, precipitation or complexation. These interactions usu‐
ally occur in the delivery device.
• Type II interactions affect absorption. They cause either an increase or decrease in the oral
bioavailability of a drug. The precipitant agent may modify the function of enzymes or
transport mechanisms that are responsible for biotransformation.
• Type III interactions affect the systemic or physiologic disposition and occur after the
drug or the nutritional element has been absorbed from the gastrointestinal tract and en‐
tered the systemic circulation. Changes in the cellular or tissue distribution, systemic
transport, or penetration to specific organs or tissues can occur.
• Type IV interactions refer to the elimination or clearance of drugs or nutrients, which may
involve the antagonism, impairment or modulation of renal and/or enterohepatic elimina‐
tion [13].
Drug metabolizing enzymes and drug transporters play important roles in modulating drug
absorption, distribution, metabolism, and elimination. Acting alone or in concert with each
other, they can affect the pharmacokinetics and pharmacodynamics of a drug. The interplay
between drug metabolizing enzymes and transporters is one of the confounding factors that
have been recently shown to contribute to potential complex drug interactions [14].
3. Food and drug transporters
The oral administration of drugs to patients is convenient, practical, and preferred for many
reasons. Oral administration of drugs, however, may lead to limited and variable oral bioa‐
vailability because of absorption across the intestinal barrier [15,16]. Drug absorption across
the gastrointestinal tract is highly dependent on affinity for membrane transporters as well
as lipophilicity [17]. On the other hand, the liver plays a key role in the clearance and excre‐
tion of many drugs. Hepatic transporters are membrane proteins that primarily facilitate nu‐
trient and endogenous substrate transport into the cell via uptake transporters, or protect
the cell by pumping out toxic chemicals via canalicular transporters [18]. Consequently,
drug transporters in both the gut and the liver are important in determining oral drug dis‐
position by controlling absorption and bioavailability [19]
The major uptake transporters responsible for nutrient and xenobiotic transport, both up‐
take and efflux transporters, belong to the two solute carrier (SLC and SLCO) superfamilies
[20]. The SLC superfamily encompasses a variety of transporters, including the organic
anion transporters (OAT, SLC22A), the organic cation transporters (OCT, SLC22A), the elec‐
troneutral organic cation transporters (OCTN, SLC22A), the equilibrative nucleoside trans‐
Drug Discovery4
porters (ENT, SLC29), the concentrative nucleoside transporters (CNT, SLC28), the apical
Na+−dependent bile salt transporter (ASBT, SLC10), the monocarboxylate transporters
(MCT, SLC16), and the peptide transporters (PEPT, SLC15) [21]. The SLCO family is made
up of the organic anion transporting polypeptides (OATP) [22]. Efflux transporters ex‐
pressed in the intestine and liver include P-glycoprotein (Pgp, ABCB1), bile salt export
pump (BSEP, ABCB11), multidrug resistance proteins (MRP1- 6, ABCC1-6), and breast can‐
cer resistance protein (BCRP, ABCG2), all members of the ATP-Binding Cassette superfami‐
ly (ABC transporters) [23]. Members of this superfamily use ATP as an energy source,
allowing them to pump substrates against a concentration gradient. In the liver, uptake
transporters are mainly expressed in the sinusoid, and excretion transporters are mainly ex‐
pressed on the lateral and canalicular membranes. There are transporters on the lateral
membrane the primary function of which is pumping drugs back into the blood circulation
from the hepatocytes. Nowadays, a large amount of work has identified and characterized
intestinal and hepatic transporters in regards to tissue expression profiles, regulation, mech‐
anisms of transport, substrate and inhibitor profiles, species differences, and genetic poly‐
morphisms. Given the circumstances outlined above, there is no doubt of the overall
relevance of drug transport for clinical pharmacokinetics.
Until recently, little regard was given to the possibility that food and food components
could cause significant changes to the extent of drug absorption via effects on intestinal and
liver transporters. It is now well known that drug-food interactions might affect the pharma‐
cokinetics of prescribed drugs when co-administered with food [24]. Common foods, such
as fruits and vegetables, contain a large variety of secondary metabolites known as phyto‐
chemicals (Tabla 1), many of which have been associated with health benefits [25]. However,
we know little about the processes through which these phytochemicals (and/or their me‐
tabolites) are absorbed into the body, reach their biological target, and are eliminated. Re‐
cent studies show that some of these phytochemicals are substrates and modulators of
specific members of the superfamily of ABC transporting proteins [26]. Indeed, in vitro and
preclinical data in rats suggest that a variety of foodstuffs [27,28], including herbal teas
[29,30] and vegetables and herbs [31,32] can modulate the activity of drug transporters. It is
not yet known whether these effects are predictive of what will be observed clinically.
4. Foods and drug-metabolizing enzyme
It has been shown that, before reaching the systemic circulation, the metabolism of orally in‐
gested drugs (‘first-pass metabolism’ or ‘presystemic clearance’) has clinically relevant influ‐
ences on the potency and efficacy of drugs. Both the intestine and liver account for the
presystemic metabolism in humans. Drug metabolism reactions are generally grouped into
2 phases. Phase I reactions involve changes such as oxidation, reduction, and hydrolysis and
are primarily mediated by the cytochrome P450 (CYP) family of enzymes. Phase II reactions
use an endogenous compound such as glucuronic acid, glutathione, or sulfate, to conjugate
with the drug or its phase I–derived metabolite to produce a more polar end product that
can be more readily excreted [33].
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2 phases. Phase I reactions involve changes such as oxidation, reduction, and hydrolysis and
are primarily mediated by the cytochrome P450 (CYP) family of enzymes. Phase II reactions
use an endogenous compound such as glucuronic acid, glutathione, or sulfate, to conjugate
with the drug or its phase I–derived metabolite to produce a more polar end product that
can be more readily excreted [33].
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The CYP enzymes involved in drug metabolism in humans are expressed predominantly
in the liver.  However,  they are  also present  in  the large and small  intestine,  lungs and
brain [34]. CYP proteins are categorized into families and subfamilies and can metabolize
almost any organic xenobiotic [35]. CYP enzymes combined with drug transport proteins
constitute the first-pass effect  of  orally administered drugs [33].  On the other  hand,  the
Phase II  drug metabolizing or conjugating enzymes consist  of  many enzyme superfami‐
lies,  including  sulfotransferases  (SULT),  UDP-glucuronosyltransferases  (UGT),  DT-dia‐
phorase or NAD(P)H:quinone oxidoreductase (NQO) or NAD(P)H: menadione reductase
(NMO), epoxide hydrolases (EPH), glutathione S-transferases (GST) and N-acetyltransfer‐
ases  (NAT).  The  conjugation  reactions  by  Phase  II  drug-metabolizing  enzymes  increase
hydrophilicity and thereby enhance excretion in the bile and/or the urine and consequent‐
ly affect detoxification [36].
The metabolism of a drug can be altered by foreign chemicals and such interactions can of‐
ten be clinically significant [37]. The most common form of drug interactions entail a foreign
chemical acting either as an inhibitor or an inducer of the CYP enzyme isoform responsible
for metabolizing an administered medicinal drug, subsequently leading to an unusually
slow or fast clearance of said drug [38,39]. Inhibition of drug metabolism will result in a con‐
centration elevation in tissues, leading to various adverse reactions, particularly for drugs
with a low therapeutic index.
Often, influence on drug metabolism by compounds that occur in the environment, most re‐
markably foodstuffs, is bypassed. Dietary changes can alter the expression and activity of
hepatic drug metabolizing enzymes. Although this can lead to alterations in the systemic
elimination kinetics of drugs metabolized by these enzymes, the magnitude of the change is
generally small [8, 40]. Metabolic food-drug interactions occur when a certain food alters the
activity of a drug-metabolizing enzyme, leading to a modulation of the pharmacokinetics of
drugs metabolized by the enzyme [12]. Foods, such as fruits, vegetables, alcoholic beverag‐
es, teas, and herbs, which consist of complex chemical mixtures, can inhibit or induce the
activity of drug-metabolizing enzymes [41].
The observed induction and inhibition of CYP enzymes by natural products in the presence
of a prescribed drug has (among other reasons) led to the general acceptance that natural
therapies can have adverse effects, contrary to popular beliefs in countries with active ethno‐
medicinal practices. Herbal medicines such as St. John's wort, garlic, piperine, ginseng, and
gingko, which are freely available over the counter, have given rise to serious clinical inter‐
actions when co-administered with prescription medicines [42]. Such adversities have spur‐
red various pre-clinical and in vitro investigations on a series of other herbal remedies, with
their clinical relevance yet to be established. The CYP3A4-related interaction based on food
component is the best known; it might be related to the high level of expression of CYP3A4
in the small intestine, as well as its broad substrate specificity. If we consider that CYP3A4 is
responsible for the metabolism of more than 50% of clinical pharmaceuticals, all nutrient-
drug interactions should be considered clinically relevant, in which case all clinical studies
of drugs should include a food-drug interaction screening [43].
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5. Nutrient-drug interactions: examples with clinical relevance
Fruits and vegetables are known to be important components in a healthy diet, since they
have low energy density and are sources of micronutrients, fiber, and other components
with functional properties, called phytochemicals (See Figure 2). Increased fruit and vegeta‐
ble consumption can also help displace food high in saturated fats, sugar or salt. Low fruit
and vegetable intake is among the top 10 risk factors contributing to mortality. According to
the World Health Organization (WHO), increased daily fruit and vegetable intake could
help prevent major chronic non-communicable diseases [44]. Evidence is emerging that spe‐
cific combinations of phytochemicals may be far more effective in protecting against some
diseases than isolated compounds (Table 1 and 2). Observed drug-phytochemical interac‐
tions, in addition to interactions among dietary micronutrients, indicate possibilities for im‐
proved therapeutic strategies. However, several reports have examined the effects of plant
foods and herbal medicines on drug bioavailability. As shown in Tables 3 and 4 and as dis‐
cussed below, we have surveyed the literature to identify reports suggesting important food
and phytochemical modulation of drug-metabolizing enzymes and drug transporters lead‐
ing to potential important nutrient-drug interactions.
Data from: [26,52,53,55, 82, 111, 112]
Table 1. Commonly Consumed Fruits
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Data from: [26,105,114,126, 151]
Table 2. Commonly Consumed Vegetables
Table 3. Fruit-Drug Interactions
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Table 4. Vegetable-Drug Intractions
5.1. Grapefruit (Citrus paradisi)
The interaction of grapefruit with certain drugs was unintentionally discovered two decades
ago [45]. Since then, there have been numerous reports on the effects of grapefruit and its
components on CYP450 drug oxidation and transportation [46,47]. Several findings showed
that grapefruit juice had a major effect on the intestinal CYP system with a minor effect at
the hepatic level [48]. The predominant mechanism for this interaction is the inhibition of
cytochrome P-450 3A4 in the small intestine, which results in a significant reduction of drug
presystemic metabolism. Grapefruit juice intake has been found to decrease CYP3A4 mRNA
activity through a post transcriptional activity, possibly by facilitating degradation of the en‐
zyme [49]. An additional mechanism may be the inhibition of P-glycoprotein and MRP2-
mediated drug efflux, transporters that carry drugs from enterocytes back to the gut lumen,
all of which results in a further increase in the fraction of drug absorbed and increased sys‐
temic drug bioavailability [50-52]. It has also been reported that the major constituents of
grapefruit significantly inhibit the OATP-B function in vitro [53,54].
The interaction between grapefruit juice and drugs has been potentially ascribed to a num‐
ber of constituents [27]. It has been suggested that flavonoids such as naringin, naringenin,
quercetin, and kaempferol, major components in grapefruit, are responsible for drug inter‐
action. Some of these chemicals are also found in other fruit juices. Pomegranate, for exam‐
ple, shares certain properties with grapefruit, suggesting that both could modify the
bioavailability of drugs [55,56]. Another group of compounds that has been detected in
grapefruit juice are the furanocoumarins (psoralens), which are known to be mechanism-
Fruit/Vegetable-Drug Interactions: Effects on Drug Metabolizing Enzymes and Drug Transporters
http://dx.doi.org/10.5772/48283
9
Data from: [26,105,114,126, 151]
Table 2. Commonly Consumed Vegetables
Table 3. Fruit-Drug Interactions
Drug Discovery8
Table 4. Vegetable-Drug Intractions
5.1. Grapefruit (Citrus paradisi)
The interaction of grapefruit with certain drugs was unintentionally discovered two decades
ago [45]. Since then, there have been numerous reports on the effects of grapefruit and its
components on CYP450 drug oxidation and transportation [46,47]. Several findings showed
that grapefruit juice had a major effect on the intestinal CYP system with a minor effect at
the hepatic level [48]. The predominant mechanism for this interaction is the inhibition of
cytochrome P-450 3A4 in the small intestine, which results in a significant reduction of drug
presystemic metabolism. Grapefruit juice intake has been found to decrease CYP3A4 mRNA
activity through a post transcriptional activity, possibly by facilitating degradation of the en‐
zyme [49]. An additional mechanism may be the inhibition of P-glycoprotein and MRP2-
mediated drug efflux, transporters that carry drugs from enterocytes back to the gut lumen,
all of which results in a further increase in the fraction of drug absorbed and increased sys‐
temic drug bioavailability [50-52]. It has also been reported that the major constituents of
grapefruit significantly inhibit the OATP-B function in vitro [53,54].
The interaction between grapefruit juice and drugs has been potentially ascribed to a num‐
ber of constituents [27]. It has been suggested that flavonoids such as naringin, naringenin,
quercetin, and kaempferol, major components in grapefruit, are responsible for drug inter‐
action. Some of these chemicals are also found in other fruit juices. Pomegranate, for exam‐
ple, shares certain properties with grapefruit, suggesting that both could modify the
bioavailability of drugs [55,56]. Another group of compounds that has been detected in
grapefruit juice are the furanocoumarins (psoralens), which are known to be mechanism-
Fruit/Vegetable-Drug Interactions: Effects on Drug Metabolizing Enzymes and Drug Transporters
http://dx.doi.org/10.5772/48283
9
based inactivators of CYP450. The major furanocoumarin present in grapefruit is bergamot‐
tin, which demonstrated a time- and concentration-dependent inactivation of CYP enzymes
in vitro [49]. One interesting characteristic of this interaction is that grapefruit juice does not
need to be taken simultaneously with the medication in order to produce the interaction.
The bioavailability of drugs has been reported to be doubled by grapefruit juice, even when
taken 12 h after ingestion. Colored grapefruit juice and white grapefruit juice are equally ef‐
fective in producing drug interactions.
This inhibitory interaction should be kept in mind when prescribing drugs metabolized by
CYP3A4. Examples of drugs affected by grapefruit or its components include: calcium chan‐
nel antagonists such as felodipine, nisoldipine, amlodipines, verapamil, and diltiazem [57];
central nervous system modulators, including diazepam, triazolam, midazolam, alprazolam,
carbamazepine, buspurone and sertraline [58]; HMG-CoA reductase inhibitors, such as sim‐
vastatin, lovastatin, atorvastatin, and pravastatin [59]; immunosuppressants such as cyclo‐
sporine [60]; anti-virals such as saquinavir [61]; a phosphodiesterases-5 inhibitor such as
sildenafil [62]; antihistamines, including as terfenadine and fexofenadine [63]; antiarhyth‐
mics such as amiodarone [62]; and antibiotics such as eritromicine [64].
Epidemiologic studies reveal that approximately 2% of the population in the United States
consumes at least one glass of regular strength grapefruit juice per day. This becomes perti‐
nent if we consider that many people suffer from chronic metabolic diseases (including hy‐
pertension, hyperlipidemia, and cardiovascular diseases) and receive calcium channel
antagonis therapy and HMG-CoA reductase inhibitors. Patients with mental disorders also
chronically receive central nervous system modulators. In the case of many drugs, an in‐
crease in serum drug concentration has been associated with increased frequency of dose-
dependent adverse effects [65-67]. In light of the wide ranging effects of grapefruit juice on
the pharmacokinetics of various drugs, physicians need to be aware of these interactions
and should make an attempt to warn and educate patients regarding the potential conse‐
quences of concomitant ingestion of these agents.
5.2. Orange (Citrus sinensis)
Consumption of most types of orange juice does not appear to alter CYP3A4 activity in vivo
[55]. However, orange juice made from Seville oranges appears to be somewhat similar to
grapefruit juice and can affect the pharmacokinetics of CYP3A4 substrates [68]. It has been
previously shown that consumption of a single 240 mL serving of Sevilla orange juice result‐
ed in a 76% increase in felodipine exposure, comparable to what is observed after grapefruit
juice consumption [11]. Presumably, the mechanism of this effect is similar to that of grape‐
fruit juice-mediated interactions, because Sevilla orange contains significant concentrations
of flavonoids, mainly bergamottin and 6´,7´-dihydroxybergamottin [69]. Orange juice has al‐
so been shown to exert inhibitory effects on P-glycoprotein (P-gp)-mediated drug efflux. Ta‐
kanaga and others showed that 3,3′,4′,5,6,7,8-heptamethoxyflavon and tangeretin were the
major P-gp inhibitors present in orange juice and showed that another component, nobiletin,
was also a P-gp inhibitor [55]. Therefore, the intake of orange juice might inhibit the efflux
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transporters by P-gp, which could enhance the bioavailability of drugs and thus lead to an
increase in the risk of adverse events [52].
It has also been observed that components of orange juice -naringin in particular- are in vitro
inhibitors of OATP transport activity [70]. Dresser et al., have previously reported that or‐
ange juice inhibits the function of human OATP-A (OATP1A2, gene symbol SLC21A3/
SLCO1A2) in vitro [29]. OATP-A, however, is predominantly expressed in the brain, but not
in the intestine. On the other hand, Satoh et al. reported that OATP-B-mediated uptake of
glibenclamide as well as estrone-3-sulfate was significantly inhibited by 5% orange juice
[53]. Orange juice might reduce the intestinal absorption of substrates of OATP-B (e.g., di‐
goxin, benzylpenicillin, and hormone conjugates), resulting in a decrease in concentration in
the blood.
Previous studies in humans using fexofenadine as a probe showed that oral coadministra‐
tion with orange juice decreased the oral bioavailability of fexofenadine [63]. Orange juice
and its constituents were shown to interact with members of the OATP transporter family
by reducing their activities. The functional consequences of such an interaction are reflect‐
ed in a significant reduction in the oral bioavailability of fexofenadine, possibly by prefer‐
ential direct inhibition of intestinal OATP activity. Other reports indicate that orange juice
slightly reduced the absorption of ciprofloxacin, levofloxacin and celiprolol [65] A study
of  an  interaction  between  orange  juice  and  pravastatin  showed  an  increase  in  AUC
[54].Orange juice also moderately reduces the bioavailability of atenolol, which may neces‐
sitate a dose adjustment [71,72].
5.3. Tangerine (Citrus reticulata)
Early studies demonstrated the influence of tangeretin, a flavonoid found in high levels in
tangerine juice, on drug metabolizing liver enzymes. It was demonstrated that tangeretin in‐
hibits P450 1A2 and P450 3A4 activity in human liver microsomes [73]. Tangeretin is a po‐
tent regioselective stimulator of midazolam 1'-hydroxylation by human liver microsomes
CYP3A4. Although, clinical studies have shown no influence on midazolam pharmacokinet‐
ics in vivo, further studies are needed to evaluate its effects on other drugs [74]. Diosmin is
one of the main components of citrus fruits, such as tangerine. Diosmin may increase the ab‐
sorption or bioavailability of co-administered drugs able to serve as P-gp substrates. As a
result, some caution may be required with its clinical use [52].
5.4. Grapes (Vitis vinifera)
Grapes are one of the most valued conventional fruits worldwide. The grape is considered a
source of unique and potentially useful medicinal natural products; they are also used in the
manufacturing of various industrial products [75,76](Yadav and others 2009; Vislocky and
Fernandez 2010). The main biologically active and well-characterized constituent from the
grape is resveratrol, which is known for various medicinal properties in treating human dis‐
eases [75](Yadav and others 2009). Resveratrol was shown to be an irreversible (mechanism-
based) inhibitor of CYP3A4 and a non-competitive reversible inhibitor for CYP2E1 in
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microsomes from rat liver and human liver cells containing cDNA-expressed CYPs [77,78]
(Chan and Delucchi 2000; Piver and others 2001). Resveratrol is an electron-rich molecule
with two aromatic benzene rings linked by an ethylene bridge. CYP3A-mediated aromatic
hydroxylation and epoxidation of resveratrol are possible, resulting in a reactive p-benzo‐
quinone methide metabolite which is capable of binding covalently to CYP3A4, leading to
inactivation and potential drug interactions.
5.5. Cranberry (Vaccinium macrocarpon)
American cranberry is a fruit used as a prophylactic agent against urinary tract infections
[79]. Drug interactions with cranberry juice might be related to the fact that the juice is rich
in flavonol glycosides, anthocyanins, proanthocyanidins, and organic and phenolic acids
[80]. Izzo [81] described a total of eight cases of interaction between cranberry juice and war‐
farin, leading to changes in international normalized ratio (INR) values and bleeding. The
mechanism behind this interaction might be the inhibition by cranberry flavonoids of
CYP3A4 and/or CYP2C9 enzymes, which are responsible for warfarin metabolism [31,82].
It has also been shown that cranberry juice inhibits diclofenac metabolism in human liver
microsomes, but this has not been demonstrated clinically in human subjects [83]. Cranberry
juice may increase the bioavailability of CYP3A4 substrates (e.g., calcium antagonists or cal‐
cineurin inhibitors) as was discussed [61]. Uesawa and Mohri have demonstrated that nife‐
dipine metabolism in rat intestinal and human hepatic microsomes are inhibited by
preincubation with cranberry juice. Furthermore, cranberry juice increased the nifedipine
concentration in rat plasma. These findings suggest that cranberry juice might affect the
plasma concentration of nifedipine in humans as well [84].
5.6. Pomegranate (Punica granatum)
Pomegranate is commonly eaten around the world and has been used in folk medicine for a
wide variety of therapeutic purposes [85-86]. Pomegranate is a rich source of several chemi‐
cals such as pectin, tannins, flavonoids, and anthocyanins. It has been have reported that
pomegranate juice influenced the pharmacokinetics of carbamazepine in rats by inhibiting
enteric CYP3A activity. Such inhibition of the enteric CYP3A activity by a single exposure to
pomegranate juice appears to last for approximately 3 days [56]. Nagata and others [88]
found that pomegranate juice inhibited human CYP2C9 activity and increased tolbutamide
bioavailability in rats. Recently, pomegranate juice was shown to potently inhibit the sulfo‐
conjugation of 1-naphthol in Caco-2 cells. It has been suggested that some constituents of
pomegranate juice, most probably punicalagin, may impair the metabolic functions of the
intestine (specifically sulfoconjugation) and therefore might have effects upon the bioavaila‐
bility of drugs [89].
5.7. Mango (Mangifera indica)
The beneficial effects of mango include anti-inflammatory and antimicrobial activities
[90,91] Preliminary phytochemical screening revealed the presence of flavonoids, including
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quercetin and glycosylated xanthones such as mangiferin [92,93] Quercetin has been shown
to possess antioxidant, antimicrobial, antitumor, antihypertensive, antiatherosclerosis, and
anti-inflammatory properties [94]. In a series of studies, Rodeiro and others have shown the
effects of mango on drug metabolizing enzymes and drug transporters [95, 96] They found
that exposure of hepatocytes to mango extract produced a significant reduction (60%) in 7-
methoxyresorufin-O-demethylase (MROD; CYP1A2) activity and an increase (50%) in 7-
penthoxyresorufin-O-depentylase (PROD; CYP2B1) activity. This group also studied the
effect of mangiferin on CYP enzymes and found that mangiferin reduced the activities of
five P450s: POD (CYP1A2), midazolam 1'-hydroxylation (M1OH; CYP3A1), diclofenac 4'-hy‐
droxylation (D4OH; CYP2C6), S-mephenytoin 4'-hydroxylation (SM4OH), and chlorzoxa‐
zone 6-hydroxyaltion (C6OH; CYP2E1). Recently, mango and mango-derived polyphenols
have been shown to potentially affect the activity of the multidrug transporter P-gp ABCB1
[97]. These findings suggest that mango and its components inhibit the major human P450
enzymes involved in drug metabolism and some transporters. The potential for drug inter‐
actions with mango fruit should therefore be considered.
5.8. Guava (Psidium guajava L)
Guava is an important food crop and medicinal plant in tropical and subtropical countries;
it is widely used as food and in folk medicine around the world [98, 99]. A number of me‐
tabolites such as phenolics, flavonoid, carotenoid, terpenoid and triterpene have been found
in this fruit. Extracts and metabolites of this plant, particularly those from the leaves and
fruit, possess useful pharmacological activities [100]. There is only one report about the ef‐
fect of guava extracts on drug transport: guava extract showed a potent inhibitory effect on
P-gp mediated efflux in Caco-2 cells. It was also found to inhibit efflux transport from seros‐
al to mucosal surfaces in the rat ileum [101]. This means that guava could interact with P-gp
substrates such as digoxin, fexofenadine, indinavir, vincristine, colchicine, topotecan, and
paclitaxel in the small intestine. For this reason, this fruit should be consumed with caution
by patients taking medicines.
5.9. Raspberry (Rubus spp.)
Berries have been shown to have a positive impact on several chronic conditions including
obesity, cancer, and cardiovascular and neurodegenerative diseases [102-104]. Like other
fruits, raspberries contain micro- and macronutrients such as vitamins, minerals, and fiber.
Their biological properties, however, have been largely attributed to high levels of various
phenolic compounds, as well as the interactive synergies among their natural phytochemical
components (e.g., ellagic acid, quercetin, gallic acid, anthocyanins, cyanidins, pelargonidins,
catechins, kaempferol and salicylic acid). Raspberry or raspberry constituents have antioxi‐
dant and anti-inflammatory properties, and inhibit cancer cell growth [105-107]. Black rasp‐
berries (Rubus coreanus) have been called the “king of berries” for their superior health
benefits, whereas black mulberry (Morus nigra) is most commonly used for its antioxidants
properties and for its high bioactive content of phenolics, anthocyanins, and gallic acid. It
has been shown that black raspberry and black mulberry are able to inhibit the human
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microsomes from rat liver and human liver cells containing cDNA-expressed CYPs [77,78]
(Chan and Delucchi 2000; Piver and others 2001). Resveratrol is an electron-rich molecule
with two aromatic benzene rings linked by an ethylene bridge. CYP3A-mediated aromatic
hydroxylation and epoxidation of resveratrol are possible, resulting in a reactive p-benzo‐
quinone methide metabolite which is capable of binding covalently to CYP3A4, leading to
inactivation and potential drug interactions.
5.5. Cranberry (Vaccinium macrocarpon)
American cranberry is a fruit used as a prophylactic agent against urinary tract infections
[79]. Drug interactions with cranberry juice might be related to the fact that the juice is rich
in flavonol glycosides, anthocyanins, proanthocyanidins, and organic and phenolic acids
[80]. Izzo [81] described a total of eight cases of interaction between cranberry juice and war‐
farin, leading to changes in international normalized ratio (INR) values and bleeding. The
mechanism behind this interaction might be the inhibition by cranberry flavonoids of
CYP3A4 and/or CYP2C9 enzymes, which are responsible for warfarin metabolism [31,82].
It has also been shown that cranberry juice inhibits diclofenac metabolism in human liver
microsomes, but this has not been demonstrated clinically in human subjects [83]. Cranberry
juice may increase the bioavailability of CYP3A4 substrates (e.g., calcium antagonists or cal‐
cineurin inhibitors) as was discussed [61]. Uesawa and Mohri have demonstrated that nife‐
dipine metabolism in rat intestinal and human hepatic microsomes are inhibited by
preincubation with cranberry juice. Furthermore, cranberry juice increased the nifedipine
concentration in rat plasma. These findings suggest that cranberry juice might affect the
plasma concentration of nifedipine in humans as well [84].
5.6. Pomegranate (Punica granatum)
Pomegranate is commonly eaten around the world and has been used in folk medicine for a
wide variety of therapeutic purposes [85-86]. Pomegranate is a rich source of several chemi‐
cals such as pectin, tannins, flavonoids, and anthocyanins. It has been have reported that
pomegranate juice influenced the pharmacokinetics of carbamazepine in rats by inhibiting
enteric CYP3A activity. Such inhibition of the enteric CYP3A activity by a single exposure to
pomegranate juice appears to last for approximately 3 days [56]. Nagata and others [88]
found that pomegranate juice inhibited human CYP2C9 activity and increased tolbutamide
bioavailability in rats. Recently, pomegranate juice was shown to potently inhibit the sulfo‐
conjugation of 1-naphthol in Caco-2 cells. It has been suggested that some constituents of
pomegranate juice, most probably punicalagin, may impair the metabolic functions of the
intestine (specifically sulfoconjugation) and therefore might have effects upon the bioavaila‐
bility of drugs [89].
5.7. Mango (Mangifera indica)
The beneficial effects of mango include anti-inflammatory and antimicrobial activities
[90,91] Preliminary phytochemical screening revealed the presence of flavonoids, including
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quercetin and glycosylated xanthones such as mangiferin [92,93] Quercetin has been shown
to possess antioxidant, antimicrobial, antitumor, antihypertensive, antiatherosclerosis, and
anti-inflammatory properties [94]. In a series of studies, Rodeiro and others have shown the
effects of mango on drug metabolizing enzymes and drug transporters [95, 96] They found
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methoxyresorufin-O-demethylase (MROD; CYP1A2) activity and an increase (50%) in 7-
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droxylation (D4OH; CYP2C6), S-mephenytoin 4'-hydroxylation (SM4OH), and chlorzoxa‐
zone 6-hydroxyaltion (C6OH; CYP2E1). Recently, mango and mango-derived polyphenols
have been shown to potentially affect the activity of the multidrug transporter P-gp ABCB1
[97]. These findings suggest that mango and its components inhibit the major human P450
enzymes involved in drug metabolism and some transporters. The potential for drug inter‐
actions with mango fruit should therefore be considered.
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it is widely used as food and in folk medicine around the world [98, 99]. A number of me‐
tabolites such as phenolics, flavonoid, carotenoid, terpenoid and triterpene have been found
in this fruit. Extracts and metabolites of this plant, particularly those from the leaves and
fruit, possess useful pharmacological activities [100]. There is only one report about the ef‐
fect of guava extracts on drug transport: guava extract showed a potent inhibitory effect on
P-gp mediated efflux in Caco-2 cells. It was also found to inhibit efflux transport from seros‐
al to mucosal surfaces in the rat ileum [101]. This means that guava could interact with P-gp
substrates such as digoxin, fexofenadine, indinavir, vincristine, colchicine, topotecan, and
paclitaxel in the small intestine. For this reason, this fruit should be consumed with caution
by patients taking medicines.
5.9. Raspberry (Rubus spp.)
Berries have been shown to have a positive impact on several chronic conditions including
obesity, cancer, and cardiovascular and neurodegenerative diseases [102-104]. Like other
fruits, raspberries contain micro- and macronutrients such as vitamins, minerals, and fiber.
Their biological properties, however, have been largely attributed to high levels of various
phenolic compounds, as well as the interactive synergies among their natural phytochemical
components (e.g., ellagic acid, quercetin, gallic acid, anthocyanins, cyanidins, pelargonidins,
catechins, kaempferol and salicylic acid). Raspberry or raspberry constituents have antioxi‐
dant and anti-inflammatory properties, and inhibit cancer cell growth [105-107]. Black rasp‐
berries (Rubus coreanus) have been called the “king of berries” for their superior health
benefits, whereas black mulberry (Morus nigra) is most commonly used for its antioxidants
properties and for its high bioactive content of phenolics, anthocyanins, and gallic acid. It
has been shown that black raspberry and black mulberry are able to inhibit the human
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CYP3A-catalyzed midazolam 1-hydroxylation activity in liver microsomes, and the inhibito‐
ry effects are somewhat greater than those of pomegranate [49, 56]. It has also been reported
that black mulberry extract potently inhibits OATP-B function at concentrations that seem to
be physiologically relevant in vitro [53]. These results suggest that black raspberry and black
mulberry may decrease the plasma concentrations of concomitantly ingested OATP-B sub‐
strate drugs or increase the plasma concentration levels of concomitantly ingested CYP3A-
substrate drugs. In vivo studies on the interaction between black mulberry and black
raspberry and CYP3A substrates are needed to determine whether inhibition of CYP3A ac‐
tivity by fruit juices is clinically relevant.
5.10. Apple (Malus domestica)
Apple and its products contain high amounts of polyphenols, which show diverse biological
activities and may contribute to beneficial health effects such as protecting the intestine
against inflammation due to chronic inflammatory bowel diseases [108, 109]. It has been
found that apple juice extract inhibits CYP1A1 at levels of CYP1A1 mRNA, protein, and en‐
zymatic activity [110]. On the other hand, it has also been reported that apple juice and its
constituents can interact with members of the OATP transporter family (OATP-1, OATP-3
and NTCP) by reducing their activities in vitro. The functional consequence of such an inter‐
action was a significant reduction in the oral bioavailability of fexofenadine in human plas‐
ma levels, possibly by preferential direct inhibition of intestinal OATP activity [29]. These
findings suggest that apple might interact with OATP substrates (e.g., estrone-3-sulfate, del‐
torphin II, fexofenadine, vasopressin, and rosuvastatin).
5.11. Papaya (Carican papaya L.)
Papaya is prized worldwide for its flavor and nutritional properties. An ethno-botanical sur‐
vey showed that papaya is commonly used in traditional medicine for the treatment of vari‐
ous human diseases, including abdominal discomfort, pain, malaria, diabetes, obesity,
infections, and oral drug poisoning [111,112]. Papaya leaves and seeds are known to contain
proteolytic enzymes (papain, chymopapain), alkaloids (carpain, carpasemine), sulfurous
compounds (benzyl iso- thiocyanate), flavonoids, tannins, triterpenes, anthocyanins, organic
acids and oils. Papaya fruit is a good source of nutrients and some phytochemicals such as
beta-cryptoxanthin and benzyl isothiocyanates [113]. Hidaka et al. found that papaya pro‐
duced an inhibition of CYP3A activity in human microsomes [114]. So far, there has been no
clinical report suggesting adverse food-drug interaction caused by the intake of papaya. Ac‐
cordingly, the inhibition of CYP3A by papaya may not be observed in vivo. However, the
results obtained by others raised the hypothesis that papaya extracts were capable of alter‐
ing the pharmacokinetics of therapeutic drugs coadministered via CYP3A inhibition, as in
the case of grapefruit. Thus, the possibility of adverse food-drug interaction involving pa‐
paya and medicine acting via CYP3A metabolism should be examined in vivo. The empiri‐
cal evidence regarding the wide use of fermented papaya preparation (FPP), especially by
elderly people, has indicated an unknown collateral effect, i.e., drops in blood sugar levels,
especially in the afternoon. Those findings have been corroborated by a clinical study that
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shows that FPP use can induce a significant decrease in plasma sugar levels in both healthy
subjects and type 2 diabetic patients [115]. Therefore, patients consuming papaya and taking
antidiabetic therapy could suffer from potential drug-food interaction.
5.12. Leafy vegetables
Broccoli (Brassica oleracea var. italica) and cauliflower (Brassica oleracea var. botrytis) are unique
among the common cruciferous vegetables that contain high levels of the aliphatics glucosi‐
nolate and glucoraphanin [116]. Upon hydrolysis, glucoraphanin produces several products
that include the bioactive isothiocyanate sulforaphane. The percentage of isothiocyanate sul‐
foraphane present in these vegetables may vary depending on conditions of hydrolysis,
food handling, and preparation procedures [117, 118]. In animal studies, dietary freeze-
dried broccoli was found to offer protection against several cancers [119]. However, brocco‐
li, cauliflower and their glucosinolate hydrolysis products have been shown to induce phase
I and phase II drug-metabolizing enzymes in intact liver cells from both rats and humans.
The isothiocyanate sulforaphane decreased the enzyme activities hepatocytes associated
with CYP1A1 and 2B1/2, namely ethoxyresorufin-O-deethylase and pentoxyresorufin-O-
dealkylase, respectively, in a dose-dependent manner [120]. An increase in hGSTA1/2
mRNA has been observed in isothiocyanate sulforaphane-treated human hepatocytes,
whereas the expression of CYP3A4, the major CYP in the human liver, markedly decreased
at both mRNA and activity levels [121]. Conversely, it was recently shown that sulforaphane
induces mRNA levels of MRP1 and MRP2 in primary hepatocytes and Caco-2 cells [122]. It
has been additionally reported that broccoli is able to induce the activity of phenolsulfo‐
transferases [123]. These results suggest that other vegetables with a high content of isothio‐
cyanates, such as those of the family Cruciferae (e.g., cabbage, cauliflower, Brussels sprouts,
watercress, broccoli, and kale) and the genus Raphanus (radishes and daikons) may have
pharmacological and toxicological implications in humans.
Watercress is another important member of the cruciferous vegetables, an excellent source
for glucosinolates and other bioactive phytochemicals [124]. Watercress (Nasturtium offici‐
nale) is an exceptionally rich dietary source of beta-phenylethyl isothiocyanate (PEITC)
[125]. Previous studies have shown that a single ingestion of watercress inhibits the hydrox‐
ylation of chlorzoxazone, an in vivo probe for CYP2E1, in healthy volunteers [126]. It has al‐
so been shown that watercress is a bifunctional agent with the ability to induce both phase I
(CYP450) and II enzymes. Adding watercress juice to human liver cells induced the activity
of CYP4501A and ethoxyresorufin-O-deethylase and NAD(P)H-quinone reductase [127]. Ac‐
cording to reports, PEITC also has several anti-carcinogenic effects given that it can inhibit
phase I enzymes and/or activate phase II enzymes. Watercress juice can increase the en‐
zymes SOD and GPX in blood cells in vitro and in vivo [128]. Isothiocyanates also interact
with ATP-binding cassette (ABC) efflux transporters such as P-glycoprotein, MRP1, MRP2
and BCRP, and may influence the pharmacokinetics of substrates of these transporters [26].
According to current data, watercress and isothiocyanate may have clinical repercussions by
inducing changes in the bioavailability of some drugs.
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CYP3A-catalyzed midazolam 1-hydroxylation activity in liver microsomes, and the inhibito‐
ry effects are somewhat greater than those of pomegranate [49, 56]. It has also been reported
that black mulberry extract potently inhibits OATP-B function at concentrations that seem to
be physiologically relevant in vitro [53]. These results suggest that black raspberry and black
mulberry may decrease the plasma concentrations of concomitantly ingested OATP-B sub‐
strate drugs or increase the plasma concentration levels of concomitantly ingested CYP3A-
substrate drugs. In vivo studies on the interaction between black mulberry and black
raspberry and CYP3A substrates are needed to determine whether inhibition of CYP3A ac‐
tivity by fruit juices is clinically relevant.
5.10. Apple (Malus domestica)
Apple and its products contain high amounts of polyphenols, which show diverse biological
activities and may contribute to beneficial health effects such as protecting the intestine
against inflammation due to chronic inflammatory bowel diseases [108, 109]. It has been
found that apple juice extract inhibits CYP1A1 at levels of CYP1A1 mRNA, protein, and en‐
zymatic activity [110]. On the other hand, it has also been reported that apple juice and its
constituents can interact with members of the OATP transporter family (OATP-1, OATP-3
and NTCP) by reducing their activities in vitro. The functional consequence of such an inter‐
action was a significant reduction in the oral bioavailability of fexofenadine in human plas‐
ma levels, possibly by preferential direct inhibition of intestinal OATP activity [29]. These
findings suggest that apple might interact with OATP substrates (e.g., estrone-3-sulfate, del‐
torphin II, fexofenadine, vasopressin, and rosuvastatin).
5.11. Papaya (Carican papaya L.)
Papaya is prized worldwide for its flavor and nutritional properties. An ethno-botanical sur‐
vey showed that papaya is commonly used in traditional medicine for the treatment of vari‐
ous human diseases, including abdominal discomfort, pain, malaria, diabetes, obesity,
infections, and oral drug poisoning [111,112]. Papaya leaves and seeds are known to contain
proteolytic enzymes (papain, chymopapain), alkaloids (carpain, carpasemine), sulfurous
compounds (benzyl iso- thiocyanate), flavonoids, tannins, triterpenes, anthocyanins, organic
acids and oils. Papaya fruit is a good source of nutrients and some phytochemicals such as
beta-cryptoxanthin and benzyl isothiocyanates [113]. Hidaka et al. found that papaya pro‐
duced an inhibition of CYP3A activity in human microsomes [114]. So far, there has been no
clinical report suggesting adverse food-drug interaction caused by the intake of papaya. Ac‐
cordingly, the inhibition of CYP3A by papaya may not be observed in vivo. However, the
results obtained by others raised the hypothesis that papaya extracts were capable of alter‐
ing the pharmacokinetics of therapeutic drugs coadministered via CYP3A inhibition, as in
the case of grapefruit. Thus, the possibility of adverse food-drug interaction involving pa‐
paya and medicine acting via CYP3A metabolism should be examined in vivo. The empiri‐
cal evidence regarding the wide use of fermented papaya preparation (FPP), especially by
elderly people, has indicated an unknown collateral effect, i.e., drops in blood sugar levels,
especially in the afternoon. Those findings have been corroborated by a clinical study that
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shows that FPP use can induce a significant decrease in plasma sugar levels in both healthy
subjects and type 2 diabetic patients [115]. Therefore, patients consuming papaya and taking
antidiabetic therapy could suffer from potential drug-food interaction.
5.12. Leafy vegetables
Broccoli (Brassica oleracea var. italica) and cauliflower (Brassica oleracea var. botrytis) are unique
among the common cruciferous vegetables that contain high levels of the aliphatics glucosi‐
nolate and glucoraphanin [116]. Upon hydrolysis, glucoraphanin produces several products
that include the bioactive isothiocyanate sulforaphane. The percentage of isothiocyanate sul‐
foraphane present in these vegetables may vary depending on conditions of hydrolysis,
food handling, and preparation procedures [117, 118]. In animal studies, dietary freeze-
dried broccoli was found to offer protection against several cancers [119]. However, brocco‐
li, cauliflower and their glucosinolate hydrolysis products have been shown to induce phase
I and phase II drug-metabolizing enzymes in intact liver cells from both rats and humans.
The isothiocyanate sulforaphane decreased the enzyme activities hepatocytes associated
with CYP1A1 and 2B1/2, namely ethoxyresorufin-O-deethylase and pentoxyresorufin-O-
dealkylase, respectively, in a dose-dependent manner [120]. An increase in hGSTA1/2
mRNA has been observed in isothiocyanate sulforaphane-treated human hepatocytes,
whereas the expression of CYP3A4, the major CYP in the human liver, markedly decreased
at both mRNA and activity levels [121]. Conversely, it was recently shown that sulforaphane
induces mRNA levels of MRP1 and MRP2 in primary hepatocytes and Caco-2 cells [122]. It
has been additionally reported that broccoli is able to induce the activity of phenolsulfo‐
transferases [123]. These results suggest that other vegetables with a high content of isothio‐
cyanates, such as those of the family Cruciferae (e.g., cabbage, cauliflower, Brussels sprouts,
watercress, broccoli, and kale) and the genus Raphanus (radishes and daikons) may have
pharmacological and toxicological implications in humans.
Watercress is another important member of the cruciferous vegetables, an excellent source
for glucosinolates and other bioactive phytochemicals [124]. Watercress (Nasturtium offici‐
nale) is an exceptionally rich dietary source of beta-phenylethyl isothiocyanate (PEITC)
[125]. Previous studies have shown that a single ingestion of watercress inhibits the hydrox‐
ylation of chlorzoxazone, an in vivo probe for CYP2E1, in healthy volunteers [126]. It has al‐
so been shown that watercress is a bifunctional agent with the ability to induce both phase I
(CYP450) and II enzymes. Adding watercress juice to human liver cells induced the activity
of CYP4501A and ethoxyresorufin-O-deethylase and NAD(P)H-quinone reductase [127]. Ac‐
cording to reports, PEITC also has several anti-carcinogenic effects given that it can inhibit
phase I enzymes and/or activate phase II enzymes. Watercress juice can increase the en‐
zymes SOD and GPX in blood cells in vitro and in vivo [128]. Isothiocyanates also interact
with ATP-binding cassette (ABC) efflux transporters such as P-glycoprotein, MRP1, MRP2
and BCRP, and may influence the pharmacokinetics of substrates of these transporters [26].
According to current data, watercress and isothiocyanate may have clinical repercussions by
inducing changes in the bioavailability of some drugs.
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Spinach (Spinacia oleracea) is an important antioxidant vegetable usually consumed after
boiling the fresh or frozen leaves [129]. Freshly cut spinach leaves contain approximately
1,000 mg of total flavonoids per kilogram, and the occurrence of at least 10 flavonoid glyco‐
sides has been reported [130]. These are glucuronides and acylated di-and triglycosides of
methylated and methylene dioxide derivatives of 6-oxygenated flavonols [131]. While epide‐
miological and preclinical data support the nutritional benefits of spinach and the safety of
its consumption there are no publications about its effects on drug metabolizing enzymes
and drug transporters. Little is currently known about the in vivo effects these compounds
have on the bioavailability of xenobiotics the clearance and/or tissue distribution of which is
determined by active transport and biotransformation. Platt and others [132] reported the
protective effect of spinach against the genotoxic effects of 2-amino-3-methylimidazo[4,5-
f]quinoline (IQ) by interaction with CYP1A2 as a mechanism of anti-genotoxicity. Its high
isothiocyanate and flavonoid content demands additional research to evaluate possible nu‐
trient-drug interactions.
5.13. Vegetable fruits
Tomatoes (Lycopersicon esculentum) and tomato-based products are a source of important nu‐
trients and contain numerous phytochemicals, such as carotenoids, that may influence
health (carotenoids such as phytofluene, phytoene, neurosporene, γ-carotene, and ζ-caro‐
tene) [133,134]. Tomatoes are also a source of a vast array of flavonols (e.g., quercetin and
kaempferol), phytosterols, and phenylpropanoids [135]. Lycopene is the most important car‐
otenoid present in tomatoes and tomato products, and their dietary intake has been linked
to a decreased risk of chronic illnesses such as cancer and cardiovascular disease [136,137].
Studies performed on human recombinant CYP1 showed that lycopene inhibits CYP1A1
and CYP1B1. Lycopene has also been shown to slightly reduce the induction of ethoxyresor‐
ufin-O-deethylase activity by 20% by DMBA in MCF-7 cells [138]. It appears to inhibit bioac‐
tivation enzymes and induce detoxifying enzymes. It has been suggested that lycopene
might have a potential advantage over other phytochemicals by facilitating the elimination
of genotoxic chemicals and their metabolites [138]. Recent in vitro evidence suggests that
high dose lycopene supplementation increases hepatic cytochrome P4502E1 protein and in‐
flammation in alcohol-fed rats [139].
Carrots (Daucus carrota) are widely consumed as food. The active components of carrots,
which include beta-carotene and panaxynol have been studied by many researchers
[140-142]. Carrots induce phenolsulfotransferase activity [123] and decrease CYP1A2 activity
[122]. It has been reported that a carrot diet increased the activity of ethoxycoumarin O-dee‐
thylase ECD activity in a mouse model [143].
Avocado (Persea americana) is a good source of bioactive compounds such as monounsatu‐
rated fatty acids and sterols [144]. Growing evidence on the health benefits of avocadoes
have led to increased consumption and research on potential health benefits [145, 146]. Phy‐
tochemicals extracted from avocado can selectively induce several biological functions
[147,148]. Two papers published in the 1990’s reported avocados interact with warfarin, stat‐
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ing that the fruit inhibited the effect of warfarin. They, however, did not establish the cause
of such inhibition [149, 150].
Red pepper (Capsicum annuum L.) is used as a spice that enhances the palatability of food
and drugs such as the counterirritant present in stomach medicines across many countries
[151]. The pungencyof red pepper is derived from a group of compounds called capsaici‐
noids, which possess an array of biological properties and give it its spicy flavor. Two major
capsaicinoids, dihydrocapsaicin (DHC) and capsaicin (CAP) are responsible for up to 90% of
the total pungency of pepper fruits. Red pepper has several uses as a fruit stimulant and ru‐
bifacient in traditional medicine; it is also used in the treatment of some diseases such as
scarlatina, putrid sore throat, hoarseness, dispepsia, yellow fever, piles and snakebite [152].
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a fundamental component of Capsicum
fruits. Capsaicin is known to have antioxidant properties and has therefore been associated
with potent antimutagenic and anticarcinogenic activities [153]. Early studies have reported
that capsaicin strongly inhibited the constitutive enzymes CYP 2A2, 3A1, 2C11, 2B1, 2B2 and
2C6 [154]. There is also a report indicating that capsaicin is a substrate of CYP1A2 [155].
Pharmacokinetic studies in animals have shown that a single dose of Capsicum fruit could
affect the pharmacokinetic parameters of theophylline, while a repeated dose affected the
metabolic pathway of xanthine oxidase [156]. Therefore, a potential interaction may occur
when is taken along with some medicines that are CYP450 substrates. Recently, it has been
evidenced that red pepper induces alterations in intestinal brush border fluidity and passive
permeability properties associated with the induction of increased microvilli length and pe‐
rimeter, resulting in an increased absorptive surface for the small intestine and an increased
bioavailability not only of micronutrients but also of drugs [157]. Cruz et al. have shown
that pepper ingestion reduces oral salicylate bioavailability, a likely result of the gastrointes‐
tinal effects of capsaicin [158]. On the other hand, Imaizumi et al. have reported capsaici‐
noid-induced changes of glucose in rats. Therefore, there is a possible interaction risk
between red pepper and hypoglycemic drugs in diabetic patients [159]. Patients consuming
red pepper and taking antidiabetic therapy could suffer potential drug-food interaction.
5.14. Other vegetables
Yeh and Yen have reported that asparagus, cauliflower, celery and eggplant induced signifi‐
cant phenol sulfotransferase –P (PST-P) activity, whereas asparagus, eggplant and potato in‐
duced PST-M activity [123]. It has been have also reported that a diet supplemented with
apiaceous vegetables (dill weed, celery, parsley, parsnip) resulted in a 13-15% decrease in
CYP1A2 activity [122]. The authors speculate that furanocumarins present in the apiaceous
vegetables were responsible for the inhibitory effects on CYP1A2 ^115 [117,160].
Vegetables such as cabbage, celery, onion and parsley are known to have a high content of
polyphenols. It has been reported that polyphenols can potentially affect phase I metabolism
either by direct inhibition of phase I enzymes or by regulating the expression of enzyme lev‐
els via their interactions with regulatory cascades. Several studies have directly and indirect‐
ly shown that dietary polyphenols can modulate phase II metabolism [161]. In addition,
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Spinach (Spinacia oleracea) is an important antioxidant vegetable usually consumed after
boiling the fresh or frozen leaves [129]. Freshly cut spinach leaves contain approximately
1,000 mg of total flavonoids per kilogram, and the occurrence of at least 10 flavonoid glyco‐
sides has been reported [130]. These are glucuronides and acylated di-and triglycosides of
methylated and methylene dioxide derivatives of 6-oxygenated flavonols [131]. While epide‐
miological and preclinical data support the nutritional benefits of spinach and the safety of
its consumption there are no publications about its effects on drug metabolizing enzymes
and drug transporters. Little is currently known about the in vivo effects these compounds
have on the bioavailability of xenobiotics the clearance and/or tissue distribution of which is
determined by active transport and biotransformation. Platt and others [132] reported the
protective effect of spinach against the genotoxic effects of 2-amino-3-methylimidazo[4,5-
f]quinoline (IQ) by interaction with CYP1A2 as a mechanism of anti-genotoxicity. Its high
isothiocyanate and flavonoid content demands additional research to evaluate possible nu‐
trient-drug interactions.
5.13. Vegetable fruits
Tomatoes (Lycopersicon esculentum) and tomato-based products are a source of important nu‐
trients and contain numerous phytochemicals, such as carotenoids, that may influence
health (carotenoids such as phytofluene, phytoene, neurosporene, γ-carotene, and ζ-caro‐
tene) [133,134]. Tomatoes are also a source of a vast array of flavonols (e.g., quercetin and
kaempferol), phytosterols, and phenylpropanoids [135]. Lycopene is the most important car‐
otenoid present in tomatoes and tomato products, and their dietary intake has been linked
to a decreased risk of chronic illnesses such as cancer and cardiovascular disease [136,137].
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ing that the fruit inhibited the effect of warfarin. They, however, did not establish the cause
of such inhibition [149, 150].
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5.14. Other vegetables
Yeh and Yen have reported that asparagus, cauliflower, celery and eggplant induced signifi‐
cant phenol sulfotransferase –P (PST-P) activity, whereas asparagus, eggplant and potato in‐
duced PST-M activity [123]. It has been have also reported that a diet supplemented with
apiaceous vegetables (dill weed, celery, parsley, parsnip) resulted in a 13-15% decrease in
CYP1A2 activity [122]. The authors speculate that furanocumarins present in the apiaceous
vegetables were responsible for the inhibitory effects on CYP1A2 ^115 [117,160].
Vegetables such as cabbage, celery, onion and parsley are known to have a high content of
polyphenols. It has been reported that polyphenols can potentially affect phase I metabolism
either by direct inhibition of phase I enzymes or by regulating the expression of enzyme lev‐
els via their interactions with regulatory cascades. Several studies have directly and indirect‐
ly shown that dietary polyphenols can modulate phase II metabolism [161]. In addition,
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polyphenols have been shown to interact with ABC drug transporters involved in drug re‐
sistance and drug absorption, distribution and excretion [32].
6. Drug-food interaction in specific diets with high content of fruits and
vegetables
Weight-reduction diets, vegetarian diets, hospitalization, or post-operative regimes all lead
to dietary modifications. These diets are often maintained for long periods of time and are
likely to result in metabolic changes due to subsequently administered drugs or exposure to
environmental chemicals. Several epidemiologic, clinical, and experimental studies have es‐
tablished that certain types of diet may have beneficial effects on health. For example, the
traditional Mediterranean diet has been shown to reduce overall mortality and coronary
heart disease events [162]. This diet, however, varies across at least 16 countries bordering
the Mediterranean Sea. Cultural, ethnic, religious, economic and agricultural differences in
these regions account for variations in dietary patterns, which are widely characterized by
the following: daily consumption of fruits, vegetables, whole grain breads, non-refined cere‐
als, olive oil, and dairy products; moderate weekly consumption of fish, poultry, nuts, pota‐
toes, and eggs; low monthly consumption of red meat, and daily moderate wine
consumption [163]. Increasing evidence suggests that a Mediterranean-style diet rich in
fruits, vegetables, nuts, fish and oils with monounsaturated fat and low in meat promotes
cardiovascular health and aids cancer prevention because of its positive effects on lipid pro‐
file, endothelial function, vascular inflammation, insulin resistance, and its antioxidant
properties [164,165].
Vegetarians, on the other hand, exhibit a wide diversity of dietary practices often described
by what is omitted from their diet. When a vegetarian diet is appropriately planned and in‐
cludes fortified foods, it can be nutritionally suitable for adults and children and can promote
health and lower the risk of major chronic diseases [166]. A vegetarian diet usually provides a
low intake of saturated fat and cholesterol and a high intake of dietary fiber and many health-
promoting phytochemicals. This is achieved by an increased consumption of fruits, vegeta‐
bles, whole-grains, legumes, nuts, and various soy products. As a result of these factors,
vegetarians typically have a lower body mass index, low-density lipoprotein cholesterol lev‐
els, and lower blood pressure; a reduced ischemic heart disease death rate; and decreased in‐
cidence of hypertension, stroke, type 2 diabetes, and certain cancers that are more common
among non-vegetarians [167]. The vegan dietary category may be more comparable across
countries and cultures because avoiding all animal products leaves little choice but to include
large quantities of vegetables, fruit, nuts, and grains for nutritional adequacy. Admittedly,
vegetable and fruit variety may also vary widely according to location [168].
Due to their high content of fruits and vegetables, all these diets contain a large propor‐
tion of antioxidant vitamins, flavonoids, and polyphenols [169]. Phenolic compounds may
help protect the gastrointestinal tract against damage by reactive species present in foods
or generated within the stomach and intestines.  However,  they may be beneficial  in the
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gut in correct amounts. The overall health benefits of polyphenols are uncertain, and con‐
sumption of large quantities of them in fortified foods or supplements should not yet be
encouraged [170].
Flavonoids have been known as plant pigments for over a century and belong to a vast
group of phenolic compounds that are widely distributed in all foods of plant origin. Un‐
fortunately, the potentially toxic effects of excessive flavonoid intake are largely ignored. At
higher doses, flavonoids may act as mutagens, pro-oxidants that generate free radicals, and
as inhibitors of key enzymes involved in hormone metabolism [171]. It has been shown that
phenol ring-containing flavonoids yield cytotoxic phenoxyl radicals upon oxidation by per‐
oxidases; co-oxidize unsaturated lipids, GSH, NADH, ascorbate, and nucleic acids; and
cause ROS formation and mitochondrial toxicity [172]. In high doses, the adverse effects of
flavonoids may outweigh their beneficial ones, and caution should be exercised when in‐
gesting them at levels above those which would be obtained from a typical vegetarian diet
[173]. Moreover, it is possible that people ingesting a vegetarian or Mediterranean diet may
be taking medication and thus have drug-food interaction.
Inhibition of CYP enzymes, which are necessary for carcinogen activation, is a beneficial
chemopreventive property of various flavonoids but may be a potential toxic property in
flavonoid-drug interactions. Inhibition of CYP activities by flavonoids has been extensively
studied because of their potential use as blocking agents during the initial stage of carcino‐
genesis [174]. The general conclusion after an analysis of available data on CYP-flavonoid
interactions is that flavonoids possessing hydroxyl groups inhibit CYP activity, whereas
those lacking hydroxyl groups may induce the metabolizing enzyme [175]. Flavonoids can
either inhibit or induce human CYP enzymes depending on their structure, concentration, or
experimental conditions [176]. The interaction of flavonoids with CYP3A4, the predominant
human hepatic and intestinal CYP responsible for metabolizing 50% of therapeutic agents as
well as the activation of some carcinogens, is of particular interest [177].
The simultaneous administration of flavonoids present in fruits or vegetables and clinically
used drugs may cause flavonoid-drug interactions by modulating the pharmacokinetics of
certain drugs, which results in an increase in their toxicity or a decline in their therapeutic
effect, depending on the flavonoid structure [178]. Additional reasons for concern regarding
mega flavonoid supplements include potential flavonoid-drug interactions, since flavonoids
have been shown to both induce and inhibit drug-metabolizing enzymes [38, 39]. Further re‐
search regarding the potential toxicities associated with flavonoids and other dietary phe‐
nolics is required if these plant-derived products are to be used as therapy.
It is a fact that diets based on fruits and vegetables may have a variety of phytochemicals, as
was mentioned earlier, so the possibility of developing a drug-food interaction is high.
While dietary polyphenols may be beneficial in the correct amount, but too much may not
be good and combining them with medication should be avoided.
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WHO and the Food and Agriculture Organization of the United Nations (FAO) recommend
a daily intake of at least 400 grams or five servings of fruits and vegetables to aid in the pre‐
vention of chronic illnesses such as heart disease, cancer, diabetes, and obesity. As a conse‐
quence, there is an increased global consumer demand for fruits and vegetables, and some
consumers purchase organic foods with the understanding that they are healthy. The use of
natural products for improving human health has evolved independently in different re‐
gions of the world and production, use, attitudes, and regulatory aspects vary globally. Al‐
though modern medicine may be available in most countries for the treatment of many
chronic degenerative diseases, folk medicine (phytomedicine) has remained popular for his‐
torical and cultural reasons. Although the significance of interactions between drugs is
widely appreciated, little attention has been given to interactions between drugs and nu‐
trients. Most of the documented information about the effects of fruit and vegetables on me‐
tabolizing enzymes and drug transporters comes from preclinical studies. However, the
possibility that these effects could occur in humans should not be ignored. Several clinical
studies on the interactions of grapefruit juice and drugs have been conducted with impres‐
sive results. Most of the fruits and vegetables examined in this review contain a similar phy‐
tochemical mix to that of grapefruit juice. In vitro models and animal models have shown
that many of these agents influence drug metabolizing enzymes and drug transporters. It is
possible that other fruits and vegetables could have the same potential for fruit and drug
interactions, and this should be taken into account. This review shows evidence of the influ‐
ence of fruit, vegetables or their components (phytochemicals) on the CYP3A4 enzyme,
which metabolizes most drugs used by the human population. A more consistent approach
to the evaluation of nutrient-drug interactions in human beings is therefore needed. Said ap‐
proach must be systematic in order to a) assess the influence of nutritional status, foodstuffs,
or specific nutrients on a drug’s pharmacokinetics and pharmacodynamics, and b) evaluate
the influence of a drug on overall nutritional status or the status of a specific nutrient. In ad‐
dition to all this, we must account for the fact that we live in an era of very varied lifestyles.
Some people are vegetarians, others take high doses of flavonoids or antioxidants as supple‐
ments, some ingest large amounts of bottled water from plastic bottles, or use chlorinated
disinfectants. In industrialized countries, fruits and vegetables tend have been subjected to
some sort of processing (e.g., refrigeration, acidification, fermentation, and thermal, high
pressure, chemical, or physical processing) that might have an effect on the bioactive com‐
pound. All of these factors could have an impact on the metabolism or transport of drugs in
a individual, potentially altering pharmacological responses. Our knowledge regarding the
potential risk of nutrient-drug interactions is still limited. Therefore, efforts to elucidate po‐
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1. Introduction
Cancer is nowadays used as a generic term describing a group of about 120 different diseases,
which can affect any part of the body and defined as the state characterized by the uncontrolled
growth and invasion of normal tissues and spread of cells [1]. According to WHO reports
cancer is a leading cause of premature death worldwide, accounting for 7.6 million deaths
(around 13% of all deaths) only in 2008 [2]. The deaths from cancer worldwide are projected
to continue rising, reaching an estimated 13.1 million in 2030 (WHO 2012). The number of all
cancer cases around the world reached 12.7 million in 2008 and is expected to increase to 21
million by 2030. Approximately one in five people before age 75 will suffer from cancer during
their lifetime, while one in ten in this age range is predicted to die due to cancer [2]. About
70% of all cancer deaths occurred in low- and middle-income countries. Cancer statistics
indicate that most common new cancer cases (excluding common non-melanoma skin cancer)
include lung, breast, colorectum, stomach, prostate and liver. These statistics are affected by
a few factors including the increase in the number of carcinogens in daily life conditions (food,
alcohol, tobacco etc.; high levels of chemicals and pollutants in environment, exposure to UV
and ionizing radiation and viruses), genetic disposition [1] but also higher effectiveness of the
treatment regimes. The number of recognized carcinogens (agents, mixtures, oncoviruses,
environmental factors) increased from 50 in 1987 to 108 in 2012. Although it seems small, this
number increases continually with the evidence of new (probably and possibly) carcinogens
(64 and 271 in 2012) to humans [3]. What is significant only one compound is listed as probably
not carcinogenic - caprolactam. Moreover, since not all chemicals have been tested yet, the
number of human carcinogens is undervalued and will increase in the near future. Although
mortality rates for some cancers (e.g. leukaemia, testicular or ovarian cancer) are reduced and
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the overall survival time increased significantly, especially in high-developed countries, but
in fact the metastases, not the cancer itself, are the major cause of death. In 1971, only 50% of
people diagnosed with the cancer went on to live at least five years, while nowadays, the five-
year survival rate is 63% [2]. However if a cancer has spread the chances of survival are only
scarcely better than in the 1970s. These numbers indicate that although the knowledge about
cancer in the last two decades raised, even to a larger degree than in all preceding centuries,
but the problem of cancer diseases persists and our knowledge is still insufficient to solve it.
Despite the remarkable progress in cancer prevention, early detection, and treatment, made
during the last few decades, the methods of cancer diagnosis and treatment are still not
sufficiently specific and effective thus cancer still takes a heavy toll.
Not so long ago in the beginning of 20th century, neither carcinogens nor cellular targets were
identified while the treatment was carried out exclusively by surgeries or natural products
selected by trial and error. Modern cancer therapy based on the so-called holistic approach -
the combined use of surgical methods, radiotherapy, chemotherapy, hormonal therapy and
immunotherapy - is applied in the treatment of cancer at most stages. In fact this approach
originated from the ancient Sumerian, Akkadian, Babylonian, Assyrian and Egyptian medi‐
cine, and was largely influenced by the Roman and Greek ideas concerning anatomy, physi‐
ology as well as the achievements of practical medicine and natural science. The chemotherapy,
hormonal therapy, immunotherapy and radiotherapy as the methods of cancer treatment
joined to the oldest surgical one only in the 20th c. An important component of the combined
therapy, but sometimes when cancer had already metastasised, the only available therapeutic
method, is chemotherapy using natural or synthetic anticancer drugs and treated as curative,
palliative, adjuvant or neoadjuvant. Over the centuries anticancer drugs evolved from natural
products, discovered mainly from green plants and minerals to fully chemically synthesized
chemotherapeutic agents. However, even today drugs of natural origin play an important role
in the treatment of cancer as 14 of them were on the list of the top 35 drugs worldwide sales
[4]. The process of anticancer drug discovery leading from natural products to chemothera‐
peutic agents, often illicitly limited only to cytostatic and antiproliferative, has evolved from
serendipity to rational design based on advances in chemistry, physics and biology in a long
and complicated process. Nowadays both cancer itself and anticancer drugs are investigated
at the molecular level thus methods of drug discovery have changed diametrically. The
dominant direction of contemporary aniticancer drug discovery is the search for the possibil‐
ities to influence the pathogenetic mechanisms specific of the tumour structures at the cellular
and molecular levels, which require the knowledge of cancer origins.
This chapter will focus on the factors which influenced the direction of anticancer drug
discovery methods from guessing to the targeted search i.e. from serendipity to rational design.
2. Cancer origins
Cancer (proper medical name - malignant neoplasm) commonly considered to be a civilization
disease, has in fact been traced to occur even before the ancestral species of man [5]. The oldest
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evidence of cancer dates back to several million years ago and has been found in fossilized
remains (bones) of a dinosaur in Wyoming. The oldest specimens of cancer, a hominid
malignant tumour (probably Burkitt's lymphoma) and bone cancer - were found in the remains
of a body of either Homo erectus or an Australopithecus and in the remains of a female skull
dating to the Bronze Age (1900-1600 B.C.), respectively. Bone cancers have been also discov‐
ered in mummies in the Great Pyramid of Giza and in mummified skeletal remains of Peruvian
Incas. The earliest written records differentiating between benign and malignant cancers date
back to ancient times (3000-1500 B.C., Mesopotamia and Egypt). Seven Egyptian Papyruses
including the Edwin Smyth (2500 B.C.), Leyde (1500 B.C.), and George Ebers (1500 B.C.)
described not only the symptoms but also the first primitive forms of treatment, i.e. the removal
of a malignant tissue. The Hindu epic, the Ramayana (500 B.C.), mentioned not only cancer
cases but also the first medicines in the form of arsenic pastes, for treatment of cancerous
growth. Ancient Greek physician Hippocrates of Kos (ca. 460-370 B.C.) described many
different types of cancer (breast, uterus, stomach, skin, and rectum) recognised the difference
between benign and malignant tumours and formulated the humoral theory of cancer genesis.
As the veins surrounding the tumour resembled the crab claws, he named the disease after the
Greek word carcinos. Cornelus Celsus (ca. 25 B.C.-50 A.D.), who described the first surgeries
on cancers, translated Greek carcinos into now commonly used Latin term cancer. Claudius
Galen (129-216 A.D.), the most famous Roman Empire physician, who wrote about 500 medical
treatises, left a comprehensive descriptions of many neoplasms. He introduced the Greek word
oncos (swelling) to describe tumours. Nowadays the use of Hippocrates and Celsus term is
limited to describe malignant tumours, while Galen’s term is used as a part of the name of the
branch of medicine that deals with cancer - that is oncology. Followers of his works in
Constantinople, Alexandria, Athens explained the appearance of cancer as a result of an excess
of black bile. This idea prevailed through up to the 16th century.
The intensive studies in the field of anatomy and physiology during the Renaissance, resulted
in advancement of surgery and development of rational therapies based on clinical observa‐
tions. Based on autopsies William Harvey (1578-1657) described the systemic circulation of
blood through the heart and body. Although cancers were still incurable, their temporary
inhibition was often observed thanks to complementary remedies including the most common
arsenic-based creams and pastes. In the beginning of the 16th c. Zacutus Lusitani (1575-1642)
and Nicholas Tulp (1593−1674) formulated the contagion theory and proposed isolation of
patients in order to prevent the spread of cancer. Throughout the 17th and 18th centuries, this
theory was so popular that the first cancer hospital founded in Reims, France, was forced to
move outside the city. Nowadays, we know that their certain viruses, bacteria, and parasites
can increase a risk of developing cancer. Gaspare Aselli (1581-1625), who discovered the
lymphatic system, suggested a connection between the lymphatic system and cancer. Georg
Ernst Stahl (1660-1734) and Friedrich Hoffman (1660-1742) proposed a concept that tumours
grow from degenerating lymph constantly excreted by the blood. This idea was accepted by
John Hunter (1728-1793), who described methods to identify surgically removable tumours.
At that time the so-called humoral theory of cancer was replaced by the lymph theory. Claude-
Deshasis Gendron (1663-1750) was convinced that cancer arises as a solid and growing mass
untreatable with drugs, and must be completely removed. The discovery of a microscope by
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untreatable with drugs, and must be completely removed. The discovery of a microscope by
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Antonie van Leeuwenhoek (1632-1723) in the late 17th century extended the knowledge about
the cancer formation process and accelerated the search for the origin of cancer. It was realised
that the progress in cancer treatment critically depends on the ability to distinguish between
normal and malignant cells. Giovanni Battista Morgagni (1682-1771), father of pathomorphol‐
ogy, related the illness to pathological changes that laid the foundation for scientific oncology.
This observation in connection with discovery of anaesthesia in 1844 by Horace Wells
(1815-1848) enabled development of precise diagnosis of cancer and modern radical cancer
surgery. In 1838, Johannes Peter Muller (1801-1858) indicated cells as basic units of tumours
and proposed the blastema theory that cancer cells developed from budding elements
(blastema) between normal tissues. In 1860, Karl Thiersch (1822-1895), showed that cancers
metastasize through the spread of malignant cells and described establishment of secondary
cancer as a result of their spread by lymph. Rudolf Virchow (1821-1902), the founder of cellular
pathology, recognized leukaemia cells. He showed that cancer cells can be differentiated from
surrounding normal cells from which they originated and the stage of cancer can be deter‐
mined using microscopic images. Virchow also properly recognized chronic irritation as one
of the factors favouring cancer development. Nowadays, we are aware that cancers arise from
sites of infection, chronic irritation and inflammation. The next key step in understanding the
mechanism of cancer development was the discovery of chromosome and mitosis credited to
German botanist Wilhelm Hofmeister (1824-1877). In 1902 Theodor Boveri (1862-1915)
reasoned that a cancerous tumour begins with a single cell, which divided uncontrollably,
while David Paul von Hansemann (1858–1920), included multipolar mitoses among the factors
responsible for the arise of abnormal chromosome numbers in cells leading to tumour
formation. In fact Hansemann formulated chromosomal theory of cancer, while Boveri
proposed the existence of cell-cycle checkpoints, tumour suppressor genes, and oncogenes and
speculated that uncontrolled growth might be caused by physical (radiation), chemical (some
chemicals) or biological (microscopic pathogens) factors. Thomas Hunt Morgan (1866-1945)
made a key observations of chromosomal changes and demonstrated in 1915 the correctness
of this theory. But still the carcinogens like chemical agents or irradiation could not explain
the fact that sometimes cancer seemed to run in families. Already in the 17th c. Lusitani and
Tulp observed the appearance of breast cancer in whole families.
A rapid progress in understanding the cancer origins was possible thanks to the scientific
progress and appearance of instruments required to solve complex interdisciplinary problems
of chemistry and biology. The turning points in the research on cancer were the mapping of
locations of the fruit fly (Drosophila melanogaster) genes by Alfred Sturtevant (1891-1970), the
discovery that DNA is the genetic material by Oswald Avery (1877-1955), Colin Munro
MacLeod (1909-1972) and Maclyn McCarty (1911-2005) and the resolution of the exact chemical
structure of DNA, the basic material in genes, by James Watson and Francis Crick (1916-2004).
Their results indicated that DNA was the cellular target for carcinogens and that mutations
were the key to understanding the mechanisms of cancer. In 1970 the first oncogene (SRC, from
sarcoma) a defective proto-oncogene i.e. gene which after mutation, predispose the cell to
become a cancerous (stimulate cell proliferation) was discovered by G. Steve Martin in a
chicken retrovirus. One year later, but long before the human genome was sequenced, Alfred
George Knudson identified first tumour suppressor gene, the Rb gene, located on a region of
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long arm of chromosome 13 at position 14.2 in humans. Its mutation results in retinoblastoma
juvenile eye tumour. On the basis of the earlier (dated to 1953) findings of Carl Nordling, he
has formulated the accepted till now “two-hit hypothesis” which assumes that both alleles
coding a particular protein must be affected before an effect is manifested. Knudson provided
an explanation of the relationship between the hereditary and non-hereditary origins of cancer
and predicted the existence of tumor suppressor genes that can suppress cancer cell growth.
It was later discovered that both classes of genes proto-oncogenes and tumor-suppressor genes
encode many kinds of proteins controlling cell growth and proliferation and the mutations in
these genes can contribute to carcinogenesis.
In 1976 John Michael Bishop and Harold Elliot Varmus discovered the presence of oncogenes
in many organisms including humans. Nowadays, after human genome sequencing in 2004,
we know that human DNA contains approximately 20,500 genes [6]. About 50 of them are
known to be proto-oncogenes, while 30 tumour suppressor genes. The proto-oncogenes (c-
onc) initiate the process of cell division and code enzymes which control grows and division
of cells. Proto-oncogenes can be activated to oncogenes by many factors including chromosome
rearrangements, gene duplication, mutation or overexpression. For example, a chromosome
rearrangement results in formation of BCR-ABL gene which leads to chronic myeloid leukae‐
mia [7], acquired mutation activate the KIT gene which results in gastrointestinal stromal
tumour [8], while inheritance of BRCA1 or BRCA2 increase the risk of breast, ovarian, fallopian
tube, and prostate cancers [9]. To cause cancer most oncogenes require an additional step, for
example mutations in another gene or introduction of foreign DNA (e.g. by viral infection).
Infection and inflammation significantly contribute to about 25% of cancer cases. During the
inflammatory response to viral infection the free radicals - reactive oxygen and nitrogen species
- are generated as a physiological protective response. During chronic inflammation the
mechanism is different - free radicals induce genetic and epigenetic changes including somatic
mutations in cancer-related genes and posttranslational modifications in proteins involved in
DNA repair or apoptosis. However, irrespective of the origins, the tumour microenvironment
created by inflammatory cells, is an essential factor in the whole neoplastic process. It facilitates
proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts
adaptive immune responses, and alters responses to chemotherapeutic agents. If a cell
accumulates critical mutations in a few of these proto-oncogenes (five or six), it will survive
instead of undergoing apoptosis, will proliferate and become capable of forming a tumour.
The protecting mechanism involves the tumour suppressor genes, "anti-oncogenes", which
protect from developing or growing cancer by repairing DNA damages (mutations), inhibiting
cell division and cell proliferation or prevent reproduction by stimulating apoptosis. Mutation
of these genes may lead to cessation of the inhibition of cell division. As a result the cell will
divide uncontrollably, and produce daughter cells with the same defect. For example, mutation
in the TP53 gene (initially after discovery in 1979 by Arnold Levine, David Lane and William
Old incorrectly believed to be an oncogene), one of the most commonly mutated tumour
suppressor genes which encoding tumour protein - so called p53 protein, a key element in
stress-induced apoptosis, is involved in the pathophysiology of leukaemias, lymphomas,
sarcomas, and neurogenic tumours [10,11]. Homozygous loss of p53 is found in 70% of colon
cancers, 50% of lung cancers and 30–50% of breast cancers. Other important tumour suppressor
Anticancer Drug Discovery — From Serendipity to Rational Design
http://dx.doi.org/10.5772/52507
39
Antonie van Leeuwenhoek (1632-1723) in the late 17th century extended the knowledge about
the cancer formation process and accelerated the search for the origin of cancer. It was realised
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normal and malignant cells. Giovanni Battista Morgagni (1682-1771), father of pathomorphol‐
ogy, related the illness to pathological changes that laid the foundation for scientific oncology.
This observation in connection with discovery of anaesthesia in 1844 by Horace Wells
(1815-1848) enabled development of precise diagnosis of cancer and modern radical cancer
surgery. In 1838, Johannes Peter Muller (1801-1858) indicated cells as basic units of tumours
and proposed the blastema theory that cancer cells developed from budding elements
(blastema) between normal tissues. In 1860, Karl Thiersch (1822-1895), showed that cancers
metastasize through the spread of malignant cells and described establishment of secondary
cancer as a result of their spread by lymph. Rudolf Virchow (1821-1902), the founder of cellular
pathology, recognized leukaemia cells. He showed that cancer cells can be differentiated from
surrounding normal cells from which they originated and the stage of cancer can be deter‐
mined using microscopic images. Virchow also properly recognized chronic irritation as one
of the factors favouring cancer development. Nowadays, we are aware that cancers arise from
sites of infection, chronic irritation and inflammation. The next key step in understanding the
mechanism of cancer development was the discovery of chromosome and mitosis credited to
German botanist Wilhelm Hofmeister (1824-1877). In 1902 Theodor Boveri (1862-1915)
reasoned that a cancerous tumour begins with a single cell, which divided uncontrollably,
while David Paul von Hansemann (1858–1920), included multipolar mitoses among the factors
responsible for the arise of abnormal chromosome numbers in cells leading to tumour
formation. In fact Hansemann formulated chromosomal theory of cancer, while Boveri
proposed the existence of cell-cycle checkpoints, tumour suppressor genes, and oncogenes and
speculated that uncontrolled growth might be caused by physical (radiation), chemical (some
chemicals) or biological (microscopic pathogens) factors. Thomas Hunt Morgan (1866-1945)
made a key observations of chromosomal changes and demonstrated in 1915 the correctness
of this theory. But still the carcinogens like chemical agents or irradiation could not explain
the fact that sometimes cancer seemed to run in families. Already in the 17th c. Lusitani and
Tulp observed the appearance of breast cancer in whole families.
A rapid progress in understanding the cancer origins was possible thanks to the scientific
progress and appearance of instruments required to solve complex interdisciplinary problems
of chemistry and biology. The turning points in the research on cancer were the mapping of
locations of the fruit fly (Drosophila melanogaster) genes by Alfred Sturtevant (1891-1970), the
discovery that DNA is the genetic material by Oswald Avery (1877-1955), Colin Munro
MacLeod (1909-1972) and Maclyn McCarty (1911-2005) and the resolution of the exact chemical
structure of DNA, the basic material in genes, by James Watson and Francis Crick (1916-2004).
Their results indicated that DNA was the cellular target for carcinogens and that mutations
were the key to understanding the mechanisms of cancer. In 1970 the first oncogene (SRC, from
sarcoma) a defective proto-oncogene i.e. gene which after mutation, predispose the cell to
become a cancerous (stimulate cell proliferation) was discovered by G. Steve Martin in a
chicken retrovirus. One year later, but long before the human genome was sequenced, Alfred
George Knudson identified first tumour suppressor gene, the Rb gene, located on a region of
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long arm of chromosome 13 at position 14.2 in humans. Its mutation results in retinoblastoma
juvenile eye tumour. On the basis of the earlier (dated to 1953) findings of Carl Nordling, he
has formulated the accepted till now “two-hit hypothesis” which assumes that both alleles
coding a particular protein must be affected before an effect is manifested. Knudson provided
an explanation of the relationship between the hereditary and non-hereditary origins of cancer
and predicted the existence of tumor suppressor genes that can suppress cancer cell growth.
It was later discovered that both classes of genes proto-oncogenes and tumor-suppressor genes
encode many kinds of proteins controlling cell growth and proliferation and the mutations in
these genes can contribute to carcinogenesis.
In 1976 John Michael Bishop and Harold Elliot Varmus discovered the presence of oncogenes
in many organisms including humans. Nowadays, after human genome sequencing in 2004,
we know that human DNA contains approximately 20,500 genes [6]. About 50 of them are
known to be proto-oncogenes, while 30 tumour suppressor genes. The proto-oncogenes (c-
onc) initiate the process of cell division and code enzymes which control grows and division
of cells. Proto-oncogenes can be activated to oncogenes by many factors including chromosome
rearrangements, gene duplication, mutation or overexpression. For example, a chromosome
rearrangement results in formation of BCR-ABL gene which leads to chronic myeloid leukae‐
mia [7], acquired mutation activate the KIT gene which results in gastrointestinal stromal
tumour [8], while inheritance of BRCA1 or BRCA2 increase the risk of breast, ovarian, fallopian
tube, and prostate cancers [9]. To cause cancer most oncogenes require an additional step, for
example mutations in another gene or introduction of foreign DNA (e.g. by viral infection).
Infection and inflammation significantly contribute to about 25% of cancer cases. During the
inflammatory response to viral infection the free radicals - reactive oxygen and nitrogen species
- are generated as a physiological protective response. During chronic inflammation the
mechanism is different - free radicals induce genetic and epigenetic changes including somatic
mutations in cancer-related genes and posttranslational modifications in proteins involved in
DNA repair or apoptosis. However, irrespective of the origins, the tumour microenvironment
created by inflammatory cells, is an essential factor in the whole neoplastic process. It facilitates
proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts
adaptive immune responses, and alters responses to chemotherapeutic agents. If a cell
accumulates critical mutations in a few of these proto-oncogenes (five or six), it will survive
instead of undergoing apoptosis, will proliferate and become capable of forming a tumour.
The protecting mechanism involves the tumour suppressor genes, "anti-oncogenes", which
protect from developing or growing cancer by repairing DNA damages (mutations), inhibiting
cell division and cell proliferation or prevent reproduction by stimulating apoptosis. Mutation
of these genes may lead to cessation of the inhibition of cell division. As a result the cell will
divide uncontrollably, and produce daughter cells with the same defect. For example, mutation
in the TP53 gene (initially after discovery in 1979 by Arnold Levine, David Lane and William
Old incorrectly believed to be an oncogene), one of the most commonly mutated tumour
suppressor genes which encoding tumour protein - so called p53 protein, a key element in
stress-induced apoptosis, is involved in the pathophysiology of leukaemias, lymphomas,
sarcomas, and neurogenic tumours [10,11]. Homozygous loss of p53 is found in 70% of colon
cancers, 50% of lung cancers and 30–50% of breast cancers. Other important tumour suppressor
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genes include p16, BRCA-1, BRCA-2, APC or PTEN [12]. Mutation of these genes may lead to
melanoma (p16), breast and ovarian cancer in genetically related families (BRCA), colorectal
cancer (APC) or glioblastoma, endometrial cancer, and prostate cancer (PTEN).
In general cancerogenesis is a multistep process thus it is usually a combination of proto-
oncogene activation and tumour suppressor gene loss or inactivation is required. However,
in a few cases (only 5-10% of cancer cases) this abnormal change in gene can be inherited,
passed from generation to generation, in most cases it is a result of sporadic or somatic
mutation acquired during a person's lifetime. Although cancer is generally believed to arise
as a result of slow accumulation of multiple mutations, but in some cases (2-3%) massive
multiple mutation can also arise in a single event. Thus cancer is described as a disease of
abnormal gene function, genetically caused by the interaction of two factors: genetic suscept‐
ibility and environmental mutagens and carcinogens. Of key importance for the recognition
of the molecular mechanism underlying cancer treatment - cell apoptosis - was the discovery
of telomeres and telomerase. In the early 1970s, Alexei Olovnikov, on the basis of the Leonard
Hayflick's concept of limited somatic cell divisions (Hayflick limit), suggested that chromo‐
somes cannot completely replicate their ends. In 1978 Elizabeth Blackburn discovered the
unusual nature of stretches of DNA in the ends of the chromosomes of protozon Tetrahyme‐
na - the so-called telomeres. The sequence of human telomere was established 10 years later,
in 1988, by Robin Allshire. Blackburn described telomere-shortening mechanism which limits
cells to a fixed number of divisions and protect chromosomes from fusing each other or
rearranging that can lead to cancer. Shortened telomeres have been found in many cancers,
including pancreatic, bone, prostate, bladder, lung, kidney, and head and neck. In 1985, Carol
Greider isolated the enzyme telomerase, controlling the elongation of telomeres. Four years
later, in 1989, Gregg B. Morin reported the presence of telomerase in human tumour cells and
linked its activity with the immortality of these cells (inability to apoptosis), while Greider
discovered the lack of active telomerase in normal somatic cells apart from stem cells, kerati‐
nocytes, intestines, and hair follicle. It was discovered that deactivation of telomerase prompts
the apoptosis of human breast and prostate cancer cells. These results indicated the important
role of telomerase in the process of oncogenesis.
Carcinogenesis have been found a complex and multi-step (preinitiation, initiation, promotion
and metastasis) biological process characterised by independence from growth factors,
insensitivity to inhibitors of growth, unlimited potential for replication (reactivation of
telomerase), invasiveness, the ability to metastasis and to sustain angiogenesis, and resistance
of apoptosis [13]. DNA mutation inherited and caused by exposure to carcinogens (chemical:
compounds including drugs, physical: radiation, or biological: the introduction of new DNA
sequences by viruses) have been found to be the true origin of uncontrolled growth of cells
coupled with malignant behaviour: invasion and metastasis (Fig. 1).
The knowledge of the molecular mechanisms involving the above mentioned factors, espe‐
cially apoptosis and cancer resistance to it, can improve cancer therapy through resensitization
of tumour cells. Fundamental method of cancer treatment - classical chemotherapy (and
radiotherapy) which is harmful also to normal cells, act primarily by inducing cell apoptosis
either locally, in tumour, or globally, when cancer metastasize. Any disturbance in apoptosis
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results in a decrease in the effectiveness of the therapy. The recent targeted therapies instead
of interfering with rapidly dividing cells, interfere with selected targets in the cell and use
small molecules to interfere with abnormal proteins (required for carcinogenesis and tumour
growth) or cell receptors, or use monoclonal antibodies, which destroy malignant tumour cells
and prevent tumour growth by blocking specific receptors. Targeted cancer therapy, which
may be more effective and less harmful than classical chemotherapy but still are based on the














Figure 1. Multi-step process of carcinogenesis.
3. Cancer risk — Carcinogens and co-carcinogens
Currently we are aware that apart of inherited mutations, an important role in carcinogenesis
play the factors connected with the expression to carcinogens [14]. This includes environmental
factors (pollutions), lifestyle factors (tobacco smoking, diet, alcohol consumption, obesity,
sedentary life), occupational factors (e.g. synthesis, dyes, fumes) and other factors (excessive
exposure to sunlight, radiation, viruses, etc). Carcinogens (of chemical, physical or biological
origin) include chemicals or non-chemical agents, which under certain conditions are able to
induce cancer. Co-carcinogens, are not carcinogenic themselves but with other chemicals or
non-chemical carcinogens, such as for example UV or ionizing radiation, promote the effects
of a carcinogen in carcinogenesis. Carcinogens as well as co-carcinogens can be of natural or
synthetic origins. In general, their carcinogenic action relay on direct or indirect action in the
cellular DNA. Carcinogens acting directly can initiate the carcinogenesis by yielding highly
reactive species that bind covalently to cellular DNA, while those acting indirectly can induce
mutations to cellular DNA. Thus carcinogens are able to distort the conformation or function
(replication/transcription) of DNA, which results not only in oncogene activation but also DNA
amplification, gene transposition or chromosome translocation. Carcinogens may induce
carcinogenesis directly by mutational activation of protooncogenes and/or inactivation of
tumour suppression genes. Indirect action is realised through the mechanisms that generate
chemical species (free radicals, reactive oxygen species, carcinogenic metabolites) which are
capable of entering the nucleus of the cell.
Over 80% of carcinogenic substances are of environmental origins [15]. Restriction of the
exposition to carcinogens can substantially reduce the risk of cancers also those of occupational
type, which make approximately 4-5% of all human cancers. Thus evaluation and classification
of the carcinogens is required from the cancer prevention point of view. Although there are
many international and national organizations that classify carcinogens, but only a few are
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genes include p16, BRCA-1, BRCA-2, APC or PTEN [12]. Mutation of these genes may lead to
melanoma (p16), breast and ovarian cancer in genetically related families (BRCA), colorectal
cancer (APC) or glioblastoma, endometrial cancer, and prostate cancer (PTEN).
In general cancerogenesis is a multistep process thus it is usually a combination of proto-
oncogene activation and tumour suppressor gene loss or inactivation is required. However,
in a few cases (only 5-10% of cancer cases) this abnormal change in gene can be inherited,
passed from generation to generation, in most cases it is a result of sporadic or somatic
mutation acquired during a person's lifetime. Although cancer is generally believed to arise
as a result of slow accumulation of multiple mutations, but in some cases (2-3%) massive
multiple mutation can also arise in a single event. Thus cancer is described as a disease of
abnormal gene function, genetically caused by the interaction of two factors: genetic suscept‐
ibility and environmental mutagens and carcinogens. Of key importance for the recognition
of the molecular mechanism underlying cancer treatment - cell apoptosis - was the discovery
of telomeres and telomerase. In the early 1970s, Alexei Olovnikov, on the basis of the Leonard
Hayflick's concept of limited somatic cell divisions (Hayflick limit), suggested that chromo‐
somes cannot completely replicate their ends. In 1978 Elizabeth Blackburn discovered the
unusual nature of stretches of DNA in the ends of the chromosomes of protozon Tetrahyme‐
na - the so-called telomeres. The sequence of human telomere was established 10 years later,
in 1988, by Robin Allshire. Blackburn described telomere-shortening mechanism which limits
cells to a fixed number of divisions and protect chromosomes from fusing each other or
rearranging that can lead to cancer. Shortened telomeres have been found in many cancers,
including pancreatic, bone, prostate, bladder, lung, kidney, and head and neck. In 1985, Carol
Greider isolated the enzyme telomerase, controlling the elongation of telomeres. Four years
later, in 1989, Gregg B. Morin reported the presence of telomerase in human tumour cells and
linked its activity with the immortality of these cells (inability to apoptosis), while Greider
discovered the lack of active telomerase in normal somatic cells apart from stem cells, kerati‐
nocytes, intestines, and hair follicle. It was discovered that deactivation of telomerase prompts
the apoptosis of human breast and prostate cancer cells. These results indicated the important
role of telomerase in the process of oncogenesis.
Carcinogenesis have been found a complex and multi-step (preinitiation, initiation, promotion
and metastasis) biological process characterised by independence from growth factors,
insensitivity to inhibitors of growth, unlimited potential for replication (reactivation of
telomerase), invasiveness, the ability to metastasis and to sustain angiogenesis, and resistance
of apoptosis [13]. DNA mutation inherited and caused by exposure to carcinogens (chemical:
compounds including drugs, physical: radiation, or biological: the introduction of new DNA
sequences by viruses) have been found to be the true origin of uncontrolled growth of cells
coupled with malignant behaviour: invasion and metastasis (Fig. 1).
The knowledge of the molecular mechanisms involving the above mentioned factors, espe‐
cially apoptosis and cancer resistance to it, can improve cancer therapy through resensitization
of tumour cells. Fundamental method of cancer treatment - classical chemotherapy (and
radiotherapy) which is harmful also to normal cells, act primarily by inducing cell apoptosis
either locally, in tumour, or globally, when cancer metastasize. Any disturbance in apoptosis
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results in a decrease in the effectiveness of the therapy. The recent targeted therapies instead
of interfering with rapidly dividing cells, interfere with selected targets in the cell and use
small molecules to interfere with abnormal proteins (required for carcinogenesis and tumour
growth) or cell receptors, or use monoclonal antibodies, which destroy malignant tumour cells
and prevent tumour growth by blocking specific receptors. Targeted cancer therapy, which
may be more effective and less harmful than classical chemotherapy but still are based on the














Figure 1. Multi-step process of carcinogenesis.
3. Cancer risk — Carcinogens and co-carcinogens
Currently we are aware that apart of inherited mutations, an important role in carcinogenesis
play the factors connected with the expression to carcinogens [14]. This includes environmental
factors (pollutions), lifestyle factors (tobacco smoking, diet, alcohol consumption, obesity,
sedentary life), occupational factors (e.g. synthesis, dyes, fumes) and other factors (excessive
exposure to sunlight, radiation, viruses, etc). Carcinogens (of chemical, physical or biological
origin) include chemicals or non-chemical agents, which under certain conditions are able to
induce cancer. Co-carcinogens, are not carcinogenic themselves but with other chemicals or
non-chemical carcinogens, such as for example UV or ionizing radiation, promote the effects
of a carcinogen in carcinogenesis. Carcinogens as well as co-carcinogens can be of natural or
synthetic origins. In general, their carcinogenic action relay on direct or indirect action in the
cellular DNA. Carcinogens acting directly can initiate the carcinogenesis by yielding highly
reactive species that bind covalently to cellular DNA, while those acting indirectly can induce
mutations to cellular DNA. Thus carcinogens are able to distort the conformation or function
(replication/transcription) of DNA, which results not only in oncogene activation but also DNA
amplification, gene transposition or chromosome translocation. Carcinogens may induce
carcinogenesis directly by mutational activation of protooncogenes and/or inactivation of
tumour suppression genes. Indirect action is realised through the mechanisms that generate
chemical species (free radicals, reactive oxygen species, carcinogenic metabolites) which are
capable of entering the nucleus of the cell.
Over 80% of carcinogenic substances are of environmental origins [15]. Restriction of the
exposition to carcinogens can substantially reduce the risk of cancers also those of occupational
type, which make approximately 4-5% of all human cancers. Thus evaluation and classification
of the carcinogens is required from the cancer prevention point of view. Although there are
many international and national organizations that classify carcinogens, but only a few are
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highly influential, the oldest and setting the standards, World Health Organization of the
United Nations (WHO) International Agency for Research on Cancer (IARC) headquartered
in Lyon, France, established in 1965; United Nations initiative from 1992 called Globally
Harmonized System of Classification and Labelling of Chemicals (GHS), National Toxicology
Program of the U.S. Department of Health and Human Services established in 1978, profes‐
sional organization American Conference of Governmental Industrial Hygienists, founded in
1938 in Washington and reorganized in 1946, European Union directives Dangerous Substan‐
ces Directive (67/548/EEC) and the Dangerous Preparations Directive (1999/45/EC) and Safe
Work Australia (Independent Statutory Agency) which evolved from National Occupational
Health and Safety Council (NOHSC) established in 1985. One of the prime roles of these
organizations is to evaluate and classify the chemical, physical and biological carcinogens
targeted to develop strategies for cancer prevention and control used by international and
national health and regulatory agencies to protect public health. Since 1971 IARC evaluated
the carcinogenicity of approximately 400 and collected data about 900 agents and published
them in a series (101 till 2012) of Monographs on the Evaluation of Carcinogenic Risks to
Humans [3]. Up to now IARC has identified 108 definitely, 66 probably, 284 possibly carcino‐
gens, 515 not classifiable as carcinogens and 1 probably not carcinogenic, Table 1. Alternative
to IARC, a complex GSH classification system, collects data from tests, literature, and practical
experience [16]. Since 2003 four editions of GHS have been published, but only most recent
one, dated to 2011, has the form convenient for worldwide implementation. GSH delivers a
global system of classification of chemicals (substances, alloys, mixtures) divided into three
groups of hazards: physical (16 classes), health and environmental (12 and 2 classes, respec‐
tively) and a unique system of labelling and collecting the information in the form of safety
data sheets (SDS). GSH requires the use of the harmonized classification scheme and the
harmonized label elements for any carcinogenic chemical. Within the GSH system, the class
of carcinogens was clearly separated as health hazard risk factor and divided to two categories:
known and presumed carcinogens (subcategories 1A and 1B, respectively) and suspected
carcinogens (category 2), Table 2. Irrespective of the classification system, the epidemiological
evidence indicates that many drugs, including antineoplastic, sex hormones, antithyroid,
antibacterial, antiparasitic, immunosuppressive ones used as single agents or in combinations
as well as radiation (γ, X or UV) are known carcinogens.
3.1. Carcinogens of chemical/environmental origins
As early as in 16th c. Phillippus Aureolus Theophratus Bombastus von Hohenheim (1493-1541)
known as Paracelsus suggested that the “wasting disease of miners” might be linked to
exposure to realgar (tetra-arsenic tetra-sulphide). Since the 17th c. cancer was associated with
the presence of some chemicals. For example John Hill (1716-1775) linked tobacco use with
nasal cancer, while Percivall Pot (1814-1788) described occupational risk of epithelial cancer
of the scrotum connected with soot, in chimney sweepers. In 1795 Samuel Thomas von
Soemmerring (1755-1830) cautioned that pipe smokers were excessively prone to cancer of the
lip. Since then epidemiological evidence has been important in detecting carcinogens. In 1858,
a Montpellier surgeon Etienne-Frédéric Bouisson (1813-1884) found that 63 of his 68 patients
suffering from oral cancer were pipe smokers. Shortly after replacement of natural dyes by
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synthetic aromatic amine dye in German industry, Ludwig Rehn (1849-1930) reported an
increased incidence of bladder cancer in workers exposed to it. Many years later exact
carcinogen, 2-naphthylamine, was recognized. In the 1930s the first company in American dye
industry, DuPont, reported first cases of occupational cancer connected with the use of dyes,
bladder cancer, at the Chambers Works plant. In 1935, Takaoki Sasaki and Tomizo Yoshida
(1903-1973) induced malignant tumours (hepatoma) in a digestive organ by feeding rats by
one of the azo dyes - o-aminoazotoluene.
IARC
classification





sufficient evidence of carcinogenicity to
humans, epidemiologic evidence,
occupational exposure, and animal studies;
strong evidence that the agent acts through














limited evidence of carcinogenicity to humans,
but sufficient evidence of carcinogenicity in
experimental animals; strong evidence that
the carcinogenesis is mediated by mechanisms
that are also operate in humans




limited evidence in humans; less than
sufficient evidence in experimental animals;
inadequate evidence in humans but sufficient




Group 3 not classifiable
as
carcinogenic
inadequate evidence in humans; inadequate
or limited to experimental animals;
mechanisms of carcinogenesis in animals does
not operate in humans.
515 ifosfamide, isophosphamide,
actinomycin D
Group 4 probably not
carcinogenic
negative evidence of carcinogenicity,
not used
1 caprolactam
Table 1. Classification of carcinogens according to IARC, 2012
But the first chemical carcinogen - coal tar - was identified as early as in 1915 by Katsusaburo
Yamagiwa (1863-1930) and Koichi Ichikawa (1888-1948) who induced cancer in laboratory
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highly influential, the oldest and setting the standards, World Health Organization of the
United Nations (WHO) International Agency for Research on Cancer (IARC) headquartered
in Lyon, France, established in 1965; United Nations initiative from 1992 called Globally
Harmonized System of Classification and Labelling of Chemicals (GHS), National Toxicology
Program of the U.S. Department of Health and Human Services established in 1978, profes‐
sional organization American Conference of Governmental Industrial Hygienists, founded in
1938 in Washington and reorganized in 1946, European Union directives Dangerous Substan‐
ces Directive (67/548/EEC) and the Dangerous Preparations Directive (1999/45/EC) and Safe
Work Australia (Independent Statutory Agency) which evolved from National Occupational
Health and Safety Council (NOHSC) established in 1985. One of the prime roles of these
organizations is to evaluate and classify the chemical, physical and biological carcinogens
targeted to develop strategies for cancer prevention and control used by international and
national health and regulatory agencies to protect public health. Since 1971 IARC evaluated
the carcinogenicity of approximately 400 and collected data about 900 agents and published
them in a series (101 till 2012) of Monographs on the Evaluation of Carcinogenic Risks to
Humans [3]. Up to now IARC has identified 108 definitely, 66 probably, 284 possibly carcino‐
gens, 515 not classifiable as carcinogens and 1 probably not carcinogenic, Table 1. Alternative
to IARC, a complex GSH classification system, collects data from tests, literature, and practical
experience [16]. Since 2003 four editions of GHS have been published, but only most recent
one, dated to 2011, has the form convenient for worldwide implementation. GSH delivers a
global system of classification of chemicals (substances, alloys, mixtures) divided into three
groups of hazards: physical (16 classes), health and environmental (12 and 2 classes, respec‐
tively) and a unique system of labelling and collecting the information in the form of safety
data sheets (SDS). GSH requires the use of the harmonized classification scheme and the
harmonized label elements for any carcinogenic chemical. Within the GSH system, the class
of carcinogens was clearly separated as health hazard risk factor and divided to two categories:
known and presumed carcinogens (subcategories 1A and 1B, respectively) and suspected
carcinogens (category 2), Table 2. Irrespective of the classification system, the epidemiological
evidence indicates that many drugs, including antineoplastic, sex hormones, antithyroid,
antibacterial, antiparasitic, immunosuppressive ones used as single agents or in combinations
as well as radiation (γ, X or UV) are known carcinogens.
3.1. Carcinogens of chemical/environmental origins
As early as in 16th c. Phillippus Aureolus Theophratus Bombastus von Hohenheim (1493-1541)
known as Paracelsus suggested that the “wasting disease of miners” might be linked to
exposure to realgar (tetra-arsenic tetra-sulphide). Since the 17th c. cancer was associated with
the presence of some chemicals. For example John Hill (1716-1775) linked tobacco use with
nasal cancer, while Percivall Pot (1814-1788) described occupational risk of epithelial cancer
of the scrotum connected with soot, in chimney sweepers. In 1795 Samuel Thomas von
Soemmerring (1755-1830) cautioned that pipe smokers were excessively prone to cancer of the
lip. Since then epidemiological evidence has been important in detecting carcinogens. In 1858,
a Montpellier surgeon Etienne-Frédéric Bouisson (1813-1884) found that 63 of his 68 patients
suffering from oral cancer were pipe smokers. Shortly after replacement of natural dyes by
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synthetic aromatic amine dye in German industry, Ludwig Rehn (1849-1930) reported an
increased incidence of bladder cancer in workers exposed to it. Many years later exact
carcinogen, 2-naphthylamine, was recognized. In the 1930s the first company in American dye
industry, DuPont, reported first cases of occupational cancer connected with the use of dyes,
bladder cancer, at the Chambers Works plant. In 1935, Takaoki Sasaki and Tomizo Yoshida
(1903-1973) induced malignant tumours (hepatoma) in a digestive organ by feeding rats by
one of the azo dyes - o-aminoazotoluene.
IARC
classification
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negative evidence of carcinogenicity,
not used
1 caprolactam
Table 1. Classification of carcinogens according to IARC, 2012
But the first chemical carcinogen - coal tar - was identified as early as in 1915 by Katsusaburo
Yamagiwa (1863-1930) and Koichi Ichikawa (1888-1948) who induced cancer in laboratory
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animals by prolonged application of coal tar to rabbit skin. Inflammation accompanying the
coal tar application and cancer formation was in a good agreement with Virchow findings.
The search for specific chemical carcinogens led to the discovery of pure carcinogenic chemi‐
cals including polycyclic aromatic hydrocarbons PAHs (e.g. benzo[a]pyrene, 1,2,5,6-diben‐
zanthracene) by Ernest Lawrence Kennaway (1881-1958) and Izrael Hieger (1901-1986), which
were shown to be carcinogenic in mouse skin by Hieger et al. in 1933 [17]. Nowadays, we know
that PAHs, mainly benzo[a]pyrene and heterocyclic amines (HCAs) belong to definite
carcinogens which appear in smoke as a result of incomplete combustion [18] and thus are
present not only in tobacco smoke but also in a fried/smoked meat as well as barbeque. PAHs
often induce stomach cancer.
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Table 2. Classification of carcinogens according to GSH, 2011
Although cancer-causing substances are often considered to be exclusively synthetic, there are
numerous natural carcinogens, chemical compounds that occur in environment, and in food
plants [19]. Isaac Berenblum (1903-2000) discovered the potent inflammatory agent, croton oil
extracted from Croton Tiglium L. native or cultivated in Asia (India, Ceylon, China), Malay
Argipelago and Africa (Zanzibar, Tanzania), and its most active ingredient, 12-O-tetradeca‐
noylphorbol-13-acetate (TPA) in 1941 [20]. Both agents now belong to classic tumour promot‐
ers. In 1956, John Barnes (1913-1975) and Peter Magee, reported an example of synergistic
interaction of chemical carcinogens with proinflammatory agents. i.e. liver tumors in rats
induced by N-nitrosdimethylamine (NDMA) [21]. In 1972, another case, the influence of
chronic respiratory infection with influenza virus on the development of lung cancer in rats
induced by carcinogenic N-nitrosamine was reported [22], which occurs in some foodstuffs,
latex, cosmetics. Since then about 90% of nitrosamine derivatives including hydrazines from
raw mushrooms Agaricus bisporus (Lange) Imbach and Gyromitra (Pers.) Fr. have been deemed
to be carcinogenic and promoters of benign hepatomas, liver cell carcinomas, angiomas and
angiosarcomas of blood vessels, adenomas and adenocarcinomas of lungs.
One of the most potent naturally occurring microbial carcinogen is Aflatoxin B1, which is
produced as secondary metabolite by the fungi Aspergillus flavus and Aspergillus parasiticm [23]
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growing on stored grains, nuts and peanut butter and found worldwide as a contaminant in
food. The discovery of Alfatoxin B1 followed upon “Turkey X Disease” (a liver disease) which
killed over 100,000 turkeys in the UK in the early 1960s. The major metabolite of Aflatoxin B1,
Aflatoxin B1-8,9-epoxide, exerts hepatotoxic effect, but synergistic interaction between
Aflatoxin B1 and hepatitis B virus results in hepatocellular carcinoma. Another fungal
contaminant is mycotic toxin Ochratoxin-A (OTA) produced by Penicillium viridicatum
discovered during laboratory studies in the mid-1960s and encountered as a natural contam‐
inant in maize in 1969 in the USA [24]. Large group of carcinogens are tannins and tannic acid,
which occur widely in plants (tea, coffee, and cocoa) but in concentrated doses reveal hepa‐
tocarcinogenic properties in both animals and humans. They have been found capable of
causing liver tumours in experimental animals and oesophageal, throat & mouth cancers in
humans. Cycads, important food sources in tropical regions, contain unique toxines cycasin
and macrozamin that cause liver and kidney tumours in rats [25]. Safrole, 5-Allyl-1,3-benzo‐
dioxole found in sassafras tea, cinnamin, cocoa, nutmeg, black pepper, and other herbs and
spices as well as isosafrole, 1,2-(Methylenedioxy)-4-propenylbenzene belong to liver carcino‐
gens in rats, they produce liver tumours following their oral administration [26]. Dihydrosa‐
frole is also carcinogenic in rats and mice, in which it produces tumours of the oesophagus,
and liver tumours in males and lung tumours in both males and females, respectively. There
is an evidence of the carcinogenic properties of estragole from anise, star anise, basil, bay,
tarragon, fennel, marjoram or American wood turpentine oil, which proceeds through a
genotoxic mechanism identical to that of safrole and also induce liver cancer in mice [27]. Black
pepper (Piper nigrum L.), apart of tannic acid and safrole contains secondary amines pypera‐
dine and alpha-methylpyrroline, which can be nitrosated to N-nitroso-piperidine, a strong
carcinogen, carcinogenic to experimental mice. It has been known since the 1960s that Comfrey
(Symphytum officinale L.) contains carcinogenic hepatoxines belonging to pyrrolizidine
alkaloids (PAs) e.g. lasiocarpine and symphatine, which can interfere with RNA and DNA
synthesis within the liver cells and cause liver damage, cancer, and death [28].
Some chemical carcinogens have been discovered as a result of industrial or environmental
accidents. For example in 1976, notoriety was gained by Seveso disaster - an explosion occurred
in a TCP (2,4,5-trichlorophenol) reactor at the ICMESA chemical plant located about 20 km
north of Milan, Italy. A mixture of different chemicals including dioxin was released into the
atmosphere. This industrial accident caused the highest known exposure to 2,3,7,8-tetrachlor‐
odibenzo-p-dioxin (TCDD) in residential populations and linked dioxin exposure to chloracne,
genetic impairments and excessive risk of lymphatic and hematopoietic tissue [29-32]. Another
environmental disaster related to dioxines was contamination of a landfill of Love Canal in
the Niagara Falls, New York, USA. This region was turned in 1920 to municipal and industrial
chemical dumpsite by Hooker Chemica and in 1942-1953 it was contaminated by eleven highly
toxic carcinogens including TCDD. In 1978 a record amount of rainfall in Love Canal resulted
in leaching the chemicals from corroding waste-disposal drums in this area which caused
environmental disaster, a drastic increase in birth defects, nervous disorders, high white-
blood-cell counts in residents, a possible precursor of leukaemia and cancers [33-35]. Many
years later probable carcinogenic action of triclosan, an antibacterial agent added to soaps,
toothpastes etc., has been linked to its degradation to TCDD in chlorinated water [36]. In the
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animals by prolonged application of coal tar to rabbit skin. Inflammation accompanying the
coal tar application and cancer formation was in a good agreement with Virchow findings.
The search for specific chemical carcinogens led to the discovery of pure carcinogenic chemi‐
cals including polycyclic aromatic hydrocarbons PAHs (e.g. benzo[a]pyrene, 1,2,5,6-diben‐
zanthracene) by Ernest Lawrence Kennaway (1881-1958) and Izrael Hieger (1901-1986), which
were shown to be carcinogenic in mouse skin by Hieger et al. in 1933 [17]. Nowadays, we know
that PAHs, mainly benzo[a]pyrene and heterocyclic amines (HCAs) belong to definite
carcinogens which appear in smoke as a result of incomplete combustion [18] and thus are
present not only in tobacco smoke but also in a fried/smoked meat as well as barbeque. PAHs
often induce stomach cancer.
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Although cancer-causing substances are often considered to be exclusively synthetic, there are
numerous natural carcinogens, chemical compounds that occur in environment, and in food
plants [19]. Isaac Berenblum (1903-2000) discovered the potent inflammatory agent, croton oil
extracted from Croton Tiglium L. native or cultivated in Asia (India, Ceylon, China), Malay
Argipelago and Africa (Zanzibar, Tanzania), and its most active ingredient, 12-O-tetradeca‐
noylphorbol-13-acetate (TPA) in 1941 [20]. Both agents now belong to classic tumour promot‐
ers. In 1956, John Barnes (1913-1975) and Peter Magee, reported an example of synergistic
interaction of chemical carcinogens with proinflammatory agents. i.e. liver tumors in rats
induced by N-nitrosdimethylamine (NDMA) [21]. In 1972, another case, the influence of
chronic respiratory infection with influenza virus on the development of lung cancer in rats
induced by carcinogenic N-nitrosamine was reported [22], which occurs in some foodstuffs,
latex, cosmetics. Since then about 90% of nitrosamine derivatives including hydrazines from
raw mushrooms Agaricus bisporus (Lange) Imbach and Gyromitra (Pers.) Fr. have been deemed
to be carcinogenic and promoters of benign hepatomas, liver cell carcinomas, angiomas and
angiosarcomas of blood vessels, adenomas and adenocarcinomas of lungs.
One of the most potent naturally occurring microbial carcinogen is Aflatoxin B1, which is
produced as secondary metabolite by the fungi Aspergillus flavus and Aspergillus parasiticm [23]
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growing on stored grains, nuts and peanut butter and found worldwide as a contaminant in
food. The discovery of Alfatoxin B1 followed upon “Turkey X Disease” (a liver disease) which
killed over 100,000 turkeys in the UK in the early 1960s. The major metabolite of Aflatoxin B1,
Aflatoxin B1-8,9-epoxide, exerts hepatotoxic effect, but synergistic interaction between
Aflatoxin B1 and hepatitis B virus results in hepatocellular carcinoma. Another fungal
contaminant is mycotic toxin Ochratoxin-A (OTA) produced by Penicillium viridicatum
discovered during laboratory studies in the mid-1960s and encountered as a natural contam‐
inant in maize in 1969 in the USA [24]. Large group of carcinogens are tannins and tannic acid,
which occur widely in plants (tea, coffee, and cocoa) but in concentrated doses reveal hepa‐
tocarcinogenic properties in both animals and humans. They have been found capable of
causing liver tumours in experimental animals and oesophageal, throat & mouth cancers in
humans. Cycads, important food sources in tropical regions, contain unique toxines cycasin
and macrozamin that cause liver and kidney tumours in rats [25]. Safrole, 5-Allyl-1,3-benzo‐
dioxole found in sassafras tea, cinnamin, cocoa, nutmeg, black pepper, and other herbs and
spices as well as isosafrole, 1,2-(Methylenedioxy)-4-propenylbenzene belong to liver carcino‐
gens in rats, they produce liver tumours following their oral administration [26]. Dihydrosa‐
frole is also carcinogenic in rats and mice, in which it produces tumours of the oesophagus,
and liver tumours in males and lung tumours in both males and females, respectively. There
is an evidence of the carcinogenic properties of estragole from anise, star anise, basil, bay,
tarragon, fennel, marjoram or American wood turpentine oil, which proceeds through a
genotoxic mechanism identical to that of safrole and also induce liver cancer in mice [27]. Black
pepper (Piper nigrum L.), apart of tannic acid and safrole contains secondary amines pypera‐
dine and alpha-methylpyrroline, which can be nitrosated to N-nitroso-piperidine, a strong
carcinogen, carcinogenic to experimental mice. It has been known since the 1960s that Comfrey
(Symphytum officinale L.) contains carcinogenic hepatoxines belonging to pyrrolizidine
alkaloids (PAs) e.g. lasiocarpine and symphatine, which can interfere with RNA and DNA
synthesis within the liver cells and cause liver damage, cancer, and death [28].
Some chemical carcinogens have been discovered as a result of industrial or environmental
accidents. For example in 1976, notoriety was gained by Seveso disaster - an explosion occurred
in a TCP (2,4,5-trichlorophenol) reactor at the ICMESA chemical plant located about 20 km
north of Milan, Italy. A mixture of different chemicals including dioxin was released into the
atmosphere. This industrial accident caused the highest known exposure to 2,3,7,8-tetrachlor‐
odibenzo-p-dioxin (TCDD) in residential populations and linked dioxin exposure to chloracne,
genetic impairments and excessive risk of lymphatic and hematopoietic tissue [29-32]. Another
environmental disaster related to dioxines was contamination of a landfill of Love Canal in
the Niagara Falls, New York, USA. This region was turned in 1920 to municipal and industrial
chemical dumpsite by Hooker Chemica and in 1942-1953 it was contaminated by eleven highly
toxic carcinogens including TCDD. In 1978 a record amount of rainfall in Love Canal resulted
in leaching the chemicals from corroding waste-disposal drums in this area which caused
environmental disaster, a drastic increase in birth defects, nervous disorders, high white-
blood-cell counts in residents, a possible precursor of leukaemia and cancers [33-35]. Many
years later probable carcinogenic action of triclosan, an antibacterial agent added to soaps,
toothpastes etc., has been linked to its degradation to TCDD in chlorinated water [36]. In the
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early 1980s the high risk of lung, skin, kidney and bladder cancer due to chronic low level
arsenic poisoning of water in different countries (Bangladesh, Vietnam, Cambodia, Tibet,
Argentina, Chile, China, India, Mexico, Thailand, and US) caused by contamination of water
by pesticides and various alloys containing arsenic, which resemble and thus substitute
phosphorus in chemical reactions, was discovered [37]. In 1980 it was realized that exposure
to formaldehyde (a hazard in embalming and production of plastics and vinyl chloride, from
which PVC is manufactured) could cause nasal cancer in rats [38]. In the early 1970s, the
carcinogenicity of vinyl chloride was linked to occupational angiosarcoma cancers in workers
in industry. A few years later PVC was classified as a carcinogen [39-41]. Since then specific
substances: aniline and benzidine, asbestos, wool/wood/leather dust have been linked to
different types of cancer in humans bladder cancer, sinuses and lung cancer, mesothelioma,
nasal sinuses, respectively [3]. Many drugs, including chemotherapeutic anticancer agents,
diuretics, hormones have been recognized as a source of secondary cancers and thus classified
as definite carcinogens. Most of anticancer drugs is classified as group 1 agents in IARC
classification [3].
3.2. Carcinogens of biological origins (Oncogenic viruses/bacteria/parasites)
The hypothesis that cancer can originate from a virus comes from Danish scientists Oluf Bang
(1881-1937) and Vilhelm Ellerman (1871-1924), who was the first to show, in 1908, that avian er‐
ythroblastosis (chicken leukaemia) can be transmitted by cell-free extracts. In 1911, Francis Pey‐
ton Rous (1879-1970), American pathologist, described a solid cancer, sarcoma, in domestic
chickens caused by exposing the healthy bird to a cell-free filtrate containing retrovirus later be‐
came known as the Rous sarcoma virus [42]. Abbie Lathrop (1868-1918) and Leo Loeb (1869-1959)
described breast cancer in mice caused by a transmissible agent as early as in 1915 [43]. Since
then several oncoviruses have been linked to different types of cancer [44]. In 1933 Richard Ed‐
win Shope (1901-1966) discovered the first mammalian tumour caused in cottontail rabbit by fi‐
broma virus and papilloma virus (Shope papilloma virus). Shortly later, in 1936, a geneticist and
cancer biologists John Joseph Bittner (1904-1961) discovered a mouse mammary tumour virus
(MMTV), the so-called Bittner virus, causing a breast cancer, which is a promoter in models of
human breast cancer [45]. In 1957, Sarah Elizabeth Stewart (1905-1976) and Berenice E. Eddy
(1903-1989), pioneers in the field of viral oncology research, discovered the Stewart-Eddy poly‐
oma virus, which produced several types of cancer in a variety of small mammals [46]. John J.
Trentin (1908-2005) and others were the first to report of cancer (sarcoma) produced in animals
(hamsters) by inoculation of virus of human origin (Adenovirus) [47]. Michael Anthony Ep‐
stein, Bert Achong (1928-1996) and Yvonne Barr identified the first human cancer virus (Ep‐
stein-Barr  Virus  or  EBV)  from  Burkitt  lymphoma  cells  in  1964  [48].  Baruch  Blumberg
(1925-2011) isolated Hepatitis B virus (HBV), a cause of hepatitis, and suggested that it contrib‐
uted to liver cancer hepatocellular carcinoma. It was confirmed to be an oncovirus in the 1980s.
Hepatitis C virus (HCV) was shown to be a major contributor to liver cancer (hepatocellular
carcinoma) by Michael Houghton and Daniel W. Bradley in 1987. The first human retroviruses,
Human T-lymphotropic virus 1 (HTLV I) and 2 (HTLV 2), linked to T-cell lymphoma/T-cell leu‐
kaemia and Hairy-cell leukaemia, respectively, were discovered by Bernard J. Poiesz, Robert
Charles Gallo and Mistuaki Yoshida. In 1984 Harald zur Hausen and Lutz Gissman discovered
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that the human papillomaviruses HPV16 and HPV18 were responsible for approximately 70%
of cervical cancers, while Alan Storey, Kit Osborn and Lionel Crawford in 1990 indicated that
HPV types 6 and 11 were responsible for 90% of genital warts. Valerie Beral, Thomas A. Peter‐
man, Harold W. Jaffe related Kaposi’s sarcoma-associated herpesvirus (KSHV) with AIDS [49],
which prompted Patrick S. Moore, Yuan Chang, Frank Lee and Ethel Cesarman to isolate Kapo‐
si sarcoma-associated herpesvirus (KSHV or HHV8) in 1994 [50]. Very recently in 2008, Chang
and Moore developed a new method to identify oncoviruses called digital transcriptome sub‐
traction (DTS) and isolated DNA fragments of Merkel cell polyomavirus from a Merkel cell car‐
cinoma, considered to be responsible for 70–80% of these cancers [51].
There is also evidence of a link between the bacteria Helicobacter pylori (HP) responsible for
development of gastric and duodenal ulcers and cancer risk [52,53]. The human oncogenic
viruses, which include HBV, HCV, HIV, HPVs, EBV, KSHV, HTLV-I and HTLV-II and HP are
associated with nearly 20% of the human cancer cases. The elimination of these pathogens
would decrease by 23.6% the cases of cancer in developing countries and by 7.7% in developed
countries [54]. The commonly omitted advantage of the discovery of oncoviruses was the
possibility of transplantation of carcinogen-induced tumour systems in mice, which delivered
models for the studies on anticancer drugs.
Rare source of cancer are also parasitic diseases caused by Clonorchis sinensis (Japan, Korea,
Vietnam) and Opisthorchis viverrini (Thailand, Laos, and Malaysia) or Schistosomas species
(Africa, Asia). All of them are known to be carcinogenic and linked with biliary tract cancer
(cholangiocarcinoma) and bladder cancer, respectively [55]. Most of the biological carcinogens
are classified as group 1 agents in IARC classification [3].
3.3. Carcinogens of physical origins (Radiation)
Shortly after the discovery of chemical carcinogens, i.e. factors that suppress and activate the
cell growth and division, the first physical carcinogens were identified. After discovery of X-
rays by Wilhelm Roentgen (1845-1923) in 1895 and radioactive radiation by Henri Becquerel
(1852-1908) in 1896, the exposure to radiation has been identified as one of the causes of can‐
cer. Working with early X-ray generators resulted in the acute skin reactions and the first radi‐
ation-induced cancer arising in an ulcerated area of the skin was reported in 1902. In 1910 to
1912, Pierre Marie, Jean Clunet and Gaston Raulot-Lapointe reported the induction of sarco‐
ma in rats by the application of X-irradiation. As early as in 1911 the first report of leukaemia in
radiation workers appeared [56]. The 20th century pioneers in X-Ray/radium studies fell vic‐
tims to their  work;  surgeon Robert  Abbe (1851-1928),  physicist  Marie  Skłodowska-Curie
(1867-1934) and physician Jean Bergonie (1857-1925) died due to leukaemia. The use of urani‐
um/plutonium based bombs against Hiroshima/Nagasaki during World War II revealed that
ionising radiation irrespective of its origin is a cause of cancer [57]. Increased incidence of can‐
cer of bone marrow and essentially all organs was noted in Japan years to decades later. Some
physical carcinogens have been discovered as a result of nuclear disasters. In 1957, the cooling
system failed and the radioactive wastes chemical explosion of at Mayak nuclear fuel reproc‐
essing plant, Ozyorsk/Mayak, Russia caused radiation contamination which spread over hun‐
dred kilometres and pollution of the Techa River.  This accident called Kyshtym disaster
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chickens caused by exposing the healthy bird to a cell-free filtrate containing retrovirus later be‐
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described breast cancer in mice caused by a transmissible agent as early as in 1915 [43]. Since
then several oncoviruses have been linked to different types of cancer [44]. In 1933 Richard Ed‐
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broma virus and papilloma virus (Shope papilloma virus). Shortly later, in 1936, a geneticist and
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(MMTV), the so-called Bittner virus, causing a breast cancer, which is a promoter in models of
human breast cancer [45]. In 1957, Sarah Elizabeth Stewart (1905-1976) and Berenice E. Eddy
(1903-1989), pioneers in the field of viral oncology research, discovered the Stewart-Eddy poly‐
oma virus, which produced several types of cancer in a variety of small mammals [46]. John J.
Trentin (1908-2005) and others were the first to report of cancer (sarcoma) produced in animals
(hamsters) by inoculation of virus of human origin (Adenovirus) [47]. Michael Anthony Ep‐
stein, Bert Achong (1928-1996) and Yvonne Barr identified the first human cancer virus (Ep‐
stein-Barr  Virus  or  EBV)  from  Burkitt  lymphoma  cells  in  1964  [48].  Baruch  Blumberg
(1925-2011) isolated Hepatitis B virus (HBV), a cause of hepatitis, and suggested that it contrib‐
uted to liver cancer hepatocellular carcinoma. It was confirmed to be an oncovirus in the 1980s.
Hepatitis C virus (HCV) was shown to be a major contributor to liver cancer (hepatocellular
carcinoma) by Michael Houghton and Daniel W. Bradley in 1987. The first human retroviruses,
Human T-lymphotropic virus 1 (HTLV I) and 2 (HTLV 2), linked to T-cell lymphoma/T-cell leu‐
kaemia and Hairy-cell leukaemia, respectively, were discovered by Bernard J. Poiesz, Robert
Charles Gallo and Mistuaki Yoshida. In 1984 Harald zur Hausen and Lutz Gissman discovered
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models for the studies on anticancer drugs.
Rare source of cancer are also parasitic diseases caused by Clonorchis sinensis (Japan, Korea,
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(Africa, Asia). All of them are known to be carcinogenic and linked with biliary tract cancer
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(1852-1908) in 1896, the exposure to radiation has been identified as one of the causes of can‐
cer. Working with early X-ray generators resulted in the acute skin reactions and the first radi‐
ation-induced cancer arising in an ulcerated area of the skin was reported in 1902. In 1910 to
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ma in rats by the application of X-irradiation. As early as in 1911 the first report of leukaemia in
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(1867-1934) and physician Jean Bergonie (1857-1925) died due to leukaemia. The use of urani‐
um/plutonium based bombs against Hiroshima/Nagasaki during World War II revealed that
ionising radiation irrespective of its origin is a cause of cancer [57]. Increased incidence of can‐
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essing plant, Ozyorsk/Mayak, Russia caused radiation contamination which spread over hun‐
dred kilometres and pollution of the Techa River.  This accident called Kyshtym disaster
Anticancer Drug Discovery — From Serendipity to Rational Design
http://dx.doi.org/10.5772/52507
47
belongs to three most serious nuclear accidents ever recorded, although it was revealed only in
1976 [58]. The scarce epidemiological studies suggest very different numbers of cancer deaths
among residents associated to radiation exposure. In 1979 the cooling system of Three Mile Is‐
land nuclear power plant near Harrisburg, Pennsylvania failed and the reactor core was parti‐
ally melted. Radiation from the reactor contributed to the premature deaths and cancers in
local residents, but the disaster was relatively small [59]. There is still vivid discussion about
the carcinogenic effects of nuclear power plant explosion in 1986 in Chernobyl located 80 miles
from Kiev, Ukraine, which was the greatest source of long-lived radioactive plutonium and
short-lived radioactive caesium (137Cs), iodines (particularly 131I) and strontium (90Sr). The ma‐
jor health effect of Chernobyl was an elevated thyroid-cancer incidence due to iodine absorp‐
tion by the thyroid gland in adolescents and children some of whom were not yet born at the
time of the accident, and drastic increase in leukaemia cases caused by distribution the stronti‐
um incorrectly recognized by the body as calcium throughout the bone structure [60]. Radioac‐
tive isotopes of barium, caesium, iodine and tellurium were detected in a radiation plume
released by damaged nuclear reactors at the nuclear plant in Fukushima, Japan in 2011. Fu‐
kushima Daiichi disaster was the most serious accident in global scale. As the prolonged expo‐
sure to radiation in the air, ground and food can result in leukaemia and other cancers thus
about 160,000 people were evacuated from the region surrounding the plant. According to the‐
oretical 3-D global atmospheric models this nuclear disaster may cause as many as 2,500 cases
of cancer, mostly in Japan. Only recently, in the 1990s, much-less energetic UV radiation has
been also recognized as carcinogen causing not only genetic mutations but also melanoma or
non-melanoma cancers. In 2011 WHO/IARC classified radiofrequency electromagnetic fields
as possibly carcinogenic to humans (Group 2B), on the basis of an increased risk of glioma, a
malignant type of brain cancer, associated with wireless phone use [3]. Nowadays we are
aware that exposure to radiation can be incidental like in Hiroshima, Nagasaki, Chernobyl, Fu‐
kushima [1,61] or systematic due to repeated doses of radiation like UV during sun-bathing or
MW during phone-cell use. Anyway the most common radiation induced cancers are basal cell
carcinoma and squamous carcinoma of the skin, leukaemia and thyroid cancer. The first two
can arise from excessive exposure to UV radiation, while the other are mainly result of ionis‐
ing radiation e.g. γ, X-Ray [1]. The controlled use of ionising radiation in medicine and indus‐
try and annual limits of doses for each individual [62] has reduced the risk connected with
ionising radiation but the awareness of UV or MW related risk is still low. Common feature of
cancers induced by physical factor is late onset and long period of risk persisting. Most of the
physical carcinogens are classified as group 1 or 2 agents in IARC classification [3].
4. Chemotherapeutical agents
4.1. Drugs of natural origin
In the second half of the 20th century, one more type of cancer therapy was added to surgery,
irradiation and hormonotherapy, which was chemotherapy. Nowadays this term primarily
refers to the treatment of cancer with an antineoplastic drug or a combination of drugs, but
when it was introduced in 1909 by Paul Ehrlich (1854-1915) it had a broader meaning as it
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referred as well to antibacterial chemotherapy and treatment of autoimmune diseases, in
general use of chemicals to treat disease. Chemotherapy, generally assumed as the youngest
method of cancer treatment, is in fact rooted in ancient times. Although cutting out the cancer
changed tissue was early found as the main treatment, it was not always effective. Thus various
substances of natural origin were applied as complementary medications. Many even ancient
cultures had proposed theories explaining the cause of cancer. These theories influenced the
search for medicaments. For example Egyptians believed that natural substances similar in
look or function to human organs can be used to treat ailments in those organs, thus the use
of mixtures of pigs eyes or ears was popular.
Although the products of animal and mineral origin had made an important contribution to
drug development, the main source of drugs for millennia have been green plants. The most
frequently used included castor oil plant (Ricinus communis L.), exploding cucumber (Ecballium
elateritum L.), belladonna (Atropa belladonna L.), myrrh (dried sap from trees Commiphora
Myrcha L.), incense (dried sap from trees Boswellia thurifera L., Boswellia frereana Birdw., Boswellia
bhawdajiana Birdw.), stinging nettle (Urtica dioica L.), gingers (Zingiber Boehm. L.), red clover
(Trifolium pratense L.) and autumn crocus (Colchicum autumnale L.). Although, in nature most
of them cause sickness, but in small doses or after chemical modifications, they revealed
therapeutic effects. Some of them were rediscovered by modern medicine. For example from
Colchicum autumnale L. described by Pedanius Dioscorides (40-90 A.D.) in De Materia Medica
a toxic alkaloid colchicine was extracted in 1820 by Pierre Joseph Pelletier (1788-1842) and
Joseph Bienaimé Caventou (1795–1877). Albert Pierre Dustin (1914-1993), described its
antymitotic properties in 1934 [63]. In 2009 it was accepted by Food and Drug Administration
(FDA) as a drug for gout and Familial Mediterranean Fever. Another interesting case described
by Dioscorides is red viscous sap called the dragon's blood mostly collected from Dracaena
cinnabari Balf. f or Croton lechleri L. and used as a dye and anti-inflammatory, antimicrobial
and anticancer folk remedy not only by ancient Greek but also Romans and Arabs. Recently
methanolic extract of Croton lechleri was shown to exert cytotoxic effects on HeLa (Human
epithelial carcinoma cell line) cells and its antitumor effect in HeLa tumour in mice was
documented [64]. Two other commonly used antileukemic drugs, vinblastine and vincristine,
were extracted in 1950 from the species of Madagascar periwinkle (Catharanthus roseus L.), for
centuries known as folk remedy, and shortly after approved by FDA. Nowadays vinblastine,
which binds tubulin, thereby inhibiting the assembly of microtubules, is an important
component of a number of chemotherapy regimens, including ABVD for Hodgkin lymphoma,
advanced testicular cancer, breast and lung cancers, and Kaposi’s sarcoma [65]. Realgar widely
used in Chinese traditional medicine because of its anti-inflammation, antiulcer, anticonvul‐
sion, and anti-schistosomiasis activity was recently found capable to induce cell apoptosis and
thus effective in the treatment of hematological malignant diseases [66]. As early as in 1021,
Avicenna described the medicinal use of Taxus baccata L. (Zarnab) as cardiac remedy in The
Canon of Medicine. Various parts of Taxus brevifolia Peattie, Taxus Canadensis Marshall, Taxus
baccata L. have been used by several Native American Tribes mainly for the treatment of non-
cancerous diseases [65] but the use for the treatment of cancer was noted only in the Hindu
Ayurvedic medicine. Paclitaxel (Taxol®), used in treatment for breast, ovarian, small and non-
small cell lung cancer and Kaposi sarcoma, was isolated in 1967 by Monroe E. Wall and
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try and annual limits of doses for each individual [62] has reduced the risk connected with
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cancers induced by physical factor is late onset and long period of risk persisting. Most of the
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documented [64]. Two other commonly used antileukemic drugs, vinblastine and vincristine,
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centuries known as folk remedy, and shortly after approved by FDA. Nowadays vinblastine,
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sion, and anti-schistosomiasis activity was recently found capable to induce cell apoptosis and
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baccata L. have been used by several Native American Tribes mainly for the treatment of non-
cancerous diseases [65] but the use for the treatment of cancer was noted only in the Hindu
Ayurvedic medicine. Paclitaxel (Taxol®), used in treatment for breast, ovarian, small and non-
small cell lung cancer and Kaposi sarcoma, was isolated in 1967 by Monroe E. Wall and
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Mansukh C. Wani from the bark of the 200-years old Pacific yew (Taxus brevifolia Nutt.) tree
[67]. Its structure was elucidated in 1971 [67,68]. Its cytostatic mechanism of action (mitosis
inhibition) was discovered by Susan B. Horowitz in the late 1970s, but only the discovery of
total chemical synthesis of Paclitaxel in 1994 by Robert A. Holton widespread its use [69].
Camptothecin isolated from the Chinese and Tibetan ornamental joy tree Decne (Camptotheca
acuminata var. rotundifolia B. M. Yang & L. D. Duan), Nyssaceae Arnott family, was discovered
in 1966 by Wall and Wani in systematic screening of natural products [70]. Although it is a
potent topoisomerase inhibitor, it was dropped in the 1970s from clinical trials because of
severe bladder toxicity [71]. But two of its semi-synthetic derivatives - topotecan and irinotecan
are used for the treatment of ovarian and small cell lung and colon-rectal cancers, respectively
[72,73]. Epipodophyllotoxines also belong to active anti-tumour agents derived from plants.
Podophyllotoxin and deoxypodophyllotoxin were obtained from the roots of American
mandrake or May apple (Podophyllum peltatum L.), Himalayan mayapple (Podophyllum emodi
Wallich ex Hook. f. & Thomson) and Chinese or Asian Mayapple (Podophyllum pleianthum L.),
respectively [74], all belongs to Berberidaceae Juss. family. Podophyllum peltatum and Podophyl‐
lum emodii were used by the Native American Tribes for the treatment of cancer including skin-
cancers. Podophyllotoxin was isolated from the rhizome in 1880 by V. Podwyssotski [75]. More
cytotoxic 4-deoxypodophyllotoxin was isolated from Cow Parsley (Anthriscus sylvestris L.) and
Korean pasque flower (Pulsatilla koreana Y.Yabe ex Nakai). Although native epipodophyllo‐
toxines are not used but its synthetic analogues - etoposide and teniposide, which belongs to
topoisomerase II inhibitors, are effective in the treatment of lymphomas and bronchial and
testicular cancers [65,76]. Another example is bruceantin isolated from a tree, Brucea antidy‐
senterica Mill from Simaroubaceae DC family, used traditionally for the tumour treatment in
Ethiopia [77]. Recently it was discovered that bruceantin can be an effective agent for the
treatment of hematological malignancies (leukaemia, lymphoma and myeloma). Its activity
has been linked with the down-regulation of a key oncoprotein. Omacetaxine mepesuccinat
(Homoharringtonine), alkaloid isolated from the Cowtail Pine called Japanese Plum Yew
(Cephalotaxus harringtonia Koch), is one more example of plant-derived anticancer agent [78,79].
Its racemate (harringtonine mixed with homoharringtonine) which induces apoptosis by
inhibition of protein synthesis, particularly Mcl-1 (induced myeloid leukemia cell differentia‐
tion protein), is used for the treatment of chronic leukaemia - acute lymphoblastic leukaemia
and chronic myelogenous leukaemia [65]. Elliptinium acetate, a derivative of ellipticine, which
was isolated from a Fijian plant Bleekeria vitensis A.C. Sm., is used for the treatment of breast
cancer [65]. Recently numerous potential anticancer compounds have been isolated from
different plants. A few of them are currently in clinical or preclinical trials but most require
further investigation. A case of considerable interest is indirubine extracted from Mu Lan
(Indigofera tinctoria L.) from Leguminosae Lindl. family called Indigo plant a main component
of traditional Chinese herbal remedy called Dang Gui Long Hui Wan used to treat chronic
myelogenous leukaemia. Synthetic agents flavopiridol derived from the indirubins - plant
alkaloid rohitukine, which was isolated from Dysoxylum binectariferum Hook. f. (Meliaceae Juss.)
[80] and roscovitine derived from olomucine, which was isolated from Raphanus sativus L.
(Brassicaceae Burnett), are respectively in Phase I and II of clinical trials [65,81] against a broad
range of cancers including leukaemia, lymphomas and solid tumours [82]. Both are belongs
Drug Discovery50
to inhibitors of cyclin-dependent kinases (Cdks), key regulatory proteins in the cell cycle. Most
recent studies indicate that drugs of the indirubin family may block brain tumour and thus
improve survival in glioblastoma. Other synthetic derivatives of indirubins (3'-monooxime
and 5-bromo) reveal comparable activity to other Cdk inhibitors and thus are promising for
drug development [83]. Unique source of indirubines are gastropod molluscs: Bolinus branda‐
ris L. and Hexaplex trunculus L. (Muricidae L.) used for over 2,500 years to obtain purplish red
dye known as “Tyrian Purple”. The 6-bromoindirubine treated as impurity to indigo dye and
its synthetic derivative show selective inhibition of glycogen synthase kinase-3 (GSK-3) [81].
The discovery of GSK-3 functions resulted in the search for its inhibitors as potential drugs
against neurodegenerative diseases, inflammation and cancer. Combretastatin isolated from
the bark of the South African “bush willow”, tree Combretum caffrum (Eckl. & Zeyh.) Kuntze
(Combretaceae Loefl. familly) [84] belongs to the most cytotoxic phytomolecules isolated so far
[85,86] and is promising in the treatment of colon, lung cancers, lymphomas and leukaemias.
Combretastatins belongs to stilbenes, which are anti-angiogenic agents, causing vascular
shutdown resulting in tumour necrosis. Combretum was widely used in African and Hindu
medicine for the treatment of a variety of diseases, but Terminalia L. flowering plant from the
same family Combretaceae Loefl., have been used traditionally for cancer treatment. Another
promising stilbene is trans-Resveratrol natural phenol produced by several plants (eg. Vitis
vinifera L., Vitis labrusca L., Vitis rotundifolia Michx.), when under attack by pathogens (bacteria
or fungi like Botrytis cinerea (De Bary) Whetzel). It was extracted from False Helleborine
(Veratrum Album L.) by Michio Takaoka in 1939. More than 60 years later in 1997, Ming-Hua
Jang reported that trans-Resveratrol prevented skin cancer development in mice treated with
a carcinogen, which gain attention to its potential anticancer applications. It was shown that
trans-Resveratrol acts on all steps of the process of carcinogenesis [87]. It triggered apoptosis
in uterine, colon cancer cell line, colon, human breast, prostate, lung cancer and pancreatic
cancer cell lines in vitro, but is also able to arrest the cell cycle or to inhibit kinase pathways.
The inhibition in the development of oesophageal, intestinal, and breast cancer after oral
administration of resveratrol was revealed in studies on animal models. The human clinical
trials for cancer have not been reported. A few promising substances betulinic acid, lupeol
have been obtained from white part of Betula species (Betulaceae Gray) bark. The alcohol
precursor of betulinic acid - betulin - was isolated as long ago as in 1788 by Tobias Lowitz
(1757-1804). Betulinic acid, a pentacyclic triterpene, is a common secondary metabolite of
plants, it was isolated also from Ziziphus zizyphus L. H. Karst. species, e.g. Ziziphus Mauriti‐
ana Lam., Ziziphus Rugosa Lam. and Ziziphus Oenoplia (L.) Mill. [88,89], while lupeol was found
in a variety of plants, including mango (Mangifera L.) and acacia visco (Acacia visite Griseb.).
All of them are potent anti-inflammatory agents and displayed selective cytotoxicity against
human melanoma cell lines [90]. A case of considerable interest is birch polypore fungus Chaga
(Inonotus obliquus Pers. Pill.), which belongs to Basidiomycetes R.T. Moore. It forms black
perennial woody growth called a conk on birch trees. It is traditionally used in Russia for the
treatment of a number of conditions including cancer, gastritis and ulcers. Two phenolic
compounds, hispidin and hispolon extracted from Chaga but also from Japan, Chinese and
Korean medicinal fungus Phellinus linteus (Japanese meshimakobu, Chinese song gen, Korean
sanghwang) were reported to be cytotoxic against human cell line HeLa [91], while the poly‐
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saccharides ß (1→3)-D glucopyrans and ß (1→6)-D-glucosyl, found also in ornamental plant
Pteris ensiformis Burm., originating from tropical Africa, Asia and Pacific region, have prom‐
ising anticancer activity against a number of different cell lines.
Claims for another efficient plant derivative - Tabebuia Gomes (Bignoniaceae Juss.) used
traditionally by the indigenous people in the Amazonian region for the treatment of variable
diseases, appeared in the 1960s. Numerous bioactive compounds including naphthaquinones,
particularly lapachol and ß-lapachone have been isolated from the stem bark and wood of
Tabebuia impetiginosa (Mart. Ex DC.) Standl., Tabebuia rosea Bertol., and Tabebuia serratifolia
(Vahl) Nicholson. Lapachol revealed potent in vivo anti-tumour activity, but was dropped out
because of unacceptable level of toxicity [92]. ß-lapachone was recently found active against
breast cancer, leukaemia, prostate tumour and several multidrug resistant (MDR) cell lines
and more promising than lapachol [93]. It is a potent inhibitor of Cdc25 phosphatases enzyme
that play a key role in cell cycle progression [83]. Another potent and promising in the field of
MDR is pervilleine A, aromatic ester tropane, selectively cytotoxic against oral epidermoid
cancer cell line which was isolated from the roots of the Madagascar tree Erythroxylum
pervillei Baill. from Erythroxylaceae Kunth family [94,95]. In the early 1970s another plant
originated substance, maytansine was isolated from the Ethiopian plant, Maytenus serrata
(Hochst. Ex A. Rich.) Wilczek from Celastraceae R. Br. family. Although the results of preclinical
animal tests were very promising but the lack of efficacy in clinical trials in the early 1980s
resulted in dropping it out from further study. However, related compounds, the ansamito‐
cins, isolated from actinomycete Actinosynnema pretiosum shed some light on its possible
microbial origin [96]. Its synthetic derivative - cytotoxic Mertansine is a component of human‐
ized monoclonal antibodies: Cantuzumab mertansine, Bivatuzumab mertansine, Lorvotuzu‐
mab mertansine and Trastuzumab emtansine effective in colorectal, squamous cell carcinoma,
small-cell lung or ovarian cancer and breast cancer, respectively. Another case of considerable
interest is thapsigargin isolated from the umbelliferous plant, Thapsia garganica L. (Apiaceae
Lindl.) from Mediterranean island of Ibiza [97]. Thapsigargin, induces apoptosis in prostate
cancer cells and synthetic prodrug derived from it called "G-202" is in Phase II clinical trials.
Silvestrol isolated from the fruits of Aglaila sylvestre Roemer from Meliaceae Juss. family [98],
exhibit cytotoxicity against lung and breast cancer cell lines [65]. Its synthetic analogue 4′-
desmethoxyepisilvestrol is cytotoxic against lung and colon cancer cell lines. Two alkaloids,
schischkinnin and montamine isolated recently from the seeds of Centaurea schischkinii Tzvelev
and Centaurea montana L. [99,100] exhibit significant cytotoxicity against HCCLs (human colon
cancer cell lines). The essential oil of Salvia officinalis L., most popular folk remedy in Middle
East known for its antitumor effects, which contains monoterpenes thujone, β-pinene, and 1,8-
cineol was shown to be cytotoxic against squamous human cell carcinoma cell line of the oral
cavity [101]. There are many other natural substances like extracts of unknown composition
from Colubrina macrocarpa (Cav.) G. Don., Hemiangium excelsum (Kunth) A.C. Sm, Acacia
pennatula (Schltdl. & Cham.) Benth., Commiphora opobalsamum Jacq., Astragalus L., Paris
polyphylla Sm., Teucrium polium L., Pistacia lentiscus L. used as anticancer remedies on folk
medicine in China, Israel, Plestina, Saudi Arabia etc.
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In general, over 120 currently prescribed drugs including anticancer ones being the basis of
modern chemotherapy were first extracted from plants. About 60% of the anticancer drugs
available prior to 1983 were of natural origin [65]. As much as 40% of anticancer drugs
developed from 1940 to 2002 had natural or natural-product origins, while another 8% were
natural-product mimics. Although nowadays about 300,000 different plant species are known
but less than 5,000 have been studied for their potential drug usefulness. Since 1989, the
National Cancer Institute (NCI) has screened up to 10,000 potential anticancer agents per year
including minerals, exotic plants from tropical rain forests and animal venoms and toxins.
Animal venoms and toxins which has been used as therapeutics in ancient Ayurvedic, Unani,
Chinese folk medicine as well as in Homeopathy are also screened. Venoms of snakes,
scorpions, toads, frogs and their derivatives protein or non-protein toxins, peptides, enzymes
are promising and show some potential in cancer treatment. Léon Charles Albert Calmette
(1863-1933) a French physician, bacteriologist and immunologist, was the first to describe an
antitumor effect of the venom of Indian cobra Naja naja sp. on adenocarcinoma cells. Thereafter
many reports have established the anticancer potential of venoms of different species of
Elapidae, Viperidae, Crotalidae snakes [102-107] and Hydrophis spimlis sea snake [108,109]
and assigned it to phospholipase activity. Scorpions venom has been used by traditional and
folk medicine in India, China, Africa and Cuba. Chinese red scorpion (Buthus martensi Karsch)
venom and skin extracts, known as Chan Su in China and Senso in Japan, have been used by
traditional Chinese medicine for as long as 2000 years also as anti-leukaemia agents. 4',6-
diamidino-2-phenylindole extracted from Buthus martensi Karsch induced cell apoptosis in
malignant glioma cells in vitro [110], while serine proteinase and hylauronidase have prom‐
ising anticancer activity against a number of different cell lines including breast ones [111].
Bengalin protein isolated from Hindu black scorpion is suspected to have anti-leukemic
properties [112]. Chlorotoxin and Charybdotoxin, 36- and 37-amino acid peptides, respectively
isolated from the venom of death stalker scorpion (Leiurus quinqestriatus Hebraeus) are
promising for the treatment of several types of cancers including glioma and human breast
cancer [113,114]. The anticancer effect of the venom of Cuba red scorpions (Rhopalurus
junceus) was discovered 20 years ago in Guantanamo, but after 15 years of studies Vidatox
drug was announced in 2011. The skin extract from Hindu toads (Bufo melanostictus, Bufo
gargarizans Cantor), Chan Su used by Chinese traditional medicine, was discovered to contain
a few bufadineolides showing specific activity against human leukemic, liver carcinoma and
melanoma cell lines. Species belonging to the families Bufonidae (toads), Lampyridae (fireflies)
and Colubridae (snakes) as well as mammalian tissues contain bufadienolides, but the richest
source of them are toad species. Although all the bufadienolides showed potent cytotoxicity
in vitro, but the evidence of their activity in vivo is limited to human hepatocellular carcinoma
and HeLa human cancer cells in mice and require further investigation.
Some hope rises with the use of minerals as a source of anticancers drugs. Most important
example is sodium bicarbonate, NaHCO3, which was originally derived from Nahcolite
(thermokalite) carbonate mineral. The ancient Egyptians used natural natron, a mixture of
sodium carbonate decahydrate, and sodium bicarbonate as a soap and embalming tool.
Recently it has been shown that sodium bicarbonate administered orally causes a selective
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increase in the pH of tumour and reduces the formation of spontaneous metastases in mouse
models of metastatic breast cancer [115,116]. Another interesting case is selenite known since
ancient times but recently revealed as a promising anticancer agent capable of inducing
apoptosis in malignant mesothelioma and sarcoma cells [117].
As yet none of the new natural venom, toxin or minerals derived anticancer agents have
reached the status of the clinical drug, but a number of agents are still in study or in preclinical
development.
4.2. Synthetic drugs
The first steps toward chemical synthesis of drugs were undertaken by iatrochemistry, a
branch of chemistry and medicine concerned with seeking chemical solutions to diseases and
ailments. Paracelsus pioneered the use of chemicals and minerals in medicine. He introduced
alcohol, arsenic, copper, lead and silver salts into medicine, and developed rules for drug
administration and dosages of drugs. Paracelsus also devised methods of extracting the
arcanum (active ingredient) from plant materials. For this reason he is considered to be the
father of phytochemistry and pharmacognosy. Ehrlich, the father of chemotherapy, developed
the animal model to screen a series of chemicals for their potential activity against diseases,
which had a major influence on the direction of cancer drug development. He also studied the
usability of aniline dyes and the first primitive alkylating agents in cancer treatment. The first
overall cancer treatment programme was the work of another pioneer of modern chemother‐
apy - George Clowes (1915-1988). He developed the first transplantable carcinogen-induced
tumour systems in mice, which allowed the standardization of models for cancer drug testing.
These early model systems including Sarcoma 37 (S37), Sarcoma 180 (S180), Walker 256, and
Ehrlich's ascites tumour have been used for several decades [118]. In 1935 Murray Shear
developed the most organized program for cancer drug screening. About 3,000 compounds
including natural ones, were screened with S37 as a model system. The reason for the failure
of this first systematic attempt to search for anticancer drugs - only two drugs have been
subjected to clinical trials, but finally dropped because of unacceptable toxicity - was the lack
of knowledge on how to test cytotoxic effects in humans. An extension of the number of tumour
systems available for studies by the Yoshida’s ascites sarcoma model and a murine leukaemia
induced by a carcinogen, Leukaemia 1210, described by Lloyd Law allowed fast progress.
4.3. Cell Cycle Non Specific Agents (CCNSA)
4.3.1. Alkylating agents
The first real breakthrough in the search for chemotherapeutics was the chemical synthesis of
nitrogen mustards [4,119]. Sulphur mustard was synthesised much earlier, in 1822, but its
harmful effects were not known until 1860. It was first used as chemical warfare weapon agent
during the latter part of the First World War but its therapeutic activity against squamous cell
carcinoma was discovered by accident. In fact most of the first so-called true synthetic
chemotherapeutics, were discovered by serendipity, the special term Serendipity for accidental
discoveries was introduced by Horace Walpole (1717-1797) in the 18th c. Nitrogen mustard, an
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analogue of the highly toxic sulphur mustard gas, was introduced in 1942 as the first alkylating
agent and a true chemotherapeutic. Alfred G. Gilman, Louis S. Goodman and Thomas
Dougherty, examined the potential therapeutic effects of nitrogen mustard in rabbits and mice
bearing a transplanted lymphoid tumour, while Gustaf E. Lindskog (1903-2002), a thoracic
surgeon, administered it to patients with non-Hodgkin's lymphoma. Many cases of cancer
regression succeed intensive screening of related alkylating compounds and discovery of
busulphan by L.A. Elson, G.M. Timmis, and David A. G. Galton (1922-2006) in 1951, Chlor‐
ambucil by James Everatt in 1953, melphalan by Frank Bergel and John Stock in 1954, Cyclo‐
phosphamide by Herbert Arnold, Friedrich Bourseaux and Norbert Brock in 1956, Lomustine
and Carmustine by John A. Montgomery, George S. McCaleb, Thomas P. Johnston in 1966.
While many different classes of alkylating agents (nitrogen mustards, nitrosoureas, alkyl
sulphonates, triazines, and ethylenimines) are known, the chemical mechanism of their action
is common and based on three different mechanisms all of which achieve the same end result
- disruption of DNA function and apoptosis. The first mechanism of DNA alkylation results
in its fragmentation by repair enzymes to prevent DNA synthesis and RNA transcription from
the affected DNA. The second mechanism is the formation of intrastrand or interstrand cross-
links by an alkylating agent, which prevents DNA from being separated for synthesis or
transcription. The third mechanism of action is the induction of mispairing of the nucleotides,
which leads to mutations, even permanent ones.
Alkylating agent acts on a cancer cell in every phase of its life cycle, Fig. 2, thus can be used in
the treatment of a wide range of cancers from various solid tumours to leukaemia. However
strong adverse effect is their ability to induce secondary cancers, which is reflected by their
classification as definite carcinogens by IARC [3].
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Figure 2. Cell replication occurs in the cell cycle (G0, G1, S, G2 and M). The cell cycle nonspecific agents (alkylating
agents, platinum compounds, cytotoxic antibiotics) are able to kill a cell during any phase of the cycle, while cell cycle
specific (antimetabolites, antifoliates, planta alkaloids, some cytotoxic antiniotics line bleomycin) are only able to kill
only during a specific phase.
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A number of cytotoxic antibiotics that have been derived from natural sources such as gram-
positive bacteria in soil and water, belonging to genus Streptomyces (phylum Actinobacteria)
[4,119]. They produce secondary metabolites, many of which have been successfully isolated
and used as antifungals, antibiotics and anticancer drugs. The large-scale screening of
fermentation products by the pharmaceutical industry which resulted in the discovery of
antibiotics to treat wound infections is one more example of finding anticancer drugs by
serendipity. Although penicillin, which was the basic compound for the above mentioned
studies has no antitumor properties itself, but the chromo oligopeptide actinomycin D, isolated
from Streptomyces antibioticus by Selman Abraham Waksman (1888-1973) and Boyd Woodruff
in the 1940s as a result of search for drugs to treat tuberculosis, has significant antitumor
properties and was applied in the 1950/1960s in paediatric oncology. This antibiotic was
approved by the U.S. Food and Drug Administration (FDA) in 1964. In 1950, the search for
anticancer compounds from soil-based microbes in the area of Castel del Monte, Italy, resulted
in the discovery of an antibiotic - Daunorubicin (red pigment) - independently by Aurelio di
Marco, Arpad Grein and Celestino Spalla from bacterium Streptomyces peucetius and by M.
Dubost from Streptomyces caeruleorubidus. It was found to be active against murine tumours
(Yoshida sarcoma). Although clinical trials which began in the 1960s suggested its significant
activity against acute leukaemia and lymphoma, but shortly after, in 1967, it was recognized
that daunorubicin had significant cardiac toxicity. In general, many antibiotics produced by
Streptomyces are too toxic for use as antibiotics in humans, but their activity towards specific
cells lines makes them useful in chemotherapy. The search for more effective antitumor
antibiotics over 2,000 analogues of slightly modified structures yielded in a series of com‐
pounds, some of which are in common use till today. In 1969, Federico Arcamone developed
a derivative of Doxorubicin which in the same year was tested against animal tumours by di
Marco. Daunroubicin and Doxorubicin belongs to inhibitors of the topoisomerase II, one of
two enzymes that regulate overwinding/underwinding of DNA. Inhibition of the topoiso‐
merase II block cleavage of both strands of the DNA which ultimately leads to cell death. An
important antibiotic of a wide spectrum of anticancer activity is Mitomycin C isolated from
Streptomyces caespitosu in 1955 and Streptomyces lavendulae in 1958 and clinically used since the
first successful trials against childhood leukaemia reported by Charlotte Tan in 1965. Mito‐
mycin C belongs to bifunctional alkylating agents, whose biological activity mode is DNA
alkylation and cross-linking. It has a broad activity against a range of tumours. In 1966 Hamao
Umezawa discovered an important unique antibiotic in this group - bleomycin - a glycopeptide
showing anticancer activity, while screening a culture filtrates of Streptomyces verticullus.
Bleomycin is used to treat many types of cancer, including testicular cancer, non Hodgkin’s
lymphoma, Hodgkin’s lymphoma and cancers of the head and neck. Anticancer antibiotics,
apart from Bleomycin, act on a cancer cell in every phase of its life cycle and prevent cell
divisions, but Bleomycin is considered as cell cycle agent specifically working in G2 and M
phase, Fig. 2. However, the risk connected with the use of cytotoxic antibiotics classified as
group 2 or 3 agent in IARC classification is smaller than that related to alkylating agents [3].
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4.3.3. Platinum compounds
Cisplatin was synthesized in 1845 but its potential as an antitumour agent was not recognized
until 1965 when its capabilities were discovered by Barney Rosenberg, Loretta van Camp and
Thomas Krigas. The inhibition of growth caused by platinum complex of ammonia and
chloride (Peyrone's salt i.e. Cis-platinum) was discovered by serendipity during the studies of
the influence of electric current on bacterial growth. The positive result during the studies of
murine tumours in vivo confirmed its antitumor activity and prompted the studies of other
compounds from this class [4,56,119]. It was introduced into clinical practice one decade later
in the 1970s [120]. By 1978 about 1,000 platinum complexes had been screened, but only seven
were selected for detailed pharmacological evaluation on rats and only two - Carboplatin and
Oxaliplatin - were non-toxic at effective antitumour dose. Although Cisplatin belongs to three
most commonly used chemotherapeutics, progress made to improve its use since its discovery
is in fact limited. The mechanism of action of Cisplatin and other platinum compounds
resemble that of the alkylating agents. They interact covalently with DNA and form intrastrand
(within the same DNA molecule; >90%) or interstrand (between two different DNA molecules;
<5%), cross links between adjacent guanine molecules [121]. The formation of DNA adducts
results in an inhibition of DNA synthesis and transcription. Platinum compounds act on a
cancer cell in every phase of its life cycle, Fig.2. Their use is widespread and includes the
treatment of bladder and colorectal cancer, upper gastrointestinal disease, germ cell tumours,
head and neck malignancies, lung and ovarian cancer. Their ability to induce secondary
cancers reflected by their classification as definite carcinogens by IARC is high [3].
4.4. Cell Cycle Specific Agents (CCSA)
4.4.1. Antifolates
Antimetabolites (folic acid, pyrimidine or purine analogues), which structurally resemble
naturally occurring molecules necessary for DNA and RNA synthesis and either inhibit
enzymes needed for nucleic acid production or induce apoptosis during the S phase of cell
growth, Fig. 2, were among the first effective chemotherapeutics discovered. In the early 1940s,
Sidney Faber (1903–1973) studied the effect of folic acid (pteroylglutamic acid; Vitamin B9)
first isolated from spinach leaves. In 1945, Rudolf Leuchtenberger reported that folic acid
inhibited tumour growth in mice, while Richard Lewisohn reported complete regression of
spontaneous breast in mice observed with folic acid. Farber, Robert D. Heinle, and Arnold D.
Welch tested folic acid in leukaemia and concluded spuriously that deficiency of Vitamin B9
accelerates leukaemia cell growth. Efforts to treat leukaemia resulted in pharmacological folic
acid analogues with effects antagonistic to those of Vitamin B9. Shortly after Sidney Farber
and Harriet Kilte developed a series of foliate antagonists including highly active aminopterin
(4-amino-pteroylglutamic acid). Its analogue 4-amino-4-deoxy-10-N-methyl-pteroylglutamic
acid, known nowadays as Methotrexate, was discovered by Yellapragada Subbarao
(1895-1948) and successfully applied by Sidney Farber in 1947 to induce remissions in children
with leukaemia. In 1958 Min Chiu Li, reported fully effective treatment of a very rare tumour
of the placenta, choriocarcinoma with Methotrexate, which was the first-ever intentionally




A number of cytotoxic antibiotics that have been derived from natural sources such as gram-
positive bacteria in soil and water, belonging to genus Streptomyces (phylum Actinobacteria)
[4,119]. They produce secondary metabolites, many of which have been successfully isolated
and used as antifungals, antibiotics and anticancer drugs. The large-scale screening of
fermentation products by the pharmaceutical industry which resulted in the discovery of
antibiotics to treat wound infections is one more example of finding anticancer drugs by
serendipity. Although penicillin, which was the basic compound for the above mentioned
studies has no antitumor properties itself, but the chromo oligopeptide actinomycin D, isolated
from Streptomyces antibioticus by Selman Abraham Waksman (1888-1973) and Boyd Woodruff
in the 1940s as a result of search for drugs to treat tuberculosis, has significant antitumor
properties and was applied in the 1950/1960s in paediatric oncology. This antibiotic was
approved by the U.S. Food and Drug Administration (FDA) in 1964. In 1950, the search for
anticancer compounds from soil-based microbes in the area of Castel del Monte, Italy, resulted
in the discovery of an antibiotic - Daunorubicin (red pigment) - independently by Aurelio di
Marco, Arpad Grein and Celestino Spalla from bacterium Streptomyces peucetius and by M.
Dubost from Streptomyces caeruleorubidus. It was found to be active against murine tumours
(Yoshida sarcoma). Although clinical trials which began in the 1960s suggested its significant
activity against acute leukaemia and lymphoma, but shortly after, in 1967, it was recognized
that daunorubicin had significant cardiac toxicity. In general, many antibiotics produced by
Streptomyces are too toxic for use as antibiotics in humans, but their activity towards specific
cells lines makes them useful in chemotherapy. The search for more effective antitumor
antibiotics over 2,000 analogues of slightly modified structures yielded in a series of com‐
pounds, some of which are in common use till today. In 1969, Federico Arcamone developed
a derivative of Doxorubicin which in the same year was tested against animal tumours by di
Marco. Daunroubicin and Doxorubicin belongs to inhibitors of the topoisomerase II, one of
two enzymes that regulate overwinding/underwinding of DNA. Inhibition of the topoiso‐
merase II block cleavage of both strands of the DNA which ultimately leads to cell death. An
important antibiotic of a wide spectrum of anticancer activity is Mitomycin C isolated from
Streptomyces caespitosu in 1955 and Streptomyces lavendulae in 1958 and clinically used since the
first successful trials against childhood leukaemia reported by Charlotte Tan in 1965. Mito‐
mycin C belongs to bifunctional alkylating agents, whose biological activity mode is DNA
alkylation and cross-linking. It has a broad activity against a range of tumours. In 1966 Hamao
Umezawa discovered an important unique antibiotic in this group - bleomycin - a glycopeptide
showing anticancer activity, while screening a culture filtrates of Streptomyces verticullus.
Bleomycin is used to treat many types of cancer, including testicular cancer, non Hodgkin’s
lymphoma, Hodgkin’s lymphoma and cancers of the head and neck. Anticancer antibiotics,
apart from Bleomycin, act on a cancer cell in every phase of its life cycle and prevent cell
divisions, but Bleomycin is considered as cell cycle agent specifically working in G2 and M
phase, Fig. 2. However, the risk connected with the use of cytotoxic antibiotics classified as
group 2 or 3 agent in IARC classification is smaller than that related to alkylating agents [3].
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4.3.3. Platinum compounds
Cisplatin was synthesized in 1845 but its potential as an antitumour agent was not recognized
until 1965 when its capabilities were discovered by Barney Rosenberg, Loretta van Camp and
Thomas Krigas. The inhibition of growth caused by platinum complex of ammonia and
chloride (Peyrone's salt i.e. Cis-platinum) was discovered by serendipity during the studies of
the influence of electric current on bacterial growth. The positive result during the studies of
murine tumours in vivo confirmed its antitumor activity and prompted the studies of other
compounds from this class [4,56,119]. It was introduced into clinical practice one decade later
in the 1970s [120]. By 1978 about 1,000 platinum complexes had been screened, but only seven
were selected for detailed pharmacological evaluation on rats and only two - Carboplatin and
Oxaliplatin - were non-toxic at effective antitumour dose. Although Cisplatin belongs to three
most commonly used chemotherapeutics, progress made to improve its use since its discovery
is in fact limited. The mechanism of action of Cisplatin and other platinum compounds
resemble that of the alkylating agents. They interact covalently with DNA and form intrastrand
(within the same DNA molecule; >90%) or interstrand (between two different DNA molecules;
<5%), cross links between adjacent guanine molecules [121]. The formation of DNA adducts
results in an inhibition of DNA synthesis and transcription. Platinum compounds act on a
cancer cell in every phase of its life cycle, Fig.2. Their use is widespread and includes the
treatment of bladder and colorectal cancer, upper gastrointestinal disease, germ cell tumours,
head and neck malignancies, lung and ovarian cancer. Their ability to induce secondary
cancers reflected by their classification as definite carcinogens by IARC is high [3].
4.4. Cell Cycle Specific Agents (CCSA)
4.4.1. Antifolates
Antimetabolites (folic acid, pyrimidine or purine analogues), which structurally resemble
naturally occurring molecules necessary for DNA and RNA synthesis and either inhibit
enzymes needed for nucleic acid production or induce apoptosis during the S phase of cell
growth, Fig. 2, were among the first effective chemotherapeutics discovered. In the early 1940s,
Sidney Faber (1903–1973) studied the effect of folic acid (pteroylglutamic acid; Vitamin B9)
first isolated from spinach leaves. In 1945, Rudolf Leuchtenberger reported that folic acid
inhibited tumour growth in mice, while Richard Lewisohn reported complete regression of
spontaneous breast in mice observed with folic acid. Farber, Robert D. Heinle, and Arnold D.
Welch tested folic acid in leukaemia and concluded spuriously that deficiency of Vitamin B9
accelerates leukaemia cell growth. Efforts to treat leukaemia resulted in pharmacological folic
acid analogues with effects antagonistic to those of Vitamin B9. Shortly after Sidney Farber
and Harriet Kilte developed a series of foliate antagonists including highly active aminopterin
(4-amino-pteroylglutamic acid). Its analogue 4-amino-4-deoxy-10-N-methyl-pteroylglutamic
acid, known nowadays as Methotrexate, was discovered by Yellapragada Subbarao
(1895-1948) and successfully applied by Sidney Farber in 1947 to induce remissions in children
with leukaemia. In 1958 Min Chiu Li, reported fully effective treatment of a very rare tumour
of the placenta, choriocarcinoma with Methotrexate, which was the first-ever intentionally
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discovered synthetic anticancer drug i.e. first true chemotherapeutic. Starting from the 1950s,
Methotrexate has replaced the more toxic aminopterin and is still in widespread clinical use.
In general folate antagonists mechanism of action is linked with competing with folates for
uptake into cells and inhibition of the formation of folate co-enzymes or reactions that are
mediated by them. Only one of those mechanisms is clinically important, it is the prevention
of formation of tetrahydrofolate by inhibition of the enzymes: dihydrofolate reductase (DHFR)
or thymidylate synthase (TS). Methotrexate inhibits only DHFR, while a new-generation
antifolate Pemetrexed developed by Edward C. Taylor in 1992 inhibits DHFR, TS and also
transformylases (GAR and AICAR), but primarily acts as a TS inhibitor. Thus both act similarly
by hindering enzymes needed for de novo synthesis of the thymidine and purine nucleotides
but show different spectrum of activity. Methotrexate is effective mainly in the treatment of
leukaemia, lymphoma and choriocarcinoma but also cancers of breast, head and neck,
colorectal, osteosarcoma and bladder, while Pemetrexed is approved for the treatment of
mesothelioma and non–small cell lung cancer, active in solid tumours treatment, especially
those drug resistant. The risk connected with the use of Methotrexate classified as group 3
agent in IARC classification is smaller than that of alkylating agents [3].
4.4.2. Antimetabolites
The discovery of nitrogen mustard and Methotrexate and their success in medical applications
was a breakthrough and stimulated the search for the other antimetabolites as well as new
classes of cell cycle specific synthetic anticancer drugs [4,56,119]. In 1944, Richard O. Roblin
and James W. Clapp synthesised 8-azaguanine (8-AZA), while 5 years later George W. Kidder
and Virginia C., reported that 8-AZA was a guanine antagonist in the metabolism of Tetrahy‐
mena geleii (S) (Colpidium campylum L.) and inhibited the growth of transplanted mammary
adenosarcoma in mice. Since 1944, George Herbert Hitchings (1905-1998) and Gertrude Belle
Elion (1918-1999) have investigated the role of purines in nucleic acid metabolism and methods
to prevent them from being incorporated to DNA synthesis along the metabolic pathway that
would lead to interruption of cell reproduction. By the early 1950s, Hitchings & Elion synthe‐
sized more than 100 purine analogues including 2,6-diaminopurine, 6-thioguanine (6-TG), 6-
mercaptopurine (6-MP) and Azathioprine (AZA) as a result of their rational approach to drug
development. 6-TG, 6-MP and AZA although categorized as growth inhibitory antimetabo‐
lites, exert their functions more like a genotoxic methylating agents, such as alkylating drug
Temozolomide, which methylates DNA. 6-MP, one of the early analogues, is widely used not
only for acute leukaemias but also in gout and herpes viral infections, and as immunosup‐
pressive agents in the organ transplantations, 6-TG is predominantly used as antileukaemic
agent, while AZA as an immunosuppressive. The discovery of a few purine analogues
Fludarabine (FLU), Cladribine (2CDA), and Pentostatin (DCF) was a result of further targeted
studies performed within a NIH programme. Fludarabine discovered by John Montgomery
and Kathleen Hewson in 1968 was the first halogenated ribonucleotide reductase inhibitor, a
new-generation pro-drug of the purine class successfully used in treating refractory chronic
lymphocytic and chronic B cell leukaemias, non-Hodgkin’s lymphoma and T-cell lymphoma.
Cladribine, resembling deoxyadenosine and remarkably active in hairy cell leukaemia was
synthesised in 1972 by L.F. Christensen, A. Broom, M.J. Robins, and A.J. Bloch and in 1978
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selected by Dennis A. Carson as the most potent enzyme adenosine deaminase (ADA) inhibitor
from many candidate congeners. Pentostatin, which also inhibits ADA and similarly to 2CDA
is active in hairy cell leukaemia and chronic lymphocytic leukaemia was synthesised by Hollis
D.H. Showalter and David C. Baker in 1983. Recently, three new purine antimetabolites
nerlabine, clofarabine, and forodesine have been found highly promising. Although these
compounds belong to purine antimetabolites and reveal activity against specific types of
leukaemia, they differ in metabolic properties and mechanism of action. As long ago as in 1964
Elmer Reist and Leon Goodman synthesized 9-β-Darabinofuranosyl guanine (ara-G), which
despite of its antitumor properties in in-vitro canine leukaemia models evaluated by Elion &
Kurtzberg was rejected because of inadequate solubility. In 1988, nelarabine, the 6-methoxy
derivative of Ara-G, which is 10-fold more soluble than Ara-G, was synthesized by Thomas
A. Krenitsky. In 2012, 48 years after synthesis of Ara-G, Nelarabine entered phase II of clinical
studies with indication to T-cell acute lymphoblastic leukaemia or T-cell lymphoblastic
lymphoma treatment. Clofarabine, a hybrid of Fludarabine and Cladribine, was synthesised
by Mongomery in 1992. It also recently entered phase II of clinical studies with indication as
antileukemic agent active in acute lymphoblastic leukaemia as well as in myeloid disorders in
paediatrics. The third intensively studied purine antimetabolite is forodesine, synthesised by
Peter C. Tyler and Vern L. Schramm in 1998. Forodesine, which is not incorporated into DNA
and has unexplored mechanism of action is effective for the treatment of relapsed B-cell chronic
lymphocytic leukaemia.
In the 1950s Robert Duschinsky synthesised the first pyrimidine analogue, 5-fluorouracil (5-
FU). His discovery was based on the observation of the role of greater uptake of uracil in rat
hepatoma metabolism, thus it was the first known case of “targeted” studies. 5-FU introduced
into the clinic in 1957 by Charles Heidelberger has broad-spectrum activity against non-
hematologic cancers, thus is now widely applied for treatment of many kinds of solid tumours
of breast, head and neck, adrenal, pancreatic, gastric, colon, rectal, oesophageal, liver and G-
U (bladder, penile, vulva, prostate). Even nowadays, 5-FU apart of its analogue Floxuridine,
remains a fundamental drug in the treatment of colorectal cancer. Discovery of 5-FU was not
only the first example of targeted studies but also the first targeted therapy, which later
attracted much attention in current cancer drug development. However, the target in this case
was understood not as a molecular target but as a biochemical pathway. In 1950 two spongo-
nucleosides (spongouridine and spongothymidine) were isolated by Werner Bergman and
Robert Feeney from a Caribbean sponge Cryptotethya crypta. It inspired Richard Walwick,
Walden Roberts, and Charles Dekker to synthesise Cytarabine and Vidarabine in 1959. In 1964,
John Evans tested activity of Cytarabine using in-vitro murine S180 model while four years
later Rose Ruth Ellison introduced it into clinic for the B-cell leukaemia treatment. Cytarabine
is effective in acute non-lymphocytic, lymphocytic, myelogenous, chronic myelocytic leukae‐
mias, as well as leptominingeal carcinomatosis and non-Hodgkin’s lymphoma, Other pyri‐
midine antagonists include Capecitabine, which is an oral 5-FU pro-drug adjuvant in colon
and breast metastasis therapy, Gemcitabine which is a prodrug of Cytarabine, effective in
pancreatic, metastatic breast, bladder, ovarian and non-small cell lung cancers and Decitabine,
used in myeloplastic syndrome. The antimetabolites of purines and pyrimidine compounds
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discovered synthetic anticancer drug i.e. first true chemotherapeutic. Starting from the 1950s,
Methotrexate has replaced the more toxic aminopterin and is still in widespread clinical use.
In general folate antagonists mechanism of action is linked with competing with folates for
uptake into cells and inhibition of the formation of folate co-enzymes or reactions that are
mediated by them. Only one of those mechanisms is clinically important, it is the prevention
of formation of tetrahydrofolate by inhibition of the enzymes: dihydrofolate reductase (DHFR)
or thymidylate synthase (TS). Methotrexate inhibits only DHFR, while a new-generation
antifolate Pemetrexed developed by Edward C. Taylor in 1992 inhibits DHFR, TS and also
transformylases (GAR and AICAR), but primarily acts as a TS inhibitor. Thus both act similarly
by hindering enzymes needed for de novo synthesis of the thymidine and purine nucleotides
but show different spectrum of activity. Methotrexate is effective mainly in the treatment of
leukaemia, lymphoma and choriocarcinoma but also cancers of breast, head and neck,
colorectal, osteosarcoma and bladder, while Pemetrexed is approved for the treatment of
mesothelioma and non–small cell lung cancer, active in solid tumours treatment, especially
those drug resistant. The risk connected with the use of Methotrexate classified as group 3
agent in IARC classification is smaller than that of alkylating agents [3].
4.4.2. Antimetabolites
The discovery of nitrogen mustard and Methotrexate and their success in medical applications
was a breakthrough and stimulated the search for the other antimetabolites as well as new
classes of cell cycle specific synthetic anticancer drugs [4,56,119]. In 1944, Richard O. Roblin
and James W. Clapp synthesised 8-azaguanine (8-AZA), while 5 years later George W. Kidder
and Virginia C., reported that 8-AZA was a guanine antagonist in the metabolism of Tetrahy‐
mena geleii (S) (Colpidium campylum L.) and inhibited the growth of transplanted mammary
adenosarcoma in mice. Since 1944, George Herbert Hitchings (1905-1998) and Gertrude Belle
Elion (1918-1999) have investigated the role of purines in nucleic acid metabolism and methods
to prevent them from being incorporated to DNA synthesis along the metabolic pathway that
would lead to interruption of cell reproduction. By the early 1950s, Hitchings & Elion synthe‐
sized more than 100 purine analogues including 2,6-diaminopurine, 6-thioguanine (6-TG), 6-
mercaptopurine (6-MP) and Azathioprine (AZA) as a result of their rational approach to drug
development. 6-TG, 6-MP and AZA although categorized as growth inhibitory antimetabo‐
lites, exert their functions more like a genotoxic methylating agents, such as alkylating drug
Temozolomide, which methylates DNA. 6-MP, one of the early analogues, is widely used not
only for acute leukaemias but also in gout and herpes viral infections, and as immunosup‐
pressive agents in the organ transplantations, 6-TG is predominantly used as antileukaemic
agent, while AZA as an immunosuppressive. The discovery of a few purine analogues
Fludarabine (FLU), Cladribine (2CDA), and Pentostatin (DCF) was a result of further targeted
studies performed within a NIH programme. Fludarabine discovered by John Montgomery
and Kathleen Hewson in 1968 was the first halogenated ribonucleotide reductase inhibitor, a
new-generation pro-drug of the purine class successfully used in treating refractory chronic
lymphocytic and chronic B cell leukaemias, non-Hodgkin’s lymphoma and T-cell lymphoma.
Cladribine, resembling deoxyadenosine and remarkably active in hairy cell leukaemia was
synthesised in 1972 by L.F. Christensen, A. Broom, M.J. Robins, and A.J. Bloch and in 1978
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selected by Dennis A. Carson as the most potent enzyme adenosine deaminase (ADA) inhibitor
from many candidate congeners. Pentostatin, which also inhibits ADA and similarly to 2CDA
is active in hairy cell leukaemia and chronic lymphocytic leukaemia was synthesised by Hollis
D.H. Showalter and David C. Baker in 1983. Recently, three new purine antimetabolites
nerlabine, clofarabine, and forodesine have been found highly promising. Although these
compounds belong to purine antimetabolites and reveal activity against specific types of
leukaemia, they differ in metabolic properties and mechanism of action. As long ago as in 1964
Elmer Reist and Leon Goodman synthesized 9-β-Darabinofuranosyl guanine (ara-G), which
despite of its antitumor properties in in-vitro canine leukaemia models evaluated by Elion &
Kurtzberg was rejected because of inadequate solubility. In 1988, nelarabine, the 6-methoxy
derivative of Ara-G, which is 10-fold more soluble than Ara-G, was synthesized by Thomas
A. Krenitsky. In 2012, 48 years after synthesis of Ara-G, Nelarabine entered phase II of clinical
studies with indication to T-cell acute lymphoblastic leukaemia or T-cell lymphoblastic
lymphoma treatment. Clofarabine, a hybrid of Fludarabine and Cladribine, was synthesised
by Mongomery in 1992. It also recently entered phase II of clinical studies with indication as
antileukemic agent active in acute lymphoblastic leukaemia as well as in myeloid disorders in
paediatrics. The third intensively studied purine antimetabolite is forodesine, synthesised by
Peter C. Tyler and Vern L. Schramm in 1998. Forodesine, which is not incorporated into DNA
and has unexplored mechanism of action is effective for the treatment of relapsed B-cell chronic
lymphocytic leukaemia.
In the 1950s Robert Duschinsky synthesised the first pyrimidine analogue, 5-fluorouracil (5-
FU). His discovery was based on the observation of the role of greater uptake of uracil in rat
hepatoma metabolism, thus it was the first known case of “targeted” studies. 5-FU introduced
into the clinic in 1957 by Charles Heidelberger has broad-spectrum activity against non-
hematologic cancers, thus is now widely applied for treatment of many kinds of solid tumours
of breast, head and neck, adrenal, pancreatic, gastric, colon, rectal, oesophageal, liver and G-
U (bladder, penile, vulva, prostate). Even nowadays, 5-FU apart of its analogue Floxuridine,
remains a fundamental drug in the treatment of colorectal cancer. Discovery of 5-FU was not
only the first example of targeted studies but also the first targeted therapy, which later
attracted much attention in current cancer drug development. However, the target in this case
was understood not as a molecular target but as a biochemical pathway. In 1950 two spongo-
nucleosides (spongouridine and spongothymidine) were isolated by Werner Bergman and
Robert Feeney from a Caribbean sponge Cryptotethya crypta. It inspired Richard Walwick,
Walden Roberts, and Charles Dekker to synthesise Cytarabine and Vidarabine in 1959. In 1964,
John Evans tested activity of Cytarabine using in-vitro murine S180 model while four years
later Rose Ruth Ellison introduced it into clinic for the B-cell leukaemia treatment. Cytarabine
is effective in acute non-lymphocytic, lymphocytic, myelogenous, chronic myelocytic leukae‐
mias, as well as leptominingeal carcinomatosis and non-Hodgkin’s lymphoma, Other pyri‐
midine antagonists include Capecitabine, which is an oral 5-FU pro-drug adjuvant in colon
and breast metastasis therapy, Gemcitabine which is a prodrug of Cytarabine, effective in
pancreatic, metastatic breast, bladder, ovarian and non-small cell lung cancers and Decitabine,
used in myeloplastic syndrome. The antimetabolites of purines and pyrimidine compounds
Anticancer Drug Discovery — From Serendipity to Rational Design
http://dx.doi.org/10.5772/52507
59
acts on a cancer cell in S phase of its life cycle, Fig.2 and are classified as a group 3 agents in
IARC classification.
4.4.3. Plant alkaloids
A true breakthrough in chemotherapeutics came by in the 1950s as the discovery of the activity
of plant alkaloids from Madagascar periwinkle plant Vinca rosea (Catharanthus roseus (L.) G.
Don) by Canadian scientists Robert Laing Noble, Charles T. Beer and Gordon Sloboda [56].
The vinca alkaloids extracted from Vinca rosea consist of a subset of structurally similar
compounds comprising two multiringed units, vindoline and catharanthine. Initially, they
were investigated because of putative hypoglycaemic properties, but strong marrow suppres‐
sion observed in rats and significant antileukaemic effects in vitro decided about their clinical
use shortly after the discovery of their properties, in 1959. Nowadays, vinca alkaloids are
produced synthetically and only four major ones - Vinblastine, Vincristine, Vinorelbine and
Vindesine - are in the oncological clinical use. Vinblastine is most often applied in Hodgkin’s
disease, non-Hodgkin’s lymphoma, breast cancer, and germ cell tumours, Vincristine is
effective against leukaemia and Hodgkin's, Vinorelbine has significant antitumor activity in
patients with breast cancer and antiproliferation effects on osteosarcoma, while Vindesine is
used in the treatment of leukaemia, lymphoma, melanoma, breast cancer, and lung cancer. All
vinca alkaloids have a unique mechanism of action; they bind to the microtubular proteins of
the mitotic spindle, which leads to crystallization of the microtubule and mitotic arrest or
apoptosis.
Another group of novel cytotoxic agents from plant alkaloids, taxane diterpenes, was discov‐
ered during long-term screening in the 1970s. The main compound in this class, Paclitaxel, was
the first taxane introduced into clinical practice for the treatment of recurrent ovarian cancer
metastatic, breast cancer, often in combination with Cisplatin. Nowadays, Paclitaxel is totally
synthesized, but less popular than vinca because of its poor solubility. Both plant alkaloids
vinca and taxanes are mitotic inhibitors M phase specific, Fig. 2, but they act in different ways.
Their principal mechanism of action is the disruption of microtubule function, but in contrast
to the vinca alkaloids, taxanes do not destroy mitotic spindles. The plant alkaloids are classified
as a group 3 agents in IARC classification [3].
4.4.4. Combination regimens
In 2005, conventional chemotherapeutics still made the majority of the Top 20 Cancer Thera‐
peutics. Their popularity was dictated not only by wide spectrum of activity and also long
history of use in oncology but also their key role in the multidrug treatment programs. In the
early 1960s, single alkylating agents were basic for all cancer treatment programmes. Although
the remissions were observed for example up to 25% in advanced Hodgkin's disease but they
were still incomplete and temporary. Increasing resistance of the cancer cells to classical drugs
and numerous side effects forced new strategies. After Jacob Furth and Morton Kahn discovery
that a single leukemic cell was sufficient to cause the death of an animal, Howard E. Skipper
formulated “Cell Kill” hypothesis, according to which a given dose of drug is able to kill only
a constant fraction of tumour cells. This hypothesis favoured search for more aggressive
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chemotherapeutics but also resulted in the use of drug combinations. In 1965 Emil Frei and
Emil J. Freireich developed the new treatment program for children leukaemia known as
"VAMP" (Nethotrexate, 6-MP, Vincristine and Prednisone). The use of multiple drugs:
Methotrexate, which disrupt folic-acid uptake, 6-MP which inhibits synthesis of purine, both
critical in cell division, Vincristine which interfered with cell division by binding to spindle
protein and Prednisone, anti-inflammatory steroid resulted in the remission rate level as high
as 60%. Further modifications like “MOMP” (nitrogen mustard, Vincristine, Methotrexate, and
Prednisone), “MOPP” (Procarbazine, nitrogen mustard, Vincristine, and Prednisone) and C-
MOPP (Procarbazine, Cyclophosphamide, Vincristine, and Prednisone) resulted in the 80%
complete remission rate in advanced Hodgkin's disease in the 1970s. On the basis of the above
mentioned first programs dedicated exclusively to leukaemias many modifications - e.g. four
drug EBVP (Epirubicin, Bleomycin, Vinblastine, Prednisone) and ABVD (Adriamycin,
Bleomycin, Vinblastine and Dacarbazine) and six-drug STANFORD-V (Cyclophosphamide/
Mechlorethamine/Ifosfamide, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide) -
have been developed. Nowadays, some cancer diseases like Hodgkin's or acute lymphocytic
leukaemia are curable in 90% within the modern protocols using aggressive chemotherapy
programs. Despite the reasonable position of classical chemotherapeutics in multidrug
combined regimens, their capabilities inevitably decrease because of multidrug resistance (a
major factor in the failure of many forms of treatment) and secondary effects (adverse or
paradoxically carcinogenic). Significant limitation is also the need for multiple chemotherapy
in long-term, sequential multidrug regimens and in-hospital administration.
4.4.5. Modern chemotherapeutics
At the beginning of the 20th c., Paul Ehrlich postulated the idea of a "Magic Bullet" (Zauber‐
kugel) i.e. drugs that reach directly intended cell-structural targets. To some extent this idea
is the driving force behind the development of modern targeted chemotherapeutics. Conven‐
tional chemotherapeutics are cytotoxic, but affect all cells and work in the so-called statistical
manner. Because cancer cells multiply faster than normal, the cancerous cells are killed by the
drug with a higher ratio than the normal ones, which are not spared. Therefore the principal
criterion applied in the modern anticancer drug design is the principle of selective toxicity,
which require activity restricted exclusively to the cancer cells. From the point of view of
selective activity directed on tumour cells and mechanisms of carcinogenesis, a few different
classes of modern drugs can be distinguished: inhibitors of cytokine stimulating cell prolifer‐
ation, dissociation, motility; cytokine receptor blockers; intracellular kinases inhibitors;
transcription factors inhibitors; cell cycle inhibitors; cell adhesion inhibitors and proteasome
inhibitors.
Short-lived hopes were raised in the 1990s at the discovery of the inhibitors of angiogenesis,
which hold back the growth of capillary vessels in cancer. Avastin, humanized monoclonal
antibody, discovered by Napoleone Ferrara in 1997 was the first drug from this class approved
by FDA in 2004 to use for several types of metastatic cancer, but the approval of the breast
cancer indication was revoked in 2011. Two other inhibitors of angiogenesis include Cetuxi‐
mab invented by Joseph Schlessinger, Michael Sela in 1988, approved for by FDA in 2009 to
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acts on a cancer cell in S phase of its life cycle, Fig.2 and are classified as a group 3 agents in
IARC classification.
4.4.3. Plant alkaloids
A true breakthrough in chemotherapeutics came by in the 1950s as the discovery of the activity
of plant alkaloids from Madagascar periwinkle plant Vinca rosea (Catharanthus roseus (L.) G.
Don) by Canadian scientists Robert Laing Noble, Charles T. Beer and Gordon Sloboda [56].
The vinca alkaloids extracted from Vinca rosea consist of a subset of structurally similar
compounds comprising two multiringed units, vindoline and catharanthine. Initially, they
were investigated because of putative hypoglycaemic properties, but strong marrow suppres‐
sion observed in rats and significant antileukaemic effects in vitro decided about their clinical
use shortly after the discovery of their properties, in 1959. Nowadays, vinca alkaloids are
produced synthetically and only four major ones - Vinblastine, Vincristine, Vinorelbine and
Vindesine - are in the oncological clinical use. Vinblastine is most often applied in Hodgkin’s
disease, non-Hodgkin’s lymphoma, breast cancer, and germ cell tumours, Vincristine is
effective against leukaemia and Hodgkin's, Vinorelbine has significant antitumor activity in
patients with breast cancer and antiproliferation effects on osteosarcoma, while Vindesine is
used in the treatment of leukaemia, lymphoma, melanoma, breast cancer, and lung cancer. All
vinca alkaloids have a unique mechanism of action; they bind to the microtubular proteins of
the mitotic spindle, which leads to crystallization of the microtubule and mitotic arrest or
apoptosis.
Another group of novel cytotoxic agents from plant alkaloids, taxane diterpenes, was discov‐
ered during long-term screening in the 1970s. The main compound in this class, Paclitaxel, was
the first taxane introduced into clinical practice for the treatment of recurrent ovarian cancer
metastatic, breast cancer, often in combination with Cisplatin. Nowadays, Paclitaxel is totally
synthesized, but less popular than vinca because of its poor solubility. Both plant alkaloids
vinca and taxanes are mitotic inhibitors M phase specific, Fig. 2, but they act in different ways.
Their principal mechanism of action is the disruption of microtubule function, but in contrast
to the vinca alkaloids, taxanes do not destroy mitotic spindles. The plant alkaloids are classified
as a group 3 agents in IARC classification [3].
4.4.4. Combination regimens
In 2005, conventional chemotherapeutics still made the majority of the Top 20 Cancer Thera‐
peutics. Their popularity was dictated not only by wide spectrum of activity and also long
history of use in oncology but also their key role in the multidrug treatment programs. In the
early 1960s, single alkylating agents were basic for all cancer treatment programmes. Although
the remissions were observed for example up to 25% in advanced Hodgkin's disease but they
were still incomplete and temporary. Increasing resistance of the cancer cells to classical drugs
and numerous side effects forced new strategies. After Jacob Furth and Morton Kahn discovery
that a single leukemic cell was sufficient to cause the death of an animal, Howard E. Skipper
formulated “Cell Kill” hypothesis, according to which a given dose of drug is able to kill only
a constant fraction of tumour cells. This hypothesis favoured search for more aggressive
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chemotherapeutics but also resulted in the use of drug combinations. In 1965 Emil Frei and
Emil J. Freireich developed the new treatment program for children leukaemia known as
"VAMP" (Nethotrexate, 6-MP, Vincristine and Prednisone). The use of multiple drugs:
Methotrexate, which disrupt folic-acid uptake, 6-MP which inhibits synthesis of purine, both
critical in cell division, Vincristine which interfered with cell division by binding to spindle
protein and Prednisone, anti-inflammatory steroid resulted in the remission rate level as high
as 60%. Further modifications like “MOMP” (nitrogen mustard, Vincristine, Methotrexate, and
Prednisone), “MOPP” (Procarbazine, nitrogen mustard, Vincristine, and Prednisone) and C-
MOPP (Procarbazine, Cyclophosphamide, Vincristine, and Prednisone) resulted in the 80%
complete remission rate in advanced Hodgkin's disease in the 1970s. On the basis of the above
mentioned first programs dedicated exclusively to leukaemias many modifications - e.g. four
drug EBVP (Epirubicin, Bleomycin, Vinblastine, Prednisone) and ABVD (Adriamycin,
Bleomycin, Vinblastine and Dacarbazine) and six-drug STANFORD-V (Cyclophosphamide/
Mechlorethamine/Ifosfamide, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide) -
have been developed. Nowadays, some cancer diseases like Hodgkin's or acute lymphocytic
leukaemia are curable in 90% within the modern protocols using aggressive chemotherapy
programs. Despite the reasonable position of classical chemotherapeutics in multidrug
combined regimens, their capabilities inevitably decrease because of multidrug resistance (a
major factor in the failure of many forms of treatment) and secondary effects (adverse or
paradoxically carcinogenic). Significant limitation is also the need for multiple chemotherapy
in long-term, sequential multidrug regimens and in-hospital administration.
4.4.5. Modern chemotherapeutics
At the beginning of the 20th c., Paul Ehrlich postulated the idea of a "Magic Bullet" (Zauber‐
kugel) i.e. drugs that reach directly intended cell-structural targets. To some extent this idea
is the driving force behind the development of modern targeted chemotherapeutics. Conven‐
tional chemotherapeutics are cytotoxic, but affect all cells and work in the so-called statistical
manner. Because cancer cells multiply faster than normal, the cancerous cells are killed by the
drug with a higher ratio than the normal ones, which are not spared. Therefore the principal
criterion applied in the modern anticancer drug design is the principle of selective toxicity,
which require activity restricted exclusively to the cancer cells. From the point of view of
selective activity directed on tumour cells and mechanisms of carcinogenesis, a few different
classes of modern drugs can be distinguished: inhibitors of cytokine stimulating cell prolifer‐
ation, dissociation, motility; cytokine receptor blockers; intracellular kinases inhibitors;
transcription factors inhibitors; cell cycle inhibitors; cell adhesion inhibitors and proteasome
inhibitors.
Short-lived hopes were raised in the 1990s at the discovery of the inhibitors of angiogenesis,
which hold back the growth of capillary vessels in cancer. Avastin, humanized monoclonal
antibody, discovered by Napoleone Ferrara in 1997 was the first drug from this class approved
by FDA in 2004 to use for several types of metastatic cancer, but the approval of the breast
cancer indication was revoked in 2011. Two other inhibitors of angiogenesis include Cetuxi‐
mab invented by Joseph Schlessinger, Michael Sela in 1988, approved for by FDA in 2009 to
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use in colorectal cancer therapy and Sunitinib discovered by Joseph Schlessinger and Axel
Ullrich approved by FDA in 2006 to use for renal cell carcinoma and gastrointestinal stromal
tumour. Recent progress in genetic sequencing has led to the discovery of Vemurafenib by
Fritz Hoffmann, approved by FDA in 2011. It targets the B-Raf gene that signals the growth of
new blood cells in melanoma tumours, which are extremely difficult to treat.
Recently widespread attention has been given to inhibitors of protein kinases, enzymes that
catalyze phosphorylation reactions, a principal mechanism of signal transduction governing
various cellular processes including growth, division, migration and apoptosis. Imatinib,
developed in the late 1990s by Nicholas Lydon, introduced to clinic by Brian Druker and
approved to treat chronic myelogenous leukaemia by FDA in 2001 was the first drug of this
new class of small active molecules. It inhibits the oncogene BCR-ABL1 and blocks the signals
for cell proliferation, controlling tumour growth. Many imatinib analogues: including
Nilotnib, Dasatinib, Bosutinib, Ponatinib, Bafetinib were obtained further by rational drug
design. Gefitinib invented by ASTRA/ZENECA (approved by FDA in 2003 but withdrawn in
2005) and Erlotinib invented by OSI (approved by FDA in 2004), were the first selective
inhibitors of epidermal growth factor receptor among the kinase inhibitors used for treatment
of lung cancer.
Monoclonal antibodies that allow the cytotoxin to reach a target required to kill the malignant
cells (induce apoptosis), without harming normal cells belong to the unique class of chemo‐
immunotherapeutics. In contrast to small molecule drugs which have a direct impact on their
targets, the monoclonal antibodies stimulate the immune system i.e. re-direct targets to the
immune system. Most popular includes: Gemtuzumab ozogamicin invented by Wyeth Ayerst
and used for the treatment of acute myelogenous leukaemia, but withdrawn from the market
in 2010 due to its toxicity, Ibritumomab tiuxetan developed by IDEC Pharmaceuticals used for
the treatment of non-Hodgkin’s lymphoma, but known to cause serious side effects, Panitu‐
mumab used for the treatment of colon cancer but ineffective, Rituximab developed by IDEC
Pharmaceuticals and still used for the treatment of B-cell non-Hodgkin’s lymphoma and
tositumomab developed by Mark Kaminski and Richard Wahl used for the treatment of non-
Hodgkin’s lymphoma (mainly follicular lymphoma), currently in the clinical trials.
Although modern targeted therapies provide a new approach to cancer therapy and similarly
to conventional ones are able to suppress tumour growth, but they also have drawbacks and
limitations, while true cancer treatment is still a challenge for oncology.
5. Summary
Throughout history of medicine the process of new drug discovery has been based on natural
sources and drugs have been discovered by serendipity (sheer luck) or in a trial-and-error
process. While until the mid-1980s new drugs were discovered mainly by serendipity, over
the next decade, till mid-1990s, the knowledge of structure was the basis for research, then the
starting point was to identify a target and a relationship between structure and function [122].
Nowadays a few major classes of drugs useful in cancer treatment have been defined: (1)
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General Chemotherapy Drugs (the alkylating agents, anti-neoplastics, anti-metabolites), (2)
Steroids, (3) Bisphosphonates, (4) Hormone therapies and (5) Biological therapies/Immuno‐
therapy. This modern classification reflects the fact that anticancer drugs evolved from classical
chemotherapeutics discovered mostly by serendipity to drugs acting directly against abnormal
proteins in cancer cells designed by rational drug design. All of them have remarkable
influence on the growth of cancer cells and on the mechanisms whereby cells replicate,
transmit, and translate genetic information.
Current research are so multidirectional that it is impossible to discuss all of them in a short
chapter. New directions in this field include the search for the improved pharmaceutical forms,
new analogues of currently used drugs, new chemical compounds (natural or synthetic) of
anticancer activity, selective anticancer agents (acting on the basis of pathophysiological
mechanisms), the search for drugs among old-known drugs currently used for other indica‐
tions than cancer, search for the methods of precise delivering the anticancer drugs to cancer
tissue and stroma or to stimulate the immune system to generate anti-tumor immune responses
and protect against cancer.
Even nowadays precursors or generic drugs are frequently discovered by serendipity, while
their analogues are developed by purely rational design. Often the newly synthesised drug
proved effective in quite different than expected applications. For example Aminoglutethi‐
mide was found to be effective in breast cancer treatment instead of being an antiepileptic,
Cisplatin, an electrolysis product, was discovered to be cytotoxic or Tamoxifen antiestrogenic
activity of cis-isomer was discovered as unexpected bonus in the search for drugs to treat mania
in bipolar disorder. Sometimes surprisingly a new field of activity is revealed for a long known
drug. For example potassium-sparing diuretic Amiloride is effective in glioma; sedative
Thalidomide, linked to birth defects, slows the propagation prostate cancer; Tebrophen,
antiviral drug, slows the propagation of breast cancer; S-dimethylarsin-gluthathione, an
organic form of arsenic, slow solid tumours expansion; anti-epileptic Valproic and Rapamycin,
immunosuppressor in organ transplantation are valuable in antitumor therapy; Gossypol,
potential male contraceptive overcome resistance to Cisplatin; antimalarial chloroquine may
address a critical cell nutrition issue with proliferating cancer cells while insecticide benzoyl‐
phenylurea helps understand the microtubule assembly process important for growth of the
pancreatic cancer cell. Anticancer properties have been ascertained to be shown by aspirin
used commonly as analgesic, antipyretic and an anti-inflammatory medication, 9-aminoacri‐
dine used as an antiprotozoa and antibacterial agent and Quinacrine commonly used antima‐
larial drug. The use of long know drugs fasten modern process of drug discovery, which
involves the identification of candidates, synthesis, characterization, screening, and assays for
therapeutic efficacy and proceeds through many stages including discovery, product charac‐
terisation, formulation, pharmacokinetics, preclinical toxicology testing and IND (Investiga‐
tional New Drug) application, bioanalytical testing and clinical trials. The new drugs (new
completely or a long known one) often have many adverse effects. Sometimes in the final step
the new drug proves toxic, ineffective or even carcinogenic. Many widely applied chemother‐
apeutic anticancer agents (nitrogen mustards, HN2 and HN3, treatamine, Chlorambucil,
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Fritz Hoffmann, approved by FDA in 2011. It targets the B-Raf gene that signals the growth of
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Nilotnib, Dasatinib, Bosutinib, Ponatinib, Bafetinib were obtained further by rational drug
design. Gefitinib invented by ASTRA/ZENECA (approved by FDA in 2003 but withdrawn in
2005) and Erlotinib invented by OSI (approved by FDA in 2004), were the first selective
inhibitors of epidermal growth factor receptor among the kinase inhibitors used for treatment
of lung cancer.
Monoclonal antibodies that allow the cytotoxin to reach a target required to kill the malignant
cells (induce apoptosis), without harming normal cells belong to the unique class of chemo‐
immunotherapeutics. In contrast to small molecule drugs which have a direct impact on their
targets, the monoclonal antibodies stimulate the immune system i.e. re-direct targets to the
immune system. Most popular includes: Gemtuzumab ozogamicin invented by Wyeth Ayerst
and used for the treatment of acute myelogenous leukaemia, but withdrawn from the market
in 2010 due to its toxicity, Ibritumomab tiuxetan developed by IDEC Pharmaceuticals used for
the treatment of non-Hodgkin’s lymphoma, but known to cause serious side effects, Panitu‐
mumab used for the treatment of colon cancer but ineffective, Rituximab developed by IDEC
Pharmaceuticals and still used for the treatment of B-cell non-Hodgkin’s lymphoma and
tositumomab developed by Mark Kaminski and Richard Wahl used for the treatment of non-
Hodgkin’s lymphoma (mainly follicular lymphoma), currently in the clinical trials.
Although modern targeted therapies provide a new approach to cancer therapy and similarly
to conventional ones are able to suppress tumour growth, but they also have drawbacks and
limitations, while true cancer treatment is still a challenge for oncology.
5. Summary
Throughout history of medicine the process of new drug discovery has been based on natural
sources and drugs have been discovered by serendipity (sheer luck) or in a trial-and-error
process. While until the mid-1980s new drugs were discovered mainly by serendipity, over
the next decade, till mid-1990s, the knowledge of structure was the basis for research, then the
starting point was to identify a target and a relationship between structure and function [122].
Nowadays a few major classes of drugs useful in cancer treatment have been defined: (1)
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General Chemotherapy Drugs (the alkylating agents, anti-neoplastics, anti-metabolites), (2)
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therapy. This modern classification reflects the fact that anticancer drugs evolved from classical
chemotherapeutics discovered mostly by serendipity to drugs acting directly against abnormal
proteins in cancer cells designed by rational drug design. All of them have remarkable
influence on the growth of cancer cells and on the mechanisms whereby cells replicate,
transmit, and translate genetic information.
Current research are so multidirectional that it is impossible to discuss all of them in a short
chapter. New directions in this field include the search for the improved pharmaceutical forms,
new analogues of currently used drugs, new chemical compounds (natural or synthetic) of
anticancer activity, selective anticancer agents (acting on the basis of pathophysiological
mechanisms), the search for drugs among old-known drugs currently used for other indica‐
tions than cancer, search for the methods of precise delivering the anticancer drugs to cancer
tissue and stroma or to stimulate the immune system to generate anti-tumor immune responses
and protect against cancer.
Even nowadays precursors or generic drugs are frequently discovered by serendipity, while
their analogues are developed by purely rational design. Often the newly synthesised drug
proved effective in quite different than expected applications. For example Aminoglutethi‐
mide was found to be effective in breast cancer treatment instead of being an antiepileptic,
Cisplatin, an electrolysis product, was discovered to be cytotoxic or Tamoxifen antiestrogenic
activity of cis-isomer was discovered as unexpected bonus in the search for drugs to treat mania
in bipolar disorder. Sometimes surprisingly a new field of activity is revealed for a long known
drug. For example potassium-sparing diuretic Amiloride is effective in glioma; sedative
Thalidomide, linked to birth defects, slows the propagation prostate cancer; Tebrophen,
antiviral drug, slows the propagation of breast cancer; S-dimethylarsin-gluthathione, an
organic form of arsenic, slow solid tumours expansion; anti-epileptic Valproic and Rapamycin,
immunosuppressor in organ transplantation are valuable in antitumor therapy; Gossypol,
potential male contraceptive overcome resistance to Cisplatin; antimalarial chloroquine may
address a critical cell nutrition issue with proliferating cancer cells while insecticide benzoyl‐
phenylurea helps understand the microtubule assembly process important for growth of the
pancreatic cancer cell. Anticancer properties have been ascertained to be shown by aspirin
used commonly as analgesic, antipyretic and an anti-inflammatory medication, 9-aminoacri‐
dine used as an antiprotozoa and antibacterial agent and Quinacrine commonly used antima‐
larial drug. The use of long know drugs fasten modern process of drug discovery, which
involves the identification of candidates, synthesis, characterization, screening, and assays for
therapeutic efficacy and proceeds through many stages including discovery, product charac‐
terisation, formulation, pharmacokinetics, preclinical toxicology testing and IND (Investiga‐
tional New Drug) application, bioanalytical testing and clinical trials. The new drugs (new
completely or a long known one) often have many adverse effects. Sometimes in the final step
the new drug proves toxic, ineffective or even carcinogenic. Many widely applied chemother‐
apeutic anticancer agents (nitrogen mustards, HN2 and HN3, treatamine, Chlorambucil,
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Sacrolysin, Melphalan, and Busulphan), have been recognized as a source of secondary cancers
and thus classified as definite carcinogens.
Sometimes known carcinogens have became invaluable drugs widely applied in clinical
oncology. The most impressive example is arsenic - a component of the well known Poison of
Kings (As2O3). It was used in traditional Chinese medicine in the treatment of promyelocytic
leukaemia and acute myelogenous leukaemia. Reaglar containing arsenic was used by
Hipocrates as a component of antitumor liniment. Avicenna in the 11th c. recommended it for
cancer, both internally and topically. In the 16th century Paracelsus used it as a drug but linked
with a cancer disease. In 1786 Thomas Fowler discovered Fowler's Solution (a 1% aqueous
solution of potassium arsenite, KAsO2),which was applied as first chemotherapeutic in chronic
myeloid leukaemia treatment in 1865 by Lissauer and persisted till the introduction of the first
modern cytotoxic drugs in the 1940s. In 1931, its use in chronic myeloid leukaemia was
described. In the late 1960s in China, an arsenic containing liniment was rediscovered for use
as an effective anticancer treatment in melanoma. First reports of the intravenous administra‐
tion of Fowler's Solution in acute promyelocytic leukaemia appeared in the 1990s, also in
China. But in the 1990s IARC classified arsenic compounds as definite carcinogens. Despite
this, in 2001 Fowler’s Solution was accepted by FDA for the treatment of relapsed or refractory
acute promyelocytic leukaemia in children. After being abandoned for decades, arsenic
trioxide in the 21st c started to be prescribed as a drug for acute promyelocytic leukaemia, and
still it is classified as definite anticancer. Recently some hope rises with realgar as well as new
arsenic-based compounds (e.g. C-glycosides), which have been intensively studied. On the
other hand, a very recent studies performed by Peter S. Nelson et al. indicated that chemo‐
therapy can damage healthy cells which secrete a protein WNT16B that sustains tumour
growth and results in a resistance to further treatment [123]. This proves that chemotherapy
itself can boost cancer growth. The paradox drug/carciogen concerns not only chemothera‐
peutics but also the methods, which revolutionized the treatment of cancer, being on the other
hand carcinogenic, like X-Ray widely used in the diagnosis of cancer cells, cancer treatment
and anticancer drug design, UV radiation being a basis of the photodynamic therapy. Para‐
celsus, father of toxicology already wrote "All substances are poisons: there is none which is not a
poison. The right dose differentiates a poison and a remedy." Paraphrasing him - the method and
conditions of the use differentiates a carcinogen and anticancer drug. Thus the search for new
drugs among carcinogens seems quite reasonable, while the protection against contact with
or exposure to a carcinogen is a necessity.
The recent advances in genomics and proteomics deliver a promise of understanding the true
internal mechanisms of cancerogenesis - a basis for cancer diseases. They cover the knowledge
of genes alteration caused by cancer, its influence on the proteins encoded by them, the
interaction of these proteins with each other in living cells, the resulting changes in the specific
tissues and finally the effect on the entire body. The achievements in this field delimit new
fully rational directions in anticancer drug discovery and development of drugs addressing
the specific needs (targeted drugs).
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1. Introduction
Early identification of patients who will be at a higher risk for the development of adverse
side effects and who will need dosage adjustment has the potential to help the clinician to
limit a patient’s exposure to drug side effects. When on multiple medications and complex
regimens, cardiac patients are at increased risk and particularly vulnerable to drug interac‐
tions. A rational and informed approach to drug interactions, based on scientific knowledge,
can reduce the chance of adverse effects and improve patient outcomes.
Cardiovascular drugs are used to treat various forms of illnesses, but there are often large
differences between individual patients in drug response and dosage requirement. Treat‐
ment that has been proven effective for one person can be ineffective or even dangerous for
another.
A drug produces its therapeutic effect when it reaches its target concentration in the blood‐
stream. Whether a steady therapeutic concentration is obtained largely depends on the bal‐
ance between the dose administered and the rate at which the body metabolises the drug.
An individual patient’s response to a drug is not totally predictable. Below the target thera‐
peutic range, a drug may be ineffective or, when it is higher, the drug may cause adverse
reactions or become toxic. To ensure the safe and effective action of many drugs, the concen‐
tration in the bloodstream and their clinical effects are monitored. If necessary, the dose can
be adjusted or the medication changed to achieve the best possible outcome.
To avoid unintended and untoward adverse drug reactions, the prescriber should use the
fundamental principles of pharmacology and pharmacogenetics. Several drugs are metabol‐
ised through the same pathways and knowledge of the potential pathway capacity could
help to predict treatment success. Variability in the reaction to medication may be due to
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1. Introduction
Early identification of patients who will be at a higher risk for the development of adverse
side effects and who will need dosage adjustment has the potential to help the clinician to
limit a patient’s exposure to drug side effects. When on multiple medications and complex
regimens, cardiac patients are at increased risk and particularly vulnerable to drug interac‐
tions. A rational and informed approach to drug interactions, based on scientific knowledge,
can reduce the chance of adverse effects and improve patient outcomes.
Cardiovascular drugs are used to treat various forms of illnesses, but there are often large
differences between individual patients in drug response and dosage requirement. Treat‐
ment that has been proven effective for one person can be ineffective or even dangerous for
another.
A drug produces its therapeutic effect when it reaches its target concentration in the blood‐
stream. Whether a steady therapeutic concentration is obtained largely depends on the bal‐
ance between the dose administered and the rate at which the body metabolises the drug.
An individual patient’s response to a drug is not totally predictable. Below the target thera‐
peutic range, a drug may be ineffective or, when it is higher, the drug may cause adverse
reactions or become toxic. To ensure the safe and effective action of many drugs, the concen‐
tration in the bloodstream and their clinical effects are monitored. If necessary, the dose can
be adjusted or the medication changed to achieve the best possible outcome.
To avoid unintended and untoward adverse drug reactions, the prescriber should use the
fundamental principles of pharmacology and pharmacogenetics. Several drugs are metabol‐
ised through the same pathways and knowledge of the potential pathway capacity could
help to predict treatment success. Variability in the reaction to medication may be due to
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age, gender, morbidity, co-medication, food components, smoking and environmental fac‐
tors. However, polymorphisms present in genes, are responsible for most of the variation.
Pharmacogenetic research and candidate gene approaches have succeeded in the identifica‐
tion of several genetic factors influencing treatment response. In particular, associations be‐
tween variants in CYP enzymes and transporter genes have been repeatedly associated with
different response and treatment--associated side effects [1-6]. Knowledge of pharmacoge‐
nomics is providing a key to understanding fundamentals of the drug interaction process.
A specific genotype might differ in its frequency in different ethnic populations, leading to
differences in drug response. However, gene combination between ethnic groups makes it
impossible for the practitioner to simply predict if a drug will be efficient or not. There is no
specific genetic definition of ethnicity and ethnicity does not sufficiently separate those for
whom a given therapy will be effective.
In contrast, the pharmacogenetics potentially presents a more effective way of identifying
responders, nonresponders and potential adverse drug reactions. Pharmacogenetics pro‐
vides defined clinical biomakers for individualised therapy [7].
Personalised medicine can be defined as a form of medicine that uses information about a
person's genes, proteins and environment to prevent, diagnose and treat diseases, including
predicting therapeutic response, nonresponse and likelihood of adverse reactions. Diagnos‐
tic biomarkers are necessary to successfully select patients for therapy, distinguish likely res‐
ponders from nonresponders, identify patients at high risk for adverse events, or select an
appropriate dose for safe and efficacious use of the therapy.
The human genome consists of approximately 3 billion base pairs (NCBI database) and the
sequence of these varies among individuals. These variations can change the function of
proteins that interact with a drug and hence, the response to a drug may differ among indi‐
viduals. Sequence variations in drug-disposition genes can alter the pharmacokinetics of a
drug and those in drug-target genes can change the pharmacodynamics of a drug.
When a genetic polymorphism alters the function of a protein that is involved in the absorp‐
tion, metabolism, distribution and excretion of a drug, the concentrations of the parent drug
or its active metabolites may be affected. For example, CYP2D6*4 polymorphism leads to
lower activity of a metabolising enzyme and the plasma concentrations of the parent drug
metabolised by cytochrome P-450 isoenzyme 2D6 may increase and concentration of metab‐
olites may decrease (some antidepressants). As a result, it could lead to the development of
toxicity. For prodrugs, when metabolites have pharmacologic activity, the genetic polymor‐
phism may reduce the drug response (some analgesics). Genetic polymorphisms that
change the activity of the drug target (pharmacodynamics) may also alter the drug response.
For example, vitamin K epoxide reductase complex subunit 1 gene polymorphisms influ‐
ence warfarin response and β1-adrenergic receptor gene polymorphisms after β-blocker re‐
sponse. Therefore, drugs can compete for binding sites on the receptors or be metabolised
by the same enzyme, consequently create dug-drug interaction problem.
The information about pharmacogenetic terms and recourses is presented in the Appendix.
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Early identification of patients who will be at a higher risk for the development of adverse
side effects and who will need dosage adjustment has the potential to help the clinician to
limit a patient’s exposure to drug side effects. Characterisation of drug metabolising poly‐
morphisms has been shown to be useful for identifying individuals who are poor drug me‐
tabolisers and at risk of developing adverse reactions, and several genotyping methods are
already being used in clinical settings (Table1). The evidence provided by pharmacogenetics
and pharmacogenomics can be successfully used for drug interaction interpretation.
Drugs Tests of polymorphisms Affected WSLHD Population*
Wafarin CYP2C9 1% - Poor Metabolisers, 15% - Intermediate
Phenytoin
Warfarin VKORC1 11% with altered function
Clopidogrel CYP2C19 4% - Poor Metabolisers, 13% - Intermediate, 20% -
Ultra fast metabolisers






Isosorbide NAT1, NAT2 10-90%
Hydralazine
Warfarin Protein C Deficiencies 1/200 population, 2-5% Patients with Venous
Thromboembolism
Atorvastatin LDLR 1-5% Familial Cholesterolemia Patients
Statins SINM PhyzioType (50 genes) 10-30% Patients on statin (multi-gene biomarker
system manufacture results, no data available)
Table 1. Available Pharmacogenetics tests for cardiovascular medication. (*Western Sydney Population combined
data. WSLHD population is a mix of Caucasians, Asians and Africans.)
Drug Interactions, Pharmacogenomics and Cardiovascular Complication
http://dx.doi.org/10.5772/48423
77
age, gender, morbidity, co-medication, food components, smoking and environmental fac‐
tors. However, polymorphisms present in genes, are responsible for most of the variation.
Pharmacogenetic research and candidate gene approaches have succeeded in the identifica‐
tion of several genetic factors influencing treatment response. In particular, associations be‐
tween variants in CYP enzymes and transporter genes have been repeatedly associated with
different response and treatment--associated side effects [1-6]. Knowledge of pharmacoge‐
nomics is providing a key to understanding fundamentals of the drug interaction process.
A specific genotype might differ in its frequency in different ethnic populations, leading to
differences in drug response. However, gene combination between ethnic groups makes it
impossible for the practitioner to simply predict if a drug will be efficient or not. There is no
specific genetic definition of ethnicity and ethnicity does not sufficiently separate those for
whom a given therapy will be effective.
In contrast, the pharmacogenetics potentially presents a more effective way of identifying
responders, nonresponders and potential adverse drug reactions. Pharmacogenetics pro‐
vides defined clinical biomakers for individualised therapy [7].
Personalised medicine can be defined as a form of medicine that uses information about a
person's genes, proteins and environment to prevent, diagnose and treat diseases, including
predicting therapeutic response, nonresponse and likelihood of adverse reactions. Diagnos‐
tic biomarkers are necessary to successfully select patients for therapy, distinguish likely res‐
ponders from nonresponders, identify patients at high risk for adverse events, or select an
appropriate dose for safe and efficacious use of the therapy.
The human genome consists of approximately 3 billion base pairs (NCBI database) and the
sequence of these varies among individuals. These variations can change the function of
proteins that interact with a drug and hence, the response to a drug may differ among indi‐
viduals. Sequence variations in drug-disposition genes can alter the pharmacokinetics of a
drug and those in drug-target genes can change the pharmacodynamics of a drug.
When a genetic polymorphism alters the function of a protein that is involved in the absorp‐
tion, metabolism, distribution and excretion of a drug, the concentrations of the parent drug
or its active metabolites may be affected. For example, CYP2D6*4 polymorphism leads to
lower activity of a metabolising enzyme and the plasma concentrations of the parent drug
metabolised by cytochrome P-450 isoenzyme 2D6 may increase and concentration of metab‐
olites may decrease (some antidepressants). As a result, it could lead to the development of
toxicity. For prodrugs, when metabolites have pharmacologic activity, the genetic polymor‐
phism may reduce the drug response (some analgesics). Genetic polymorphisms that
change the activity of the drug target (pharmacodynamics) may also alter the drug response.
For example, vitamin K epoxide reductase complex subunit 1 gene polymorphisms influ‐
ence warfarin response and β1-adrenergic receptor gene polymorphisms after β-blocker re‐
sponse. Therefore, drugs can compete for binding sites on the receptors or be metabolised
by the same enzyme, consequently create dug-drug interaction problem.
The information about pharmacogenetic terms and recourses is presented in the Appendix.
Drug Discovery76
Early identification of patients who will be at a higher risk for the development of adverse
side effects and who will need dosage adjustment has the potential to help the clinician to
limit a patient’s exposure to drug side effects. Characterisation of drug metabolising poly‐
morphisms has been shown to be useful for identifying individuals who are poor drug me‐
tabolisers and at risk of developing adverse reactions, and several genotyping methods are
already being used in clinical settings (Table1). The evidence provided by pharmacogenetics
and pharmacogenomics can be successfully used for drug interaction interpretation.
Drugs Tests of polymorphisms Affected WSLHD Population*
Wafarin CYP2C9 1% - Poor Metabolisers, 15% - Intermediate
Phenytoin
Warfarin VKORC1 11% with altered function
Clopidogrel CYP2C19 4% - Poor Metabolisers, 13% - Intermediate, 20% -
Ultra fast metabolisers






Isosorbide NAT1, NAT2 10-90%
Hydralazine
Warfarin Protein C Deficiencies 1/200 population, 2-5% Patients with Venous
Thromboembolism
Atorvastatin LDLR 1-5% Familial Cholesterolemia Patients
Statins SINM PhyzioType (50 genes) 10-30% Patients on statin (multi-gene biomarker
system manufacture results, no data available)
Table 1. Available Pharmacogenetics tests for cardiovascular medication. (*Western Sydney Population combined
data. WSLHD population is a mix of Caucasians, Asians and Africans.)




Hypertension is a common condition associated with increased risk of stroke, heart failure,
ischemic heart disease, and chronic renal failure. Thiazide diuretics, β-blockers, ACE inhibi‐
tors, angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) are a com‐
mon first line treatment for hypertension [8].
Despite availability of many effective agents, only about 40 percent [9] of treated hyperten‐
sive patients have their blood pressure controlled, mostly due to the unpredictable individu‐
al responses to treatment. Blood pressure responses to monotherapy vary widely within
ethnic and gender subgroups [10].
Numerous studies have tried to establish associations between genetic polymorphisms and
response to antihypertensive drugs. New developments in pharmacogenetics and pharma‐
cogenomics already offer in pharmacogenetics and pharmacogenomics already offers the
opportunity to provide individualised drug therapy on the basis of a person's genetic make‐
up for some drugs, despite varied approaches in study designs and methodology. These
tests are provided by several laboratories and available at some hospitals; pharmacogenetic
methods will not only help to achieve treatment goals and limit adverse effects, but also
avoid drug interactions.
2.1. β-blockers
β-blockers through binding to β-adrenergic receptors (BAR) antagonise the binding of en‐
dogenous agonists. Variations in the gene encoding the β1-adrenergic receptor probably in‐
fluence the treatment outcome. Two single nucleotide polymorphism (SNPs), resulting in
Ser49Gly and Arg389Gly were identified and these variants demonstrate altered biological
function in vitro, including enhanced agonist induced adenylyl cyclase activation by Gly49
compared to Ser49 and by Arg389 compared to Gly389 [11].
Some studies have shown that the Arg389Arg genotype and Ser49/Arg389 haplotype are as‐
sociated with a greater response to blood pressure-lowering metoprolol [12].
The  differential  survival  of  Acute  Coronary  Syndrome  (ACS)  patients  treated  with  β-
blockers  was  associated  with  patients'  β-adrenergic  receptors  2  variant  Gly16Arg  and
Gln27Glu genotypes; however, β-adrenergic receptors 1 variants showed no significant as‐
sociations [13, 14].
No significant correlation has been found for outcomes of death, MI or stroke in coronary
artery disease patients on atenolol treatment and β-adrenergic receptors variants or haplo‐
types [15] and β-adrenergic receptors 2 variants in MI and stroke outcomes. However, the
case-control study found significant interaction with two SNPs in β-adrenergic receptors
variant and cardiovascular complications [16, 17].
Angiotensin-converting enzyme (ACE) genes variations were also associated with β-block‐
ers therapy outcome. In heart failure, patients survival without a transplant, has been as‐
sociated  with  the  angiotensin-converting  enzyme  I/D  genotype  (insertion/deletion).
Drug Discovery78
Patients with the D allele may derive greater benefits  from pharmacologic interventions
with Beta-blocker treatment,  probably through the decrease of  sympathetic  nervous sys‐
tem activity [18].
The effects of the CYP450 enzyme systems has been studied intensively during the last years
and its role in the metabolism of drugs and other endogenous and exogenous chemicals is
well defined. Numerous publications confirm the association of these enzymes with drug-
drug, drug-toxins and drug-food interactions. Polymorphisms in the gene coding for the
CYP2D6 isoenzyme, which catalyses the metabolism of β-blockers such as metoprolol, car‐
vedilol, timolol, and propranolol, may also affect blocker response. It has been demonstrat‐
ed that the clearance of the R(+) enantiomer of carvedilol was 66% lower and the area under
the concentration-versus-time curve 156% higher among poor metabolizers than extensive
metabolizers [19-22].
Some studies showed association with other genes. Genes involved in calcium signalling -
CACNA1C, CACNB2, and KCNMB1- were found to be associated with myocardial infarc‐
tion or stroke with β-blockers versus calcium channel blockers [23-25]. Variable stroke risk
by genotype was described for an MMP3 promoter polymorphism in patients treated with
lisinopril [26] and different treatment-related outcomes with thiazides and β-blockers, but
not diltiazem, by NEDD4L (protein reduce renal tubular expression of epithelial Na+ chan‐
nel) genotype [27].
Finally, the two studies by Schelleman et al reported no β-blocker interactions (for outcomes
MI or stroke) variants of angiotensin receptor II type 1 (AGTR1) and ACE [28, 29].
2.2. Diuretics
Diuretics may act at a number of sites, including the proximal tubule, the Loop of Henle,
and the distal and collecting tubules. Diuretics are thought to indirectly activate the renin-
angiotensin-aldosterone system and block sensitivity of blood vessels to catecholamines.
Thiazide diuretics are the drug of choice for initial therapy, but genes responsible for renal
sodium reabsorption can affect the patient's responsiveness to diuretic therapy.
Antihypertensive response in black African Americans is found to be associated with locus
at chromosome12q15 [30, 31] where the FRS2 gene is located, which is involved in fibroblast
growth factor signalling. FRS2 plays a role in vascular smooth muscle cell regulation.
Genome-wide association (GWA) studies are aimed at identifying common genetic variants
modulating disease susceptibility, physiological traits and variable drug responses. These
studies also provide further evidence for the large effects that single gene variants may exert
for some drugs. GWA has explained relatively large proportions of variability compared to
studies of traits such as disease susceptibility or physiological measurements. GWAS dem‐
onstrated that SNPs in lysozyme and Yeats domain-containing protein 4 (YEATS4 ) were as‐
sociated with response to diuretic [30].
Lynch et al. found that C carriers of the NPPA T2238C variant, which codes for the precur‐
sor of atrial natriuretic polypeptide, had more favourable clinical outcomes when treated
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with a diuretic, whereas individuals homozygous for the T allele responded better to a calci‐
um channel blocker [32].
Patients with SNP of T594M gene (epithelial sodium channel) variant responded more fa‐
vourably to amiloride therapy for BP control than to thiazide-based drugs. In cases of severe
hypokalemia, potassium-sparing diuretics such as amiloride or triamterene should be used
according to serum sodium and potassium levels [33, 34].
NEDD4L is also a candidate gene with a documented functional SNP, a role in sodium reab‐
sorption, and several studies have found an association between this SNP and blood pres‐
sure response with thiazides [27, 35].
A common functional polymorphism resulting in Gly460Trp in the α-adducin gene ADD1
has been associated with response to thiazides. This finding led to the development of a
novel antihypertensive drug class targeting adducin [36, 37]. Manunta et al. performed sin‐
gle SNP association analysis and combination analysis on ADD1 (Gly460Trp), NEDD4L,
WNK1 in a 4-week diuretic trial. They found ADD1 460Trp carriers had significantly greater
BP reduction than Gly460 homozygotes. When considered together, there was a significant
trend in decreases of systolic blood pressure (SBP) (ranging from −3.4 mm Hg to −23.2 mm
Hg) for different combinations of genotypes [35].The ADD1 Gly460Trp polymorphism has
been associated with an increased risk of myocardial infarction or stroke during thiazide di‐
uretic treatment [38] In contrast, these findings were not confirmed by other studies [39, 40].
The 825T allele in the G-protein is probably associated with a sodium-sensitive form of hy‐
pertension. Blood pressure declines for both the C/T and T/T genotypes were significantly
greater than for the C/C genotype. The study revealed that the decreases in blood pressure
varied on the basis of genotype and even after multiple regression analysis, genotype re‐
mained a significant predictor of blood pressure lowering [41].
2.3. Renin-angiotensin system inhibitors
Numerous genes from the renin-angiotensin system (RAS) pathway have been shown to
play a key role in the regulation of blood pressure and influence the cardiovascular sys‐
tem. Several  pharmacogenetic  studies of  the RAS were conducted.  However,  due to the
complexity  of  RAS,  associations  between  drug  efficiency  and  polymorphisms  are  not
consistent [42-45].
Angiotensin-converting enzyme (ACE) inhibitors prevent the conversion of angiotensin I to
angiotensin II in plasma and tissue and prevent the degradation of bradykinin. Clinically,
ACE inhibitors reduce peripheral vascular resistance and pulmonary capillary wedge pres‐
sure and increase cardiac output and renal blood flow. Treatment with ACE inhibitors in
hypertension has been associated with improvements in vascular compliance, regression of
left ventricular hypertrophy, improved systolic and diastolic function, and improvements in
insulin sensitivity [46]. One study showed that ACE DD polymorphism is associated with
poor collateral circulation (PCC). PCC in patients carrying the D allele may be associated
with endothelial dysfunction and elevated blood ACE levels in these patients [47].
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The insertion/deletion (I/D) in the angiotensin I-converting enzyme (ACE) gene is one of the
candidates for studies. The D allele has been associated with more improvement in coronary
endothelial dysfunction with ACE inhibitor therapy than the I allele [48]. Reductions in sys‐
tolic and diastolic blood pressures were significantly greater for patients with the D/D geno‐
type than for patients with the I/D and I/I genotypes [49].
Diastolic blood pressure tended to decrease more for the ACE I/I genotype than for other
ACE genotypes and the I/I genotype was also predictive of greater diastolic blood pressure
decline [50]. Decline in renal function during ACE inhibitor treatment tended to be greater
in heart failure patients with the ACE I/I genotype [51]. The I/I genotype has also been asso‐
ciated with increased susceptibility to the development of cough during ACE inhibitor ther‐
apy. After four weeks of therapy with an ACE inhibitor in healthy volunteers, the threshold
for cough was significantly reduced for the I/I genotype but not the D/D genotype [52].
Another gene of interest is the angiotensinogen (AGT) gene. It was reported that the angio‐
tensinogen 235Met/Thr polymorphism is also associated with RAS activity and drug re‐
sponses. In subjects on ACE inhibitor monotherapy with 235Thr allele the response is higher
than in the control group. Systolic and diastolic blood pressures were higher and the likeli‐
hood of using two or more antihypertensive medications was 2.1 times higher with the
235Thr polymorphism [53].
An association with polymorphisms in the angiotensin AT1 receptor (AGT1R) gene and
ACE inhibitors’ efficiency are found in some studies. The AGT1R mediates some negative
effects of angiotensin II, such as vasoconstriction, cardiac remodelling, and aldosterone se‐
cretion. Angiotensin II blockers bind to angiotensin II receptors, thereby antagonizing the ef‐
fect of angiotensin II, a potent vasoconstrictor [54]. The 1166C allele of AGT1R has been
associated with increased arterial responsiveness to angiotensin II in ischemic heart disease
and increased aortic stiffness in hypertension. During ACE inhibitor treatment, reductions
in aortic stiffness were reported to be three times greater in carriers of the 1166C allele than
in 1166A homozygotes [55, 56]. AGTR1 (C573T) and ACE (ID) association between ACE in‐
hibitor therapy and increased MI risk for carriers of the AGTR1 C573 allele were reported;
however, no significant interaction between ACE inhibitor treatment and ACE (ID) alleles
for either stroke or MI were found [28]. One research group found no associations between
BP response and ACE (ID), AGTR1 (A1166C), CYP11B2 (-344 C/T), AGT (-6 A/G) [57].
After 12 weeks of treatment with irbesartan (Angiotensin II Blocker), plasma concentration
of the drug was related to change in systolic BP in TT homozygotes of AGTR1 (C5245T) but
not for other genotypes [58].
3. Calcium Channel Blockers (CCBs)
Drugs in this class block voltage-gated calcium channels in the heart and vasculature, there‐
by reducing intracellular calcium. Calcium channel blockers drugs vary in their effect on
cardiac versus vascular calcium channels. CCBs fall into three subclasses: phenylalkyla‐
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sorption, and several studies have found an association between this SNP and blood pres‐
sure response with thiazides [27, 35].
A common functional polymorphism resulting in Gly460Trp in the α-adducin gene ADD1
has been associated with response to thiazides. This finding led to the development of a
novel antihypertensive drug class targeting adducin [36, 37]. Manunta et al. performed sin‐
gle SNP association analysis and combination analysis on ADD1 (Gly460Trp), NEDD4L,
WNK1 in a 4-week diuretic trial. They found ADD1 460Trp carriers had significantly greater
BP reduction than Gly460 homozygotes. When considered together, there was a significant
trend in decreases of systolic blood pressure (SBP) (ranging from −3.4 mm Hg to −23.2 mm
Hg) for different combinations of genotypes [35].The ADD1 Gly460Trp polymorphism has
been associated with an increased risk of myocardial infarction or stroke during thiazide di‐
uretic treatment [38] In contrast, these findings were not confirmed by other studies [39, 40].
The 825T allele in the G-protein is probably associated with a sodium-sensitive form of hy‐
pertension. Blood pressure declines for both the C/T and T/T genotypes were significantly
greater than for the C/C genotype. The study revealed that the decreases in blood pressure
varied on the basis of genotype and even after multiple regression analysis, genotype re‐
mained a significant predictor of blood pressure lowering [41].
2.3. Renin-angiotensin system inhibitors
Numerous genes from the renin-angiotensin system (RAS) pathway have been shown to
play a key role in the regulation of blood pressure and influence the cardiovascular sys‐
tem. Several  pharmacogenetic  studies of  the RAS were conducted.  However,  due to the
complexity  of  RAS,  associations  between  drug  efficiency  and  polymorphisms  are  not
consistent [42-45].
Angiotensin-converting enzyme (ACE) inhibitors prevent the conversion of angiotensin I to
angiotensin II in plasma and tissue and prevent the degradation of bradykinin. Clinically,
ACE inhibitors reduce peripheral vascular resistance and pulmonary capillary wedge pres‐
sure and increase cardiac output and renal blood flow. Treatment with ACE inhibitors in
hypertension has been associated with improvements in vascular compliance, regression of
left ventricular hypertrophy, improved systolic and diastolic function, and improvements in
insulin sensitivity [46]. One study showed that ACE DD polymorphism is associated with
poor collateral circulation (PCC). PCC in patients carrying the D allele may be associated
with endothelial dysfunction and elevated blood ACE levels in these patients [47].
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The insertion/deletion (I/D) in the angiotensin I-converting enzyme (ACE) gene is one of the
candidates for studies. The D allele has been associated with more improvement in coronary
endothelial dysfunction with ACE inhibitor therapy than the I allele [48]. Reductions in sys‐
tolic and diastolic blood pressures were significantly greater for patients with the D/D geno‐
type than for patients with the I/D and I/I genotypes [49].
Diastolic blood pressure tended to decrease more for the ACE I/I genotype than for other
ACE genotypes and the I/I genotype was also predictive of greater diastolic blood pressure
decline [50]. Decline in renal function during ACE inhibitor treatment tended to be greater
in heart failure patients with the ACE I/I genotype [51]. The I/I genotype has also been asso‐
ciated with increased susceptibility to the development of cough during ACE inhibitor ther‐
apy. After four weeks of therapy with an ACE inhibitor in healthy volunteers, the threshold
for cough was significantly reduced for the I/I genotype but not the D/D genotype [52].
Another gene of interest is the angiotensinogen (AGT) gene. It was reported that the angio‐
tensinogen 235Met/Thr polymorphism is also associated with RAS activity and drug re‐
sponses. In subjects on ACE inhibitor monotherapy with 235Thr allele the response is higher
than in the control group. Systolic and diastolic blood pressures were higher and the likeli‐
hood of using two or more antihypertensive medications was 2.1 times higher with the
235Thr polymorphism [53].
An association with polymorphisms in the angiotensin AT1 receptor (AGT1R) gene and
ACE inhibitors’ efficiency are found in some studies. The AGT1R mediates some negative
effects of angiotensin II, such as vasoconstriction, cardiac remodelling, and aldosterone se‐
cretion. Angiotensin II blockers bind to angiotensin II receptors, thereby antagonizing the ef‐
fect of angiotensin II, a potent vasoconstrictor [54]. The 1166C allele of AGT1R has been
associated with increased arterial responsiveness to angiotensin II in ischemic heart disease
and increased aortic stiffness in hypertension. During ACE inhibitor treatment, reductions
in aortic stiffness were reported to be three times greater in carriers of the 1166C allele than
in 1166A homozygotes [55, 56]. AGTR1 (C573T) and ACE (ID) association between ACE in‐
hibitor therapy and increased MI risk for carriers of the AGTR1 C573 allele were reported;
however, no significant interaction between ACE inhibitor treatment and ACE (ID) alleles
for either stroke or MI were found [28]. One research group found no associations between
BP response and ACE (ID), AGTR1 (A1166C), CYP11B2 (-344 C/T), AGT (-6 A/G) [57].
After 12 weeks of treatment with irbesartan (Angiotensin II Blocker), plasma concentration
of the drug was related to change in systolic BP in TT homozygotes of AGTR1 (C5245T) but
not for other genotypes [58].
3. Calcium Channel Blockers (CCBs)
Drugs in this class block voltage-gated calcium channels in the heart and vasculature, there‐
by reducing intracellular calcium. Calcium channel blockers drugs vary in their effect on
cardiac versus vascular calcium channels. CCBs fall into three subclasses: phenylalkyla‐
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mines, which are selective for the myocardium; dihydropyridines which mostly affecting
smooth muscle and benzothiazepines with a broad range.
A few studies describe some association; three SNPs in CACNA1C had significant associa‐
tions with treatment in a study of BP lowering with calcium channel blockers [59]; between
CYP3A5*3 and *6 variants and verapamil treatment for BP and hypertension risk outcomes
in blacks and Hispanics [60]; individuals that are homozygous for the T allele of NPPA
T2238C had more favourable clinical outcomes when treated with a calcium channel blocker
whereas C carriers responded better to a diuretic [32]. Beta Adrenergic Receptor 1 (BAR1)
Ser49-Arg389 haplotype carriers had higher death rates than those with other haplotypes
when treated with verapamil [15].
4. Anticoagulants
4.1. Warfarin
Warfarin is a widely used anticoagulant in the treatment and prevention of thrombosis. It
was initially marketed as a pesticide against rats and mice and is still used for this purpose.
It was approved for use as a medication in the early 1950s and is widely prescribed. Despite
its common use, warfarin therapy can be associated with significant bleeding complications.
Achieving a safe therapeutic response can be difficult because of warfarin’s narrow thera‐
peutic index and great individual variability in the dose required, which is mostly a conse‐
quence of individual genetic variants. This fact is well known among clinicians and the wide
range, from 1 mg/day to 20 mg/day, of warfarin maintenance doses are observed across the
population. To maintain a therapeutic level of anti-thrombosis and to minimise the risk of
bleeding complications, warfarin therapy requires intensive monitoring via the International
Normalized Ratio (INR) to guide its dosing. The INR is used to monitor the effectiveness of
warfarin and measures the pathway of blood coagulation. It is used to standardize the re‐
sults for a prothrombin time. INR is the ratio of a patient's prothrombin time to a control
sample, raised to the power of the index value for the analytical system used.
Several factors increase the risk of over-anticoagulation: genetic polymorphisms affecting
the metabolising enzymes, impaired liver function, drug interactions, congestive heart fail‐
ure, diarrhoea, fever, and diets rich in vitamin K [61] [62]. Nevertheless, genetic factors and
drug interactions mostly account for the risk of over-anticoagulation. Warfarin metabolism
involves primarily the cytochrome P450 (CYP) enzymes. Some loss-of-function CYP2C9 and
vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphisms are known to be
associated with decreased enzymatic activity and as a result, with an increased risk of hae‐
morhage. These are CYP2C9*2 (Cysl44/Ile359), CYP2C9*3 (Argl44/Leu359) and VKORC1
(-1639G>A) [63-65].
Warfarin-induced haemorrhage is an important complication of anticoagulation therapy. A
review of many studies shows average yearly rates of warfarin-related bleeding as high as
0.8%, 4.9%, and 15%, for fatal, major and minor bleeding complications respectively [66].
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Vitamin K is required by proteins C and S, together with clotting factors II, VII, IX, and X, to
allow assembly of the procoagulant enzyme complexes necessary to generate fibrin. Warfar‐
in as an anticoagulant agent has the ability to interfere with the recycling of vitamin K in the
liver. The pharmacologic effect of warfarin is mediated by the inhibition of vitamin K epox‐
ide reductase complex subunit 1 (EC 1.1.4.1) [67].
Warfarin consists of (R)- and (S)-warfarin enantiomers. (R)- and (S)-warfarins differ in their
relative plasma concentrations, in their antithrombotic potency and in the specific isoen‐
zymes responsible for their metabolism. (S)-warfarin has a 3 to 5 times greater anticoagulant
effect than the (R)-enantiomer and accounts for 60% to 70% of warfarin's overall anticoagu‐
lant activity. (S)-warfarin is metabolised almost exclusively by CYP2C9 [68-70].
The activity of the CYP2C9 enzyme has a significant impact on the clearance of (S)-warfarin
and as a consequence on anticoagulant effect. In the presence of genetic variations where the
activity of CYP2C9 is reduced, clearance of (S)-warfarin is also reduced. Activity of CYP2C9
between individuals can vary by more than 20-fold. (R)-warfarin is metabilised by multiple
different CYP enzymes [71].
While several single-nucleotide polymorphisms of CYP2C9 have been reported, the
CYP2C9*2 (Cysl44/Ile359) and CYP2C9*3 (Argl44/Leu359) polymorphisms have been identi‐
fied as clinically relevant [72]. Both of these variants are associated with decreased enzymat‐
ic activity [24, 73-78].
Homozygous CYP2C9*3 variant genotypes have only 5% to 10% metabolic efficiency com‐
pared to the wild-type genotype. As a result, compared to wild-type CYP2C9*1*1 controls,
enzyme activity and the median maintenance warfarin dose for CYP2C9*3*1 heterozygotes
was reduced by 40%, and by approximately 90% for CYP2C9*3*3 homozygotes [72-74].
Furuya [79] and Steward [75] showed that the CYP2C9*2 variant is also associated with re‐
duced warfarin elimination. Heterozygotes demonstrate 40% and homozygotes 15% of the
wild-type enzyme activity, causing dose adjustment for heterozygote CYP2C9*2 individuals
down to 20% less than the standard dose.
Margaglione [76] has also demonstrated bleeding rates as high as 27.9 per 100 patient-years
in carriers of CYP variants. In this study, findings were adjusted for other common variables
associated with increased bleeding risk, such as increased age, drug interactions and abnor‐
mal liver function.
Several studies of the *2 and *3 CYP2C9 polymorphisms consistently show that patients
with at least one CYP2C9 allele polymorphism have reduced warfarin requirements [76,
80-84]. Freeman [85] reported reduced warfarin weekly dosages for carriers of CYP2C9*2 or
CYP2C9*3 alleles compared with patients who were homozygous for the wild-type allele
(0.307 mg/kg/wk and 0.397 mg/kg/wk, respectively). Taube [83] compared warfarin mainte‐
nance dosages in 683 patients carrying different CYP2C9 genotypes. Mean warfarin mainte‐
nance dosages were 86% in patients with CYP2C9*1*2, 79% in patients with CYP2C9*1*3,
82% in compound heterozygotes CYP2C9*2/*3, and 61% in patients homozygous for
CYP2C9*2. Furthermore, Aithal [80] warns that even when warfarin dosages are decreased,
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Normalized Ratio (INR) to guide its dosing. The INR is used to monitor the effectiveness of
warfarin and measures the pathway of blood coagulation. It is used to standardize the re‐
sults for a prothrombin time. INR is the ratio of a patient's prothrombin time to a control
sample, raised to the power of the index value for the analytical system used.
Several factors increase the risk of over-anticoagulation: genetic polymorphisms affecting
the metabolising enzymes, impaired liver function, drug interactions, congestive heart fail‐
ure, diarrhoea, fever, and diets rich in vitamin K [61] [62]. Nevertheless, genetic factors and
drug interactions mostly account for the risk of over-anticoagulation. Warfarin metabolism
involves primarily the cytochrome P450 (CYP) enzymes. Some loss-of-function CYP2C9 and
vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphisms are known to be
associated with decreased enzymatic activity and as a result, with an increased risk of hae‐
morhage. These are CYP2C9*2 (Cysl44/Ile359), CYP2C9*3 (Argl44/Leu359) and VKORC1
(-1639G>A) [63-65].
Warfarin-induced haemorrhage is an important complication of anticoagulation therapy. A
review of many studies shows average yearly rates of warfarin-related bleeding as high as
0.8%, 4.9%, and 15%, for fatal, major and minor bleeding complications respectively [66].
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and as a consequence on anticoagulant effect. In the presence of genetic variations where the
activity of CYP2C9 is reduced, clearance of (S)-warfarin is also reduced. Activity of CYP2C9
between individuals can vary by more than 20-fold. (R)-warfarin is metabilised by multiple
different CYP enzymes [71].
While several single-nucleotide polymorphisms of CYP2C9 have been reported, the
CYP2C9*2 (Cysl44/Ile359) and CYP2C9*3 (Argl44/Leu359) polymorphisms have been identi‐
fied as clinically relevant [72]. Both of these variants are associated with decreased enzymat‐
ic activity [24, 73-78].
Homozygous CYP2C9*3 variant genotypes have only 5% to 10% metabolic efficiency com‐
pared to the wild-type genotype. As a result, compared to wild-type CYP2C9*1*1 controls,
enzyme activity and the median maintenance warfarin dose for CYP2C9*3*1 heterozygotes
was reduced by 40%, and by approximately 90% for CYP2C9*3*3 homozygotes [72-74].
Furuya [79] and Steward [75] showed that the CYP2C9*2 variant is also associated with re‐
duced warfarin elimination. Heterozygotes demonstrate 40% and homozygotes 15% of the
wild-type enzyme activity, causing dose adjustment for heterozygote CYP2C9*2 individuals
down to 20% less than the standard dose.
Margaglione [76] has also demonstrated bleeding rates as high as 27.9 per 100 patient-years
in carriers of CYP variants. In this study, findings were adjusted for other common variables
associated with increased bleeding risk, such as increased age, drug interactions and abnor‐
mal liver function.
Several studies of the *2 and *3 CYP2C9 polymorphisms consistently show that patients
with at least one CYP2C9 allele polymorphism have reduced warfarin requirements [76,
80-84]. Freeman [85] reported reduced warfarin weekly dosages for carriers of CYP2C9*2 or
CYP2C9*3 alleles compared with patients who were homozygous for the wild-type allele
(0.307 mg/kg/wk and 0.397 mg/kg/wk, respectively). Taube [83] compared warfarin mainte‐
nance dosages in 683 patients carrying different CYP2C9 genotypes. Mean warfarin mainte‐
nance dosages were 86% in patients with CYP2C9*1*2, 79% in patients with CYP2C9*1*3,
82% in compound heterozygotes CYP2C9*2/*3, and 61% in patients homozygous for
CYP2C9*2. Furthermore, Aithal [80] warns that even when warfarin dosages are decreased,
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carriers of CYP2C9 poor metaboliser alleles experience a rate of major bleeding that is 3.68-
fold higher than the rate seen in patients with the wild type genotype.
The frequency of CYP2C9 alleles is ethnically related [82, 86]. Approximately 20% of the
Caucasian population carries one of the loss-of-function CYP2C9 alleles, and it is estimated
that 1% of Caucasian carry two such alleles [71]. The frequency of the CYP2C9*2 allele re‐
portedly ranges from 8-13% in different Caucasian populations. CYP2C9*2 is present in 4%
of African-Americans and is rare among Japanese individuals [87, 88]. The frequency of
CYP2C9*3 is 6-10% among Caucasian populations and 3.8% in Japanese populations [88, 89].
This data suggests that a substantial fraction of the Caucasian patient population may carry
at least one defective CYP2C9 allele. In this group, the usual prescription dosage of warfarin
may lead to major or even life-threatening haemorrhage.
Warfarin is commonly prescribed in combination with selective serotonin reuptake inhibi‐
tors (SSRIs), as depression often coexists with cardiovascular disease. Case reports suggest
that some SSRIs can interact with warfarin to increase the likelihood of bleeding [90]. SSRIs
cause adverse effects in isolation [91, 92] and can interact with other medications by inhibit‐
ing various isoenzymes of the CYP450 enzyme group [93, 94]. It has been shown that metro‐
nidazole and cimetadine increase the prothrombin time in patients on warfarin therapy.
Chloramphenicol enhances warfarin's effect by inhibiting the action of the hepatic P450 sys‐
tem [71]. Some authors [95], [96] have warned that antidepressants with a known or predict‐
able interaction with warfarin, such as fluoxetine and fluvoxamine, should be avoided in
patients receiving warfarin because of the risk of adverse outcomes.
Drug-drug interaction is a main concern in adverse drug reactions. The primary complica‐
tion occurring with warfarin treatment is bleeding. SSRIs may increase the risk of bleeding
during warfarin therapy by hindering platelet aggregation through depletion of platelet se‐
rotonin levels [97-99]. Some SSRIs may also inhibit the oxidative metabolism of warfarin by
CYP 2C9 [95].
It has been shown that concurrent use of selective serotonin reuptake inhibitors and warfar‐
in increases the risk of hospitalisation due to haemorrhage [90, 98]. Drugs which affect sero‐
tonin may have a detrimental effect on platelet function, as drugs which inhibit the reuptake
of serotonin may decrease platelet serotonin levels leading to a reduction in serotonin-medi‐
ated platelet aggregation. Potential drug interactions can involve modification in either of
these mechanisms and may result in pharmacodynamic interference or enhancement of war‐
farin's action.
It  was  shown  that  major  and  moderate  drug-drug  interactions  with  warfarin  are  very
common  in  inpatients  and  are  associated  with  INR  results  outside  the  therapeutic
range.  The  most  common drugs  involved in  the  increase  of  anticoagulation effect  were
enoxaparin,  simvastatin,  omeprazole  and  tramadol.  Multivariate  analysis  showed  that
age,  length of  hospital  stay,  exposure  to  >/=4  major  or  moderate  drug interactions,  and
refusal  of  pharmacist  recommendations  contribute  significantly  to  the  patient's  INR  re‐
sult >5 [100].
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One study demonstrated that acetaminophen, at 2 g/day or 3 g/day, enhanced the anticoa‐
gulant effect of warfarin in stable patients, thus requiring close INR monitoring in the clini‐
cal setting [101].
4.2. Heparin
One of the preventative treatments of thromboembolic disease in patients is a prescription
of heparin. However, heparin induced thrombocytopenia (HIT) is one of the most serious
adverse reactions. HIT consequences can include thromboembolic complications and death.
An association between the Fc receptor gene and the risk for HIT has been found in some
studies and it was demonstrated that the homozygous 131Arg/Arg genotype occurred sig‐
nificantly more often in patients with HIT than in the healthy volunteers’ group [102] [103] ;
however, another group have found no association [104]. Results are very preliminary and
more evidence are needed before it may be possible to genotype candidates for heparin ther‐
apy to identify those at risk for drug-induced thromboembolic complications.
5. Statins
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) have reduced coronary
and cerebrovascular events and overall mortality when used for both primary and secon‐
dary prevention of ischemic heart disease [105]. Several known gene polymorphisms are as‐
sociated with the treatment progress [106, 107].
Some studies examined polymorphism in the gene encoding cholesteryl ester transfer pro‐
tein (CETP), which is involved in the metabolism of high-density lipoprotein (HDL). Pravas‐
tatin-treated patients with either the B1/B1 or B1/B2 genotype (B1 presence and B2 absence
of polymorphism) had significantly less atherosclerotic progression than patients receiving a
placebo. Placebo-treated patients with the B2/B2 genotype had the least progression. How‐
ever, pravastatin-treated patients with the B2/B2 genotype (16% of the study population) de‐
rived no benefit from pravastatin [108, 109].
The substitution (-455G/A) of the fibrinogen gene was found to be associated with an in‐
creased  risk  of  myocardial  infarction  and  stroke.  During  follow-up,  placebo-treated  pa‐
tients  homozygous  for  the  -455A  genotype  had  the  greatest  disease  progression;
although,  no  association  was  found  with  benefit  in  disease  progression  in  patients  on
pravastatin therapy [110].
A five year study of pravastatin therapy in patients with a history of myocardial infarction
and hypercholesterolemia showed that the largest benefit of pravastatin treatment in reduc‐
ing these events occurred in patients with the platelet GP IIIa PlA1/A2 genotype who also
carried at least one D allele of the ACE gene [111, 112].
An effect of polymorphism in the alloprotein gene was found on simvastatin therapy in a
Scandinavian study. Among patients who received the placebo and had at least one apolipo‐
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at least one defective CYP2C9 allele. In this group, the usual prescription dosage of warfarin
may lead to major or even life-threatening haemorrhage.
Warfarin is commonly prescribed in combination with selective serotonin reuptake inhibi‐
tors (SSRIs), as depression often coexists with cardiovascular disease. Case reports suggest
that some SSRIs can interact with warfarin to increase the likelihood of bleeding [90]. SSRIs
cause adverse effects in isolation [91, 92] and can interact with other medications by inhibit‐
ing various isoenzymes of the CYP450 enzyme group [93, 94]. It has been shown that metro‐
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able interaction with warfarin, such as fluoxetine and fluvoxamine, should be avoided in
patients receiving warfarin because of the risk of adverse outcomes.
Drug-drug interaction is a main concern in adverse drug reactions. The primary complica‐
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CYP 2C9 [95].
It has been shown that concurrent use of selective serotonin reuptake inhibitors and warfar‐
in increases the risk of hospitalisation due to haemorrhage [90, 98]. Drugs which affect sero‐
tonin may have a detrimental effect on platelet function, as drugs which inhibit the reuptake
of serotonin may decrease platelet serotonin levels leading to a reduction in serotonin-medi‐
ated platelet aggregation. Potential drug interactions can involve modification in either of
these mechanisms and may result in pharmacodynamic interference or enhancement of war‐
farin's action.
It  was  shown  that  major  and  moderate  drug-drug  interactions  with  warfarin  are  very
common  in  inpatients  and  are  associated  with  INR  results  outside  the  therapeutic
range.  The  most  common drugs  involved in  the  increase  of  anticoagulation effect  were
enoxaparin,  simvastatin,  omeprazole  and  tramadol.  Multivariate  analysis  showed  that
age,  length of  hospital  stay,  exposure  to  >/=4  major  or  moderate  drug interactions,  and
refusal  of  pharmacist  recommendations  contribute  significantly  to  the  patient's  INR  re‐
sult >5 [100].
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of polymorphism) had significantly less atherosclerotic progression than patients receiving a
placebo. Placebo-treated patients with the B2/B2 genotype had the least progression. How‐
ever, pravastatin-treated patients with the B2/B2 genotype (16% of the study population) de‐
rived no benefit from pravastatin [108, 109].
The substitution (-455G/A) of the fibrinogen gene was found to be associated with an in‐
creased  risk  of  myocardial  infarction  and  stroke.  During  follow-up,  placebo-treated  pa‐
tients  homozygous  for  the  -455A  genotype  had  the  greatest  disease  progression;
although,  no  association  was  found  with  benefit  in  disease  progression  in  patients  on
pravastatin therapy [110].
A five year study of pravastatin therapy in patients with a history of myocardial infarction
and hypercholesterolemia showed that the largest benefit of pravastatin treatment in reduc‐
ing these events occurred in patients with the platelet GP IIIa PlA1/A2 genotype who also
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protein e4 allele, the relative risk of death from all causes was higher than in simastatin pa‐
tients with the same polymorphism [113]. This study demonstrates the potential clinical
value of the alloprotein APOE genotype as a robust marker for low-density lipoprotein
(LDL) responses to statin drugs, which might contribute to the identification of a particular‐
ly drug-resistant subgroup of patients [114].
Genetic variants in CYP3A4, which metabolises simvastatin, atorvastatin and lovastatin,
have been associated with variability in statin efficacy. Both a nonsynonymous polymor‐
phism (M445T) as well the CYP3A4*4 haplotype have been associated with lower LDL cho‐
lesterol levels with atorvastatin. However, in carriers of either a CYP3A4 promoter
polymorphism (A290G) or the CYP3A4*1G haplotype the lipid-lowering effect of statins is
not demonstrated [115-117].
Variation in Hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and low-density lip‐
oprotein receptor (LDLR) genes are associated with the LDL-lowering effect of statins. The
H7 haplotype within HMGCR, defined by the presence of three intronic SNPs, has been as‐
sociated with an 11% to 19% reduction in LDL cholesterol with statin treatment in multiple
independent populations as well as ethnically diverse population-based cohorts [107, 114,
118]. The H7 haplotype has been shown to interact with other genetic variants, including a
second HMGCR haplotype, H2, as well as the LDLR L5 haplotype, defined by six SNPs
within the LDLR 3′ untranslated region. Ethnic variations in LDL cholesterol-lowering with
statin treatment is also demonstrated in African-Americans who carry multiple copies of
these haplotypes versus any haplotype alone [106, 118, 119].
Statin-related myotoxicity, especially rhabdomyolysis, is the subject of medical concerns as
it requires changes in medications and treatment discontinuation. It was found that variants
in CYP3A5 and solute carrier organic anion transporter family (SLCO1B1) gene can be po‐
tential predictors of myotoxicity [120-123].
Increased risk of coronary artery disease, coronary heart disease and myocardial infarction
are associated in some studies with a missense SNP, Trp719Arg, in the KIF6 gene (kinesin
family member 6). Statin treatment significantly reduce coronary events in carriers of
Trp719Arg, and SNPs in high linkage disequilibrium with it, whereas no benefit of statin
treatment is reported in noncarriers [124].
The differences in drug-drug interaction profiles among available statins offer the possibility
of reducing the risk of myotoxicity among high-risk patients. The risk of developing the
rhabdomyolysis condition with statin therapy increases at higher therapeutic doses. This ef‐
fect is increased by combination with certain other medications due to drug-drug interac‐
tions. Co-administration of drugs that inhibit the cytochrome P450 (CYP) enzymes
responsible for metabolizing statins, or that interact with the organic anion-transporting pol‐
ypeptides (OATPs) responsible for statin uptake into hepatocytes, substantially increases the
risk of developing myotoxicity. Pitavastatin, a novel statin approved for the treatment of hy‐
percholesterolemia and combined (mixed) dyslipidemia, is not catabolized by CYP3A4, un‐
like other lipophilic statins, and may be less dependent on the OATP1B1 transporter for its
uptake into hepatocytes before clearance [125].
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6. Antiarrhythmic
Many antiarrhythmic agents have antagonistic  effects  on sodium ion and potassium ion
channels  in  the  heart.  A  risk  of  proarrhythmic  effects  of  antiarrhythmic  drugs  and  its
mechanism is  associated with genetic  variations.  Some evidence indicates  that  polymor‐
phisms in genes encoding components of cardiac ion channels have been associated with
congenital arrhythmia syndromes, such as long-QT and idiopathic ventricular fibrillation
syndromes [126].
The fact that the risk of drug-induced arrhythmia usually increases with increasing drug
concentrations also indicates the involvement of liver enzyme polymorphisms. The CYP2D6
gene regulates cytochrome P450 metabolic pathways and some evidence shows an associa‐
tion between poor metaboliser phenotype and antiarrhythmic drug toxicity {127}.
A number of polymorphisms in the N-acetyltransferace 2 gene contribute to different acety‐
lator phenotypes. Rapid acetylators have increased conversion of procainamide by N-acetyl‐
transferase 2 to N-acetylprocainamide (NAPA) consequently leading to the QT-interval
prolongation, and life-threatening ventricular arrhythmias. Slow acetylators will attain an
increased concentration of procainamide levels with normal procainamide dosages, which
can lead to a procainamide- induced lupus-like syndrome [128].
Sotalol, dofetilide and quinidine increase the chances of QT interval prolongation, polymor‐
phic ventricular tachycardia and torsades de pointes. Several genes encoding ion channels
or function-modifying subunits were associated with these syndromes [129],[130-132].
One study suggested that a NOS1AP variant in the gene encoding an accessory protein for
neuronal nitric oxide synthase, was associated with total and cardiovascular mortality dur‐
ing treatment with dihydropyridine calcium channel blockers. Variants in NOS1AP also
have been reported to modulate the risk of arrhythmias, at equivalent QT interval durations,
in patients with the congenital long QT syndrome and to modulate risk for sudden death in
the general population [133-135].
7. Antiplatelet agents
7.1. Aspirin
Pharmacogenetic studies of aspirin response to date have found associations with a few
genes. It was reported that PLA2 (Leu59Pro) carriers, the variant in platelet glycoprotein
IIIa, have impaired aspirin responses. After seven days of aspirin therapy in healthy volun‐
teers, plasma prothrombin fragment concentrations in bleeding-time wounds were reduced
in 23 of 25 PLA1 homozygotes, compared with 9 of 15 PLA2 carriers [136]. A meta-analysis
[137] of 50 polymorphisms in 11 genes reported in 31 studies with a combined sample size
of 2834 subjects suggested that the common PLA1/2 polymorphism does confer aspirin re‐
sistance (odds ratio in healthy subjects=2.36; P=0.009); however, when combining both
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Pharmacogenetic studies of aspirin response to date have found associations with a few
genes. It was reported that PLA2 (Leu59Pro) carriers, the variant in platelet glycoprotein
IIIa, have impaired aspirin responses. After seven days of aspirin therapy in healthy volun‐
teers, plasma prothrombin fragment concentrations in bleeding-time wounds were reduced
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healthy subjects and those with cardiovascular disease, the odds ratio was 1.14 (P=0.40). The
PLA2 allele occurs with a frequency of approximately 15% in humans and has been associat‐
ed with increased platelet activation and aggregation in vitro [138].
Associations between the PLA polymorphisms and subacute thrombosis after coronary in‐
tervention have been described in some reports [139-141] and it was shown that an in‐
creased risk of subacute thrombosis is associated with the PLA2 allele. In one study, the risk
of subacute thrombosis after coronary angioplasty and stent placement was five times great‐
er in coronary artery disease patients with the PLA2 polymorphism than in patients homo‐
zygous for the PLA1 allele, despite similar antiplatelet therapy and similar clinical,
angiographic and procedural characteristics [139].
7.2. Clopidogrel
The obvious candidates for pharmacogenetic analysis are genes involved in clopidogrel me‐
tabolism. Clopidogrel is a prodrug and its active form, thiol, is formed during the biotrans‐
formation in the liver. CYP2C19, CYP3A4/5, CYP1A2, and CYP2B6 are involved in this
process [142].
P2Y12 belongs to the G protein-coupled purinergic receptor for adenosine diphosphate
(ADP). The P2Y12 protein is found mainly, but not exclusively, on the surface of blood pla‐
telets, and is an important regulator in blood clotting. The active clopidogrel metabolite irre‐
versibly binds to platelet ADP P2Y12 receptors. ADP P2Y12 receptors and loss-of-function
CYP2C19*2 was identified as the single major genetic determinant of biochemical response
to clopidogrel, accounting for approximately 12% of the variation in ADP-stimulated plate‐
let aggregation during drug treatment [143]. CYP2C19*2 carriers treated with clopidogrel
have an increased risk for major adverse cardiovascular events compared to noncarriers and
increased risks of stent thrombosis [144].
Loss-of-function CYP2C19*2 allele has been reproducibly shown to be associated with a de‐
creased conversion of clopidogrel into its active metabolite, reduced antiplatelet effect and
increased risk for cardiovascular events in patients using clopidogrel [4, 145].
The frequency of CYP2C19*2 polymorphism varies in different populations: in Caucasian,
African American, and Mexicans it presence is 18% to 33% (2%–3% homozygotes) and the
allele frequency is higher in Asians. The loss-of-function *3 variant is also associated with
poorer response and is highly prevalent in Asians [146, 147].
P-glycoprotein, also known as multidrug resistance protein 1 (MDR1) or ATP-binding cas‐
sette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243), is a glyco‐
protein that in humans is encoded by the ABCB1 gene. ABC transporters are
transmembrane proteins that utilize the energy of adenosine triphosphate hydrolysis to car‐
ry out certain biological processes including translocation of various substrates across mem‐
branes and non-transport-related processes such as translation of RNA and DNA repair.
Contradicting results have been reported for variants in ABCB1 and Gln192Arg allele in par‐
aoxonase 1, which have been implicated in clopidogrel responsiveness. These associations
need further confirmation [148-150].
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8. Conclusion
Adverse drug reactions (ADRs) have been reported to be the cause for drug withdrawal af‐
ter marketing, hospital admissions, death in hospitalised patients and to be the fourth lead‐
ing cause of death in developed countries. The costs associated with ADRs may radically
escalate the cost for healthcare.
There is an increasing use of multiple medications to treat patients with chronic illnesses.
Drug-drug interactions are common and growing in frequency due to increasing numbers of
medications available and the number of patients on multiple medications. The knowledge
of the pharmacodynamics and pharmacokinetics of the drugs helps to avoid unintended
and problematic drug interactions. Several web sites, books, and cards are available for the
clinician. The web sites are updated on a regular basis and are useful tools for prescribers.
The necessity to understand drug combination pharmacokinetics and pharmacodinamics
in drug interactions is illustrated by the following example: a patient who is taking a drug
equally cleared by CYP2D6 and CYP3A. That patient may not be at  substantial  risk for
toxicity when treated with either a CYP2D6 or CYP3A inhibitor alone, but may be if treat‐
ed  with  both  inhibitors  at  the  same  time  [151].  Pharmacodynamic  or  pharmacokinetic
drug interaction is a complex process and includes understanding of individual variations
in drug metabolism.
Pharmacogenetics has a potential role in reducing ADRs at the pre-marketing and post-mar‐
keting stages of drug development and in clinical care. A priori identification of individuals
at risk of developing ADRs for a given drug will help develop strategies to reduce the risk
for ADRs in these patients. It can also be used to identify individuals at risk of developing
serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs
that are traditionally considered unavoidable to avoidable ADRs.
Although pharmacogenetics is a highly complex and ever-evolving science, it has amassed
knowledge that can readily be used to provide efficient care to patients. It has been shown
that gene variants that play a role in drug metabolism pathways can alter a patient's re‐
sponse or increase toxicity at normal dosage range, especially in combinational drug treat‐
ments. Pharmacogenetics seeks to understand the nature of variable drug responses. Several
pharmacogenetics tests are already available for cardiovascular medications in biomedical
laboratories (Table 1).
Pharmacogenetic findings may help to explain ethnic differences in drug response. The ac‐
cumulated facts of ethnic differences in cardiovascular drug responses and the fact that
many genetic polymorphisms differ in frequency on the basis of ethnicity (example in the
Western Sydney population, Fig. 1) will undoubtedly support future development of phar‐
macogenetics in patient care and in drug interaction interpretation.
It  is  possible  that  use  of  genetic  and other  patient-specific  information,  including  envi‐
ronmental  factors  will  help  guide  drug  therapy  decisions  for  certain  drugs  and  drug
combinations.
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Figure 1. Example of diversity in prevalence of clinically relevant polymorphisms. (*Western Sydney Population com‐
bined data. WSLHD population is a mix of Caucasians, Asians and Africans.)
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Appendix
Glossary of some Pharmacogenetic Terms
• Allele: An alternative form of a gene at a given locus.
• Genetic polymorphism: Minor allele frequency of ≥1% in the population.
• Genome: The complete DNA sequence of an organism. Sum total of the genetic material
included in every cell of the human body, apart from the red blood cells.
• Genomewide association study (GWAS): A genetic association study in which the densi‐
ty of genetic markers and the extent of linkage disequilibrium are sufficient to capture a
large proportion of the common variation in the human genome in the population under
study, and the number of specimens genotyped provides sufficient power to detect var‐
iants of modest effect.
• Genotype: The alleles at a specific locus an individual carries. The genetic constitution of
an individual, i.e. the specific allelic makeup of an individual.
• Haplotype: A group of alleles from two or more loci on a chromosome; inherited as a
unit.
• Heterozygote: A person who has two copies of an allele that are different.
• Homozygote: A person who has two copies of an allele that are the same.
• Pharmacogenetics: A study of genetic causes of individual variations in drug response. In
this review, the term "pharmacogenetics" is interchangeable with "pharmacogenomics."
• Pharmacogenomics: Genomewide analysis of the genetic determinants of drug efficacy
and toxicity. Pharmacogenetics focuses on a single gene while pharmacogenomics studies
multiple genes.
• Phenotype: Observable expression of a particular gene or genes.
• Single nucleotide polymorphism (SNP): is a DNA sequence variation occurring when a
single nucleotide in the genome differs between members of a biological species or paired
chromosomes in an individual.
Useful Internet Resources and databases:
• OMIM (Online Mendelian Inheritance in Man), National Centre for Biotechnology Infor‐
mation (NCBI): www.ncbi.nlm.nih.gov/sites/entrez?db=omim
• PharmGKB (The Pharmacogenetics and Pharmacogenomics Knowledge Base):
www.pharmgkb.org/#public
• NCBI, Individual SNP information, such as genetic location, nucleotide and amino acid
changes, and allele frequencies in diverse populations, can be obtained from dbSNP:
www.ncbi.nlm.nih.gov/sites/entrez?db=snp
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• Databases: ensembl (www.ensembl.org/index.html) and HapMap (www.hapmap.org/cgi-
perl/gbrowse/hapmap_B35)
• FDA: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics
• FDA: Table of Pharmacogenomic Biomarkers in Drug Labels: http://www.fda.gov/Drugs/
ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
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1. Introduction
Obesity and overweight have increasingly become major global health issues. Data from the
World Health Organization (WHO) reports a near doubling of the prevalence of obesity
worldwide from 1998 to 2008 [1]. In the European Region, an average of over 50% of adults
are overweight and nearly 23% obese, with the prevalence of overweight and obesity being
highest in Finland (67.1%), Germany (67.2%), the United Kingdom (67.8%), Malta (73.3%), and
Greece (77.5%) [2]. Similar alarming trends are seen in the United States NHANES data where
68% of adults have a body mass index (BMI) greater than 25 (overweight or obese) and nearly
37% of the population is considered obese [3-7]. A large burden of health care costs can be
attributed to overweight and obesity since multiple disease states such as diabetes, cancer,
heart disease can be linked overweight and obesity [8-10]. The WHO estimates that up to 6%
of health care expenditures in the European Region, while estimates for the United States have
been estimated at 5.7% of the National Health Expenditure [8-11]. Most major organizations,
like the WHO, and governmental agencies such as the U.S. Department of Agriculture Center
for Nutrition Policy and Promotion have a major focus on the treatment of the obesity epidemic
through promotion of proper healthy lifestyle changes [11, 12]. Although multiple anti-obesity
agents have progressed through the development process, few drug products have made it
through the approval process due to safety or lack of efficacy concerns. Several products, such
as amphetamine, fenfluramine and sibutramine, have had their approval removed and/or have
been removed from the market following reports linking the drugs to cardiovascular side
effects (e.g. hypertension and myocardial infarction), addiction, and death [13-15]. As an
alternative, overweight or obese patients may turn to less regulated dietary supplements as a
means to assist in weight loss. Multiple herbal products are available that are indicated, often
without significant scientific basis, for the treatment of overweight and obesity. The safety and
© 2013 Jordan; licensee InTech. This is an open access article distributed under the terms of the Creative
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1. Introduction
Obesity and overweight have increasingly become major global health issues. Data from the
World Health Organization (WHO) reports a near doubling of the prevalence of obesity
worldwide from 1998 to 2008 [1]. In the European Region, an average of over 50% of adults
are overweight and nearly 23% obese, with the prevalence of overweight and obesity being
highest in Finland (67.1%), Germany (67.2%), the United Kingdom (67.8%), Malta (73.3%), and
Greece (77.5%) [2]. Similar alarming trends are seen in the United States NHANES data where
68% of adults have a body mass index (BMI) greater than 25 (overweight or obese) and nearly
37% of the population is considered obese [3-7]. A large burden of health care costs can be
attributed to overweight and obesity since multiple disease states such as diabetes, cancer,
heart disease can be linked overweight and obesity [8-10]. The WHO estimates that up to 6%
of health care expenditures in the European Region, while estimates for the United States have
been estimated at 5.7% of the National Health Expenditure [8-11]. Most major organizations,
like the WHO, and governmental agencies such as the U.S. Department of Agriculture Center
for Nutrition Policy and Promotion have a major focus on the treatment of the obesity epidemic
through promotion of proper healthy lifestyle changes [11, 12]. Although multiple anti-obesity
agents have progressed through the development process, few drug products have made it
through the approval process due to safety or lack of efficacy concerns. Several products, such
as amphetamine, fenfluramine and sibutramine, have had their approval removed and/or have
been removed from the market following reports linking the drugs to cardiovascular side
effects (e.g. hypertension and myocardial infarction), addiction, and death [13-15]. As an
alternative, overweight or obese patients may turn to less regulated dietary supplements as a
means to assist in weight loss. Multiple herbal products are available that are indicated, often
without significant scientific basis, for the treatment of overweight and obesity. The safety and
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efficacy of herbal products is often unknown, especially given the presence of multiple
chemical compounds, lack of known active constituents or lack of standardization of known
compounds [16-19].This chapter presents a review of the chemistry and pharmacology of
approved anti-obesity drug products, the proposed mechanism of action for common dietary
supplements used in the management of weight loss, and potential drug-drug or herb-drug
interactions.
2. Drugs used in weight LOcSS
2.1. Sympathomiometic agents
2.1.1. Diethylpropion hydrochloride (Tenuate®; Tenuate® Dospan®; Durad®)
Diethylpropion HCl (amfepramone, Figure 1a) is a sympathomimetic aminoketone agent with
some similarity both chemically and pharmacologically to amphetamines and other related
stimulant drugs. Similarly to amphetamine, diethylpropion stimulates release while inhibiting
reuptake of dopamine, norepinephrine, and 5-hydroxytryptamine [20, 21]. The increase in
norepinephrine and dopamine levels along with inhibition of their reuptake is proposed as
the mechanism of diethylpropion anorectic effects [22]. Diethylpropion is indicated for short
term management of obesity in patients with a body mass index (BMI) of > 30 kg/m2 who have
not responded to diet and exercise alone [23]. Because of its similarity to amphetamine, some
patients become psychologically dependent on diethylpropion with an increased risk of self-
medicating at higher dosages, increasing potential for drug interactions.
Diethylpropion is a monoamine and therefore can interact with monoamine oxidase inhibitors
(MAOI), resulting in hypertension [23]. The manufacturer recommends avoiding use of
diethylpropion during or within 14 days of discontinuation of MAOI administration. There is
also one reported case of diethylpropion -induced psychosis in a 26 year old female patient
taking phenelzine [24]. The authors hypothesized that chronic diethylpropion use led to an
increased sensitivity to MAOI psychosis-inducing effects. Although the additive effects of
diethylpropion in combination with other anorectic agents has not been studied, combined
use of these agents is contraindicated due to the potential increased risk of cardiovascular
issues [23]. In an early study of diethylpropion in 32 obese hypertensive patients, a drop in
blood pressure was observed [25]. However, it was unclear if the drop in blood pressure in
these subjects was due to weight loss or the additive effect of additional hypertensive agents
that the patients were taking. The manufacturer also recommends potential modification of
insulin dosing, although no strong evidence to support this statement can be found. In one
study done in the rat, it was determined that anorectic drugs acting via the dopaminergic
system antagonize hyperphagia induced by 2-deoxy-D-glucose, although the authors did not
find any modifications to insulin-induced hypoglycemia [26]. There are no reported cases of
drug-herb interactions with diethylpropion. However, theoretically herbal products with CNS
stimulant properties (e.g. ephedra, caffeine, bitter orange), potential for interaction with
sympathomimetic agents (e.g. Indian snakeroot), or MAOI activity (e.g. yohimbe) should be
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Figure 1. Molecular structures of anorectic drugs.
2.1.2. Phentermine / Phentermine hydrochloride (Fastin®, Ionamin®, Adipex-P®, Suprenza®)
Phentermine (Figure 1b), a member of the β-phenylethylamine family of compounds, exerts
anorectic activity centrally through appetite suppression and is indicated in the short term
treatment of obesity in patients with a BMI ≥ 30 kg/m2 [28]. A meta-analysis of six randomized
controlled trials of phentermine cumulatively show an added 3.6 kg weight loss over 2 to 24
weeks compared to control groups [29]. Phentermine acts by increasing the release of and
inhibiting the reuptake of norepinephrine or dopamine [22]. Although one of the oldest
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efficacy of herbal products is often unknown, especially given the presence of multiple
chemical compounds, lack of known active constituents or lack of standardization of known
compounds [16-19].This chapter presents a review of the chemistry and pharmacology of
approved anti-obesity drug products, the proposed mechanism of action for common dietary
supplements used in the management of weight loss, and potential drug-drug or herb-drug
interactions.
2. Drugs used in weight LOcSS
2.1. Sympathomiometic agents
2.1.1. Diethylpropion hydrochloride (Tenuate®; Tenuate® Dospan®; Durad®)
Diethylpropion HCl (amfepramone, Figure 1a) is a sympathomimetic aminoketone agent with
some similarity both chemically and pharmacologically to amphetamines and other related
stimulant drugs. Similarly to amphetamine, diethylpropion stimulates release while inhibiting
reuptake of dopamine, norepinephrine, and 5-hydroxytryptamine [20, 21]. The increase in
norepinephrine and dopamine levels along with inhibition of their reuptake is proposed as
the mechanism of diethylpropion anorectic effects [22]. Diethylpropion is indicated for short
term management of obesity in patients with a body mass index (BMI) of > 30 kg/m2 who have
not responded to diet and exercise alone [23]. Because of its similarity to amphetamine, some
patients become psychologically dependent on diethylpropion with an increased risk of self-
medicating at higher dosages, increasing potential for drug interactions.
Diethylpropion is a monoamine and therefore can interact with monoamine oxidase inhibitors
(MAOI), resulting in hypertension [23]. The manufacturer recommends avoiding use of
diethylpropion during or within 14 days of discontinuation of MAOI administration. There is
also one reported case of diethylpropion -induced psychosis in a 26 year old female patient
taking phenelzine [24]. The authors hypothesized that chronic diethylpropion use led to an
increased sensitivity to MAOI psychosis-inducing effects. Although the additive effects of
diethylpropion in combination with other anorectic agents has not been studied, combined
use of these agents is contraindicated due to the potential increased risk of cardiovascular
issues [23]. In an early study of diethylpropion in 32 obese hypertensive patients, a drop in
blood pressure was observed [25]. However, it was unclear if the drop in blood pressure in
these subjects was due to weight loss or the additive effect of additional hypertensive agents
that the patients were taking. The manufacturer also recommends potential modification of
insulin dosing, although no strong evidence to support this statement can be found. In one
study done in the rat, it was determined that anorectic drugs acting via the dopaminergic
system antagonize hyperphagia induced by 2-deoxy-D-glucose, although the authors did not
find any modifications to insulin-induced hypoglycemia [26]. There are no reported cases of
drug-herb interactions with diethylpropion. However, theoretically herbal products with CNS
stimulant properties (e.g. ephedra, caffeine, bitter orange), potential for interaction with
sympathomimetic agents (e.g. Indian snakeroot), or MAOI activity (e.g. yohimbe) should be
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Figure 1. Molecular structures of anorectic drugs.
2.1.2. Phentermine / Phentermine hydrochloride (Fastin®, Ionamin®, Adipex-P®, Suprenza®)
Phentermine (Figure 1b), a member of the β-phenylethylamine family of compounds, exerts
anorectic activity centrally through appetite suppression and is indicated in the short term
treatment of obesity in patients with a BMI ≥ 30 kg/m2 [28]. A meta-analysis of six randomized
controlled trials of phentermine cumulatively show an added 3.6 kg weight loss over 2 to 24
weeks compared to control groups [29]. Phentermine acts by increasing the release of and
inhibiting the reuptake of norepinephrine or dopamine [22]. Although one of the oldest
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approved anti-obesity drugs, the safety of monotherapy of phentermine is relatively scarce
due to the long history of combination products, most notably phentermine/fenfluramine
(Phen-Fen), which was removed from the market due to serious and potentially fatal cardio‐
vascular effects [30, 31]. More recently a combination product containing phentermine and
topiramate has been investigated (see Topiramate below) and is currently under review by the
US Food and Drug Administration (FDA).
Because of the similarity in activity and mechanism of action, drug interactions with phenter‐
mine are similar to those for diethylpropion (see Diethylpropion above) including avoidance of
alcohol, potential changes to antidiabetic agent therapy, and avoidance of coadministration of
MAOIs [28]. There is one case report of a female patient experiencing two penropative
hypertensive crises, which were attributed to an interaction between phentermine and
anesthetic agents [32].
2.2. Antiepileptic agents
Several antiepileptic agents are known to have an effect on weight gain [33]. However, two
newer antiepileptic agents, topiramate and zonisamide, have shown an associated decrease in
weight in patients taking these medications [34]. Therefore, these two drugs are being looked
at as potential anorectic agents.
2.2.1. Topiramate (Topamax®)
Topiramate is a carbonic anhydrase inhibitor (Figure 1c) that is typically used in the treatment
of migraines and as an anticonvulsant [35]. Topiramate is proposed to exert its antiepileptic
activity via gamma-aminobutyric acid (GABA)-A-mediated inhibition via a benzodiazepine
insensitive pathway, although the drug also blocks voltage dependent sodium channels
[35-37]. Weight loss has been a commonly reported adverse effect of topiramate; therefore, the
drug has recently come into focus as a potential anorectic agent [38-42]. Topiramate has shown
promise as a combination low-dose therapy with phentermine (Qsymia(R) (originally
Qnexa(R), Vivus Pharmaceuticals, Mountain View, CA, USA) for long term treatment of
obesity [43-46]. Despite, safety concerns related to teratogenicity and cardiovascular effects,
the product has recently been approved by the U.S. Food and Drug Administration.”
Drug interactions with topiramate include coadministration with other antiepileptic agents.
Although no changes in carbamazepine or phenytoin levels were seen, topiramate levels
decreased by 40% or 48%, respectively [35]. However, there have been two case reports of
antiepileptic drug intoxications in patients initiated on topiramate who were already taking
the maximum carbamazepine dose [47]. Decrease in carbamazepine dosage resolved the
interaction. Hyperammonemia, hypothermia and potentially encephalopathy can result from
a synergistic interaction between topiramate, valproic acid, and phenobarbital, although the
exact mechanism of this interaction is unknown [35, 48-50]. Levels of ethinyl estradiol can be
significantly decreased in patients taking topiramate as an adjunctive therapy with valproic
acid [35]. As a carbonic anhydrase inhibitor, topiramate can cause metabolic acidosis, and
therefore is contraindicated in patients taking metformin, while patients taking other carbonic
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anhydrase inhibitors should be monitored due to the potential additive effects when coadmi‐
nistered with topiramate [51-55]. High doses of topiramate (600 mg/day) can increase systemic
exposure to lithium. However, since topiramate dosage proposed to anorectic effects is low,
this interaction may not be a significant concern when used as anti-obesity treatment [56]. No
clinical studies or case studies are available for interactions with CNS depressants (e.g alcohol),
although combined use is contraindicated by the manufacturer due to combined CNS
depression [35]. No data supporting herb-drug interactions are available specifically related
to use of topiramate at low doses as an anorectic agent [27].
2.2.2. Zonisamide (Zonegran®)
Zonisamide (Figure 1d), a methanesulfonamide, is an antiepileptic agent which has broad
spectrum activity and has proven to be useful in patients not responding to other antiepileptic
treatments [57]. The drug blocks sustained and repetitive neuronal firing by blocking voltage
sensitive sodium channels and decreasing voltage sensitive T-type calcium channels [58, 59].
Additionally, it was found that zonisamide has dopaminergic and serotonergic activity, which
contributes to the anorectic effects of the drug [60, 61]. In one randomized placebo-controlled
trial, 30 subjects were administered zonisamide 100 mg daily along with a low calorie diet (500
kcal/day) for a period of 16 weeks. Dosage was increased to up to 600 mg/day for patients not
losing >5% of their initial body weight within the first 12 weeks. The zonisamide group lost
significantly more body weight at the end of the trial compared to the placebo group (approx.
6% loss vs. 1% loss) [62].
Zonisamide is metabolized by the cytochrome P450 3A4 system and therefore can potentially
interact with other drugs metabolized via this route. In one study, the half-life of zonisamide
(t½ = 60 h) was decreased in patients receiving both zonisamide and phenytoin (t½ = 27 h),
carbamazepine (t½ = 38 h, and sodium valproate (t½ = 46 h) [57, 63]. Another study in the dog
demonstrated decreased plasma levels of zonisamide during administration of phenobarbital
[64]. However, any associated decrease in levels of other antiepileptic drugs was not found to
be clinically significant [65, 66]. Cigarette smoking may alter the pharmacokinetics of zonisa‐
mide. Coadministration of carbonic anhydrase inhibitors may increase risk of metabolic
acidosis and kidney stone formation, therefore monitoring is recommended in this patient
population [66]. One study on the effects of cigarette smoke on zonisamide concentrations in
rats suggests that cigarette smoke may decrease plasma levels of the drug due to decreased
oral absorption [67]. Brain, but not plasma levels of zonisamide may be affected by chronic
ethanol consumption. In one study inbred EL mice were administered zonisamide 75 mg/kg
for 1 – 4 weeks along with 10% ethanol ad libidum. In groups with 4 week coadministration,
representing chronic use of alcohol, a decrease in zonisamide brain concentrations, but not
serum concentration were observed [68].
2.3. Orlistat (Xenical®, Alli®)
Orlistat (Figure 1e) is a gastrointestinal lipase inhibitor approved both as a prescription
(Xenical®) and over-the-counter (Alli®) weight loss aid in the long term treatment of obesity
[69]. The drug exhibits antiobesity activity by inhibiting the absorption of dietary fat from the
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approved anti-obesity drugs, the safety of monotherapy of phentermine is relatively scarce
due to the long history of combination products, most notably phentermine/fenfluramine
(Phen-Fen), which was removed from the market due to serious and potentially fatal cardio‐
vascular effects [30, 31]. More recently a combination product containing phentermine and
topiramate has been investigated (see Topiramate below) and is currently under review by the
US Food and Drug Administration (FDA).
Because of the similarity in activity and mechanism of action, drug interactions with phenter‐
mine are similar to those for diethylpropion (see Diethylpropion above) including avoidance of
alcohol, potential changes to antidiabetic agent therapy, and avoidance of coadministration of
MAOIs [28]. There is one case report of a female patient experiencing two penropative
hypertensive crises, which were attributed to an interaction between phentermine and
anesthetic agents [32].
2.2. Antiepileptic agents
Several antiepileptic agents are known to have an effect on weight gain [33]. However, two
newer antiepileptic agents, topiramate and zonisamide, have shown an associated decrease in
weight in patients taking these medications [34]. Therefore, these two drugs are being looked
at as potential anorectic agents.
2.2.1. Topiramate (Topamax®)
Topiramate is a carbonic anhydrase inhibitor (Figure 1c) that is typically used in the treatment
of migraines and as an anticonvulsant [35]. Topiramate is proposed to exert its antiepileptic
activity via gamma-aminobutyric acid (GABA)-A-mediated inhibition via a benzodiazepine
insensitive pathway, although the drug also blocks voltage dependent sodium channels
[35-37]. Weight loss has been a commonly reported adverse effect of topiramate; therefore, the
drug has recently come into focus as a potential anorectic agent [38-42]. Topiramate has shown
promise as a combination low-dose therapy with phentermine (Qsymia(R) (originally
Qnexa(R), Vivus Pharmaceuticals, Mountain View, CA, USA) for long term treatment of
obesity [43-46]. Despite, safety concerns related to teratogenicity and cardiovascular effects,
the product has recently been approved by the U.S. Food and Drug Administration.”
Drug interactions with topiramate include coadministration with other antiepileptic agents.
Although no changes in carbamazepine or phenytoin levels were seen, topiramate levels
decreased by 40% or 48%, respectively [35]. However, there have been two case reports of
antiepileptic drug intoxications in patients initiated on topiramate who were already taking
the maximum carbamazepine dose [47]. Decrease in carbamazepine dosage resolved the
interaction. Hyperammonemia, hypothermia and potentially encephalopathy can result from
a synergistic interaction between topiramate, valproic acid, and phenobarbital, although the
exact mechanism of this interaction is unknown [35, 48-50]. Levels of ethinyl estradiol can be
significantly decreased in patients taking topiramate as an adjunctive therapy with valproic
acid [35]. As a carbonic anhydrase inhibitor, topiramate can cause metabolic acidosis, and
therefore is contraindicated in patients taking metformin, while patients taking other carbonic
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anhydrase inhibitors should be monitored due to the potential additive effects when coadmi‐
nistered with topiramate [51-55]. High doses of topiramate (600 mg/day) can increase systemic
exposure to lithium. However, since topiramate dosage proposed to anorectic effects is low,
this interaction may not be a significant concern when used as anti-obesity treatment [56]. No
clinical studies or case studies are available for interactions with CNS depressants (e.g alcohol),
although combined use is contraindicated by the manufacturer due to combined CNS
depression [35]. No data supporting herb-drug interactions are available specifically related
to use of topiramate at low doses as an anorectic agent [27].
2.2.2. Zonisamide (Zonegran®)
Zonisamide (Figure 1d), a methanesulfonamide, is an antiepileptic agent which has broad
spectrum activity and has proven to be useful in patients not responding to other antiepileptic
treatments [57]. The drug blocks sustained and repetitive neuronal firing by blocking voltage
sensitive sodium channels and decreasing voltage sensitive T-type calcium channels [58, 59].
Additionally, it was found that zonisamide has dopaminergic and serotonergic activity, which
contributes to the anorectic effects of the drug [60, 61]. In one randomized placebo-controlled
trial, 30 subjects were administered zonisamide 100 mg daily along with a low calorie diet (500
kcal/day) for a period of 16 weeks. Dosage was increased to up to 600 mg/day for patients not
losing >5% of their initial body weight within the first 12 weeks. The zonisamide group lost
significantly more body weight at the end of the trial compared to the placebo group (approx.
6% loss vs. 1% loss) [62].
Zonisamide is metabolized by the cytochrome P450 3A4 system and therefore can potentially
interact with other drugs metabolized via this route. In one study, the half-life of zonisamide
(t½ = 60 h) was decreased in patients receiving both zonisamide and phenytoin (t½ = 27 h),
carbamazepine (t½ = 38 h, and sodium valproate (t½ = 46 h) [57, 63]. Another study in the dog
demonstrated decreased plasma levels of zonisamide during administration of phenobarbital
[64]. However, any associated decrease in levels of other antiepileptic drugs was not found to
be clinically significant [65, 66]. Cigarette smoking may alter the pharmacokinetics of zonisa‐
mide. Coadministration of carbonic anhydrase inhibitors may increase risk of metabolic
acidosis and kidney stone formation, therefore monitoring is recommended in this patient
population [66]. One study on the effects of cigarette smoke on zonisamide concentrations in
rats suggests that cigarette smoke may decrease plasma levels of the drug due to decreased
oral absorption [67]. Brain, but not plasma levels of zonisamide may be affected by chronic
ethanol consumption. In one study inbred EL mice were administered zonisamide 75 mg/kg
for 1 – 4 weeks along with 10% ethanol ad libidum. In groups with 4 week coadministration,
representing chronic use of alcohol, a decrease in zonisamide brain concentrations, but not
serum concentration were observed [68].
2.3. Orlistat (Xenical®, Alli®)
Orlistat (Figure 1e) is a gastrointestinal lipase inhibitor approved both as a prescription
(Xenical®) and over-the-counter (Alli®) weight loss aid in the long term treatment of obesity
[69]. The drug exhibits antiobesity activity by inhibiting the absorption of dietary fat from the
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lumen of the stomach and small intestine through covalent binding with gastric and pancreatic
lipase active serine residues [70]. Multiple randomized controlled trials have reported
significant weight loss in patients taking orlistat compared to placebo controlled groups. One
meta-analysis cites mean weight loss compared to control of -2.59 kg [95%CI, -3.46 to -1.74] or
-2.9 kg [95%CI, -3.2 to -2.5] over 6 or 12 months, respectively, with a corresponding decrease
in waist circumference, blood pressure, and blood glucose and lipid profiles [71-73].
A large number of preclinical and clinical studies and case reports related to potential drug
interactions with orlistat have been published. There have been several cases of orlistat
interaction with cyclosporine [74-79]. In all cases, significant decreases in plasma cyclosporine
levels were observed following adjunct treatment with orlistat for cyclosporine-associated
weight gain. Although one proposed mechanism for the reduction in plasma cyclosporine is
a decrease in drug absorption, decreased levels may be due to rapid gastrointestinal transit
time resulting from contraindicated high fat diets rather than a true drug-drug interaction [80].
Because orlistat is designed to inhibit gastrointestinal lipases, theoretically absorption of
lipophilic molecules would also be inhibited [81-83]. In one open-label, placebo-controlled
randomized two-way crossover study, orlistat (120 mg) was administered to 12 healthy
subjects three times daily for 9 days followed by administration of Vitamin A (25,000 IU) or
Vitamin E (400 IU) [82]. Although no effect was seen on Vitamin A levels, a significant
reduction in Cmax (approx. 43%) and AUC (approx. 60%) were observed for Vitamin E,
suggesting impaired absorption of Vitamin E by orlistat. In another study, approximately a
30% reduction in beta-carotene levels was observed after administration of orlistat (120 mg)
for four days followed by administration of 0 – 120 mg of beta-carotene three times a day for
six days [83]. Absorption of lipophilic drugs such as the CNS agent lamotrigene can also be
affected by orlistat. In one report, increased frequency of seizures was reported in an 18 year
old female taking lamotrigene following initiation of an orlistat regimen [84]. One case of
hypothyroidism in thyroid carcinoma was reported, presumably due to decreased absorption
of thyroxine [85]. Although orlistat was not found to alter warfarin kinetics per se, but the drug
may alter absorption of the fat soluble vitamin K which can have an effect warfarin levels and
therefore these patients should be monitored for changes in coagulation parameters [86].
2.4. Rimonabant (Acomplia®, Zumulti®)
Rimonabant (Figure 1f) is a cannabanoid receptor antagonist that suppresses appetite by
preventing activation of CB1 receptors by the endogenous cannabanoids anandamide and 2-
arachidonoyl-glycerol [87]. In clinical trials the drug resulted in improvement of multiple
endpoints associated with obesity and metabolic syndrome compared to control groups
including significant weight loss, reduction in waist circumference, decreased triglycerides,
blood glucose, fasting insulin, and leptin levels with increased HDL cholesterol and adipo‐
nectin levels [88-96]. Although rimonabant proved a potentially successful drug in the
treatment of obesity, especially given lack of cardiovascular risks compared to other weight
loss drugs (see Sibutramine below), the drug has not been approved by the U.S. Food and Drug
Administration (FDA). Additionally, although the drug was initially approved in 2006 by the
European Medicines Agency (EMEA), later studies indicating serious neuropsychiatric
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adverse events, especially related to increased risk of suicide, caused the Agency to rescind
the approval in 2009. Although rimonabant is not available in most major markets, ongoing
investigations surrounding the development of the drug continue, while the drug has been
approved in other markets [97-100]. Additionally, the drug appears to be available readily via
online pharmacy services and has been identified as an adulterant in dietary supplements
marketed for weight loss (see Adulteration of Dietary Supplements below) [101-103].
Given the limited and short-lived approval status of rimonabant, there is little information
regarding potential drug-drug and herb-drug interactions available. According to package
insert data submitted to the EMEA, rimonabant is known to be eliminated hepatically and into
the bile by amidohydrolase and CYP3A4, with a 104% increase in rimonabant AUC (95% CI
40 – 197%) upon coadministration of ketoconazole [92, 96, 104, 105]. Therefore, the manufac‐
turer indicated potential interactions with strong CYP3A4 inhibitors (e.g. ketoconazole,
itraconazole, ritonavir, telithromycin, clarithromycin, and nefazodone) and inducers (e.g.
rifampicin, phenytoin, phenobarbital, carbamazepine, and St. John’s Wort). Because rimona‐
bant can decrease levels of fasting insulin and blood sugar, use of rimonabant in diabetic
patients taking anti-diabetic agents is cautioned [92, 96, 104, 105].
2.5. Sibutramine (Meridia®, Reductil®)
Sibutramine hydrocholoride (Figure 1g), and its active primary (M1) and secondary (M2)
metabolites, is a selective serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine
reuptake inhibitor [106-110]. Clinical data supported the efficacy of sibutramine as a weight
loss agent, reporting significant weight loss compared to placebo for patients taking at least
10 mg/day for up to one year [107, 110-114]. The drug was approved as an anti-obesity agent
in 1997 by the U.S. FDA and in 2002 by the EMEA, despite evidence of increased risk of
hypertension and tachycardia, with a requirement that additional post-marketing safety data
be collected relative to cardiotoxicity. As a result, the SCOUT (Sibutramine Cardiovascular
OUTcomes) trial was implemented, which enrolled 10,000 overweight or obese patients aged
55 and older with coexisting diabetes and/or heart disease in a randomized controlled trial
with a 6-month lead in period [115-118]. At the end of the six year study period, data showed
a significant decrease in body weight compared to placebo but increased cardiovascular
morbidity in the randomized sibutramine group [115-118]. Following publication of the
SCOUT trial results in 2010, the EMEA and most other major markets pulled sibutramine while
the United States and Australia required stricter labeling. By 2011 sibutramine was pulled from
all major markets globally. However, as with the case of rimonabant (see above), sibutramine
is of note since it is the primary contaminant found in dietary weight loss supplements (see
Adulteration of Dietary Supplements below).
Sibutramine is known to be metabolized by CYP 3A4 into two active metabolites (M1 and M2).
Data reported by the manufacturer in limited clinical trials (n = 12 – 27 patients) suggest
potential pharmacokinetic changes in AUC and Cmax for sibutramine when taken in combina‐
tion with CYP 3A4 inhibitors such as cimetidine, ketoconazole, erythromycin, simvastatin, and
omeprazole; while sibutramine does not generally have a significant impact on the levels of
these drugs in return [106]. Because of the role of CYP 3A4 in sibutramine elimination, use of
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lumen of the stomach and small intestine through covalent binding with gastric and pancreatic
lipase active serine residues [70]. Multiple randomized controlled trials have reported
significant weight loss in patients taking orlistat compared to placebo controlled groups. One
meta-analysis cites mean weight loss compared to control of -2.59 kg [95%CI, -3.46 to -1.74] or
-2.9 kg [95%CI, -3.2 to -2.5] over 6 or 12 months, respectively, with a corresponding decrease
in waist circumference, blood pressure, and blood glucose and lipid profiles [71-73].
A large number of preclinical and clinical studies and case reports related to potential drug
interactions with orlistat have been published. There have been several cases of orlistat
interaction with cyclosporine [74-79]. In all cases, significant decreases in plasma cyclosporine
levels were observed following adjunct treatment with orlistat for cyclosporine-associated
weight gain. Although one proposed mechanism for the reduction in plasma cyclosporine is
a decrease in drug absorption, decreased levels may be due to rapid gastrointestinal transit
time resulting from contraindicated high fat diets rather than a true drug-drug interaction [80].
Because orlistat is designed to inhibit gastrointestinal lipases, theoretically absorption of
lipophilic molecules would also be inhibited [81-83]. In one open-label, placebo-controlled
randomized two-way crossover study, orlistat (120 mg) was administered to 12 healthy
subjects three times daily for 9 days followed by administration of Vitamin A (25,000 IU) or
Vitamin E (400 IU) [82]. Although no effect was seen on Vitamin A levels, a significant
reduction in Cmax (approx. 43%) and AUC (approx. 60%) were observed for Vitamin E,
suggesting impaired absorption of Vitamin E by orlistat. In another study, approximately a
30% reduction in beta-carotene levels was observed after administration of orlistat (120 mg)
for four days followed by administration of 0 – 120 mg of beta-carotene three times a day for
six days [83]. Absorption of lipophilic drugs such as the CNS agent lamotrigene can also be
affected by orlistat. In one report, increased frequency of seizures was reported in an 18 year
old female taking lamotrigene following initiation of an orlistat regimen [84]. One case of
hypothyroidism in thyroid carcinoma was reported, presumably due to decreased absorption
of thyroxine [85]. Although orlistat was not found to alter warfarin kinetics per se, but the drug
may alter absorption of the fat soluble vitamin K which can have an effect warfarin levels and
therefore these patients should be monitored for changes in coagulation parameters [86].
2.4. Rimonabant (Acomplia®, Zumulti®)
Rimonabant (Figure 1f) is a cannabanoid receptor antagonist that suppresses appetite by
preventing activation of CB1 receptors by the endogenous cannabanoids anandamide and 2-
arachidonoyl-glycerol [87]. In clinical trials the drug resulted in improvement of multiple
endpoints associated with obesity and metabolic syndrome compared to control groups
including significant weight loss, reduction in waist circumference, decreased triglycerides,
blood glucose, fasting insulin, and leptin levels with increased HDL cholesterol and adipo‐
nectin levels [88-96]. Although rimonabant proved a potentially successful drug in the
treatment of obesity, especially given lack of cardiovascular risks compared to other weight
loss drugs (see Sibutramine below), the drug has not been approved by the U.S. Food and Drug
Administration (FDA). Additionally, although the drug was initially approved in 2006 by the
European Medicines Agency (EMEA), later studies indicating serious neuropsychiatric
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adverse events, especially related to increased risk of suicide, caused the Agency to rescind
the approval in 2009. Although rimonabant is not available in most major markets, ongoing
investigations surrounding the development of the drug continue, while the drug has been
approved in other markets [97-100]. Additionally, the drug appears to be available readily via
online pharmacy services and has been identified as an adulterant in dietary supplements
marketed for weight loss (see Adulteration of Dietary Supplements below) [101-103].
Given the limited and short-lived approval status of rimonabant, there is little information
regarding potential drug-drug and herb-drug interactions available. According to package
insert data submitted to the EMEA, rimonabant is known to be eliminated hepatically and into
the bile by amidohydrolase and CYP3A4, with a 104% increase in rimonabant AUC (95% CI
40 – 197%) upon coadministration of ketoconazole [92, 96, 104, 105]. Therefore, the manufac‐
turer indicated potential interactions with strong CYP3A4 inhibitors (e.g. ketoconazole,
itraconazole, ritonavir, telithromycin, clarithromycin, and nefazodone) and inducers (e.g.
rifampicin, phenytoin, phenobarbital, carbamazepine, and St. John’s Wort). Because rimona‐
bant can decrease levels of fasting insulin and blood sugar, use of rimonabant in diabetic
patients taking anti-diabetic agents is cautioned [92, 96, 104, 105].
2.5. Sibutramine (Meridia®, Reductil®)
Sibutramine hydrocholoride (Figure 1g), and its active primary (M1) and secondary (M2)
metabolites, is a selective serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine
reuptake inhibitor [106-110]. Clinical data supported the efficacy of sibutramine as a weight
loss agent, reporting significant weight loss compared to placebo for patients taking at least
10 mg/day for up to one year [107, 110-114]. The drug was approved as an anti-obesity agent
in 1997 by the U.S. FDA and in 2002 by the EMEA, despite evidence of increased risk of
hypertension and tachycardia, with a requirement that additional post-marketing safety data
be collected relative to cardiotoxicity. As a result, the SCOUT (Sibutramine Cardiovascular
OUTcomes) trial was implemented, which enrolled 10,000 overweight or obese patients aged
55 and older with coexisting diabetes and/or heart disease in a randomized controlled trial
with a 6-month lead in period [115-118]. At the end of the six year study period, data showed
a significant decrease in body weight compared to placebo but increased cardiovascular
morbidity in the randomized sibutramine group [115-118]. Following publication of the
SCOUT trial results in 2010, the EMEA and most other major markets pulled sibutramine while
the United States and Australia required stricter labeling. By 2011 sibutramine was pulled from
all major markets globally. However, as with the case of rimonabant (see above), sibutramine
is of note since it is the primary contaminant found in dietary weight loss supplements (see
Adulteration of Dietary Supplements below).
Sibutramine is known to be metabolized by CYP 3A4 into two active metabolites (M1 and M2).
Data reported by the manufacturer in limited clinical trials (n = 12 – 27 patients) suggest
potential pharmacokinetic changes in AUC and Cmax for sibutramine when taken in combina‐
tion with CYP 3A4 inhibitors such as cimetidine, ketoconazole, erythromycin, simvastatin, and
omeprazole; while sibutramine does not generally have a significant impact on the levels of
these drugs in return [106]. Because of the role of CYP 3A4 in sibutramine elimination, use of
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the drug with other CYP 3A4 substrates, including coadministration with grapefruit juice, is
contraindicated [111]. One case report describes a possible interaction between sibutramine
and citalopram in a 43 year old female patient who experienced hypomanic symptoms shortly
after adding 10 mg sibutramine to her current citalopram and fluoxetine regimen [119].
Symptoms ceased within one day of discontinuing sibutramine. Although the exact mecha‐
nism of the interaction is unknown, the author hypothesized a possible amphetamine-like
hypomania or serotonin syndrome due to increased brain serotonin levels via the combination
of a serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor. Another
case report notes a possible interaction between sibutramine and cyclosporine in a 26 year old
transplant patient resulting in significant increases in cyclosporine trough plasma levels, likely
due to inhibition of CYP 3A4 metabolism [120]. Coadministration of α2 adrenergic blockers,
such as the herb yohimbine, with sibutramine has been recognized as potentially life threat‐
ening due to potential sympathetic side effects resulting in hypertension and tachycardia [121].
Due to the potential risk of bleeding caused by sibutramine, the drug should be used with
caution in patients taking warfarin and other anticoagulants [106].
3. Herbs and dietary supplements used in weight loss
3.1. Açaí (Euterpe oleracea)
The açaí berry is harvested from the palm species Euterpe oleracea and is used mainly for dietary
consumption as whole fruit, juice, or as a flavoring and coloring agent [27]. The fruit, widely
used in Brazil, has gained in popularity as a food product and dietary supplement in the past
several years, mainly due to its antioxidant and anti-inflammatory effects related to high
polyphenol content [122-126]. Although there is little scientific evidence to support the berry for
any of its purported health benefits, it can be found in several dietary supplements promoted
for weight loss. In a pilot study investigating the effect of açaí supplementation on metabolic
parameters in healthy overweight patients, the authors found a significant decrease in fasting
glucose, insulin and cholesterol levels and a mild decrease in LDL-cholesterol and ratio of total
cholesterol to HDL-cholesterol [127]. However, the authors did not assess weight loss in this
study and therefore the activity of açaí as an anorectic agent cannot be determined. There have
been no reported adverse drug interactions or interactions with others herbs and açaí [27].
3.2. Bitter orange (Citrus aurantium, Citrus naringin, synephrine)
Bitter orange is the fruit of Citrus aurantium or Citrus naringin, used as both a food product and
the medicinal properties of the juice and peel [27]. There are multiple active constituents in
bitter orange including several flavonoids (e.g. naringin) and the adrenergic agonists syn‐
ephrine and octopamine [128-134]. Synephrine is structurally similar to ephedrine, therefore
prompting the replacement of ephedra with bitter orange in weight loss supplements,
although the fruit has been used dichotomously as both an appetite stimulant and for weight
loss [27]. However, there is insufficient evidence to confirm the efficacy of bitter orange as an
anti-obesity agent, especially given its inclusion in combination products [27].
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Interactions with bitter orange are varied. Synephrine, like ephedrine, is known to cause
adverse cardiovascular effects at high doses, the risk of which are heightened when combina‐
tion products also including caffeine are ingested and therefore patients taking cardiac
medications should be cautioned on its use [135, 136]. Some evidence demonstrates that bitter
orange can inhibit cytochrome P450 3A4, although to a lesser extent than with grapefruit
[137-140]. A 76% increase in AUC was observed following administration of 10 mg extended
release felodipine administered with 240 mL Seville orange juice compared to control [139];
while a significant increase in indinavir tmax was observed with administration of 8 ounces of
Seville orange juice compared to control [140]. Because synephrine and octopamine, both
endogenous substances, can interact with monoamine oxidase there is a theoretical interaction
of bitter orange with MAOIs [141, 142].
3.3. Caffeine-containing herbs
Caffeine is a methylxanthine that is commonly found in food, beverages, and dietary supple‐
ments. It is used as an additive in beverages and dietary supplements for its energy enhancing
properties. Many dietary supplements marketed for weight loss contain high levels of caffeine,
often from multiple sources, for increased thermogenesis and lipid metabolism [143, 144]. Most
studies investigating the anti-obesity effects of caffeine have been done using combination
products that include ephedra, or have looked at enhancement of athletic endurance [145-151].
Therefore, it is difficult to assess the effect of caffeine alone on weight loss. One study dem‐
onstrated an increase in thermogenic metabolic rate in subjects drinking coffee along with food,
compared to ingestion of decaffeinated coffee [144].
Adverse effects associated with caffeine consumption include restlessness, jitteriness, anxiety,
insomnia, and cardiovascular effects [152-156]. Most drug and herb interactions with caffeine
are mild to moderate and are related to increased adverse effects resulting from decreased
caffeine elimination or additive effects with other methylxanthine containing products [157].
For example, estrogen drugs (e.g. oral contraceptives and estrogen replacement therapy) have
been shown to decrease clearance of caffeine up to 50 – 65% [158, 159]. The most significant
caffeine interaction occurs with coadministration of Ephedra or ephedrine containing products
(see Ephedra below). The ban on ephedra in the United States has resulted in marketing of
“ephedra-free” dietary supplements using ephedra alternatives, including caffeine containing
herbs and bitter orange (see Bitter Orange above). In one randomized controlled trial study,
subjects were administered products containing Citrus aurantium standardized to either a high
dose of synephrine (46.9 mg) or a product containing caffeine and a low synephrine dose (5.5
mg) [136]. A significant increase on blood pressure was observed in patients taking the product
containing both caffeine and synephrine, but not high dose synephrine alone, suggesting an
interaction between the two herbs.
3.3.1. Green tea (Camellia sinensis; EGCG)
Green tea has gained in popularity for the treatment of a wide variety of diseases and for
promotion of general wellbeing. The addition of green tea to weight loss supplements is due
in part to the caffeine content of Camellia sinensis. However, in addition to alkaloid content
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and citalopram in a 43 year old female patient who experienced hypomanic symptoms shortly
after adding 10 mg sibutramine to her current citalopram and fluoxetine regimen [119].
Symptoms ceased within one day of discontinuing sibutramine. Although the exact mecha‐
nism of the interaction is unknown, the author hypothesized a possible amphetamine-like
hypomania or serotonin syndrome due to increased brain serotonin levels via the combination
of a serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor. Another
case report notes a possible interaction between sibutramine and cyclosporine in a 26 year old
transplant patient resulting in significant increases in cyclosporine trough plasma levels, likely
due to inhibition of CYP 3A4 metabolism [120]. Coadministration of α2 adrenergic blockers,
such as the herb yohimbine, with sibutramine has been recognized as potentially life threat‐
ening due to potential sympathetic side effects resulting in hypertension and tachycardia [121].
Due to the potential risk of bleeding caused by sibutramine, the drug should be used with
caution in patients taking warfarin and other anticoagulants [106].
3. Herbs and dietary supplements used in weight loss
3.1. Açaí (Euterpe oleracea)
The açaí berry is harvested from the palm species Euterpe oleracea and is used mainly for dietary
consumption as whole fruit, juice, or as a flavoring and coloring agent [27]. The fruit, widely
used in Brazil, has gained in popularity as a food product and dietary supplement in the past
several years, mainly due to its antioxidant and anti-inflammatory effects related to high
polyphenol content [122-126]. Although there is little scientific evidence to support the berry for
any of its purported health benefits, it can be found in several dietary supplements promoted
for weight loss. In a pilot study investigating the effect of açaí supplementation on metabolic
parameters in healthy overweight patients, the authors found a significant decrease in fasting
glucose, insulin and cholesterol levels and a mild decrease in LDL-cholesterol and ratio of total
cholesterol to HDL-cholesterol [127]. However, the authors did not assess weight loss in this
study and therefore the activity of açaí as an anorectic agent cannot be determined. There have
been no reported adverse drug interactions or interactions with others herbs and açaí [27].
3.2. Bitter orange (Citrus aurantium, Citrus naringin, synephrine)
Bitter orange is the fruit of Citrus aurantium or Citrus naringin, used as both a food product and
the medicinal properties of the juice and peel [27]. There are multiple active constituents in
bitter orange including several flavonoids (e.g. naringin) and the adrenergic agonists syn‐
ephrine and octopamine [128-134]. Synephrine is structurally similar to ephedrine, therefore
prompting the replacement of ephedra with bitter orange in weight loss supplements,
although the fruit has been used dichotomously as both an appetite stimulant and for weight
loss [27]. However, there is insufficient evidence to confirm the efficacy of bitter orange as an
anti-obesity agent, especially given its inclusion in combination products [27].
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orange can inhibit cytochrome P450 3A4, although to a lesser extent than with grapefruit
[137-140]. A 76% increase in AUC was observed following administration of 10 mg extended
release felodipine administered with 240 mL Seville orange juice compared to control [139];
while a significant increase in indinavir tmax was observed with administration of 8 ounces of
Seville orange juice compared to control [140]. Because synephrine and octopamine, both
endogenous substances, can interact with monoamine oxidase there is a theoretical interaction
of bitter orange with MAOIs [141, 142].
3.3. Caffeine-containing herbs
Caffeine is a methylxanthine that is commonly found in food, beverages, and dietary supple‐
ments. It is used as an additive in beverages and dietary supplements for its energy enhancing
properties. Many dietary supplements marketed for weight loss contain high levels of caffeine,
often from multiple sources, for increased thermogenesis and lipid metabolism [143, 144]. Most
studies investigating the anti-obesity effects of caffeine have been done using combination
products that include ephedra, or have looked at enhancement of athletic endurance [145-151].
Therefore, it is difficult to assess the effect of caffeine alone on weight loss. One study dem‐
onstrated an increase in thermogenic metabolic rate in subjects drinking coffee along with food,
compared to ingestion of decaffeinated coffee [144].
Adverse effects associated with caffeine consumption include restlessness, jitteriness, anxiety,
insomnia, and cardiovascular effects [152-156]. Most drug and herb interactions with caffeine
are mild to moderate and are related to increased adverse effects resulting from decreased
caffeine elimination or additive effects with other methylxanthine containing products [157].
For example, estrogen drugs (e.g. oral contraceptives and estrogen replacement therapy) have
been shown to decrease clearance of caffeine up to 50 – 65% [158, 159]. The most significant
caffeine interaction occurs with coadministration of Ephedra or ephedrine containing products
(see Ephedra below). The ban on ephedra in the United States has resulted in marketing of
“ephedra-free” dietary supplements using ephedra alternatives, including caffeine containing
herbs and bitter orange (see Bitter Orange above). In one randomized controlled trial study,
subjects were administered products containing Citrus aurantium standardized to either a high
dose of synephrine (46.9 mg) or a product containing caffeine and a low synephrine dose (5.5
mg) [136]. A significant increase on blood pressure was observed in patients taking the product
containing both caffeine and synephrine, but not high dose synephrine alone, suggesting an
interaction between the two herbs.
3.3.1. Green tea (Camellia sinensis; EGCG)
Green tea has gained in popularity for the treatment of a wide variety of diseases and for
promotion of general wellbeing. The addition of green tea to weight loss supplements is due
in part to the caffeine content of Camellia sinensis. However, in addition to alkaloid content
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(caffeine, theobromine, theophylline) green tea also contains polyphenols, most notably the
catechin epigallocatechin-3-gallate (EGCG) [160-164]. EGCG, in concert with caffeine, is
proposed to elicit anti-obesity effects via inhibition of catechol O-methyl transferase and
phosphodiesterase [164]. A meta-analysis of clinical trials involving green tea in weight loss
concluded that weight loss is decreased, relative to placebo, in treatment involving both green
tea ECGC and caffeine but not with decaffeinated green tea products [165].
As expected, the majority of drug interactions associated with green tea are related to caffeine
content. However, a few interactions described in the literature are due to other constituents
of green tea. Green tea may be contraindicated, especially at high doses, in patients taking
anticoagulants such as warfarin due to the high Vitamin K content of the herb. There is one
case report of a patient taking warfarin who experienced a significant reduction in INR
following initiation of daily consumption of one-half to one gallon of green tea [166]. Once
green tea consumption was stopped INR normalized. Green tea is also thought to cause
decreased estrogen levels and combination products containing the herb have been used to
improve fertility and relieve menopausal symptoms [167-170]. Therefore, use of high doses of
green tea in patients taking oral contraceptives or estrogen replacement therapy may be
cautioned.
3.3.2. Guarana (Paullinia cupana)
Guarana (Paullinia cupana) is a plant native to South America that is used traditionally and in
anti-obesity supplements for its high caffeine content, although other minor constituents
including theophylline, theobromine, catechin and epicatechin are found in these extracts
[171-176]. There are no studies investigating the effects of Guarana alone on weight loss so it
is difficult to determine the anti-obesity properties of the herb. In one double-blind, parallel,
placebo controlled trial 47 subjects were administered three capsules containing yerba mate
(Ilex paraguayensis, 112 mg), guarana (95 mg) and damiana (Turnera diffusa, 36 mg) daily for 45
days, resulting in significant weight loss (-5.1 ± 0.5 kg) compared to placebo (-0.3 ± 0.08 kg)
[145]. One of the few interactions reported with guarana not related to caffeine content suggests
possible interference with anticoagulants since platelet aggregation was observed in vitro and
in animal studies [177].
3.4. Dandelion (Taraxacum officinale)
Dandelion is a perennial herb of multiple global varieties that has traditionally been used for
liver, spleen, kidney, and gastrointestinal disorders, although there have been no clinical trials
investigating the effects of dandelion in weight loss [27, 178]. It is commonly added to weight loss
supplements, mainly for its diuretic properties, although the herb does possess some mild laxative
properties [179-181]. There are no known drugs interactions between Taraxacum and other herbs
or drugs, although one study in rats suggests a probable interaction with quinolone antibiotics
due to the high mineral content of Taraxacum [182]. In the study, ciprofloxacin (20 mg/kg) Cmax
significantly decreased while Vd and t½ significantly increased when administered with crude
dandelion extract (2 g/kg) compared to control. There is one case report of hypoglycemia in a 58
year old diabetic patient following a 2-week period of dandelion consumption in salads [183].
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The patient denied changes in calorie consumption, exercise, or insulin dosing. Diabetic patients
taking hypoglycemic agents while consuming dandelion should be monitored.
3.5. Ephedra (Ephedra sinica, ma huang)
Ephedra, derived from the evergreen shrub Ephedra sinica, contains multiple plant alkaloids
including ephedrine and pseudoephedrine that are chemically related to amphetamines. These
compounds act by increasing availability and activity of endogenous neurotransmitters such
as epinephrine and norepinephrine, resulting in brain and cardiovascular catecholamine
receptor stimulation [184]. The herb has traditionally been used for bronchodilation in the
treatment of respiratory ailments such as asthma, as an athletic performance enhancer, and for
its thermogenic properties in weight loss [148, 185-189]. Ephedra as a weight loss dietary
supplement is commonly found in combination products also containing caffeine or caffeine-
containing herbs. In one study a product containing 90 mg and 192 mg of ephedra alkaloids
and caffeine, respectively, administered daily over six months in a randomized, double-blind
placebo controlled trial resulted in significant decreases in body weight, body fat and LDL-
cholesterol with an increase in HDL-cholesterol [148]. The addition of aspirin to ephedrine
containing products can potentiate the thermogenic properties of ephedra, improving weight
loss compared to products containing ephedra alone [190-201]. Due to high risk of cardiovas‐
cular toxicities and cardiomyopathies, ephedra has been banned in the United States [202-211].
However, the herb is still available in other countries [212].
Because of the controversial nature of ephedra related to cardiac toxicity and its eventual ban
via the U.S. FDA, there are a significant number of clinical studies and case reports related to
toxicities and interactions with ephedra and ephedrine. Ephedra can potentially interact with
anesthetics since it is known that administration of ephedrine can reverse anesthesia induced
hypotension and regression of analgesia following epidural blockade [213, 214]. Ephedrine
has both chrontropic and inotropic effects, and therefore interactions with cardiovascular
agents may be possible [184, 211, 215, 216]. However, no effects on heart rate or blood pressure
were seen in clinical trials investigating the efficacy of ephedra in weight loss [192, 217, 218].
Theoretically interactions with antiadrenergic agents and MAOIs can occur due to sympatho‐
mimetic effects of ephedrine, potentially increasing risk of hypertensive crisis. There is a case
report of a patient taking a product containing caffeine, ephedrine, and theophylline who
experienced multiple adverse effects including encephalopathy, hypotension, tachycardia,
and hypothermia 24 hours following discontinuation of phenelzine [219]. Interactions with
ephedrine and tricyclic antidepressants are also possible [220]. Some evidence from clinical
trials suggests that ephedra in combination with caffeine can cause hyperglycemia, and
therefore interactions with antidiabetic agents is possible [147, 148, 221]. A lowering of seizure
threshold has been observed in patients taking ephedrine, and therefore use of ephedra in this
patient population is cautioned [222]. A major interaction between ephedra and methylxan‐
thines (e.g. caffeine, theophylline) is possible due to increased risk of cardiovascular, neuro‐
logic and psychiatric adverse effects due to additive sympathomimetic and CNS stimulant
activity [184, 223, 224]. One case study reports a 21 year old male patient admitted to the
hospital emergency room with a blood pressure of 220/110 mmHg and ventricular arrhythmia
following ingestion of a caffeine/ephedra containing product (“Herbal Ecstasy”) [225].
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proposed to elicit anti-obesity effects via inhibition of catechol O-methyl transferase and
phosphodiesterase [164]. A meta-analysis of clinical trials involving green tea in weight loss
concluded that weight loss is decreased, relative to placebo, in treatment involving both green
tea ECGC and caffeine but not with decaffeinated green tea products [165].
As expected, the majority of drug interactions associated with green tea are related to caffeine
content. However, a few interactions described in the literature are due to other constituents
of green tea. Green tea may be contraindicated, especially at high doses, in patients taking
anticoagulants such as warfarin due to the high Vitamin K content of the herb. There is one
case report of a patient taking warfarin who experienced a significant reduction in INR
following initiation of daily consumption of one-half to one gallon of green tea [166]. Once
green tea consumption was stopped INR normalized. Green tea is also thought to cause
decreased estrogen levels and combination products containing the herb have been used to
improve fertility and relieve menopausal symptoms [167-170]. Therefore, use of high doses of
green tea in patients taking oral contraceptives or estrogen replacement therapy may be
cautioned.
3.3.2. Guarana (Paullinia cupana)
Guarana (Paullinia cupana) is a plant native to South America that is used traditionally and in
anti-obesity supplements for its high caffeine content, although other minor constituents
including theophylline, theobromine, catechin and epicatechin are found in these extracts
[171-176]. There are no studies investigating the effects of Guarana alone on weight loss so it
is difficult to determine the anti-obesity properties of the herb. In one double-blind, parallel,
placebo controlled trial 47 subjects were administered three capsules containing yerba mate
(Ilex paraguayensis, 112 mg), guarana (95 mg) and damiana (Turnera diffusa, 36 mg) daily for 45
days, resulting in significant weight loss (-5.1 ± 0.5 kg) compared to placebo (-0.3 ± 0.08 kg)
[145]. One of the few interactions reported with guarana not related to caffeine content suggests
possible interference with anticoagulants since platelet aggregation was observed in vitro and
in animal studies [177].
3.4. Dandelion (Taraxacum officinale)
Dandelion is a perennial herb of multiple global varieties that has traditionally been used for
liver, spleen, kidney, and gastrointestinal disorders, although there have been no clinical trials
investigating the effects of dandelion in weight loss [27, 178]. It is commonly added to weight loss
supplements, mainly for its diuretic properties, although the herb does possess some mild laxative
properties [179-181]. There are no known drugs interactions between Taraxacum and other herbs
or drugs, although one study in rats suggests a probable interaction with quinolone antibiotics
due to the high mineral content of Taraxacum [182]. In the study, ciprofloxacin (20 mg/kg) Cmax
significantly decreased while Vd and t½ significantly increased when administered with crude
dandelion extract (2 g/kg) compared to control. There is one case report of hypoglycemia in a 58
year old diabetic patient following a 2-week period of dandelion consumption in salads [183].
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3.5. Ephedra (Ephedra sinica, ma huang)
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including ephedrine and pseudoephedrine that are chemically related to amphetamines. These
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receptor stimulation [184]. The herb has traditionally been used for bronchodilation in the
treatment of respiratory ailments such as asthma, as an athletic performance enhancer, and for
its thermogenic properties in weight loss [148, 185-189]. Ephedra as a weight loss dietary
supplement is commonly found in combination products also containing caffeine or caffeine-
containing herbs. In one study a product containing 90 mg and 192 mg of ephedra alkaloids
and caffeine, respectively, administered daily over six months in a randomized, double-blind
placebo controlled trial resulted in significant decreases in body weight, body fat and LDL-
cholesterol with an increase in HDL-cholesterol [148]. The addition of aspirin to ephedrine
containing products can potentiate the thermogenic properties of ephedra, improving weight
loss compared to products containing ephedra alone [190-201]. Due to high risk of cardiovas‐
cular toxicities and cardiomyopathies, ephedra has been banned in the United States [202-211].
However, the herb is still available in other countries [212].
Because of the controversial nature of ephedra related to cardiac toxicity and its eventual ban
via the U.S. FDA, there are a significant number of clinical studies and case reports related to
toxicities and interactions with ephedra and ephedrine. Ephedra can potentially interact with
anesthetics since it is known that administration of ephedrine can reverse anesthesia induced
hypotension and regression of analgesia following epidural blockade [213, 214]. Ephedrine
has both chrontropic and inotropic effects, and therefore interactions with cardiovascular
agents may be possible [184, 211, 215, 216]. However, no effects on heart rate or blood pressure
were seen in clinical trials investigating the efficacy of ephedra in weight loss [192, 217, 218].
Theoretically interactions with antiadrenergic agents and MAOIs can occur due to sympatho‐
mimetic effects of ephedrine, potentially increasing risk of hypertensive crisis. There is a case
report of a patient taking a product containing caffeine, ephedrine, and theophylline who
experienced multiple adverse effects including encephalopathy, hypotension, tachycardia,
and hypothermia 24 hours following discontinuation of phenelzine [219]. Interactions with
ephedrine and tricyclic antidepressants are also possible [220]. Some evidence from clinical
trials suggests that ephedra in combination with caffeine can cause hyperglycemia, and
therefore interactions with antidiabetic agents is possible [147, 148, 221]. A lowering of seizure
threshold has been observed in patients taking ephedrine, and therefore use of ephedra in this
patient population is cautioned [222]. A major interaction between ephedra and methylxan‐
thines (e.g. caffeine, theophylline) is possible due to increased risk of cardiovascular, neuro‐
logic and psychiatric adverse effects due to additive sympathomimetic and CNS stimulant
activity [184, 223, 224]. One case study reports a 21 year old male patient admitted to the
hospital emergency room with a blood pressure of 220/110 mmHg and ventricular arrhythmia
following ingestion of a caffeine/ephedra containing product (“Herbal Ecstasy”) [225].
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3.6. Glucomannan (Amorphophallus konjac)
Glucomannan is a soluble but highly viscous dietary fiber derived from the root of the
Amorphophallus konjac (elephant yam) plant that grows native to Asia [27]. Although tradi‐
tionally used as a food, the plant has gained popularity as an additive in weight loss supple‐
ments since the dietary fiber absorbs water in the gastrointestinal tract, helping to promote a
sense of satiety and act as a bulk laxative [226-228]. There is also evidence that fiber content of
glucomannan helps to reduce cholesterol levels [67, 229-232]. In a double blind crossover study
involving 63 healthy males, 3.9 grams of glucomannan administered daily for four weeks
resulted in a 10% reduction in total cholesterol, 7.2% reduction in LDL cholesterol, and a 23%
decrease in triglyceride levels [67]. A meta-analysis of clinical trials involving glucomannan
reported overall decreases in the above markers as well as fasting blood glucose [230].
There are relatively few reported drug interactions with glucomannan, most of which are likely
due to associated decreases in cholesterol and lipid levels as well as interference with absorp‐
tion of some drugs. Monitoring of patients taking antihypertensives, antilipemics, and other
anti-obesity agents is warranted. Several studies note a significant decrease in fasting blood
glucose levels following glucomannan administration while decreased absorption of the
sulfonylurea drugs is possible [230, 231, 233-237]. Glucomannan can significantly decrease
circulating levels of T3, T4, and FT3 in the treatment of thyrotoxicosis and therefore its use
may be contraindicated in patients taking thyroid medications [238]. Glucomannan can
potentially affect the absorption of certain drugs and supplements as demonstrated in one
study in which absorption of the fat soluble Vitamin E was decreased potentially via the
reduction of bile acids necessary for absorption of the vitamin [239].
3.7. Hoodia gordonii
Hoodia gordonii, a small succulent of the Apocynaceae family native to the Kalahari Desert,
has been used traditionally by native tribes for its appetite and thirst suppressing proper‐
ties [240, 241]. The active constituent of Hoodia (P57 or P57AS3) is an oxypregnane steroi‐
dal glycoside which is purported to increase ATP production in the hypothalamus, resulting
in a feeling of satiety [242]. There is little known regarding potential drug or herb interac‐
tions  with  Hoodia,  although  in  vitro  studies  suggest  a  potential  interaction  with  drugs
metabolized by CYP 3A4 [243].
3.8. Hydroxycitric acid (HCA, Garcinia cambogia)
Garcinia cambogia is a plant native to Southeast Asia which yields a small purple fruit used in
weight loss products for its hydroxycitric acid (HCA) content [27, 244]. The anorectic activity
of HCA is due to the inhibition of the adenosine triphosphate-citrate (pro-3S)-lyase, which
catalyzes the formation of acetyl-CoA, resulting in decreased fatty acid synthesis and lipo‐
genesis [245]. The evidence for HCA as an effective weight loss agent is contradictory. One
randomized controlled trial reported a 5-6% reduction in weight and BMI following approx‐
imately a 4.5 gram daily dose of HCA, while two other studies reported no significant weight
loss or effect on appetite at lower doses of 1.5 – 2.4 gram daily HCA doses [246-248]. There are
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a minimal number of reported interactions with Garcinia or HCA. Antilipemic agents such as
HMG-CoA reductase inhibitors should be avoided due to an increased risk of rhabdomyolysis.
In one case report a healthy 54 year old female patient reported chest pain following ingestion
of an herbal product containing ephedra, guarana, chitosan, Gymnena sylvestre, Garcinia
cambogia (50% HCA), and chromium. Lab results indicated elevated serum creatine kinase
(1028 IU/mL), which declined following cessation of the supplement [249]. Although the exact
interaction was not determined, cautionary use of HCA-containing products in patients at risk
of rhabdomyolysis is warranted.
3.9. Herbal laxatives
Frequently laxatives and diuretics are used alone or in combination products to promote
weight loss. However, there is little to no evidence supporting these supplements as anti-
obesity agents, although subgroups of this patient population may abuse laxatives and
diuretics for the purpose of weight loss [250].
3.9.1. Bulk laxatives
Bulk laxatives generally consist of soluble dietary fiber which expands in the gastrointestinal
tract in the presence of water resulting in improved bowel function. Common sources of bulk
laxatives include Amorphophallus konjac (glucomannan, see above), guar gum (Cyamopsis
tetragonoloba), and psyllium husk (Plantago psyllium). Although the efficacy of bulk laxatives
for weight loss is not proven, adsorption of dietary glucose and lipids to these agents in the
gastrointestinal tract results in decreased absorption of lipids, cholesterol, and carbohydrates
into the body, thereby promoting weight loss [230, 234, 251-253]. Because of changes in
carbohydrate and glucose absorption, dosing of antidiabetic agents may require modification
and therefore patients in this population should be monitored when taking bulk laxatives
[254-261]. Bulk laxatives appear to have some effect on the absorption of orally administered
medications, which can result in changes in drug plasma levels [262-272]. For example, in one
study the effect of guar gum on digoxin and phenoxymethyl penicillin absorption was studied
in 10 healthy volunteers, with significant reductions in both peak penicillin plasma concen‐
trations and AUC, but little effect on overall digoxin levels [269]. In one case report of a patient
with adrenal insufficiency treated with fludrocortisone and prednisolone, the patient experi‐
enced symptoms of acute adrenal crisis including fatigue, nausea, abdominal pain, and
weakness approximately 3 – 4 days after initiation of psyllium [262]. The authors postulated
that psyllium inhibited absorption of fludrocortisone and/or prednisolone. Other evidence
related to changes in absorption of ethinyl estradiol, metformin, and lithium have also been
reported [264-266, 270, 272].
3.9.2. Stimulant laxatives
Stimulant laxatives act by irritating the lining of the gastrointestinal tract, resulting in increased
propulsive muscle contractions that aid elimination of intestinal contents. Because of the quick
and efficacious activity, stimulant laxatives are most frequently abused to promote weight loss
by increasing gastrointestinal transit time [273, 274]. The most common stimulant laxative
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3.6. Glucomannan (Amorphophallus konjac)
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Amorphophallus konjac (elephant yam) plant that grows native to Asia [27]. Although tradi‐
tionally used as a food, the plant has gained popularity as an additive in weight loss supple‐
ments since the dietary fiber absorbs water in the gastrointestinal tract, helping to promote a
sense of satiety and act as a bulk laxative [226-228]. There is also evidence that fiber content of
glucomannan helps to reduce cholesterol levels [67, 229-232]. In a double blind crossover study
involving 63 healthy males, 3.9 grams of glucomannan administered daily for four weeks
resulted in a 10% reduction in total cholesterol, 7.2% reduction in LDL cholesterol, and a 23%
decrease in triglyceride levels [67]. A meta-analysis of clinical trials involving glucomannan
reported overall decreases in the above markers as well as fasting blood glucose [230].
There are relatively few reported drug interactions with glucomannan, most of which are likely
due to associated decreases in cholesterol and lipid levels as well as interference with absorp‐
tion of some drugs. Monitoring of patients taking antihypertensives, antilipemics, and other
anti-obesity agents is warranted. Several studies note a significant decrease in fasting blood
glucose levels following glucomannan administration while decreased absorption of the
sulfonylurea drugs is possible [230, 231, 233-237]. Glucomannan can significantly decrease
circulating levels of T3, T4, and FT3 in the treatment of thyrotoxicosis and therefore its use
may be contraindicated in patients taking thyroid medications [238]. Glucomannan can
potentially affect the absorption of certain drugs and supplements as demonstrated in one
study in which absorption of the fat soluble Vitamin E was decreased potentially via the
reduction of bile acids necessary for absorption of the vitamin [239].
3.7. Hoodia gordonii
Hoodia gordonii, a small succulent of the Apocynaceae family native to the Kalahari Desert,
has been used traditionally by native tribes for its appetite and thirst suppressing proper‐
ties [240, 241]. The active constituent of Hoodia (P57 or P57AS3) is an oxypregnane steroi‐
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3.8. Hydroxycitric acid (HCA, Garcinia cambogia)
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weight loss products for its hydroxycitric acid (HCA) content [27, 244]. The anorectic activity
of HCA is due to the inhibition of the adenosine triphosphate-citrate (pro-3S)-lyase, which
catalyzes the formation of acetyl-CoA, resulting in decreased fatty acid synthesis and lipo‐
genesis [245]. The evidence for HCA as an effective weight loss agent is contradictory. One
randomized controlled trial reported a 5-6% reduction in weight and BMI following approx‐
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loss or effect on appetite at lower doses of 1.5 – 2.4 gram daily HCA doses [246-248]. There are
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for weight loss is not proven, adsorption of dietary glucose and lipids to these agents in the
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into the body, thereby promoting weight loss [230, 234, 251-253]. Because of changes in
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and therefore patients in this population should be monitored when taking bulk laxatives
[254-261]. Bulk laxatives appear to have some effect on the absorption of orally administered
medications, which can result in changes in drug plasma levels [262-272]. For example, in one
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in 10 healthy volunteers, with significant reductions in both peak penicillin plasma concen‐
trations and AUC, but little effect on overall digoxin levels [269]. In one case report of a patient
with adrenal insufficiency treated with fludrocortisone and prednisolone, the patient experi‐
enced symptoms of acute adrenal crisis including fatigue, nausea, abdominal pain, and
weakness approximately 3 – 4 days after initiation of psyllium [262]. The authors postulated
that psyllium inhibited absorption of fludrocortisone and/or prednisolone. Other evidence
related to changes in absorption of ethinyl estradiol, metformin, and lithium have also been
reported [264-266, 270, 272].
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Stimulant laxatives act by irritating the lining of the gastrointestinal tract, resulting in increased
propulsive muscle contractions that aid elimination of intestinal contents. Because of the quick
and efficacious activity, stimulant laxatives are most frequently abused to promote weight loss
by increasing gastrointestinal transit time [273, 274]. The most common stimulant laxative
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herbs are senna (Cassia senna), aloe latex (Aloe vera), and Cascara sagrada (Frangula purshiana).
The leaves and pods from Cassia senna contain anthroquinone stimulant laxative compounds
effective in the treatment of constipation and for bowel evacuation prior to medical procedures
[27, 275-295]. The herb has been approved by the U.S. FDA as a non-prescription medication.
Similarly, aloe latex, derived from the peripheral bundle sheath cells of the aloe leaf, contains
anthracene compounds that are cleaved in the colon by bacterial enzymes into active anthrone
compounds with stimulant laxative properties [296-299]. However, concerns over possible
carcinogenic properties of certain anthraquinones in aloe latex, along with lack of safety
evidence, prompted the U.S. FDA to ban aloe latex in 2002, although the herb is still used in
other countries [178, 300, 301]. The bark of the deciduous buckthorn shrub Cascara sagrada is
effective for the treatment of constipation due to the stimulant laxative properties of its
anthraglycoside constituents [27, 302]. Like aloe latex, Cascara had previously been approved
by the U.S. FDA as a non-prescription medication, but the designation was withdrawn into
2002 based on lack of safety and efficacy evidence, although the herb is still available as a
supplement [300].
Stimulant laxatives share multiple common adverse effects and potential drug interactions.
Because of decreased gastrointestinal transit time, absorption of some drugs, especially those
with poor permeability, may be decreased [303, 304]. Experimental evidence in rats suggests
absorption of carbohydrates may result in decreased blood glucose levels and therefore
monitoring of patients receiving hypoglycemic agents or insulin is warranted [305-307].
Concomitant use of stimulant laxatives with diuretics, cardiac glycosides and licorice is
contraindicated due to hypokalemic effects, especially with long term use of these laxatives
[27, 178, 304, 308, 309]. Senna can potentially interfere with antiplatelet and anticoagulant
activity by causing excessive bleeding [310]. There is one case report of a possible interaction
of aloe and sevoflurane, in which a 35 year old female patient undergoing surgery for heman‐
gioma experienced perioperative bleeding [311]. Although the size and vascularization of the
hemangioma were noted as partial root causes of the bleeding episodes, the authors felt that
the combination of anesthetic and aloe administration (4 tablets daily for 2 weeks prior to
surgery) may have contributed to the adverse event.
3.10. Licorice (Glycyrrhiza glabra)
Licorice has historically been used both medicinally and as a food product and its relative
safety at low doses has placed it on the U.S. FDA GRAS (generally recognized as safe) list,
although  at  high  doses  licorice  can  cause  severe  adverse  effects  [27].  The  main  active
components of licorice are glycyrrhizin and glycyrrhizic acid, although several other active
constituents have been identified [312, 313]. One of the main adverse effects of high licorice
consumption includes mineralocorticoid excess syndrome and resulting hypokalemia with
associated  increases  in  blood  pressure,  as  well  as  secondary  pseudohyperaldosteronism
[314-338]. Licorice consumption may also alter blood glucose levels, potentially via binding
to  PPAR-γ [339,  340].  Although licorice  is  used in  dietary supplements  for  weight  loss,
contradictory evidence reports weight gain with licorice consumption [341-343]. However,
one study in which 3.5 grams daily licorice consumption was administered to 15 normal
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weight subjects for two months reports a significant decrease in body fat mass but not body
mass index [344, 345].
Acquisition of mineralocorticoid excess syndrome following high dose consumption of licorice
results in the potential for licorice-drug interactions with multiple drug classes, including
aldosterone receptor antagonists, antiarrhythmics, antihypertensives, cardiac glycosides,
corticosteroids, diuretics, and potassium lowering agents [321-324, 326]. In one study, 10
healthy subjects were given 32 grams of licorice daily for two weeks along with 25 mg of
hydrochlorothiazide (HCTZ); a significant reduction in potassium levels was observed, while
two patients experience hypokalemia, compared to HCTZ alone [346]. Glycyrrhizin and β-
glycyrrhetinic acid may also affect complement activity and decrease neutrophil generated
oxides and peroxides, resulting in anti-inflammatory activity [347-350]. Therefore, licorice
should be used with caution in patients taking other anti-inflammatory medications. Licorice
constituents may also have an effect on hormonal agents via anti-estrogenic activity, inhibition
of 17β-hydroxysteroid dehydrogenase, or associated decreases in prolactin levels [351-358]. In
in vitro and animal studies it has been shown that constituents in licorice can promote the
intestinal absorption of some drugs and therefore it is recommended that oral drugs be taken
at least an hour before or two hours after licorice consumption [359]. Theoretically licorice may
interact with antidepressant agents, since increases in norepinephrine and dopamine have
been observed in mice while in vitro cell culture studies suggest potential serotonin reuptake
inhibition [360, 361].
3.11. St. John’s Wort (Hypericum perforatum)
St. John’s Wort (SJW) is a perennial herb native to Europe that is commonly used to treat
depression, anxiety, post-menopausal symptoms, attention deficit hyperactivity disorder
(ADHD), and other mood disorders [362-367]. The active constituents of SJW are hypericin
and hyperforin, which are thought to act by inhibiting the synaptic uptake of serotonin (5-HT),
GABA, noradrenaline, dopamine, and L-glutamate via a novel mechanism compared to
synthetic antidepressants [362, 368-373]. Although there are no official studies regarding the
use of SJW for weight loss, anecdotal reports suggest a positive effect on satiety, which may
be attributable to the serotonergic uptake inhibition (see Sibutramine above). Following the
removal of fenfluramine, an anorectic agent commonly used in the combination product
“Phen-Fen” (phentermine – fenfluramine), from the market in 1997, SJW was combined with
Ephedra or Citrus aurantium (see above) and marketed for weight loss as “Herbal Phen-Fen”.
Because of the expanding popularity of SJW in the 1990s – 2000s, a great deal of research on
the mechanism of action and herb-drug interactions has been reported.
Drug interactions with SJW are primarily related to binding of active constituents to the
pregnane X receptor leading to induction of cytochrome P450 metabolizing or induction of p-
glycoprotein efflux mechanisms via the MDR-1 drug transporter [374-388]. As a result,
pharmacokinetics of many cytochrome P450 drug substrates is altered, often leading to
decreased plasma concentrations and reduced efficacy [27]. There have been numerous studies
that have demonstrated potential metabolism-related drug interactions with CYP 3A4, 1A2,
2C9 and 2C19 [389]. Kinetics of antiplatelet and anticoagulant agents may be altered in the
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presence of SJW [390, 391]. In one open-label, three-way crossover randomized study, 12
healthy male subjects were given 1 gram of SJW (standardized to hypericin 0.825 mg/g and
hyperforin 12.5 mg/g) for 21 days, with administration of a single 25 mg dose of warfarin on
day 14 [390]. A significant increase in warfarin (Cl/F) was observed compared to warfarin
alone, with a corresponding decrease in AUC and half-life. However, there was no significant
impact on INR or platelet aggregation. The interaction is likely caused not only by alteration
of drug metabolism via CYP 450 induction, but also binding of warfarin to the SJW constituents
hypericin and pseudohypericin, leading to decreased absorption of the drug [392]. In another
study, patients not responding to clopidogrel therapy alone experienced an increase in
therapeutic activity when clopidogrel and SJW were coadministered; therefore it is possible
that patients responding to stand alone clopidogrel treatment may be at increased risk of
bleeding [391]. There has been one case report of a possible interaction between theophylline
and SJW in which theophylline levels significantly increased following discontinuation of SJW
in a smoker also taking 11 other drugs [393]. However, another study in healthy subjects
showed no impact of SJW on theophylline kinetics [394]. Plasma concentrations of protease
inhibitors such as indinavir may be reduced in the presence of SJW due to induction of p-
glycoprotein efflux in the gastrointestinal tract [395-398]. Decreased plasma levels of the
“statins” simvastatin and atorvastatin have been reported in controlled, randomized, cross‐
over studies [399, 400]. Reports of pharmacokinetic interactions have also been reported for
digoxin, gliclazide, imatinib, irinotecan, methadone, omeprazole, verapamil, and voriconazole
have also been published [401-412]. In general, coadministration of SJW with drugs signifi‐
cantly eliminated via these enzymes should be avoided.
Several studies and case reports describe interactions between SJW and oral contraceptives,
resulting in breakthrough or irregular bleeding and unplanned pregnancy [413-416]. In one
case report, an unwanted pregnancy occurred in a 36-year old patient while taking an ethinyl
estradiol/dinogesterol oral contraceptive (Valette®). The patient had previously been taking
fluvastatin (20 mg/day) for 2 years, but had discontinued the drug and started 1700 mg SJW
extract daily for 3 months prior to conception [414]. One randomized controlled trial in 18
female subjects taking low dose oral contraceptives (0.02 mg ethinyl estradiol / 0.150 mg
desogestrel) in combination with 300 mg SJW twice daily reported a significant increase in
breakthrough bleeding compared to subjects taking oral contraceptive alone [417]. Progestins
and estrogens contained in oral contraceptives are known to be metabolized by various CYP
enzymes and therefore induction of these enzymes by SJW results in decreased plasma
concentrations and therapeutic failure [417-420].
Interactions between SJW and with drugs used in the prevention of organ transplant rejection
such as tacrolimus and cyclosporine have been reported [421-431]. Several transplant patients
have experienced transplant rejection potentially related to coadministration of SJW. In one
case report a patient treated with 75 mg cyclosporine daily for several years following kidney
transplant experienced a drop in cyclosporin plasma levels attributed to SJW administration
[427]. Levels returned to normal when SJW was discontinued and dropped upon rechallenge
with SJW extract. Similarly, tacrolimus plasma levels markedly decreased in a study involving
10 stabilized renal transplant patients administered 600 mg SJW extract for two weeks,
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requiring dosage adjustments during and for up to two weeks following discontinuation of
SJW [431].
SJW may interact with selective serotonin reuptake inhibitors (SSRIs), monoamines, and other
antidepressant and psychiatric medications due to the serotonin uptake inhibitory properties
of hypericin and hyperforin, although metabolic induction plays a role for some drugs [368,
370-373, 432-446]. In one case report, a patient who had been taking paroxetine 40 mg daily for
treatment of depression discontinued her medication and began taking SJW 600 mg daily [434].
No adverse events were reported with the switch, but upon coadministration of a 20 mg dose
of paroxetine to aid in sleep the patient experience extreme grogginess, weakness, fatigue, and
incoherency. The author cited the potential for additive serotonin uptake inhibition resulting
in “serotonin syndrome”. One case of a male adult patient stabilized on methylphenidate for
attention deficit hyperactivity disorder (ADHD) is reported in which the patient experienced
increased ADHD symptoms after taking SJW 600 mg daily for four months [438]. The mech‐
anism of the interaction is unknown. Interactions have also been reported for amitriptyline,
clozapine, fexofenadine, and sertraline; therefore administration of SJW in patients taking
these and similar drugs should be avoided [440, 443, 444, 446, 447].
An interaction between SJW and drugs known to cause phototoxic adverse reactions is also
possible, due to the photosensitizing nature of hypericin [448-450]. In one study, 11 subjects
were exposed to UVA1 radiation at baseline and following 10 days treatment with 1020 mg
(3000 mcg hypericin) extract [449]. Minimum erythemal dose (MED) as measured 8, 24 and
48 hours after exposure to radiation and was found to be significantly lower at 8 and 48,
but not 24 hours, after exposure compared to control. There is one case report of a patient
experiencing severe phototoxicity upon exposure to laser light (532 nm) and pulsed dye
laser light (585 nm), presumably due to ingestion of SJW [451]. SJW may also increase the
sensitivity and skin toxicity of radiation treatment in patients undergoing radiation therapy,
possibly through photosensitizing effects although the exact underlying mechanism is not
known [452].
3.12. Willow bark (Salix alba)
Willow bark from the Salix alba tree is often contained in weight loss supplements, presumably
due to earlier studies that noted enhanced thermogenic properties of ephedra in combination
products also including aspirin (see Ephedra above). The active constituents of white willow
are predominantly the salicylates (acetylsalicylic acid) and, therefore, the bark has traditionally
been used in the treatment of pain [27, 453, 454]. The analgesic and anti-inflammatory activity
of willow bark is due to inhibition of cyclooxygenase-2 (COX-2) mediated prostaglandin E2
release [455, 456]. Although there are few case reports dealing with willow bark extract
specifically, drug and herb interactions seen with other salicylates are possible [455, 457].
Generally, caution should be used in concomitant administration of drugs contraindicated for
aspirin, such as beta-blockers, NSAIDs, carbonic anhydrase inhibitors (e.g. acetazolamide),
probenecid, alcohol, and salicylates, while the kinetics of protein bound drugs can also be
modified [27]. Salicin may also have an effect on platelet aggregation, and therefore interac‐
tions with anticoagulants and antiplatelet drugs are possible [458, 459]. In one randomized
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presence of SJW [390, 391]. In one open-label, three-way crossover randomized study, 12
healthy male subjects were given 1 gram of SJW (standardized to hypericin 0.825 mg/g and
hyperforin 12.5 mg/g) for 21 days, with administration of a single 25 mg dose of warfarin on
day 14 [390]. A significant increase in warfarin (Cl/F) was observed compared to warfarin
alone, with a corresponding decrease in AUC and half-life. However, there was no significant
impact on INR or platelet aggregation. The interaction is likely caused not only by alteration
of drug metabolism via CYP 450 induction, but also binding of warfarin to the SJW constituents
hypericin and pseudohypericin, leading to decreased absorption of the drug [392]. In another
study, patients not responding to clopidogrel therapy alone experienced an increase in
therapeutic activity when clopidogrel and SJW were coadministered; therefore it is possible
that patients responding to stand alone clopidogrel treatment may be at increased risk of
bleeding [391]. There has been one case report of a possible interaction between theophylline
and SJW in which theophylline levels significantly increased following discontinuation of SJW
in a smoker also taking 11 other drugs [393]. However, another study in healthy subjects
showed no impact of SJW on theophylline kinetics [394]. Plasma concentrations of protease
inhibitors such as indinavir may be reduced in the presence of SJW due to induction of p-
glycoprotein efflux in the gastrointestinal tract [395-398]. Decreased plasma levels of the
“statins” simvastatin and atorvastatin have been reported in controlled, randomized, cross‐
over studies [399, 400]. Reports of pharmacokinetic interactions have also been reported for
digoxin, gliclazide, imatinib, irinotecan, methadone, omeprazole, verapamil, and voriconazole
have also been published [401-412]. In general, coadministration of SJW with drugs signifi‐
cantly eliminated via these enzymes should be avoided.
Several studies and case reports describe interactions between SJW and oral contraceptives,
resulting in breakthrough or irregular bleeding and unplanned pregnancy [413-416]. In one
case report, an unwanted pregnancy occurred in a 36-year old patient while taking an ethinyl
estradiol/dinogesterol oral contraceptive (Valette®). The patient had previously been taking
fluvastatin (20 mg/day) for 2 years, but had discontinued the drug and started 1700 mg SJW
extract daily for 3 months prior to conception [414]. One randomized controlled trial in 18
female subjects taking low dose oral contraceptives (0.02 mg ethinyl estradiol / 0.150 mg
desogestrel) in combination with 300 mg SJW twice daily reported a significant increase in
breakthrough bleeding compared to subjects taking oral contraceptive alone [417]. Progestins
and estrogens contained in oral contraceptives are known to be metabolized by various CYP
enzymes and therefore induction of these enzymes by SJW results in decreased plasma
concentrations and therapeutic failure [417-420].
Interactions between SJW and with drugs used in the prevention of organ transplant rejection
such as tacrolimus and cyclosporine have been reported [421-431]. Several transplant patients
have experienced transplant rejection potentially related to coadministration of SJW. In one
case report a patient treated with 75 mg cyclosporine daily for several years following kidney
transplant experienced a drop in cyclosporin plasma levels attributed to SJW administration
[427]. Levels returned to normal when SJW was discontinued and dropped upon rechallenge
with SJW extract. Similarly, tacrolimus plasma levels markedly decreased in a study involving
10 stabilized renal transplant patients administered 600 mg SJW extract for two weeks,
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requiring dosage adjustments during and for up to two weeks following discontinuation of
SJW [431].
SJW may interact with selective serotonin reuptake inhibitors (SSRIs), monoamines, and other
antidepressant and psychiatric medications due to the serotonin uptake inhibitory properties
of hypericin and hyperforin, although metabolic induction plays a role for some drugs [368,
370-373, 432-446]. In one case report, a patient who had been taking paroxetine 40 mg daily for
treatment of depression discontinued her medication and began taking SJW 600 mg daily [434].
No adverse events were reported with the switch, but upon coadministration of a 20 mg dose
of paroxetine to aid in sleep the patient experience extreme grogginess, weakness, fatigue, and
incoherency. The author cited the potential for additive serotonin uptake inhibition resulting
in “serotonin syndrome”. One case of a male adult patient stabilized on methylphenidate for
attention deficit hyperactivity disorder (ADHD) is reported in which the patient experienced
increased ADHD symptoms after taking SJW 600 mg daily for four months [438]. The mech‐
anism of the interaction is unknown. Interactions have also been reported for amitriptyline,
clozapine, fexofenadine, and sertraline; therefore administration of SJW in patients taking
these and similar drugs should be avoided [440, 443, 444, 446, 447].
An interaction between SJW and drugs known to cause phototoxic adverse reactions is also
possible, due to the photosensitizing nature of hypericin [448-450]. In one study, 11 subjects
were exposed to UVA1 radiation at baseline and following 10 days treatment with 1020 mg
(3000 mcg hypericin) extract [449]. Minimum erythemal dose (MED) as measured 8, 24 and
48 hours after exposure to radiation and was found to be significantly lower at 8 and 48,
but not 24 hours, after exposure compared to control. There is one case report of a patient
experiencing severe phototoxicity upon exposure to laser light (532 nm) and pulsed dye
laser light (585 nm), presumably due to ingestion of SJW [451]. SJW may also increase the
sensitivity and skin toxicity of radiation treatment in patients undergoing radiation therapy,
possibly through photosensitizing effects although the exact underlying mechanism is not
known [452].
3.12. Willow bark (Salix alba)
Willow bark from the Salix alba tree is often contained in weight loss supplements, presumably
due to earlier studies that noted enhanced thermogenic properties of ephedra in combination
products also including aspirin (see Ephedra above). The active constituents of white willow
are predominantly the salicylates (acetylsalicylic acid) and, therefore, the bark has traditionally
been used in the treatment of pain [27, 453, 454]. The analgesic and anti-inflammatory activity
of willow bark is due to inhibition of cyclooxygenase-2 (COX-2) mediated prostaglandin E2
release [455, 456]. Although there are few case reports dealing with willow bark extract
specifically, drug and herb interactions seen with other salicylates are possible [455, 457].
Generally, caution should be used in concomitant administration of drugs contraindicated for
aspirin, such as beta-blockers, NSAIDs, carbonic anhydrase inhibitors (e.g. acetazolamide),
probenecid, alcohol, and salicylates, while the kinetics of protein bound drugs can also be
modified [27]. Salicin may also have an effect on platelet aggregation, and therefore interac‐
tions with anticoagulants and antiplatelet drugs are possible [458, 459]. In one randomized
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double-blind study involving 16 patients administered standardized extracts of Salicis cortex
(240 mg salicin/day), mean arachidonic induced platelet aggregation was reduced (61%
compared to 78% in placebo group), but not as significantly as in the acetylsalicylic acid group
(13% reduction) [458]. One randomized placebo-controlled trial investigating the efficacy of
willow bark extract in osteoarthritis reported an increase in triglyceride levels, suggesting a
potential interaction between willow bark and antihyperlipidemics [460]. Some patients in
another randomized controlled trial, who were given 240 mg salicin daily for four weeks,
suffered blood pressure instability and edema; use of willow bark in patients taking antihy‐
pertensives should be cautioned [461].
4. Adulteration of dietary supplements
A final note is necessary regarding the adulteration of weight loss supplements with drug
products and other chemical substances. This adulteration is often the underlying cause for
the purported activity of a dietary supplement and can result in serious toxicity. The most
commonly cited contaminant in weight loss supplements is sibutramine (Meridia®; see above),
a weight loss supplement removed from the market in October 2010 for significant cardiac
toxicities [462-466]. One U.S. FDA report cites 72 different herbal products containing adul‐
terants, 94.4% of which contained sibutramine as an additive [102]. Multiple products listed
in the report were contaminated with phenolphthalein (11.1%) or the anti-seizure drug
phenytoin (2.8%). Other reported contaminants (1.4%) included the experimental anti-obesity
agent cetilistat, the recalled anti-obesity agent rimonabant (see above), the anti-obesity
amphetamine stimulant drug fenproporex, the antidepressant fluoxetine, or the diuretics
furosemide and bumetanide[103]. Phenophthalein was previously used as a laxative in over-
the-counter products but was removed from the U.S. market in 1999 due to concerns of
carcinogenicity and genotoxicity [467]. Another study investigating contamination of 20
different dietary supplements using 1H-NMR methods found contamination of 14 of the
products (70%), with eight products containing sibutramine, five containing both sibutramine
and phenolphthalein, and one formulation containing undeclared synephrine [468]. There
have been other reports of contamination of weight loss supplements with the diuretic
hydrochlorothiazide [462, 469]. Given that tainting of weight loss supplements is common,
patients and health care professionals should be made aware of the risks associated with
ingestion of herbal products, especially those with minimal evidence backing their claims of
efficacy.
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double-blind study involving 16 patients administered standardized extracts of Salicis cortex
(240 mg salicin/day), mean arachidonic induced platelet aggregation was reduced (61%
compared to 78% in placebo group), but not as significantly as in the acetylsalicylic acid group
(13% reduction) [458]. One randomized placebo-controlled trial investigating the efficacy of
willow bark extract in osteoarthritis reported an increase in triglyceride levels, suggesting a
potential interaction between willow bark and antihyperlipidemics [460]. Some patients in
another randomized controlled trial, who were given 240 mg salicin daily for four weeks,
suffered blood pressure instability and edema; use of willow bark in patients taking antihy‐
pertensives should be cautioned [461].
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products and other chemical substances. This adulteration is often the underlying cause for
the purported activity of a dietary supplement and can result in serious toxicity. The most
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1. Introduction
In the 1940’s, the development of penicillin as a potent broad-range antibiotic revolutionized
the treatment of infectious disease and ushered in a prolific discovery period of natural
small molecules produced by microorganisms that were antagonistic towards the growth of
other bacteria. Antibiotics have generally been classified by their mechanism of action. For
example, the β-lactam compounds, penicillin and cephalosporins, disrupt the synthesis of
the peptidoglycan layer of the bacterial cell wall, whereas protein synthesis inhibitors, such
as tetracycline and some aminoglycosides, bind to the 30S ribosomal subunit and block ad‐
dition of amino acids to the growing peptide chain. By the 1960’s, the majority of all antibi‐
otics in use today had been isolated and developed for public consumption, leading the U.S.
Surgeon General to declare in 1968 that the war on infectious disease had been won.
Unfortunately, nature has found a way to thwart mankind’s effort to contain infectious dis‐
ease. Under the selective pressure of antibiotics that target different cell processes, bacteria
have evolved to become resistant to the lethal effects of many classes of antibiotics. One
stark example that has emerged as a major public health threat is methicillin-resistant Staph‐
ylococcus aureus (MRSA), which is estimated to cause ~19,000 deaths in the US annually [1].
MRSA has become resistant to β-lactam antibiotics by acquiring the resistance gene mecA,
which encodes for a unique penicillin binding protein PBP2A that can function as a surro‐
gate for native staphylococcal PBPs normally inactivated by β-lactam antibiotics. In the last
decades of the 20th century, MRSA has continued to evolve in response to a continually
changing human environment, from a primary agent of hospital-acquired infections to a
multi-drug resistant strain that has also acquired Tn1546 transposon-based vancomycin re‐
sistance. Furthermore, the appearance of MRSA strains in a community setting may be a
stepping stone to the evolution of a completely drug-resistant strain.
© 2013 Hong-Geller and Micheva-Viteva; licensee InTech. This is an open access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
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There is no question that new strategies that target different aspects of pathogen function
are urgently needed to combat multi-drug resistant bacteria. However, very few new scaf‐
folds for drug discovery developed after the 1960s have been found to be effective [2]. To
date, only four new classes of antibiotics, including mutilins and lipopeptides, have been in‐
troduced, but none of these have proven to be as effective as the panel of classic antibiotics.
Instead, established scaffolds have been modified or re-purposed to develop successive gen‐
erations of effective antibiotics. For example, the core structure of cephalosporins have been
left intact to preserve activity, but the peripheral chemical groups have been modified to im‐
part the molecule with the ability to penetrate the bacterial membrane more efficiently or be
more resistant to β-lactamase [3]. Modifications of four classic antibiotics, cephalosporin,
penicillin, quinolone, and macrolide, account for ~73% of the “new” antibiotics filed be‐
tween 1981 and 2005 [4]. It is also important to note that small compounds need to exhibit
not only anti-microbial activity, but also minimized cytotoxic properties to widen their ther‐
apeutic window.
Although advances in organic synthesis have extended the lifetime of classic antibiotics
through synthetic modifications, new scaffolds are also needed. Recent efforts to search for
new modalities amongst previously-overlooked natural sources, such as unmined bacterial
taxa and ecological niches, have started to bear fruit. The increasingly rapid data acquisition
and low cost of ultra high-throughput sequencing has provided rich coverage of bacterial
genomes and transcriptomes. For example, genomic analyses of a vancomycin-resistant
strain of Amycolatopsis orientalis revealed the presence of genetic loci that encode for at least
10 other secondary metabolites. One compound, ECO-0501, exhibited strong anti-bacterial
properties against Gram-positive pathogens, including several strains of MRSA [5]. Mass
spectroscopy (MS) is another primary methodology used to identify small molecule metabo‐
lites with potential anti-microbial properties. The polycyclic small molecule, abyssomicin C,
from the marine actinomycete Verrucosispora was characterized as an inhibitor of p-amino‐
benzoate biosynthesis by MS and also exhibited antimicrobial properties against MRSA
strains [6].
2. Methodology for high-throughput screens (HTS) using small molecule
libraries
The workhorse platform for anti-bacterial drug discovery is a chemical genetics HTS ap‐
proach using small molecule compound libraries to identify candidates that inhibit bacterial
growth or the function of key bacterial enzymes. Small molecules, generally <500 molecular
weight, have the potential to enter cells and selectively perturb specific protein activity, thus
functioning as therapeutic agents against disease. In general, the precise mechanism of in‐
hibitor activity remains unknown in the initial screen. Subsequent identification of the mo‐
lecular targets of small molecules will have to be performed to implicate the specific
bacterial functions that were inactivated in the screen. Thus, HTS can sample a large un‐
biased collection of structurally diverse molecules to select compounds that perturb the de‐
fined cell phenotype of interest. (Fig. 1)
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Various chemical compound libraries are now available through commercial and public re‐
sources that include FDA-approved bioactive compounds, therapeutic agents, and natural
products. To maximize the structural complexity and diversity of small molecule libraries,
scientists have also employed diversity-oriented synthesis,
Figure 1. General flowchart of high-throughput methodology to screen small molecule libraries for inhibitors of host-
pathogen interactions
in which different scaffolds are modified with highly diverse functional groups. [7, 8]. To
bolster academic research in chemical biology efforts for HTS-driven identification of bioac‐
tive compounds, the NIH launched the Molecular Libraries Program in 2005 to offer ac‐
cess to ten large-scale automated HTS centers in the Molecular Libraries Probe Production
Centers Network, including diverse compound libraries through the Small Molecule Repo‐
sitory and information on biological activities of small molecules in the PubChem BioAs‐
say public database.
A variety of different molecular and cellular methods have been developed for HTS using
small molecule libraries. Automated microscopy has been utilized for high-content, image-
based screens of cells exposed to small molecules. Acquired cell images can be analyzed by
automated image analysis software to quantitate physiological changes at the single-cell lev‐
el, including phenotypes such as morphology and cell toxicity. Small molecule microarrays,
in which ~10,000 small molecules are covalently bound to a glass slide, has been generated
to detect high affinity binding to a protein of interest, as a potential inhibitor of function.
Binding of the protein of interest to specific compounds on the microarray was then detect‐
ed with fluorescent antibodies [9].
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3. Disruption of host-pathogen interactions for novel drug discovery
Given the innovation gap in the discovery of novel antibiotics post-1960, strategies to inhibit
novel targets are greatly needed to combat infectious disease. Multiple studies have identi‐
fied small molecule inhibitors that target gene expression of pathogen TTSS components in
P. aeruginosa, enteropathogenic E. coli, and Y. pestis [10, 11, 12]. The small molecule virstatin,
4-[N1,8-naphthalimide)]-n-butyric acid, was identified as an inhibitor of the transcriptional
regulator ToxT in Vibrio cholerae [13]. The small molecule, 2-imino-5-arylidene thiazolidi‐
none, which blocks TTSS-dependent functions in S. typhimurium, was also found to inhibit
virulence in Yersinia, Pseudomonas, and Francisella strains, indicating that compounds can be
identified that target common processes in multiple pathogens [14].
Research efforts have recently begun to focus on disruption of host-pathogen interactions as
a new approach to identify potential targets for drug discovery, rather than solely on specif‐
ic pathogen targets or processes. In particular, the screening of small molecule libraries to
identify inhibitors that block pathogen infection of the host, using such phenotypes as
pathogen invasion, host morphology, and pathogen replication in the host, is a powerful ap‐
proach for therapeutic development that may uncover fundamental mechanisms of patho‐
genesis and potentially lead to discovery of new classes of anti-infective agents. Here, we
describe case studies of the use of small molecules in host infection screens to identify novel
inhibitors against infectious disease, including bacterial, viral, parasitic, and fungal infec‐
tions. We will discuss these studies in the context of re-purposing known drugs, inhibitor
specificity, and discovery of basic mechanisms of host-pathogen interactions. The screen re‐
sults are summarized in Table 1.
Screening for inhibitors of intracellular infection
Intracellular pathogens, including viruses, parasites, and some bacteria, manipulate specific
host factors in order to downregulate the host immune response or modulate host actin cy‐
toskeleton rearrangements to induce phagocytic uptake of the pathogen. L. monocytogenes,
an intracellular Gram-positive bacteria, infects the human host primarily through ingestion
of contaminated foods and causes gastrointestinal infection. In 2011, Listeria contamination
of cantaloupes led to at least 30 deaths and ~150 illnesses in 28 states. Following internaliza‐
tion of L. monocytogenes in host membrane-bound vacuoles, the pore-forming cytolysin, lis‐
teriolysin O (LLO) and a phosphatidylinositol-specific phospholipase C (PI-PLC) mediates
lysis of the vacuoles to release the pathogen into the host cell cytosol. L. monocytogenes then
polymerizes host actin to propel itself into adjacent host cells to continue the infection proc‐
ess. To identify compounds that inhibited L. monocytogenes intracellular infection, a screen of
480 small molecules from the Biomol ICCB Known Bioactives library was performed using
automated microscopy and image analysis [15]. Murine bone marrow-derived macrophages
were infected with a GFP-expressing L. monocytogenes strain to assess efficiency of invasion,
survival, and replication in the host. Twenty-one compounds, affecting cell functions such
as actin polymerization, calcium signaling, and apoptosis, were identified that markedly de‐
creased Listeria monocytogenes infection efficiency. In particular, the FDA-approved anti-psy‐
chotic drug pimozide, used to treat Tourette’s syndrome and schizophrenia, was shown to
Drug Discovery160
decrease internalization of not just L. monocytogenes, but other bacterial species as well, in‐
cluding Bacillus subtilis, Salmonella typhimurium, and E. coli. Furthermore, pimozide de‐
creased vacuole escape and cell-to-cell spread of L. monocytogenes in the host. Thus,
pimozide is an example of a small molecule that can be re-purposed to treat infectious dis‐
ease with potential for broad spectrum anti-microbial applications.
Parasites also employ a life cycle of host cell invasion, replication, and host cell lysis during
onset of infection. Taxoplasma gondii is the protozoan intracellular human parasite of the
phylum Apicomplexa and is related to Plasmodium and Cryptosporidium, the causative agents
of malaria and diarrheal disease, respectively. To discover inhibitors of T. gondii invasion, a
high-throughput
Table 1 Small molecule screens using host-pathogen systems
microscopy assay was developed to distinguish between extracellular and intracellular para‐
sites in a BS-C-1 epithelial cell model, using differential labeling with fluorescent dyes [16]. Out
of a 12,160 structurally-diverse small molecule library, 24 non-cytotoxic inhibitors were identi‐
fied that reduced parasite invasion to <20% compared to control wells. These molecules inhib‐
ited different aspects of the infection process, including gliding motility and secretion of host
cell adhesins. One of these inhibitors, tachypleginA, was found to post-translationally modify
TgMLC1, a myosin light chain component of the T. gondii myosin motor complex, which drives
host cell penetration and parasite mobility [17]. TgMLC1 exposed to the small molecule exhib‐
ited a rapid and irreversible change in electrophoretic mobility on SDS-PAGE gels. Although
the exact nature of the modification remains unclear, the modification has been mapped to
amino acids V46-R59 by mass spectroscopy. These studies provide key mechanistic informa‐
tion on the importance of T. gondii motility in pathogenesis and illustrate the potential for small
molecules to form covalent interactions with target proteins.
Targeting virulence toxin mechanisms of infection
Many Gram-negative bacteria, including Pseudomonas and Yersinia, utilize the TTSS as a pri‐
mary mechanism of virulence to inject effector proteins into the host cytosol to downregu‐
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the exact nature of the modification remains unclear, the modification has been mapped to
amino acids V46-R59 by mass spectroscopy. These studies provide key mechanistic informa‐
tion on the importance of T. gondii motility in pathogenesis and illustrate the potential for small
molecules to form covalent interactions with target proteins.
Targeting virulence toxin mechanisms of infection
Many Gram-negative bacteria, including Pseudomonas and Yersinia, utilize the TTSS as a pri‐
mary mechanism of virulence to inject effector proteins into the host cytosol to downregu‐
Small Molecule Screens to Identify Inhibitors of Infectious Disease
http://dx.doi.org/10.5772/52502
161
late the host immune response. A host cytotoxicity assay was designed to screen for small
molecule inhibitors of Pseudomonas aeruginosa, a leading cause of hospital-acquired infec‐
tions in cystic fibrosis patients. P. aeruginosa ExoU, a TTSS effector protein, is a member of
the patatin family of phospholipase A2 (PLA2) that can lyse host cell membranes during in‐
fection. A high-throughput screen of 50,000 compounds from the Chembridge Microformat
Library E was performed using a colorimetric live/dead assay to identify small molecules
that protected Chinese hamster ovary (CHO) cells from cytotoxicity mediated by P. aerugino‐
sa expressing ExoU as the sole TTSS effector [18]. A primary list of 88 compounds exhibited
rescue of CHO cells from ExoU-mediated cytotoxicity. The most effective compound, pseu‐
dolipasin A, inhibited ExoU function downstream of TTSS delivery into the host. In addition
to inhibition of CHO cytotoxicity, pseudolipasin A also protected the amoeba Dictyolstelium
discoideum from ExoU-mediated killing by P. aeruginosa and inhibited cytotoxicity in the
yeast Saccharomyces cerevisiae expressing ExoU. Interestingly, pseudolipasin A did not affect
eukaryotic PLA2, suggesting that this small molecule may specifically target bacterial PLA2.
Pseudolipasin A is representative of small molecules that do not kill or inhibit the growth of
pathogens, but instead attenuate their virulence.
Inhibitors of P. aeruginosa virulence have also been identified using a cell-based yeast pheno‐
typic assay in combination with a large-scale small molecule screen. A total of 505 P. aerugi‐
nosa virulence factors and essential genes were individually overexpressed in S. cerevisae to
downselect genes that inhibited yeast growth [19]. Nine genes strongly or partially impaired
yeast growth, including three TTSS effectors, ExoS, ExoT, and ExoY. ExoS has been previ‐
ously shown to ADP-ribosylate multiple downstream targets, including vimentin, the Ras
family of small GTP-binding proteins, and cyclophilin A. Given that ExoS is a critical media‐
tor of P. aeruginosa chronic infections, a library of 56,280 compounds was screened to find
inhibitors of ExoS ADP-ribosylation activity that rescued cytotoxicity in yeast. Six com‐
pounds were identified that restored yeast growth. The most promising compound, exosin,
was found to modulate ExoS enzymatic activity in vitro and exhibited a protective effect
against P. aeruginosa infection in mammalian CHO cells. This study demonstrates the effec‐
tive use of a simple eukaryotic host, baker’s yeast, as a tool for drug screening for applica‐
tions in controlling infectious disease in humans.
Another pathogen family that employs the TTSS is Yersinia, which secrete Yop effectors into
the host cell. There are three Yersinia human pathogens, Y. pestis, the etiological agent of pla‐
gue via intradermal fleabites or inhalation, and Y. pseudotuberculosis and Y. enterocolitica,
which cause mild and self-limiting enteric disease by the oral route. HTS strategies have
been developed to identify small molecules that inhibit translocation of the Yops into host
cells. A recombinant Y. pseudotuberculosis strain was constructed to express a chimeric pro‐
tein containing the first 100 amino acids of YopE, which contains the proper translocation
signals to inject into the host, fused to a fragment of β-lactamase. [20]. This bacterial strain
was used to infect HEp-2 host cells treated with a non-membrane-permeating, non-fluores‐
cent dye CCF2-AM, which fluoresces green at 520nm, as a result of intramolecular FRET be‐
tween the 7-hydroxycoumarin and fluorescein molecules, conjugated by a lactam ring. Upon
cellular uptake, CCF2-AM is modified by cytoplasmic esterases and is trapped in the host
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cell. If the YopE-β-lactamase fusion is introduced into the host, the β-lactamase will cleave
the lactam ring in CCF2-AM and liberate the fluorescein, leaving the coumarin to fluoresce
blue at 447nm. Using this differential fluorescence assay, 100,000 compounds from a number
of sources, including the ChemDiv 2, ChemDiv 3, ChemDiv 4, Maybridge 3, Maybridge 4,
and Biomol ICCB libraries, were screened for low ratios of blue-to-green fluorescence. In to‐
tal, 200 compounds were deemed potential hits, and 45 were assessed further using secon‐
dary assays, including rounded host morphology in response to Yersinia infection. Finally, 6
compounds were found that inhibited translocation of effectors into the host without affect‐
ing expression and function of TTSS components. Several of these compounds also inhibited
host cell rounding when induced by Pseudomonas effectors, suggesting that these com‐
pounds may have a broad-spectrum anti-infective effect.
A screen to identify small molecule inhibitors of B. anthracis also employed the CCF2-AM
FRET assay. B. anthracis, the Gram-positive causative agent of anthrax, secretes three major
toxins during infection, lethal factor (LF), protective antigen (PA), and edema factor (EF). A
fusion protein between LF and β-lactamase was introduced into host cells by PA-directed
endocytosis to hydrolyze the CCF2-AM fluorogenic substrate [21]. Out of 70,094 compounds
tested, 1170 initial hits exhibited concentration-dependent inhibition of β-lactamase activity.
Thirty compounds with known biological activities and/or were high confidence hits were
selected for further analysis. Three compounds, NCGC00084148-01, diphyllin, and niclosa‐
mide, exhibited protective effects from anthrax LF, a LF fusion to Pseudomonas exotoxin, and
diphtheria toxin in RAW264.7 murine macrophages and CHO cells, and are thought to inter‐
fere with toxin internalization in the host.
The interaction between B. anthracis EF and its cellular activator, calmodulin (CaM), became
the basis of a two-step tandem screen to identify small molecule inhibitors of anthrax infec‐
tion. A library of 10,000 compounds (Chembridge, Library # ET350-1) in pools of 8 was
screened to identify small molecules that blocked an EF-induced flat to round morphology
change in Y1 murine adrenocortical cells [22]. Twenty-four initial hits were then individual‐
ly tested using surface plasmon resonance (SPR) to identify molecules that block interactions
between EF and immobilized CaM. One compound, (4-[4-(3,4-cichlorophenyl)-thiazolylami‐
no]-benzenesulfonamide) 10506-2A, efficiently inhibited EF-CaM binding in a dose-depend‐
ent manner, and was found to specifically target the CaM binding region of EF by
fluorescence spectroscopy. Since this compound was found to be toxic in cultured mammali‐
an cells, a series of structurally-related compounds was synthesized, and a new inhibitory
compound with reduced toxicity was subsequently identified.
Small molecule discovery in plant-pathogen interactions
Discovery of small molecule inhibitors has also been extended to plant pathogen systems as
an approach to develop commercially-relevant chemicals to protect crops assets from dis‐
ease. The Gram-negative pathogen Pseudomonas syringae expresses a TTSS, enters plant tis‐
sues through the stomata or wounds, and infects a wide range of plant species. A major
challenge in the application of small molecule screens to plant-pathogen interactions is the
development of high-throughput methodology with a plant model system. A high-through‐
put liquid assay was developed based on P. syringae-induced bleaching of Arabidopsis thali‐
Small Molecule Screens to Identify Inhibitors of Infectious Disease
http://dx.doi.org/10.5772/52502
163
late the host immune response. A host cytotoxicity assay was designed to screen for small
molecule inhibitors of Pseudomonas aeruginosa, a leading cause of hospital-acquired infec‐
tions in cystic fibrosis patients. P. aeruginosa ExoU, a TTSS effector protein, is a member of
the patatin family of phospholipase A2 (PLA2) that can lyse host cell membranes during in‐
fection. A high-throughput screen of 50,000 compounds from the Chembridge Microformat
Library E was performed using a colorimetric live/dead assay to identify small molecules
that protected Chinese hamster ovary (CHO) cells from cytotoxicity mediated by P. aerugino‐
sa expressing ExoU as the sole TTSS effector [18]. A primary list of 88 compounds exhibited
rescue of CHO cells from ExoU-mediated cytotoxicity. The most effective compound, pseu‐
dolipasin A, inhibited ExoU function downstream of TTSS delivery into the host. In addition
to inhibition of CHO cytotoxicity, pseudolipasin A also protected the amoeba Dictyolstelium
discoideum from ExoU-mediated killing by P. aeruginosa and inhibited cytotoxicity in the
yeast Saccharomyces cerevisiae expressing ExoU. Interestingly, pseudolipasin A did not affect
eukaryotic PLA2, suggesting that this small molecule may specifically target bacterial PLA2.
Pseudolipasin A is representative of small molecules that do not kill or inhibit the growth of
pathogens, but instead attenuate their virulence.
Inhibitors of P. aeruginosa virulence have also been identified using a cell-based yeast pheno‐
typic assay in combination with a large-scale small molecule screen. A total of 505 P. aerugi‐
nosa virulence factors and essential genes were individually overexpressed in S. cerevisae to
downselect genes that inhibited yeast growth [19]. Nine genes strongly or partially impaired
yeast growth, including three TTSS effectors, ExoS, ExoT, and ExoY. ExoS has been previ‐
ously shown to ADP-ribosylate multiple downstream targets, including vimentin, the Ras
family of small GTP-binding proteins, and cyclophilin A. Given that ExoS is a critical media‐
tor of P. aeruginosa chronic infections, a library of 56,280 compounds was screened to find
inhibitors of ExoS ADP-ribosylation activity that rescued cytotoxicity in yeast. Six com‐
pounds were identified that restored yeast growth. The most promising compound, exosin,
was found to modulate ExoS enzymatic activity in vitro and exhibited a protective effect
against P. aeruginosa infection in mammalian CHO cells. This study demonstrates the effec‐
tive use of a simple eukaryotic host, baker’s yeast, as a tool for drug screening for applica‐
tions in controlling infectious disease in humans.
Another pathogen family that employs the TTSS is Yersinia, which secrete Yop effectors into
the host cell. There are three Yersinia human pathogens, Y. pestis, the etiological agent of pla‐
gue via intradermal fleabites or inhalation, and Y. pseudotuberculosis and Y. enterocolitica,
which cause mild and self-limiting enteric disease by the oral route. HTS strategies have
been developed to identify small molecules that inhibit translocation of the Yops into host
cells. A recombinant Y. pseudotuberculosis strain was constructed to express a chimeric pro‐
tein containing the first 100 amino acids of YopE, which contains the proper translocation
signals to inject into the host, fused to a fragment of β-lactamase. [20]. This bacterial strain
was used to infect HEp-2 host cells treated with a non-membrane-permeating, non-fluores‐
cent dye CCF2-AM, which fluoresces green at 520nm, as a result of intramolecular FRET be‐
tween the 7-hydroxycoumarin and fluorescein molecules, conjugated by a lactam ring. Upon
cellular uptake, CCF2-AM is modified by cytoplasmic esterases and is trapped in the host
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cell. If the YopE-β-lactamase fusion is introduced into the host, the β-lactamase will cleave
the lactam ring in CCF2-AM and liberate the fluorescein, leaving the coumarin to fluoresce
blue at 447nm. Using this differential fluorescence assay, 100,000 compounds from a number
of sources, including the ChemDiv 2, ChemDiv 3, ChemDiv 4, Maybridge 3, Maybridge 4,
and Biomol ICCB libraries, were screened for low ratios of blue-to-green fluorescence. In to‐
tal, 200 compounds were deemed potential hits, and 45 were assessed further using secon‐
dary assays, including rounded host morphology in response to Yersinia infection. Finally, 6
compounds were found that inhibited translocation of effectors into the host without affect‐
ing expression and function of TTSS components. Several of these compounds also inhibited
host cell rounding when induced by Pseudomonas effectors, suggesting that these com‐
pounds may have a broad-spectrum anti-infective effect.
A screen to identify small molecule inhibitors of B. anthracis also employed the CCF2-AM
FRET assay. B. anthracis, the Gram-positive causative agent of anthrax, secretes three major
toxins during infection, lethal factor (LF), protective antigen (PA), and edema factor (EF). A
fusion protein between LF and β-lactamase was introduced into host cells by PA-directed
endocytosis to hydrolyze the CCF2-AM fluorogenic substrate [21]. Out of 70,094 compounds
tested, 1170 initial hits exhibited concentration-dependent inhibition of β-lactamase activity.
Thirty compounds with known biological activities and/or were high confidence hits were
selected for further analysis. Three compounds, NCGC00084148-01, diphyllin, and niclosa‐
mide, exhibited protective effects from anthrax LF, a LF fusion to Pseudomonas exotoxin, and
diphtheria toxin in RAW264.7 murine macrophages and CHO cells, and are thought to inter‐
fere with toxin internalization in the host.
The interaction between B. anthracis EF and its cellular activator, calmodulin (CaM), became
the basis of a two-step tandem screen to identify small molecule inhibitors of anthrax infec‐
tion. A library of 10,000 compounds (Chembridge, Library # ET350-1) in pools of 8 was
screened to identify small molecules that blocked an EF-induced flat to round morphology
change in Y1 murine adrenocortical cells [22]. Twenty-four initial hits were then individual‐
ly tested using surface plasmon resonance (SPR) to identify molecules that block interactions
between EF and immobilized CaM. One compound, (4-[4-(3,4-cichlorophenyl)-thiazolylami‐
no]-benzenesulfonamide) 10506-2A, efficiently inhibited EF-CaM binding in a dose-depend‐
ent manner, and was found to specifically target the CaM binding region of EF by
fluorescence spectroscopy. Since this compound was found to be toxic in cultured mammali‐
an cells, a series of structurally-related compounds was synthesized, and a new inhibitory
compound with reduced toxicity was subsequently identified.
Small molecule discovery in plant-pathogen interactions
Discovery of small molecule inhibitors has also been extended to plant pathogen systems as
an approach to develop commercially-relevant chemicals to protect crops assets from dis‐
ease. The Gram-negative pathogen Pseudomonas syringae expresses a TTSS, enters plant tis‐
sues through the stomata or wounds, and infects a wide range of plant species. A major
challenge in the application of small molecule screens to plant-pathogen interactions is the
development of high-throughput methodology with a plant model system. A high-through‐
put liquid assay was developed based on P. syringae-induced bleaching of Arabidopsis thali‐
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ana cotyledon seedlings, which signifies a loss of chlorophyll from plant tissues and is
indicative of bacterial pathogenesis [23]. A screen of ~200 small molecules active in Arabidop‐
sis (LATCA, Library of Active Compounds in Arabidopsis) identified several sulfanilamide
compounds, including sulfamethoxazole, sulfadiazine, and sulfapyridine, that prevented co‐
tyledon bleaching upon P. syringae infection. The most potent compound, sulfamethoxazole,
also inhibited P. syringae growth in mature soil-grown plants. A similar assay was used to
implicate the same compound, sulfamethoxazole, and the indole alkaloid gramine as inhibi‐
tors of Fusarium graminearum fungal infection in Arabidopsis and wheat, indicating that this
strategy represents a relevant surrogate system for identification of compounds that can pre‐
vent agriculturally-important infectious disease [24].
Combinational antiviral therapies for HIV
Given that viral pathogens are absolutely dependent on the host for propagation, even more
so than bacterial pathogens, research in host-directed anti-virals has advanced at a faster
pace than that for anti-bacterial agents. Human Immunodeficiency virus type 1 (HIV-1), a
lentivirus of the retroviral family and the causative agent of AIDS, is the most-widely stud‐
ied viral pathogen to date. HIV-1 infection causes a dramatic decline in host CD4+ T cell
numbers and a progressive failure of the immune response, which makes the host suscepti‐
ble to opportunistic infections and cancer. The highly glycosylated HIV-1 envelope, in com‐
bination with the extreme diversity of circulating viral strains, have presented daunting
challenges for development of an effective vaccine. Furthermore, the virus establishes chron‐
ic infection that resists the highly active antiretroviral therapy (HAART). Conventional
HAART for HIV-1 infection combines three main classes of anti-viral drugs:
1. nucleoside reverse transcriptase inhibitors (NRTIs),
2. non-nucleoside RT inhibitors (NNRTIs), which target the non-catalytic domain of RT,
and
3. protease inhibitors (PIs).
HAART is usually patient-specific, and its formulation is determined by the viral load and
drug resistance. A traditional HAART consists of two NRTIs and a NNRTI or a PI [25]. More
advanced combination therapies include a fourth class of antiretroviral drugs, HIV entry in‐
hibitors. HIV-1 entry into human cells is dependent on several sequential steps that include
binding of viral envelope protein gp120 to the CD4 receptor, and conformational change in
gp120 that increases its affinity to the chemokine co-receptors (CCR5 or CXCR4) and expos‐
es gp41, an HIV envelope protein that executes the fusion of HIV and host cell membranes.
Currently, there are two approved inhibitors of HIV-1 entry:
1. enfuvirtide, a peptide fusion inhibitor that binds to gp41 and
2. maraviroc, a small molecule entry inhibitor that prevents interaction between gp120
and CCR5.
The β-chemokine receptor CCR5 was found to act as a major co-receptor for the macro‐
phage-tropic HIV-1 R5 strains, predominant in the early asymptomatic stages of virus infec‐
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tion, whereas the T-cell-tropic strains (using the CXCR4 co-receptor) become prevalent in
the symptomatic stages concomitant with the decline of CD4+ T-cells [26]. CCR5 is an attrac‐
tive target for development of HIV-1 entry inhibitors, given the discovery that HIV-1 non-
progressors, individuals homozygous for a 32-bp deletion in the coding region of CCR5
gene (CCR5Δ32) were naturally resistant to infection with R5 HIV-1 [27]. Natural and syn‐
thetic CCR5 ligands such as RANTES, AOP-RANTES, Mip-1α, Mip-1β,and Met-RANTES
were found to efficiently protect against R5 HIV-1 infection [28, 29]. Thus, the first published
high throughput screen (HTS) for discovery of non- peptide inhibitors of HIV-1 entry was
performed in a virus-free cell-based system using [125I]-labeled RANTES. A strong inhibitor
of RANTES binding to CCR5 stably expressed on the surface of CHO cells was identified
from the library of Takeda Chemical Industries. Further chemical modifications of the lead
compound designated TAK-779 produced a potent (IC50 1.4 nM in CHO/CCR cells) and se‐
lective CCR5 antagonist capable of blocking R5 HIV-1 infection in vitro [30].
The number of CCR5 inhibitors has significantly grown since the discovery of TAK-779, but
very few compounds have entered clinical trials, and only maraviroc has been approved for
clinical use [31]. A radiolabeled-chemokine binding assay similar to one applied for the
identification of TAK-779 was used in a HTS of a small molecule library at Pfizer for the dis‐
covery of UK-107,543, which had become a scaffold for intensive medicinal chemistry, pro‐
ducing ~1,000 analog compounds, from which maraviroc (UK-427,857) was selected for its
excellent preclinical pharmacokinetics (90% inhibitory concentration of 2 nM in pool of
PBMCs from various donors) [32]. Despite its proven efficacy against HIV-1 R5 infection,
maraviroc is vulnerable to gp120 escape mutations [33]. Site-directed mutagenesis and mo‐
lecular modeling studies have identified a common binding pocket on CCR5 that is shared
by various small-molecule CCR5 inhibitors [34, 35, 36]. Emerging details on gp120 and
CCR5 points of interaction and binding thermodynamics provide valuable information that
can be applied in developing tools for rational design of novel HIV-1 entry inhibitors [37,
38]. Efficient block of HIV entry into host cells is essential to curtail virus dissemination and
is a key step towards eradication of HIV infection. The current HAART regiment can reduce
HIV replication to very low levels (below 50 copies/ml plasma) and can lead to recovery of
CD4+ T-cell counts but not cure the infection. Patients that have been successfully treated
with HAART for years have experienced a rapid virus rebound upon termination of the
therapeutic regiment [39, 40]. Such clinical cases present evidence that HIV establishes a
chronic infection that resists current HAART designed to target actively replicating virus. A
deliberate and controllable induction of HIV-1 replication from its latent reservoirs in com‐
bination with HAART is a novel and actively pursued approach that aims to eliminate both
active and latent viral pools [41].
Researchers often seek new anti-infective agents amongst small molecules that have previ‐
ously been approved for the treatment of cancer and neurological diseases, since they have
well-established pharmacokinetics and in most cases, known molecular mechanisms of ac‐
tion. One example of this is the histone deacetylase (HDAC) inhibitor, valproic acid (VA),
which had previously been approved for treatment of neurological and psychiatric disor‐
ders. HIV-1 has been shown to enter dormancy using epigenetic silencing via deaceylation
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compounds, including sulfamethoxazole, sulfadiazine, and sulfapyridine, that prevented co‐
tyledon bleaching upon P. syringae infection. The most potent compound, sulfamethoxazole,
also inhibited P. syringae growth in mature soil-grown plants. A similar assay was used to
implicate the same compound, sulfamethoxazole, and the indole alkaloid gramine as inhibi‐
tors of Fusarium graminearum fungal infection in Arabidopsis and wheat, indicating that this
strategy represents a relevant surrogate system for identification of compounds that can pre‐
vent agriculturally-important infectious disease [24].
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Given that viral pathogens are absolutely dependent on the host for propagation, even more
so than bacterial pathogens, research in host-directed anti-virals has advanced at a faster
pace than that for anti-bacterial agents. Human Immunodeficiency virus type 1 (HIV-1), a
lentivirus of the retroviral family and the causative agent of AIDS, is the most-widely stud‐
ied viral pathogen to date. HIV-1 infection causes a dramatic decline in host CD4+ T cell
numbers and a progressive failure of the immune response, which makes the host suscepti‐
ble to opportunistic infections and cancer. The highly glycosylated HIV-1 envelope, in com‐
bination with the extreme diversity of circulating viral strains, have presented daunting
challenges for development of an effective vaccine. Furthermore, the virus establishes chron‐
ic infection that resists the highly active antiretroviral therapy (HAART). Conventional
HAART for HIV-1 infection combines three main classes of anti-viral drugs:
1. nucleoside reverse transcriptase inhibitors (NRTIs),
2. non-nucleoside RT inhibitors (NNRTIs), which target the non-catalytic domain of RT,
and
3. protease inhibitors (PIs).
HAART is usually patient-specific, and its formulation is determined by the viral load and
drug resistance. A traditional HAART consists of two NRTIs and a NNRTI or a PI [25]. More
advanced combination therapies include a fourth class of antiretroviral drugs, HIV entry in‐
hibitors. HIV-1 entry into human cells is dependent on several sequential steps that include
binding of viral envelope protein gp120 to the CD4 receptor, and conformational change in
gp120 that increases its affinity to the chemokine co-receptors (CCR5 or CXCR4) and expos‐
es gp41, an HIV envelope protein that executes the fusion of HIV and host cell membranes.
Currently, there are two approved inhibitors of HIV-1 entry:
1. enfuvirtide, a peptide fusion inhibitor that binds to gp41 and
2. maraviroc, a small molecule entry inhibitor that prevents interaction between gp120
and CCR5.
The β-chemokine receptor CCR5 was found to act as a major co-receptor for the macro‐
phage-tropic HIV-1 R5 strains, predominant in the early asymptomatic stages of virus infec‐
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the symptomatic stages concomitant with the decline of CD4+ T-cells [26]. CCR5 is an attrac‐
tive target for development of HIV-1 entry inhibitors, given the discovery that HIV-1 non-
progressors, individuals homozygous for a 32-bp deletion in the coding region of CCR5
gene (CCR5Δ32) were naturally resistant to infection with R5 HIV-1 [27]. Natural and syn‐
thetic CCR5 ligands such as RANTES, AOP-RANTES, Mip-1α, Mip-1β,and Met-RANTES
were found to efficiently protect against R5 HIV-1 infection [28, 29]. Thus, the first published
high throughput screen (HTS) for discovery of non- peptide inhibitors of HIV-1 entry was
performed in a virus-free cell-based system using [125I]-labeled RANTES. A strong inhibitor
of RANTES binding to CCR5 stably expressed on the surface of CHO cells was identified
from the library of Takeda Chemical Industries. Further chemical modifications of the lead
compound designated TAK-779 produced a potent (IC50 1.4 nM in CHO/CCR cells) and se‐
lective CCR5 antagonist capable of blocking R5 HIV-1 infection in vitro [30].
The number of CCR5 inhibitors has significantly grown since the discovery of TAK-779, but
very few compounds have entered clinical trials, and only maraviroc has been approved for
clinical use [31]. A radiolabeled-chemokine binding assay similar to one applied for the
identification of TAK-779 was used in a HTS of a small molecule library at Pfizer for the dis‐
covery of UK-107,543, which had become a scaffold for intensive medicinal chemistry, pro‐
ducing ~1,000 analog compounds, from which maraviroc (UK-427,857) was selected for its
excellent preclinical pharmacokinetics (90% inhibitory concentration of 2 nM in pool of
PBMCs from various donors) [32]. Despite its proven efficacy against HIV-1 R5 infection,
maraviroc is vulnerable to gp120 escape mutations [33]. Site-directed mutagenesis and mo‐
lecular modeling studies have identified a common binding pocket on CCR5 that is shared
by various small-molecule CCR5 inhibitors [34, 35, 36]. Emerging details on gp120 and
CCR5 points of interaction and binding thermodynamics provide valuable information that
can be applied in developing tools for rational design of novel HIV-1 entry inhibitors [37,
38]. Efficient block of HIV entry into host cells is essential to curtail virus dissemination and
is a key step towards eradication of HIV infection. The current HAART regiment can reduce
HIV replication to very low levels (below 50 copies/ml plasma) and can lead to recovery of
CD4+ T-cell counts but not cure the infection. Patients that have been successfully treated
with HAART for years have experienced a rapid virus rebound upon termination of the
therapeutic regiment [39, 40]. Such clinical cases present evidence that HIV establishes a
chronic infection that resists current HAART designed to target actively replicating virus. A
deliberate and controllable induction of HIV-1 replication from its latent reservoirs in com‐
bination with HAART is a novel and actively pursued approach that aims to eliminate both
active and latent viral pools [41].
Researchers often seek new anti-infective agents amongst small molecules that have previ‐
ously been approved for the treatment of cancer and neurological diseases, since they have
well-established pharmacokinetics and in most cases, known molecular mechanisms of ac‐
tion. One example of this is the histone deacetylase (HDAC) inhibitor, valproic acid (VA),
which had previously been approved for treatment of neurological and psychiatric disor‐
ders. HIV-1 has been shown to enter dormancy using epigenetic silencing via deaceylation
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of histones in the vicinity of the integrated viral genome [42]. Thus, VA was tested as a po‐
tential agent to disrupt HIV-1 latent infection. However, years of VA treatment in combina‐
tion with HAART showed no clearance of the latent HIV reservoir [43]. A more potent
HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), approved for treatment of cuta‐
neous T-cell lymphoma, was subsequently tested as a potential agent that could ‘flush out’
HIV-1 from latently infected cells, based on its superior effect to VA in cell culture models
[44, 45]. A substantial effort has also been invested in the design and synthesis of bryostatin
chemical analogs, small molecules that activate protein kinase C (PKC) with single nanomo‐
lar concentration [46]. PKC activation leads to phosphorylation of nuclear factor κB (NFκB),
a key transcription factor regulator of HIV-1 gene expression [47]. However, modulation of
NFκB activity requires great caution, since abnormal NFκB signaling has been related to the
pathophysiology of inflammatory diseases and neurodegenerative disorders [48].
A HTS of a small molecule library recently identified novel HIV latency activators [49]. The
screen was performed using a lymphoma CD4+ T-cell line (SupT1) harboring latent recombi‐
nant HIV-1 and two reporters that reflect early and late virus gene expression incorporated
in the HIV-1 genome [50]. A luminescent assay based on secreted alkaline phosphatase
(SEAP) activity, incorporated in the late virus gene transcripts, was applied to screen a
chemical library of ~200,000 compounds. Validation of 27 hits with diverse chemical struc‐
tures demonstrated induction of latent virus from various cell models. Compounds with a
selective index (CC50/EC50) above 25 were chosen for downstream medicinal chemistry mod‐
ifications. Moreover, the lead compounds were shown to reactivate latent HIV from primary
resting CD4+ T-cells with no induction of cell proliferation. Small molecule activators of la‐
tent HIV that act in concert using different mechanisms have a better chance of purging the
virus out of infected cells [49]. Such pre-clinical data strongly suggests that successful treat‐
ment of HIV infection can be achieved only through combinational therapy consisting of di‐
verse class of antiviral drugs.
4. Whole animal small molecule screens using C. elegans
In vitro high-throughput screens have several limitations for the discovery of therapeutic in‐
hibitors with high efficacy. Synthetic compound libraries often contain toxic compounds
with poor pharmacokinetic properties, and many in vitro assays are not physiologically-rele‐
vant in the context of which a specific drug is expected to function. In a previous section, we
had described the use of a HTS whole organism-based assay based on Arabidopsis seedlings
as the host system. Here, we detail the use of a whole animal model, the nematode worm C.
elegans, in chemical screens that permit simultaneous assessment of the immunomodulatory
effects, potential toxicity of compounds, and drug efficacy in a host with a functioning im‐
mune system. The results of these screens are summarized in Table 2. Whole animal screens
have the distinct advantage of being able to directly discard compounds that induce organ‐
ismal toxicity and can identify compounds that target host-pathogen interactions in a rele‐
vant physiological context.
Drug Discovery166
C. elegans, a hermaphroditic nematode normally found in soil, is a versatile, more ethically-
acceptable whole animal system for high-throughput analysis of host response to pathogen
infection. C. elegans contains a fully sequenced genome that facilitates both genetic and ge‐
nomic analysis, offering an ideal compromise between organismal complexity and experi‐
mental tractability. C. elegans offers other experimental advantages, including a rapid 2-3
week life span, simple growth conditions, target-selected gene inactivation, and a relatively
low cost of maintenance compared to other whole animal systems. A wealth of experimental
data has demonstrated that many developmental, neurological, and biochemical processes
have been highly conserved between C. elegans and mammals. For example, cellular func‐
tions as diverse as innate immunity, the first line of defense against pathogen infection, and
RNA interference to downregulate gene expression via double-stranded RNA, are found in
both C. elegans and higher eukaryotes, suggesting the existence of a common ancestor of
these diverse species. Thus, anti-infective compounds identified using a C. elegans infection
model may also be translatable in humans.
C. elegans as a model host system has been well-studied for numerous bacterial pathogens, in‐
cluding the Gram-positive S. aureus, S. pneumoniae, and B. thuringiensis, and the Gram-nega‐
tive B. pseudomallei, P. aeruginosa, and S. marcescens. In general, different types of bacteria are
fed to C. elegans in place of their normal E. coli food source to provoke detectable symptoms of
illness, such as locomotion dysregulation, intestinal cell lysis, and shortened life span.
Small molecule inhibitors of bacterial infection
A small manual screen of 6000 synthetic compounds and 1136 natural extracts were ana‐
lyzed in an immunocompromised mutant of C. elegans infected with Enterococcus faecalis to
identify compounds that promoted host survival. [51]. A total of 16 compounds and 9 ex‐
tracts were identified that either modulated bacterial growth in vitro, impaired pathogen vir‐
ulence, or boosted host innate immunity. Furthermore, 15 out the 16 compounds did not kill
C. elegans or mammalian erythrocytes, indicating that the compounds are not toxic.
The development of automated sorting and handling of C. elegans rapidly enabled high-
throughput screening of small chemical libraries to identify compounds that enhanced sur‐
vival of C. elegans in response to bacterial infection. This methodology was enabled by the
Complex Object Parametric Analyzer and Sorter (COPAS) BioSort worm sorter (Union Bio‐
metrica) to dispense a defined number of living worms into multi-well plates, which were
then imaged using automated microscopy to quantify worm survival. A library of 37,200
compounds and natural product extracts was screened using the same C. elegans-E. faecalis
infection system described above [52]. Twenty-eight compounds and extracts were identi‐
fied that enhanced survival of infected C. elegans. Six structural classes of identified com‐
pounds did not affect the growth of E. faecalis itself, suggesting that the small molecules
inhibited a specific aspect of the host-pathogen interaction. Interestingly, two structural
classes are similar to compounds previously identified in a high-throughput screen to iden‐
tify inhibitors of P. aeruginosa biofilm development, indicating the presence of common mo‐
lecular targets across multiple bacterial species for drug discovery [53].
A P. aeruginosa infection model of C. elegans has also been developed to screen for novel anti-
infective compounds. The high-throughput assay was based on P. aeruginosa-induced slow
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of histones in the vicinity of the integrated viral genome [42]. Thus, VA was tested as a po‐
tential agent to disrupt HIV-1 latent infection. However, years of VA treatment in combina‐
tion with HAART showed no clearance of the latent HIV reservoir [43]. A more potent
HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), approved for treatment of cuta‐
neous T-cell lymphoma, was subsequently tested as a potential agent that could ‘flush out’
HIV-1 from latently infected cells, based on its superior effect to VA in cell culture models
[44, 45]. A substantial effort has also been invested in the design and synthesis of bryostatin
chemical analogs, small molecules that activate protein kinase C (PKC) with single nanomo‐
lar concentration [46]. PKC activation leads to phosphorylation of nuclear factor κB (NFκB),
a key transcription factor regulator of HIV-1 gene expression [47]. However, modulation of
NFκB activity requires great caution, since abnormal NFκB signaling has been related to the
pathophysiology of inflammatory diseases and neurodegenerative disorders [48].
A HTS of a small molecule library recently identified novel HIV latency activators [49]. The
screen was performed using a lymphoma CD4+ T-cell line (SupT1) harboring latent recombi‐
nant HIV-1 and two reporters that reflect early and late virus gene expression incorporated
in the HIV-1 genome [50]. A luminescent assay based on secreted alkaline phosphatase
(SEAP) activity, incorporated in the late virus gene transcripts, was applied to screen a
chemical library of ~200,000 compounds. Validation of 27 hits with diverse chemical struc‐
tures demonstrated induction of latent virus from various cell models. Compounds with a
selective index (CC50/EC50) above 25 were chosen for downstream medicinal chemistry mod‐
ifications. Moreover, the lead compounds were shown to reactivate latent HIV from primary
resting CD4+ T-cells with no induction of cell proliferation. Small molecule activators of la‐
tent HIV that act in concert using different mechanisms have a better chance of purging the
virus out of infected cells [49]. Such pre-clinical data strongly suggests that successful treat‐
ment of HIV infection can be achieved only through combinational therapy consisting of di‐
verse class of antiviral drugs.
4. Whole animal small molecule screens using C. elegans
In vitro high-throughput screens have several limitations for the discovery of therapeutic in‐
hibitors with high efficacy. Synthetic compound libraries often contain toxic compounds
with poor pharmacokinetic properties, and many in vitro assays are not physiologically-rele‐
vant in the context of which a specific drug is expected to function. In a previous section, we
had described the use of a HTS whole organism-based assay based on Arabidopsis seedlings
as the host system. Here, we detail the use of a whole animal model, the nematode worm C.
elegans, in chemical screens that permit simultaneous assessment of the immunomodulatory
effects, potential toxicity of compounds, and drug efficacy in a host with a functioning im‐
mune system. The results of these screens are summarized in Table 2. Whole animal screens
have the distinct advantage of being able to directly discard compounds that induce organ‐
ismal toxicity and can identify compounds that target host-pathogen interactions in a rele‐
vant physiological context.
Drug Discovery166
C. elegans, a hermaphroditic nematode normally found in soil, is a versatile, more ethically-
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nomic analysis, offering an ideal compromise between organismal complexity and experi‐
mental tractability. C. elegans offers other experimental advantages, including a rapid 2-3
week life span, simple growth conditions, target-selected gene inactivation, and a relatively
low cost of maintenance compared to other whole animal systems. A wealth of experimental
data has demonstrated that many developmental, neurological, and biochemical processes
have been highly conserved between C. elegans and mammals. For example, cellular func‐
tions as diverse as innate immunity, the first line of defense against pathogen infection, and
RNA interference to downregulate gene expression via double-stranded RNA, are found in
both C. elegans and higher eukaryotes, suggesting the existence of a common ancestor of
these diverse species. Thus, anti-infective compounds identified using a C. elegans infection
model may also be translatable in humans.
C. elegans as a model host system has been well-studied for numerous bacterial pathogens, in‐
cluding the Gram-positive S. aureus, S. pneumoniae, and B. thuringiensis, and the Gram-nega‐
tive B. pseudomallei, P. aeruginosa, and S. marcescens. In general, different types of bacteria are
fed to C. elegans in place of their normal E. coli food source to provoke detectable symptoms of
illness, such as locomotion dysregulation, intestinal cell lysis, and shortened life span.
Small molecule inhibitors of bacterial infection
A small manual screen of 6000 synthetic compounds and 1136 natural extracts were ana‐
lyzed in an immunocompromised mutant of C. elegans infected with Enterococcus faecalis to
identify compounds that promoted host survival. [51]. A total of 16 compounds and 9 ex‐
tracts were identified that either modulated bacterial growth in vitro, impaired pathogen vir‐
ulence, or boosted host innate immunity. Furthermore, 15 out the 16 compounds did not kill
C. elegans or mammalian erythrocytes, indicating that the compounds are not toxic.
The development of automated sorting and handling of C. elegans rapidly enabled high-
throughput screening of small chemical libraries to identify compounds that enhanced sur‐
vival of C. elegans in response to bacterial infection. This methodology was enabled by the
Complex Object Parametric Analyzer and Sorter (COPAS) BioSort worm sorter (Union Bio‐
metrica) to dispense a defined number of living worms into multi-well plates, which were
then imaged using automated microscopy to quantify worm survival. A library of 37,200
compounds and natural product extracts was screened using the same C. elegans-E. faecalis
infection system described above [52]. Twenty-eight compounds and extracts were identi‐
fied that enhanced survival of infected C. elegans. Six structural classes of identified com‐
pounds did not affect the growth of E. faecalis itself, suggesting that the small molecules
inhibited a specific aspect of the host-pathogen interaction. Interestingly, two structural
classes are similar to compounds previously identified in a high-throughput screen to iden‐
tify inhibitors of P. aeruginosa biofilm development, indicating the presence of common mo‐
lecular targets across multiple bacterial species for drug discovery [53].
A P. aeruginosa infection model of C. elegans has also been developed to screen for novel anti-
infective compounds. The high-throughput assay was based on P. aeruginosa-induced slow
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killing of C. elegans in the presence of 1300 bioactive extracts produced by endophytic fungi
associated with medicinal plants [54]. The screen identified 36 extracts that promoted the
survival of the infected worms, while 4 extracts were found to inhibit P. aeruginosa growth
using a disc diffusion assay. Given that these extracts contain a mixture of metabolites, the
specific compound against P. aeruginosa remains to be determined. Nevertheless, this study
illustrates the rich reservoir of small molecules in natural symbiotic organisms with anti-
bacterial activity.
Table 2 Small molecule screens using C. elegans as host model for infection
Discovery of novel antifungal agents
The C. elegans infection model was also used to screen for compounds that prolonged host
survival following infection with the human pathogenic fungus Candida albicans. [55]. Given
that most compounds that have antifungal activity are also toxic to the human host, high-
throughput methods can greatly increase the likelihood of discovering specific antifungal
inhibitors. From a screen of 1266 compounds with known pharmaceutical activities, 15 small
molecules were identified that increased survival of C. albicans-infected nematodes and in‐
hibited in vivo filamentation of C. albicans, a mechanism of pathogenesis seen during mam‐
malian infection. Two compounds, caffeic acid phenethyl ester (CAPE), a natural
component of honeybee propolis, and the fluoroquinolone agent enoxacin, were further
shown to exhibit antifungal activity in a mouse model, validating the use of a C. elegans
model for potential targets in a mammalian system. Interestingly, CAPE is known to inhibit
the mammalian transcription factor NF-κΒ and to induce immunomodulatory effects in
mice [56, 57]. Since C. elegans does not express a NF-κΒ homolog, it may be the case that
CAPE affects alternative targets to achieve antifungal activity.
An automated high-throughput screen using the COPAS Biosort was also applied to C. albi‐
cans infection of C. elegans to assess a library of 3,228 compounds consisting of 1948 bioactive
compounds and 1280 small molecules derived from diversity-oriented synthesis [58]. In to‐
tal, 19 compounds were identified that increased C. elegans survival in response to C. albicans
infection, 7 of which are currently used antifungal agents. Several immunosuppressant
agents identified in this screen, including ascomycin, cyclosporin A, and FK-506, were previ‐
ously found to exhibit weak antifungal activity against Cryptococcus and Aspergillus, in addi‐
tion to C. albicans [59, 60]. Other hits were predicted to affect an array of biological activities,
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such as dequalinium chloride, a potent anti-tumor and protein kinase C inhibitor, and tria‐
dimefon, an inhibitor of ergosterol biosynthesis.
5. Conclusion
Chemical library screens are a potent and valuable molecular tool for HTS identification of
potential inhibitors of infectious disease. The long-standing paradigm to treat pathogen in‐
fection with small molecules that specifically target pathogen growth or metabolism has led
to our current dilemma of microbial drug resistance and re-emergence of once-contained in‐
fectious diseases. Thus, new approaches to target pathogen virulence or host response fac‐
tors rather than essential pathogen functions have become increasingly more attractive
strategies that are less likely to induce microbial resistance. Some compounds, such as the
FDA-approved anti-psychotic, pimozide, exhibited inhibitory properties against infection by
several pathogens, suggesting that small molecules can potentially be developed as broad-
spectrum anti-infectives. Although the molecular mechanism of inhibition by small mole‐
cules remains unknown in most cases, it may be possible to make an educated guess if
targeted pathogens share a common virulence strategy, such as the Type III secretion system
in Gram-negative bacteria. In other cases, identification of an inhibitor can lead to a molecu‐
lar understanding of the infection mechanism. For example, the small molecule, tachyplegi‐
nA, was found to post-translationally modify TgMLC1, a myosin light chain component, to
drive host cell penetration by the parasite T. gondii [17].
From the various studies detailed in this review, it is apparent that the library screens repre‐
sent a first step on the road of drug discovery. There has been a growing realization that
fundamental discovery of biological mechanisms oftentimes reaches a ‘valley of death’, in
which potential translation avenues into clinical therapies and diagnostics for disease treat‐
ment comes to a standstill and is lost. NIH is addressing this widening gap between basic
and clinical research with the establishment of Clinical and Translational Science Centers
across the country. The research community will have to remain pro-active to move promis‐
ing leads from the initial screen stage into downstream validation and development modes
in a timely manner. As with any drug development strategy, there still remain multiple
technical challenges that need to be overcome before small molecule inhibitors can success‐
fully transition into the clinic. Researchers will need to assess such parameters as compound
toxicity, pharmacokinetics and pharmacodynamics, and validation in animal models. How‐
ever, FDA-approved small molecule libraries can be applied to HTS as a cost-effective meth‐
od to identify existing licensed drugs for repurposing from diseases unrelated to microbial
infection. Furthermore, the development of the C. elegans whole organism model for small
molecule screening provides a novel methodology to simultaneously assess compound tox‐
icity and host response to pathogen infection. It would be informative to determine whether
small molecules identified from conventional host cell culture studies can also inhibit patho‐
gen infection in the C. elegans model. Future anti-infective treatments will most likely be
comprised of combination therapies that produce additive or synergistic effects to target key
processes in both the pathogen and the host. The overall promise of discovering novel anti-
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killing of C. elegans in the presence of 1300 bioactive extracts produced by endophytic fungi
associated with medicinal plants [54]. The screen identified 36 extracts that promoted the
survival of the infected worms, while 4 extracts were found to inhibit P. aeruginosa growth
using a disc diffusion assay. Given that these extracts contain a mixture of metabolites, the
specific compound against P. aeruginosa remains to be determined. Nevertheless, this study
illustrates the rich reservoir of small molecules in natural symbiotic organisms with anti-
bacterial activity.
Table 2 Small molecule screens using C. elegans as host model for infection
Discovery of novel antifungal agents
The C. elegans infection model was also used to screen for compounds that prolonged host
survival following infection with the human pathogenic fungus Candida albicans. [55]. Given
that most compounds that have antifungal activity are also toxic to the human host, high-
throughput methods can greatly increase the likelihood of discovering specific antifungal
inhibitors. From a screen of 1266 compounds with known pharmaceutical activities, 15 small
molecules were identified that increased survival of C. albicans-infected nematodes and in‐
hibited in vivo filamentation of C. albicans, a mechanism of pathogenesis seen during mam‐
malian infection. Two compounds, caffeic acid phenethyl ester (CAPE), a natural
component of honeybee propolis, and the fluoroquinolone agent enoxacin, were further
shown to exhibit antifungal activity in a mouse model, validating the use of a C. elegans
model for potential targets in a mammalian system. Interestingly, CAPE is known to inhibit
the mammalian transcription factor NF-κΒ and to induce immunomodulatory effects in
mice [56, 57]. Since C. elegans does not express a NF-κΒ homolog, it may be the case that
CAPE affects alternative targets to achieve antifungal activity.
An automated high-throughput screen using the COPAS Biosort was also applied to C. albi‐
cans infection of C. elegans to assess a library of 3,228 compounds consisting of 1948 bioactive
compounds and 1280 small molecules derived from diversity-oriented synthesis [58]. In to‐
tal, 19 compounds were identified that increased C. elegans survival in response to C. albicans
infection, 7 of which are currently used antifungal agents. Several immunosuppressant
agents identified in this screen, including ascomycin, cyclosporin A, and FK-506, were previ‐
ously found to exhibit weak antifungal activity against Cryptococcus and Aspergillus, in addi‐
tion to C. albicans [59, 60]. Other hits were predicted to affect an array of biological activities,
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such as dequalinium chloride, a potent anti-tumor and protein kinase C inhibitor, and tria‐
dimefon, an inhibitor of ergosterol biosynthesis.
5. Conclusion
Chemical library screens are a potent and valuable molecular tool for HTS identification of
potential inhibitors of infectious disease. The long-standing paradigm to treat pathogen in‐
fection with small molecules that specifically target pathogen growth or metabolism has led
to our current dilemma of microbial drug resistance and re-emergence of once-contained in‐
fectious diseases. Thus, new approaches to target pathogen virulence or host response fac‐
tors rather than essential pathogen functions have become increasingly more attractive
strategies that are less likely to induce microbial resistance. Some compounds, such as the
FDA-approved anti-psychotic, pimozide, exhibited inhibitory properties against infection by
several pathogens, suggesting that small molecules can potentially be developed as broad-
spectrum anti-infectives. Although the molecular mechanism of inhibition by small mole‐
cules remains unknown in most cases, it may be possible to make an educated guess if
targeted pathogens share a common virulence strategy, such as the Type III secretion system
in Gram-negative bacteria. In other cases, identification of an inhibitor can lead to a molecu‐
lar understanding of the infection mechanism. For example, the small molecule, tachyplegi‐
nA, was found to post-translationally modify TgMLC1, a myosin light chain component, to
drive host cell penetration by the parasite T. gondii [17].
From the various studies detailed in this review, it is apparent that the library screens repre‐
sent a first step on the road of drug discovery. There has been a growing realization that
fundamental discovery of biological mechanisms oftentimes reaches a ‘valley of death’, in
which potential translation avenues into clinical therapies and diagnostics for disease treat‐
ment comes to a standstill and is lost. NIH is addressing this widening gap between basic
and clinical research with the establishment of Clinical and Translational Science Centers
across the country. The research community will have to remain pro-active to move promis‐
ing leads from the initial screen stage into downstream validation and development modes
in a timely manner. As with any drug development strategy, there still remain multiple
technical challenges that need to be overcome before small molecule inhibitors can success‐
fully transition into the clinic. Researchers will need to assess such parameters as compound
toxicity, pharmacokinetics and pharmacodynamics, and validation in animal models. How‐
ever, FDA-approved small molecule libraries can be applied to HTS as a cost-effective meth‐
od to identify existing licensed drugs for repurposing from diseases unrelated to microbial
infection. Furthermore, the development of the C. elegans whole organism model for small
molecule screening provides a novel methodology to simultaneously assess compound tox‐
icity and host response to pathogen infection. It would be informative to determine whether
small molecules identified from conventional host cell culture studies can also inhibit patho‐
gen infection in the C. elegans model. Future anti-infective treatments will most likely be
comprised of combination therapies that produce additive or synergistic effects to target key
processes in both the pathogen and the host. The overall promise of discovering novel anti-
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infective compounds has generated great hope in the biomedical community for discovery
of new countermeasures against infectious disease.
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1. Introduction
Automated liquid handling has become an indispensable tool in drug discovery, particular‐
ly in screening campaigns ranging millions of compounds. Intense innovations of these de‐
vices go hand in hand with the progression towards assay miniaturization, accelerating
dramatically the discovery of drug candidates and chemical probes for querying biological
systems. The advancement in this technology is driven in large part by much impetus in cost
reduction and efficiency. In addition to increased throughput, streamlining screening opera‐
tions using automated fluid devices ensures consistency and reliability while avoiding hu‐
man error.
In this chapter, we provide a general overview of existing liquid handlers, with emphasis on
their strengths and limitations. Notably, we discuss practical considerations in the imple‐
mentation of these devices, methods to discern performance quality and potential sources of
error.
2. Types of liquid handling devices
A whole array of liquid handlers has been developed for every aspect of drug discovery.
These instruments encompass different technologies for distinct purposes. In terms of appli‐
cation, they are broadly classified as bulk liquid dispensers, transfer devices and plate wash‐
ers (Rudnicki and Johnston 2009).
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Based on the way the reagent is being transferred, these instruments can follow two dis‐
pensing modes: contact or non-contact (Kong et al. 2012). Contact-based devices allow the
fluid to be transferred to touch the surface of the destination container or solution, offering a
simple and dependable alternative to sub-microliter fluid handling. Non-contact devices uti‐
lize additional force other than gravity to eject liquids, as minute volumes cannot be dis‐
pensed efficiently with gravity alone (Kong et al. 2012). The process is faster than using
permanent tips or pins (Fig.1), because there is no washing step between delivery, while re‐
ducing cross-contamination and evaporation (Dunn and Feygin 2000).
Figure 1. Various types of liquid handling tips, pins and heads from A) washer B) pintool C) peristaltic pump-based
bulk dispenser D) liquid handler with single and 8-channel pipettors E) pipettor with 8-independent channels.
2.1. Peristaltic-based devices
The peristaltic pump is used for bulk reagent dispensing in conjunction with a nozzle head
(Fig.1C) and a flexible tubing cartridge. The tubings stretch around a set of rollers connected
to a motor. With the rotating motion of the motor, the rollers compress the tubings creating
a continuous fluid motion due to positive displacement.
Typically, this type of dispenser is capable of handling volumes as low as 5 µL, offering a
fast dispensing option for 96-/384-/1536-well plate formats. The disposable tubing cartridge
is pre-sterilized, and the entire liquid path can be autoclaved. Additionally, these devices
are normally equipped with programing capabilities that allow discrete column-wise dis‐
pensing, variable rolling speed settings and adjustable dispensing volume. The pump can
roll both forward and backwards to execute priming and emptying functions, respectively.
A major limitation is the lack of capabilities to dispense into individual wells.
2.2. Fixed-tip transfer devices
Fluid handlers that utilize fixed-tips (Fig.1E) are usually efficient at transferring relatively
small  volumes  (100  µL  or  above)  and  have  been  largely  used  for  compound pipetting
(“cherry picking”) and serial dilutions. They incorporate 2-/ 4-/ 8-channel expandable liq‐
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uid handling arms in addition to 96- and 384-channel heads. This type of liquid handling
device  functions  based on  air  displacement  mechanism.  The  dilutor  or  syringe  plunger
pulls system liquid from the pipette tubing to aspirate the sample, with an air gap sepa‐
rating both fluids.  The plunger speed,  syringe size and resolution are factors that  affect
pipetting flow rate.
2.3. Changeable-tip transfer devices
The use of disposable tips (Fig.1D) is a simple alternative to avoid washing steps required
for fixed-tip based systems, while eliminating completely the risk of cross-contamination.
These instruments employ a conventional air displacement mechanism. A wide array of
commercially-available tip sizes, materials and molding qualities offers the scientist great
flexibility. There are even specialized tips with nanoliter-scale transfer capabilities that can
be used in any conventional pipettor (Murthy et al. 2011; Ramírez et al. 2008).
2.4. Pintool transfer devices
Pintool is a contact-based dispensing method widely used for handling volumes at the
nanoliter scale (Cleveland and Koutz 2005). It consists of a set of stainless steel pins (Fig. 1B)
carefully crafted for consistent dimensions. The bottom end of the pins can be solid, grooved
or slotted, with the option of having a hydrophobic coating to prevent non-specific binding
(Dunn and Feygin 2000; Rudnicki and Johnston 2009). Solutions are transferred through a
combination of capillary action and surface tension, with the volume being highly depend‐
ent on the contact surfaces and solution properties (Dunn and Feygin 2000). The pin array is
normally assembled in a floating pin cassette to ensure soaking of all the pins amid uneven
surfaces, which also minimizes pin damage. After liquid transfer, the pins have to cycle
through washing steps to prevent cross-contamination.
2.5. Piezoelectric devices
The piezoelectric dispenser is a non-contact technology, where solutions are delivered as
multiple tiny drops of defined size (Niles and Coassin 2005). This technology has been uti‐
lized in contemporary inject printers and refined to be implemented in the biological scien‐
ces. Various biochemical solutions (DNA, RNA, proteins) and bacterial suspensions have
been tested with no negative effects (Schober et al. 1993). The system is composed of a capil‐
lary tube made of quartz or steel, with one end connected to the reagent reservoir and the
other end ending in an orifice from which droplets are ejected (Niles and Coassin 2005). A
piezoelectric crystal collar is bound to the capillary, which is filled with solution. Upon volt‐
age application, the piezoelectric element contracts causing pressure on the capillary to gen‐
erate fine drops. The ejection is at high acceleration with minimal wetting of the nozzle
(Schober et al. 1993). Several thousand drops can be dispensed per second, with attainable
drop sizes spanning the picoliter and nanoliter range (Schober et al. 1993). Droplet volume
depends on several factors, including bore diameter, solution viscosity and the voltage pulse
amplitude and frequency (James and Papen 1998; Kong et al. 2012).
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Solenoid-based devices are non-contact dispensers that use a positive displacement mecha‐
nism (Bateman et al. 1999). The flow of pressurized liquid is occluded by a solenoid valve,
which is actuated by electric current to allow for liquid to pass through the valve. The dis‐
pensed volume is regulated by the fluid pressure, duration of the valve in the open position,
solution properties and orifice diameter (Bateman et al. 1999; Niles and Coassin 2005). De‐
pending on the time the valve stays in the open position, the device can eject droplets or a
continuous stream (Niles and Coassin 2005).
2.7. Acoustic devices
Acoustic droplet ejection (ADE) is a recent touch-less technology that surges in popularity in
recent years. It adopts acoustic energy to propel droplets from various types of solutions
with good precision (Ellson et al. 2003; Harris et al. 2008; Rudnicki and Johnston 2009; Shieh
et al. 2006). The source plate remains stationary as the transducer and destination plate shuf‐
fle to allow for solution transfer from any well in the source plate to any well in the destina‐
tion plate, the latter one lying in an inverted position (Olechno et al. 2006). This system does
not require any additional consumable other than microplates (Olechno et al. 2006), and it
speeds up the process by avoiding washing steps and having the capability to prepare as‐
say-ready plates (Turmel et al. 2010)
2.8. Microplate washers
Microplate washers are laboratory instruments designed to automate and expedite assay ap‐
plications, where a washing step is essential. They play an important role in areas such as
high-content screening and enzyme-linked immunosorbent assays (ELISA). In 1990, Stobbs
developed the first multiple plate washer using readily available materials as a low cost al‐
ternative to the commercially available plate washers of the era (Stobbs 1990). Over the
years, fully programmable plate washers have been developed with numerous features. The
development of automated plate washers has decreased the time required for laborious
washing steps involved in many screening assays and improved reproducibility through
standardized plate handling across multiple wash cycles (defined as a single dispense and
aspirate step per cycle).
The two most critical components of a plate washer are a plate carrier and a manifold con‐
taining a number of fixed stainless steel needle probes for solution dispensing (Fig.1A). This
manifold (or a separate manifold depending on the design) aspirates the liquid from the
wells after an optional soaking period, leaving a pre-defined residual volume in the wells. A
third component is the vacuum/pump assembly, which supplies the necessary pressure dif‐
ferential to drive efficient aspiration. Sunghou Lee first developed an additional vacuum fil‐
tration system integrated with a conventional plate washer to speed up the wash process for
applications involving filter plates (Lee 2006). Some plate washers have a built-in magnet or
a vacuum filtration module for handling bead-based assays.
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Microplate washers can be categorized into two types: strip washers, which wash a single
column or row of a plate at a time, and full plate washers (Rudnicki and Johnston 2009). The
availability of 8-/12-/16-channel manifolds for strip washers provides both single strip wash‐
ing and full-plate washing capability in the same device, but at the cost of increased wash
time for full plates. On the other hand, full plate washers with either a 96- or 384-channel
manifold may be preferred for time-efficient wash operations (from a few seconds to a few
minutes), but lack the flexibility of the 8-/12-/16-channel units.
The combination of plate washing and bulk dispensing features within the same device may
be favored for a space-efficient solution. They are designed to dispense reliably low volumes
and reduce prime volume (Rudnicki and Johnston 2009). A major advantage of the washer-
dispenser combination comes into play with assay protocols that require the direct addition
of fluid after or between the washing steps, such as cell fixation or microplate surface coat‐
ing reagents.
3. Considerations for using liquid handling devices
3.1. Determination of quality assessment descriptors
Assessment of instrument performance has become important in order to minimize false-
positive and false-negative rates in high-throughput screening (Taylor et al. 2002). One of
the most important figures of merit in evaluating the performance of liquid handlers is accu‐
racy, which is commonly reported as %bias (Rose 1999):
%bias =100 ×  ( V M - V TV T ) (1)
where VM is the measured volume and VTis the theoretical volume (desired). %bias repre‐
sents the deviation from the desired volume, with a value of 0% indicating no deviation
from the true value.
The precision, a measure of reproducibility, is calculated from the mean and standard devia‐
tion (SD) of a set of measurements, and it is reported as percent coefficient of variation
(%CV) or relative standard deviation (RSD), as shown in Eq. 2. For most cases, it is adequate
to have a bias value below 5% and a CV below 10% (Rose 1999).
%CV=100 × SDmean (2)
There have been several approaches for volume verification, which typically consist of
gravimetric or photometric methods. Gravimetric measurements utilize the mass and the
density (ρ) of the dispensed solution to determine the volume. It has been used extensively
to calibrate and verify the accuracy of liquid dispensers (Bergsdorf et al. 2006; Rhode et al.
2004; Taylor et al. 2002). Typically, the solution is dispensed across a pre-weighed microtiter
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plate, which is weighed immediately after dispensing to prevent evaporation. %bias can be
calculated based on the total weight of the dispensed solution (Wtotal) and the number of dis‐
pensed wells (n):






Environmental conditions (e.g. temperature and humidity) have major effects on the relia‐
bility of gravimetric methods, which facilitates evaporation and water uptake for hygro‐
scopic solvents such as dimethyl sulfoxide (DMSO). These factors of variation can be
minimized by placing gasketed lids on the microtiter plates immediately following dispense
(Taylor et al. 2002).
Absorbance and fluorescence are the most common photometric methods utilized to test the
accuracy and precision of the transferred volumes of a liquid handling device. In a study
comparing the performance of the two methods on determining the precision in 96-/384-/
1536-well plates, no significant difference was observed between the 96- and 384-well plates
(Petersen and Nguyen 2005). However, to achieve similar results for both fluorescence and
absorbance measurements in the 1536-well plate, a centrifugation step was required because
of the irregular meniscus shape enhanced by the small well geometry. In another study per‐
formed on liquid handlers with two different mechanisms, absorbance was found to be a
more reliable method as long as the pH stability of the dye-buffer solution is maintained
(Rhode et al. 2004).
Fluorescence signal is also known to be susceptible to photobleaching, which can be pre‐
vented by shorter excitation times, suitable buffer solutions and adequate concentration of
fluorophore (Diaspro et al. 2006; Harris and Mutz 2006). To overcome the problems encoun‐
tered due to signal quenching in DMSO, sulforhodamine 101 was presented as an alterna‐
tive fluorescence dye (Walling 2011). Fluorescein was found to be a suitable probe to use in
liquid handling performance quantification as long as the DMSO concentration in the buffer
solution does not exceed 1% and the stock solutions are stored in 70-100% DMSO in a dark
environment (Harris and Mutz 2006). While photobleaching is not an issue in absorbance,
the method is limited by high background levels and lower sensitivity compared to fluores‐
cence (Bradshaw et al. 2007). Based on the physical characteristics of a transferred sample
and the material of the consumables, unforeseen interactions may be observed influencing
the assay results. Especially, DMSO-containing samples are highly affected by the hydro‐
scopic properties of the solvent, which inflates sample volume (Berg et al. 2001).
3.2. Considerations for using bulk reagent dispensers: Peristaltic-based devices
A single screening experiment can be costly, requiring valuable compounds and biological
reagents. Routine evaluation of liquid handlers, in particularly prior to each run, is a neces‐
sary mean for preventing disastrous outcomes. Simple procedures can be integrated to iden‐
tify problems in a relatively short period of time, which in many instances, can be easily
corrected. Routine analysis should be performed with the actual reagents, because there are
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several factors that affect the dispensed volumes, including viscosity, density, and tempera‐
ture (McGown and Hafeman 1998). General considerations to prevent undesirable dispens‐
ing performance and common sources of variations include:
3.2.1. Uneven dispensing
Tubings tend to stretch after certain period of use, affecting the intended volume to be deliv‐
ered. When not in use, the cartridges should be placed in the “rest” position. In addition,
autoclaving the cassettes should be minimized. Dispensing speed and the height of the tips
in relation to the plate have to be optimized for the intended reagent, as viscous solutions
could miss the targeted well at low dispensing speed and large spacing between the tips and
microtiter plate. When working with cells, uneven dispensing can be reduced by increasing
the prime volume, constant mixing/stirring the cell suspension source and minimizing cell
clumps. Solutions should be dispensed in the center of the well, and plates have to be centri‐
fuged when dispensing low volumes to force droplets at the walls to the bottom of the well.
Cassettes should be calibrated regularly as recommended by the supplier and checked for
tip clogging.
3.2.2. Protein binding
Protein binding to dispensing components is an important point to consider in the imple‐
mentation of biochemical assays, particularly at low protein concentrations. In some instan‐
ces, enzymes appear to be inactivated over time when dispensing multiple plates using a
liquid handler, when in reality the enzymes have been depleted from the solution due to
non-specific binding to plastic, silicone and other polymer-based surfaces. This effect is am‐
plified when dispensing sizeable number of plates, as there is larger exposure time of the
assay components to the surfaces of reagent reservoirs and dispensing cassette elements. In
order to circumvent this problem, blocking reagents can be added to the buffer, plastic sur‐
faces can be coated, or a combination of both. The two major types of blocking reagents are
detergents and proteins. It is preferable to use non-ionic detergents such as Tween-20, Triton
X-100 or Nonidet-P40. Among the most widely-used protein blockers are bovine serum al‐
bumin (BSA) and casein. Protein blockers are better suited for coating surfaces, as detergents
can be easily washed away. Typical working concentrations for detergents range from 0.01
to 0.1%, while protein blockers are used between 0.1 to 3 %. The selection of the appropriate
type of blocking reagent and concentration is central to a robust assay. Other less common
blocking reagents include polyethylene glycol (PEG), polyvinyl alcohol (PVA) and polyvinyl
pyrrolidone (PVP). Additionally, the use of glass reagent reservoirs is recommended.
3.2.3. Clogging
Particles can obstruct the flow of a dispensing cassette mainly by blocking the tips. Com‐
plete clogging is fairly easy to recognize, as the lack of fluid coming out of the tips can be
visibly noticed. Depending on the degree of obstruction, partial clogging may not be easily
perceived by the naked eye, and it is detected only by photometric or gravimetric testing.
However, there are certain indications of partial clogging, such as slanted fluid spray or
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more reliable method as long as the pH stability of the dye-buffer solution is maintained
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and the material of the consumables, unforeseen interactions may be observed influencing
the assay results. Especially, DMSO-containing samples are highly affected by the hydro‐
scopic properties of the solvent, which inflates sample volume (Berg et al. 2001).
3.2. Considerations for using bulk reagent dispensers: Peristaltic-based devices
A single screening experiment can be costly, requiring valuable compounds and biological
reagents. Routine evaluation of liquid handlers, in particularly prior to each run, is a neces‐
sary mean for preventing disastrous outcomes. Simple procedures can be integrated to iden‐
tify problems in a relatively short period of time, which in many instances, can be easily
corrected. Routine analysis should be performed with the actual reagents, because there are
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several factors that affect the dispensed volumes, including viscosity, density, and tempera‐
ture (McGown and Hafeman 1998). General considerations to prevent undesirable dispens‐
ing performance and common sources of variations include:
3.2.1. Uneven dispensing
Tubings tend to stretch after certain period of use, affecting the intended volume to be deliv‐
ered. When not in use, the cartridges should be placed in the “rest” position. In addition,
autoclaving the cassettes should be minimized. Dispensing speed and the height of the tips
in relation to the plate have to be optimized for the intended reagent, as viscous solutions
could miss the targeted well at low dispensing speed and large spacing between the tips and
microtiter plate. When working with cells, uneven dispensing can be reduced by increasing
the prime volume, constant mixing/stirring the cell suspension source and minimizing cell
clumps. Solutions should be dispensed in the center of the well, and plates have to be centri‐
fuged when dispensing low volumes to force droplets at the walls to the bottom of the well.
Cassettes should be calibrated regularly as recommended by the supplier and checked for
tip clogging.
3.2.2. Protein binding
Protein binding to dispensing components is an important point to consider in the imple‐
mentation of biochemical assays, particularly at low protein concentrations. In some instan‐
ces, enzymes appear to be inactivated over time when dispensing multiple plates using a
liquid handler, when in reality the enzymes have been depleted from the solution due to
non-specific binding to plastic, silicone and other polymer-based surfaces. This effect is am‐
plified when dispensing sizeable number of plates, as there is larger exposure time of the
assay components to the surfaces of reagent reservoirs and dispensing cassette elements. In
order to circumvent this problem, blocking reagents can be added to the buffer, plastic sur‐
faces can be coated, or a combination of both. The two major types of blocking reagents are
detergents and proteins. It is preferable to use non-ionic detergents such as Tween-20, Triton
X-100 or Nonidet-P40. Among the most widely-used protein blockers are bovine serum al‐
bumin (BSA) and casein. Protein blockers are better suited for coating surfaces, as detergents
can be easily washed away. Typical working concentrations for detergents range from 0.01
to 0.1%, while protein blockers are used between 0.1 to 3 %. The selection of the appropriate
type of blocking reagent and concentration is central to a robust assay. Other less common
blocking reagents include polyethylene glycol (PEG), polyvinyl alcohol (PVA) and polyvinyl
pyrrolidone (PVP). Additionally, the use of glass reagent reservoirs is recommended.
3.2.3. Clogging
Particles can obstruct the flow of a dispensing cassette mainly by blocking the tips. Com‐
plete clogging is fairly easy to recognize, as the lack of fluid coming out of the tips can be
visibly noticed. Depending on the degree of obstruction, partial clogging may not be easily
perceived by the naked eye, and it is detected only by photometric or gravimetric testing.
However, there are certain indications of partial clogging, such as slanted fluid spray or
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drop formation at the tip. To prevent clogging, the tubing should be primed with deionized
water shortly after use, especially prior to priming with alcohol, as salts in the buffer may
precipitate and biological reagents may clump. When working with cells, it is recommended
to wet the tubing with buffer or media before dispensing cells, and if possible, not to allow
the cells to settle in the tubing by emptying the contents back to the reservoir immediate af‐
ter dispensing (prime/empty cycle).
3.2.4. Foaming
Solutions with high protein content can cause frothing, including media containing serum
and biochemical buffers with high percentage of BSA (used as blocking protein). To mini‐
mize frothing, it is recommended not to empty the tubing between dispensing (as ordinarily
performed in fully automated platforms for large screenings). If tubing emptying is un‐
avoidable, it is advisable to empty a volume smaller than the dead volume. Other means to
reduce frothing involve decreasing dispensing speed and applying grease to the cassette
tips. Torn or cracked tubing can pull air generating bubbles.
3.2.5. Reservoir container
The reservoir container is an important component of a liquid dispenser that is often ne‐
glected in troubleshooting. The material of the container can have a detrimental effect on
the  assay  robustness,  such  as  sticking  of  proteins  to  plastic  surfaces.  For  peristaltic
pump-based  dispensers,  we  suggest  using  a  jacketed  glass  flask  connected  to  a  water
chiller (waterbath with adjustable temperature). Careful monitoring of the temperature in
the  flask  using a  thermometer  is  recommended,  as  the  temperature  set  in  the  chiller  is
not  always  reflected in  the  container.  Suspensions  of  cells,  beads  or  nanoparticles  have
to be constantly  stirred to  prevent  settling,  which could result  in  uneven dispensing or
clogging.  The  stirring  speed  needs  to  be  optimized,  as  fast  stirring  can  create  bubbles
and disturb biological  components (cells).  When working with large reagent volumes at
the start  of  dispensing, the stirring may have to be reduced as the volume decreases to
prevent foaming or bubble formation.
3.2.6. Tubing extension
Extensions can be implemented when the dispensing tubings cannot be immersed in the
reservoir  container  because  of  its  large  dimensions.  Some commercially  available  exten‐
sions allow for the 8 tubings of a standard cartridge to be coupled into single elongated
tubing  through  metallic  cannulas  sticking  out  of  a  joint  casing.  For  viscous  solutions,
these  types  of  elongations  can  introduce  bubbles  due  to  the  joint  design,  particularly
during prime/empty cycles.  The  metallic  cannulas  can easily  tear  the  tubing during fit‐
ting, which is ameliorated by using glycerol or alcohol to smoothen the surfaces. A bet‐
ter alternative is to build home-made extensions by attaching each of the new tubings to
separate discarded tubings through connectors, which can be made by cutting the end of
a pipette tip.
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3.2.7. Routine quality assessment
During assay development and validation, factors affecting liquid dispenser performance
are identified and corrected. However, setbacks can occur randomly regardless of detailed
preparations ahead of the screens. For instance, torn tubing, tip blockage or incorrect car‐
tridge setup cannot be prevented a priori. Therefore, it is recommended to rapidly monitor
dispensing variations at the start of a screen, where problems encountered at this stage can
be usually corrected fairly quickly.
We normally dispense a solution of fluorescein isothiocyanate (FITC) in PBS into a couple of
384-well plates. Fluorescence intensities are analyzed for signal variations corresponding to
each cassette channel, as described by %CV and %bias’ (Fig.2). Determination of %CV for
the entire plate is frequently performed in many laboratories, but this approach cannot dis‐
tinguish issues with individual channels. In addition, a flawed channel does not necessarily
change drastically the %CV of the whole plate, as illustrated by Fig. 2A. The types of prob‐
lems commonly associated to high %CV include improper cassette mounting, tubing
stretching and damage.
There are instances when the tip is partially obstructed, leading to reduced volume deliv‐
ered. Even when a channel displays low fluorescence counts, the signal can still have small
%CV values (Fig. 2B). We have adapted the concept of %bias to detect significant deviations
in signal intensity for each row (SR) compared to that of the whole plate (ST), resulting in
%bias‘ (Eq. 4). Values lower than 10 %CV and 10 %bias’ are acceptable.
% bias '=100 × ( SR-STST ) (4)
3.3. Considerations for using transfer devices: Pintool
The pintool has become a mature technology for transferring nanoliter to sub-microliter vol‐
umes. Even though the system is regarded as fairly simple and robust, there are a number of
points to consider for a consistent and reliable performance:
3.3.1. Volume variation
The volume delivered by a pin can change due to a number of factors. To minimize volume
variations, there should be consistency in immersion depth (Dunn and Feygin 2000). There
is a minimum volume required in the source plate, and the destination plate should not be
dry (Rudnicki and Johnston 2009). The dwell time that pins spend in the fluid and with‐
drawal speed from the liquid surface should be optimized for solutions of very different
properties (e.g. viscosity).
The slot of a pin can be tainted by compound precipitation or formation of suspension de‐
posits (Fig. 3B). Sufficient and robust washing and drying steps are effective in preventing
deposition and being critical to avoid carry-over and cross-contamination. The pins can be
physically damaged by dipping in highly uneven surfaces, particularly when using slotted
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clogging.  The  stirring  speed  needs  to  be  optimized,  as  fast  stirring  can  create  bubbles
and disturb biological  components (cells).  When working with large reagent volumes at
the start  of  dispensing, the stirring may have to be reduced as the volume decreases to
prevent foaming or bubble formation.
3.2.6. Tubing extension
Extensions can be implemented when the dispensing tubings cannot be immersed in the
reservoir  container  because  of  its  large  dimensions.  Some commercially  available  exten‐
sions allow for the 8 tubings of a standard cartridge to be coupled into single elongated
tubing  through  metallic  cannulas  sticking  out  of  a  joint  casing.  For  viscous  solutions,
these  types  of  elongations  can  introduce  bubbles  due  to  the  joint  design,  particularly
during prime/empty cycles.  The  metallic  cannulas  can easily  tear  the  tubing during fit‐
ting, which is ameliorated by using glycerol or alcohol to smoothen the surfaces. A bet‐
ter alternative is to build home-made extensions by attaching each of the new tubings to
separate discarded tubings through connectors, which can be made by cutting the end of
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tridge setup cannot be prevented a priori. Therefore, it is recommended to rapidly monitor
dispensing variations at the start of a screen, where problems encountered at this stage can
be usually corrected fairly quickly.
We normally dispense a solution of fluorescein isothiocyanate (FITC) in PBS into a couple of
384-well plates. Fluorescence intensities are analyzed for signal variations corresponding to
each cassette channel, as described by %CV and %bias’ (Fig.2). Determination of %CV for
the entire plate is frequently performed in many laboratories, but this approach cannot dis‐
tinguish issues with individual channels. In addition, a flawed channel does not necessarily
change drastically the %CV of the whole plate, as illustrated by Fig. 2A. The types of prob‐
lems commonly associated to high %CV include improper cassette mounting, tubing
stretching and damage.
There are instances when the tip is partially obstructed, leading to reduced volume deliv‐
ered. Even when a channel displays low fluorescence counts, the signal can still have small
%CV values (Fig. 2B). We have adapted the concept of %bias to detect significant deviations
in signal intensity for each row (SR) compared to that of the whole plate (ST), resulting in
%bias‘ (Eq. 4). Values lower than 10 %CV and 10 %bias’ are acceptable.
% bias '=100 × ( SR-STST ) (4)
3.3. Considerations for using transfer devices: Pintool
The pintool has become a mature technology for transferring nanoliter to sub-microliter vol‐
umes. Even though the system is regarded as fairly simple and robust, there are a number of
points to consider for a consistent and reliable performance:
3.3.1. Volume variation
The volume delivered by a pin can change due to a number of factors. To minimize volume
variations, there should be consistency in immersion depth (Dunn and Feygin 2000). There
is a minimum volume required in the source plate, and the destination plate should not be
dry (Rudnicki and Johnston 2009). The dwell time that pins spend in the fluid and with‐
drawal speed from the liquid surface should be optimized for solutions of very different
properties (e.g. viscosity).
The slot of a pin can be tainted by compound precipitation or formation of suspension de‐
posits (Fig. 3B). Sufficient and robust washing and drying steps are effective in preventing
deposition and being critical to avoid carry-over and cross-contamination. The pins can be
physically damaged by dipping in highly uneven surfaces, particularly when using slotted
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pins (Fig. 3C). Coated pins should avoid harsh washing procedures, such as going through
powerful sonication washes.
Figure 2. A-B) Delivery variation by a bulk reagent dispenser distributing a FITC solution into 384-well plates. Certain
dispensing cassette channels display either higher %CV or %bias’ values than the anticipated cut-off of 10%. C) Cell
settling in the reagent reservoir when transferring to a microtiter plate using an automated pipetting system with an
8-channel head, with 1 min delay between transfers to each column. Cell settling is uneven due to the v-shaped bot‐
tom of the reservoir, causing the intensity pattern observed in the plate. The cells (HEK293T) were incubated with Cell‐
Titer-Glo® for 20 min prior to luminescence reading.
Figure 3. Magnified view of FP1NS50H pins (V&P Scientific, Inc.) with A) clean slot B) dirty slot C) damaged slot.
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3.3.2. Carry-over
After transferring compounds from one plate to another, the pins are washed in DMSO, al‐
cohol, water or a combination of these solutions. The pintool protocol involves dipping the
pins in each solution bath certain number of times, at a particular speed and soaking time.
The pins are then dried on lint-free blotting paper. Protocols of pintool devices used on ro‐
botic platforms are optimized for effectiveness in removing previous transfers while spend‐
ing the minimum time between wash cycles. In many cases, the drugging (i.e., addition of
compound to assay well) step using pintool becomes the bottleneck in a screening cam‐
paign, and the washing step accounts for most of the time consumed. However, certain as‐
says can be very sensitive to compound carry-over, particularly if the compounds are very
potent modulators and bind avidly to the pin surface. In such cases, increasing the number
of dips and soaking time can improve cleanliness, albeit at the cost of increasing total trans‐
fer time.
Fig. 4 illustrates the effect of four different wash protocols in a kinase assay using stauro‐
sporine as the inhibitor. After compound transfer by pintool to the first assay plate, the pins
are immersed in DMSO and isopropanol reservoirs, followed by drying on blotting paper.
Subsequently, the pins are dipped in a second assay plate containing the kinase system. Re‐
sidual staurosporine in the pins increases the signal variation as determined by %CV of a set
of multiple wells. Protocol 1 has the least number of dips and soaking time per bath, result‐
ing in the most dramatic signal variation due to carry-over. This general approach is recom‐
mended for detecting carry-over and selecting the appropriate pintool wash.
Figure 4. General approach to detect compound carry-over and optimize pintool washing. A single wash cycle con‐
sists of dipping the pins in DMSO and isopropanol baths, followed by blotting on lint-free paper.
3.3.3. Routine quality assessment
Regular pintool calibration and quality assessment can considerably improve data quality.
In screening runs at a single compound concentration, well-maintained pins can lead to a
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are immersed in DMSO and isopropanol reservoirs, followed by drying on blotting paper.
Subsequently, the pins are dipped in a second assay plate containing the kinase system. Re‐
sidual staurosporine in the pins increases the signal variation as determined by %CV of a set
of multiple wells. Protocol 1 has the least number of dips and soaking time per bath, result‐
ing in the most dramatic signal variation due to carry-over. This general approach is recom‐
mended for detecting carry-over and selecting the appropriate pintool wash.
Figure 4. General approach to detect compound carry-over and optimize pintool washing. A single wash cycle con‐
sists of dipping the pins in DMSO and isopropanol baths, followed by blotting on lint-free paper.
3.3.3. Routine quality assessment
Regular pintool calibration and quality assessment can considerably improve data quality.
In screening runs at a single compound concentration, well-maintained pins can lead to a
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reduction of false negative hits, as damaged or dirty pins would usually deliver lower vol‐
umes than anticipated. In dose-response analysis, the quality of the curve fit is highly de‐
pendent on the variability of the data points.
A good quality control procedure should provide the transferred volume and the variation
associated with the pin set. We implemented a relatively quick and simple procedure using
a fluorescent dye (FITC). Prior to the test, the pins are washed as described above. A calibra‐
tion curve is generated of fluorescence intensity as a function of FITC concentration. Using
the pintool, FITC in DMSO is transferred from a source plate to several destination plates
containing PBS (the use of 4 plates was shown to be sufficient). The average transferred vol‐
ume per pin is calculated using the fluorescence signal of the destination plates and the cali‐
bration curve. Volume variation across the microtiter plate can be readily appreciated by
plotting volume against well position (Fig. 5, top charts). The pink and green solid lines rep‐
resent the upper and lower boundaries within 10% CV of the average volume, where outli‐
ers can be clearly identified. The frequency chart (Fig. 5, bottom chart) displays outliers
present in 1, 2, 3 or all of the 4 destination plates, and it can be used to identify pins that
consistently provide volumes outside a specified range. In the example shown in Fig. 5, pins
corresponding to positions A13, B21, D8, F13, K1, N14 and P20 will have to be replaced. De‐
pending on the need, stringency can be adjusted by changing the boundaries as specified by
%CV. It is highly recommended to utilize the same freshly prepared fluorescent dye and
buffer solutions in all aspects of the protocol. A template for data analysis can be easily cre‐
ated in conventional software such as MS-Excel.
Figure 5. A simple and comprehensive approach to analyze pintool performance. Individual pins can be selected for
replacement based on consistent variation across multiple transfers.
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3.4. Considerations for using transfer devices: Pipettors
3.4.1. Pipette stations
The automation station is an integral part of any high throughput pipettor, regardless of the
type of tips (fixed or disposable) it employs. It typically consists of ANSI/SBS standard com‐
pliant single or multiple deck positions on a stationary or moving platform to hold the lab‐
ware, with a moving arm situated above the platform containing the single- or multi-
channel pipette head. A major advantage of automated pipettor devices over manual or
electronic multichannel hand-held pipettes is the elimination of inconsistency in the transfer
process by minimizing human intervention, which also enables high throughput applica‐
tions that are not otherwise feasible. The three major tasks that can be performed with suita‐
ble hardware settings are liquid transfer, cherry-picking and serial-dilution.
For plate-to-plate liquid transfers, 96- or 384-well pipette heads are preferred to work with
96-/384-/1536-well microplates to speed up the process and increase the throughput. While
4-/8-/12-/16-pipette heads can also be used for direct transfer applications, they are primarily
used to perform serial-dilutions. On the other hand, a single channel pipette tip is an essen‐
tial component to accomplish cherry-picking tasks.
The speed of an automated pipettor is important for time-sensitive experiments. Especially
when performing small volume transfers into microplates, the amount of time spent to
transfer liquids in a column-by-column or row-by-row manner may be problematic due to
quick evaporation. If the speed of transfer is too slow, some evaporation in the first column
or row may be observed before dispensing to the last column or row, causing inconsistent
volume across the plate. To avoid evaporation issues during liquid transfers, deck size, pi‐
pettor speed, head type and the transfer volume should be considered.
3.4.2. Tip contamination
Sample carry-over is a common problem in liquid handling tasks requiring sequential dip‐
ping steps into various sample reservoirs. With fixed-tips, an adequate cleaning step is es‐
sential between two transfer operations to prevent sample carry-over. An on-deck cleaning
protocol often consists of immersion in a bath (DMSO, alcohol and/or water) with optional
sonication step. The tips should be allowed sufficient drying time to prevent sample dilution
in the following transfer phase. Appropriate wash solutions should be selected and the opti‐
mum length of washing time should be determined during the assay development stage. Al‐
though fixed-tips may have the risk of carry-over, they enable more accurate and precise
transfers in smaller volume ranges (Felton 2003).
Contamination can also be associated with disposable tips, especially when sterile and nu‐
clease-free assay conditions are required. The speed at which the pipette tips are removed
from a sample fluid was found to correlate to the amount of macroscopic droplets stuck to
the outer surface of the polypropylene tips, which contributed to cross-contamination (Berg
et al. 2001). It was also reported that to decrease this form of cross-contamination, which is
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reduction of false negative hits, as damaged or dirty pins would usually deliver lower vol‐
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the outer surface of the polypropylene tips, which contributed to cross-contamination (Berg
et al. 2001). It was also reported that to decrease this form of cross-contamination, which is
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influenced by the tip shape and the sample-polypropylene interactions, the removal speed
should be slow enough to diminish droplet generation.
Impurities can also leach out of the disposable tips when in contact with solvents such as
DMSO. Studies have shown that bioactive compounds released from plastic labware may
interfere with assay readouts causing misleading experimental results (McDonald et al.
2008; Niles and Coassin 2008; Watson et al. 2009). Consumable materials, especially polypro‐
pylene tips, tend to adsorb certain compounds, leading to unreliable concentrations in the
destination plates (Harris et al. 2010). Therefore, it is recommended to test and validate the
influence of consumables on an assay during assay development and whenever there is a
change in labware.
3.4.3. Foaming
Pipetting viscous and “sticky” samples is challenging due to bubble formation. Among the
most important parameters to consider in avoiding these issues are the speed that the tips exit
the sample fluid and the aspirate/dispense rates; they should be slow enough to avoid residu‐
als at the inside and outside of the tips. Pre- and post-air pipetting options should be avoided.
3.4.4. Pipette behavior affecting dispensing variation
Most pipettor systems provide pre- and post-air aspiration functions to ensure accurate liq‐
uid transfers. Introduction of air into the tips before or after the aspiration of the sample liq‐
uid is recommended to improve volume accuracy by forcing all the liquid out of the tips. In
a study performed to optimize the automated parameters to achieve a 10 µL transfer volume
in a sequential transfer experiment, introduction of a 5 µL pre-air gap significantly reduced
the relative volume inaccuracy along with the CV of the final transferred volume in a 96-
well plate (Albert et al. 2007). While this method may help to achieve more precise results
especially with small volume transfers, bubble formation in the destination wells may be in‐
evitable unless proceeded by a shaking or centrifugation step. Post-air aspiration may also
be applied to create an air gap between liquids, preventing unsought contamination in the
source reservoirs when multiple samples are picked up sequentially into a single tip before
the delivery into the destination reservoir.
When small and repetitive volume transfers into multiple destinations are needed, it is a
common practice to pick up a single large volume and deliver smaller amounts in a sequen‐
tial mode. However, with this method, it is hard to achieve accurate delivery in each step. In
a study of multi-sequential dispense accuracy, it was shown that the first and last dispense
steps led to relatively higher and lower transferred volumes, respectively, in addition to in‐
creased relative inaccuracy (Albert et al. 2007). Therefore, it is recommended to dispense the
first and last steps into the source reservoir to enhance the precision in the destination plate.
Delivery performance of the dry versus pre-wetted tips may also exhibit differences in vari‐
ability depending on the sample characteristics.
Droplet formation at the end of the pipette tips after a dispense action remains an issue for
liquids with high viscosity or low densities. Besides the selection of the optimum dispense
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speed, a “tip touch” function is a useful feature offered in some automated pipettors, where
the tips contact the well wall at the end of a dispense step to force the release of the droplet.
The path of the moving pipetting arm across the deck should be carefully determined to re‐
duce the chance of contaminating other labware by hanging droplets.
Proper mixing of solutions in the source reservoir before aspiration and in the destination
reservoir after dispensing may greatly affect the final assay quality due to the necessity of
uniform sample concentrations. To avoid the formation of concentration gradient in wells,
mixing can be performed by repetitive pipetting cycles. Mixing of the well contents by pi‐
petting up and down is proven to be a quicker and more efficient method compared to free
diffusion or shaking, which are not as successful due to the correlations between well size,
content volume and the exerted capillary forces (Berg et al. 2001; Shieh et al. 2010; Travis et
al. 2010). Mixing is necessary when dealing with suspensions (cells, beads, etc.). For in‐
stance, cell settling creates uneven cell density in the source reservoir, which would lead to
aspiration of decreasing number of cells over time (Fig. 2C)
3.4.5. Routine quality assessment
Verification of transferred volumes and routine quality control (QC) are the most important
and inevitable processes when working with liquid handling devices. While the verification
method should be reliable enough to quantify the pipettor performance, it should also be
easy and fast to be applied routinely. The performance assessment described for bulk liquid
dispensers (section 3.2.7.) can also be applied to pipettors as long as the same volume is dis‐
tributed throughout the plate for %CV and %bias’ calculations.
As mentioned previously, liquid handlers are heavily used to perform serial dilutions, and
suitable QC techniques should be employed to validate dilution performance, particularly
when accurate compound potency is directly dependent on concentration accuracy. Dilution
ratio, accuracy, precision and outlier distribution constitute the four major criteria that
should be evaluated (Popa-Burke et al. 2009). Artel developed an approach to determine di‐
lution and transferred volume accuracy by using dual-wavelength photometry, where two
absorbance dyes with baseline resolved spectra are mixed at various ratios using a liquid
handler (Albert 2007; Dong et al. 2007). This dual-dye ratiometric method can be applied by
using a multichannel verification system (MVS) equipped with the necessary instrumenta‐
tion and analysis (Bradshaw et al. 2005). Dual-dye photometry is also proven to be suitable
to measure the efficiency of different mixing methods (Spaulding et al. 2006) and when pi‐
petting non-aqueous solutions (Bradshaw et al. 2007).
3.5. Considerations for using microplate washers
3.5.1. General considerations
One of the major concerns with any high throughput microplate handler device is its com‐
patibility with plates of various types and sizes. While most high throughput instruments
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3.5. Considerations for using microplate washers
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One of the major concerns with any high throughput microplate handler device is its com‐
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are designed to accommodate labware with dimensions conforming to ANSI/SBS standards,
an ideal plate washer is also able to support flat, v-shaped and round-bottom plates.
Both the vacuum assembly and the bottle setup are also important aspects of the plate wash‐
er. Although most washers operate through changes in vacuum pressure, pump-based vac‐
uum-free and pressure-free systems are also offered.
Plate washers functioning by positive displacement principle are also available, enabling
non-contact washing with no residual volume (Rudnicki and Johnston 2009). For assays
where more than one wash buffer may need to be used, plate washers with multiple dis‐
pense channels and automatic buffer switching capability are preferred to minimize both
operation time and contamination. Examples of other optional features for safe instrument
operation include waste liquid level sensors and plate detection sensors to avoid unwanted
overflows and jams. For BSL2 or higher level experiments, a washer with aerosol cover
should be chosen to prevent spread of the contagious material.
3.5.2. Washer performance
Although compatibility and control properties are important, plate washers are predomi‐
nantly evaluated by their wash performance. Plate washers provide a range of user-defined
dispense/aspirate heights, flow rates, and needle probe positioning in reference to the well
walls. By adjusting these parameters for each step of the wash cycle, optimal wash perform‐
ance can be ensured. On the other hand, an adequate wash quality needs to be reached to
diminish extensive background signal and high signal variations amongst wells. This can be
primarily achieved by minimizing the amount of liquid left inside each well at the end of the
aspiration step. Besides their effects on wash power, the above-mentioned parameters also
have an impact on the residual volume and need to be fine-tuned in conjunction with the
vacuum/pump settings. Some plate washers may also provide multipoint, secondary, cross-
wise or delayed aspiration modes aiming to deliver the best results. The number of wash
cycles and the length of soaking time are other settings that can be modified to reduce back‐
ground noise levels.
3.5.3. Washer maintenance
Since plate washers consist of tubing and needles which transport buffer solutions or waste
liquid to or from the device, they require special cleaning processes as they are prone to be
clogged by chemical residues such as salt and proteins from the wash liquids. Depending on
the frequency of use, the fluid path may need to be rinsed daily to prevent blockage and
contamination, especially if different buffers are being delivered through the same tubing.
An efficient cleaning method alternates deionized water and a detergent such as Terg-a-
Zyme®, which is highly recommended by plate washer manufacturers. Plate washers which
provide an automatic cleaning feature or integrated ultrasonic washing technology are often
easier to maintain. Models which do not contain built-in cleaning functionality are generally
supplied with removable dispense/aspiration manifolds to ease the maintenance tasks.
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Cleaning of the other detachable or fixed plate washer components should also be per‐
formed periodically.
3.5.4. Troubleshooting
Plate washers serve as an excellent alternative to time consuming manual wash procedures
for many applications. Since all the wash parameters should be optimized for each specific
application during the assay development stage, a tedious troubleshooting process may be
inevitable while setting up wash protocols to meet specific assay needs. Table 1 presents a
summary of wash parameters/components and their contributions to the wash performance
along with various troubleshooting tips. Different assay types may require distinct consider‐
ations. With biochemical assays, minimizing the background signal and well-to-well varia‐
tions are the most important tasks in the optimization process. Low background signal
levels can be achieved by reducing the leftover liquid volume in each well. Decreasing the
aspiration height and lowering the aspiration rate can greatly affect the residual volume
leading to minimal liquid amounts in the wells. In order to prevent high standard devia‐
tions in the assay readouts, equal residual volumes should be attempted by optimizing the
aspiration/dispense heights and rates. Depending on the viscosity of the wash buffer, high
aspiration rates or low dispense rates may lead to unequal volumes. Inadequate priming
volumes, unadjusted dispense or aspiration heights, clogged tubing, and physical misalign‐
ments between the manifolds and plate carrier should also be avoided to prevent high sig‐
nal variations. The effect of the aspiration height on the final residual volume is presented in
Fig. 6 for both 96- and 384-well black plates with clear bottom. The volume of the residual
liquid (water) per well was measured with the gravimetric technique at several selected as‐
piration heights on a Biotek EL405 microplate washer, while all the other wash parameters
were kept constant. A rising trend is observed in the final volume as the aspiration height is
increased.
Figure 6. Effects of aspiration height on residual volume. Residual volume was measured in a) 96-well and B) 384-well
plates at various aspiration heights. Residual volume was increased as the aspiration height from the bottom of the
well was increased.
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In cell-based assays, gentle cell washing is one of the most critical factors to produce repro‐
ducible assay results, and it can be controlled by several settings such as aspiration and dis‐
pense rates, heights and horizontal positions. For loosely-adherent cells, the cell layer
attached to the bottom of the well may be easily disrupted by rigorous wash cycles, and the
aspiration and dispense rates should be set low enough to prevent turbulence inside the
wells. For the same purpose, wash fluid should be dispensed at a distance from the well bot‐
tom and may be even be aimed at the well walls when possible. To observe the consequen‐
ces of inadequate washing and dispensing parameters on the cell layer endurance, a 3-cycle
wash experiment was performed on HEK 293T cells, which are known for their low adher‐
ence and propensity to be frequently washed away in cell-based assays. The fixing solution
was dispensed at medium speed, and the cells were washed before and after fixation. Repre‐
sentative images from wells containing an intact or damaged cell layer are presented in Fig.
7. When dealing with adherent cells, each step of the assay protocol should be optimized,
including those involving other liquid handling devices such as bulk dispensers, pintools
and pipettors.
Figure 7. Effects of non-optimized dispensing and washing on low-adherent cells. HEK293T cells were fixed, stained
with Hoechst 33258 and imaged with Acumen eX3 in a 384-well black clear bottom plates. The fixing solution was
dispensed by a Thermo Scientific Matrix® Wellmate®. Representative images (shown here in false color green) of A) an
intact cell layer and B) disrupted cell layers indicated cell loss due to harsh dispense and wash settings.
As with most high throughput instrument operations, it is a common practice to perform a
periodic quality check on plate washers to assure a satisfactory wash performance at each
use. It is important to perform these assessments with a wash buffer that has a similar vis‐
cosity to the buffers used in most of the applications. For evaluations on the residual vol‐
ume, one can perform a mock wash with a dummy plate and measure the leftover liquid
volume inside the wells with a single or multichannel manual pipettor. For more accurate
results, gravimetric or colorimetric techniques can be used to calculate the average volume
per well. This way, one can also test if dispensing/aspiration is consistent in all the probes,
and if there is any physical failure with any of the device components.
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parameter/component effect troubleshooting tips
prime dispense performance
• prevent air bubble formation or no/uneven




• higher residual volume if too fast
• perturbed cell layer if too fast




• higher residual volume if too high
• uneven aspiration if too low or too high
• perturbed cell layer if aspiration probes touch the
well bottom
• undisturbed cell layer if high enough
horizontal aspirate position gentle/rigorous washing
• prevent bead loss by offsetting the aspirate




• uneven dispensing if too slow
• fluid overflow if too slow or too fast
• perturbed cell layer if too fast




• uneven dispensing if too low or too high
• fluid overflow if too high
horizontal dispense position gentle/rigorous washing
• undisturbed cell layer if dispense position is offset





• optimize for viscous/non-viscous buffer solutions





• no/uneven aspiration with insufficient vacuum
supply
• no/uneven aspiration or leakage if tubing is




• uneven aspiration/dispense if plate carrier is not
leveled or movement is blocked
• plate is placed on the carrier with A1 in the correct
position
• enough plate clearance to prevent jams
• higher throughput with lower plate clearance
Table 1. Wash parameters and troubleshooting advices
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In order to fulfill the need for higher throughput options, the technology behind liquid han‐
dling devices is in constant progression, with systems capable of delivering smaller volumes
at a faster rate with accuracy and precision. These developments should consider cost reduc‐
tion by minimizing reagent and solvent expenditure, as well as reducing consumables.
The main concerns and limitations that liquid handling systems face are reproducibility and
reliability. The devices should be robust to execute extensive experiments in a daily basis
with minimal downtime and maintenance. However, as a single screen can generate thou‐
sands of data points, the user is required to ensure all the devices are functioning up to
standards by implementing routine quality assessments. Regardless of the technological in‐
novations and advancements, scientists are compelled to spend significant amount of time
optimizing the liquid handling parameters to suit specific assay conditions. A thorough un‐
derstanding of the principles, strengths and limitations of the instruments is advantageous
in preventing undesirable results and facilitating troubleshooting.
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In order to fulfill the need for higher throughput options, the technology behind liquid han‐
dling devices is in constant progression, with systems capable of delivering smaller volumes
at a faster rate with accuracy and precision. These developments should consider cost reduc‐
tion by minimizing reagent and solvent expenditure, as well as reducing consumables.
The main concerns and limitations that liquid handling systems face are reproducibility and
reliability. The devices should be robust to execute extensive experiments in a daily basis
with minimal downtime and maintenance. However, as a single screen can generate thou‐
sands of data points, the user is required to ensure all the devices are functioning up to
standards by implementing routine quality assessments. Regardless of the technological in‐
novations and advancements, scientists are compelled to spend significant amount of time
optimizing the liquid handling parameters to suit specific assay conditions. A thorough un‐
derstanding of the principles, strengths and limitations of the instruments is advantageous
in preventing undesirable results and facilitating troubleshooting.
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1. Introduction
With the advances in biotechnology, identification of new therapeutic targets, and better un‐
derstanding of human diseases, pharmaceutical companies and academic institutions have
accelerated their efforts in drug discovery. The pipeline to obtain therapeutics often involves
target identification and validation, lead discovery and optimization, pre-clinical animal
studies, and eventually clinical trials to test the safety and effectiveness of the new drugs. In
most cases, screening using genome-scale RNA interference (RNAi) technology or diverse
compound libraries comprises the first step of the drug discovery initiatives. Small interfer‐
ing RNA (siRNA, a class of double-stranded RNA molecules 20-25 nucleotides in length ca‐
pable of interfering with the expression of specific genes with complementary nucleotide
sequence) screen is an effective tool to identify upstream or downstream regulators of a spe‐
cific target gene, which may also potentially serve as drug targets for a more efficient and
successful treatment. On the other hand, screening of diverse small molecule libraries
against a known target or disease-relevant pathway facilitates the discovery of chemical
tools as candidates for further development.
Conducting either genome-wide RNAi or small molecule screens has become possible with
the advances in high throughput (HT) technologies, which are indispensible to carry out
massive screens in a timely manner (Macarron 2006; Martis et al. 2011; Pereira and Williams
2007). In screening campaigns, large quantities of data are collected in a considerably short
period of time, making rapid data analysis and subsequent data mining a challenging task
(Harper and Pickett 2006). Numerous automatic instruments and operational steps partici‐
pate in an HT screening process, requiring appropriate data processing tools for data quality
assessment and statistical analysis. In addition to quality control (QC) and “hit” selection
strategies, pre- and post-processing of the screening data are essential steps in a comprehen‐
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sive HT operation for subsequent interpretation and annotation of the large data sets. In this
chapter, we review statistical data analysis methods developed to meet the needs for han‐
dling large datasets generated from HT campaigns. We first discuss the influence of proper
assay design on statistical outcomes of the HT screening data. We then highlight similarities
and differences among various methods for data normalization, quality assessment and
“hit” selection. Information presented here provides guidance to researchers on the major
aspects of high throughput screening data interpretation.
2. Role of statistics in HT screening design
2.1. HT screening process
A typical HT screening campaign can be divided into five major steps regardless of the as‐
say type and the assay read-out (Fig. 1). Once target or pathway is identified, assay develop‐
ment is performed to explore the optimal assay conditions, and to miniaturize the assay to a
microtiter plate format. Performance of an HT assay is usually quantified with statistical pa‐
rameters such as signal window, signal variability and Z-factor (see definition in section 4).
To achieve acceptable assay performances, one should carefully choose the appropriate re‐
agents, experimental controls and numerous other assay variables such as cell density or
protein/substrate concentrations.
The final distribution of the activities from a screening data set depends highly on the target
and pathway (for siRNA) or the diversity of the compound libraries, and efforts have been
continuously made to generate more diverse libraries (Entzeroth et al. 2009; Gillet 2008;
Kummel and Parker 2011; Zhao et al. 2005). Furthermore, the quality and reliability of the
screening data is affected by the stability and the purity of the test samples in the screening
libraries, where storage conditions should be monitored and validated in a timely manner
(Baillargeon et al. 2011; Waybright et al. 2009). For small molecules, certain compounds
might interfere with the detection system by emitting fluorescence or by absorbing light,
and they should be avoided whenever possible to obtain reliable screening results.
Assay development is often followed by a primary screen, which is carried out at a single con‐
centration (small molecule) or single point measurements (siRNA). As the “hits” identified in
the primary screen are followed-up in a subsequent confirmatory screen, it is crucial to opti‐
mize the assay to satisfactory standards. Sensitivity - the ability to identify an siRNA or com‐
pound as a “hit” when it is a true “hit”, and specificity - the ability to classify an siRNA or
compound as a “non-hit” when it is not a true “hit”, are two critical aspects to identify as many
candidates while minimizing false discovery rates. Specificity is commonly emphasized in the
confirmatory screens which follow the primary screens. For instance, the confirmatory screen
for small molecules often consists of multiple measurements of each compound’s activity at
various concentrations using different assay formats to assess the compound’s potency and se‐
lectivity. The confirmatory stage of an RNAi screen using pooled siRNA may be performed in a
deconvolution mode, where each well contains a single siRNA. Pooling strategy is also applica‐
ble to primary small molecule screens, where a keen pooling design is necessary (Kainkaryam
Drug Discovery202
and Woolf 2009). The confirmatory screens of compounds identified from small molecule libra‐
ries are followed by lead optimization efforts involving structure-activity relationship investi‐
gations and molecular scaffold clustering. Pathway and genetic clustering analysis, on the
other hand, are widespread hit follow-up practices for RNAi screens. The processes encom‐
passing hit identification from primary screens and lead optimization methods require power‐
ful software tools with advanced statistical capabilities.
Figure 1. The HT screening process.
Accuracy and precision of an assay are also critical parameters to consider for a successful
campaign. While accuracy is a measurement of how close a measured value is to its true val‐
ue, precision is the proximity of the measured values to each other. Therefore, accuracy of
an assay is highly dependent on the performance of the HT instruments in use. Precision, on
the other hand, can be a function of sample size and control performances as well as instru‐
ment specifications, indicating that the experimental design has a significant impact on the
statistical evaluation of the screening data.
2.2. Classical versus robust (resistant) statistics
One of the main assumptions when analyzing HT screening data is that the data is normally
distributed, or it complies with the central limit theorem, where the mean of the distributed
values converge to normal distribution unless there are systematic errors associated with the
screen (Coma et al. 2009). Therefore, log transformations are often applied to the data in the
pre-processing stage to achieve more symmetrically distributed data around the mean as in
a normal distribution, to represent the relationship between variables in a more linear way
especially for cell growth assays, and to make an efficient use of the assay quality assess‐
ment parameters (Sui and Wu 2007).
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Assay development is often followed by a primary screen, which is carried out at a single con‐
centration (small molecule) or single point measurements (siRNA). As the “hits” identified in
the primary screen are followed-up in a subsequent confirmatory screen, it is crucial to opti‐
mize the assay to satisfactory standards. Sensitivity - the ability to identify an siRNA or com‐
pound as a “hit” when it is a true “hit”, and specificity - the ability to classify an siRNA or
compound as a “non-hit” when it is not a true “hit”, are two critical aspects to identify as many
candidates while minimizing false discovery rates. Specificity is commonly emphasized in the
confirmatory screens which follow the primary screens. For instance, the confirmatory screen
for small molecules often consists of multiple measurements of each compound’s activity at
various concentrations using different assay formats to assess the compound’s potency and se‐
lectivity. The confirmatory stage of an RNAi screen using pooled siRNA may be performed in a
deconvolution mode, where each well contains a single siRNA. Pooling strategy is also applica‐
ble to primary small molecule screens, where a keen pooling design is necessary (Kainkaryam
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and Woolf 2009). The confirmatory screens of compounds identified from small molecule libra‐
ries are followed by lead optimization efforts involving structure-activity relationship investi‐
gations and molecular scaffold clustering. Pathway and genetic clustering analysis, on the
other hand, are widespread hit follow-up practices for RNAi screens. The processes encom‐
passing hit identification from primary screens and lead optimization methods require power‐
ful software tools with advanced statistical capabilities.
Figure 1. The HT screening process.
Accuracy and precision of an assay are also critical parameters to consider for a successful
campaign. While accuracy is a measurement of how close a measured value is to its true val‐
ue, precision is the proximity of the measured values to each other. Therefore, accuracy of
an assay is highly dependent on the performance of the HT instruments in use. Precision, on
the other hand, can be a function of sample size and control performances as well as instru‐
ment specifications, indicating that the experimental design has a significant impact on the
statistical evaluation of the screening data.
2.2. Classical versus robust (resistant) statistics
One of the main assumptions when analyzing HT screening data is that the data is normally
distributed, or it complies with the central limit theorem, where the mean of the distributed
values converge to normal distribution unless there are systematic errors associated with the
screen (Coma et al. 2009). Therefore, log transformations are often applied to the data in the
pre-processing stage to achieve more symmetrically distributed data around the mean as in
a normal distribution, to represent the relationship between variables in a more linear way
especially for cell growth assays, and to make an efficient use of the assay quality assess‐
ment parameters (Sui and Wu 2007).
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In HT screening practices, the presence of outliers - data points that do not fall within the
range of the rest of the data - is generally experienced. Distortions to the normal distribution
of the data caused by outliers impact the results negatively. Therefore, an HT data set with
outliers needs to be analyzed carefully to avoid an unreliable and inefficient “hit” selection
process. Although outliers in control wells can be easily identified, it should be clear that
outliers in the test sample may be misinterpreted as real “hits” instead of random errors.
There are two approaches for statistical analysis of data sets with outliers: classical and ro‐
bust. One can choose to replace or remove outliers based on the truncated mean or similar
approaches, and continue the analysis process with classical methods. However, robust stat‐
istical approaches have gained popularity in HT screening data analysis in recent decades.
In robust statistics, median and median absolute deviation (MAD) are utilized as statistical
parameters as opposed to mean and standard deviation (std), respectively, to diminish the
effect of outliers on the final analysis results. Although there are numerous approaches to
detect and abolish/replace outliers with statistical methods (Hund et al. 2002; Iglewicz and
Hoaglin 1993; Singh 1996), robust statistics is preferred for its insensitivity to outliers (Huber
1981). In statistics, while the robustness of an analysis technique can be determined by two
main approaches, i.e. influence functions (Hampel et al. 1986) and breakdown point (Ham‐
pel 1971), the latter is a more intuitive technique in the concept of HT screening, where the
breakdown point of a sample series is defined as the amount of outlier data points that can
be tolerated by the statistical parameters before the parameters take on drastically different
values that are not representing anymore distribution of the original dataset. In a demon‐
strated example on a five sample data set, robust parameters were shown to perform superi‐
or to the classical parameters after the data set was contaminated with outliers (Rousseeuw
1991). It was also emphasized that median and MAD have a breakdown point of 50%, while
mean and std have 0%, indicating that sample sets with 50% outlier density can still be suc‐
cessfully handled with robust statistics.
2.3. False discovery rates
As mentioned previously, depending on the specificity and sensitivity of an HT assay, erro‐
neous assessment of “hits” and “non-hits” is likely. Especially in genome-wide siRNA
screens, false positive and negative results may mislead the scientists in the confirmatory
studies. While the cause of false discovery results may be due to indirect biological regula‐
tions of the gene of interest through other pathways that are not in the scope of the experi‐
ment, it may also be due to random errors experienced in the screening process. Although
the latter can be easily resolved in the follow-up screens, the former may require a better
assay design (Stone et al. 2007). Lower false discovery rates can also be achieved by careful
selection of assay reagents to avoid inconsistent measurements (outliers) during screening.
The biological interference effects of the reagents in RNAi screens can be considered in two
categories: sequence-dependent and sequence-independent (Echeverri et al. 2006; Mohr and
Perrimon 2012). Therefore, off-target effects and low transfection efficiencies are the main
challenges to be overcome in these screens. Moreover, selection of the appropriate controls
for either small molecule or RNAi screens is very crucial for screen quality assessment as
Drug Discovery204
well as for “hit” selection, so that the false discovery rates can be inherently reduced. Posi‐
tive controls are often chosen from small-molecule compounds or gene silencing agents that
are known to have the desired effect on the target of interest; however, this may be a diffi‐
cult task if very little is known about the biological process (Zhang et al. 2008a). On the other
hand, selection of negative controls from non-targeting reagents is more challenging due to
higher potential of biological off-target effects in RNAi screens compared to the negative
controls used in small-molecule screens (Birmingham et al. 2009). Another factor that might
interfere with the biological process in an HT screening assay is the bioactive contaminants
that may be released from the consumables used in the screening campaign, such as plastic
tips and microplates (McDonald et al. 2008; Watson et al. 2009). Unreliable and misleading
screening results may be obtained from altered assay conditions caused by leached materi‐
als, and boosted false discovery rates may be unavoidable. Hence, the effects of laboratory
consumables on the assay readout should be carefully examined during assay development.
The false discovery rates are also highly dependent on the analysis methods used for “hit”
selection, and they can be statistically controlled. False discovery rate is defined as the ratio
of false discoveries to the total number of discoveries. A t-test and the associated p value are
often used for hypothesis testing in a single experiment and can be interpreted as the false
positive discovery rate (Chen et al. 2010). However, the challenge arises when multiple hy‐
pothesis testing is needed or when the comparison of results across multiple experiments is
required. For HT applications, a Bayesian approach was developed to enable plate-wise and
experiment-wise comparison of results in a single process, while the false discovery rates
can still be controlled (Zhang et al. 2008b). Another method utilizing the strictly standar‐
dized mean difference (SSMD) parameter was proven to control the false discovery and
non-discovery rates in RNAi screens (Zhang 2007a; Zhang 2010 b; Zhang et al. 2010). By tak‐
ing the data variability into account, SSMD method is capable of determining “hits” with
higher assurance compared to the Z-score and t-test methods.
3. Normalization and systematic error corrections
3.1. Normalization for assay variability
Despite meticulous assay optimization efforts considering all the factors mentioned previ‐
ously, it is expected to observe variances in the raw data across plates even within the same
experiment. Here, we consider these variances as “random” assay variability, which is sepa‐
rate from the systematic errors that can be linked to a known reason, such as failure of an
instrument. Uneven assay performances may unpredictably occur at any given time during
screening. Hence, normalization of data within each plate is necessary to enable comparable
results across plates or experiments allowing a single cut-off for the selection of “hits”.
When normalizing the HT screening data, two main approaches can be followed: controls-
based and non-controls-based. In controls-based approaches, the assay-specific in-plate pos‐
itive and negative controls are used as the upper (100%) and lower (0%) bounds of the assay
activity, and the activities of the test samples are calculated with respect to these values. Al‐
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ously, it is expected to observe variances in the raw data across plates even within the same
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rate from the systematic errors that can be linked to a known reason, such as failure of an
instrument. Uneven assay performances may unpredictably occur at any given time during
screening. Hence, normalization of data within each plate is necessary to enable comparable
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When normalizing the HT screening data, two main approaches can be followed: controls-
based and non-controls-based. In controls-based approaches, the assay-specific in-plate pos‐
itive and negative controls are used as the upper (100%) and lower (0%) bounds of the assay
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though, it is an intuitive and easily interpretable method, there are several concerns with the
use of controls for normalization purposes. With controls-based methods, too high or too
low variability in the control wells does not necessarily represent the variability in the sam‐
ple wells, and the outliers and biases within the control wells might impair the upper and
lower activity bounds (Brideau et al. 2003; Coma et al. 2009). Therefore, non-control-based
normalizations are favored for better understanding of the overall activity distribution
based on the sample activities per se. In this method, most of the samples are assumed to be
inactive in order to serve as their own “negative controls”. However, this approach may be
misleading when the majority of the wells in a plate consist of true “hits” (such as screening
a library of bioactive molecules) or siRNAs (e.g., focused library). Since the basal activity
level would shift upwards under these conditions, non-controls-based method would result
in erroneous decision making.
Plate-wise  versus  experiment-wise  normalization  and  “hit”  picking  is  another  critical
point to consider when choosing the best fitting analysis technique for a screen. Experi‐
ment-wise normalizations are advantageous in screens where active samples are clustered
within certain plates. In this case, each plate is processed in the context of all plates in the
experiment. On the other hand, plate-wise normalizations can effectively correct systemat‐
ic  errors  occurring  in  a  plate-specific  manner  without  disrupting  the  results  in  other
plates (Zhang et  al.  2006).  Therefore,  the normalization method that  fits  best  with one’s
experimental  results  should be carefully chosen to perform efficient  “hit” selection with
low false discovery rates.
The calculation used in  the  most  common controls-based normalization methods are  as
follows:
• Percent of control (PC): Activity of the ith sample (Si) is divided by the mean of either the




• Normalized percent inhibition (NPI): Activity of the ith sample is normalized to the activi‐
ty of positive and negative controls. The sample activity is subtracted from the high con‐
trol (Chigh) which is then divided by the difference between mean of the low control (Clow)
and the mean of the high control. This parameter may be termed normalized percent ac‐
tivity if the final result is subtracted from 100. Additionally, control means may be pref‐





The calculation used in the most common non-controls-based normalization methods are as
follows.
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• Percent of samples (PS): The mean of the control wells in the PC parameter (only when





• Robust percent of samples (RPS): In order to desensitize the PS calculation to the outliers,
robust statistics approach is preferred, where mean of Sall in PS calculation is replaced
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Table 1. Summary of HT screening data normalization methods.
• Z-score: Unlike the above parameters, this method accounts for the signal variability in
the sample wells by dividing the difference of Si and the mean of Sall by the std of Sall. Z-
score is a widely used measure to successfully correct for additive and multiplicative off‐





• Robust Z-score: Since Z-score calculation is highly affected by outliers, robust version of
Z-score is available for calculations insensitive to outliers. In this parameter, the mean and
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• Percent of samples (PS): The mean of the control wells in the PC parameter (only when
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MAD(Sall)=1.4826 x median(|Si-median(Sall)|) (7)
3.2. Normalization for systematic errors
Besides the data variability between plates due to random fluctuations in assay perform‐
ance, systematic errors are one of the major concerns in HT screening. For instance plate-
wise spatial patterns play a crucial role in cell-based assay failures. As an example,
incubation conditions might be adjusted to the exact desired temperature and humidity set‐
tings, but the perturbed air circulations inside the incubator unit might cause an uneven
temperature gradient, resulting in different cell-growth rates in each well due to evapora‐
tion issues. Therefore, depending on the positions of the plates inside the incubator, column-
wise, row-wise or bowl-shape edge effects may be observed within plates (Zhang 2008b;
Zhang 2011b). On the other hand, instrumental failures such as inaccurate dispensing of re‐
agents from individual dispenser channels might cause evident temporal patterns in the fi‐
nal readout. Therefore, experiment-wise patterns should be carefully examined via proper
visual tools. Although some of these issues might be fixed at the validation stage such as
performing routine checks to test the instrument performances, there are numerous algo‐
rithms developed to diminish these patterns during data analysis, and the most common
ones are listed as follows and summarized in Table 1.
• Median polish: Tukey’s two-way median polish (Tukey 1977) is utilized to calculate the
row and column effects within plates using a non-controls-based approach. In this meth‐
od, the row and column medians are iteratively subtracted from all wells until the maxi‐
mum tolerance value is reached for the row and column medians as wells as for the row
and column effects. The residuals in pth plate (rijp) are then calculated by subtracting the
estimated plate average (µ̂p), ith row effect (roŵi) and jth column effect (col
^
j) from the true
sample value (Sijp). Since median parameter is used in the calculations, this method is rela‐




• B-score: This is a normalization parameter which involves the residual values calculated
from median polish and the sample MAD to account for data variability. The details of
median polish technique and an advanced B-score method, which accounts for plate-to-





MADp= 1.4826 x median(|(rijp)all- median((rijp)all)|) (10)
• BZ-score: This is a modified version of the B-score method, where the median polish is
followed by Z-score calculations. While BZ-score is more advantageous to Z-score be‐
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cause of its capability to correct for row and column effects, it is less powerful than B-





• Background correction: In this correction method, the background signal corresponding to
each well is calculated by averaging the activities within each well (S’ijp representing the nor‐
malized signal of a well in ith row and jth column in pth plate) across all plates. Then, a polyno‐
mial fitting is performed to generate an experiment-wise background surface for a single
screening run. The offset of the background surface from a zero plane is considered to be the
consequence of present systematic errors, and the correction is performed by subtracting the
background surface from each plate data in the screen. The background correction per‐
formed on pre-normalized data was found to be more efficient, and exclusion of the control
wells was recommended in the background surface calculations. The detailed description of








• Well-correction: This method follows an analogous strategy to the background correction
method; however, a least-squares approximation or polynomial fitting is performed inde‐
pendently for each well across all plates. The fitted values are then subtracted from each
data point to obtain the corrected data set. In a study comparing the systematic error cor‐
rection methods discussed so far, well-correction method was found to be the most effec‐
tive for successful “hit” selection (Makarenkov et al. 2007).
• Diffusion-state model: As mentioned previously, the majority of the spatial effects are
caused by uneven temperature gradients across assay plates due to inefficient incubation
conditions. To predict the amount of evaporation in each well in a time and space de‐
pendent manner, and its effect on the resulting data set, a diffusion-state model was de‐
veloped by (Carralot et al. 2012). As opposed to the above mentioned correction methods,
the diffusion model can be generated based on the data from a single control column in‐
stead of sample wells. The edge effect correction is then applied to each plate in the
screening run based on the generated model.
Before automatically applying a systematic error correction algorithm on the raw data set, it
should be carefully considered whether there is a real need for such data manipulation. To de‐
tect the presence of systematic errors, several statistical methods were developed (Coma et al.
2009; Root et al. 2003). In a demonstrated study, the assessment of row and column effects was
performed based on a robust linear model, so called R score, and it was shown that performing
a positional correction using R score on the data that has no or very small spatial effects results
in lower specificity. However, correcting a data set with large spatial effects decreases the false
discovery rates considerably (Wu et al. 2008). In the same study, receiver operating characteris‐
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tics (ROC) curves were generated to compare the performance of several positional correction
algorithms based on sensitivity and “1-specificity” values, and R-score was found to be the
most superior. On the other hand, application of well-correction or diffusion model on data sets
with no spatial effects was shown to have no adverse effect on the final “hit” selection (Carralot
et al. 2012; Makarenkov et al. 2007). Additionally, reduction of thermal gradients and associat‐
ed edge effects in cell-based assays was shown to be possible by easy adjustments to the assay
workflow, such as incubating the plates at room temperature for 1 hour immediately after dis‐
pensing the cells into the wells (Lundholt et al. 2003).
4. QC methods
There are various environmental, instrumental and biological factors that contribute to as‐
say performance in an HT setting. Therefore, one of the key steps in the analysis of HT
screening data is the examination of the assay quality. To determine if the data collected
from each plate meet the minimum quality requirements, and if any patterns exist before
and after data normalization, the distribution of control and test sample data should be ex‐
amined at experiment-, plate- and well-level. While there are numerous graphical methods
and tools available for the visualization of the screening data in various formats (Gribbon et
al. 2005; Gunter et al. 2003; Wu and Wu 2010), such as scatter plots, heat maps and frequen‐
cy plots, there are also many statistical parameters for the quantitative assessment of assay
quality. Same as for the normalization techniques, both controls-based and non-controls-
based approaches exist for data QC methods. The most commonly-used QC parameters in
HT screening are listed as follows and summarized in Table 2.
• Signal-to-background (S/B): This is a simple measure of the ratio of the positive control





• Signal-to-noise (S/N): This is a similar measure to S/B with the inclusion of signal variabil‐
ity in the formulation. Two alternative versions of S/N are presented below. Both S/B and
S/N are considered week parameters to represent dynamic signal range for an HT screen
and are rarely used.
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• Signal window (SW): This is a more indicative measure of the data range in an HT assay
than the above parameters. Two alternative versions of the SW are presented below,
which only differ by denominator.
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• Assay variability ratio (AVR): This parameter captures the data variability in both con‐
trols as opposed to SW, and can be defined as (1-Z’-factor) as presented below.
AVR=
3 x std(Cpos) + 3 x std(Cneg)
|mean(Cpos) - mean(Cneg)|
(16)
• Z’-factor:  Despite  of  the  fact  that  AVR and Z’-factor  has  similar  statistical  properties,
the latter is the most widely used QC criterion, where the separation between positive
(Cpos)  and negative (Cneg)  controls  is  calculated as  a  measure of  the signal  range of  a
particular assay in a single plate. Z’-factor has its basis on normality assumption, and
the use  of  3  std’s  of  the  mean of  the  group comes from the 99.73% confidence limit
(Zhang  et  al.  1999).  While  Z’-factor  accounts  for  the  variability  in  the  control  wells,
positional  effects  or  any  other  variability  in  the  sample  wells  are  not  captured.  Al‐
though  Z’-factor  is  an  intuitive  method  to  determine  the  assay  quality,  several  con‐
cerns were raised about the reliability of  this  parameter as an assay quality measure.
Major issues associated with the Z’-factor method are that the magnitude of the Z’-fac‐
tor does not necessarily correlate with the hit  confirmation rates,  and that Z’-factor is
not an appropriate measure to compare the assay quality across different screens and
assay types (Coma et al. 2009; Gribbon et al. 2005).
Z'-factor=1 -
3 x std(Cpos) + 3 x std(Cneg)
|mean(Cpos) - mean(Cneg)|
(17)
• Z-factor:  This is the modified version of the Z’-factor,  where the mean and std of the
negative control are substituted with the ones for the test  samples.  Although Z-factor
is  more advantageous than Z’-factor due to its ability to incorporate sample variabili‐
ty  in  the  calculations,  other  issues  associated with  Z’-factor  (as  discussed above)  still
apply.  Additionally,  in  a  focused library in  which many possible  “hits”  are  clustered
in  certain  plates,  Z-factor  would  not  be  an  appropriate  QC  parameter.  While  assays
with Z’- or Z-factor values above 0.5 are considered to be excellent, one may want to
include additional measures, such as visual inspection or more advanced formulations
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negative control are substituted with the ones for the test  samples.  Although Z-factor
is  more advantageous than Z’-factor due to its ability to incorporate sample variabili‐
ty  in  the  calculations,  other  issues  associated with  Z’-factor  (as  discussed above)  still
apply.  Additionally,  in  a  focused library in  which many possible  “hits”  are  clustered
in  certain  plates,  Z-factor  would  not  be  an  appropriate  QC  parameter.  While  assays
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in  the  decision  process,  especially  for  cell-based  assays  with  inherently  high  signal
variability. The power of the above mentioned parameters were discussed in multiple
studies  (Gribbon  et  al.  2005;  Iversen  et  al.  2006;  Macarron  and  Hertzberg  2009;  Ste‐
vens et al. 1998).
Z-factor=1 -
3 x std(Cpos) + 3 x std(Sall)
|mean(Cpos) - mean(Sall)|
(18)
• SSMD: It is an alternative quality metric to Z’- and Z-factor, which was recently devel‐
oped to assess the assay quality in HT screens (Zhang 2007a; Zhang 2007b). Due to its ba‐
sis on probabilistic and statistical theories, SSMD was shown to be a more meaningful
parameter than previously mentioned methods for QC purposes. SSMD differs from Z’-
and Z-factor by its ability to handle controls with different effects, which enables the se‐
lection of multiple QC criteria for assays (Zhang et al. 2008a). The application of SSMD-
based QC criterion was demonstrated in multiple studies in comparison to other
commonly-used methods (Zhang 2008b; Zhang 2011b; Zhang et al. 2008a). Although
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Table 2. Summary of HT screening data QC methods.
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5. “Hit” selection methods
The main purpose of HT screens is to obtain a list of compounds or siRNAs with desirable activ‐
ity for further confirmation. Therefore, the ultimate goal of an HT screening campaign is to nar‐
row down a big and comprehensive compound or siRNA library to a manageable number of
“hits” with low false discovery rates. While the initial library of test samples undergoes multi‐
ple phases of elimination, the most critical factor is to select as many true “hits” as possible. Af‐
ter data normalization is applied as necessary, “hit” selection is performed on the plates that
pass the QC criterion. As stated previously in Section 2.1, HT processes in primary and confir‐
matory screens differ in design. The “hit” selection process following a primary screen is simi‐
lar for RNAi and small-molecule screens, where the screening run is often performed in single
copy, and a single data point (obtained from either endpoint or kinetic reading) is collected for
each sample. On the other hand, a confirmatory RNAi screen is typically performed in repli‐
cates using pooled or individual siRNA, while the confirmatory small-molecule screens are
executed in dose-response mode. Here, we classify the “hit” selection methodologies in two
major categories: primary and confirmatory screen analysis.
5.1. “Hit” selection in primary screen
Although RNAi and small molecule assays differ in many ways, a common aim is to classify the
test samples with relatively higher or lower activities than the reference wells as “hits”. Hence,
it is required to select an activity cut-off, where test samples with values above or below the cut-
off are identified as “hits”. It is very crucial to select a sensible cut-off value with enough differ‐
ence from the noise level in order to reduce false positive rates. Depending on the specific goals
of the projects, the cut-off might need to be a reasonable value that leads to a manageable quan‐
tity of “hits” for follow-up studies. To guide scientists in the process, numerous “hit” selection
methods have been developed for HT screens as presented below.
• Percent inhibition cut-off: The “hits” from HT screening data that is normalized for per‐
cent inhibition (NPI method in Section 3.1) can be selected based on a percent cut-off val‐
ue that is arbitrarily assigned relative to an assay’s signal window. As this method does
not have much statistical basis to it, it is primarily preferred for small molecule screens
with strong controls.
• Mean +/- k std: In this method, cut-off is set to the value that is k std’s above or below the
sample mean. While the cut-off can be applied to the normalized data, a k value of 3 is
typically used, which is associated with the false positive error rate of 0.00135 (Zhang et
al. 2006). As this cut-off calculation method is primarily based on normality assumption,
it is also equivalent to a Z-score of 3. Since the use of mean and std make this method
sensitive to outliers, a more robust version is presented next.
• Median +/- k MAD: To desensitize the “hit” selection to outliers, a cut-off that is k MADs
above or below the sample median was developed, and a study comparing the std- and
MAD-based “hit” selection methods showed lower false non-discovery rates with the lat‐
ter (Chung et al. 2008).
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in  the  decision  process,  especially  for  cell-based  assays  with  inherently  high  signal
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vens et al. 1998).
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sample mean. While the cut-off can be applied to the normalized data, a k value of 3 is
typically used, which is associated with the false positive error rate of 0.00135 (Zhang et
al. 2006). As this cut-off calculation method is primarily based on normality assumption,
it is also equivalent to a Z-score of 3. Since the use of mean and std make this method
sensitive to outliers, a more robust version is presented next.
• Median +/- k MAD: To desensitize the “hit” selection to outliers, a cut-off that is k MADs
above or below the sample median was developed, and a study comparing the std- and
MAD-based “hit” selection methods showed lower false non-discovery rates with the lat‐
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• Quartile-based method: Similar to the previous approaches, the quartile-based “hit” selec‐
tion method is based on the idea of treating the true “hits” as outliers and identifying
them by setting upper and lower cut-off boundaries based on the quartiles and interquar‐
tiles of the data. The major advantage of the quartile-based method over median +/- k
MAD is its more effective cut-off calculation formulation for non-symmetrical data, where
upper and lower cut-offs can be determined independently. In the comparison of the
three “hit” selection criteria presented so far, the quartile-based method outperformed the
other two methods to detect true “hits” with moderate effects (Zhang et al. 2006).
• SSMD and Robust SSMD: This parameter has become a widely-used method for RNAi
screening data analysis mainly due to its ability to quantify RNAi effects with a statistical
basis, and its better control on false negative and false positive rates (Zhang 2007a; Zhang
2007b; Zhang 2009; Zhang 2010a; Zhang 2010 b; Zhang 2011b; Zhang et al. 2010). SSMD is
a robust parameter to capture the magnitude of the RNAi effects with various sample
sizes. This scoring method also provides comparison of values across screens. Mean and
std in the standard SSMD formula is substituted with median and MAD in the robust ver‐
sion. The SSMD parameter used for the primary screens without replicates holds a linear
relationship with the Z-score method.
• Bayesian method: This method is used to combine both plate-wise and experiment-wise
information within single “hit” selection calculation based on Bayesian hypothesis testing
(Zhang et al. 2008b). Bayesian statistics incorporates a prior data distribution and a likeli‐
hood function to generate a posterior distribution function. In HT screening data analysis
using this method, the experiment- and plate-wise information is incorporated into the
prior and likelihood functions, respectively. With the availability of various prior distri‐
bution models, the Bayesian method can be applied either with positive and negative con‐
trols or with test sample wells. As this method enables the control of false discovery rates,
it is a more powerful “hit” selection measure than the median +/- k MAD when the sam‐
ple data is used to generate the prior distribution.
5.2. “Hit” selection in confirmatory screen
Different strategies are pursued for the confirmation of “hits” from RNAi and small mole‐
cule primary screens. While dose response screens are very common to test the compound
activities in a dose-dependent manner in small molecule screens, this is not applicable to
RNAi screens. Here, we will present the “hit” selection methods for screens with replicates
in two categories: dose-response analysis and others.
5.2.1. Dose-response analysis
After running a primary screen, in which a single concentration of compound is used, a sub‐
set of compounds is selected for a more quantitative assessment. These molecules are tested
at various concentrations and plotted against the corresponding assay response. These types
of curves are commonly referred to as “dose-response” or “concentration-response” curves,
and they are generally defined by four parameters: top asymptote (maximal response), bot‐
tom asymptote (baseline response), slope (Hill slope or Hill coefficient), and the EC50 value.
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A plot of signal as a function of concentration results in a rectangular hyperbola when the
hill coefficient is 1 (Fig. 2A). Because the concentration range covers several orders of magni‐
tude, the x-axis is normally displayed in the logarithm scale, resulting in a sigmoidal curve
(Fig. 2B), which is generally fitted with the Hill equation:
signal=B+ T-B
1+( EC50x )h (20)
The most accepted benchmark for drug potency is the EC50 value, which corresponds to the
concentration of compound (x) that generates a signal midway between the top (T) and bot‐
tom (B) asymptotes (Fig. 2B). The steepness is indicated by the Hill slope (h), also known as
the Hill coefficient or the slope factor (Fig. 2C).
It is preferable to apply the Hill equation to concentrations on a logarithmic scale, because
the error associated with the EC50 (log form) follows a Gaussian distribution (Motulsky and
Neubig 2010), as indicated in Eq. 21. The x values represent log[compound].
signal=B+ T-B
1+( 10Log EC5010x )
h (21)
In biochemical experiments, a Hill coefficient of 1 is indicative of a 1:1 stoichiometry of en‐
zyme-inhibitor or protein-ligand complexes. Under such condition, an increase from 10% to
90% response requires 81-fold change in compound concentration. Hill coefficient values
that deviate from unity could reflect mechanistic implications (such as cooperativity or mul‐
tiple binding sites) or non-ideal behavior of the compound (acting as protein denaturant or
causing micelle formation) (Copeland 2005).
For  symmetrical  curves,  the  inflection  point  corresponds  to  the  relative  EC50  value,
which lies halfway between the asymptotes. This relative EC50 may be different from the
actual EC50  if  the top and bottom plateaus do not accurately represent 0% and 100% re‐
sponse. For instance, in Fig. 2D, the midpoint in the black curve dictates a value of 60%
based on the positive and negative controls. When using the relative EC50,  careful analy‐
sis  of  data  fitting  is  necessary  to  avoid  deceptive  results,  as  exemplified  by  the  green
curve  in  Fig.  2D.  Curve  fitting  would  provide  a  relative  EC50  value  of  1  for  both  the
green and black curves,  but based on controls,  the compound associated with the green
curve  would  inhibit  the  assay  only  by  20%.  Therefore,  it  is  argued  that  the  best  ap‐
proach  is  to  use  a  two-parameter  curve  fit,  where  only  two parameters  are  allowed to
float  (EC50  and  Hill  coefficient  values),  while  fixing  the  top  and  bottom  boundaries  as
presented in Fig. 2E. (Copeland 2005).
Although EC50 is normally the main criterion to categorize compounds for downstream
analysis, the value is highly dependent on assay conditions, such as cell number and en‐
zyme/substrate amount (Copeland 2003). For enzymatic assays, a more attractive approach
is to consider relative affinities. Cheng and Prusoff formulated a way to convert EC50 values
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Different strategies are pursued for the confirmation of “hits” from RNAi and small mole‐
cule primary screens. While dose response screens are very common to test the compound
activities in a dose-dependent manner in small molecule screens, this is not applicable to
RNAi screens. Here, we will present the “hit” selection methods for screens with replicates
in two categories: dose-response analysis and others.
5.2.1. Dose-response analysis
After running a primary screen, in which a single concentration of compound is used, a sub‐
set of compounds is selected for a more quantitative assessment. These molecules are tested
at various concentrations and plotted against the corresponding assay response. These types
of curves are commonly referred to as “dose-response” or “concentration-response” curves,
and they are generally defined by four parameters: top asymptote (maximal response), bot‐
tom asymptote (baseline response), slope (Hill slope or Hill coefficient), and the EC50 value.
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Although EC50 is normally the main criterion to categorize compounds for downstream
analysis, the value is highly dependent on assay conditions, such as cell number and en‐
zyme/substrate amount (Copeland 2003). For enzymatic assays, a more attractive approach
is to consider relative affinities. Cheng and Prusoff formulated a way to convert EC50 values
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to dissociation constants, thus reducing the overload of performing multiple titrations asso‐
ciated with standard enzyme kinetics (Cheng and Prusoff 1973). Nevertheless, the caveat of
using this convenient alternative is to recognize the inhibitory modality of the compounds
(Copeland 2005): competitive (Eq. 22), non-competitive (Eq. 23) and uncompetitive (Eq. 24).
Figure 2. Dose-response curves. A) Response vs. compound concentration resulting in a rectangular hyperbola curve.
B) Response vs. logarithm of compound concentration resulting in a sigmoidal curve. The dashed lines indicate the
concentration corresponding to half-maximal signal. C) Curves at different Hill slopes: 0.5 (black, closed circles), 1 (red,
open circles), 2 (blue, closed squares), 3 (green, open squares) and -1 (pink, closed triangles). D) Relative (blue dash
lines) and actual (red dash lines) EC50 values for a curve with different top boundary from that of the control (black
curve). The green and black curves have the same relative EC50. E) The red curve fits the data points (black circles) al‐
lowing 2 parameters (EC50, hill coefficient) to float, while the blue curve fits the data refining all 4 parameters (EC50, hill
coefficient, top and bottom asymptotes). F) Curves corresponding to a full agonist (red), partial agonist (black), antag‐
onist (green) and inverse agonist (blue).
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substrate concentration (S) and the Michaelis constant (KM). The constant α delineates the ef‐
fect of inhibitor binding on the affinity of the substrate for the enzyme. It becomes evident
that EC50 and Ki are roughly the same at much lower substrate concentration relative to KM
(Eq. 22) or when α=1 (Eq. 23).
Dose-response  curves  can  follow  various  patterns,  depending  on  the  biological  system
to  be  investigated.  For  assays  with  certain  basal  level,  increasing  concentrations  of  a
full  agonist  triggers  a  maximal  response  for  the  system  (Fig.  2F,  red  curve).  A  partial
agonist  displays  a  reduced  response  (efficacy)  relative  to  a  full  agonist  (Fig.  2F,  black
curve),  even though they both exhibit  the same potency (i.e.  same EC50  values).  An an‐
tagonist  might  have  certain  affinity  or  potency,  but  it  would  not  show  any  change  in
basal activity as the efficacy has a value of zero (Fig. 2F, green curve). However, an an‐
tagonist  reverses  the  actions  of  an  agonist.  In  pharmacological  terms,  the  effects  of  a
competitive  antagonist  can  be  overcome  by  augmenting  the  amount  of  agonist,  but
such  agonist  increment  has  no  effect  on  the  effects  of  non-competitive  antagonists.  In‐
verse  agonists  reduce  the  basal  response  of  systems  with  constitutive  activity  (Fig.  2F,
blue curve).
5.2.2. Other methods
In  “hit”  selection  for  confirmatory  screens  with  single  concentration  of  compound  or
siRNA,  hypothesis  testing  is  a  commonly-used  method to  incorporate  sample  variabili‐
ty  of  each sample from its  replicates.  Therefore,  confirmatory screens (or  some primary
screens)  are  chosen  to  be  performed  in  replicates  to  statistically  calculate  the  signifi‐
cance  of  the  sample  activity  in  relation  to  a  negative  reference  group.  Since  previously
listed  Z-  and  robust  Z-score  methods  assume  that  the  variability  of  the  test  samples
and the  negative  controls  or  references  is  equal,  it  is  not  a  reliable  measure  for  confir‐
matory  screens  with  replicates,  where  the  sample  variability  can  be  individually  calcu‐
lated.  The  most  common  methods  to  analyze  screening  data  with  replicates  are  listed
below.
• t-test:  For “hit” selection in confirmatory screens,  t  statistics and the associated p  val‐
ue is  used to calculate if  a  sample compound or siRNA is  behaving significantly dif‐
ferent  than  the  majority  of  the  test  samples  or  controls.  A  t-test  determines  whether
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the  null  hypothesis,  which  is  the  mean of  a  test  sample  being  equal  to  the  mean of
the negative reference group, is  accepted or not.  Paired t-test  (first  pairing of the test
sample  and  reference  value  within  each  plate,  then  calculating  t  statistic  on  the
paired  values)  is  often  preferred  to  avoid  the  distortion  of  results  due  to  inter-plate
variability,  whereas unpaired t-test is used for global comparison of the sample repli‐
cates with all  reference values in the experiment (Zhang 2011a).  The p  value calculat‐
ed  from  t  statistic  is  then  used  to  determine  the  significance  of  the  sample  activity
compared to the reference.  An alternative to standard t-test,  namely randomized var‐
iance  model  (RVM) t-test  (Wright  and Simon 2003),  was  found to  be  more  advanta‐
geous  for  screens  with  few replicates  to  detect  relatively  less  strong  “hits” (Malo  et
al.  2010).
• SSMD: While t-test is a useful method to calculate the significance of the sample activ‐
ity  by  incorporating  its  variability  across  replicates,  it  lacks  the  ability  to  rank  the
samples  by  their  effect  sizes.  As  an  alternative  to  t-test,  SSMD-based  “hit”  selection
method for replicates was proposed to enable the calculation of RNAi effects as previ‐
ously  illustrated  in  (Zhang  2011a).  While  SSMD-based  method  is  more  robust  with
small  sample  sizes  as  opposed to  t-test  (Zhang 2008a),  at  least  4  replicates  is  recom‐
mended in  confirmatory  screens  to  identify  samples  with  moderate  or  higher  effects
(Zhang and Heyse 2009).
• Various other p value calculation methods (e.g., redundant siRNA activity, or RSA) (Ko‐
nig et al. 2007) and rank products method (Breitling et al. 2004)) are available, which can
be adapted to detect “hits” in RNAi screens (Birmingham et al. 2009).
6. Conclusion
HT screening is a comprehensive process to discover new drug targets using siRNA and
drug candidates from small molecule libraries. Statistical evaluation of the assay perform‐
ance is a very critical step in HT screening data analysis. A number of data analysis methods
have been developed to correct for plate-to-plate assay variability and systematic errors, and
assess assay quality. Statistical analysis is also pivotal in the “hit” selection process from pri‐
mary screens and in the evaluation during confirmatory screens. While some of these meth‐
ods may be intuitively applied using spreadsheet programs (e.g., Microsoft Excel), others
may require the development of computer programs using more advanced programming
environments (e.g., R, Perl, C++, Java, MATLAB). Besides commercially available compre‐
hensive analysis tools, there are also numerous open-access software packages designed for
HT screening data management and analysis for scientist with little or no programming
knowledge. A short compilation of freely available analysis tools is listed in Table 3. The





Web-based laboratory information management
system for management of library and screen
information
(Tolopko et al. 2010)
Java
MScreen
Web-based compound library and siRNA plate
management, QC and dose-response fitting tools
(Jacob et al. 2012)
PHP, Oracle/MySQL
NEXT-RNAi
Library design and evaluation tools for RNAi screens
(Horn et al. 2010)
Perl
K-Screen
Analysis, visualization, management and mining of
HT screening data including dose-response curve
fitting
(Tai et al. 2011)
R, PHP, MySQL
HTS-Corrector
Statistical analysis, visualization and correction of
systematic errors for all HT screens
(Makarenkov et al. 2006)
C#
web cellHTS2
Web-based analysis toolbox for normalization, QC,
“hit” selection and annotation for RNAi screens
(Boutros et al. 2006; Pelz et al. 2010)
R/Bioconductor project
RNAither
Automated pipeline for normalization, QC, “hit”
selection and pathway generation for RNAi screens
(Rieber et al. 2009)
R/Bioconductor project
HTSanalyzeR
Gene set enrichment, network and gene set
comparison analysis for post-processing of RNAi
screening data
(Wang et al. 2011)
R/Bioconductor project
Table 3. Examples of open-access software packages for library management and statistical analysis of HT screening
data.
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1. Introduction
Infectious diseases caused by parasites are a major threat for entire mankind, especially in
the tropics. These infections are not only restricted to humans, they are also predominant in
animal health. Just a few years ago infectious diseases caused by parasites were classified as
an issue of the past. Due to the elevating level of drug resistance of these pathogens against
the current chemotherapeutics, the need for new drugs became even more important. In
particular parasitic diseases such as malaria, leishmaniasis, trypanosomiasis, amoebiasis, tri‐
chomoniasis, soil-transmitted helminthiasis, filariasis and schistosomiasis are major health
problems, especially in “developing” areas (Renslo and McKerrow, 2006; Pal and Bandyo‐
padhyay, 2012). A variety of these parasitic diseases, which comprises the so called neglect‐
ed diseases Chagas disease, leishmaniasis, sleeping sickness, schistosomiasis, lymphatic
filariasis, onchocerciasis and of course malaria (Chatelain and Ioset, 2011), are transmitted
by vectors and therefore attempts to combat transmission became prominent. In contrast to
the treatment of bacterial infections with antibiotics there are no “general” antiparasitic
drugs. The use of a specific drug is dependent on the parasitic organism and therefore has to
be individually chosen (Khaw et al., 1995).
Reactive oxygen species (ROS) and oxidative stress are the inevitable consequences of aero‐
bic metabolism, with partially reduced and highly reactive metabolites of O2 being formed
in the mitochondria (Andreyev et al., 2005) or as by-products of other cellular sources such
as the cytoplasm, the endoplasmatic reticulum, the plasma membrane and peroxisomes.
Furthermore, environmental agents such as ionizing and UV radiation or xenobiotic expo‐
sure can generate intracellular ROS. O2 metabolites include superoxide anion (O2-) and hy‐
drogen peroxide (H2O2), formed by one- and two electron reductions of O2 or the highly
reactive hydroxyl radical (‧OH) which is formed in the presence of metal ions via Fenton
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an issue of the past. Due to the elevating level of drug resistance of these pathogens against
the current chemotherapeutics, the need for new drugs became even more important. In
particular parasitic diseases such as malaria, leishmaniasis, trypanosomiasis, amoebiasis, tri‐
chomoniasis, soil-transmitted helminthiasis, filariasis and schistosomiasis are major health
problems, especially in “developing” areas (Renslo and McKerrow, 2006; Pal and Bandyo‐
padhyay, 2012). A variety of these parasitic diseases, which comprises the so called neglect‐
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drugs. The use of a specific drug is dependent on the parasitic organism and therefore has to
be individually chosen (Khaw et al., 1995).
Reactive oxygen species (ROS) and oxidative stress are the inevitable consequences of aero‐
bic metabolism, with partially reduced and highly reactive metabolites of O2 being formed
in the mitochondria (Andreyev et al., 2005) or as by-products of other cellular sources such
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Furthermore, environmental agents such as ionizing and UV radiation or xenobiotic expo‐
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and/or Haber-Weiss reactions (Massimine et al., 2006). At physiologically low levels, ROS
can function as second messenger in redox signaling, with H2O2 best providing the specifici‐
ty in its interaction with effectors in signaling processes (Forman et al., 2010). Balancing the
generation and elimination of ROS maintains the proper function of redox-sensitive signal‐
ling proteins. However, severe increases of ROS induce oxidative modifications in the cellu‐
lar macromolecules DNA, proteins and lipids, this leading to a disruption of redox
homeostasis and irreversible oxidative damage (Trachootham et al., 2008). Depending on
the cellular context, the levels of ROS and the redox state of the cells, alterations of the deli‐
cate redox balance can promote cell proliferation and survival or induce cell death.
To maintain redox homeostasis and eliminate ROS, aerobes are equipped with enzymatic/
nonenzymatic antioxidants and metal sequestering proteins to either prevent or intercept
the formation of pro-oxidants. Furthermore, protective mechanisms are put in place to re‐
pair and replace damaged macromolecules. Two central thiol/disulfide couples are involved
in controlling the redox state of the cell: glutathione/glutathione disulfide (GSH/GSSG) is the
major redox couple that determines the antioxidative capacity of cells, other redox couples
include the active site dithiol/disulfide of thioredoxins (Trxred/Trxox) interacting with a differ‐
ent subset of proteins and thus forming a distinct but complementary redox system (Jones
and Go, 2010).
Enzymatic antioxidants can be categorized into primary or secondary antioxidants, the first
reacting directly with pro-oxidants (e.g. catalase, superoxide dismutase), the latter are in‐
volved in the regeneration of low molecular weight antioxidant species (Halliwell, 1999).
Here, the reduced state of GSSG and Trx-enzymes is restored by the glutathione reductase
(GSR) and the Trx reductase using electrons obtained from NADPH. Additionally glutare‐
doxins (Glrx) utilize GSH for the reduction of intracellular disulfides (Fernandes and
Holmgren, 2004). While Trx, Trx reductase and Trx peroxidase (peroxiredoxin, Prx) consti‐
tute the Trx-system, the versatile GSH-system includes enzymes required for GSH synthesis
and recycling, for its use in metabolism, in defense against ROS-induced damage and in a
multitude of detoxification processes. Furthermore, for normal GSH turnover and disposi‐
tion of GSH-conjugated metabolites and xenobiotics, export from the cell is required that is
carried out by GSH efflux transporters and pumps (Sies, 1999) (Fig. 1).
In spite of the diversity of parasites, all are faced with similar biological problems that are
related to their lifestyle. Besides coping with ROS levels generated from intrinsic sources, all
have to deal with the oxidative stress imposed by the host´s immune response. Furthermore,
parasites are faced with ROS that are produced during the epithelial innate immune re‐
sponse of their vector, by vector-resident gut bacteria (Cirimotich et al., 2011) or during mel‐
anotic encapsulation processes (Kumar et al., 2003).
Since the redox system plays such a fundamental and indispensable role for parasite surviv‐
al within their host (Massimine et al., 2006), drugs that either promote ROS generation or
inhibit cellular antioxidant systems will lead to redox imbalance by pushing ROS levels
above a certain threshold level that will ultimately lead to parasite death (Müller et al.,
2003). In general, drugs that target vital redox reactions or promote oxidative stress are
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named redox-active antiparasitic drugs (Seeber et al., 2005) on which we will mainly focus
within this chapter.
2. The role of the antioxidant system in Leishmania
Leishmaniasis is caused by the protozoan flagellate Leishmania which is transmitted by sand‐
flies of the genus Phlebotomus (Sharma and Singh, 2008). There are several species of the ge‐
nus Leishmania which are known to cause this infectious disease. Leishmaniasis shows a
broad spectrum of clinical manifestations and includes visceral, cutaneous and mucocutane‐
ous leishmaniasis. Whereas the two latter ones are not considered to be lethal (Herwaldt,
1999), infection with Leishmania donovani/infantum – resulting in kala azar or visceral leish‐
maniasis - can be lethal without treatment. Although treatment of leishmaniasis with che‐
motherapeutics is the only current option, drug resistance to first-line drugs is increasing
which is accompanied by frequently occurring toxic side effects and by the high cost of
treatment (Van Assche et al., 2011). Additionally, the small number of novel drugs com‐
bined with the low number of identified and subsequently validated number of Leishmania
drug targets in clinical use, reveals an alarming situation for the current status in chemother‐
apy. The predominant target for the application of chemotherapy is the amastigote stage
which proliferates intracellularly in tissue macrophages (Dedet et al., 2009), thereby hinder‐
ing the accessibility of antileishmanial drugs to the pathogen.
3. Antimonials
Despite the fact that antimonials were already identified in 1921, they still remain the first-
line treatment, although the precise mode of action is not known. But it is generally accepted
that pentavalent antimonials (SbV) represent a pro-drug which is converted to trivalent anti‐
monials (SbIII) for antileishmanial activity. Recently it has been indicated that thiols act as re‐
ducing agents in this conversion. Furthermore, the participation of a unique parasite-specific
trimeric glutathione transferase TDR1 in the activation of antimonial prodrugs has been sug‐
gested (Fyfe et al., 2012).
Treatment with antimonials requires parenteral administration and is accompanied by toxic
side effects such as cardiac arrhythmia and acute pancreatitis (Sundar and Rai, 2002). Some
studies have been carried out to investigate the activity mechanism of antimonials which
correlates with an interference with the antioxidant defence system of the parasite: Trivalent
antimonials decrease the thiol-reducing capacity of Leishmania by inducing an efflux of try‐
panothione. In contrast to Leishmania, mammalian cells depend on GSH to control their in‐
tracellular thiol-redox status. Here, ROS and oxidized cell components are efficiently
reduced by GSH, thereby generating GSSG. The glutathione disulfide form can then be re‐
generated by the GSR (Monostori et al., 2009). In contrast, the redox metabolism of Leishma‐
nia relies on a modified GSH-system, N1,N8-bis(l-γ-glutamyl-l-hemicystinylglycyl)
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monials (SbIII) for antileishmanial activity. Recently it has been indicated that thiols act as re‐
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trimeric glutathione transferase TDR1 in the activation of antimonial prodrugs has been sug‐
gested (Fyfe et al., 2012).
Treatment with antimonials requires parenteral administration and is accompanied by toxic
side effects such as cardiac arrhythmia and acute pancreatitis (Sundar and Rai, 2002). Some
studies have been carried out to investigate the activity mechanism of antimonials which
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antimonials decrease the thiol-reducing capacity of Leishmania by inducing an efflux of try‐
panothione. In contrast to Leishmania, mammalian cells depend on GSH to control their in‐
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spermidine, also known as trypanothione (Fairlamb et al., 1985). The oxidised form, trypa‐
nothione disulfide, is generated when trypanothione reduces ROS and its reconversion is
catalysed by the trypanothione reductase. Antimonials inhibit this enzyme, leading to an ac‐
cumulation of trypanothione disulfide, which subsequently is not accessible for the reduc‐
tion of ROS (Krauth-Siegel and Comini, 2008). The influence of antimonials on the parasite's
redox biology has been verified on cellular level by the fact that trivalent antimonials-resist‐
ant parasites display an increased IC50-value for nitric oxide donors such as NaNO2, SNAP,
and DETA NONOate compared to antimonial-sensitive strains (Souza et al., 2010; Holzmül‐
ler et al., 2005; Vanaerschot et al., 2010). Whether nitric oxide resistance is due to elevated
trypanothione levels or due to another antioxidant mode of action is not yet clear.
4. Amphotericin B
Amphotericin B (Fig. 2), a polyene macrolide, has been employed in the treatment of Leish‐
mania since 1960, but just as a second-line drug. This drug exhibits an excellent antileishma‐
nia activity with more than 90% cure rates. Because the pure compound creates severe side
effects and requires long-term treatment and extensive monitoring, liposomal application of
amphotericin B is used at the moment which results in cure rates of 3–5 days (up to 100%), is
convenient for the patient and is less expensive (Gradoni et al., 2008; Manandhar et al., 2008;
Sundar et al., 2002; Thakur et al., 1996). The mode of action can be explained based on its
chemical structure, polyene macrolide has been shown to bind to ergosterol, one of the main
sterols within Leishmania membranes. Interference with this molecule results in an increas‐
ing permeability of the cell membrane which leads to the parasite’s death (Balana-Fouce et
al., 1998; Amato et al., 2008). Additionally there is some evidence that amphotericin B has an
effect on the oxidative response of macrophages (Mukherjee et al., 2010), however further
experiments are required to verify this effect.
5. Miltefosine
Miltefosine (hexadecylphosphocholine) is the first and currently the only, orally adminis‐
tered antileishmanial drug (Fig. 2). However, despite cure rates of up to 98% (Roberts, 2006),
the drug reveals serious side effects such as vomiting, diarrhea and can cause abnormal
physiological development of the foetus. Furthermore, the drug has a relatively long half-
life of about 150 hours (Seifert et al., 2007; Maltezou, 2010) which could lead to the develop‐
ment of rapid resistance. Related to its structure, the drug possibly interferes with
membranes and membrane-linked enzymes. Currently no verified implications of the drug
within the redox biology of the parasite have been found (Rakotomanga et al., 2004; Saint-
Pierre-Chazalet et al., 2009).
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6. Oxidative chemotherapeutic intervention
of Trypanosoma infections
Trypanosoma  infections,  caused  by  the  flagellate  protozoan  Trypanosoma  are  responsible
for  a  high  degree  of  health  problems  in  endemic  countries.  They  can  be  divided  into
two types  of  pathogens:  Trypanosoma  cruzi,  the  causative  agent  of  Chagas  disease,  also
known as  American trypanosomiasis,  since  it  occurs  in  Latin  America  and Trypanosoma
brucei  ssp.,  the  causative  agent  of  sleeping  sickness,  or  human African  trypanosomiasis,
since it is endemic to sub-Saharan Africa. The current medication is known for its toxici‐
ty, poor activity in immune-suppressed patients and long-term treatment combined with
high costs. Moreover, vaccines are not foreseeable in the near future. The T. cruzi life cy‐
cle includes three fundamental forms characterized by the relative positions of the flagel‐
lum, kinetoplast and nucleus: Trypomastigotes,  epimastigotes and amastigotes,  the latter
one  characterized  by  their  proliferation  in  any  nucleated  cell  (Prata,  2001).  On  the  one
hand  Chagas'  disease  is  controlled  through  elimination  of  its  vectors  by  using  insecti‐
cides and on the other side by chemotherapy.  Currently,  the drugs used are nifurtimox
(4[(5-nitrofurfurylidene)amino]-3-methylthiomorpholine-1,1-dioxide),  derived  from  nitro‐
furan, and benznidazole (N-benzyl-2-nitroimidazole-1-acetamide),  a nitroimidazole deriv‐
ative.  Nifurtimox and benznidazole (Fig.  2)  are trypanocidal to all  forms of the parasite
(Rodriques  Coura  and de  Castro,  2002).  However,  severe  side  effects  and toxicity  have
been observed (Kirchhoff, 2000). In addition, there are also reports of mutagenesis result‐
ing  in  DNA damage  (Zahoor  et  al.,  1987).  An  additional  aspect  that  complicates  treat‐
ment  is  the  different  susceptibility  of  different  parasite  strains  to  the  applied
chemotherapeutics  (Filardi  and  Brener,  1987).  The  mode  of  action  of  nifurtimox  and
benznidazole  (Fig.  2)  is  via  the  formation  of  free  radicals  and/or  charged  metabolites.
The nitro group of both drugs is reduced to an amino group by the catalysis of nitro-re‐
ductases,  leading  to  the  formation  of  various  free  radical  intermediates.  Cytochrome
P450-related  nitro-reductases  initiate  this  process  by  producing  a  nitro  anion  radical
(Moreno  et  al.,  1982).  Subsequently,  the  radical  reacts  with  oxygen,  which  regenerates
the  drug  (Mason  and  Holtzman,  1975).  For  example,  nifurtimox-derived  free  radicals
may undergo redox cycling with O2,  thereby producing H2O2 in a reaction catalysed by
the  SOD (Temperton et  al.,  1998).  Furthermore,  in  the  presence  of  Fe3+  the  highly  reac‐
tive ‧OH is also being formed according to the Haber-Weiss reaction. These free radicals
can subsequently bind to cellular macromolecules such as lipids,  proteins and DNA, re‐
sulting in severe damage of parasitic cells (Díaz de Toranzo et al.,  1988). In contrast, the
trypanocidal effect of benznidazole does not depend on ROS but it is likely that reduced
metabolites  of  benznidazole  are  covalently  binding  to  cellular  macromolecules,  thereby
revealing their trypanocidal effect (Díaz de Toranzo et al., 1988; Maya et al., 2004). Addi‐
tionally,  it  has  been  demonstrated  that  benznidazole  inhibits  the  T.  cruzi  NADH-fuma‐
rate reductase (Turrens et al., 1996).
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chemical structure, polyene macrolide has been shown to bind to ergosterol, one of the main
sterols within Leishmania membranes. Interference with this molecule results in an increas‐
ing permeability of the cell membrane which leads to the parasite’s death (Balana-Fouce et
al., 1998; Amato et al., 2008). Additionally there is some evidence that amphotericin B has an
effect on the oxidative response of macrophages (Mukherjee et al., 2010), however further
experiments are required to verify this effect.
5. Miltefosine
Miltefosine (hexadecylphosphocholine) is the first and currently the only, orally adminis‐
tered antileishmanial drug (Fig. 2). However, despite cure rates of up to 98% (Roberts, 2006),
the drug reveals serious side effects such as vomiting, diarrhea and can cause abnormal
physiological development of the foetus. Furthermore, the drug has a relatively long half-
life of about 150 hours (Seifert et al., 2007; Maltezou, 2010) which could lead to the develop‐
ment of rapid resistance. Related to its structure, the drug possibly interferes with
membranes and membrane-linked enzymes. Currently no verified implications of the drug
within the redox biology of the parasite have been found (Rakotomanga et al., 2004; Saint-
Pierre-Chazalet et al., 2009).
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6. Oxidative chemotherapeutic intervention
of Trypanosoma infections
Trypanosoma  infections,  caused  by  the  flagellate  protozoan  Trypanosoma  are  responsible
for  a  high  degree  of  health  problems  in  endemic  countries.  They  can  be  divided  into
two types  of  pathogens:  Trypanosoma  cruzi,  the  causative  agent  of  Chagas  disease,  also
known as  American trypanosomiasis,  since  it  occurs  in  Latin  America  and Trypanosoma
brucei  ssp.,  the  causative  agent  of  sleeping  sickness,  or  human African  trypanosomiasis,
since it is endemic to sub-Saharan Africa. The current medication is known for its toxici‐
ty, poor activity in immune-suppressed patients and long-term treatment combined with
high costs. Moreover, vaccines are not foreseeable in the near future. The T. cruzi life cy‐
cle includes three fundamental forms characterized by the relative positions of the flagel‐
lum, kinetoplast and nucleus: Trypomastigotes,  epimastigotes and amastigotes,  the latter
one  characterized  by  their  proliferation  in  any  nucleated  cell  (Prata,  2001).  On  the  one
hand  Chagas'  disease  is  controlled  through  elimination  of  its  vectors  by  using  insecti‐
cides and on the other side by chemotherapy.  Currently,  the drugs used are nifurtimox
(4[(5-nitrofurfurylidene)amino]-3-methylthiomorpholine-1,1-dioxide),  derived  from  nitro‐
furan, and benznidazole (N-benzyl-2-nitroimidazole-1-acetamide),  a nitroimidazole deriv‐
ative.  Nifurtimox and benznidazole (Fig.  2)  are trypanocidal to all  forms of the parasite
(Rodriques  Coura  and de  Castro,  2002).  However,  severe  side  effects  and toxicity  have
been observed (Kirchhoff, 2000). In addition, there are also reports of mutagenesis result‐
ing  in  DNA damage  (Zahoor  et  al.,  1987).  An  additional  aspect  that  complicates  treat‐
ment  is  the  different  susceptibility  of  different  parasite  strains  to  the  applied
chemotherapeutics  (Filardi  and  Brener,  1987).  The  mode  of  action  of  nifurtimox  and
benznidazole  (Fig.  2)  is  via  the  formation  of  free  radicals  and/or  charged  metabolites.
The nitro group of both drugs is reduced to an amino group by the catalysis of nitro-re‐
ductases,  leading  to  the  formation  of  various  free  radical  intermediates.  Cytochrome
P450-related  nitro-reductases  initiate  this  process  by  producing  a  nitro  anion  radical
(Moreno  et  al.,  1982).  Subsequently,  the  radical  reacts  with  oxygen,  which  regenerates
the  drug  (Mason  and  Holtzman,  1975).  For  example,  nifurtimox-derived  free  radicals
may undergo redox cycling with O2,  thereby producing H2O2 in a reaction catalysed by
the  SOD (Temperton et  al.,  1998).  Furthermore,  in  the  presence  of  Fe3+  the  highly  reac‐
tive ‧OH is also being formed according to the Haber-Weiss reaction. These free radicals
can subsequently bind to cellular macromolecules such as lipids,  proteins and DNA, re‐
sulting in severe damage of parasitic cells (Díaz de Toranzo et al.,  1988). In contrast, the
trypanocidal effect of benznidazole does not depend on ROS but it is likely that reduced
metabolites  of  benznidazole  are  covalently  binding  to  cellular  macromolecules,  thereby
revealing their trypanocidal effect (Díaz de Toranzo et al., 1988; Maya et al., 2004). Addi‐
tionally,  it  has  been  demonstrated  that  benznidazole  inhibits  the  T.  cruzi  NADH-fuma‐
rate reductase (Turrens et al., 1996).
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7. Approaches to increase oxidative stress within the malaria parasite
Malaria is a devastating and quite often a deadly parasitic disease, which causes important
public health problems in the tropics. The population in more than 90 countries, with more
than 2000 million citizens, is exposed to the infection. Malaria infection is responsible for an
estimated 500 million clinical cases per annum, causing more than one million deaths; most
of these are children in Africa. The malaria parasite Plasmodium falciparum, the causative
agent of Malaria tropica, is proliferating within human red blood cells, thereby exploiting
host’s nutrient sources and hiding from the human immune response. A vaccine is not avail‐
able and the control of the disease depends solely on the administration of a small number
of drugs. Due to mutational modification of the genome of the malaria parasite, an ongoing
rapid adaptation to environmental changes and drug resistance is occurring (Greenwood et
al., 2008). At the moment – which is just a question of time - solely artemesinin is still effec‐
tive against the malaria parasite. However, first reports already demonstrated drug resist‐
ance against artemisinin (Wangroongsarb et al., 2011). Therefore, continuous discovery and
development of new drugs are urgently needed. A variety of the current anti-malaria drugs
are targeting the redox balance of the parasite. As outlined above, redox systems are essen‐
tial for the intracellular proliferation of the plasmodial pathogen.
In general, P. falciparum uses the two interacting systems, GSH- and TRX-system, to protect
against reactive ROS (Kanzok et al., 2002; Kanzok et at., 2000; Kawazu et al., 2001; Kehr et
al., 2011; Krnajski et al., 2001; Krnajski et al., 2002; Kumar et al., 2008; Liebau et al., 2002).
Both systems can be link by the redox protein plasmoredoxin (Becker et al., 2003). Active in‐
terference by employing redox-active antiparasitic drugs, however, harms the parasite and
results in its death. Compounds which disturb the redox balance can be categorised into
three different groups: (i) molecules that are responsible for the de novo synthesis of ROS and
thus lead to parasite death, (ii) molecules which inhibit the activities of redox balancing en‐
zymes and (iii) molecules that interfere in the scavenging of pro-oxidant metabolic products
like hemozoin.
8. Molecules which inhibit the activities of redox balancing enzymes
The GSH-system plays an important role in the maintenance of the redox status in Plasmodi‐
um (Kehr et al., 2011). It is involved in detoxifying free heme (ferriprotoporphyrin IX)
(Atamna et al., 1995; Müller, 2003) and in the termination of radical-based chain reactions
(Frey, 1997). Therefore, enzymatic reactions within this system are highly druggable. The
GSR is one of the key enzymes of the GSH-system and consequently several compounds
have been synthesized to successfully interfere with its catalysis in vitro and in vivo (Biot et
al., 2004; Gallo et al., 2009; Grellier et al., 2010; Muller et al., 2011). Inhibitory compounds
comprise for example isoalloxazines, quinacrines, tertiary amides that reveal antimalarial ac‐
tivity at low doses against the chloroquine sensitive P. falciparum strain 3D7 (Sarma et al.,
2003; Friebolin et al., 2008; Chibale et al., 2001). Methylene blue (Fig. 2), a noncompetitive
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inhibitor of the P. falciparum GR, shows antiplasmodial activity against all blood stage forms,
whereas only a marginal cytotoxic effect against mammalian cells has been reported (Biot et
al., 2004; Buchholz et al., 2008; Atamna et al., 1996; Akoachere et al., 2005; Badyopadhyay et
al., 2004; Krauth-Siegel et al., 2005; Garavito et al., 2007).
The GST is one of the most abundant proteins expressed in P. falciparum. Additionally to its
detoxifying role, it efficiently binds parasitotoxic heme not only in the presence of GSH, but
also when GSSG is present, thereby protecting the parasite from hemin even under severe
oxidative stress conditions. Here, a peculiar loop region, that is both crucial for the gluta‐
thione-dependent tetramerization/inactivation process and for hemin-binding, represents an
ideal drug target (Liebau et al., 2005; 2009). Recently chemical synthesis to design effective
compounds to target GST has been performed which show some promising antiplasmodial
activity (Ahmad et al., 2007; Sturm et al., 2009). Furthermore, the development of drugs that
overcome resistance to available antimalarial drugs also are of great interest. The action of
multidrug resistance protein (MRP)-like transporters is associated with the efflux of xenobi‐
otics in both unaltered and GSH-conjugated form and it is conceivable that they are in‐
volved in the development of drug resistance in malarial parasites (Koenderink et al., 2010).
Since coordinated expression and synergistic interactions between GST and efflux pumps
have been observed (Sau et al., 2010), a promising new intervening strategy might be the in‐
hibition of GST and/or the development of GST-activated pro-drugs that overcome drug re‐
sistance by blocking the drug binding sites of the transporters.
Another promising antimalarial drug target is the P. falciparum TrxR (Banerjee et al., 2009).
Chalcone derivatives and Eosin B exhibit antiplasmodial activity by inhibiting the plasmo‐
dial TrxR (Li et al., 1995; Massimine et al., 2006).
For many years it was thought that the malaria parasite had no need for an endogenous
SOD and simply adopted the host´s enzyme for its purpose. However, in 2002, an iron-de‐
pendent SOD was described in P. falciparum (Boucher et al., 2006). Being quite distinct from
the human tetrameric Mn and Cu/Zn SOD, it is exploited as anti-malaria drug target (Sou‐
lere et al., 2003).
9. Drugs inhibiting hemozoin formation and thereby inducing oxidative
stress
Besides the attacks of the immune systems of the respective host, where ROS are deployed to
kill invading pathogens, the parasite faces another even bigger challenge: Plasmodium relies al‐
so on the digestion of human haemoglobin to obtain amino acids for its metabolism (Sherman,
1977). Haemoglobin is the major protein inside the erythrocyte and the parasite has evolved a
unique pathway to utilise this molecule (Muller et al., 2011). Heme is the degradation product
of haemoglobin, which has to be detoxified and stored as hemozoin within the food vacuole of
the parasite – the place where the haemoglobin degradation occurs. Non-detoxified heme is
extremely toxic (Papalexis et al., 2001) and leads not only to the generation of H2O2, ‧OH and O2-.
(Francis et al., 1997), but also to the highly reactive, non-radical molecule, singlet oxygen (1O2)
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(Freinbicherler et al., 2011). Moreover, one 1O2 molecule can be either synthesised by the reac‐
tion of ‧OH and O2-. or two O2-. with two hydrogen ions (Khan and Kasha, 1994). In order to de‐
toxify these ROS, Plasmodium has developed – as outlined above - multiple antioxidant defence
systems. However - excluding the membrane located lipophilic tocopherol (vitamin E) (Wang
and Quinn, 1999) - none of the above mentioned defense systems are capable to detoxify 1O2.
The fact that vitamin B6 is linked to the defense against 1O2 in plants and fungi (Tambasco-Stu‐
dart et al., 2005; Ehrenshaft et al., 1999), suggests that the vitamin B6 biosynthesis might also
play a yet unrecognized role in combating 1O2 in the malaria parasite P. falciparum. Very recent‐
ly this role of 1O2 detoxification has been verified in the malaria parasite (Wrenger et al., 2005;














































Figure 1. Schematic illustration of the glutathione (GSH) system. GSH homeostasis involves intra- and extracellular
mechanisms. GSH is synthesized from amino acids (AA) by the action of γ-glutamylcysteine synthetase (γ-GCS) and
glutathione synthase (GSH-S), both requiring ATP. As antioxidant, GSH participates in the reduction of peroxides, cata‐
lysed by glutathione peroxidase (GPx), in the reduction of protein-disulfides, catalysed by glutaredoxins (Grx) and in
conjugation reactions with electrophils (eg. xenobiotics, X), catalysed by glutathione transferases (GSTs). The gluta‐
thione conjugates (GS-X) and GSSG are transported out of the cell via GS-X/GSSG pumps. The NADPH-dependent GSH
reductase (GR) is responsible for the intracellular recycling of GSH, while extracellular GSH gets sequentially hydro‐
lysed by γ-glutamyl transpeptidase (γ-GT) and dipeptidase (DPD), with glutamate, cysteine and glycine being recycled
for GSH synthesis (γ-glutamyl cycle).
A number of drugs have been identified that act as inhibitors of the hemozoin formation
by binding to  heme.  This  leads  to  an accumulation of  free  heme,  causes  high levels  of
oxidative stress  and ends in  the death of  the parasite  (Meunier  et  al.,  2010).  Quinoline-
containing derivatives such as amopyroquine,  amodiaquine,  tebuquine,  halofantrine,  py‐
ronaridine,  quinine,  mepacrine,  epiquinine,  quinidine,  bisquinoline  chloroquine  (see
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figure  2)  are  highly  potent  antimalarials  that  inhibit  hemozoin formation at  EC50-values
in the low nano-molar range (Egan et al.,  2000; Kotecka et al.,  1997; O’Neill  et  al.,  2003;
Vennerstrom et  al.,  1992).  Azole  derivatives  are  also  inhibitors  of  the  hemozoin  forma‐
tion  and  reveal  efficacy  against  chloroquine  sensitive  as  well  as  resistant  plasmodial
strains (Banerjee et al., 2009; Rodrigues et al., 2011). Another novel class, which has been
identified  to  interact  with  heme and thereby prevent  the  hemozoin  formation,  are  xan‐
thones  (Docampo et  al.,  1990;  Ignatushchenko et  al.,  1997;  Xu Kelly  et  al.,  2001).  More‐
over,  a  variety of  isonitrile  derivatives gain their  antimalarial  activity from inhibition of
the hemozoin synthesis (Kumar et  al.,  2007;  Wright et  al.,  2001) resulting in EC50-values
in the low nano-molar range (Badyopadhyay et al., 2001; Singh et al., 2002; Kumar et al.,
2007).  Benzylmenadione  derivatives  do  not  show  any  cytotoxicity  against  two  human
cell  lines  while  they  are  effective  against  the  chloroquine  resistant  P.  falciparum  strain
Dd2  (Muller  et  al.,  2011).  The  precise  mode  of  action  of  benzylmenadione  remains  for
elucidation,  but  it  has  been suggested that  the molecule  is  initially  oxidized to  a  naph‐
thoquinone derivative within the food vacuole of  the parasite which leads subsequently
to the inhibition of the hemozoin formation (Davioud-Charvet et al., 2003).
10. Druggability of oxidative stress systems in helminths
Helminths are parasitic worms that encompass nematodes (roundworms), cestodes and
trematodes (flatworms) and affect humans in all areas of the world, with more than one-
third of humans harbouring these parasites that cause chronic, debilitating morbidity. Fur‐
thermore, co-endemicity and polyparasitism increase the burden of millions (Hotez et al.,
2008). In the absence of vaccines, control relies on pharmacotherapy and pharmacoprophy‐
laxis to easy symptoms and reduce transmission. Helminthosis are treated with a limited
number of anthelmintics by chemotherapy of symptomatic individuals or, more general, by
control programmes that rely on mass drug administration (MDA) and require annual or bi‐
annual treatment of at-risk populations over prolonged period of time (Prichard et al., 2012).
A major problem, however, is the development of resistance or tolerance by the parasites to
these common antiparasitic drugs (Vercruysse et al., 2011). It is therefore essential to under‐
stand the underlying mechanisms of drug resistance and find new drugs to circumvent it.
Praziquantel has been used for over 20 years to treat a variety of human trematode infec‐
tions. Its precise mechanism of action has not been fully elucidated, however, there is exper‐
imental evidence that praziquantel acts by increasing the permeability of cell membranes
towards calcium ions and/or by interfering with adenosine uptake (Jeziorski and Greenberg,
2006; Angelucci et al., 2007). Furthermore, it has been suggested that praziquantel reduces
GSH concentrations, making the parasite more susceptible to the host immune response
(Ribeiro et al., 1998). Interestingly, exposure to sub-lethal concentrations of praziquantel
shows that schistosomes undergo a transcriptomic response similar to that observed during
oxidative stress (Aragon et al., 2009).
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(Freinbicherler et al., 2011). Moreover, one 1O2 molecule can be either synthesised by the reac‐
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oxidative stress (Aragon et al., 2009).
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Figure 2. Molecular structures of chemotherapeutics which are used to treat infectious disease by generating directly
or indirectly high levels reactive oxygen species.
Reliance on a single drug for mass treatment is risky. Therefore, anti-schistosomiasis drug
development is on the way to identify new compounds with different modes of action. Re‐
cently it was demonstrated that artemisinin-based compounds (e.g. artemether, figure 2) are
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active against immature stages of schistosomes. Although a number of potential drug tar‐
gets have been proposed, the mode of action remains ambiguous (O´Neill et al., 2010). It is
thought that the primary activator of the drug is an iron source. Therefore, interaction with
heme in the worm gut has been suggested, leading to the formation of an unstable species
that generates ROS and thus kills the worm (Utzinger et al., 2001). Since artemisinins are
critically important for malaria chemotherapy, they are not available for MDA.
Schistosomes seem to be poorly adapted to cope with oxidative stress. This is surprising,
since they have to deal with host-immune and self-generated ROS and, furthermore, with
ROS generated during the consumption of host haemoglobin (Huang et al., 2012).The highly
restricted antioxidant network has been widely accepted as an excellent drug target for
schistosomes and other platyhelminths, since it is unique and differs significantly from the
human host. Interestingly, the parasites have merged the Trx- and GSH-system using a hy‐
brid enzyme, the thioredoxin-glutathione reductase (TGR) (Salinas et al., 2004, Huang et al.,
2012). Using RNA interference, the TGR was found to be essential for parasite survival
(Kuntz et al., 2007). TGR was indicated to be the main target of schistosomicidal drugs used
in the past (antimonyl potassium tartrate and oltipraz) and of the anti-arthritic drug aurano‐
fin (Fig. 2), with a significant worm reduction observed in infected mice (Kuntz et al., 2007;
Angelucci et al., 2009). A quantitative high-throughput screen identified highly potent lead
compounds against the Schistosoma TGR (Simeonov et al., 2008), with low inhibitory con‐
stants being found with derivatives of phosphinic amides, isoxazolones and the oxadia‐
zole-2-oxide chemotype (Furoxan) (Fig. 2) (Huang et al., 2012).
Preventive chemotherapy is the mainstay in the control of human soil-transmitted helmin‐
thiasis (STH). STH is primarily caused by the nematodes Ancylostoma duodenale and Necator
americanus (hookworms), Ascaris lumbricoides (roundworm) and Trichuris trichiura (whip‐
worm) that parasitize the human gastrointestinal tract. Four anthelminthics that exhibit a
broad spectrum of activity are currently recommended by the World Health Organization:
The benzimidazoles albendazole and mebendazole, the synthetic phenylimidazolthiazole le‐
vamisole and the pyrimidine derivative pyrantel pamoate. While benzimidazoles bind to
free β-tubulin, leading to tubule capping and degradation (Beech et al., 2011), the choliner‐
gic agonist levamisole activates ligand-gated acetylcholine receptors (Lewis et al., 1980) and
the pyrimidine derivative pyrantel pamoate induces persistent activation of nicotinic acetyl‐
choline receptors (Utzinger and Keiser, 2004). The GABA agonist piperazine, the nicotinic
acetylcholine receptor agonist tribendimidine are further drugs used in STH. Currently nei‐
ther drug class used to control or treat STH, has been implicated as influencing the redox
biology of parasites. Instead, most of the currently used or proposed drugs (Olliaro et al.,
2011) of gastro-intestinal nematodes affect ion channel function of the neuromuscular syn‐
apses. These neuroactive drugs cause paralysis of the worm and result in its rapid expulsion
or killing.
Filarial parasites are classified according to the habitat of the adult worms in the vertebral
host, with the cutaneous (Loa loa and Onchocerca volvulus) and lymphatic (Wuchereria bancrof‐
ti, Brugia malayi and Brugia timori) groups being the most clinically significant. Chemothera‐
peutic approaches to control parasite transmission and to treat onchocerciasis rely on the
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critically important for malaria chemotherapy, they are not available for MDA.
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2012). Using RNA interference, the TGR was found to be essential for parasite survival
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zole-2-oxide chemotype (Furoxan) (Fig. 2) (Huang et al., 2012).
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thiasis (STH). STH is primarily caused by the nematodes Ancylostoma duodenale and Necator
americanus (hookworms), Ascaris lumbricoides (roundworm) and Trichuris trichiura (whip‐
worm) that parasitize the human gastrointestinal tract. Four anthelminthics that exhibit a
broad spectrum of activity are currently recommended by the World Health Organization:
The benzimidazoles albendazole and mebendazole, the synthetic phenylimidazolthiazole le‐
vamisole and the pyrimidine derivative pyrantel pamoate. While benzimidazoles bind to
free β-tubulin, leading to tubule capping and degradation (Beech et al., 2011), the choliner‐
gic agonist levamisole activates ligand-gated acetylcholine receptors (Lewis et al., 1980) and
the pyrimidine derivative pyrantel pamoate induces persistent activation of nicotinic acetyl‐
choline receptors (Utzinger and Keiser, 2004). The GABA agonist piperazine, the nicotinic
acetylcholine receptor agonist tribendimidine are further drugs used in STH. Currently nei‐
ther drug class used to control or treat STH, has been implicated as influencing the redox
biology of parasites. Instead, most of the currently used or proposed drugs (Olliaro et al.,
2011) of gastro-intestinal nematodes affect ion channel function of the neuromuscular syn‐
apses. These neuroactive drugs cause paralysis of the worm and result in its rapid expulsion
or killing.
Filarial parasites are classified according to the habitat of the adult worms in the vertebral
host, with the cutaneous (Loa loa and Onchocerca volvulus) and lymphatic (Wuchereria bancrof‐
ti, Brugia malayi and Brugia timori) groups being the most clinically significant. Chemothera‐
peutic approaches to control parasite transmission and to treat onchocerciasis rely on the
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macrocyclic lactone ivermectin, an effective and safe microfilaricide (Basáňez et al., 2008).
Ivermectin is an agonist of ligand-gated Cl− channels, with particular activity against gluta‐
mate-gated Cl− channels of invertebrates (Martin et al., 1997). While ivermectin is less effec‐
tive against adult worms, it causes reproductive quiescence and disappearance of
microfilaria from skin or blood. Interestingly, cultured microfilariae are unaffected by iver‐
mectin at concentrations found in treated patients (Bennett et al., 1993), making interference
of the drug with protective mechanisms employed against the human immune response fea‐
sible (Geary et al., 2010). The development of ivermectin-resistant strains of Caenorhabditis
elegans has shown that resistance to low levels of ivermectin is associated with an increased
expression of drug efflux pumps and an increase in GSH-synthesis and -conjugation is ob‐
served. Since the overall levels of glutathione decrease, increased drug conjugation and re‐
moval from the cells is suggested (James and Davey, 2009). In a recent study, ivermectin has
been identified as a cytotoxic agent to leukemia cells and a previously unknown indirect in‐
fluence of ivermectin on the intracellular redox balance was demonstrated. Mechanistically,
ivermectin induced chloride influx, membrane hyperpolarization, and generated ROS, the
latter being functionally important for ivermectin-induced cell death (Shrameen et al., 2010).
Diethylcarbamazine (DEC) is still the mainstay for the treatment of lymphatic filariasis and
first choice of therapy of loiasis. Surprisingly, its molecular mechanism of action is still not
completely understood. Since pharmacologically relevant concentrations of DEC do not
have an effect on microfilariae in culture, its mode of action must involve both the worm
and its host. A possible involvement of host arachidonate- and NO-dependent pathways
was observed (McGarry et al., 2005). Currently no verification of an influence on the redox
biology of helminths is available.
It has been postulated that antioxidant enzymes, that defend against host-generated ROS,
are of particular importance for long-lived tissue-dwelling parasites that are involved in
chronic infections. Here, surface or secreted antioxidant enzymes are of great importance
since they can directly neutralize ROS that pose real danger, thereby protecting surface
membranes against peroxides. Secreted filarial antioxidant enzymes include SOD, GPx and
Prx (Henkle-Dührsen and Kampkötter, 2001). Additionally to their antioxidant role, the Prx
have recently been shown to contribute to the development of Th2-responses by altering the
function of macrophages (Donnelly et al., 2008). Interestingly, GSH-dependent proteins
have been observed that are capable of modifying the local environment via modulation of
the immune response. Here the secretory GSTs from O. volvulus combine several features
that make them excellent drug target: they are accessible since they are located directly at
the parasite–host interface, they detoxify and/or transport various electrophilic compounds
and secondary products of lipid peroxidation and they are involved in the synthesis of po‐
tential immunmodulators. Significant structural differences to the host homologues are ob‐
served in the xenobiotic binding site; this may support the structure-based design of specific
inhibitors (Sommer et al., 2003; Perbandt et al., 2008; Liebau et al., 2008).
As outlined above, GSH-dependent detoxification pathways defend against current drugs
and also play a role in mediating resistance to anthelmintics. The antioxidant pathways also
provide the parasite with a means to protect against ROS-attack by its host and/or vector. In
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the model nematode C. elegans, GSH-synthesis and a large variety of primary and secondary
antioxidant enzymes and GSH-dependent detoxification enzymes are tightly regulated by
the sole NF-E2-related (Nrf) transcription factor SKN-1 (An and Blackwell, 2003). Inhibiton
of SKN-1 would thus target the expression of a multitude of enzymatic antioxidants and de‐
toxification enzymes rather than affecting only one single protein or protein class, resulting
in the downregulation of xenobiotic detoxification and in an enormous increase of oxidative
stress. Since SKN-1 is also essential for embryonic development, this would be an additional
bonus. Nematode-specific structural differences are observed that make SKN-1 an excellent
candidate for the development of specific nematocidal drugs (Choe et al., 2012).
11. Conclusion
The current bottle-neck for the treatment of parasitic diseases with chemotherapeutics is the
increasing drug resistance which forces the continuous discovery and development of new
antiparasitic drugs. There is an urgent need for novel chemotherapeutic targets. New drugs
should be generated to specifically target the parasite with minimal (or no) toxicity to the
human host. Therefore, good drug targets should be distinctly different from processes in
the host, or ideally be absent in the latter. Targeting the peculiarities - which are absent in
the host - is proposed as such a strategy. In this sense, the parasite-specific biosyntheses rep‐
resent ideal drug targets; similar to the already exploited antifolate interference with the
parasite’s dihydrofolate (vitamin B9) biosynthesis. There are a variety of reports about reac‐
tive compounds that have antiparasitic activity; however, not all of these are therapeutically
viable drug-like molecules due to various limitations such as toxicity, low bioavailability,
rapid inactivation under in vivo conditions and development of resistance. Recently studies
on drug synergism raised special attention, which can open new avenues to improve the ef‐
ficacy of antiparasitic drugs in combination with others. Since parasites such as Plasmodium,
Trypanosoma or helminths are highly susceptible to oxidative stress - as outlined within this
chapter - the identification of new lead compounds that target the parasite’s redox systems
by inducing oxidative stress, will be an efficient approach to discover novel drugs.
In this chapter we have tried to give an outline of the present situation of redox-active anti‐
parasitic molecules that target human infectious diseases. In future the mechanisms, evolu‐
tionarily developed by the parasite to circumvent the crucial presence of ROS, will open
new avenues for the development of novel antiparasitic drugs that combat resistant human
pathogens effectively.
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1. Introduction
Palmitoylation is a reversible, post-translational modification of a protein through the addi‐
tion of the 16-carbon fatty acid, palmitate, to a cysteine residue. There are two types of pal‐
mitoylation, one called thio- or S-palmitoylation in which palmitate is added to the thiol
side chain of a cysteine residue via a labile thioester bond [1]. The other type, N-palmitoyla‐
tion, is the addition of palmitate to an N-terminal cysteine via a stable amide bond [2]. The
two forms of palmitoylation are regulated by different families of palmitoyl acyltransferases
(PATs)—S-palmitoylation via a family of multi-pass transmembrane proteins called DHHC
(Asp-His-His-Cys) proteins [3] and N-palmitoylation via a family of multi-pass transmem‐
brane proteins termed membrane-bound O-acyltransferase [4]. S-palmitoylation, the focus
of this chapter, is more common and because of the labile thioester bond, can dynamically
regulate protein sorting and function.
Palmitoylation increases the lipophilicity of the modified protein often changing its subcel‐
lular distribution in both dramatic and subtle ways. The larger-scale changes occur when cy‐
toplasmic proteins relocate from the cytoplasm to membrane and when integral membrane
proteins move from one membrane system to another, such as from the endoplasmic reticu‐
lum (ER) to the plasma membrane (PM). The more subtle changes, in terms of distance, oc‐
cur at the nanoscale level within a membrane. The increase in lipophilicity upon
palmitoylation often results in an altered affinity for a particular lipid microenvironment
within that membrane [5]. For example, lipid rafts are small islands in membranes with dis‐
tinct lipid compositions that selectively attract or exclude both peripheral (often exclusively
by virtue of palmitoylation) and integral membrane palmitoylated proteins. Palmitoylated
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1. Introduction
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cur at the nanoscale level within a membrane. The increase in lipophilicity upon
palmitoylation often results in an altered affinity for a particular lipid microenvironment
within that membrane [5]. For example, lipid rafts are small islands in membranes with dis‐
tinct lipid compositions that selectively attract or exclude both peripheral (often exclusively
by virtue of palmitoylation) and integral membrane palmitoylated proteins. Palmitoylated
proteins have affinity for lipid rafts that are rich in cholesterol, while prenylated proteins
have little or no affinity for these rafts [5]. Such lipophilicity-driven changes in protein dis‐
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tribution may alter access of a palmitoylated protein to extracellular ligands (when the pro‐
tein moves from the ER to the PM), protein-protein interactions, or the engagement of the
palmitoyl-protein in multi-molecular signaling complexes. The role of palmitoylation as a
versatile protein sorting signal, regulating intracellular protein trafficking and targeting to
membrane microdomains has been reviewed recently [6]. Palmitate may be the most com‐
mon lipid species to occupy cysteine residues, but it is not the only one. Marilyn Resh and
colleagues identified the lipid moieties resident on the cysteine residue of the N-terminal tail
of Src family kinases [7-9]. While for these proteins the cysteine residue near the N-terminus
is most frequently palmitoylated, it is also modified by palmitoleate, stearate, or oleate with
a frequency that is apparently related to the abundance of palmitate in cells [10]. The phys‐
iological differences that result from proteins being modified by these other lipids has not
been explored extensively; however, given their different physical properties, it seems rea‐
sonable that their impact on a protein should be subtly different than palmitate.
Unlike other forms of lipidation such as myristoylation and prenylation, palmitoylation is
reversible, by virtue of the labile thioester bond. This allows for dynamic regulation of the
protein’s lipophilicity [11-13]. By contrast, prenyl groups are attached to cysteines by a sta‐
ble thioether bond and myristate to glycines by a stable amide bond. It is now apparent that
many instances of palmitoylation are enzymatically mediated by a family of palmitoyl acyl‐
transferases (PATs), whereas the mechanisms for depalmitoylation are poorly understood.
Nevertheless, it is known that palmitate cycles on and off of many proteins at variable rates
ranging from minutes to days. Such dynamic regulation makes palmitoylation unique
among post-translational protein lipid modifications and places it in a category similar to
phosphorylation. Discovering the molecular identity of PATs was a pivotal event that dra‐
matically accelerated the pace of discovery in the field. Likewise, there has been increased
interest in palmitoylation partly because many of the genes encoding PATs have been
linked to human diseases like cancer. With a greater understanding of how palmitate is en‐
zymatically attached to proteins, some of the most interesting questions include: What are
the substrate(s) of each PAT?; how does a PAT recognize and palmitoylated a substrate?;
how are PATs regulated?; and how is depalmitoylation regulated? The answers to these
questions are beginning to unfold due to the recent discovery of pharmacological modula‐
tors of palmitoylation as well as the development of novel assays and refinement of existing
assays. Our ability to understand palmitoylation and its importance to human health and
disease is only as good as the methods we use to test our hypotheses. Thus, the discovery of
potent and selective inhibitors of palmitoylation as well as the continued development of as‐
says with increased sensitivity and selectivity is critical to this venture.
2. Palmitoylation and DHHC proteins
2.1. Molecular identity of palmitoyl acyltransferases (PATs)
It has been known for many years that palmitoylation is a critical regulator of diverse and
complex signaling networks, but the mechanism responsible for palmitoylation of most pro‐
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teins remained a mystery and somewhat controversial until only recently. The apparent ab‐
sence of a consensus site for palmitoylation encoded by the sequence of amino acid residues
surrounding palmitoyl cysteines, as well as the difficulty in purifying and identifying the
enzymes capable of mediating the reaction, led many to believe that it was autocatalytic.
Given these issues and the high reactivity of cysteines and palmitoyl-CoA, especially in in
vitro protein palmitoylation assays, the possibility was not unreasonable [11, 14, 15]. Many
of the arguments for and against autocatalytic palmitoylation have been reviewed recently
[16].Yet, given the prevalence of palmitoylated proteins in parts of cells where signaling
events are so highly concentrated, complex, and regulated, such as the neuronal synapse, it
seemed somewhat unreasonable that all regulation of palmitoylation could be left to diffu‐
sion—a nagging reality that kept the search for an enzymatic mechanism alive despite the
arguments to the contrary. Additionally, there was evidence over the years in support of the
idea that these enzymes existed because PAT activity in detergent solubilized protein frac‐
tions had been measured using viral glycoproteins [17], p59fyn [18], and H-Ras [19] as sub‐
strates among others.
The experiments that conclusively provided the molecular identity of PATs were presented in
a series of papers spanning almost a decade. The experimental model organism that ultimate‐
ly provided the information was yeast. First, palmitoylation-dependent alleles of yeast RAS2
were identified. A genetic screen designed to identify mutations that rendered cells non-via‐
ble if Ras2p was not palmitoylated was utilized to identify mutations in two genes- ERF2 and
ERF4/SHR5 [20, 21]. These mutations resulted in diminished palmitoylation of Ras2p and mis‐
localization of GFP-Ras2p (respectively or it takes both mutations to cause both effects [20, 22]).
However, it could not be decisively concluded if the mutations in ERF2 and ERF4 were affect‐
ing Ras2p palmitoylation directly or indirectly by altering Ras2p trafficking (which could have
prevented an interaction between the palmitoyl acyltransferase and Ras2p).
In collaboration with Maurine Linder, Deschenes and colleagues used an in vitro palmitoyla‐
tion assay to show that Erf2p and Erf4p together constituted a Ras2p PAT that used palmito‐
yl-CoA as a donor [23]. Erf2p is a ~42-kDa integral membrane protein that is expressed in
the ER. The protein contains the DHHC-CRD (Asp-His-His-Cys-cysteine rich domain), also
referred to as the NEW1 or zf-DHHC domain (PF01529), which is found in an extensive fam‐
ily of membrane proteins ranging from unicellular eukaryotes to humans [24, 25]. This do‐
main is now recognized as the molecular signature for PATs that add palmitate to cysteines
via a labile thioester bond.
At almost the same time that the Erf2p/Erf4p complex was identified as the Ras2p PAT,
Akr1p was identified as a PAT with specificity for Yck2p [26]. An important clue leading to
the relationship between these two proteins came from the fact that mutants in both Ras2p
and Yck2P exhibited a reduced rate of pheromone receptor internalization [27, 28]. Akr1p
contains a DHYC-CRD instead of a DHHC-CRD as well as ankyrin repeats not present in
Erf2p. The DHYC motif present in three yeast proteins (Akr1p, Akr2p and Pfa5) does not
appear to occur in the mammalian genome. Akr1p and Akr2p are most closely related to the
mammalian HIP14 (DHHC17) and HIP14L (DHHC13) which contains the variant DQHC—
the only observed mammalian deviation from DHHC [3].
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questions are beginning to unfold due to the recent discovery of pharmacological modula‐
tors of palmitoylation as well as the development of novel assays and refinement of existing
assays. Our ability to understand palmitoylation and its importance to human health and
disease is only as good as the methods we use to test our hypotheses. Thus, the discovery of
potent and selective inhibitors of palmitoylation as well as the continued development of as‐
says with increased sensitivity and selectivity is critical to this venture.
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tions had been measured using viral glycoproteins [17], p59fyn [18], and H-Ras [19] as sub‐
strates among others.
The experiments that conclusively provided the molecular identity of PATs were presented in
a series of papers spanning almost a decade. The experimental model organism that ultimate‐
ly provided the information was yeast. First, palmitoylation-dependent alleles of yeast RAS2
were identified. A genetic screen designed to identify mutations that rendered cells non-via‐
ble if Ras2p was not palmitoylated was utilized to identify mutations in two genes- ERF2 and
ERF4/SHR5 [20, 21]. These mutations resulted in diminished palmitoylation of Ras2p and mis‐
localization of GFP-Ras2p (respectively or it takes both mutations to cause both effects [20, 22]).
However, it could not be decisively concluded if the mutations in ERF2 and ERF4 were affect‐
ing Ras2p palmitoylation directly or indirectly by altering Ras2p trafficking (which could have
prevented an interaction between the palmitoyl acyltransferase and Ras2p).
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tion assay to show that Erf2p and Erf4p together constituted a Ras2p PAT that used palmito‐
yl-CoA as a donor [23]. Erf2p is a ~42-kDa integral membrane protein that is expressed in
the ER. The protein contains the DHHC-CRD (Asp-His-His-Cys-cysteine rich domain), also
referred to as the NEW1 or zf-DHHC domain (PF01529), which is found in an extensive fam‐
ily of membrane proteins ranging from unicellular eukaryotes to humans [24, 25]. This do‐
main is now recognized as the molecular signature for PATs that add palmitate to cysteines
via a labile thioester bond.
At almost the same time that the Erf2p/Erf4p complex was identified as the Ras2p PAT,
Akr1p was identified as a PAT with specificity for Yck2p [26]. An important clue leading to
the relationship between these two proteins came from the fact that mutants in both Ras2p
and Yck2P exhibited a reduced rate of pheromone receptor internalization [27, 28]. Akr1p
contains a DHYC-CRD instead of a DHHC-CRD as well as ankyrin repeats not present in
Erf2p. The DHYC motif present in three yeast proteins (Akr1p, Akr2p and Pfa5) does not
appear to occur in the mammalian genome. Akr1p and Akr2p are most closely related to the
mammalian HIP14 (DHHC17) and HIP14L (DHHC13) which contains the variant DQHC—
the only observed mammalian deviation from DHHC [3].
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2.2. The ZDHHC family of PATs
The mammalian genome contains at least 23 members of the ZDHHC PAT gene family iden‐
tified by the presence of the signature DHHC-cysteine rich domain. Members of the family
had been identified as being genes of interest (e.g., “REAM” in metastatic cancer [29]) prior
to understanding their function. The genomic structure of ZDHHC genes varies widely, in‐
cluding the number and differential use of exons that are spliced together to generate the
mRNA. EC gene analyses (http://genome.ewha.ac.kr/ECgene/) of the mRNAs that encode
PATs suggest that all of the genes are alternatively spliced at various sites throughout the
protein coding sequence as well as within untranslated regions. Many of the putative, alter‐
natively-spliced exons are predicted to encode small peptides that change the structure of
the protein in a way that may alter substrate specificity. Similarly, splicing may alter sites
for other post-translational modifications, such as phosphorylation or glycosylation, all of
which may regulate activity, substrate specificity, subcellular distribution, or interactions
with non-substrate proteins. ZDHHC7, for example, alters the use of a 111 bp exon that is
differentially and specifically expressed in tissues such as placenta, lung, liver, thymus, and
small intestine [30]. This exon encodes a 37-residue peptide (EKSSDCRP‐
SACTVKTGLDPTLVGICGEGTESVQSLLL) within the intracellular loop between trans‐
membrane domain 2 (TM2) and TM3 that contains a PKC phosphorylation site. It is
conceivable that phosphorylation of this serine changes DHHC7 in such a way that sub‐
strate specificity or the rate of palmitate transfer activity is altered. In addition to alternative
mRNA splicing, aberrant splicing induced by mutations or single nucleotide polymor‐
phisms has been shown to occur in at least two ZDHHC genes. A splice-site mutation in
highly conserved residues of ZDHHC9, a PAT that has been shown to palmitoylate H-Ras
and N-Ras [31], has been described in families with X-linked mental retardation (XLMR)
[32]. This mutation creates an additional, stronger splice-donor site 140 nt before (toward
the 5’ end) the normal donor site. Usage of the new site results in a mRNA that is frame-
shifted and that encodes a truncated protein. Single nucleotide polymorphisms that affect
splicing of ZDHHC8 have also been implicated in schizophrenia [33] (also see: [34-36]).
Hydropathy analyses predict that the PATs encoded by these genes all pass through a mem‐
brane multiple times (at least four) and are expressed predominantly in the ER and Golgi
membranes [30, 37, 38]. Currently, there is little published data on the numbers of TM do‐
mains in any of the PATs with the exception of Akr1p in yeast [39]. Predictions using
TopPred II 1.1 [40] as presented by Ohno and colleagues [30] show that most PATs have an
even number of TM domains with the DHHC-CRD motif in the cytoplasm. However for
DHHC13, -16, -11, and -22, the DHHC-CRD motif resides just C-terminal to the first or third
TM domain. Assuming the N-terminus is cytoplasmic, this places the DHHC-CRD motif ei‐
ther in the lumen of the ER (the membrane compartment of residence reported for each by
Ohno and colleagues 2006) or outside of the cell if expressed on the PM. Given that the envi‐
ronment in these two locations is oxidizing in nature [41, 42] and assuming this topological
model is correct, it is possible that the cysteines of the DHHC-CRD motif could form inter-
or intra-molecular disulfide bridges rather than being involved in the transfer of palmitate.
However, while it is possible that PATs may assume duties in addition to palmitoylation, it
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seems somewhat unlikely they would do so in this arrangement as it represents a state in
which it would be difficult to perform these functions. The highest-scoring predictions of
the membrane topology using TMpred show that the human protein sequence of DHHC11
and -16 should contain four TM domains, DHHC13 eight TM domains, and DHHC22 either
four or five TM domains, with each model placing the DHHC-CRD motif inside the cells.
There is clear disparity among the predictions generated by the algorithms available and ul‐
timately, any of these predictions of topology must be confirmed or disproved by experi‐
mental data. In any case, for a member of the PAT family to function as a PAT, the DHHC-
CRD motif should probably reside in the cytoplasm (Figure 1A). The regions of the PAT
proteins that contain the greatest diversity at the amino-acid level are the N- and C-terminal











Figure 1. Predicted general structure of PATs. A) The predicted topology of PATs places the DHHC-CRD domain in the
cytoplasm but such predictions must be confirmed experimentally. B) Each PAT is predicted to span the membrane
four to six times; each is ~40 kDa with the greatest degree of sequence variability residing in the cytoplasmic N- and C-
termini. The DHHC-CRD motif defines PATs. Palmitoylation of the cysteine in the DHHC portion is required for transfer
of palmitate to a substrate. Most PATs also have a conserved DPG (aspartate-proline-glycine) motif and TTxE (threo‐
nine-threonine-asparagine-glutamate) motif, but their role in the function of PATs is not yet known.
In addition to the importance of PAT membrane topology, their membrane system of resi‐
dence is likely to be an important aspect of their function. PATs have been localized to ER, Gol‐
gi, plasma membrane, endosomes, and the yeast vacuole [30, 43-48]; yet, little is known about
how these proteins achieve their respective localizations. Immunolocalization of epitope-tag‐
ged DHHC proteins has been somewhat inconsistent among various cell types, between labo‐
ratories (e.g. DHHC2 [30, 37], and even in our own laboratory (unpublished observations SLP)
in terms of within which membrane system a protein resides. Such inconsistencies suggest that
the cell type, cell cycle, health of the cells, or even the location of the epitope tag may affect sub‐
cellular distribution. An interesting exception is DHHC2. DHHC2 has recently been shown to
traffic between the PM and intracellular membranes via recycling endosomes [47]. Important‐
ly, the C-terminal 68 amino acids of DHHC2 was shown to play an important role in defining
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phisms has been shown to occur in at least two ZDHHC genes. A splice-site mutation in
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[32]. This mutation creates an additional, stronger splice-donor site 140 nt before (toward
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mains in any of the PATs with the exception of Akr1p in yeast [39]. Predictions using
TopPred II 1.1 [40] as presented by Ohno and colleagues [30] show that most PATs have an
even number of TM domains with the DHHC-CRD motif in the cytoplasm. However for
DHHC13, -16, -11, and -22, the DHHC-CRD motif resides just C-terminal to the first or third
TM domain. Assuming the N-terminus is cytoplasmic, this places the DHHC-CRD motif ei‐
ther in the lumen of the ER (the membrane compartment of residence reported for each by
Ohno and colleagues 2006) or outside of the cell if expressed on the PM. Given that the envi‐
ronment in these two locations is oxidizing in nature [41, 42] and assuming this topological
model is correct, it is possible that the cysteines of the DHHC-CRD motif could form inter-
or intra-molecular disulfide bridges rather than being involved in the transfer of palmitate.
However, while it is possible that PATs may assume duties in addition to palmitoylation, it
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dence is likely to be an important aspect of their function. PATs have been localized to ER, Gol‐
gi, plasma membrane, endosomes, and the yeast vacuole [30, 43-48]; yet, little is known about
how these proteins achieve their respective localizations. Immunolocalization of epitope-tag‐
ged DHHC proteins has been somewhat inconsistent among various cell types, between labo‐
ratories (e.g. DHHC2 [30, 37], and even in our own laboratory (unpublished observations SLP)
in terms of within which membrane system a protein resides. Such inconsistencies suggest that
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its intracellular localization; however, a defined targeting signal present within this region of
DHHC2 and in other DHHC proteins has yet to be defined.
2.3. PAT genes, palmitoylation and human disease
PATs have already been linked, in varying degrees, to human disease despite their recent
discovery. At least 7 genes encoding PATs have been implicated in human disorders, in‐
cluding ZDHHC8 with schizophrenia [33], ZDHHC17 with Huntington’s disease [49],
ZDHHC15 and ZDHHC9 with X-linked mental retardation [32, 50], and ZDHHC2, ZDHHC9,
ZDHHC17, and ZDHHC11 with cancer [29, 51-53]; most of the demonstrated and putative
connections are with cancer.
Overexpression of some PATs has also been shown to alter cancer-related signaling.
DHHC17 (HIP14) is oncogenic. DHHC9 and DHHC11 display characteristics that strongly
suggest they also are oncogenic. Overexpression of DHHC17 has the ability to induce colo‐
ny formation and anchorage-independent growth in cell culture and tumors in mice [53]. It
has been shown that these effects occur, at least in part, by DHHC17-mediated palmitoyla‐
tion of H-, N-, and K2A- RAS proteins [53]. DHHC9 is strongly upregulated in some adeno‐
carcinomas of the gastrointestinal tract at the transcript and protein levels [52] and has also
been shown to palmitoylate H- and N- RAS proteins in vitro [31]. ZDHHC11 has a high inci‐
dence of additional genomic copies in cases of non-small cell lung cancer and bladder cancer
in which it is strongly linked to high-grade, advanced stage and disease progression [51].
Conversely to the behavior of the oncogenic PATs, a failure to express ZDHHC2 results in
an increase in metastasis in an in vivo model leading to the suggestion that ZDHHC2 is a tu‐
mor/metastasis suppressor [29]. This absence of expression suggests that substrates of
DHHC2 are no longer palmitoylated, and that whatever role palmitoylation had in signaling
downstream from that event has been disrupted. Such is the case of DHHC2, where due to a
lack of palmitoylation, one of its substrates, CKAP4, is no longer normally palmitoylated.
One consequence of this is that CKAP4 no longer traffics efficiently (or at all) to the cell sur‐
face where it acts as a receptor for antiproliferative factor (APF) [37] [or presumably its other
two known ligands, tissue plasminogen activator [54] and surfactant protein A [55]]. With‐
out surface expression of CKAP4, APF is unable to initiate a wide range of downstream ef‐
fects, including halting cellular proliferation and altering the expression of genes related to
the progression of cancer [44].
CD9 and CD151, both tetraspanin proteins, have also been identified as substrates of
DHHC2 [56]. CD9, which has been suggested to be a tumor suppressor [57, 58], is palmitoy‐
lated on multiple cysteines, but which of these are palmitoylated by DHHC2 is not known.
Nonetheless, it is clear that suppression of DHHC2-mediated palmitoylation of CD9 in A431
cells affects cell behaviors that are consistent with it playing a role in tumor suppression. In
particular, the cells undergo what appears to be epithelial-mesenchymal transition (EMT)—
a process in which epithelial cells lose epithelial morphology and markers and gain a fibro‐
blastic morphology during tumor progression [59-61]. It is not yet clear whether this change
in cellular behavior was mediated solely by the reduction in CD9 palmitoylation or through
reduced palmitoylation of this and other DHHC2 substrates such as CKAP4. It will be inter‐
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esting to learn if a select subset of cysteines of CD9 is palmitoylated by DHHC2 and also
how decreasing palmitoylation of specific cysteines results in the observed cellular behavior.
Several other substrates of DHHC2 have been identified ranging from the neuronal adaptor/
scaffold protein PSD95 [62], the SNARE proteins SNAP-23/25 [63], the non-receptor tyrosine
kinase Lck [64], and the intracellular signaling proteins Gαi2 [65], GAP43 [62], R7BP [66],
and eNOS [48]. Notably, there is no apparent structural similarity between the reported sub‐
strates of DHHC2, or even any sequence similarities surrounding the palmitoylated cysteine
residues. Thus, DHHC2 can apparently palmitoylate cysteines located in the N-terminal re‐
gions (PSD-95, GAP-43, and Gα), internally in the protein sequence (SNAP-23/25), in the jux‐
tamembrane region of transmembrane proteins (CD9, CD151, and CKAP4) and close to an
N-terminal myristoylated glycine (Lck and eNOS).
From these examples, it is clear that upsetting the homeostatic balance of protein palmitoy‐
lation, in either direction, can have significant and deleterious effects on signaling networks.
It is also clear that identification of PAT cognate substrates will provide important informa‐
tion concerning the molecular mechanisms underlying the oncogenic nature of the affiliated
signaling systems as well as reveal important, novel targets for pharmacologic intervention.
The development of specific DHHC protein inhibitors would provide vital reagents with
which to study the physiological and pathophysiological importance of many palmitoylated
proteins and may offer potential for therapeutic development.
2.4. PAT functions in addition to palmitoylation
It is not surprising that a disruption in the homeostatic balance of protein palmitoylation, in
either direction, can have pathophysiological consequences. However, one must remain
mindful that palmitoylation may not be the sole function of these proteins. Recently, two
PATs—HIP14 (DHHC17) and HIP14L (DHHC13)—have been shown to mediate the trans‐
port of Mg2+ [67]. The first indication that these PATs were involved in Mg2+ regulation was
that the abundance of their corresponding mRNAs was increased in cells grown in medium
with reduced Mg2+ concentration. The authors then showed that Mg2+ (but not Ca2+) trans‐
port was both electrogenic and voltage dependent, and that the transport required palmitoy‐
lation of the PAT. The authors concluded that these two PATs fall into a category of
enzymes called “chanzymes” or ion channels that also have enzymatic activity; a type of
protein previously represented only by the transient receptor potential melastatin (TRPM)
family of transporters [68, 69]. The fact that GODZ (DHHC3) does not appear to mediate
Mg2+ transport [70] but can mediate the transport of Ca2+ [71] suggests that this is not a gen‐
eral property of all PATs. The discovery that these PATs transport Mg2+ was astonishing es‐
pecially in light of the fact that the DHHC-CRD motif appears, by sequence and predicted
structure, to be a Zn2+-binding protein; (a divalent cation with an atomic radius similar to
Mg2+)—not Mg2+. However, Goytain and colleagues also found that HIP14 and HIP14L
transported Zn2+ with approximately half the efficiency as Mg2+. The role of these and other
PATs in binding to and/or transporting Zn2+ remains to be elucidated, but demonstrates the
importance of not limiting ones view of PAT function (or many other proteins for that mat‐
ter) only to palmitoylation.
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2.5. Enzymatic mechanisms of palmitoylation
The physical and chemical mechanisms that result in enzymatic palmitoylation have yet to
be defined clearly, but some progress has been made using purified proteins. It has been es‐
tablished that mutation of the cysteine in the DHHC motif of all PATs studied to date abol‐
ishes autoacylation of the PAT and palmitoylation of the substrate [23, 56, 62, 72]. This
literature as well as discussion of potential physical mechanisms for the reaction have been
reviewed recently [3, 73].
3. Palmitoyl-Cysteine prediction
Prior to the discovery of PATs, attempts were made to define stretches of amino acids that
were preferred for palmitoylation. Palmitoylation near the N-terminus, following myristoy‐
lation, is among the predictable places for palmitoylation to occur provided there is one or
more nearby cysteines. Navarro-Lérida et al (2002) fused a myristoylation motif (MGCTLS)
to GFP with a short intervening sequence containing cysteines at various locations. These
authors found a preference for cysteine palmitoylation at positions 3, 9, 15 and (to a much
lesser degree) 21 residues away from the N-terminal methionine, but intervening residues
were not evaluated. Commonalities in the composition of amino acid residues surrounding
palmitoylated cysteines have been noted among members of the family of yeast amino acid
permeases [74].
As more palmitoylated proteins and specific palmitoyl-cysteines are discovered, the task of
predicting which adjacent amino acids provide a favorable environment for palmitoylation
becomes easier. Algorithms trained with data from identified palmitoyl cysteines and adja‐
cent amino acid residues are now able to provide predictions of the statistical likelihood that
a cysteine of interest may be palmitoylated [75-78]. CSS-Palm 2.0, which was designed to
predict potential palmitoylation sites, has been published [75]. The algorithm was trained to
recognize potential palmitoyl-cysteines using a dataset of 263 experimentally determined
palmitoylation sites from 109 distinct proteins. Interestingly, CSS-Palm 2.0 also successfully
predicted most (~75%) of the same novel palmitoyl-cysteines in yeast proteins previously
identified by Roth. et al [74] as well as palmitoyl-cysteines predicted by Roth et al., to be pal‐
mitoylated but not experimentally determined. This rate of success in both cases suggests
that CSS-PALM 2.0 is more conservative at calling a site, potentially resulting in a greater
rate of false negative results but is reasonably accurate nonetheless. This algorithm should
prove useful when prioritizing which cysteine(s), often among multiple potential cysteines
of a candidate palmitoyl protein, to analyze experimentally.
Patterns of amino acid residues surrounding palmitoyl-cysteines have emerged from these
analyses. A diagram of favored residues generated by an early version of CSS-Palm 2.0
(NBA-Palm) [76] shows that leucines and additional cysteines are more commonly observed
around palmitoyl-cysteines. The subsequent versions of NBA-palm used significantly im‐
proved predictive tests, but the rough sequence of preferred residues remains. An important
aspect that cannot yet be considered when attempting to predict cysteine palmitoylation
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with these algorithms is the complexity of the PAT-substrate recognition that is encoded by
residues outside of those that immediately surround the palmitoyl-cysteine; the higher or‐
der components of the recognition sites.
3.1. The physical properties of cysteines and thioester bonds
The unique physical and biochemical nature of the thioester bond that links palmitate to
cysteine residues is the basis for the design of many recent assays for palmitoylation. The
cysteine residue is among the most nucleophilic entities in a cell [79] and is the most com‐
mon site of palmitoylation. Other residues can be modified by palmitate, but their occur‐
rence is relatively rare and the bond chemistries are different [2, 80-83]. Palmitoylation can
also occur in other ways, for example, on an amine of an N-terminal cysteine as is the case
with Hedgehog [2, 83, 84], a secreted signaling protein. An example of palmitate modifying
the weaker –OH nucleophile of threonine occurs on the carboxyl terminus of a spider toxin
[81]. The ε-amino group of lysine can also be modified by palmitate linked by an amide
bond. This occurs in several secreted proteins including a bacterial toxin [80].
The reactivity of the thiolate anion of cysteine residues makes it a key component in the
structure and function of many proteins by stabilizing higher order structures via disulfide
bridges and post-translational modifications like nitrosylation, prenylation, and acylation
[85-87]. The high degree of reactivity has also provided a well-characterized, indispensable
target for modification by synthetic, thiol-reactive ligands, allowing capture and characteri‐
zation of proteins [88]. An exceptionally useful application of such thiol-specific chemistry is
isotope-coded affinity tags (ICAT) for mass spectrometric determination of relative protein
or peptide abundance among two or more samples [89-91]. With these probes, changes in
abundance of identified proteins or peptides are determined by changes in the ratio of
heavy to light-isotope-modified peptides from mixed samples. Combining ICAT technology
with functional genomics methods like siRNA-mediated PAT-gene knockdown is one of
several mechanisms that will allow us to identify substrates of PATs [37].
In healthy cells the cytoplasm is generally a reducing environment, meaning that solvent-
exposed cysteine side chains are not typically disulfides and thus available to engage in re‐
actions with other molecules [92]. The reactivity of a free cysteine depends on the pKa of the
cysteine which is a function of the local environment surrounding the residue within the
context of the whole protein. Unlike other residues with nucleophilic side chains (-OH or –
NH2), thiol side chains undergo conjugations, redox, and exchange reactions [85]. Conjuga‐
tion reactions (in addition to fatty acylation) include nitric oxide (NO) or S-nitrosylation, re‐
active oxygen species (ROS), and reactive nitrogen species (RNS) forming bonds that are not
susceptible to cleavage by hydroxylamine at neutral pH. Hydroxylamine is a reagent used
to selectively remove thioester-linked palmitate [93]. Importantly, we know that hydroxyla‐
mine does not perturb disulfides [94], and that it efficiently cleaves thioesters in a quantita‐
tive manner [95].
In addition to the linkage of palmitate to cysteines, another thioester bond that occurs in
cells is the transient association between ubiquitin and the E1, E2, and certain E3 ubiquitina‐
tion enzymes [87, 96]. However, these thioester bonds are easily distinguished from the thio‐
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ester bond that links palmitate to cysteines by their pKa; the pKa in the case of
palmitoylation is near neutral pH (~7.4) whereas, for the thioester in the ubiquitin system it
is pH 10.5 or greater. This wide differential allows for a high degree of selectivity when us‐
ing hydroxylamine to cleave palmitate from proteins on the physical characteristics of ubiq‐
uitin-related cysteines. It is highly unlikely that they are ever in a position to be
palmitoylated [97, 98].
Retinoic acid (RA) and RA-CoA have also been shown to be enzymatically attached to cys‐
teines via a thioester bond that can be cleaved by hydroxylamine and reducing reagents
such as βME at neutral pH. The reaction can be inhibited, but not fully, by myristate and
palmitate suggesting that RA competes for the same cysteines as palmitate [99-107]. There is
some debate in the RA field about how it binds to proteins, particularly the nuclear RA re‐
ceptors, to carry out its signaling functions. RA binding to a hydrophobic cleft is the favored
mechanism; however, there are many effects of RA (e.g. [108, 109] ) that are independent of
RA-receptor binding suggesting that cysteine modification may also have a place in the mo‐
lecular mechanism of RA action.
3.2. Mass spectrometric identification of acyl groups that modify cysteines via a thioester
bond
Lipid-modified thiols have been successfully identified using MALDI-TOF (matrix-assisted
laser desorption ionization time-of-flight) mass spectrometry [110]. Using this method, direct
information on the nature of the endogenous lipids on proteins or peptides (revealing interest‐
ing variability) can be obtained, whereas most other methods rely on surrogate markers for
palmitate including thiol-reactive probes or radiolabeled palmitate. Using MALDI-TOF mass
spectrometry, Marilyn Resh and colleagues found that the cysteine in the N-terminal Met-Gly-
Cys of Src family kinases and two cysteines near the N-terminus of GAP43 are modified not
only by palmitate but also (and to a lesser degree) by palmitoleate, stearate, or oleate [7, 8].
While palmitate appears to be the most common acyl group that forms a thioester bond to
modify internal, cytoplasmic cysteines, it is clearly not the only one. The 16-carbon palmitate
acyl group represents the longest chain synthesized by mammalian fatty acid synthase and is
apparently the most abundant chain length present in some tissue types [111]. This relatively
greater abundance may underlie the dominance of palmitate as the main acyl group to modi‐
fy free thiols by S-acylation. The functional implications of incorporating lipids with shorter or
longer acyl chains and especially those with different degrees of saturation may be that the
proteins have different affinities for various lipid microdomains present in membranes. The
specificity of PATs for chain-lengths different than 16 carbons has not been rigorously de‐
fined. However, it is known that acyl groups with differing carbon chain lengths and degrees
of saturation can also be incorporated [7, 112].
3.3. PAT/Substrate recognition
Determining the nature of PAT/substrate recognition remains one of the more important
tasks to be undertaken. This is especially true for PATs encoded by genes that have been
linked to disease. There are two general approaches to defining PAT/substrate relationships:
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1. identification of the PAT with specificity for a known palmitoyl protein and
2. identification of an unknown substrate of an individual PAT.
The first of these has been the most common. With this forward approach, each one of the 23
PATs is independently co-overexpressed with a known palmitoyl protein; the cells express‐
ing the pair are metabolically labeled with 3H-palmitate and the proteins analyzed by SDS-
PAGE and fluorography. The incorporation of 3H-palmitate onto the substrate protein in
one or more of the co-overexpressions at a level significantly above background suggests
that a particular PAT is responsible for palmitoylating that known substrate. Similarly, the
presumptive PAT and substrate proteins can be purified and combined with 3H-palmitoyl-
CoA in a tube, allowed to react, and the incorporation of 3H-palmitate measured as above.
The current level of understanding of PAT/substrate recognition makes it unreasonable to
assume that the more closely two PATs are related by sequence homology, the more likely
they should palmitoylate a particular substrate. For this reason, assigning substrate status of
a protein to a single PAT among a select group of tested, more closely-homologous PATs, to
the exclusion of others because they are less homologous, may lead to erroneous exclusions.
Similarly, we cannot yet assume that homology among residues surrounding palmitoyl cys‐
teines of different proteins is an indication that they are palmitoylated by a particular PAT.
The mechanism for molecular recognition is likely to be defined in part by the higher order
structure (even quaternary as is the case with ERF2p and AKR1p) of the PATs and sub‐
strates. The reverse approach, defining unknown substrates of a single PAT can occur with‐
out these same biases as has been demonstrated in yeast and in human cells [37, 74].
4. Novel methods to discover and identify PAT/substrate specificity
The chemistry supporting novel assays to study palmitoylation and the reagents that are be‐
ing incorporated into them have, for the most part, been known and available for years [88] .
Most of the methods that are now being developed to study palmitoylation capitalize on
many years of knowledge and development of cysteine-specific chemistries, developed
mainly as methods to purify and/or specifically target proteins and peptides with various
reagents. Many of the reagents that specifically label cysteines have been created as both af‐
finity and fluorescent tags, the former for purification and structure determinations [88]and
the latter as cellular reporters of protein abundance, subcellular distribution, protein confor‐
mation changes, the formation of the Golgi, and even the concentration of cellular analytes
in specific subcellular domains. The following references provide a short list of some of the
most clever uses of thiol chemistry [113-119]. Given the wealth of information on the unique
chemistry of the palmitoyl thioester bond and the tools for capturing and characterizing cys‐
teines in proteins, it is somewhat surprising that we are only now developing innovative as‐
says to increase our understanding of palmitoylation. This recent increase is most likely tied
to the dramatic increase in the utility of mass spectrometry as a proteomic tool. To provide a
general frame of reference for the recent shift in the types of assays that are being devel‐
oped, we will briefly discuss other assays that have been used successfully for a longer peri‐
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ester bond that links palmitate to cysteines by their pKa; the pKa in the case of
palmitoylation is near neutral pH (~7.4) whereas, for the thioester in the ubiquitin system it
is pH 10.5 or greater. This wide differential allows for a high degree of selectivity when us‐
ing hydroxylamine to cleave palmitate from proteins on the physical characteristics of ubiq‐
uitin-related cysteines. It is highly unlikely that they are ever in a position to be
palmitoylated [97, 98].
Retinoic acid (RA) and RA-CoA have also been shown to be enzymatically attached to cys‐
teines via a thioester bond that can be cleaved by hydroxylamine and reducing reagents
such as βME at neutral pH. The reaction can be inhibited, but not fully, by myristate and
palmitate suggesting that RA competes for the same cysteines as palmitate [99-107]. There is
some debate in the RA field about how it binds to proteins, particularly the nuclear RA re‐
ceptors, to carry out its signaling functions. RA binding to a hydrophobic cleft is the favored
mechanism; however, there are many effects of RA (e.g. [108, 109] ) that are independent of
RA-receptor binding suggesting that cysteine modification may also have a place in the mo‐
lecular mechanism of RA action.
3.2. Mass spectrometric identification of acyl groups that modify cysteines via a thioester
bond
Lipid-modified thiols have been successfully identified using MALDI-TOF (matrix-assisted
laser desorption ionization time-of-flight) mass spectrometry [110]. Using this method, direct
information on the nature of the endogenous lipids on proteins or peptides (revealing interest‐
ing variability) can be obtained, whereas most other methods rely on surrogate markers for
palmitate including thiol-reactive probes or radiolabeled palmitate. Using MALDI-TOF mass
spectrometry, Marilyn Resh and colleagues found that the cysteine in the N-terminal Met-Gly-
Cys of Src family kinases and two cysteines near the N-terminus of GAP43 are modified not
only by palmitate but also (and to a lesser degree) by palmitoleate, stearate, or oleate [7, 8].
While palmitate appears to be the most common acyl group that forms a thioester bond to
modify internal, cytoplasmic cysteines, it is clearly not the only one. The 16-carbon palmitate
acyl group represents the longest chain synthesized by mammalian fatty acid synthase and is
apparently the most abundant chain length present in some tissue types [111]. This relatively
greater abundance may underlie the dominance of palmitate as the main acyl group to modi‐
fy free thiols by S-acylation. The functional implications of incorporating lipids with shorter or
longer acyl chains and especially those with different degrees of saturation may be that the
proteins have different affinities for various lipid microdomains present in membranes. The
specificity of PATs for chain-lengths different than 16 carbons has not been rigorously de‐
fined. However, it is known that acyl groups with differing carbon chain lengths and degrees
of saturation can also be incorporated [7, 112].
3.3. PAT/Substrate recognition
Determining the nature of PAT/substrate recognition remains one of the more important
tasks to be undertaken. This is especially true for PATs encoded by genes that have been
linked to disease. There are two general approaches to defining PAT/substrate relationships:
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1. identification of the PAT with specificity for a known palmitoyl protein and
2. identification of an unknown substrate of an individual PAT.
The first of these has been the most common. With this forward approach, each one of the 23
PATs is independently co-overexpressed with a known palmitoyl protein; the cells express‐
ing the pair are metabolically labeled with 3H-palmitate and the proteins analyzed by SDS-
PAGE and fluorography. The incorporation of 3H-palmitate onto the substrate protein in
one or more of the co-overexpressions at a level significantly above background suggests
that a particular PAT is responsible for palmitoylating that known substrate. Similarly, the
presumptive PAT and substrate proteins can be purified and combined with 3H-palmitoyl-
CoA in a tube, allowed to react, and the incorporation of 3H-palmitate measured as above.
The current level of understanding of PAT/substrate recognition makes it unreasonable to
assume that the more closely two PATs are related by sequence homology, the more likely
they should palmitoylate a particular substrate. For this reason, assigning substrate status of
a protein to a single PAT among a select group of tested, more closely-homologous PATs, to
the exclusion of others because they are less homologous, may lead to erroneous exclusions.
Similarly, we cannot yet assume that homology among residues surrounding palmitoyl cys‐
teines of different proteins is an indication that they are palmitoylated by a particular PAT.
The mechanism for molecular recognition is likely to be defined in part by the higher order
structure (even quaternary as is the case with ERF2p and AKR1p) of the PATs and sub‐
strates. The reverse approach, defining unknown substrates of a single PAT can occur with‐
out these same biases as has been demonstrated in yeast and in human cells [37, 74].
4. Novel methods to discover and identify PAT/substrate specificity
The chemistry supporting novel assays to study palmitoylation and the reagents that are be‐
ing incorporated into them have, for the most part, been known and available for years [88] .
Most of the methods that are now being developed to study palmitoylation capitalize on
many years of knowledge and development of cysteine-specific chemistries, developed
mainly as methods to purify and/or specifically target proteins and peptides with various
reagents. Many of the reagents that specifically label cysteines have been created as both af‐
finity and fluorescent tags, the former for purification and structure determinations [88]and
the latter as cellular reporters of protein abundance, subcellular distribution, protein confor‐
mation changes, the formation of the Golgi, and even the concentration of cellular analytes
in specific subcellular domains. The following references provide a short list of some of the
most clever uses of thiol chemistry [113-119]. Given the wealth of information on the unique
chemistry of the palmitoyl thioester bond and the tools for capturing and characterizing cys‐
teines in proteins, it is somewhat surprising that we are only now developing innovative as‐
says to increase our understanding of palmitoylation. This recent increase is most likely tied
to the dramatic increase in the utility of mass spectrometry as a proteomic tool. To provide a
general frame of reference for the recent shift in the types of assays that are being devel‐
oped, we will briefly discuss other assays that have been used successfully for a longer peri‐
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od of time. These assays are by no means outdated and some continue to be the most
appropriate way to answer specific questions.
4.1. Chemistry and physical properties of palmitoyl cysteines: Reactions and probes
Working with palmitoylated proteins is inherently difficult due to the labile nature of the
thioester bond and the increased hydrophobicity of the protein or peptide due to palmitate.
On the other hand, the unique physical and chemical properties of thiols, palmitoylated thi‐
ols, and the thioester bond make them particularly amenable to modification by highly spe‐
cific chemistry and a wide variety of thiol reactive probes.
Reactions of free thiols in the cytoplasm
Thiol modification occurs most commonly in cells by one of two routes: disulfide exchange
or alkylation. Many of the reactive groups that undergo these two reactions are relatively
stable in aqueous environments; the reactions are rapid and provide high yields of thioether
and disulfide bonds [88]. Thiols will also react with many amine reactive reagents including
isothiocyanates and succinimidyl esters but lack a high degree of specificity, resulting in un‐
stable bonds that are much less useful for routine modification of thiols in proteins. Thiol-
specific reagents and chemistry figure strongly into the design and development of novel
assays for palmitoylation. Most investigators are limited somewhat to reagents that are
available from a catalog but, fortunately, there are already many useful reagents available.
Among the most useful are thio-reactive chemicals that are linked to another moiety (reac‐
tive or reporter) by a spacer arm of variable length and physical characteristics. Such hetero-
and homo-bifunctional crosslinking reagents have provided much of the foundation for
recent developments in palmitoylation assays and provide a fairly rich toolbox for future as‐
say development.
Chemical moieties that react with palmitoyl-cysteines
Iodoacetamide conjugates are among the most commonly used tools for modifying cysteine
thiols. These undergo nucleophilic substitution to form stable thioether bonds at physiologi‐
cal pH in aqueous environments. When using iodoacetamide and its conjugates, one should
remember that depending on the pH of the solution, they can also react with histidine, ly‐
sine, and methionine (at pH >1.7) residues and N-terminal amines. However, when used at
slightly alkaline pH in the dark and in the absence of reducing reagents, cysteine modifica‐
tion will be the exclusive reaction [88]. A good example of iodoacetamide-based probes are
the isotope-coded affinity tags or ICAT [120]. These have proved particularly useful in de‐
termining the substrates of DHHC2 [37].
Maleimides are also common constituents of heterobifunctional crosslinking reagents and
blocking reagents that target cysteines. They are ~1000 times more specific for cysteine sulf‐
hydryls at pH 6.5-7.5, but at higher pH some cross reactivity can occur with amines. Mal‐
eimides form stable thioether bonds by adding the sulfhydryl across the double bond of
the maleimide.
Phenylmercury derivatives react with thiols, including nitrosothiols, under conditions simi‐
lar to iodoacetamides and maleimides to form stable mercury-thiol bonds that can be re‐
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versed in 0.1N HCl and reducing reagents like dithiothreitol (DTT) but apparently not by
TCEP. Phenylmercury derivatives also react faster with thiols than do the commonly used
thiol-reactive N-ethylmaleimide (NEM).
Compounds containing disulfide bonds are able to undergo disulfide exchange reactions
with another thiol by the free thiol attacking the disulfide bond and subsequent formation of
a new mixed thiol. Two examples of useful compounds in this category are Methylmethane‐
thiosulfonate (MMTS) and pyridyl disulfide derivitives like biotin HPDP ((N-(6-(Biotinami‐
do)hexyl)-3'-(2'-pyridyldithio)-propionamide). MMTS can be used in some cases to block
free thiols more effectively than NEM, as it is uncharged and thus more likely to modify all
free reactive cysteines. MMTS has been shown not to react with nitrosothiols or existing di‐
sulfides [121].
4.2. Metabolic labeling with radiolabeled palmitate
The most common method to identify palmitoyl proteins and to determine the residence
half-life of palmitate on a specific protein or palmitate turnover (e.g. [122] for a particularly
interesting example) is to metabolically label cells with radiolabled palmitate. 14C-, 3H- and
125I-labeled palmitate have all been used, but 3H-palmitate is most common because it is rela‐
tively inexpensive and widely available. However, using 125I -labeled palmitate provides
some advantages. In practical terms, the time required for detection is considerably shorter -
hours instead of (often) weeks with 3H-palmitate. The γ-irradiation from the 125I is also com‐
patible with phosphorimaging technology which is much more rapid and quantitative than
densitometric measurements from films generated by autofluorography (as is used with tri‐
tium). The principle downside of using 125I-labeled palmitate is that it is not commercially
available, and the labeling must be done by the investigator. Reviews of the methods using
radiolabeled palmitate and including technical details have been published recently
[123-125].
4.3. Fluorescently-labeled peptide substrates for palmitoylation
Fluorescently-labeled peptides that mimic PAT substrates have been used to characterize
PAT activity and for the discovery of inhibitors of palmitoylation [123, 126, 127]. The use of
these peptides over the last several years was reviewed recently [123]. Peptide substrates for
palmitoylation have also been genetically fused to fluorescent proteins and expressed in
cells. This strategy has been used to determine how palmitoylation affects subcellular traf‐
ficking both between and within membranes [124]. Monomeric GFP-based reporters and
fluorescence resonance energy transfer proved to be helpful in the identification of lipid
rafts with an affinity for palmitate on the inner leaflet of the plasma membrane [5].
4.4. Acyl-biotin exchange: ABE
Most of the novel assays for palmitoylation utilize the same basic foundation first described
for a palmitoyl protein by Schmidt and colleagues [128] and now most commonly known as
acyl-exchange. First, free cysteines are blocked on proteins that have been extracted from
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od of time. These assays are by no means outdated and some continue to be the most
appropriate way to answer specific questions.
4.1. Chemistry and physical properties of palmitoyl cysteines: Reactions and probes
Working with palmitoylated proteins is inherently difficult due to the labile nature of the
thioester bond and the increased hydrophobicity of the protein or peptide due to palmitate.
On the other hand, the unique physical and chemical properties of thiols, palmitoylated thi‐
ols, and the thioester bond make them particularly amenable to modification by highly spe‐
cific chemistry and a wide variety of thiol reactive probes.
Reactions of free thiols in the cytoplasm
Thiol modification occurs most commonly in cells by one of two routes: disulfide exchange
or alkylation. Many of the reactive groups that undergo these two reactions are relatively
stable in aqueous environments; the reactions are rapid and provide high yields of thioether
and disulfide bonds [88]. Thiols will also react with many amine reactive reagents including
isothiocyanates and succinimidyl esters but lack a high degree of specificity, resulting in un‐
stable bonds that are much less useful for routine modification of thiols in proteins. Thiol-
specific reagents and chemistry figure strongly into the design and development of novel
assays for palmitoylation. Most investigators are limited somewhat to reagents that are
available from a catalog but, fortunately, there are already many useful reagents available.
Among the most useful are thio-reactive chemicals that are linked to another moiety (reac‐
tive or reporter) by a spacer arm of variable length and physical characteristics. Such hetero-
and homo-bifunctional crosslinking reagents have provided much of the foundation for
recent developments in palmitoylation assays and provide a fairly rich toolbox for future as‐
say development.
Chemical moieties that react with palmitoyl-cysteines
Iodoacetamide conjugates are among the most commonly used tools for modifying cysteine
thiols. These undergo nucleophilic substitution to form stable thioether bonds at physiologi‐
cal pH in aqueous environments. When using iodoacetamide and its conjugates, one should
remember that depending on the pH of the solution, they can also react with histidine, ly‐
sine, and methionine (at pH >1.7) residues and N-terminal amines. However, when used at
slightly alkaline pH in the dark and in the absence of reducing reagents, cysteine modifica‐
tion will be the exclusive reaction [88]. A good example of iodoacetamide-based probes are
the isotope-coded affinity tags or ICAT [120]. These have proved particularly useful in de‐
termining the substrates of DHHC2 [37].
Maleimides are also common constituents of heterobifunctional crosslinking reagents and
blocking reagents that target cysteines. They are ~1000 times more specific for cysteine sulf‐
hydryls at pH 6.5-7.5, but at higher pH some cross reactivity can occur with amines. Mal‐
eimides form stable thioether bonds by adding the sulfhydryl across the double bond of
the maleimide.
Phenylmercury derivatives react with thiols, including nitrosothiols, under conditions simi‐
lar to iodoacetamides and maleimides to form stable mercury-thiol bonds that can be re‐
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versed in 0.1N HCl and reducing reagents like dithiothreitol (DTT) but apparently not by
TCEP. Phenylmercury derivatives also react faster with thiols than do the commonly used
thiol-reactive N-ethylmaleimide (NEM).
Compounds containing disulfide bonds are able to undergo disulfide exchange reactions
with another thiol by the free thiol attacking the disulfide bond and subsequent formation of
a new mixed thiol. Two examples of useful compounds in this category are Methylmethane‐
thiosulfonate (MMTS) and pyridyl disulfide derivitives like biotin HPDP ((N-(6-(Biotinami‐
do)hexyl)-3'-(2'-pyridyldithio)-propionamide). MMTS can be used in some cases to block
free thiols more effectively than NEM, as it is uncharged and thus more likely to modify all
free reactive cysteines. MMTS has been shown not to react with nitrosothiols or existing di‐
sulfides [121].
4.2. Metabolic labeling with radiolabeled palmitate
The most common method to identify palmitoyl proteins and to determine the residence
half-life of palmitate on a specific protein or palmitate turnover (e.g. [122] for a particularly
interesting example) is to metabolically label cells with radiolabled palmitate. 14C-, 3H- and
125I-labeled palmitate have all been used, but 3H-palmitate is most common because it is rela‐
tively inexpensive and widely available. However, using 125I -labeled palmitate provides
some advantages. In practical terms, the time required for detection is considerably shorter -
hours instead of (often) weeks with 3H-palmitate. The γ-irradiation from the 125I is also com‐
patible with phosphorimaging technology which is much more rapid and quantitative than
densitometric measurements from films generated by autofluorography (as is used with tri‐
tium). The principle downside of using 125I-labeled palmitate is that it is not commercially
available, and the labeling must be done by the investigator. Reviews of the methods using
radiolabeled palmitate and including technical details have been published recently
[123-125].
4.3. Fluorescently-labeled peptide substrates for palmitoylation
Fluorescently-labeled peptides that mimic PAT substrates have been used to characterize
PAT activity and for the discovery of inhibitors of palmitoylation [123, 126, 127]. The use of
these peptides over the last several years was reviewed recently [123]. Peptide substrates for
palmitoylation have also been genetically fused to fluorescent proteins and expressed in
cells. This strategy has been used to determine how palmitoylation affects subcellular traf‐
ficking both between and within membranes [124]. Monomeric GFP-based reporters and
fluorescence resonance energy transfer proved to be helpful in the identification of lipid
rafts with an affinity for palmitate on the inner leaflet of the plasma membrane [5].
4.4. Acyl-biotin exchange: ABE
Most of the novel assays for palmitoylation utilize the same basic foundation first described
for a palmitoyl protein by Schmidt and colleagues [128] and now most commonly known as
acyl-exchange. First, free cysteines are blocked on proteins that have been extracted from
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live cells or tissue. Next, palmitates are removed from cysteines by cleavage of the thioester
bond with hydroxylamine (typically 1.0M) at neutral pH. This creates a new set of free thiols
unique in that they were all formerly palmitoylated; ideally, no others should exist. Finally,
this new set of formerly-palmitoylated cysteines is modified by any one of the many thiol-
specific reagents. The uniqueness of the individual assays that incorporate these steps lies
primarily in the choice of thiol-specific reagents, and this choice depends on what questions
the investigator wants to answer. There are also variations in the reagents used to block free
cysteines in the first step. Both NEM and MMTS have been used in the assays described be‐
low but NEM is used most commonly.
Cysteines that are palmitoylated can also be modified by fatty acids other that palmitate [7]
including stearate and oleate. The acyl-exhange method cannot yet distinguish between pal‐
mitate and the other fatty acids modifying cysteines by a thioester bond. Two additional
points that relate to the specificity of this method for palmitoylation are: 1) that it will not
report modification of cysteines by prenyl groups (geranylgeranyl or farnesyl) because they
are attached by a thioether bond that is not susceptible to cleavage by hydroxylamine and 2)
it will not report myristoylated proteins because this 14-carbon acyl group is linked to an N-
terminal glutamate by an amide bond which is also insensitive to cleavage by hydroxyla‐
mine.
The recent development of novel assays using the three-step acyl exchange method to study
palmitoylation in a broader sense was invigorated by two publications describing a new
twist on the method that incorporated the use of radiolabeled NEM assay [129, 130]. Work
described in these papers showed that labeling palmitoyl cysteines with radiolabeled NEM
resulted in a remarkable 5- to 12-fold increase in sensitivity to detect several known palmito‐
yl proteins, including PSD-95 and SNAP-25, when compared to labeling with 3H-palmitate.
In addition, the authors demonstrated the utility of the biotinylated, heterobifunctional
crosslinker, 4-[4′-(maleimidomethyl)cyclohexanecarboxamido] butane (Btn-BMCC), as an ef‐
fective tool to capture and purify (using streptavidin-agarose) palmitoylated proteins. In do‐
ing so, they also demonstrated the general potential of using the wide variety of existing
thiol-specific probes for the development of additional assays for palmitoylation that are be‐
ginning to materialize.
4.5. The palmitoyl proteome
The demonstration that one can effectively replace palmitate with a biotin group led to de‐
velopment of the first, large-scale, proteomic analysis of palmitoylation [74] in yeast, the
model system in which the molecular identify of PATs was first determined [23, 26]. This
method was dubbed “acyl biotin exchange” or ABE and used the same basic three-steps as
described above. As the name implies, the proteins were labeled with a thiol-reactive, bioti‐
nylated heterobifunctional probe, [6-(Biotinamido)hexyl]-3'-(2'-pyridyldithio)propionamide
(HPDP-biotin), with subsequent capture on streptavidin affinity matrix (for a detailed proto‐
col see Wan et al. 2007 [131]). It is interesting to note the number of proteins that Roth and
colleagues captured in the negative control samples (Figure 1a;[74]). The degree of overlap
among proteins captured in the experimental and control samples suggests that the step in
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which free thiols were blocked with NEM was not quantitative and/or that the wash steps
following binding of biotinylated proteins to the streptavidin matrix were not sufficiently
stringent (steps 7 and 16 respectively from Wan et al, 2007 [131]) thereby resulting in the po‐
tential for a higher number of false-positive hits. However, issues of signal to noise and lim‐
its of sensitivity are by no means unique to this work (avidin-biotin affinity purification is
notoriously difficult); rather they are unavoidable issues faced by all developers of novel
strategies and users of nascent technologies. Incremental improvements in important assays
like this always follow.
One of the key features of all proteomic methods is the system used for detection of specifi‐
cally-isolated proteins or peptides. Work by Roth et al. [74] identified proteins by multi-di‐
mensional protein identification technology (MudPIT), a high-throughput, tandem mass
spectrometry (MS/MS)-based proteomic technology [132] [see also [131, 133]]. Compared to
other mass spectrometric methods, MudPIT has the potential to identify less abundant pro‐
teins with a higher degree of confidence, because multiple peptides of a single protein can
be used to identify a protein of interest. One downside with MudPIT in this case is that the
palmitoyl cysteine(s) cannot be pinpointed, as there may be many candidates among the in‐
dividual peptides of a whole protein suspected as being a palmitoyl protein. After demon‐
strating the usefulness of this large-scale method for purification and identification of
palmitoylated proteins, the authors used mutant strains of yeast lacking one or more of the
seven yeast PAT proteins to identify substrates of individual PATs. Comparison of the de‐
gree of palmitoylation of individual proteins between wild type yeast (a full set of normally
palmitoylated proteins) and those not expressing one or more of the yeast PATs (each with a
specific set of hypo/depalmitoylated proteins) provided the identity of the substrates of indi‐
vidual PATs. Together, this work represents a very significant contribution to the identifica‐
tion and understanding of the yeast palmitoyl proteome and provided many important
clues about potential homologous PAT-substrate pairs in other systems.
The complexity of palmitoylation is greater in a vertebrate system. With at least 23 genes en‐
coding PATs identified in humans, the diversity at the most basic level is at least three-fold
greater than in yeast. When one considers the additional variants encoded by alternative
splicing of PAT mRNAs, the potential diversity increases even more. The greater number of
PATs suggests (but does not prove) that there are also more palmitoylated proteins in mam‐
mals. The ability to genetically manipulate mammalian cells is improving but lags behind
yeast. Nevertheless, defining the palmitoyl proteome or palmitoylosome and how it is regu‐
lated in mammals (humans in particular) is a task of significant importance and interest.
Now that the enzymes capable of mediating palmitoylation have been identified, one of the
most important questions that we face is which substrates are palmitoylated by each PAT—
a question brought sharply into focus when one considers the known connections between
mutations or deletions in PAT genes and human disease, in particular cancer. DHHC2 is de‐
leted in many types of cancer (see above). Its absence is strongly correlated with an increase
in the metastatic potential of cancer cells. The simplest inverse corollary in this case is that
palmitoylated substrates of DHHC2 are responsible for keeping cells from metastasizing.
Identification of these substrates and their associated signaling networks using novel assays
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live cells or tissue. Next, palmitates are removed from cysteines by cleavage of the thioester
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unique in that they were all formerly palmitoylated; ideally, no others should exist. Finally,
this new set of formerly-palmitoylated cysteines is modified by any one of the many thiol-
specific reagents. The uniqueness of the individual assays that incorporate these steps lies
primarily in the choice of thiol-specific reagents, and this choice depends on what questions
the investigator wants to answer. There are also variations in the reagents used to block free
cysteines in the first step. Both NEM and MMTS have been used in the assays described be‐
low but NEM is used most commonly.
Cysteines that are palmitoylated can also be modified by fatty acids other that palmitate [7]
including stearate and oleate. The acyl-exhange method cannot yet distinguish between pal‐
mitate and the other fatty acids modifying cysteines by a thioester bond. Two additional
points that relate to the specificity of this method for palmitoylation are: 1) that it will not
report modification of cysteines by prenyl groups (geranylgeranyl or farnesyl) because they
are attached by a thioether bond that is not susceptible to cleavage by hydroxylamine and 2)
it will not report myristoylated proteins because this 14-carbon acyl group is linked to an N-
terminal glutamate by an amide bond which is also insensitive to cleavage by hydroxyla‐
mine.
The recent development of novel assays using the three-step acyl exchange method to study
palmitoylation in a broader sense was invigorated by two publications describing a new
twist on the method that incorporated the use of radiolabeled NEM assay [129, 130]. Work
described in these papers showed that labeling palmitoyl cysteines with radiolabeled NEM
resulted in a remarkable 5- to 12-fold increase in sensitivity to detect several known palmito‐
yl proteins, including PSD-95 and SNAP-25, when compared to labeling with 3H-palmitate.
In addition, the authors demonstrated the utility of the biotinylated, heterobifunctional
crosslinker, 4-[4′-(maleimidomethyl)cyclohexanecarboxamido] butane (Btn-BMCC), as an ef‐
fective tool to capture and purify (using streptavidin-agarose) palmitoylated proteins. In do‐
ing so, they also demonstrated the general potential of using the wide variety of existing
thiol-specific probes for the development of additional assays for palmitoylation that are be‐
ginning to materialize.
4.5. The palmitoyl proteome
The demonstration that one can effectively replace palmitate with a biotin group led to de‐
velopment of the first, large-scale, proteomic analysis of palmitoylation [74] in yeast, the
model system in which the molecular identify of PATs was first determined [23, 26]. This
method was dubbed “acyl biotin exchange” or ABE and used the same basic three-steps as
described above. As the name implies, the proteins were labeled with a thiol-reactive, bioti‐
nylated heterobifunctional probe, [6-(Biotinamido)hexyl]-3'-(2'-pyridyldithio)propionamide
(HPDP-biotin), with subsequent capture on streptavidin affinity matrix (for a detailed proto‐
col see Wan et al. 2007 [131]). It is interesting to note the number of proteins that Roth and
colleagues captured in the negative control samples (Figure 1a;[74]). The degree of overlap
among proteins captured in the experimental and control samples suggests that the step in
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which free thiols were blocked with NEM was not quantitative and/or that the wash steps
following binding of biotinylated proteins to the streptavidin matrix were not sufficiently
stringent (steps 7 and 16 respectively from Wan et al, 2007 [131]) thereby resulting in the po‐
tential for a higher number of false-positive hits. However, issues of signal to noise and lim‐
its of sensitivity are by no means unique to this work (avidin-biotin affinity purification is
notoriously difficult); rather they are unavoidable issues faced by all developers of novel
strategies and users of nascent technologies. Incremental improvements in important assays
like this always follow.
One of the key features of all proteomic methods is the system used for detection of specifi‐
cally-isolated proteins or peptides. Work by Roth et al. [74] identified proteins by multi-di‐
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spectrometry (MS/MS)-based proteomic technology [132] [see also [131, 133]]. Compared to
other mass spectrometric methods, MudPIT has the potential to identify less abundant pro‐
teins with a higher degree of confidence, because multiple peptides of a single protein can
be used to identify a protein of interest. One downside with MudPIT in this case is that the
palmitoyl cysteine(s) cannot be pinpointed, as there may be many candidates among the in‐
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greater than in yeast. When one considers the additional variants encoded by alternative
splicing of PAT mRNAs, the potential diversity increases even more. The greater number of
PATs suggests (but does not prove) that there are also more palmitoylated proteins in mam‐
mals. The ability to genetically manipulate mammalian cells is improving but lags behind
yeast. Nevertheless, defining the palmitoyl proteome or palmitoylosome and how it is regu‐
lated in mammals (humans in particular) is a task of significant importance and interest.
Now that the enzymes capable of mediating palmitoylation have been identified, one of the
most important questions that we face is which substrates are palmitoylated by each PAT—
a question brought sharply into focus when one considers the known connections between
mutations or deletions in PAT genes and human disease, in particular cancer. DHHC2 is de‐
leted in many types of cancer (see above). Its absence is strongly correlated with an increase
in the metastatic potential of cancer cells. The simplest inverse corollary in this case is that
palmitoylated substrates of DHHC2 are responsible for keeping cells from metastasizing.
Identification of these substrates and their associated signaling networks using novel assays
Discovery of Selective and Potent Inhibitors of Palmitoylation
http://dx.doi.org/10.5772/52503
265
for palmitoylation has begun to provide supporting evidence for known mechanisms of can‐
cer progression [56] as well as a novel signaling pathway for the regulation of cellular prolif‐
eration and metastasis [37].
Figure 2. Palmitoyl-cysteine Identification Capture and Analysis (PICA): Determining PAT-substrate specificity by dif‐
ferential labeling of palmitoylated proteins with Isotope-coded Affinity Tags (ICAT) (A) In one set of cultures, ZDHHC2
expression is knocked down by transfecting HeLa cells with ZDHHC2-specific siRNA (Dharmacon). Proteins are extract‐
ed from experimental and control cells and treated with the thiol-specific blocking reagent MMTS. This step chemical‐
ly modifies or protects all thiols (“X” on the proteins P1-P3) that are free at physiological pH and leaves the
palmitoylated cysteines (P) undisturbed as depicted on P1-P3. (B) Following the protection or blocking of free thiols,
palmitates are removed by selective cleavage of the thioester bond with hydroxylamine at pH 7.4, which generates a
distinctive set of free, formerly-palmitoylated, reactive thiols (C) that can be selectively labeled with ICAT reagents. Io‐
doacetamide at one end of the ICAT reagent binds to the thiol sidechain of cysteines; on the other end, biotin pro‐
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vides a mechanism for affinity purification of thiol-captured peptides on an avidin column. (D) Proteins from
knockdown and control conditions are mixed in equal amounts and digested in-gel with trypsin. ICAT labeled pepti‐
des are enriched by avidin affinity and analyzed by LC/MS. A pair of ICAT-labeled peptides is chemically identical and
is easily visualized, because they essentially coelute and there is a 9 Da mass difference measured in a scanning mass
spectrometer. Even if equal amounts of a single protein exist in two different samples, the quantity of protein that is
captured depends directly on its degree of palmitoylation; if all of a single protein is palmitoylated under one condi‐
tion, then all of it will be captured; if only half of this protein is palmitoylated under another condition then the cap‐
ture rate of that protein will be half as much, relative to control, making it appear half as abundant. Proteins for which
there has been no change in palmitoylation (ie, equal capture rates) will yield a heavy:light (H/L) ratio of 1. The degree
to which palmitoylation is diminished will register as a decrease in the H/L ratio (ie, 50% reduction in palmitoylation
will correspond to a H/L ratio of 0.5). A change in the capture rate that results in a change in the post-purification
abundance is measured in the LC/MS phase. (E) Finally, the peptides are further fragmented into their constituent
amino acids by MS/MS, enabling identification of the proteins corresponding to the captured peptides.
4.6. Palmitoyl-cysteine Identification Capture and Analysis (PICA): Identification of PAT
substrates and palmitoyl proteins in vertebrates
With the aim of defining PAT-substrate specificity in a living vertebrate system, we devel‐
oped a method to identify substrates of specific PATs in mammalian cells and tissues called
Palmitoyl cysteine Isolation Capture and Analysis or PICA [37]. We used this method to
identify CKAP4/p63, a known palmitoyl protein [134] as one substrate of DHHC2 in HeLa
cells [37]. This method is similar to ABE as described by Roth et al (2006) but was inspired
[135] in part by the work of Drisdel and Green (2004) and incorporated several novel fea‐
tures that will be discussed below.
The ability of PICA to identify PAT substrates is based on the principle that it quantifies the
differential frequency of palmitoylation of individual proteins or peptides in control condi‐
tions versus conditions in which the function of a single PAT is reduced by siRNA-mediated
gene knockdown. The process to identify substrates of DHHC2 consisted of four basic steps
outlined in Figure 2. In the first part we generated two distinct pools of palmitoylated pro‐
teins, one from control HeLa cells and the other from HeLa cells in which the activity of one
PAT (DHHC2) was reduced. These two distinct pools of palmitoylated proteins were then
captured and compared directly to identify differences in the degree of palmitoylation of in‐
dividual proteins between the two pools. To do this, we reduced the expression of ZDDHC2
mRNA (and consequently the abundance of the encoded enzyme, DHHC2) in HeLa cells us‐
ing siRNA-mediated gene knockdown which resulted in a reduced level of palmitoylation
of DHHC2 substrates. Total protein from knockdown and control cells was prepared by first
blocking free thiols with MMTS in the presence of SDS. This was followed by selective expo‐
sure of all palmitoyl cysteines by cleavage of the palmitoyl-cysteine thioester bond with
1.0M hydroxylamine at neutral pH, thereby generating a unique population of formerly pal‐
mitoylated cysteines. Second, we selectively and differentially labeled the exposed, former‐
ly-palmitoylated cysteines from knockdown and control cells with biotinylated, thiol-
reactive heavy (H) and light (L) ICAT reagents, respectively. Third, we combined equal
quantities of the ICAT-labeled protein from ZDHHC2 knockdown and control cells and di‐
gested the mixture with trypsin. The resulting H and L ICAT-labeled tryptic peptides were
captured and purified on an avidin affinity column. Finally, ICAT-labeled, putative, former‐
ly-palmitoylated peptides were analyzed by mass spectrometry. Peptides with a reduced
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tures that will be discussed below.
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H/L ratio over four independent runs were analyzed further to confirm that the identified
cysteine was indeed palmitoylated by DHHC2 under physiological conditions. Details of the
protocol and reagents used and outlined in Figure 2 can be found in [37].
There are several unique aspects in the PICA method. First, we used MMTS to block the free
thiols in the first step. NEM is used most commonly at this step, but MMTS is more reactive
and smaller than NEM or iodoacetamide, enhancing its ability to modify all free reactive
cysteines. Inefficient blocking of free thiols in the first step is one factor that could easily
contribute to false-positive capture of proteins in the purification step. Qualitative evalua‐
tion (silver-stained SDS-PAGE) of protein capture in experimental and control (no-hydrox‐
ylamine) conditions [Figure 2, [37]] suggests that it may be more efficient than NEM (for
comparison see Figure 1A [74]). However, it may also be that we captured very few proteins
under control conditions because of a more stringent wash protocol than described by Roth
et al [74]. The use of ICAT reagents in PICA allowed us to combine formerly-palmitoylated
peptides purified from control and experimental cells in the same pool, and subsequently, a
direct, simultaneous analysis of palmitoylation in the two pools in a single analytical sam‐
ple. We defined a substrate of DHHC2 as one that had a consistently reduced H/L ratio over
four independent PICA runs. This approach provided us with many (the vast majority), con‐
venient internal control peptides which are peptides that were not substrates of DHHC2
that had unchanged H/L ratios. This approach significantly reduces the potential for identi‐
fication of false-positive hits because, if a protein can be falsely labeled by an ICAT, it
should do so with equal efficiency in both the control and experimental cells yielding a pep‐
tide with an H/L ratio of ~1. The greater risk with this approach is the failure to identify sub‐
strates that exist in low abundance. Using tandem mass spectrometry, we analyzed a sample
of significantly reduced complexity including only ICAT-tagged peptides. As is inherent in
such analyses, the most abundant peptides dominate the report. However, one advantage of
this approach is that when a peptide is identified, whether it is a substrate of a single PAT or
not, the palmitoyl cysteine(s) is also identified. In the case of CKAP4/p63 (and the majority
of other peptides) there was only a single cysteine, and it was already known to be a site for
palmitoylation [134]. Spectral counting has the potential to positively identify palmitoyl pro‐
teins of lower abundance because more than a single peptide from any given protein is fac‐
tored into to the identification. There is greater overall coverage (identified peptide
fragments of a protein) using this method thereby increasing the confidence level of identifi‐
cation. However, the disadvantage inherent in analyzing a complex mixture, including non-
palmitoylated peptides by spectral counting, is that identification of the palmitoyl cysteine
(in the cases where there are multiple candidate cysteines) must await subsequent and tedi‐
ous analyses. The tradeoff between these two complementary approaches in mass spectro‐
metric analysis is sensitivity versus specificity. Combining these analyses will provide a
much greater depth of coverage.
4.7. Forward and reverse approaches to assigning PAT-substrate pairs
The first reports that identified PAT-substrate pairings took the reverse approach: start with
a known palmitoylated protein then use metabolic labeling with radiolabeled palmitate and
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co-overexpression of one PAT and the substrate (for a review see: [72]). Using this method,
an increase in the incorporation of radiolabled palmitate on the overexpressed substrate in
the presence of an overexpressed PAT is used to claim specificity. This method is an impor‐
tant tool for increasing our understanding of palmitoylation-related phenomena including
confirmation of putative PAT-substrate pairs identified by other methods. Likewise, when
starting with a known palmitoyl protein and the intention of identifying the PAT responsi‐
ble for its palmitoylation, it remains a useful method. However, we should remember that
just because overexpression of a PAT can increase the incorporation of palmitate onto a spe‐
cific protein does not necessarily mean that it does so in a live cell. Again, problems like this
are not unique to this method and simply reflect our lack of knowledge about where and
when PATs and their substrates are expressed, the degree of promiscuity among PATs and,
how PAT function is regulated.
The potential for specific cysteines to be modified by both palmitate and RA via a thioester
bond is an issue that deserves attention from those of us interested primarily in palmitoyla‐
tion for at least two reasons. One is the potential that an exchange between the two modifi‐
cations is a physiologically relevant means of regulating signaling and second, the
possibility that proteins identified as being palmitoylated in assays utilizing some form of
ABE chemistry are RA-modified instead.
4.8. Labeling palmitoyl proteins with bioorthogonal probes
This particularly interesting approach labels cysteines with isosteric, azido-derivitives of
fatty acids that are able to substitute for fatty acids that occur naturally in cells (Figure
3) [112, 136]. Once bound to cysteines, the azido group on the fatty acid is reacted, with
a high degree of selectivity, via the Staudinger reaction [137] with (triaryl)phosphines that
are themselves derivatized with Myc, biotin, a fluorophore, or others. Using this meth‐
od Hang and colleagues [112] found that ω-azido fatty acids with 12 and 15 carbons can
be efficiently metabolized by mammalian cells and accurately report myristoylation and
thio-palmitoylation, respectively.
Work  by  Kostiuk  and  colleagues  identified  palmitoyl  proteins  from mitochondria  us‐
ing  azido-palmitate  [136].  To  accomplish  this  they  purified  proteins  from cellular  mito‐
chondrial fractions,  first  by differential  centrifugation, then by further purification based
first  on charge and subsequently by size using chromatographic  separation.  Labeling of
proteins in this  study was outside of  a  living system presumably leaving only the pos‐
sibility  of  autocatalytic/non-enzymatic  palmitoylation.  Mass spectrometric  analysis  of  se‐
lected bands identified 21 palmitoylated proteins,  19 of  which were novel.  The majority
of  the  proteins  labeled were  metabolic-type  proteins  unique to  the  mitochondrion.  This
raises  the  interesting  possibility  that  the  principle  mechanism of  palmitoylation  in  this
organelle  is  autocatalytic  rather  than  enzymatic,  and  that,  as  suggested  by  the  au‐
thors,  the key role of  palmitoylation in the mitochondrion is  to inhibit  enzymes by pal‐
mitoylation  of  cysteines  in  the  vicinity  of  the  active  site.
These so called bio-orthogonal probes have been reported to be nontoxic and very stable un‐
der physiological conditions. Importantly, this two-step reaction is rapid and more sensitive
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than labeling with 125I-palmitoyl-CoA. These features, especially their ability to effectively
substitute for endogenous fatty acids, make them ideal for labeling palmitoyl proteins in
live cells, providing a significantly more direct measure of protein palmitoylation than can
be achieved in any other assay format. It is easy to imagine that use of such probes will
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Figure 3. Using Click chemistry and bio-orthogonal probes to label palmitoyl cysteines. A) A palmitoylated protein; the
shaded box indicates the thioester bond. B) Azido-palmitate is transferred to a protein forming a thioester bond with
a cysteine residue. The azide moiety of the azido-palmitate reacts, via the Staudinger reaction, with the tagged (in this
case biotin) phosphine, forming an amide bond. The biotin-tagged proteins can then be affinity purified and analyzed
in various ways including mass spectrometry. Tags and reporters other than biotin can be added to the phosphine
providing a wide array of potential methods for subsequent analyses.
5. Pharmacological modulation of Palmitoylation
5.1. Developing compounds that selectively target individual PATs
Existing chemicals used to inhibit palmitoylation are neither selective nor potent. The com‐
pounds used most commonly are 2-bromopalmitate (2BP), tunicamycin, and cerulenin. Each
of these is a lipid-based molecule (Figure 4). 2BP has been used most frequently at a concen‐
tration of ~100 µM to block palmitoylation in spite of the fact that at least two studies have
shown that the IC50 of 2-BP is ~10 µM [138, 139]. 2BP is not tolerated well by cultured cells
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and causes death even after a brief exposure to 100 µM. 2BP inhibits several enzymes in‐
volved in lipid metabolism, including carnitine palmitoyltransferase 1, fatty acid CoA ligase,
glycerol-3-phosphate acyltransferase, and enzymes in the synthesis of triacylglycerol bio‐
synthesis [140, 141]. This high degree of promiscuity as well as the toxicity of 2BP renders it
nearly useless as a tool to determine anything specific about palmitoylation related signal‐
ing issues that equally plague cerulenin and tunicamycin. The uses and effects of these three




Figure 4. Lipid-based inhibitors of palmitoylation.
Smith and colleagues [126] recently screened a compound library in an attempt to identify
more selective and potent inhibitors of palmitoylation, in particular inhibitors of PATs. This
screen identified single compounds from five chemical classes (Compounds I-V) that inhib‐
ited cellular processes associated with palmitoylation. The assays used in the screens includ‐
ed: measuring the in vivo and in vitro growth rate of an NIH/3T3 cell line that overexpressed
DHHC17, displacement from the plasma membrane of myristoylated or farnesylated GFP,
and in vitro palmitoylation of small, non-complex, myristoylated or farnesylated, synthetic,
fluorescent peptides intended to mimic known palmitoylation substrates [123, 126, 127].
These assays could not discriminate a direct effect of any compound on any PAT. They
could only report the activity of compounds that acted at some point (not excluding direct
PAT inhibition) in any pathway that leads to or affects palmitoylation; compounds like 2BP,
cerulenin, and tunicamycin. This assertion was borne out in follow-up studies on the same
compounds [138] (see below). Perhaps the most intriguing finding in this report was that
compounds I-IV were able to suppress the oncogenic behavior of human cells that overex‐
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than labeling with 125I-palmitoyl-CoA. These features, especially their ability to effectively
substitute for endogenous fatty acids, make them ideal for labeling palmitoyl proteins in
live cells, providing a significantly more direct measure of protein palmitoylation than can
be achieved in any other assay format. It is easy to imagine that use of such probes will
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providing a wide array of potential methods for subsequent analyses.
5. Pharmacological modulation of Palmitoylation
5.1. Developing compounds that selectively target individual PATs
Existing chemicals used to inhibit palmitoylation are neither selective nor potent. The com‐
pounds used most commonly are 2-bromopalmitate (2BP), tunicamycin, and cerulenin. Each
of these is a lipid-based molecule (Figure 4). 2BP has been used most frequently at a concen‐
tration of ~100 µM to block palmitoylation in spite of the fact that at least two studies have
shown that the IC50 of 2-BP is ~10 µM [138, 139]. 2BP is not tolerated well by cultured cells
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and causes death even after a brief exposure to 100 µM. 2BP inhibits several enzymes in‐
volved in lipid metabolism, including carnitine palmitoyltransferase 1, fatty acid CoA ligase,
glycerol-3-phosphate acyltransferase, and enzymes in the synthesis of triacylglycerol bio‐
synthesis [140, 141]. This high degree of promiscuity as well as the toxicity of 2BP renders it
nearly useless as a tool to determine anything specific about palmitoylation related signal‐
ing issues that equally plague cerulenin and tunicamycin. The uses and effects of these three




Figure 4. Lipid-based inhibitors of palmitoylation.
Smith and colleagues [126] recently screened a compound library in an attempt to identify
more selective and potent inhibitors of palmitoylation, in particular inhibitors of PATs. This
screen identified single compounds from five chemical classes (Compounds I-V) that inhib‐
ited cellular processes associated with palmitoylation. The assays used in the screens includ‐
ed: measuring the in vivo and in vitro growth rate of an NIH/3T3 cell line that overexpressed
DHHC17, displacement from the plasma membrane of myristoylated or farnesylated GFP,
and in vitro palmitoylation of small, non-complex, myristoylated or farnesylated, synthetic,
fluorescent peptides intended to mimic known palmitoylation substrates [123, 126, 127].
These assays could not discriminate a direct effect of any compound on any PAT. They
could only report the activity of compounds that acted at some point (not excluding direct
PAT inhibition) in any pathway that leads to or affects palmitoylation; compounds like 2BP,
cerulenin, and tunicamycin. This assertion was borne out in follow-up studies on the same
compounds [138] (see below). Perhaps the most intriguing finding in this report was that
compounds I-IV were able to suppress the oncogenic behavior of human cells that overex‐
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pressed DHHC17. However, there is no direct evidence to indicate that compounds I-IV ex‐
ert these actions via inhibition of DHHC17 or through the palmitoylation of Ras proteins by
DHHC17 as was speculated [53, 126]. Nevertheless, since these compounds reduced the in
vivo growth of tumors from cells overexpressing DHHC17 [126], it would be worth deter‐
mining their exact mechanism of action.
Subsequent studies by Linder, Deschenes and colleagues [138] tested four of the five com‐
pounds identified by Smith and colleagues and found that they were not selective for
DHHC proteins. This report also included a wealth of information defining the mechanisms
by which 2BP inhibits palmitoylation. Briefly, only one of the four compounds re-tested,
compound V and 2BP, inhibited the activity of any of the four DHHC proteins tested. Nei‐
ther compound V nor 2BP was selective for any of the PATs tested, and 2BP was more po‐
tent. Both compound V and 2BP blocked autoacylation of the PATs; compound V was
reversible, 2BP was not. Even though compound V was able to inhibit the activity of the
four PATs tested and in the same manner as 2BP, these experiments could not determine
whether compound V also blocks palmitoylation indiscriminately at steps prior to the actual
palmitoylation event, as is the case with 2BP, cerulenin, and tunicamycin.
There would be no compelling reason to begin a drug discovery program to identify inhibi‐
tors of just any PAT. Rather one would choose to begin with a PAT that is linked to a dis‐
ease state—a situation where misregulated expression or function of that PAT was clearly
linked to a pathological state. As discussed earlier, links between PAT expression (but not
yet altered function) have been demonstrated for both neurological disorders and cancer;
thus, candidate PATs that would be appropriate targets for drug development exist. Both
overexpression and absence of PAT expression have been implicated in the development of
cancer. Dampening the activity of an existing PAT is a conceptually and mechanistically
simpler task than accurately restoring the specific activity of a PAT that is not expressed or
absent. This review is concerned with PAT assays and PAT inhibitors, so we will address
the case of PAT overexpression in ideal terms as well as the technical issues that surround
the development and implementation of the assays designed to discover PAT inhibitors.
5.2. Considerations for development of high-throughput screens to discover PAT
inhibitors
The DHHC motif in PATs defines the active site and is highly conserved in all mammalian
PATs [3]. The regions of highest diversity are primarily in the N- and C-termini of the PAT.
Mutation of the cysteine in the DHHC motif abolishes PAT autoacylation and palmitoyla‐
tion of the substrate, a property of all DHHC proteins studied so far. This high degree of
homology in the active site sequence among PATs could give the impression that develop‐
ing highly specific, active-site inhibitors for palmitoylation will be impossible. However, this
same issue exists with kinases [143, 144], and yet the development of selective and potent
active-site, ATP-competitive inhibitors has been successful (eg, [145]).
The specificity of palmitoylation must be derived in part from the unique physical interac‐
tions of individual PATs with their substrates. The sequence of amino acids surrounding a
substrate cysteine partially defines the potential for that cysteine to be palmitoylated. How‐
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ever, the physical determinants for substrate recognition will likely extend throughout the
accessible portions of the PAT and substrate as was elegantly demonstrated for DHHC17
[146]. Other factors that are likely to regulate palmitoylation are the temporal and spatial as‐
pects of PAT and substrate expression.
There are many more palmitoylated proteins than there are PATs; therefore, modulating the
activity of a single PAT, even with complete compound selectivity, will likely yield a change
in the palmitoylation of multiple substrates. This conundrum is common to the develop‐
ment of highly selective and potent pharmacological modulators of all enzymes that medi‐
ate post-translational protein modifications, again kinases being a classic example.
Another challenge is that each PAT traverses the plasma membrane multiple times. A con‐
servative guess would suggest that the membrane environment is important for determin‐
ing PAT structure and substrate recognition. However, Jennings et al.,[138] demonstrated
that at least four PATs can be purified from a membrane environment and remain enzymati‐
cally active. These findings are both remarkable and encouraging evidence that enzyme ac‐
tivity-based and drug-binding screens for selective PAT inhibitors can be accomplished with
purified proteins.
5.3. Primary screen for PAT inhibitors
The discovery and refinement of drugs to modulate PAT activity will require the use of mul‐
tiple assay types. The initial success of each can only be a matter of speculation at the begin‐
ning of the project, and the success of the primary screen will influence the choice of follow
up assays. However, one unique aspect of palmitoylation suggests a logical starting point.
The most dramatic visible change that can occur when a protein is palmitoylated is when it
moves from the cytoplasm to the plasma (or other) membrane. The technology to measure
such a translocation in living cells using high-throughput microscopy has been demonstrat‐
ed [139, 147] and along with many other such morphometric analyses, has become well es‐
tablished in drug discovery programs and the basic life sciences [148-150]. This technology
is often referred to as high-content screening (HCS). To develop an assay to identify inhibi‐
tors of a single PAT using HCS, it would be ideal to have identified the most clinically rele‐
vant, cytosolic substrate of the PAT of interest and to have determined that this substrate is
palmitoylated exclusively by this one PAT or, alternatively, by no other PAT expressed in
the cell type that will be used for the screen. However, biological systems rarely offer ideal
situations, and accommodations will inevitably need to be made. The ideal substrate would
then be fused to a monomeric fluorescent protein (FP) [5, 151] to generate a fluorescent re‐
porter of palmitoylation that localizes primarily or exclusively to the PM. Cells stably ex‐
pressing this reporter would then be grown in multi-well imaging plates and exposed to a
chemical compound library, and the subcellular distribution of the FP-tagged palmitoyla‐
tion substrate evaluated by HCS. Compounds that cause redistribution of the fluorescent re‐
porter from the PM to the cytoplasm are candidates (or hits) for follow up analyses that will
determine if they blocked palmitoylation of the reporter by directly inhibiting the PAT of
interest or indirectly by some other mechanism. Typically, compounds in a large library
(tens to hundreds of thousands of compounds) are tested at a single concentration and repli‐
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pressed DHHC17. However, there is no direct evidence to indicate that compounds I-IV ex‐
ert these actions via inhibition of DHHC17 or through the palmitoylation of Ras proteins by
DHHC17 as was speculated [53, 126]. Nevertheless, since these compounds reduced the in
vivo growth of tumors from cells overexpressing DHHC17 [126], it would be worth deter‐
mining their exact mechanism of action.
Subsequent studies by Linder, Deschenes and colleagues [138] tested four of the five com‐
pounds identified by Smith and colleagues and found that they were not selective for
DHHC proteins. This report also included a wealth of information defining the mechanisms
by which 2BP inhibits palmitoylation. Briefly, only one of the four compounds re-tested,
compound V and 2BP, inhibited the activity of any of the four DHHC proteins tested. Nei‐
ther compound V nor 2BP was selective for any of the PATs tested, and 2BP was more po‐
tent. Both compound V and 2BP blocked autoacylation of the PATs; compound V was
reversible, 2BP was not. Even though compound V was able to inhibit the activity of the
four PATs tested and in the same manner as 2BP, these experiments could not determine
whether compound V also blocks palmitoylation indiscriminately at steps prior to the actual
palmitoylation event, as is the case with 2BP, cerulenin, and tunicamycin.
There would be no compelling reason to begin a drug discovery program to identify inhibi‐
tors of just any PAT. Rather one would choose to begin with a PAT that is linked to a dis‐
ease state—a situation where misregulated expression or function of that PAT was clearly
linked to a pathological state. As discussed earlier, links between PAT expression (but not
yet altered function) have been demonstrated for both neurological disorders and cancer;
thus, candidate PATs that would be appropriate targets for drug development exist. Both
overexpression and absence of PAT expression have been implicated in the development of
cancer. Dampening the activity of an existing PAT is a conceptually and mechanistically
simpler task than accurately restoring the specific activity of a PAT that is not expressed or
absent. This review is concerned with PAT assays and PAT inhibitors, so we will address
the case of PAT overexpression in ideal terms as well as the technical issues that surround
the development and implementation of the assays designed to discover PAT inhibitors.
5.2. Considerations for development of high-throughput screens to discover PAT
inhibitors
The DHHC motif in PATs defines the active site and is highly conserved in all mammalian
PATs [3]. The regions of highest diversity are primarily in the N- and C-termini of the PAT.
Mutation of the cysteine in the DHHC motif abolishes PAT autoacylation and palmitoyla‐
tion of the substrate, a property of all DHHC proteins studied so far. This high degree of
homology in the active site sequence among PATs could give the impression that develop‐
ing highly specific, active-site inhibitors for palmitoylation will be impossible. However, this
same issue exists with kinases [143, 144], and yet the development of selective and potent
active-site, ATP-competitive inhibitors has been successful (eg, [145]).
The specificity of palmitoylation must be derived in part from the unique physical interac‐
tions of individual PATs with their substrates. The sequence of amino acids surrounding a
substrate cysteine partially defines the potential for that cysteine to be palmitoylated. How‐
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ever, the physical determinants for substrate recognition will likely extend throughout the
accessible portions of the PAT and substrate as was elegantly demonstrated for DHHC17
[146]. Other factors that are likely to regulate palmitoylation are the temporal and spatial as‐
pects of PAT and substrate expression.
There are many more palmitoylated proteins than there are PATs; therefore, modulating the
activity of a single PAT, even with complete compound selectivity, will likely yield a change
in the palmitoylation of multiple substrates. This conundrum is common to the develop‐
ment of highly selective and potent pharmacological modulators of all enzymes that medi‐
ate post-translational protein modifications, again kinases being a classic example.
Another challenge is that each PAT traverses the plasma membrane multiple times. A con‐
servative guess would suggest that the membrane environment is important for determin‐
ing PAT structure and substrate recognition. However, Jennings et al.,[138] demonstrated
that at least four PATs can be purified from a membrane environment and remain enzymati‐
cally active. These findings are both remarkable and encouraging evidence that enzyme ac‐
tivity-based and drug-binding screens for selective PAT inhibitors can be accomplished with
purified proteins.
5.3. Primary screen for PAT inhibitors
The discovery and refinement of drugs to modulate PAT activity will require the use of mul‐
tiple assay types. The initial success of each can only be a matter of speculation at the begin‐
ning of the project, and the success of the primary screen will influence the choice of follow
up assays. However, one unique aspect of palmitoylation suggests a logical starting point.
The most dramatic visible change that can occur when a protein is palmitoylated is when it
moves from the cytoplasm to the plasma (or other) membrane. The technology to measure
such a translocation in living cells using high-throughput microscopy has been demonstrat‐
ed [139, 147] and along with many other such morphometric analyses, has become well es‐
tablished in drug discovery programs and the basic life sciences [148-150]. This technology
is often referred to as high-content screening (HCS). To develop an assay to identify inhibi‐
tors of a single PAT using HCS, it would be ideal to have identified the most clinically rele‐
vant, cytosolic substrate of the PAT of interest and to have determined that this substrate is
palmitoylated exclusively by this one PAT or, alternatively, by no other PAT expressed in
the cell type that will be used for the screen. However, biological systems rarely offer ideal
situations, and accommodations will inevitably need to be made. The ideal substrate would
then be fused to a monomeric fluorescent protein (FP) [5, 151] to generate a fluorescent re‐
porter of palmitoylation that localizes primarily or exclusively to the PM. Cells stably ex‐
pressing this reporter would then be grown in multi-well imaging plates and exposed to a
chemical compound library, and the subcellular distribution of the FP-tagged palmitoyla‐
tion substrate evaluated by HCS. Compounds that cause redistribution of the fluorescent re‐
porter from the PM to the cytoplasm are candidates (or hits) for follow up analyses that will
determine if they blocked palmitoylation of the reporter by directly inhibiting the PAT of
interest or indirectly by some other mechanism. Typically, compounds in a large library
(tens to hundreds of thousands of compounds) are tested at a single concentration and repli‐
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cated, often three times, to increase the confidence of selecting biologically active com‐
pounds. But, the relationship of replicates is solely statistical, not pharmacological. An
alternative screening method for identifying hits is “titration-based screening” called qHTS
[152]. This method, which has been used successfully by Jim Inglese, Doug Auld and Collea‐
gues at the NIH Chemical Genomics Center, measures the assay system response to multi‐
ple (up to seven), different concentrations of a single compound. The increased density and
accuracy of the data produced by this method can provide many benefits over screening at a
single concentration (for a full description of the merits of qHTS see [152]). Among the most
important benefits of screening at multiple concentrations is that it alleviates the problems
of false-negatives and false-positives that plague screens run at a single concentration. The
nominal, additional effort required at the front end of the process is generously compensat‐
ed by a subsequent reduction in the effort required to choose which hits to pursue in follow-
up assays.
Displacement or translocation of the fluorescent palmitoylation reporter from the PM to the
cytoplasm in response to a compound cannot provide evidence that the compound has this
effect by direct inhibition of a PAT. Secondary screens designed to determine which of the
hits works by direct inhibition of PAT activity will be required. One option would be to de‐
termine the effects of each hit on the enzymatic activity of the PAT of interest. Jennings et al
have demonstrated that a PAT can be purified from a membrane environment and retain its
enzymatic function i.e., transfer of palmitate to a substrate. The metabolically active form of
palmitate in a living system is palmitoyl-CoA. Transfer of palmitate to a substrate results in
the liberation of CoA from palmitate, a chemical species that can be measured with accuracy
and sensitivity in a high throughput manner (Figure 5) [153].
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Retesting hits from the primary screen in this secondary, enzymatic assay would determine
if the compounds directly inhibited palmitoylation of the substrate in the reaction. It would
also identify compounds that inhibit palmitoylation by competing with palmitoyl-CoA for
access to the PAT active site, as well as allosteric inhibitors. Structural analysis of the com‐
pounds would provide information about how they inhibit palmitoylation. A binding assay
in which compounds are tested for their ability to compete directly with palmitoyl-CoA for
binding to the PAT would more conclusively determine the mechanism by which the com‐
pounds were inhibiting substrate palmitoylation.
It is likely that the inhibitors identified will represent multiple classes of compounds distin‐
guished by their chemical structures. However, the chemicals identified in these screens are
unlikely to represent the most potent or selective compounds that exist. Further refinement
by probing and refining the chemical space of each compound in a medicinal chemistry ef‐
fort will be required to achieve both objectives. Generating higher affinity analogs of the hit
compounds for the PAT of interest will improve the selectivity and potency of the com‐
pounds for an individual PAT. However, the question of how selective any of these com‐
pounds is for a single PAT must be answered by determining their ability to inhibit other
PATs—counterscreening. Since the family of PATs is relatively small (23 genes), it would
not be unreasonable to measure the effects of the compounds on each of the other PATs in
the enzymatic assay described above.
The assay development pathway proposed above is outlined only in very general and ideal
terms, glossing over inevitable technical challenges that must be overcome for the project to
be successful. However, even as brief as this description is, it exceeds by far the complexity
of any published attempt to identify selective PAT inhibitors to date. A valuable, practical
guide to choosing, developing, and validating assays including those proposed above is
available at: http://ncgc.nih.gov/guidance/manual_toc.html.
6. Conclusion
The discovery of the molecular identity of PATs was a pivotal event that has fostered sub‐
stantial progress in the field of lipidation, having a profoundly positive effect on many fields
of biology. Many long-standing questions have been greeted with answers as well as a clear‐
er direction in which new inquiries should proceed. While sometimes criticized as being
stamp collecting, defining the palmitoyl proteome of specific cells and tissues would pro‐
vide new and unforeseen insight into many cellular processes. The methods described here
provide the technical foundation for defining the palmitoyl proteome. Defining the intrinsic
and extrinsic mechanisms and factors that regulate PAT activity will also be crucial and
challenging. Future assays to investigate such details will certainly benefit from the demon‐
strated usefulness of bioorthagonal probes that appear to be treated by cells as if they were
palmitate. These probes may provide a more direct measure of palmitoylation than the ex‐
change of cysteine-reactive probes for palmitate on purified proteins.
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cated, often three times, to increase the confidence of selecting biologically active com‐
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of false-negatives and false-positives that plague screens run at a single concentration. The
nominal, additional effort required at the front end of the process is generously compensat‐
ed by a subsequent reduction in the effort required to choose which hits to pursue in follow-
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cytoplasm in response to a compound cannot provide evidence that the compound has this
effect by direct inhibition of a PAT. Secondary screens designed to determine which of the
hits works by direct inhibition of PAT activity will be required. One option would be to de‐
termine the effects of each hit on the enzymatic activity of the PAT of interest. Jennings et al
have demonstrated that a PAT can be purified from a membrane environment and retain its
enzymatic function i.e., transfer of palmitate to a substrate. The metabolically active form of
palmitate in a living system is palmitoyl-CoA. Transfer of palmitate to a substrate results in
the liberation of CoA from palmitate, a chemical species that can be measured with accuracy
and sensitivity in a high throughput manner (Figure 5) [153].
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binding to the PAT would more conclusively determine the mechanism by which the com‐
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pounds is for a single PAT must be answered by determining their ability to inhibit other
PATs—counterscreening. Since the family of PATs is relatively small (23 genes), it would
not be unreasonable to measure the effects of the compounds on each of the other PATs in
the enzymatic assay described above.
The assay development pathway proposed above is outlined only in very general and ideal
terms, glossing over inevitable technical challenges that must be overcome for the project to
be successful. However, even as brief as this description is, it exceeds by far the complexity
of any published attempt to identify selective PAT inhibitors to date. A valuable, practical
guide to choosing, developing, and validating assays including those proposed above is
available at: http://ncgc.nih.gov/guidance/manual_toc.html.
6. Conclusion
The discovery of the molecular identity of PATs was a pivotal event that has fostered sub‐
stantial progress in the field of lipidation, having a profoundly positive effect on many fields
of biology. Many long-standing questions have been greeted with answers as well as a clear‐
er direction in which new inquiries should proceed. While sometimes criticized as being
stamp collecting, defining the palmitoyl proteome of specific cells and tissues would pro‐
vide new and unforeseen insight into many cellular processes. The methods described here
provide the technical foundation for defining the palmitoyl proteome. Defining the intrinsic
and extrinsic mechanisms and factors that regulate PAT activity will also be crucial and
challenging. Future assays to investigate such details will certainly benefit from the demon‐
strated usefulness of bioorthagonal probes that appear to be treated by cells as if they were
palmitate. These probes may provide a more direct measure of palmitoylation than the ex‐
change of cysteine-reactive probes for palmitate on purified proteins.
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The number of signaling networks in which palmitoylation plays a pivotal role is large and
growing. The relationship between PAT gene expression and cancer is perhaps the most evi‐
dent as the fraction of PAT genes implicated in metastasis and tumorigenesis is notably
high. There is also a remarkable confluence between our increasing understanding of palmi‐
toylation and our increasing awareness of the importance of lipid rafts, one of the primary
residences of palmitoylated proteins in cancer [154, 155]. In instances where there is a rela‐
tionship between aberrant expression of PATs and cancer, the critical questions relate to the
substrates of these PATs and their associated signaling networks. Identification of these sig‐
naling networks will potentially provide new therapeutic targets for the prevention or rever‐
sal of cancer progression. Given the preponderance of palmitoylated proteins resident in the
neuronal synapse (which is itself a lipid raft of sorts), it is clearly another area of research
that deserves (and has already received) a great deal of attention.
While there has been some progress made in identifying pharmacological modulators of
palmitoylation [125, 126, 138], there is nothing yet known about how to specifically target
individual PATs. From a practical standpoint, inhibiting specific PATs may be a simpler
process than developing specific PAT agonists. The advent of assays with the ability to
measure changes in the activity of a single PAT along with the identification of PAT-sub‐
strate associations should enable further development of new assays to identify specific
pharmacological modulators of individual PATs as well as providing important information
on the signaling networks associated with specific PATs.
Our ability to understand palmitoylation and its importance to human health and disease is
only as good as the technological methods we use to make accurate and valid measure‐
ments. Our ability to investigate the basic mechanisms of how PATs work, of PAT/substrate
relationships, and how palmitoylation affects signaling processes related to disease would
be improved significantly by the development of selective and potent pharmacological tools.
Until such tools are available, we should be mindful that using compounds such as 2-BP,
cerulenin, and tunicamycin may lead to erroneous conclusions. Developing non-lipid, selec‐
tive inhibitors that target the PAT active site is feasible. The challenges that exist are concep‐
tually similar in some aspects to those faced during the development of selective, small-
molecule inhibitors of kinases that do not resemble ATP. Based on current knowledge, the
most logical PATs to target first are those for which overexpression is oncogenic. However,
the motivation to initiate drug discovery programs on a large scale will probably remain be‐
low the required threshold until more conclusive data are available from more sophisticat‐
ed, whole-animal experiments that link PATs to oncogenesis.
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The number of signaling networks in which palmitoylation plays a pivotal role is large and
growing. The relationship between PAT gene expression and cancer is perhaps the most evi‐
dent as the fraction of PAT genes implicated in metastasis and tumorigenesis is notably
high. There is also a remarkable confluence between our increasing understanding of palmi‐
toylation and our increasing awareness of the importance of lipid rafts, one of the primary
residences of palmitoylated proteins in cancer [154, 155]. In instances where there is a rela‐
tionship between aberrant expression of PATs and cancer, the critical questions relate to the
substrates of these PATs and their associated signaling networks. Identification of these sig‐
naling networks will potentially provide new therapeutic targets for the prevention or rever‐
sal of cancer progression. Given the preponderance of palmitoylated proteins resident in the
neuronal synapse (which is itself a lipid raft of sorts), it is clearly another area of research
that deserves (and has already received) a great deal of attention.
While there has been some progress made in identifying pharmacological modulators of
palmitoylation [125, 126, 138], there is nothing yet known about how to specifically target
individual PATs. From a practical standpoint, inhibiting specific PATs may be a simpler
process than developing specific PAT agonists. The advent of assays with the ability to
measure changes in the activity of a single PAT along with the identification of PAT-sub‐
strate associations should enable further development of new assays to identify specific
pharmacological modulators of individual PATs as well as providing important information
on the signaling networks associated with specific PATs.
Our ability to understand palmitoylation and its importance to human health and disease is
only as good as the technological methods we use to make accurate and valid measure‐
ments. Our ability to investigate the basic mechanisms of how PATs work, of PAT/substrate
relationships, and how palmitoylation affects signaling processes related to disease would
be improved significantly by the development of selective and potent pharmacological tools.
Until such tools are available, we should be mindful that using compounds such as 2-BP,
cerulenin, and tunicamycin may lead to erroneous conclusions. Developing non-lipid, selec‐
tive inhibitors that target the PAT active site is feasible. The challenges that exist are concep‐
tually similar in some aspects to those faced during the development of selective, small-
molecule inhibitors of kinases that do not resemble ATP. Based on current knowledge, the
most logical PATs to target first are those for which overexpression is oncogenic. However,
the motivation to initiate drug discovery programs on a large scale will probably remain be‐
low the required threshold until more conclusive data are available from more sophisticat‐
ed, whole-animal experiments that link PATs to oncogenesis.
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1. Introduction
An antibacterial is a compound or substance that kills or slows down the growth of bacteria.
We usually associate the beginning of the modern antibacterial era with the names of Paul
Ehrlich and Alexander Fleming. Infectious diseases are the leading causes of human mor‐
bidity and mortality for most of human existence. Antibacterials are probably one of the
most successful forms of chemotherapy in the history of medicine. They save countless lives
and make enormous contribution to the control of infectious diseases since the beginning of
antibacterial era. Perhaps most of us born since the Second World War don’t know how
much enthusiasm, dedication, and hardship have been put in antibacterial drug discovery,
and take the success of antibacterial agents too much for granted. Therefore, let’s first look
back what the human did to combat the infections before antibacterial era and how the out‐
standing scientists discovered so many efficient antibacterial agents used clinically today
and led us enter the antibacterial era.
2. The history of antibacterial discovery
2.1. Pre-antibiotic era
Before the early 20th century, treatments for infections were based primarily on medicinal
folklore. Mixtures with antimicrobial properties that were used in treatments of infections
were described over 2000 years ago [1]. Even the prehistoric peoples used a number of
plants in wound treatment and it seems possible that many plants have the properties of an‐
timicrobial effects [2; 3]. Tetracyclines can be incorporated into the hydroxyapatite mineral
portion of bones as well as tooth enamel; once people take it, permanent markers of meta‐
bolically active areas will be left. Thus it is much conveniently to trace the exposure of these
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antibacterials in ancient populations. It was found than the bone sample from Sudanese Nu‐
bian (A.D. 350 to 550) was labeled by the antibiotic tetracycline and their dietary regime con‐
tained tetracycline-containing materials by X-group cemetery and other advanced
technologies [4; 5]. Moreover, another study showed that, bones from the Dakhleh Oasis,
Egypt, in a late Roman period, exhibit discrete fluorochromelabelling, exactly like the teeth
from patients treated with tetracycline [6]. A large number of customs and anecdotes can al‐
so reveal the occurrences of other antibacterials. One popular anecdote is about the antibiot‐
ic-like properties of red soil from the Hashemite Kingdom of Jordan. Interestingly, red soil
was used for treating skin infections and diaper rash in the past and is still used in some
communities today as an inexpensive alternative to antibiotics [7]. In fact, recently, many
pharmaceutical antibiotics, such as streptomycin, actinomycin, erythromycin, vancomycin,
nystatin and amphotericin, were produced from the soil actinomycetes [8].
The traditional Chinese medicine is the summary of experience about Chinese medical treat‐
ment over millennia and may contain a lot of unknown antibiotics [9]. Many traditional Chi‐
nese medicines were tested and found effective against four common oral bacteria [10].
Discovery of active components in the ancient herbs could enrich the arsenal of antimicrobi‐
als used by the mainstream medicine.
2.2. Foundation of the antibiotic era
Bacteria were first identified in the 1670s by van Leeuwenhoek, following his invention of
the microscope. The relationship between bacteria and diseases gradually set up in the nine‐
teenth century. Since then, researchers started to try and find effective antibacterial agents.
Paul  Ehrlich is  the  father  of  chemotherapy and was honored with the Nobel  prize  due
to the molecular side-chain theory of immunity. His concept of “magic bullet” is that the
chemicals selectively target only disease-causing microbes but not the host cells. In 1906,
Ehrlich, together with Bertheim, developed hundreds of derivatives of Atoxyl, and final‐
ly discovered compound 606,  a  gold powder [9;  11].  In 1909,  he found that  Compound
606  could  cure  syphilis-infected  rabbits  in  experiments;  it  could  also  improve  terminal
patients  with  dementia  and  cured  early  stage  patients  with  infected  sores  [11].  It  was
publicly released as salvarsan in 1910. Despite the adverse side effects, salvarsan and it’s
derivative neosalvarsan kept the status of  the most frequently prescribed drug until  the
introduction of  penicillin in the 1940s [12].  Amazingly,  the chemical  structure of  salvar‐
san hadn’t been known until 2005 [13].
The systematic screening approach introduced by Paul Ehrlich became the cornerstone of
drug search strategies in the pharmaceutical industry. Sulfonamidochrysoidine (also named
prontosil), the first commercially available antibiotic, was first synthesized by Bayer chem‐
ists Josef Klarer and Fritz Mietzsch in 1930s by this approach. Then Gerhard Domagk found
its effect against Streptococcus pyogenes in mice [14]. Four years later he received the Noble
Prize. Eventually prontosil was recognized as a precursor for a new class of antibacterial
agents— sulfonamides.
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The effect of mould on bacterial colonies hadn’t been investigated until 19th century, al‐
though the antibacterial properties of mold had been known since ancient times. In 1921,
Alexander Fleming observed some substances called lyzosomes which could dissolve bacte‐
ria. In 1928, he discovered that a specific mould species inhibited the development of Staph‐
ylococcus bacteria. The species was known as Pencilliumnotatum and the filtrate was called
penicillin [15]. In 1940, Howard Florey and Ernst Chain worked out how to purify penicillin
for clinical testing [16]. All the three researchers were awarded the Nobel Prize in 1945, and
since then the era of antibiotics had been initiated. Penicillin became the top therapeutic
molecule because of its widespread use and the magnitude of the therapeutic outcomes, and
also because of the technologies developed for production of penicillin which became the
basis for production of all subsequent antibiotics and other bioproducts in use today [17].
3. Classification
Antibacterials are commonly classified based on their mechanism of action or spectrum of
activity. The main classes of antibacterial drugs target only four classical bacterial functions:
bacterial-cell-wall biosynthesis (e.g., penicillin and vancomycin); bacterial protein biosynthe‐
sis (e.g., aminoglycoside and macrolide); DNA and RNA replication (e.g., ciprofloxacin and
rifampin); and folate coenzyme biosynthesis (e.g., sulfamethoxazole) [18]. Antibacterials that
target the cell wall or cell membrane or essential bacterial enzymes are more likely to be bac‐
tericidal; but generally the bacteriostatic is the antibacterial drugs that inhibits protein syn‐
thesis [19]. Another way to distinguish the antibiotics is based on their target specificity. The
broad-spectrum antibiotic affects a wide range of disease-causing bacteria, including both
Gram-positive and Gram-negative bacteria, in contrast to a narrow-spectrum antibiotic,
which acts against specific families of bacteria. For example, ampicillin is a widely used
broad-spectrum antibiotic.
4. Antibacterial resistance and its mechanisms
Bacterial resistance to antibacterial drugs increasingly becomes a major health and economic
problem, eroding the discovery of antibiotics and their application to clinical medicine. As
early as 1946, Alexander Fleming predicted that “There is probably no chemotherapeutic
drug to which in suitable circumstances the bacteria cannot react by in some way acquiring
‘fastness’ (resistance).” Today it is really the truth. Resistance to the antibiotics will emerge
only a few years after it is introduced to clinic use [20]. Bacterial resistance is positively cor‐
related with the use of antibacterial agents in clinical practice [21; 22]. Because any use of
antibiotics can increase selective pressure in a population of bacteria, allowing survival of
the resistant bacteria and death of the susceptible ones. We can find that pathogenic bacteria
are resistant to practically all available antibacterial drugs. And many strains, which are in‐
formally called superbugs, are even resistant to several different antibiotics. Multidrug re‐
sistance has been found in Pseudomonas aeruginosa (P. aeruginosa),
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The systematic screening approach introduced by Paul Ehrlich became the cornerstone of
drug search strategies in the pharmaceutical industry. Sulfonamidochrysoidine (also named
prontosil), the first commercially available antibiotic, was first synthesized by Bayer chem‐
ists Josef Klarer and Fritz Mietzsch in 1930s by this approach. Then Gerhard Domagk found
its effect against Streptococcus pyogenes in mice [14]. Four years later he received the Noble
Prize. Eventually prontosil was recognized as a precursor for a new class of antibacterial
agents— sulfonamides.
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The effect of mould on bacterial colonies hadn’t been investigated until 19th century, al‐
though the antibacterial properties of mold had been known since ancient times. In 1921,
Alexander Fleming observed some substances called lyzosomes which could dissolve bacte‐
ria. In 1928, he discovered that a specific mould species inhibited the development of Staph‐
ylococcus bacteria. The species was known as Pencilliumnotatum and the filtrate was called
penicillin [15]. In 1940, Howard Florey and Ernst Chain worked out how to purify penicillin
for clinical testing [16]. All the three researchers were awarded the Nobel Prize in 1945, and
since then the era of antibiotics had been initiated. Penicillin became the top therapeutic
molecule because of its widespread use and the magnitude of the therapeutic outcomes, and
also because of the technologies developed for production of penicillin which became the
basis for production of all subsequent antibiotics and other bioproducts in use today [17].
3. Classification
Antibacterials are commonly classified based on their mechanism of action or spectrum of
activity. The main classes of antibacterial drugs target only four classical bacterial functions:
bacterial-cell-wall biosynthesis (e.g., penicillin and vancomycin); bacterial protein biosynthe‐
sis (e.g., aminoglycoside and macrolide); DNA and RNA replication (e.g., ciprofloxacin and
rifampin); and folate coenzyme biosynthesis (e.g., sulfamethoxazole) [18]. Antibacterials that
target the cell wall or cell membrane or essential bacterial enzymes are more likely to be bac‐
tericidal; but generally the bacteriostatic is the antibacterial drugs that inhibits protein syn‐
thesis [19]. Another way to distinguish the antibiotics is based on their target specificity. The
broad-spectrum antibiotic affects a wide range of disease-causing bacteria, including both
Gram-positive and Gram-negative bacteria, in contrast to a narrow-spectrum antibiotic,
which acts against specific families of bacteria. For example, ampicillin is a widely used
broad-spectrum antibiotic.
4. Antibacterial resistance and its mechanisms
Bacterial resistance to antibacterial drugs increasingly becomes a major health and economic
problem, eroding the discovery of antibiotics and their application to clinical medicine. As
early as 1946, Alexander Fleming predicted that “There is probably no chemotherapeutic
drug to which in suitable circumstances the bacteria cannot react by in some way acquiring
‘fastness’ (resistance).” Today it is really the truth. Resistance to the antibiotics will emerge
only a few years after it is introduced to clinic use [20]. Bacterial resistance is positively cor‐
related with the use of antibacterial agents in clinical practice [21; 22]. Because any use of
antibiotics can increase selective pressure in a population of bacteria, allowing survival of
the resistant bacteria and death of the susceptible ones. We can find that pathogenic bacteria
are resistant to practically all available antibacterial drugs. And many strains, which are in‐
formally called superbugs, are even resistant to several different antibiotics. Multidrug re‐
sistance has been found in Pseudomonas aeruginosa (P. aeruginosa),
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Acinetobacterbaumannii (A. baumannii), E. coli, and Klebsiellapneumoniae (K. pneumo‐
niae), producing extended-spectrum β-lactamases (ESBL), vancomycin-resistant enterococci
Enterococcus faecium (E. faecium) (VRE), MRSA, vancomycin-resistant S. aureus VRSA, ex‐
tensively drug-resistant (XDR) Mycobacterium tuberculosis (M. tuberculosis), Salmonella
enterica (S. enterica) serovar Typhimurium, Shigelladysenteriae (S. dysenteriae), Haemophi‐
lusinfluenzae (H. influenzae), Stenotrophomonas, and Burkholderia [23; 24].
Great amount of antibiotic is used in nonhuman niches, leading to the spread of resistant
bacteria too. Antibiotics have been used for improving the production of livestock and poul‐
try for more than 50 years [25]. The Institute of Food Technologists (IFT), once convened a
panel of internationally renowned experts to address the concern that, the emergence of an‐
timicrobial resistance may result from abuse in food production, manufacturing, and else‐
where [26].
Over the past several years, people struggled to search for the mechanisms of resistance.
Therefore today there is a large pool of information about how drug resistances come out.
Biochemical and genetic aspects of antibiotic resistance mechanisms are shown in Fig. 1.
Figure 1. Kinds of antibiotic resistance mechanisms [85].
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4.1. Genetics of antibiotic resistance
Resistance can be an intrinsic property of the bacteria themselves or it can be acquired.
There are two main ways of acquiring antibiotic resistance: i) chromosomal mutations and
ii) horizontal gene transfer. But the question is where the horizontal gene comes from? Some
of these genes have an environmental origin and began their evolution before the antibiotic
era; most likely, the primary genes originated and diversified within the environmental bac‐
terial communities, then mobilized and penetrated into pathogens. [27; 28]
4.1.1. Mutations
4.1.1.1. Spontaneous mutations
These mutations occur randomly as replication errors or an incorrect repair of a damaged
DNA in actively dividing cells, presenting an important mode of generating antibiotic resist‐
ance. They are also called the growth dependent mutations. Quinolone resistance in Escheri‐
chia coli resulted from the mutations in at least seven positions in the gyrA gene or three
positions in the parC gene [29]. There are a large number of biochemical mechanisms of an‐
tibiotic resistance related to Spontaneous Mutations. For instance, Mutations in mexR can
cause derepression of the mexAB-oprM multidrug efflux operon, causing a multidrug resist‐
ance phenotype in Pseudomonas aeruginosa [30].
4.1.1.2. Hypermutators
During a prolonged non-lethal antibiotic selective pressure a small bacterial population en‐
ters a transient state of a high mutation rate which is called hypermutable state. Hypermuta‐
tors are found in many bacteria species such as E. coli, S. enterica, Neisseria meningitides
(N. meningitides),H. influenzae, S. aureus, Helicobacter pylori (H. pylori), Streptococcus
pneumoniae (S. pneumoniae),and P. aeruginosa [85]. Various studies suggested that hyper‐
mutations play an important role in acquisition of antibiotic resistance in pathogens [31; 32;
33].
4.1.1.3. Adaptive mutagenesis
Adaptive mutations arise in non-dividing or slowly dividing cells during the presence of a
non-lethal selective pressure that favours them. A great number of antibiotic resistant mu‐
tants may come from this mutation process under bacterial natural conditions [85].
4.1.1.4. Horizontal gene transfer
Horizontal transfer of genetic material between bacteria is the most commonly used way to
spread antibiotic resistance. In general, this exchange is accomplished mainly through the
processes of transduction (via bacteriophages), conjugation (via plasmids and conjugative
transposons), and transformation (via incorporation into the chromosome of chromosomal
DNA, plasmids, and other DNAs) [34]. This type of genetic transfer not only occurred be‐
tween closely related bacteria but can also occur between phylogenetically distant bacterial
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positions in the parC gene [29]. There are a large number of biochemical mechanisms of an‐
tibiotic resistance related to Spontaneous Mutations. For instance, Mutations in mexR can
cause derepression of the mexAB-oprM multidrug efflux operon, causing a multidrug resist‐
ance phenotype in Pseudomonas aeruginosa [30].
4.1.1.2. Hypermutators
During a prolonged non-lethal antibiotic selective pressure a small bacterial population en‐
ters a transient state of a high mutation rate which is called hypermutable state. Hypermuta‐
tors are found in many bacteria species such as E. coli, S. enterica, Neisseria meningitides
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pneumoniae (S. pneumoniae),and P. aeruginosa [85]. Various studies suggested that hyper‐
mutations play an important role in acquisition of antibiotic resistance in pathogens [31; 32;
33].
4.1.1.3. Adaptive mutagenesis
Adaptive mutations arise in non-dividing or slowly dividing cells during the presence of a
non-lethal selective pressure that favours them. A great number of antibiotic resistant mu‐
tants may come from this mutation process under bacterial natural conditions [85].
4.1.1.4. Horizontal gene transfer
Horizontal transfer of genetic material between bacteria is the most commonly used way to
spread antibiotic resistance. In general, this exchange is accomplished mainly through the
processes of transduction (via bacteriophages), conjugation (via plasmids and conjugative
transposons), and transformation (via incorporation into the chromosome of chromosomal
DNA, plasmids, and other DNAs) [34]. This type of genetic transfer not only occurred be‐
tween closely related bacteria but can also occur between phylogenetically distant bacterial
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genera, in particular between gram-positive and gram-negative bacteria [35]. Plasmid-en‐
coded antibiotic resistance encompasses most classes of antibiotics in practice, such as ami‐
noglycosides, cephalosporins and fluoroquinolones [36]. Transposons spread quicker than
genes in chromosomes and are transferred by conjugation, transformation, or transduction
[23; 24]. Integrons acquire and exchange exogenous DNA, known as gene cassettes, by a
site-specific recombination mechanism. They can integrate stably into other DNAs where
they deliver multiple antibacterial resistant genes in a single exchange. Resistance gene cas‐
settes encoding the metallo-β- lactamases IMP and VIM confer resistance to the potent car‐
bapenem β-lactams imipenem and meropenem [36].
4.1.2. Biochemistry of antibiotic resistance
As so many scientists have been struggling to study the biochemical mechanisms of antibi‐
otic resistance, nowadays there is a large pool of related valuable information left. Biochemi‐
cal mechanisms may be varied among different bacterial species, but can be mainly
classified into four categories (Fig. 2). In fact, each of these four categories also contains an
amazing diversity of resistance mechanisms. Sometimes a single bacterial strain may pos‐
sess several types of resistance mechanisms. Each of the four main categories will be dis‐
cussed respectively below.
4.1.2.1. Antibiotic inactivation
Biochemical strategies include enzymatic modification and redox mechanisms (which is less
important and will not be elaborated in this paper). Enzymes can be divided into two gener‐
al classes: those such as β-lactamases that degrade antibiotics and others that perform chem‐
ical transformations. The antibiotic β-lactam has a four-atom ring known as a beta-lactamin.
The β-lactamase enzyme breaks that ring open, destroying the antibacterial properties of the
drugs. β-lactamase consists of enzymes with a serine residue at the active site, and metal‐
loenzymes with zinc ion as a cofactor and with a separate heritage [37]. β-lactamase en‐
zymes are the most common and important weapons for Gram-negative bacteria to resist
the antibiotics β-lactam [38]. The group transfer approaches are the most diverse and in‐
clude the modification by acyltransfer, phosphorylation, glycosylation, nucleotidylation, ri‐
bosylation, and thiol transfer. They can inactivate antibiotics (aminoglycosides,
chloramphenicol, streptogramin, macrolides or rifampicin) by chemical substitution. These
modifications reduce the affinity of antibiotics to a target [85]. For example, enzymatic mod‐
ification is the most prevalent mechanism to destroy aminoglycosides in clinic. Aminoglyco‐
side modifying enzymes can be divided into three classes: acetyltransferases,
nucleotidyltranferases, and phosphotransferases; they mainly catalyze the modification at –
OH or –NH2 groups of the 2-deoxystreptamine nucleus or the sugar moieties [39]. There are
a large number of genes in the chromosomes and other mobile genetic elements coding for
these enzymes which let the bacteria resist to more new antibiotics as well as horizontally
spread their resistance among bacteria more easily. As a consequence, almost all pathogens
are resistant to aminoglycosides through modifying enzymes [39].
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4.1.2.2. Target modification
Another important resistance mechanism is the modification of antibiotic targets which
makes the antibiotic unable to bind the targets properly. β-lactams target the bacterial en‐
zymes of cell wall biosynthesis (the so-called penicillin-binding proteins, PBPs). Alterations
in PBPs can reduce affinity for β-lactams, possibly causing β-lactam resistance in many bac‐
teria strains, such as H. influenzae, N. gonorrhoeae, N. meningitidis, anaerobes, S. dysenter‐
iae [40]. For instance, the mecA resistance gene which encodes PBP2a, a new penicillin
binding protein with decreased affinity for oxacillin and most other β-lactam drugs, induces
resistance to methicillin and oxacillin in S. aureus [41]. The resistance to antibiotics that in‐
terfere with protein synthesis or transcription is achieved by modification of the specific tar‐
get. rRNAmethylases encoded by a number of genes modificate the 16S rRNA molecule at
specific positions critical for aminoglycosides binding [42]. Modification in the 23S rRNA
component of the 50S ribosomal subunit also leads to resistance to the macrolide, lincosa‐
mide and streptogramin B group of antibiotics in many pathogen strains [43; 44]. Mutations
of topoisomerase IV and gyrase genes can sufficiently alter affinity of fluoroquinolones to
these enzymes [45].
4.1.2.3. Efflux pumps and outer membrane (OM) permeability
Efflux pumps Membrane proteins that export antibiotics from the cell and maintain their low
intracellular concentrations are called efflux pumps. Drug efflux pumps play a key role in
drug resistance not just because they can produce multidrug resistance but also because
they can elevate level of other resistance mechanisms [46; 47]. Bacterial drug efflux trans‐
porters are currently classified into five families: the ATP-binding cassette (ABC) superfami‐
ly, the major facilitator superfamily (MFS), the multidrug and toxic compound extrusion
(MATE) family, the small multidrug resistance (SMR) family, and the resistance-nodulation‐
division (RND) superfamily [47]. Efflux transporters can be further classified into single or
multicomponent pumps. Tetracycline and macrolide transporters are single component ef‐
flux systems that have narrow substrate profiles, while the RND family members have
broader substrates and can pump out multiple structurally unrelated compounds [24; 46].
Efflux pumps exist in both Gram-positive and Gram-negative bacteria [48; 49]. MexAB-
OprM efflux pumps in Pseudomonas aeruginosa, which belong to RND family, result in
higher inhibitory concentration of a large number of antibiotics, such as penicillins, broad‐
spectrumcephalosporins, chloramphenicol, fluoroquinolones, macrolides, novobiocin, sulfo‐
namides, tetracycline and trimethoprim, dyes and detergents [50; 51].
OM permeability The OM is an asymmetric bilayer: the phospholipid form the inner leaflet
and the lipopolysaccharides (LPS) form the outer leaflet. OM of Gram-negative bacteria pro‐
vides a formidable barrier that must be overcome by drugs. Drug molecules pass the OM by
diffusion through porins or the bilayer, or by self-promoted uptake [85]. Small hydrophilic
drugs (e.g., β-lactams), enter to the intracellular through the pore-forming porins, while
macrolides and other hydrophobic drugs diffuse during their entry [52]. Some resistant clin‐
ical strains of Neisseria meningitidis, K. pneumoniae and Enterobacteraerogenes exhibit a
noticeable porin variability resulting in decrease of antibacterial uptake [53]. Reduction of
The Antibacterial Drug Discovery
http://dx.doi.org/10.5772/52510
295
genera, in particular between gram-positive and gram-negative bacteria [35]. Plasmid-en‐
coded antibiotic resistance encompasses most classes of antibiotics in practice, such as ami‐
noglycosides, cephalosporins and fluoroquinolones [36]. Transposons spread quicker than
genes in chromosomes and are transferred by conjugation, transformation, or transduction
[23; 24]. Integrons acquire and exchange exogenous DNA, known as gene cassettes, by a
site-specific recombination mechanism. They can integrate stably into other DNAs where
they deliver multiple antibacterial resistant genes in a single exchange. Resistance gene cas‐
settes encoding the metallo-β- lactamases IMP and VIM confer resistance to the potent car‐
bapenem β-lactams imipenem and meropenem [36].
4.1.2. Biochemistry of antibiotic resistance
As so many scientists have been struggling to study the biochemical mechanisms of antibi‐
otic resistance, nowadays there is a large pool of related valuable information left. Biochemi‐
cal mechanisms may be varied among different bacterial species, but can be mainly
classified into four categories (Fig. 2). In fact, each of these four categories also contains an
amazing diversity of resistance mechanisms. Sometimes a single bacterial strain may pos‐
sess several types of resistance mechanisms. Each of the four main categories will be dis‐
cussed respectively below.
4.1.2.1. Antibiotic inactivation
Biochemical strategies include enzymatic modification and redox mechanisms (which is less
important and will not be elaborated in this paper). Enzymes can be divided into two gener‐
al classes: those such as β-lactamases that degrade antibiotics and others that perform chem‐
ical transformations. The antibiotic β-lactam has a four-atom ring known as a beta-lactamin.
The β-lactamase enzyme breaks that ring open, destroying the antibacterial properties of the
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modifications reduce the affinity of antibiotics to a target [85]. For example, enzymatic mod‐
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LPS in the outer membrane of Polymyxin-resistant P. aeruginosa strains associates with re‐
sistance development [54].
4.1.2.4. Target bypass
This kind of resistance mechanisms is somewhat specific.  Bacteria produce two kinds of
targets: one is sensitive to antibiotics and the alternative one (usually an enzyme) that is
resistant  to  inhibition  of  antibiotic.  In  ampicillin-resistant  mutant  Enterococcus  faecium
selected  in  vitro,  bypass  of  the  DD-transpeptidases  by  a  novel  class  of  peptidoglycan
polymerases,  the  LD-transpeptidases,  conveyed  resistance  to  all  β-lactams,  except  the
carbapenems [55; 56].
5. What should we do?
5.1. Extending the lifespan of existing antibacterials
Although the emergency of antibiotic resistance seems inevitable, measures must be taken to
prevent or at least delay this process. As mentioned above, many factors contribute to resist‐
ance, so we should adopt a complex approach. The most important way is to strictly control
antibiotic misuse and overuse. Interestingly, the EU has implemented a comprehensive ban
on the use of all antibiotics for growth promotion since 2006 [25]. And other developed
countries also implement similar measures, but in many developing nations antibiotic use is
relatively uncontrolled. As hospital-acquired infection is a major cause for antibiotic-resist‐
ance, strict antibiotic stewardship and policies should be adopted in the hospitals. For exam‐
ple, we can make some antibiotic policies to optimize the selection, dosing, route of
administration, duration of the drug prescribed by the doctor, and limit the unintended con‐
sequences of antibiotic utilization [57].
5.2. New antibacterial drug discovery
As serious infectious diseases and multidrug resistance are emerging repeatedly, new anti‐
biotics are needed badly to combat these bacterial pathogens, but the progress of discovery
seems relatively slow. Most chemical scaffolds of antibiotics used now were just introduced
between the mid-1930s and the early 1960s (fig 2). There are many reasons for this. The first
is scientific. We have discovered the easy-to-find antibiotics. Now we have to work harder
and think more cleverly to find new drugs. Another reason is commercial. Antibiotics are
used much less than other drugs and the new antibiotic are just used to treat serious bacteri‐
al infections at most of the time. So antibiotics have a poor return on investment. In 2008
only five major pharmaceutical companies still kept their Enthusiasm in antibacterial dis‐
covery. It is most important to delink research and development costs from drug pricing
and the return from investment on antibacterial discovery [58]. If the government could es‐
tablish some subsidies and financial assistance schemes to compensate the cost, more drug
companies will be attracted to this area.
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Figure 2. Innovation gap between 1962 and 2000 [59].
Despite the current grim situation in management of resistant bacteria, some new drugs
have recently been approved by the FDA or are in late stages of the pipeline (Table 1, 2) [60].
The new drugs belong to the following classes of compounds: oxazolidinones, glycopepti‐
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Table 2. New antibiotics in development
5.2.1. Tailoring existing scaffolds
It seems that there are many ways to search for new antibacterials, but the key question is:
how to search for new antibacterial drugs and where to look for them? The most convenient
method is to modify the existing scaffolds to generate their derivates. All antibiotics ap‐
proved between the early 1960s and 2000 were synthetic derivatives of the old scaffolds ex‐
cept carbapenems. Chemical modifications of old scaffolds may lead to improved
bactericidal activities, better resistance profiles, safety, tolerability or superior pharmacoki‐
Drug Discovery298
netic/pharmacodynamic properties. There are four generations of β-Lactam antibiotics, all of
which contains a β-lactam nucleus in their molecular structures. The second generation (e.g.,
cephalexin and cefaclor) and third generation (e.g., cefotaxime, ceftazidime) are not sensitive
to plasmid-mediated broad-spectrum β-lactamases and have less allergic reactions, com‐
pared with the first generation (penicillins) [61]. The fourth-generation cephalosporins pene‐
trate through the outer membrane of Gram-negative bacteria more easily and have low
affinity for clinically important β-lactamases, so they have the advantage of killing many
Gram-negative pathogens resistant to most third-generation [86]. Tigecycline is one of gly‐
cylcycline antibiotics derived from tetracycline and received approval from the US Food and
Drug Administration for the treatment of skin, soft-tissue, and intra abdominal infections in
2005. Tigecycline can overcome the active efflux of drug from inside the bacterial cell and
protection of ribosomes, which are two determinants of tetracycline resistance [62; 63]. But
this approach is only a good short-term strategy to find new drugs, and but the benefit of
these modified drugs will be offset quickly by the resistance to acquired through the hori‐
zontal acquisition or molecular evolution [9], which indicates that it is much more attractive
to find novel chemical scaffolds.
5.2.2. Novel scaffolds
5.2.2.1. Explore new places
More than two-thirds of clinically used antibiotics come from natural products or their semi
synthetic derivatives and most of them came out from soil actinomycetes. But recently re‐
searchers have shifted to underexplored ecological niches and bacterial species and found
some new scaffolds. Compared to the terrestrial environment, the ocean remains an under-
explored habitat with unparalleled biodiversity, leaving it the most promising place to yield
new antibacterial metabolites. New antibacterial agents with novelty and/or complexity in
chemical structure derived from marine bacteria have been elaborated clearly [64; 65]. Myx‐
obacteria, a untapped bacterial strain, can produce many useful natural products which
have great potential to develop into antibacterial drug [66].
5.2.2.2. The genomics
By the mid-1990s, pharmaceutical companies have little enthusiasm for making improve‐
ment to the existing antibacterials. Hundreds of bacterial genomes have been completely de‐
ciphered since 1995, among which are many important human pathogens, attracting large
pharmaceutical companies back into antibacterial discovery [67]. Genomics influence vari‐
ous aspects of the antibiotic development, including new drug target identification, under‐
standing the mechanism of antibiotic action, drug safety and efficacy assessment, bacterial
resistance development, and so on [68]. Ecopia Biosciences was very skilled in using ge‐
nome-scanning approach and discovered the new antibiotic scaffold ECO-0501 which is
highly effective against a series of Gram-positive pathogens [59; 69]. GlaxoSmithKline also
used a genomics-derived, target-based approach to screen for new drugs. They examined
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more than 300 genes and employed 70 high-throughput screening campaigns over a period
of 7 years, but unfortunately did not create a clinical used antibacterial [70].
5.2.2.3. New targets
It must be admitted that target-based genomic approach has not yielded satisfactory results,
nevertheless, retooled target-based strategies can still play an important role in discovery
process. Most antibiotic targets are limited to peptidoglycan synthesis, ribosomal protein
synthesis, folate synthesis, and nucleic acid synthesis and topoisomerization. In the future
we could continue to discover new antibiotics for these old targets through improvement of
the existing scaffolds or even finding new scaffolds. For instance, Lipid II is a membrane-
anchored cell-wall precursor that is essential for bacterial cell-wall biosynthesis; it is not on‐
ly classical target for several old antibacterial classes, but is also targeted by the new
antibiotics, such as lantibiotics, mannopeptimycins and ramoplanin [71]. Grouping targets
by a common inhibitor scaffold rather than by function may lead to new targets; and as
mentioned above, insights from outside the antibiotic arena are also important [59].
5.2.2.4. Forward is back
Compared with the fruitless target-based genomic approach, traditional whole-cell assays
are more effective in antibiotic discovery. Just because it is not necessary to worry about cell
permeability of a novel scaffold in the development process if whole-cell assays are used. As
most of the existing libraries have already been used to screen for antibacterial drugs, libra‐
ries with new chemical diversity are extremely important in this approach. Sometimes, look
for libraries that don’t belong to antibacterial development areas may be useful. In fact, most
pharmaceutical companies of other therapeutic areas have invested considerable resources
in synthesizing small molecule libraries [59]. Candidates with a strong hit in a whole-cell an‐
tibacterial assay should be tested in the right animal model early in development, because In
vitro experiment results are not always reliable. For example, Antimicrobial drug target type
II fatty acid synthesis (FASII) is reported to be essential for their efficacy against infections
caused by multiresistant Gram-positive bacteria. But another study showed that Streptococ‐
cus agalactiae and S. aureus could take up sufficient unsaturated fatty acids from human se‐
rum to obviate the essentiality of FAS II enzymes in vivo [72].
5.2.2.5. Focus on spectrum
Antibacterial spectrum is a major consideration when selecting a target for lead optimiza‐
tion. Permeability and target distribution determine the pectrum [73]. That is to say, the
drug candidates should possess two properties at the same time: one is penetrating the cell
and evading efflux pump systems, another is retaining potent activity at the molecular tar‐
gets. However, since almost all targets of the antibacterials in clinical use are present in all
bacteria, the antibacterial drug spectra are determined largely by the ability of permeability.
Therefore, some compounds are just Gram-positive organism-selective and have no effect
against Gram-negative pathogens which have a second membrane acting as a permeability
barrier [74; 75]. Efflux pump inhibitors (EPIs) have been explored for broadening the anti‐
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bacterial spectrum and overcoming bacterial resistance. Although no clinically useful drugs
have come out, extensive efforts have been made to test the effectiveness of EPIs across a
range of in vitro and in vivo assays, especially the compound MC-207,110 [76].
‘Broader is better’ is the rule of antibacterial activity spectrum. But developing the agents
with a narrower spectrum may be helpful in treating some special antibiotic resistant patho‐
gens or the non-multiplying bacteria. One human squalene synthase inhibitor blocked
staphyloxanthin biosynthesis in vitro, resulting in colorless bacteria which became more
sensitive to killing by human blood and innate immune clearance [77]. Rifampicin is a
standard antibiotic used for clearance of non-multiplying tuberculosis. Monoclonal antibod‐
ies (Mabs) have also become potential agents for narrow-spectrum antibacterial therapy. In
clinical experiment C. difficile Mab combination MDX-066 and MDX-1388, which targets
and neutralizes two main C. difficile toxins, can reduce the recurrence of C. difficile infec‐
tion [78; 79]. A microbiologic diagnosis should be made before using these kinds of antibiot‐
ics for therapy. Such genus-selective agents may have the benefit of leaving more of the
endogenous microfloraun unattacked compared with conventional antibiotics.
5.2.2.6. Other new methods
Bacteriophages
Bacteriophages and their fragments could kill the bacteria. They have been developed as an‐
tibacterials in humans, poultry and cattle industries, aquaculture and sewage treatment.
This approach has novel mechanism of action that is completely different from current anti‐
microbials, but the problems are that quality control and standardization are difficult. Phage
lysins, which are produced late in the viral infection cycle, can bind to cell wall peptidogly‐
can and rapidly induce Gram-positive bacteria lysis [80]. The sequencing of phages genomes
may identify more proteins suitable for novel antibacterials [81; 82].
Other methods to find new drugs could be modulating immunity, developing monoclonal
antibody for specific bacteria, designing antibacterial peptides (including antimicrobial pep‐
tides and compounds from animals and plants, the natural lipopeptides of bacteria and Fun‐
gi [83; 84]), and so on.
6. Conclusion and future issues
While the antibacterial resistance, especially multi-drug resistance continues to rise, what
we should do is to investigate the potential mechanisms of drug resistance in bacteria and
discover more effective antibacterials to deal with the terrible problems. Luckily there are
several promising antibacterial drugs with novel mechanisms of action are in development
and new types of targets have emerged. Also we need to be more precise in targeting the
pathogens and limit the misuse of antimicrobials and other practices that accelerate the
emergence of novel resistance mechanisms. The government must offer robust financial in‐
centives for antibacterial R&D, and build a sustainable model for developing and using anti‐
bacterials.
The Antibacterial Drug Discovery
http://dx.doi.org/10.5772/52510
301
more than 300 genes and employed 70 high-throughput screening campaigns over a period
of 7 years, but unfortunately did not create a clinical used antibacterial [70].
5.2.2.3. New targets
It must be admitted that target-based genomic approach has not yielded satisfactory results,
nevertheless, retooled target-based strategies can still play an important role in discovery
process. Most antibiotic targets are limited to peptidoglycan synthesis, ribosomal protein
synthesis, folate synthesis, and nucleic acid synthesis and topoisomerization. In the future
we could continue to discover new antibiotics for these old targets through improvement of
the existing scaffolds or even finding new scaffolds. For instance, Lipid II is a membrane-
anchored cell-wall precursor that is essential for bacterial cell-wall biosynthesis; it is not on‐
ly classical target for several old antibacterial classes, but is also targeted by the new
antibiotics, such as lantibiotics, mannopeptimycins and ramoplanin [71]. Grouping targets
by a common inhibitor scaffold rather than by function may lead to new targets; and as
mentioned above, insights from outside the antibiotic arena are also important [59].
5.2.2.4. Forward is back
Compared with the fruitless target-based genomic approach, traditional whole-cell assays
are more effective in antibiotic discovery. Just because it is not necessary to worry about cell
permeability of a novel scaffold in the development process if whole-cell assays are used. As
most of the existing libraries have already been used to screen for antibacterial drugs, libra‐
ries with new chemical diversity are extremely important in this approach. Sometimes, look
for libraries that don’t belong to antibacterial development areas may be useful. In fact, most
pharmaceutical companies of other therapeutic areas have invested considerable resources
in synthesizing small molecule libraries [59]. Candidates with a strong hit in a whole-cell an‐
tibacterial assay should be tested in the right animal model early in development, because In
vitro experiment results are not always reliable. For example, Antimicrobial drug target type
II fatty acid synthesis (FASII) is reported to be essential for their efficacy against infections
caused by multiresistant Gram-positive bacteria. But another study showed that Streptococ‐
cus agalactiae and S. aureus could take up sufficient unsaturated fatty acids from human se‐
rum to obviate the essentiality of FAS II enzymes in vivo [72].
5.2.2.5. Focus on spectrum
Antibacterial spectrum is a major consideration when selecting a target for lead optimiza‐
tion. Permeability and target distribution determine the pectrum [73]. That is to say, the
drug candidates should possess two properties at the same time: one is penetrating the cell
and evading efflux pump systems, another is retaining potent activity at the molecular tar‐
gets. However, since almost all targets of the antibacterials in clinical use are present in all
bacteria, the antibacterial drug spectra are determined largely by the ability of permeability.
Therefore, some compounds are just Gram-positive organism-selective and have no effect
against Gram-negative pathogens which have a second membrane acting as a permeability
barrier [74; 75]. Efflux pump inhibitors (EPIs) have been explored for broadening the anti‐
Drug Discovery300
bacterial spectrum and overcoming bacterial resistance. Although no clinically useful drugs
have come out, extensive efforts have been made to test the effectiveness of EPIs across a
range of in vitro and in vivo assays, especially the compound MC-207,110 [76].
‘Broader is better’ is the rule of antibacterial activity spectrum. But developing the agents
with a narrower spectrum may be helpful in treating some special antibiotic resistant patho‐
gens or the non-multiplying bacteria. One human squalene synthase inhibitor blocked
staphyloxanthin biosynthesis in vitro, resulting in colorless bacteria which became more
sensitive to killing by human blood and innate immune clearance [77]. Rifampicin is a
standard antibiotic used for clearance of non-multiplying tuberculosis. Monoclonal antibod‐
ies (Mabs) have also become potential agents for narrow-spectrum antibacterial therapy. In
clinical experiment C. difficile Mab combination MDX-066 and MDX-1388, which targets
and neutralizes two main C. difficile toxins, can reduce the recurrence of C. difficile infec‐
tion [78; 79]. A microbiologic diagnosis should be made before using these kinds of antibiot‐
ics for therapy. Such genus-selective agents may have the benefit of leaving more of the
endogenous microfloraun unattacked compared with conventional antibiotics.
5.2.2.6. Other new methods
Bacteriophages
Bacteriophages and their fragments could kill the bacteria. They have been developed as an‐
tibacterials in humans, poultry and cattle industries, aquaculture and sewage treatment.
This approach has novel mechanism of action that is completely different from current anti‐
microbials, but the problems are that quality control and standardization are difficult. Phage
lysins, which are produced late in the viral infection cycle, can bind to cell wall peptidogly‐
can and rapidly induce Gram-positive bacteria lysis [80]. The sequencing of phages genomes
may identify more proteins suitable for novel antibacterials [81; 82].
Other methods to find new drugs could be modulating immunity, developing monoclonal
antibody for specific bacteria, designing antibacterial peptides (including antimicrobial pep‐
tides and compounds from animals and plants, the natural lipopeptides of bacteria and Fun‐
gi [83; 84]), and so on.
6. Conclusion and future issues
While the antibacterial resistance, especially multi-drug resistance continues to rise, what
we should do is to investigate the potential mechanisms of drug resistance in bacteria and
discover more effective antibacterials to deal with the terrible problems. Luckily there are
several promising antibacterial drugs with novel mechanisms of action are in development
and new types of targets have emerged. Also we need to be more precise in targeting the
pathogens and limit the misuse of antimicrobials and other practices that accelerate the
emergence of novel resistance mechanisms. The government must offer robust financial in‐
centives for antibacterial R&D, and build a sustainable model for developing and using anti‐
bacterials.




Jie Yanling, Liang Xin and Li Zhiyuan
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China
References
[1] W.J. Lindblad. Considerations for determining if a natural product is an effective
wound-healing agent. Int J Low Extrem Wounds 2008;7(2):75-81.
[2] R.D. Forrest. Early history of wound treatment. J R Soc Med 1982;75(3):198-205.
[3] L.G. Nickell. Antimicrobial activity of vascular plants. Economic Botany 1959;13(4):
281-318.
[4] E.J. Bassett, M.S. Keith, G.J. Armelagos, et al. Tetracycline-labeled human bone from
ancient Sudanese Nubia (A.D. 350). Science 1980;209(4464):1532-1534.
[5] M.L. Nelson, A. Dinardo, J. Hochberg, et al. Brief communication: Mass spectroscop‐
ic characterization of tetracycline in the skeletal remains of an ancient population
from Sudanese Nubia 350-550 CE. Am J PhysAnthropol 2010;143(1):151-154.
[6] M. Cook, E. Molto, C. Anderson. Fluorochromelabelling in Roman period skeletons
from Dakhleh Oasis, Egypt. Am J PhysAnthropol 1989;80(2):137-143.
[7] J.O. Falkinham, 3rd, T.E. Wall, J.R. Tanner, et al. Proliferation of antibiotic-producing
bacteria and concomitant antibiotic production as the basis for the antibiotic activity
of Jordan's red soils. Appl Environ Microbiol 2009;75(9):2735-2741.
[8] J. Clardy. Using genomics to deliver natural products from symbiotic bacteria. Ge‐
nome Biol 2005;6(9):232.
[9] R.I. Aminov. A brief history of the antibiotic era: lessons learned and challenges for
the future. Front Microbiol 2010;1:134.
[10] R.W. Wong, U. Hagg, L. Samaranayake, et al. Antimicrobial activity of Chinese medi‐
cine herbs against common bacteria in oral biofilm. A pilot study. Int J Oral Maxillo‐
facSurg 2010;39(6):599-605.
[11] F. Heynick. The original 'magic bullet' is 100 years old - extra. Br J Psychiatry
2009;195(5):456.
[12] J.F. Mahoney, R.C. Arnold, A. Harris. Penicillin Treatment of Early Syphilis-A Pre‐
liminary Report. Am J Public Health Nations Health 1943;33(12):1387-1391.
[13] N.C. Lloyd, H.W. Morgan, B.K. Nicholson, et al. The composition of Ehrlich's salvar‐
san: resolution of a century-old debate. AngewChemInt Ed Engl 2005;44(6):941-944.
Drug Discovery302
[14] J. Kimmig. [Gerhard Domagk, 1895-1964. Contribution to the chemotherapy of bacte‐
rial infections]. Internist (Berl) 1969;10(3):116-120.
[15] C. Jesman, A. Mludzik, M. Cybulska. [History of antibiotics and sulphonamides dis‐
coveries]. Pol MerkurLekarski 2011;30(179):320-322.
[16] E. Chain, H.W. Florey, A.D. Gardner, et al. THE CLASSIC: penicillin as a chemother‐
apeutic agent. 1940. ClinOrthopRelat Res 2005;439:23-26.
[17] N. Kardos, A.L. Demain. Penicillin: the medicine with the greatest impact on thera‐
peutic outcomes. ApplMicrobiolBiotechnol 2011;92(4):677-687.
[18] C. Walsh. Where will new antibiotics come from? Nat Rev Microbiol 2003;1(1):65-70.
[19] R.W. Finberg, R.C. Moellering, F.P. Tally, et al. The importance of bactericidal drugs:
future directions in infectious disease. Clin Infect Dis 2004;39(9):1314-1320.
[20] S.R. Palumbi. Humans as the world's greatest evolutionary force. Science
2001;293(5536):1786-1790.
[21] S.L. Bronzwaer, O. Cars, U. Buchholz, et al. A European study on the relationship be‐
tween antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8(3):
278-282.
[22] H. Goossens, M. Ferech, R. Vander Stichele, et al. Outpatient antibiotic use in Europe
and association with resistance: a cross-national database study. Lancet
2005;365(9459):579-587.
[23] A. Giedraitiene, A. Vitkauskiene, R. Naginiene, et al. Antibiotic resistance mecha‐
nisms of clinically important bacteria. Medicina (Kaunas) 2011;47(3):137-146.
[24] M.N. Alekshun, S.B. Levy. Molecular mechanisms of antibacterial multidrug resist‐
ance. Cell 2007;128(6):1037-1050.
[25] 35 years of resistance. Nat Rev Microbiol 2012;10(6):373.
[26] M.P. Doyle, F.F. Busta. Antimicrobial resistance: implications for the food system.
Compr. Rev. Food Sci. Food Saf 2006;5:71-137.
[27] J.L. Martinez. Antibiotics and antibiotic resistance genes in natural environments.
Science 2008;321(5887):365-367.
[28] R.I. Aminov, R.I. Mackie. Evolution and ecology of antibiotic resistance genes. FEMS
MicrobiolLett 2007;271(2):147-161.
[29] D.C. Hooper. Mechanisms of fluoroquinolone resistance. Drug Resist Updat
1999;2(1):38-55.
[30] L. Adewoye, A. Sutherland, R. Srikumar, et al. The mexR repressor of the mexAB-
oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mu‐
tations compromising activity. J Bacteriol 2002;184(15):4308-4312.




Jie Yanling, Liang Xin and Li Zhiyuan
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China
References
[1] W.J. Lindblad. Considerations for determining if a natural product is an effective
wound-healing agent. Int J Low Extrem Wounds 2008;7(2):75-81.
[2] R.D. Forrest. Early history of wound treatment. J R Soc Med 1982;75(3):198-205.
[3] L.G. Nickell. Antimicrobial activity of vascular plants. Economic Botany 1959;13(4):
281-318.
[4] E.J. Bassett, M.S. Keith, G.J. Armelagos, et al. Tetracycline-labeled human bone from
ancient Sudanese Nubia (A.D. 350). Science 1980;209(4464):1532-1534.
[5] M.L. Nelson, A. Dinardo, J. Hochberg, et al. Brief communication: Mass spectroscop‐
ic characterization of tetracycline in the skeletal remains of an ancient population
from Sudanese Nubia 350-550 CE. Am J PhysAnthropol 2010;143(1):151-154.
[6] M. Cook, E. Molto, C. Anderson. Fluorochromelabelling in Roman period skeletons
from Dakhleh Oasis, Egypt. Am J PhysAnthropol 1989;80(2):137-143.
[7] J.O. Falkinham, 3rd, T.E. Wall, J.R. Tanner, et al. Proliferation of antibiotic-producing
bacteria and concomitant antibiotic production as the basis for the antibiotic activity
of Jordan's red soils. Appl Environ Microbiol 2009;75(9):2735-2741.
[8] J. Clardy. Using genomics to deliver natural products from symbiotic bacteria. Ge‐
nome Biol 2005;6(9):232.
[9] R.I. Aminov. A brief history of the antibiotic era: lessons learned and challenges for
the future. Front Microbiol 2010;1:134.
[10] R.W. Wong, U. Hagg, L. Samaranayake, et al. Antimicrobial activity of Chinese medi‐
cine herbs against common bacteria in oral biofilm. A pilot study. Int J Oral Maxillo‐
facSurg 2010;39(6):599-605.
[11] F. Heynick. The original 'magic bullet' is 100 years old - extra. Br J Psychiatry
2009;195(5):456.
[12] J.F. Mahoney, R.C. Arnold, A. Harris. Penicillin Treatment of Early Syphilis-A Pre‐
liminary Report. Am J Public Health Nations Health 1943;33(12):1387-1391.
[13] N.C. Lloyd, H.W. Morgan, B.K. Nicholson, et al. The composition of Ehrlich's salvar‐
san: resolution of a century-old debate. AngewChemInt Ed Engl 2005;44(6):941-944.
Drug Discovery302
[14] J. Kimmig. [Gerhard Domagk, 1895-1964. Contribution to the chemotherapy of bacte‐
rial infections]. Internist (Berl) 1969;10(3):116-120.
[15] C. Jesman, A. Mludzik, M. Cybulska. [History of antibiotics and sulphonamides dis‐
coveries]. Pol MerkurLekarski 2011;30(179):320-322.
[16] E. Chain, H.W. Florey, A.D. Gardner, et al. THE CLASSIC: penicillin as a chemother‐
apeutic agent. 1940. ClinOrthopRelat Res 2005;439:23-26.
[17] N. Kardos, A.L. Demain. Penicillin: the medicine with the greatest impact on thera‐
peutic outcomes. ApplMicrobiolBiotechnol 2011;92(4):677-687.
[18] C. Walsh. Where will new antibiotics come from? Nat Rev Microbiol 2003;1(1):65-70.
[19] R.W. Finberg, R.C. Moellering, F.P. Tally, et al. The importance of bactericidal drugs:
future directions in infectious disease. Clin Infect Dis 2004;39(9):1314-1320.
[20] S.R. Palumbi. Humans as the world's greatest evolutionary force. Science
2001;293(5536):1786-1790.
[21] S.L. Bronzwaer, O. Cars, U. Buchholz, et al. A European study on the relationship be‐
tween antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8(3):
278-282.
[22] H. Goossens, M. Ferech, R. Vander Stichele, et al. Outpatient antibiotic use in Europe
and association with resistance: a cross-national database study. Lancet
2005;365(9459):579-587.
[23] A. Giedraitiene, A. Vitkauskiene, R. Naginiene, et al. Antibiotic resistance mecha‐
nisms of clinically important bacteria. Medicina (Kaunas) 2011;47(3):137-146.
[24] M.N. Alekshun, S.B. Levy. Molecular mechanisms of antibacterial multidrug resist‐
ance. Cell 2007;128(6):1037-1050.
[25] 35 years of resistance. Nat Rev Microbiol 2012;10(6):373.
[26] M.P. Doyle, F.F. Busta. Antimicrobial resistance: implications for the food system.
Compr. Rev. Food Sci. Food Saf 2006;5:71-137.
[27] J.L. Martinez. Antibiotics and antibiotic resistance genes in natural environments.
Science 2008;321(5887):365-367.
[28] R.I. Aminov, R.I. Mackie. Evolution and ecology of antibiotic resistance genes. FEMS
MicrobiolLett 2007;271(2):147-161.
[29] D.C. Hooper. Mechanisms of fluoroquinolone resistance. Drug Resist Updat
1999;2(1):38-55.
[30] L. Adewoye, A. Sutherland, R. Srikumar, et al. The mexR repressor of the mexAB-
oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mu‐
tations compromising activity. J Bacteriol 2002;184(15):4308-4312.
The Antibacterial Drug Discovery
http://dx.doi.org/10.5772/52510
303
[31] J. Blazquez. Hypermutation as a factor contributing to the acquisition of antimicrobi‐
al resistance. Clin Infect Dis 2003;37(9):1201-1209.
[32] A. Oliver, R. Canton, P. Campo, et al. High frequency of hypermutable Pseudomonas
aeruginosa in cystic fibrosis lung infection. Science 2000;288(5469):1251-1254.
[33] I. Chopra, A.J. O'Neill, K. Miller. The role of mutators in the emergence of antibiotic-
resistant bacteria. Drug Resist Updat 2003;6(3):137-145.
[34] S.B. Levy, B. Marshall. Antibacterial resistance worldwide: causes, challenges and re‐
sponses. Nat Med 2004;10(12 Suppl):S122-129.
[35] P. Courvalin. Transfer of antibiotic resistance genes between gram-positive and
gram-negative bacteria. Antimicrob Agents Chemother 1994;38(7):1447-1451.
[36] P. Nordmann, L. Poirel. Emerging carbapenemases in Gram-negative aerobes. Clin‐
Microbiol Infect 2002;8(6):321-331.
[37] G.A. Jacoby, L.S. Munoz-Price. The new beta-lactamases. N Engl J Med 2005;352(4):
380-391.
[38] S.M. Drawz, R.A. Bonomo. Three decades of beta-lactamase inhibitors. ClinMicrobiol
Rev 2010;23(1):160-201.
[39] M.S. Ramirez, M.E. Tolmasky. Aminoglycoside modifying enzymes. Drug Resist Up‐
dat 2010;13(6):151-171.
[40] K. Poole. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 2004;61(17):
2200-2223.
[41] F.C. Tenover. Mechanisms of antimicrobial resistance in bacteria. Am J Med
2006;119(6 Suppl 1):S3-10; discussion S62-70.
[42] S. Jana, J.K. Deb. Molecular understanding of aminoglycoside action and resistance.
ApplMicrobiolBiotechnol 2006;70(2):140-150.
[43] G. Ackermann, A. Degner, S.H. Cohen, et al. Prevalence and association of macro‐
lide-lincosamide-streptogramin B (MLS(B)) resistance with resistance to moxifloxacin
in Clostridium difficile. J AntimicrobChemother 2003;51(3):599-603.
[44] B. Weisblum. Erythromycin resistance by ribosome modification. Antimicrob Agents
Chemother 1995;39(3):577-585.
[45] D. Ince, X. Zhang, L.C. Silver, et al. Dual targeting of DNA gyrase and topoisomerase
IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroqui‐
nolone. Antimicrob Agents Chemother 2002;46(11):3370-3380.
[46] X.Z. Li, H. Nikaido. Efflux-mediated drug resistance in bacteria. Drugs 2004;64(2):
159-204.
[47] X.Z. Li, H. Nikaido. Efflux-mediated drug resistance in bacteria: an update. Drugs
2009;69(12):1555-1623.
Drug Discovery304
[48] K.P. Langton, P.J. Henderson, R.B. Herbert. Antibiotic resistance: multidrug efflux
proteins, a common transport mechanism? Nat Prod Rep 2005;22(4):439-451.
[49] M. Putman, H.W. van Veen, W.N. Konings. Molecular properties of bacterial multi‐
drug transporters. MicrobiolMolBiol Rev 2000;64(4):672-693.
[50] J.M. Thomson, R.A. Bonomo. The threat of antibiotic resistance in Gram-negative
pathogenic bacteria: beta-lactams in peril! CurrOpinMicrobiol 2005;8(5):518-524.
[51] D.M. Livermore. Multiple mechanisms of antimicrobial resistance in Pseudomonas
aeruginosa: our worst nightmare? Clin Infect Dis 2002;34(5):634-640.
[52] A.H. Delcour. Outer membrane permeability and antibiotic resistance. BiochimBio‐
physActa 2009;1794(5):808-816.
[53] W. Achouak, T. Heulin, J.M. Pages. Multiple facets of bacterial porins. FEMS Micro‐
biolLett 2001;199(1):1-7.
[54] M.E. Falagas, S.K. Kasiakou. Colistin: the revival of polymyxins for the management
of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40(9):
1333-1341.
[55] J.L. Mainardi, R. Legrand, M. Arthur, et al. Novel mechanism of beta-lactam resist‐
ance due to bypass of DD-transpeptidation in Enterococcus faecium. J BiolChem
2000;275(22):16490-16496.
[56] S. Triboulet, M. Arthur, J.L. Mainardi, et al. Inactivation kinetics of a new target of
beta-lactam antibiotics. J BiolChem 2011;286(26):22777-22784.
[57] I.C. Gyssens. Antibiotic policy. Int J Antimicrob Ag 2011;38:11-20.
[58] T. Braine. Race against time to develop new antibiotics. Bull World Health Organ
2011;89(2):88-89.
[59] M.A. Fischbach, C.T. Walsh. Antibiotics for emerging pathogens. Science
2009;325(5944):1089-1093.
[60] G. Devasahayam, W.M. Scheld, P.S. Hoffman. Newer antibacterial drugs for a new
century. Expert OpinInvestig Drugs 2010;19(2):215-234.
[61] H.C. Neu, K.P. Fu. Cefaclor: in vitro spectrum of activity and beta-lactamase stabili‐
ty. Antimicrob Agents Chemother 1978;13(4):584-588.
[62] G.A. Noskin. Tigecycline: a new glycylcycline for treatment of serious infections.
Clin Infect Dis 2005;41Suppl 5:S303-314.
[63] P.J. Petersen, N.V. Jacobus, W.J. Weiss, et al. In vitro and in vivo antibacterial activi‐
ties of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline
(GAR-936). Antimicrob Agents Chemother 1999;43(4):738-744.
[64] H. Rahman, B. Austin, W.J. Mitchell, et al. Novel anti-infective compounds from ma‐
rine bacteria. Mar Drugs 2010;8(3):498-518.
The Antibacterial Drug Discovery
http://dx.doi.org/10.5772/52510
305
[31] J. Blazquez. Hypermutation as a factor contributing to the acquisition of antimicrobi‐
al resistance. Clin Infect Dis 2003;37(9):1201-1209.
[32] A. Oliver, R. Canton, P. Campo, et al. High frequency of hypermutable Pseudomonas
aeruginosa in cystic fibrosis lung infection. Science 2000;288(5469):1251-1254.
[33] I. Chopra, A.J. O'Neill, K. Miller. The role of mutators in the emergence of antibiotic-
resistant bacteria. Drug Resist Updat 2003;6(3):137-145.
[34] S.B. Levy, B. Marshall. Antibacterial resistance worldwide: causes, challenges and re‐
sponses. Nat Med 2004;10(12 Suppl):S122-129.
[35] P. Courvalin. Transfer of antibiotic resistance genes between gram-positive and
gram-negative bacteria. Antimicrob Agents Chemother 1994;38(7):1447-1451.
[36] P. Nordmann, L. Poirel. Emerging carbapenemases in Gram-negative aerobes. Clin‐
Microbiol Infect 2002;8(6):321-331.
[37] G.A. Jacoby, L.S. Munoz-Price. The new beta-lactamases. N Engl J Med 2005;352(4):
380-391.
[38] S.M. Drawz, R.A. Bonomo. Three decades of beta-lactamase inhibitors. ClinMicrobiol
Rev 2010;23(1):160-201.
[39] M.S. Ramirez, M.E. Tolmasky. Aminoglycoside modifying enzymes. Drug Resist Up‐
dat 2010;13(6):151-171.
[40] K. Poole. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 2004;61(17):
2200-2223.
[41] F.C. Tenover. Mechanisms of antimicrobial resistance in bacteria. Am J Med
2006;119(6 Suppl 1):S3-10; discussion S62-70.
[42] S. Jana, J.K. Deb. Molecular understanding of aminoglycoside action and resistance.
ApplMicrobiolBiotechnol 2006;70(2):140-150.
[43] G. Ackermann, A. Degner, S.H. Cohen, et al. Prevalence and association of macro‐
lide-lincosamide-streptogramin B (MLS(B)) resistance with resistance to moxifloxacin
in Clostridium difficile. J AntimicrobChemother 2003;51(3):599-603.
[44] B. Weisblum. Erythromycin resistance by ribosome modification. Antimicrob Agents
Chemother 1995;39(3):577-585.
[45] D. Ince, X. Zhang, L.C. Silver, et al. Dual targeting of DNA gyrase and topoisomerase
IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroqui‐
nolone. Antimicrob Agents Chemother 2002;46(11):3370-3380.
[46] X.Z. Li, H. Nikaido. Efflux-mediated drug resistance in bacteria. Drugs 2004;64(2):
159-204.
[47] X.Z. Li, H. Nikaido. Efflux-mediated drug resistance in bacteria: an update. Drugs
2009;69(12):1555-1623.
Drug Discovery304
[48] K.P. Langton, P.J. Henderson, R.B. Herbert. Antibiotic resistance: multidrug efflux
proteins, a common transport mechanism? Nat Prod Rep 2005;22(4):439-451.
[49] M. Putman, H.W. van Veen, W.N. Konings. Molecular properties of bacterial multi‐
drug transporters. MicrobiolMolBiol Rev 2000;64(4):672-693.
[50] J.M. Thomson, R.A. Bonomo. The threat of antibiotic resistance in Gram-negative
pathogenic bacteria: beta-lactams in peril! CurrOpinMicrobiol 2005;8(5):518-524.
[51] D.M. Livermore. Multiple mechanisms of antimicrobial resistance in Pseudomonas
aeruginosa: our worst nightmare? Clin Infect Dis 2002;34(5):634-640.
[52] A.H. Delcour. Outer membrane permeability and antibiotic resistance. BiochimBio‐
physActa 2009;1794(5):808-816.
[53] W. Achouak, T. Heulin, J.M. Pages. Multiple facets of bacterial porins. FEMS Micro‐
biolLett 2001;199(1):1-7.
[54] M.E. Falagas, S.K. Kasiakou. Colistin: the revival of polymyxins for the management
of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40(9):
1333-1341.
[55] J.L. Mainardi, R. Legrand, M. Arthur, et al. Novel mechanism of beta-lactam resist‐
ance due to bypass of DD-transpeptidation in Enterococcus faecium. J BiolChem
2000;275(22):16490-16496.
[56] S. Triboulet, M. Arthur, J.L. Mainardi, et al. Inactivation kinetics of a new target of
beta-lactam antibiotics. J BiolChem 2011;286(26):22777-22784.
[57] I.C. Gyssens. Antibiotic policy. Int J Antimicrob Ag 2011;38:11-20.
[58] T. Braine. Race against time to develop new antibiotics. Bull World Health Organ
2011;89(2):88-89.
[59] M.A. Fischbach, C.T. Walsh. Antibiotics for emerging pathogens. Science
2009;325(5944):1089-1093.
[60] G. Devasahayam, W.M. Scheld, P.S. Hoffman. Newer antibacterial drugs for a new
century. Expert OpinInvestig Drugs 2010;19(2):215-234.
[61] H.C. Neu, K.P. Fu. Cefaclor: in vitro spectrum of activity and beta-lactamase stabili‐
ty. Antimicrob Agents Chemother 1978;13(4):584-588.
[62] G.A. Noskin. Tigecycline: a new glycylcycline for treatment of serious infections.
Clin Infect Dis 2005;41Suppl 5:S303-314.
[63] P.J. Petersen, N.V. Jacobus, W.J. Weiss, et al. In vitro and in vivo antibacterial activi‐
ties of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline
(GAR-936). Antimicrob Agents Chemother 1999;43(4):738-744.
[64] H. Rahman, B. Austin, W.J. Mitchell, et al. Novel anti-infective compounds from ma‐
rine bacteria. Mar Drugs 2010;8(3):498-518.
The Antibacterial Drug Discovery
http://dx.doi.org/10.5772/52510
305
[65] C.C. Hughes, W. Fenical. Antibacterials from the sea. Chemistry 2010;16(42):
12512-12525.
[66] S.C. Wenzel, R. Muller. The biosynthetic potential of myxobacteria and their impact
in drug discovery. CurrOpin Drug DiscovDevel 2009;12(2):220-230.
[67] C. Freiberg, H. Brotz-Oesterhelt. Functional genomics in antibacterial drug discov‐
ery. Drug Discov Today 2005;10(13):927-935.
[68] S. Amini, S. Tavazoie. Antibiotics and the post-genome revolution. CurrOpinMicro‐
biol 2011;14(5):513-518.
[69] A.H. Banskota, J.B. McAlpine, D. Sorensen, et al. Genomic analyses lead to novel sec‐
ondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class. J Antibiot
(Tokyo) 2006;59(9):533-542.
[70] D.J. Payne, M.N. Gwynn, D.J. Holmes, et al. Drugs for bad bugs: confronting the
challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6(1):29-40.
[71] E. Breukink, B. de Kruijff. Lipid II as a target for antibiotics. Nat Rev Drug Discov
2006;5(4):321-332.
[72] S. Brinster, G. Lamberet, B. Staels, et al. Type II fatty acid synthesis is not a suitable
antibiotic target for Gram-positive pathogens. Nature 2009;458(7234):83-86.
[73] L.L. Silver. Challenges of antibacterial discovery. ClinMicrobiol Rev 2011;24(1):
71-109.
[74] E. Andre, L. Bastide, S. Michaux-Charachon, et al. Novel synthetic molecules target‐
ing the bacterial RNA polymerase assembly. J AntimicrobChemother 2006;57(2):
245-251.
[75] J. Wang, S. Kodali, S.H. Lee, et al. Discovery of platencin, a dual FabF and FabH in‐
hibitor with in vivo antibiotic properties. ProcNatlAcadSci U S A 2007;104(18):
7612-7616.
[76] O. Lomovskaya, K.A. Bostian. Practical applications and feasibility of efflux pump
inhibitors in the clinic--a vision for applied use. Biochemical pharmacology
2006;71(7):910-918.
[77] C.I. Liu, G.Y. Liu, Y. Song, et al. A cholesterol biosynthesis inhibitor blocks Staphylo‐
coccus aureus virulence. Science 2008;319(5868):1391-1394.
[78] I. Lowy, D.C. Molrine, B.A. Leav, et al. Treatment with monoclonal antibodies
against Clostridium difficile toxins. N Engl J Med 2010;362(3):197-205.
[79] M.N. Gwynn, A. Portnoy, S.F. Rittenhouse, et al. Challenges of antibacterial discov‐
ery revisited. Ann N Y AcadSci 2010;1213:5-19.
[80] V.A. Fischetti, D. Nelson, R. Schuch. Reinventing phage therapy: are the parts greater
than the sum? Nat Biotechnol 2006;24(12):1508-1511.
Drug Discovery306
[81] T.D. Bugg, A.J. Lloyd, D.I. Roper. Phospho-MurNAc-pentapeptidetranslocase
(MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord
Drug Targets 2006;6(2):85-106.
[82] J. Liu, M. Dehbi, G. Moeck, et al. Antimicrobial drug discovery through bacterio‐
phage genomics. Nat Biotechnol 2004;22(2):185-191.
[83] R.E. Hancock, H.G. Sahl. Antimicrobial and host-defense peptides as new anti-infec‐
tive therapeutic strategies. Nat Biotechnol 2006;24(12):1551-1557.
[84] A. Makovitzki, D. Avrahami, Y. Shai. Ultrashort antibacterial and antifungal lipopep‐
tides. ProcNatlAcadSci U S A 2006;103(43):15997-16002.
[85] S.Dzidic, J.Suskovic, B. Kos. Antibiotic resistance mechanisms in bacteria: biochemi‐
cal and genetic aspects. FoodTechnolBiotechnol2008;46(1), 11-21.
[86] J.Garau, W. Wilson, M, Wood, J,Carlet. Fourth-generation cephalosporins: a review
of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility.ClinMi‐
crobiol Infect 1997;3 (Suppl 3): S87 -S101.
The Antibacterial Drug Discovery
http://dx.doi.org/10.5772/52510
307
[65] C.C. Hughes, W. Fenical. Antibacterials from the sea. Chemistry 2010;16(42):
12512-12525.
[66] S.C. Wenzel, R. Muller. The biosynthetic potential of myxobacteria and their impact
in drug discovery. CurrOpin Drug DiscovDevel 2009;12(2):220-230.
[67] C. Freiberg, H. Brotz-Oesterhelt. Functional genomics in antibacterial drug discov‐
ery. Drug Discov Today 2005;10(13):927-935.
[68] S. Amini, S. Tavazoie. Antibiotics and the post-genome revolution. CurrOpinMicro‐
biol 2011;14(5):513-518.
[69] A.H. Banskota, J.B. McAlpine, D. Sorensen, et al. Genomic analyses lead to novel sec‐
ondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class. J Antibiot
(Tokyo) 2006;59(9):533-542.
[70] D.J. Payne, M.N. Gwynn, D.J. Holmes, et al. Drugs for bad bugs: confronting the
challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6(1):29-40.
[71] E. Breukink, B. de Kruijff. Lipid II as a target for antibiotics. Nat Rev Drug Discov
2006;5(4):321-332.
[72] S. Brinster, G. Lamberet, B. Staels, et al. Type II fatty acid synthesis is not a suitable
antibiotic target for Gram-positive pathogens. Nature 2009;458(7234):83-86.
[73] L.L. Silver. Challenges of antibacterial discovery. ClinMicrobiol Rev 2011;24(1):
71-109.
[74] E. Andre, L. Bastide, S. Michaux-Charachon, et al. Novel synthetic molecules target‐
ing the bacterial RNA polymerase assembly. J AntimicrobChemother 2006;57(2):
245-251.
[75] J. Wang, S. Kodali, S.H. Lee, et al. Discovery of platencin, a dual FabF and FabH in‐
hibitor with in vivo antibiotic properties. ProcNatlAcadSci U S A 2007;104(18):
7612-7616.
[76] O. Lomovskaya, K.A. Bostian. Practical applications and feasibility of efflux pump
inhibitors in the clinic--a vision for applied use. Biochemical pharmacology
2006;71(7):910-918.
[77] C.I. Liu, G.Y. Liu, Y. Song, et al. A cholesterol biosynthesis inhibitor blocks Staphylo‐
coccus aureus virulence. Science 2008;319(5868):1391-1394.
[78] I. Lowy, D.C. Molrine, B.A. Leav, et al. Treatment with monoclonal antibodies
against Clostridium difficile toxins. N Engl J Med 2010;362(3):197-205.
[79] M.N. Gwynn, A. Portnoy, S.F. Rittenhouse, et al. Challenges of antibacterial discov‐
ery revisited. Ann N Y AcadSci 2010;1213:5-19.
[80] V.A. Fischetti, D. Nelson, R. Schuch. Reinventing phage therapy: are the parts greater
than the sum? Nat Biotechnol 2006;24(12):1508-1511.
Drug Discovery306
[81] T.D. Bugg, A.J. Lloyd, D.I. Roper. Phospho-MurNAc-pentapeptidetranslocase
(MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord
Drug Targets 2006;6(2):85-106.
[82] J. Liu, M. Dehbi, G. Moeck, et al. Antimicrobial drug discovery through bacterio‐
phage genomics. Nat Biotechnol 2004;22(2):185-191.
[83] R.E. Hancock, H.G. Sahl. Antimicrobial and host-defense peptides as new anti-infec‐
tive therapeutic strategies. Nat Biotechnol 2006;24(12):1551-1557.
[84] A. Makovitzki, D. Avrahami, Y. Shai. Ultrashort antibacterial and antifungal lipopep‐
tides. ProcNatlAcadSci U S A 2006;103(43):15997-16002.
[85] S.Dzidic, J.Suskovic, B. Kos. Antibiotic resistance mechanisms in bacteria: biochemi‐
cal and genetic aspects. FoodTechnolBiotechnol2008;46(1), 11-21.
[86] J.Garau, W. Wilson, M, Wood, J,Carlet. Fourth-generation cephalosporins: a review
of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility.ClinMi‐
crobiol Infect 1997;3 (Suppl 3): S87 -S101.




Air, Water and Soil: Resources for Drug Discovery
Luis Jesús Villarreal-Gómez,
Irma Esthela Soria-Mercado, Ana Leticia Iglesias and
Graciela Lizeth Perez-Gonzalez
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52659
1. Introduction
Drug discovery is the process by which new candidate drugs are discovered. The chemical
compounds that are present in plants and animals have been an important source of new
bioactive compounds. Also, we can found organisms that live in air, water and soil that we
don`t see, but posses a great variety of chemical that we can use to create new medicines.
Bioactive compounds offer an enormous diversity of chemical structures with strong biolog‐
ic effect; this is one of the reasons why natural products research cannot be replaced by syn‐
thesis chemistry as a source for new bioactive compounds. Actually, more than the half of
currently used medicines came from natural sources or are related to them, specifically in
the situation of anticancer drugs that more than 60% belongs from nature [1].
Based on the experience in this field, it is considered that a chemical compound isolated from natural
origin should be fully assessed in order to be used to combat diseases; in this manner is important to
consider the type of new chemical entities potentially applicable for partial or total synthesis, as well
as its use in different kind of diseases that are treatable with these compounds (2); Therefore is very
important continue the search for new secondarymetabolites potentially usable as drugs by human.
2. Importance of drug discovery
The importance of look for new bioactive compounds to synthesize new drugs it’s based by
a main objective of saving human life that it’s lose by illness. Also, it is important to recog‐
nized that the drug discovery projects, help those countries that target their efforts in this
area to economically and sociality develop themselves, because when chemical compounds
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
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are discovered from microorganism that lives in natural environments, this chemical can be
exploited industrially and generate more jobs.
Now, the new drugs and innovative procedures are usually able to keep people alive for a
long time with better conditions that would have previously been rapidly fatal, such as can‐
cer and end-stage heart, liver, lung, kidney, and neurologic diseases. As a result, most peo‐
ple in modern countries die from long-term chronic conditions that are characterized by a
prolonged period of distressing symptoms and progressive loss of function.
According with World Health Organization (WHO) of “57 million global deaths in the last re‐
port  in 2008,  36 million (63%),  were  due to  no communicable  diseases  (NCDs).  The four main
NCDs reported are cardiovascular diseases, cancers, diabetes and chronic lung diseases. The burden
of  these  diseases  is  rising  disproportionately  among lower  income  countries  and  populations.  In
2008, nearly 80% of no communicable disease deaths -- 29 million -- occurred in low- and middle-
income countries with about 29% of deaths occurring before the age of 60 in these countries. The
leading causes of NCD deaths in 2008 were cardiovascular diseases (17 million deaths, or 48% of all
NCD deaths), cancers (7.6 million, or 21% of all NCD deaths), and respiratory diseases, including
asthma and chronic obstructive pulmonary disease (4.2 million). Diabetes caused another 1.3 mil‐
lion deaths” [3]. As we can see, in the WHO’s statistic data, there are less number of people
that die with microbial infection, it can be said to thanks to the constant development of
pharmaceutical drugs.
The discovery of new bioactive compounds from microorganism present in the ambient,
needs the previously determination of diversity, because by knowing the kind of microbes
that live in a certain site, we can be able to design strategies and culture methods adapted
for the different types of microorganism present in nature [4]. We can be able to screen
chemical bioactivity only if we can culture the microorganism, because we need the microbi‐
al biomass to obtain the compounds. To culture microorganism from natural sources is not
an easy topics, because, when we try to cultivate bacteria or fungi from substrates and con‐
ditions that are in constant change, and incubate them in a static temperature and nutrients;
many microbes don’t resist this transformation of circumstances and die.
3. Drug resistance bacteria
Some Bacteria can innately be resistant to one or more types of antimicrobial compounds
and other can be capable of acquired. In actuality, it is well know the factors that provoke
mutations in bacteria that create stronger species that are able to survive to the effects of cur‐
rents drugs. Examples of these factors are the unnecessary use of antibiotics by humans, the
use in animal feeds in low doses, availability over-the-counter in many countries, misuse by
health professionals, patient failure to follow prescribed treatment, antibiotic use in agricul‐
ture, aquaria and family pets, eating raw or undercooked foods.
It can be describe several strategies of antibiotics resistance in different bacterial genera.
Pathogens bacteria that have become resistant to the current antibiotic drug are an increas‐
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ing public health problem. Some examples of diseases that have become very hard to treat
with the current drugs are wound infections, septicemia, tuberculosis, pneumonia, and gon‐
orrhea, to name a few. One part of the problem is that bacteria and other microbes that
cause infections are remarkably adaptable and have developed several mechanisms to be
immune to antibiotics and other antimicrobial drugs.
Also, it`s been reported that over-prescription and the improper use of antibiotics has led to the
generation of antibiotic resistance bacteria that use to be susceptible at those antibiotics [5].
4. Mechanisms of bacteria to become antibiotics resistant
a. Avoiding entrance of antibiotic into the bacteria cell: Bacteria and other microbes can
actually change the properties of its membrane by changing its grade of permeability by
reducing the number of ion channels which are the entrance of some drugs to diffuse
into the cells. Another way to get rid of antibiotics in some bacteria is use adenosine tri‐
phosphate (ATP) to obtain energy to activate this ion channels and pump it out of the
cells.
b. Editing transmembrane protein expression: The mechanism of several antibiotics it`s
to interact specifically with molecules in the membrane of the microbes and preventing
it from interacting with other molecules (usually proteins) inside the cell. Some bacteria
respond by changing the chemical structure or the expression of the molecule (replac‐
ing it with another molecule) so that the antibiotic can no longer recognize it or bind to
it.
c. Bacterial enzymes that destroy antibiotics: Some bacteria can be resistant to antibiotics
by neutralizing them directly. For example, some organisms may obtain new genes that
encode proteins like enzymes that neutralize antibiotics agents before they get to their
targets. An example of this enzymes can be found in the β–lactamases like penicillinas‐
es, cephalosporinases, carbenicillinase, cloxacilanase, carbapenamase, metalloenzyme
that destroy the β-lactamics (penicillins, monobactams, carbapenems, and cephalospor‐
ins). The β–lactamases can be isolated from Gram Negative Bacteria: Escherichia coli, En‐
terobacter cloacae, Citrobacter freundii, Serrati amarcescens, and Pseudomona aeruginosa. The
mechanism of action of β–lactamases is the breaking of β-lactam ring of the antibiotic,
thus destroying the drug [6]. Other example of this is Pseudomona sp. erithromycinester‐
ases that degrade erythromycin by hydrolysis of the lactone ring of erithromycin [7].
5. Cancer
Cancer is an illness that comprises more than hundred types. This disease appears when old cells
are not replaced by new cells and are accumulated in a mass of tissue known as tumor” [4]. To
cite some statistics data; cancer is responsible for one of every four deaths in the United States.
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prolonged period of distressing symptoms and progressive loss of function.
According with World Health Organization (WHO) of “57 million global deaths in the last re‐
port  in 2008,  36 million (63%),  were  due to  no communicable  diseases  (NCDs).  The four main
NCDs reported are cardiovascular diseases, cancers, diabetes and chronic lung diseases. The burden
of  these  diseases  is  rising  disproportionately  among lower  income  countries  and  populations.  In
2008, nearly 80% of no communicable disease deaths -- 29 million -- occurred in low- and middle-
income countries with about 29% of deaths occurring before the age of 60 in these countries. The
leading causes of NCD deaths in 2008 were cardiovascular diseases (17 million deaths, or 48% of all
NCD deaths), cancers (7.6 million, or 21% of all NCD deaths), and respiratory diseases, including
asthma and chronic obstructive pulmonary disease (4.2 million). Diabetes caused another 1.3 mil‐
lion deaths” [3]. As we can see, in the WHO’s statistic data, there are less number of people
that die with microbial infection, it can be said to thanks to the constant development of
pharmaceutical drugs.
The discovery of new bioactive compounds from microorganism present in the ambient,
needs the previously determination of diversity, because by knowing the kind of microbes
that live in a certain site, we can be able to design strategies and culture methods adapted
for the different types of microorganism present in nature [4]. We can be able to screen
chemical bioactivity only if we can culture the microorganism, because we need the microbi‐
al biomass to obtain the compounds. To culture microorganism from natural sources is not
an easy topics, because, when we try to cultivate bacteria or fungi from substrates and con‐
ditions that are in constant change, and incubate them in a static temperature and nutrients;
many microbes don’t resist this transformation of circumstances and die.
3. Drug resistance bacteria
Some Bacteria can innately be resistant to one or more types of antimicrobial compounds
and other can be capable of acquired. In actuality, it is well know the factors that provoke
mutations in bacteria that create stronger species that are able to survive to the effects of cur‐
rents drugs. Examples of these factors are the unnecessary use of antibiotics by humans, the
use in animal feeds in low doses, availability over-the-counter in many countries, misuse by
health professionals, patient failure to follow prescribed treatment, antibiotic use in agricul‐
ture, aquaria and family pets, eating raw or undercooked foods.
It can be describe several strategies of antibiotics resistance in different bacterial genera.
Pathogens bacteria that have become resistant to the current antibiotic drug are an increas‐
Drug Discovery310
ing public health problem. Some examples of diseases that have become very hard to treat
with the current drugs are wound infections, septicemia, tuberculosis, pneumonia, and gon‐
orrhea, to name a few. One part of the problem is that bacteria and other microbes that
cause infections are remarkably adaptable and have developed several mechanisms to be
immune to antibiotics and other antimicrobial drugs.
Also, it`s been reported that over-prescription and the improper use of antibiotics has led to the
generation of antibiotic resistance bacteria that use to be susceptible at those antibiotics [5].
4. Mechanisms of bacteria to become antibiotics resistant
a. Avoiding entrance of antibiotic into the bacteria cell: Bacteria and other microbes can
actually change the properties of its membrane by changing its grade of permeability by
reducing the number of ion channels which are the entrance of some drugs to diffuse
into the cells. Another way to get rid of antibiotics in some bacteria is use adenosine tri‐
phosphate (ATP) to obtain energy to activate this ion channels and pump it out of the
cells.
b. Editing transmembrane protein expression: The mechanism of several antibiotics it`s
to interact specifically with molecules in the membrane of the microbes and preventing
it from interacting with other molecules (usually proteins) inside the cell. Some bacteria
respond by changing the chemical structure or the expression of the molecule (replac‐
ing it with another molecule) so that the antibiotic can no longer recognize it or bind to
it.
c. Bacterial enzymes that destroy antibiotics: Some bacteria can be resistant to antibiotics
by neutralizing them directly. For example, some organisms may obtain new genes that
encode proteins like enzymes that neutralize antibiotics agents before they get to their
targets. An example of this enzymes can be found in the β–lactamases like penicillinas‐
es, cephalosporinases, carbenicillinase, cloxacilanase, carbapenamase, metalloenzyme
that destroy the β-lactamics (penicillins, monobactams, carbapenems, and cephalospor‐
ins). The β–lactamases can be isolated from Gram Negative Bacteria: Escherichia coli, En‐
terobacter cloacae, Citrobacter freundii, Serrati amarcescens, and Pseudomona aeruginosa. The
mechanism of action of β–lactamases is the breaking of β-lactam ring of the antibiotic,
thus destroying the drug [6]. Other example of this is Pseudomona sp. erithromycinester‐
ases that degrade erythromycin by hydrolysis of the lactone ring of erithromycin [7].
5. Cancer
Cancer is an illness that comprises more than hundred types. This disease appears when old cells
are not replaced by new cells and are accumulated in a mass of tissue known as tumor” [4]. To
cite some statistics data; cancer is responsible for one of every four deaths in the United States.
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It’s second only after heart disease as a cause of death in this country. About 1.2 million Ameri‐
cans were diagnosed with cancer in 1998. Of that number, more than 500,000 are expected to die
of this disease. Cancer can attack anyone, but the chances of getting the disease increase with age.
The most common forms of cancer are skin, lung, colon, breast and prostate cancer. Cancer is a
disorder that affects the genes. There were an estimated 12.7 million cancer cases around the
world in 2008, of these 6.6 million cases were in men and 6.0 million in women. This number is ex‐
pected to increase to 21 million by 2030. Lung cancer is the most common cancer worldwide con‐
tributing nearly 13% of the total number of new cases diagnosed in 2008. Breast cancer (women
only) is the second most common cancer with nearly 1.4 million new cases in 2008 and colorectal
cancer (Figure 1) is the third most common cancer with over 1.2 million new cases in 2008 [8].
Figure 1. Cancer Colorectal HCT-116 cell culture in McCoy medium at 40 X amplification
6. Natural source for drug discovery
6.1. Drug discovery from air microorganisms
The atmosphere its well characterized for possess a good light intensity, extreme tempera‐
ture variations, low concentration of organic matter and water, hence become a very hostile
place for microorganism. However, there are a numerous quantity of microbes founded in
the atmosphere, most of them introduced by human activity.
Bioaerosols are airborne particles that are biological in foundation. Bioaerosols can be
formed from nearly any process that involves biological materials and generates enough en‐
ergy to separate small particles from the larger substance, such as wind, water, air, or me‐
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chanical movement. Plants, soil, water, and animals (including humans) all serve as sources
of bioaerosols and are present in most places where any of these sources live.
Microorganisms are frequently considered passive habitants of the air, dispersing via air‐
borne dust particles (Figure 2). However, latest studies suggest that many airborne microor‐
ganisms are metabolically active, even up to altitudes of 20,000 m. Also, it has been
suggested, that some airborne microbes may modify atmospheric conditions [9].
Figure 2. Fungal strains from air samples in Valle de las Palmas, Mexico.
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Several studies reported a great variety of microorganism present in air samples, for exam‐
ple, a study realized in Mexico, in 2007, showed 21 species of bacteria founded in air sam‐
ples from landfill, some of them are pathogenic and opportunistic bacteria, the most
abundant are Pasteurella haemolytica, Serratia plymuthica, Escherichia coli y Klebsiella pneumonia
and 19 fungal species, 7 of them allergenic, Cladosporium herbarum, Aspergillus sp y Penicilli‐
um sp. [10]. Despite this, Serratia plymuthicait’s well known to possess 2-amino-3-(oxir‐
ane-2,3-dicarboxamido)-propanoyl-valine has been shown to inhibit the growth of the
human pathogen Candida albicans efficiently [11].
Another studies found airborne microbes collected at indoor air with filters installed in two
shopping centers in Singapore. The most common microorganism appears to be several spe‐
cies of Brevundimonas (50%) [12] other study has identified Brevundimonas diminutaas pro‐
ducer of a nematicidal metabolite known as (R)-(-)-2-ethykhexan-1-ol which have a strong
activity against C. elegans and B. xylophilus [13].
6.2. Drug discovery from soil microorganisms
Soil microorganisms (Figure 3), such as bacteria and fungi, play central roles in soil fertility
and promotion of plant health. It is assessed that in 1 g of soil there are 4000 different bacte‐
rial ‘‘genomic units’’ based on culture independent identification methods. In the other
hand, an estimated 1,500,000 species of fungi, but they are more difficult to cultivated by
standard methods [14].
In soil there is a constant exchange of organic substances and flow of energy. Feeding, pre‐
dation, degradation of macromolecular substrates and absorption of nutrients have been im‐
portant in chemical processes in soil. One of the most important microorganism in drug
discovery found in natural habitat mainly in soil are the actinomycetes which are very di‐
verse family of bacteria, they are an important source of bioactive compounds with high val‐
ue in pharmaceutical industry. It’s have been reported that almost 80% of the world`s
antibiotics come from the genera Micromonospora and Streptomyces. Beside this, the majority
of the actinomycetes in soil that are potential drug sources remain uncultivable, and there‐
fore in cannot be screened for novel antibiotic discovery [5].
Has been reported that microorganisms found in soil are a plentiful source of chemically di‐
verse bioactive compounds, and have been an important source for the discovery of antibac‐
terial agents including penicillins, cephalosporins, aminoglycosides, tetracyclines, and
polyketides [2].
Also, from 117 actinomycetes strains isolated from the wasteland alkaline and garden soil
samples in India, were found 15 actinomycetes strain that showed antimicrobial activity
against at least two pathogen bacteria between them Staphylococcus aureus[5].
According to reference [15], environmental factors, such as carbon and energy sources, mineral
nutrients, growth factors, ionic composition, available water, temperature, pressure, air compo‐
sition, electromagnetic radiation, pH, oxidation–reduction potential, surfaces, spatial relation‐
ships, genetics of the microorganisms and interaction between microorganisms, can alter the
microbial diversity, activity and population dynamics of microorganisms in soil. It is important
to mention that almost 80–90% of the microorganisms habiting soil are on solid surfaces [15].
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Figure 3. Bacteria strains from soil samples in Valle de las Palmas, Mexico.
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6.3. Drug discovery from water microorganisms
The world’s oceans comprise about 70 % of the earth’s surface, where the extensive drug
discovery efforts involving soil bacteria have not been extended to this ecosystem [16]. This
environment have special attention since is known that typical microbial abundance of 106
per ml in the water column and 109 per ml in ocean bottom sediments. Actinobacteria is
among the most dominant population and successful phyla of all environments [17]. This
class takes into account 5 subclasses, 9 orders, 55 families, 240 genera and 3000 species [18].
From all actinobacteria, Marine Actinobacteria have become the most important source of
secondary metabolites with medical application, such as anticancer, antibiotics, antitumor,
anti-inflammatory, and antifungal compounds [16-17, 19].
Actinobacteria, called commonly actinomycetes are Gram positive bacteria having a higher
guanine plus cytosine (G+C) percentage in its DNA than any other bacteria. Most of these
organisms are aerobic (oxidative), some are facultative or forced anaerobes (fermentation)
[20]. These microorganisms grow as networks called mycelium. They structures are filamen‐
tous. Sometimes are on the surface, for that is called aerial mycelium, or substrate mycelium
if it attaches to the substrate surface [21]. The individual filaments of the mycelium or hy‐
phae are divided into units as a result of growth of the cell wall into the hyphae at regular
intervals along this structure. This process is called septation and each of the resulting septa
contains one DNA molecule. The mycelium bacterium is analogous to the mycelium form‐
ing filamentous fungi [22]. Actinobacteria produce spores in specialized hyphae many of
which are developed on the aerial filament, sometimes these spores are flagellated. The Acti‐
nobacteria inhabit the soil where play an important role in soil chemistry, the characteristic
odor of soil is due to special metabolites that are known as Geominas [23]. Actinobacteria
also inhabit aquatic environments including those marine. Actinomycetes are the most eco‐
nomically and biotechnologically valuable prokaryotes [24].
Almost 60 years in actinomycetes researches, more than 15000 bioactive compounds have
been discovery for academic and pharmaceutical researchers many of which are used as
drugs today. Fact more than half of the antibiotics discovered to date are obtained from the
soil-derived actinomycete bacteria Streptomyces and Micromonospora genus spores [25].
The majority of the actinomycetes isolated from marine sources was largely of terrestrial ori‐
gin and had been washed to shore and existed in the ocean as metabolically inactive spores
[25]. Recently, phylogenetic analyses of the 16S rRNA genes indicate that existing new taxa
widely distributed in ocean sediments [26], including some that appear to be unique and ob‐
ligate marine actinomycete bacteria [27]. These strains represent the most significant source
of naturally occurring microbial antibiotics [17, 28- 30] and antitumor compounds [28- 30]
with specific metabolic and physiological capabilities that had not been observed in terres‐
trial microorganisms before [31-32]. Members of this group are producers of clinically useful
antitumor drugs such as anthracyclines, glycopeptides,aureolic acids, enediynes, antimeta‐
bolites, carzinophilin, mitomycins and others [19].
The studies related with new biodiversity and drugs discovery had been examined from
waters all around the world such as San Diego Bay, Bahamas, Fiji and Guam Islands among
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others. Recently, one study in the Gulf of California [32] found Operational Taxonomic
Units (OTUs) belonging Streptomyces and Actinomadura genus and a potentially represent a
new genus-level taxon in the family Streptomycetaceae. In addition, several previously descri‐
bed marine species were isolated including Micromonospora krabiensis, Saccharomonospora
marina, Streptomyces fenhuangensis, Verrucosispora maris and Verrucosispora sediminis suggest‐
ing that these species may have broad geographic distributions.
The genes involved in secondary metabolism are responsible for the biosynthesis of small
molecules that mediate important functional traits such as allelopathy, chemical communi‐
cation and iron acquisition [33]. These compounds have been used to assess biogeographical
patterns among bacteria [34].
Polyketide synthase (PKSI) genes are called Type I and are responsible for the production of
many important secondary metabolites including the antibiotic erythromycin [35] and the
anticancer agent epothilone [35-36].
Bacteria can maintain complex assemblies of PKS genes [37], many of which are not ex‐
pressed under normal laboratory conditions [38]. Recently, a study found that HGT plays an
important role in the evolution of PKSI genes and that ketosynthase (KS) domains within
polyketide synthase genes are phylogenetically important making predictions about pro‐
duction of secondary metabolites by complex biosynthetic pathways [39-40]. Other method
used for providing further evidence for endemism associated with secondary metabolites
[33], is the terminal restriction fragment length polymorphism (T-RFLP) used to demon‐
strate that subpopulations of bacteria cluster together based on collection site [41].
According to [32] targeting KS domains provides a rapid method to assess PKS diversity
and novelty within individual strains. The results revealed evidence of common pathways
shared with other Salinispora strains but also sequences that share low levels of identity with
any characterized pathways and thus may be associated with the production of new secon‐
dary metabolites. It is noteworthy that the new sequence type “L” also possesses a KS se‐
quence that has not previously been observed in “S. pacifica”.
Secondary metabolites are linked to an organism’s fitness and therefore represent an emerg‐
ing marker to study population structure and function, taxonomically meaningful patterns
of secondary metabolite production have been detected in bacteria [42] and fungi [43].
Progress has also been made in drug discovery from actinomycetes by using high through‐
put screening and fermentation, metabolic profiling technologies, genome scanning, mining
genomes for cryptic pathways, and combinatorial biosynthesis to generate new secondary
metabolites related to existing pharmacophores [17, 44]. Metagenomic screening of DNA
from environmental samples [45-46] provides an alternative way of discovering new antibi‐
otic biosynthetic genes.
According to [47] recently published new web tools that provide automated methods to assess
the secondary metabolite gene diversity; those are the Natural Product Domain Seeker (NaP‐
DoS) analysis based on the phylogenetic relationships of sequence tags derived from polyketide
synthase and non-ribosomal peptide synthethase (NRPS) genes. These results are compared
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with an internal experimentally database. NaPDoS provides a rapid mechanism used to infer
the generalized structures of secondary metabolites biosynthetic gene richness and diversity
within a genome or environmental sample by extract and classification of ketosynthase and con‐
densation domains from PCR products, genomes, and metagenomic datasets increasing expo‐
nentially the investigations in this field of science with benefits in the field of drug discovery.
Table 1 shows a list of microorganisms isolated from different sources which produce anti‐
oxidant, antibacterial, anticoagulant, antiviral, anti-inflammatory, immune system, antidia‐
betic and nematicidal activities, as well as their action mechanisms.
Microorganism Bioactive
Compounds


























G48 JF905613 Compound Antimicrobial C. albicans, S. aureus inhibition [52] Soil
Actinomycetes 3Ba3 Compound Antibacterial E. amylovora, P. viridiflova,
A. tumefaciens, B. subtilis





Antimicrobial Unespecific [54] Soil
Eurotium HerbariorumE. Herbariorum NE-4 Antioxidant Antioxidant in vitro [55] Water





Anticoagulant Inhibition of factor II toIIa
conversion
[56] Water
Fungus 8′-O-Demethylnigerone Antituberculosis M. tuberculosis inhibition [56] Water
Algae Dolabelladienetriol Antiviral Inhibition of HIV-1
replication
[56] Water
Soft coral Durumolides A-C Anti-inflammatory Modulation of LPS-activated
murine macrophage cell line
[56] Water
Sea cucumber Frondoside A Immune system Lysosomal activity, phagocytosis
and ROS activation
[56] Water
Table 1. Microorganism isolated from natural sources that produce bioactive compounds
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7. Conclusion
Bioactive compounds isolated from aerial, terrestrial and marine organisms have extensive
past and present use in the treatment of many diseases and serve as compounds of interest
both in their natural form and as templates for synthetic modification. To found new com‐
pounds useful to develop new pharmaceutical drugs, a good potential source and diverse
bioactive chemicals is microorganism present in natural sources as air, soil and water.
Chemical compounds from natural sources are the major protagonists in chemical diversity
for pharmaceutical discovery over the past century. The interesting chemicals identified as
natural products are derived from the biodiversity in which the interactions between micro‐
bial entities and their environment formulate the diverse complex chemical entities within
the organisms that enhance their survival and competitiveness. Hence, it is important to
study inter and intraspecific interactions between microorganism in natural environments,
this will make the screening for bioactive compounds in microbes easier.
Microbial interactions can influence the secretion of bioactive compound. Has been report‐
ed, various types of contacts among bacterial species and other organism. For example,
these relations can be negative (parasitism, competition and predation) or positive (metabio‐
sis and symbiosis) for these microorganisms. Between interactions in microorganism we can
emphasize competition. Some bacteria are reduced by different species when the environ‐
mental resources are limited; therefore they produce compounds that impress negatively in
their competitors [4].
Finally, air, soil and water are the home of microorganism that compete all the time to sur‐
vive, resist changes in temperature, pressure, nutrient, carbon and nitrogen content, micro‐
organisms that are obligated to produce weapons against predators, change and mutate to
scape of detection of other microbes. All this, are the reason why we can find an unimagina‐
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[56] Water
Table 1. Microorganism isolated from natural sources that produce bioactive compounds
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1. Introduction
All chemical transformations pass through an unstable structure called the transition state,
which is poised between the chemical structures of the substrates and products. The transi‐
tion states for chemical reactions are proposed to have lifetimes near 10-13 sec, the time for a
single bond vibration. Thus, the transition state is the critical configuration of a reaction sys‐
tem situated at the highest point of the most favorable reaction path on the potential-energy
surface, with its characteristics governing the dynamic behavior of reacting systems deci‐
sively. It is used primarily to understand qualitatively how chemical reactions take place.
Yet transition state structure is crucial to understanding enzymatic catalysis, because enzymes
function by lowering activation energy. Linus Pauling coiled an accepted view, that incredible
catalytic rate enhancements caused by enzyme is governed by tight binding to the unstable
transition state structure in 1948. Because reaction rate is proportional to the fraction of the re‐
actant in the transition state complex, the enzyme was proposed to increase the concentration
of these reactive species. This proposal was further formalized by Wolfenden (1972) and cow‐
orkers, who hypothesized that the rate increase imposed by enzymes is proportional to the af‐
finity of the enzyme to the transition state structure relative to the Michaelis complex.
Transition state structures of enzymatic targets for cancer, autoimmunity, malaria and bacteri‐
al antibiotics have been explored by the systematic application of kinetic isotope effects and
computational chemistry. Today the combination of experimental and computational access to
transition-state information permits the design of transition-state analogs as powerful enzy‐
matic inhibitors and exploration of protein features linked to transition-state structure.
Molecular electrostatic potential maps of transition states serve as blueprints to guide syn‐
thesis of transition state analogue inhibitors of chosen enzymes. Substances, that ideally
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mimic geometric and electrostatic features of a transition state (or other intermediates of
high energy) are considered as excellent enzyme inhibitors (Fig.1). They bind up to 108 times
tighter than substrate. Thus, the goal of transition-state analogs design is to create stable
chemical structures with van der Waals geometry and molecular electrostatic potential sur‐
faces as close as possible to those of the transition state.
Although some reviews on the subject have been published, this concept has not been re‐
viewed in detail [Wolfenden, 1999; Robertson, 2005; Schramm, 2005; Schramm, 2007; Dyba‐
ła-Defratyka et al. 2008; Schramm, 2011]. In this review the current trends, alongside with
appropriate case studies in designing of such inhibitors will be presented.
2. Choice of the target enzyme
The sequencing of the human genome has promised a revolution in medicine. The genome
encodes 20,000- 25,000 human genes, and thousands more proteins as a result of alternative
gene splicing. Many of these hold the keys to treating disease, especially numerous enzymes of
undefined so far physiologic functions [Gonzaga-Jagureui et al., 2012]. Out of 1200 registered
drugs over 300 act as enzyme inhibitors. Most of them are simple analogs of substrates of cer‐
tain enzymatic reaction. Analogy to transition state as a mean to obtain effective inhibitors
emerged in 1970s [Lienhard, 1973]. Through the 1970s and 1980s, most of the known examples
were natural products [Wolfenden, 1976]. The situation has changed in 1990s when synthetic
inhibitors became the predominate examples of transition-state inhibitors. In 1995, there were
transition-state analogues for at least 130 enzymes [Radzicka & Wolfenden, 1995].
Figure 1. Progress of the enzymatic reaction versus uncatalyzed one.
Drug Discovery326
The design of transition-state inhibitors is likely to become more frequent in the future,
alongside with the development of theory and technology for understanding enzyme transi‐
tion states. Today the sequence of information required to obtain transition state analog of
enzymatic reaction considers: choice of the suitable enzyme (most likely suited to kinetic
isotope effect measurement), selection of presumable mechanism(s) of catalyzed reaction,
measurement of kinetic isotope effects (KIE), computer-aided calculations matching the in‐
trinsic KIEs, construction of steric and electronic map of transition state and synthesis of sta‐
ble compound(s) matching this map [Schramm, 2007]. This procedure has been developed
gradually in parallel with the advances in KIE enzymology, computational chemistry, and
synthetic organic chemistry.
3. Determination of transition state architecture
At present, the most reliable method to determine three-dimensional architecture of transi‐
tion state is through the use of computational methods in conjunction with experimentally
measured kinetic isotope effect (KIE).
Isotopic substitution is a useful technique for probing reaction mechanisms. The change of
an isotope may affect the reaction rate in a number of ways, providing clues to the pathway
of the reaction. The advantage of isotopic substitution is that this is the least disturbing
structural change that can be effected in a molecule. Replacement of one isotope of the sub‐
strate by another at vicinity where bonds are being or re-hybridizing typically leads to a
change in the rate of the reaction. Thus, kinetic isotope effects measurements compare
kcat/KM values between isotope-labeled and natural abundance reactants. This provides in‐
formation about which bonds are broken or formed, and identifies changes in hybridization
that occur during the rate limiting step of a reaction. It is reached by conversion of atom-by-
atom KIE values to a specific static model with fixed bond angles and lengths by computa‐
tional matching to a quantum chemical model of the reaction of interest. Substrate,
intermediate and product geometries are located as the global minima. Transition-state
structures are located with a single imaginary frequency, characteristic of true potential en‐
ergy saddle points.
Such an analysis was performed recently for human thymidine phosphorylase, an enzyme
responsible for thymidine homeostasis, action of which promotes angiogenesis. Thus, inhib‐
itors of this enzyme might be considered as promising anticancer agents. Its transition state
was characterized using multiple kinetic isotope effect measurements applying isotopically
(3H, 14C and 15N) enriched thymidines, which were synthesized enzymatically [Schwartz et
al, 2010]. A transition state constrained to match the intrinsic KIEs was found using density
functional theory. In the proposed mechanism (Fig.2), departure of the thymine results in a
discrete ribocation intermediate. Thymine likely leaves deprotonated at N1 and undergoes
enzyme-catalyzed protonation before the next step. In the following step, the intermediate
undergoes nucleophilic attack from an activated water molecule to form the products. The
latter step is a reaction rate limiting step as determined by energetics of its transition state.
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The transition state model predicts that deoxyribose adopts a mild 3′-endo conformation
during nucleophilic capture (Fig. 2).
Such studies, although cumbersome and difficult, are being recently more and more popu‐
lar, as demonstrated by representative studies on Escherichia coli t-RNA-specific adenosine
deaminase [Luo & Schramm, 2008], glucoside hydrolases [Lee et al, 2004], human purine nu‐
cleoside phosphorylase [Murkin et al., 2007], Trypasnosoma cruzi trans-sialidase [Pierdomini‐
ci-Sottile et al., 2011], L-dopa decarboxylase [Lin & Gao, 2011] or cis-prenyltransferase [Hu et
al., 2010].
Figure 2. Mechanism of human thymidine phosphorylase catalyzed depirymidation of thymidine. The dash line repre‐
sents protonation step.
Computational chemistry provides techniques for the generation and exploration of the
multi-dimensional energy surfaces that govern chemical reactivity. Therefore, energy mini‐
ma and saddle points can be located and characterized. The pathways that interconnect
them can be determined. Thus, computational methods are increasingly at the forefront of
elucidating mechanisms of enzyme-catalyzed reactions, and shedding light on the determi‐
nants of specificity and efficiency of catalysis [Kollman et al., 2002; Parks et al., 2010; Wil‐
liams, 2010; Lonsdake et al., 2012].
At the beginning of a molecular modeling study choice upon the specific catalytic process to
model has to be undertaken. This decision may sound simple, but it includes the nontrivial
task of exhaustively searching the literature to determine what is already known about the
selected enzymatic system, either from experiments or from previous computational stud‐
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ies. Reaction mechanisms may have already been proposed in the literature, and thus pro‐
vide a logical starting point for modeling studies. The three-dimensional structure of the
enzyme, preferably with a bound substrate analog, reaction product or inhibitor, is among
the most critical sources of information. In practice, this usually means that a high-resolu‐
tion X-ray crystal structure of a reacting enzyme complex is required.
Molecular mechanics methods are important in simulations of enzymes, even though these
methods cannot model chemical reactions. For that molecular dynamics simulations, or
combination of molecular mechanics with quantum mechanical methods are commonly
used [Senn & Thiel, 2007; Hou & Cui, 2011; Kosugi & Hayashi, 2012; Londsdale et al., 2012].
Enzymes are large molecules consisting of thousands of atoms whereas the active site may
comprise only around 100 atoms. Since quantum chemical calculations are nowadays af‐
fordable only for up to a few hundred atoms (depending on the level of accuracy) the sys‐
tem is split into two regions: a small region encapsulating the reaction at the active site is
modeled with a quantum mechanical methods, while the rest of the enzyme alongside with
surrounding water is modeled using molecular mechanics (Fig. 3.)
Figure 3. Quantum mechanics/molecular mechanics calculation of an enzymatic reaction illustrated by cytochrome
P450 with bound cyclohexene [Lonsdake et al., 2010].
These calculations do not take in the consideration such an important factor as protein dy‐
namic. There is an agreement that fast (at nano- or picosecond scale) protein motions couple
directly to transition state formation in enzymatically catalyzed reactions and are an integral
part of the reaction coordinate. Slower protein dynamic motions also influence the heights
of barriers in enzymatic reactions, however detailed description of these effects require elab‐
oration of new computational methods [Saen-oon et al., 2008].
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4. Inhibitors of proteinases
First inhibitors being transition state analogs were designed for proteolytic enzymes. The
design was based on the resemblance of transition state of phosphonamidates and phos‐
phonic, phosphinic (Fig. 4) acids to the sp3 intermediate of the hydrolysis of peptide bond.
Because the lengths of oxygen-to-phosphorus and carbon-to-phosphorus bonds are signifi‐
cantly longer than the corresponding carbon-to-carbon and carbon-to-oxygen bonds, orga‐
nophosphorus fragment of the molecule might be considered as “swollen” tetrahedral
intermediate and thus can be treated similar to the transition state of this reaction.
Figure 4. Organophosphoprus compounds as transition state analog inhibitors of hydrolysis of peptide bonds.
Crystallography of enzyme-inhibitor complexes and molecular modeling studies had shown
that their potent inhibitory activities result from both: resemblance to the transition state
and strong electrostatic interactions between positively charged active-site metal ions (pre‐
dominantly zinc ions) and negatively charged phosphonic acid (or related) group [Mucha et
al., 2010; Mucha et al., 2011]. Although the phosphonate/phosphinate group is a rather weak
zinc complexing moiety, it offers other advantageous structural and electronic features [Col‐
linsova & Jiráček, 2000].
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Figure 5. Representative organophosphorus inhibitors of metalloproteinases.
Simple phosphonic acid analogs of amino acids and pseudopeptides, containing phosphi‐
nate moiety replacing scissile peptide bond, are acting via this mechanism and rank
amongst most potent inhibitors of metalloproteinases (Fig. 5). Inhibitors of neutral alanyl
(M1) and leucine (M17) aminopeptidases are among the most recognized and most inten‐
sively studied representatives of metal-containing exopeptidases of biomedical significance
[Lowther & Matthews, 2002; Grembecka et al., 2003; Vassiliou et. al. 2007]. Functions related
to tumorigenesis and invasion makes these enzymes molecular targets for the development
of potential anticancer drugs [Grembecka & Kafarski, 2001; Zhang & Xu, 2008; Fournié-Za‐
luski et al., 2009; Grzywa et al., 2010]. The recognized role of neutral aminopeptidase in the
pathogenesis of hypertension provides also an opportunity for regulating arterial blood
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pressure by their inhibitors [Banegas et al., 2006; Bodineau et al., 2008]. Additionally, two of
these pseudodipeptides appear to be excellent inhibitors when applied to Plasmodium falcipa‐
rum M1 and M17 aminopeptidases (Fig. 5), the protozoan counterparts of neutral and leu‐
cine aminopeptidases [Stack et al., 2007; Cunningham et al, 2008; McGowan et al., 2009;
McGowan et al., 2010]. They efficiently controlled the growth of P. falciparium in cultures,
including those of malaria cells lines resistant to chloroquine, and significantly reduced ma‐
laria infections in murine model (Plasmodium chabaudi) [Skinner-Adams et al., 2007]. These
findings positively validated P. falciparum M1 and M17 aminopeptidases as promising tar‐
gets for a novel treatment of malaria and identify new leads with anti-parasite potential
[Skinner-Adams et al., 2010; Thivierge et al., 2012].
The design and development of pseudopeptidic inhibitors of aminopeptidases are greatly
facilitated by two factors. First, the results of extensive structure-activity relationship stud‐
ies, available for a wide collection of fluorogenic substrates, have defined the requirements
of the S1 binding pockets of these enzymes [Drag & Salvesen, 2009; Drag et al., 2010; Gajda
et al., 2012; Poręba et al., 2011; Poręba 2012]. Second, computer-aided analysis of numerous
crystal structures available for leucine aminopeptidase has pointed to this enzyme as a pri‐
mary molecular target for extending and optimizing interactions within the S1’ pocket
[Grembecka et al., 2001; Jørgensen et al., 2002; Evdokimov et al., 2007; Khandelwal et al.,
2005; Khaliullin et al. 2010; Li et al., 2010].
Phosphinic pseudopeptides have also clearly revealed their potential for the regulation of
matrix metalloproteinases (MMPs, matrixins), zinc-dependent endopeptidases implicated in
the breakdown of the extracellular matrix [Yiotakis at al., 2004; Fisher & Mobashery, 2006].
Cleavage of the matrix component (collagen, lamanin, elastin, gelatin, etc.) is physiologically
essential for tissue remodeling processes such as morphogenesis, embryogenesis and repro‐
duction [Overall & Kleifield, 2006; Sang et. al., 2006]. Overexpression or inadequate level of
matrix metalloproteinases leads to pathological states such as osteoarthritis, rheumatoid ar‐
thritis and inflammation, but it is most associated with tumor growth, invasion, and meta‐
stasis. Angiogenetic process favored by these enzymes is essential for vascoularization and
growth of tumors. Thus, they were the first proteinase targets seriously considered for com‐
bating cancer. Despite that preliminary clinical/preclinical studies on MMP inhibition in tu‐
mor models brought positive results the outcome in the drug market has been so far
unsatisfactory. The spectacular failure of the last-step clinical trials is mainly due to a lack of
selectivity and serious side effects [Fisher & Mobashery, 2006]. The field is now resurging
with careful reinvestigation of the precise roles of each particular MMP member and a focus
on the development of selective inhibitors that fully discriminate between different mem‐
bers of the MMP family [Reiter et al., 2003; Matziari et al., 2007; Zucker & Cao, 2009; Devel
et al., 2010; Johnson et al., 2011]. Such selectivity had been reached by variation of peptide
scaffold by means of combinatorial pseudopeptide synthesis [Buchardt et al, 2000; Dive et
al., 2004] or by application of molecular modeling based on crystallographic studies of these
enzymes [Rao, 2005; Pirard, 2007; Verma & Hansch, 2007; Anzellotti & Farrell, 2008; Kalva et
al., 2012]. Representative selective inhibitors of this class are shown in Figure 6.
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Figure 6. Representative inhibitors selective against chosen matrix metalloproteinases.
Quite interesting approach is preparation of hybrid systems as this composed of a phosphi‐
nate transition state analogue that has been incorporated within a triple-helical peptide tem‐
plate. The template sequence was based on the α1(V)436-450 collagen region, which is
hydrolyzed at the Gly439-Val440 bond selectively by MMP-2 and MMP-9. In that manner high‐
ly selective inhibitor towards these two gelatinases was found [Lauer-Fields et al., 2007; La‐
uer-Fields et al., 2008].
Phosphinic transition state analog approach has been also recently applied for the design
and synthesis of novel potent inhibitors of other proteinases of medicinal importance. Thus,
inhibitors of angiotensin converting enzyme [Mores et al., 2008; Julien et al. 2010; Akif et al.,
2011] are potential drugs against hypertension, aspartyl aminopeptidase as antimalarial
agent [Teuscher et al., 2007], inhibitors of cathepsin C and renal dipeptidase may be consid‐
ered as potential anticancer agents [Gurulingappa et al., 2003: Mucha et al., 2004], inhibitors
of sortase, which is bacterial virulence protein [Kruger et al., 2004], whereas inhibition of py‐
roglutamyl peptidase II enhances the analeptic effect of thyrotropin [Matziari et al., 2008;
Lazcano et al. 2012].
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It is worth mentioning that Monopril®, the sodium salt of fosinopril [Fig. 7], the ester prodrug
of an angiotensin-converting enzyme (ACE) inhibitor fosinoprilat, is perhaps one of the
most effective implementation of transition state analogy in medicine [Powell et al., 1984].
Figure 7. Fosinopril and fosinoprilat.
Sulfonamides also mimic both shape and electronic environment of the transition state of
peptide bond hydrolysis. This approach was used for introduction of transition state inhibi‐
tors of HIV-protease, thermolysin and thrombine as well as haptens for generation of cata‐
lytic antibodies (Fig. 8) [Moree, et al., 1993; Moree, et al., 1995; Löwik et al., 2000; Liskamp &
Kruijzer, 2004; Turcotte et al., 2012]. Unfortunately most of them appeared to be ineffective.
This might be explained by non-typical bonding of potent inhibitor of this class with HIV
protease (Fig. 9). It appeared that sulfonamide moiety displaces water molecule from active
site and forms hydrogen bonds with two isoleucines, not as expected with catalytic aspartic
acids [Meanwell, 2011]. Thus, sulfonamide group does not act as transition state analogue.
Figure 8. Sufonamides as inhibitors of proteases.
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Begacestat (Fig. 8), an effective and potent inhibitor of γ-secretase is an exception here [May‐
er et al., 2008; Martone et al., 2009]. γ-Secretase catalyzes the final step in the generation of
amyloid β peptides from amyloid precursor protein. Amyloid β-peptides aggregate to form
neurotoxic oligomers, senile plaques, and congophilic angiopathy, some of the cardinal
pathologies associated with Alzheimer's disease. Begacestat appeared to be well tolerated in
mouse and dog toxicity studies and has been advanced to human clinical trials for the treat‐
ment of this neurological disease.
Figure 9. Mode of binding of sulfonamide HIV protease inhibitor.
Figure 10. Silenediols as proteinase inhibitors.
Dialkylsilanediols are tetrahedral functional groups that can mimic hydrated carbonyls and
thus might be also considered as „swollen“ intermediates of peptide bond hydrolysis. When
silanediols are embedded in a peptide-like structure, they are recognized by proteinases and
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act as hydrolytically stable entities. Thus, dialkylsilanol is an effective functional group for
the design of active site-directed protease inhibitors. This concept has been successfully test‐
ed by replacing the presumed tetrahedral carbon of thermolysin, HIV-protease and angio‐
tensin converting enzyme substrates with silanediol groups (Fig. 10), which resulted in
potent inhibitors of these enzymes [Juers et al., 2005; Sieburth & Chen, 2006; Bo et al., 2011;
Meanwell, 2011].
5. Hydroxyethylene intermediate analogs as inhibitors of proteases
Aspartic proteases generally bind 6-10 amino acid regions of their polypeptide substrates,
which are typically processed with the aid of two catalytic aspartic acid residues in the ac‐
tive site. Thus, there is usually considerable scope for building inhibitor specificity for a par‐
ticular aspartic protease by taking advantage of the collective interactions between a
putative inhibitor on both sides of its scissile amide bond, and a substantial portion of the
substrate-binding groove of the enzyme [Eder et al., 2007]. A very effective group of their
inhibitors are simple hydroxyethylene analogs of tetrahedral oxyanion intermediates of the
hydrolysis of peptide bonds. This approach is based on the structure of bestatin, a general
inhibitor of aminopeptidases and aspartyl proteinases isolated in 1976 from Streptomyces oli‐
voreticuli [Umezawa et al., 1976].
Today, HIV protease inhibitors constitute around 40% of available drugs against HIV. Near‐
ly all of them contain hydroxyethylene unit as transition state analog mimic, to mention on‐
ly Darunavir, Atazanavir, Fosamprenavir, Lopinavir (or Ritonavir) or the oldest one
Saquinavir (Fig. 11) [Brik & Wong, 2003; Pokorna et. al, 2009].
Availability of anti-HIV drugs enabled to introduce highly active antiretroviral therapy
(HAART), which resulted in dramatic decrease of the mortality and morbidity for a wide
variety of opportunistic viral, bacterial, fungal and parasitic infections among HIV-infected
individuals in economically developed countries [Andreoni & Perno, 2012]. Thus, the de‐
sign, development and clinical success of HIV protease inhibitors represent one of the most
remarkable achievements of molecular medicine. However, both the academias, as well as,
the industry need to continue in their effort to develop novel, more potent compounds. This
is mainly connected with HIV drug resistance, which in turn results from the high mutation
rate, caused by the lack of proofreading activity of the viral reverse transcriptase. The pat‐
tern of mutations associated with the viral resistance is extremely complex as shown in Fig‐
ure 12 [Pokorna et al., 2009]. Taken together, in spite of the indisputable success of the
HAART and benefit to patients, new approaches to the antiviral treatment are highly desira‐
ble [Clarke, 2007; Adachi et al., 2009; Pokorna et al., 2009; Alfonso & Mozote, 2011].
Quite interestingly, small modifications of core structure of the inhibitor results in minute
changes in inhibitor affinity to HIV protease as demonstrated in Figure 13 [Wu et al., 2008;
Mahalingham et al., 2010].
Studies conducted in order to evaluate the influence of these antiviral drugs on the develop‐
ment of parasites, which are known to co-infect HIV-positive individuals, surprisingly
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shown, that these drugs exhibit marked antiprotozoal activity. For example Saquinavir, Lo‐
pinavir, Indinavir directly inhibited the grown of Plasmodium falciparum in vitro at clinically
relevant concentrations. This findings suggest that some inhibitors of HIV protease are ac‐
tive against the most virulent human malaria parasite P. falciparum that is known to express
number of aspartic proteases (plasmepsins) [Skinner-Adams, et al., 2004; Alfonso & Mozote,
2011].
More than 25 million people are suffering from dementia, and the annual socioeconomic
worldwide costs have been estimated to exceed U.S. $200 billion. γ-Secretase, along with β -
secretase produces the amyloid β-protein of Alzheimer’s disease. Because of its key role in
the pathogenesis γ-secretase has been a prime target for drug discovery, and many inhibi‐
tors of this protease have been developed. These enzymes are also effectively inhibited by
Figure 11. Representative examples of clinical HIV protease drugs.
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Figure 12. Three-dimensional structure of HIV protease complexed with Darunavir. Mutations associated with resist‐
ance to clinically used inhibitors are depicted as balls.
Figure 13. Influence of linker length on activity of HIV protease inhibitors.
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peptidomimetics containing hydroxyethylene fragment replacing hydrolyzed peptide bond.
Only one drug (Semagacestat, Fig. 14) reached phase III clinical studies so far, however, un‐
covered evidence of cognitive worsening in treated patients compared with placebo led to
suspension of the trials in 2010. Anyway, design, synthesis and evaluation of new low-mo‐
lecular, nanomolar inhibitors of secretases, structure of which significantly drifted away
from peptidic transition state analogs (Fig. 14), is still challenging and brought new promis‐
ing results [Osterman et al., 2006; Wolfe, 2012]. Due to rapid technological progress in chem‐
istry, bioinformatics, structural biology and computer technology, computer-aided drug
design plays more and more important role in this respect [Avram et al., 2006; Fujimoto et
al., 2008; Xu et al., 2009; Al-Tel et al. 2011; Hamada et al., 2012].
Figure 14. Inhibitors of secretases.
Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial
infarction, and heart failure, the leading causes of death in the Western world. Inhibitors of
the renin–angiotensin system have proven to be successful treatments for hypertension. As
renin specifically catalyses the rate limiting step of this system, it represents the optimal tar‐
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get for antihypertensive drugs. Aliskiren (Fig. 15), a promising drug lowering blood pres‐
sure in sodium-depleted marmosets and hypertensive human patients, was developed
using a combination of crystal structure analysis of renin–inhibitor complexes and computa‐
tional methods [Wood et al., 2003]. The therapy was introduced under the names Takturna
and Rasilez.
Figure 15. Aliskiren (left hand side) and its more potent analog.
Another possibility arose from use of fluoroketone derivatives. α-monofluoroketones are
approximately 50% hydrated, whereas the α,α-difluoroketones are 100% hydrated in aque‐
ous solutions (Fig. 16). The latter ones are obviously of choice because of their striking simi‐
larity to phosphinic inhibitors (two hydroxyls placed at terahedral atom). This approach is
applied very rarely but gave good inhibitors of fungal endothiapepsin [Tuan et al., 2007]
and matrix metalloprotease [Reiter et al., 2000] (Fig. 16).
Figure 16. Difluoroketones as transition state inhibitor.
6. Suicide substrates yielding transition state analogues
Peptide aldehydes and boronic acids are inhibitors of serine and threonine enzymes forming
both, hydrogen and covalent bonds in the enzyme active site. Tetrahedral adduct generated
from these compounds upon their action on enzymes bear a closer relationship to the struc‐
ture of the true intermediate and they may be considered as suicidal substrates. There is,
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however, an important difference between these two types of inhibitors. The boronic acid
derivative possesses a negative charge, whereas the hemiacetal adduct is neutral (Fig 17).
Figure 17. Suicidal substrates yielding transition state analogs
Hence, the peptidyl boronic acid adduct is a better transition state analog than the hemiace‐
tal formed from peptidic aldehyde [Polgár, 2005]. Aldehydes typically have a low preva‐
lence in drugs and drug candidates because of their potential chemical reactivity and
susceptibility to be engaged in a reduction/oxidation pathways in vivo. Therefore peptidyl
boronic acids are considered as far better drug candidates. Additionally slight changes in
pH can result in release of the inhibitor from the active site, which is profitous.
In 2003, bortezomib (Fig. 18), a first-in-class therapeutic, gained approval from the US Feder‐
al Drug Administration for the treatment of relapsed multiple myeloma and mantle cell
lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. It possesses a
unique mode of action. Bortezomib acts as inhibitor of the 26S proteasome, the key regulator
of intracellular protein degradation, found in the nucleus and cytosol of all eukaryotic cells,
and forming part of the critical ubiquitin-proteasome system. This inhibition results in dis‐
ruption of homeostatic mechanisms within the cell that can lead to cell death.
Figure 18. Structure of bortezomib.
This finding initiated intensive researches on boronic inhibitors of serine and threonine pro‐
teases [Trippier & McGuigan, 2010]. For, example recently inhibitors of Lon proteases (bac‐
terial ATP-dependent protease conferring bacterial virulence) afforded interesting
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antibacterial agents [Frase and Lee, 2007], inhibitors of prostate-specific antigen for prostate
cancer imaging and therapy [LeBeau et al., 2008], antifungal inhibitors of kexin (regulatory
proteins from Candida) [Holyoak et al., 2004; Wheatley & Holyoak, 2007], inhibitor of HCV
NS3 protease as potential drug against hepatitis [Zhang et al., 2003; Venkatraman et al.,
2009], and anticancer and antibacterial inhibitors of proteasome [Hu et al., 2006]. Represen‐
tative examples of these inhibitors are shown in Figure 19.
Figure 19. Boronic acid based inhibitors.
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7. Other hydrolases
The data considering transition state analogue inhibitors of other hydrolases are practically
limited to inhibitors of β–lactamases, arginase and urease.
Antibiotic resistance, especially to widely prescribed β-lactam antibiotics, is a serious threat
to public health and is responsible for the increase in morbidity, mortality, and health care
costs related to the treatment of bacterial infections. In most cases emergence of antibiotic-
resistant bacteria is primarily driven by overuse of β-lactam antibiotics in food and agricul‐
tural products. The most prominent resistance mechanism is related to the expression of β-
lactamases, which hydrolyze β–lactam fragment of the drug molecule. In nature, four
classes of these enzymes exist. Three of them are serine-based, whereas fourth is zinc-de‐
pendent-hydrolase. To counteract β-lactamases, mechanism-based inhibitors were devel‐
oped to be administered in concert with β-lactam antibiotics. Presently, there are three
commercially available β-lactamase inhibitors (clavulanate, sulbactam, and tazobactam).
The new approach to obtain such inhibitors is combination of structure of potent β-lactam
antibiotics with a boronic [Thomson, et al., 2007; Eidam et al., 2010: Ke, et al., 2011; Chan, et
al., 2012] or phosphonic [Nukaga, et al., 2004] acid moieties with the goal of mimicking the
transition state and creating a high-affinity, reversible inhibitor that cannot be inactivated by
β-lactamases since they do not bear hydrolyzable β-lactam ring.
Figure 20. Transition state inhibitors of lactamases.
Arginase is a binuclear manganese metalloenzyme that serves as a therapeutic target for the
treatment of asthma, erectile dysfunction, and atherosclerosis. The hydrolysis of L-arginine
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antibacterial agents [Frase and Lee, 2007], inhibitors of prostate-specific antigen for prostate
cancer imaging and therapy [LeBeau et al., 2008], antifungal inhibitors of kexin (regulatory
proteins from Candida) [Holyoak et al., 2004; Wheatley & Holyoak, 2007], inhibitor of HCV
NS3 protease as potential drug against hepatitis [Zhang et al., 2003; Venkatraman et al.,
2009], and anticancer and antibacterial inhibitors of proteasome [Hu et al., 2006]. Represen‐
tative examples of these inhibitors are shown in Figure 19.
Figure 19. Boronic acid based inhibitors.
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to L-ornithine and urea (Fig. 21) is also the final cytosolic step of the urea cycle in mammali‐
an liver. S-(2-Boronoethyl)-L-cysteine is one of the most effective inhibitor of the enzyme
(Fig 21). The specificity determinants of amino acid recognition by arginase were identified
by X-Ray structure of human arginase I enzyme complexed with this inhibitor. These stud‐
ies undoubtedly shown that boronate adopts tetrahedral configuration [Cama et al., 2003 &
2003a; Shishova, et al., 2009]. Also aldehydes and sulfonamides similar to boronic acids ap‐
peared to be promising inhibitors of arginases [Shin et al., 2004].
Figure 21. Arginase catalyzed reaction and representative inhibitors of the enzyme.
Urease catalyzes hydrolysis of urea in the last step of organic nitrogen mineralization to give
ammonia and carbamate, which decomposes to give a second molecule of ammonia and bi‐
carbonate (Fig. 22). The hydrolysis of the reaction products induces an overall pH increase
that has negative implications both in human and animal health as well as in the ecosphere.
Urease is a virulence factor in infections of urinary (Proteus mirabilis, Ureaplasma urealyticum)
and gastrointestinal tracts (Helicobacter pylori), causing severe diseases such as peptic ulcers,
stomach cancer, and formation of urinary stones. The efficiency of soil nitrogen fertilization
with urea (the most used fertilizer worldwide) decreases due to ammonia volatilization and
root damage caused by soil pH increase. Thus, control of the activity of urease through the
use of inhibitors could counteract these negative effects [Kosikowska & Berlicki, 2011; Zam‐
belli et al., 2011]. Di- and triamides of phosphoric acid represent a group of urease inhibitors
with the highest activity. It is the direct consequence of their similarity to the tetrahedral
transition state of the enzymatic reaction of urea hydrolysis. Takeda Chemicals have patent‐
ed a large group of N-acyltriamido phosphates and found over 90 examples with nanomolar
activity against H. pylori urease, with flurofamide being the most effective (Fig. 22) [Kosi‐
kowska & Berlicki, 2011].
Recently design, synthesis, and evaluation of novel ogranophosphonate inhibitors of bacteri‐
al urease have been described as an attractive alternative to known phosphoramidates. On
the basis of the crystal structure of Bacillus pasteurii urease, several phosphinic acids and
their short peptides have been designed by using the computer-aided techniques. The step‐
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wise scheme of inhibitor design, shown in Figure 21, led to the synthesis of compounds with
low structural complexity, high hydrolytic stability and satisfactory biological activity
against various ureases, including cytoplasmic urease from pathogenic Proteus species [Vas‐
siliou et al., 2008; Berlicki et al., 2012; Vassiliou et al., 2012].
8. Peptide bond formation by ribosome
Ribosomes are molecular machines that synthesize proteins in the cell. Recent biochemical
analyses and high-resolution crystal structures of the bacterial ribosome have shown that
the active site for the formation of peptide bonds – the peptidyl-transferase center – is com‐
posed solely of rRNA. Thus, the ribosome is the largest known RNA catalyst and the only
natural ribozyme that has a synthetic activity. Peptide bond formation during ribosomal
protein synthesis involves an aminolysis reaction between the aminoacyl α-amino group
and the carbonyl ester of the growing peptide via a transition state with a developing nega‐
tive charge - the oxyanion. Therefore the observed intermediates and transition states are
similar to those observed in proteinases (Fig. 23). Structural and molecular dynamic studies
have suggested that the ribosome may stabilize the oxyanion in the transition state of pep‐
tide bond formation via a highly ordered water molecule [Rodnina et al., 2006; Carrasco et
al., 2011].
Figure 22. Urease hydrolysed reaction and evolution of the structure of its inhibitors.
To biochemically elucidate how the ribosome stabilizes the developing negative charge in
the transition state of peptide bond formation, a series of tetrahedral transition state mimics
were synthesized. Their relative binding affinities for the ribosomes also were measured
(Fig. 23). The obtained results confirmed high affinity of predicted mechanism of ribosome
action [Green & Lorsch, 2002; Weinger et al., 2004; Carrasco, et al., 2011].
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Figure 23. Transition state analog inhibitor of peptidyl transferase.
9. Enzymes forming amide and ester bonds via carboxylic-phosphate
anhydride
Activation of carboxylic group of amino acid by ATP-phosphorylation yielding mixed car‐
boxylic-phosphate anhydride is quite popular mechanism of synthesis of amide and ester
bonds.
D-Alanyl-D-alanine ligase is one of the key enzymes in peptidoglycan biosynthesis and is an
important target for antibacterial drugs. The enzyme catalyzes the condensation of two ala‐
nine molecules using ATP to produce D-Ala-D-Ala (Fig. 24), which is the terminal peptide
of a peptidoglycan monomer. Analogs of D-Ala-D-Ala, in which phosphonate or phosphi‐
nate moiety replaces peptide bond appear to be potent inhibitors. As determined by kinetic
[Ellsworth et al., 1996], X-Ray [Wu et al., 2008], and molecular modeling studies the inhibitor
behaves as substrate and reacts with ATP to produce ADP and a tight-binding phosphory‐
lated transition state analogue, which exerts inhibitory action against the enzyme (Fig. 24).
Thus, these compounds might be rather considered as suicide substrates.
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Figure 24. Mechanism of condensation of two molecules of D-Ala catalyzed by D-alanine-D-alanine ligase.
Similarly acting inhibitors have been found for glutamine synthetase (phosphinothricin and
methionine sulfoximine and their analogs) [Berlicki et al., 2005; Berlicki & Kafarski 2006;
Berlicki, 2008], γ-glutamylcysteine synthetase [Hibi et al., 2004], or penicillin binding pro‐
teins [Dzekieva et al., 2010; Dzekieva et al., 2012] (Fig. 25).
Figure 25. Inhibitors activated by ATP.
10. Nucleotide deaminases
Enzymes of the deaminase superfamily catalyze deamination of bases in nucleotides and
nucleic acids across in diverse biological contexts. Representatives that act on free nucleoti‐
des or bases are primarily involved in the salvage of pyrimidines and purines, or in their
catabolism in bacteria, eukaryotes and phages. Other members of the deaminase superfami‐
ly catalyze the in situ deamination of bases in both RNA and DNA. Such modifications play
a central role in RNA editing, which is critical for generating the appropriate anti-codon se‐
quences for decoding the genetic code, modification of the sequences of microRNA and oth‐
Transition State Analogues of Enzymatic Reaction as Potential Drugs
http://dx.doi.org/10.5772/52504
347
Figure 23. Transition state analog inhibitor of peptidyl transferase.
9. Enzymes forming amide and ester bonds via carboxylic-phosphate
anhydride
Activation of carboxylic group of amino acid by ATP-phosphorylation yielding mixed car‐
boxylic-phosphate anhydride is quite popular mechanism of synthesis of amide and ester
bonds.
D-Alanyl-D-alanine ligase is one of the key enzymes in peptidoglycan biosynthesis and is an
important target for antibacterial drugs. The enzyme catalyzes the condensation of two ala‐
nine molecules using ATP to produce D-Ala-D-Ala (Fig. 24), which is the terminal peptide
of a peptidoglycan monomer. Analogs of D-Ala-D-Ala, in which phosphonate or phosphi‐
nate moiety replaces peptide bond appear to be potent inhibitors. As determined by kinetic
[Ellsworth et al., 1996], X-Ray [Wu et al., 2008], and molecular modeling studies the inhibitor
behaves as substrate and reacts with ATP to produce ADP and a tight-binding phosphory‐
lated transition state analogue, which exerts inhibitory action against the enzyme (Fig. 24).
Thus, these compounds might be rather considered as suicide substrates.
Drug Discovery346
Figure 24. Mechanism of condensation of two molecules of D-Ala catalyzed by D-alanine-D-alanine ligase.
Similarly acting inhibitors have been found for glutamine synthetase (phosphinothricin and
methionine sulfoximine and their analogs) [Berlicki et al., 2005; Berlicki & Kafarski 2006;
Berlicki, 2008], γ-glutamylcysteine synthetase [Hibi et al., 2004], or penicillin binding pro‐
teins [Dzekieva et al., 2010; Dzekieva et al., 2012] (Fig. 25).
Figure 25. Inhibitors activated by ATP.
10. Nucleotide deaminases
Enzymes of the deaminase superfamily catalyze deamination of bases in nucleotides and
nucleic acids across in diverse biological contexts. Representatives that act on free nucleoti‐
des or bases are primarily involved in the salvage of pyrimidines and purines, or in their
catabolism in bacteria, eukaryotes and phages. Other members of the deaminase superfami‐
ly catalyze the in situ deamination of bases in both RNA and DNA. Such modifications play
a central role in RNA editing, which is critical for generating the appropriate anti-codon se‐
quences for decoding the genetic code, modification of the sequences of microRNA and oth‐
Transition State Analogues of Enzymatic Reaction as Potential Drugs
http://dx.doi.org/10.5772/52504
347
er transcripts and alteration of the reading frames in mRNAs, defense against viruses via
hypermutation-based inactivation, and somatic hypermutation or class switching of antigen
receptor genes in vertebrates [Iyer et al., 2011].
Adenosine deaminase (ADA) is an enzyme present in all organisms and catalyzes the irre‐
versible deamination of adenosine and deoxyadenosine to inosine and deoxyinosine (Fig.
26). Both adenosine and deoxyadenosine are biologically active purines that can have a deep
impact on cellular physiology. For example it plays a vital role in regulating T-cell coactiva‐
tion. Deficiency of this enzyme in humans causes severe combined immunodeficiency. In‐
creased serum activity of this enzyme have been found in many infectious diseases caused
by microorganisms infecting the macrophages, in leprosy, brucellosis, HIV infections, viral
hepatitis, infectious mononucleosis, liver cirrhosis and tuberculosis. Its extended transition
state inhibitor – conformycin was isolated from Nocardia interforma and Streptomyces kanihar‐
aensis. Analogs of conformycin (Fig. 26) are proposed as an antineoplastic synergists and im‐
munosuppressants [Wolfenden, 2003].
The wide potential of these inhibitors may be illustrated by the fact that deaminoformycin
was recently applied to evaluate mechanisms responsible for lethality caused by genetic and
herbicide-based activity of adenosine deaminase [Sabina et al., 2007], as well as identifica‐
tion of highly selective inhibitor of purine salvage pathway in malaria parasites [Tyler et al.,
2007]. This is because of a unique feature of Plasmodium falciparum enzyme that catalyzes the
deamination of both adenosine and 5‘-methylthioadenosine.
Figure 26. Inhibitors of adenosine deaminase.
Guanine deaminase is an enzyme that hydrolyzes guanine to form xanthine that is unsuita‐
ble for DNA/RNA buildup. This enzyme has been found in normal or transformed human
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organs and sera. One of the approaches for antiviral/anticancer therapy is to design structur‐
al mimics of natural guanine as nucleic acid building blocks, with an anticipation that such
analogs would be incorporated into DNA/RNA of virus for cancer cells, interrupting their
normal replicative processes. Unfortunately these potent anticancer mimics are believed to
be substrates for the enzyme guanine deaminase, which converts them into their respective
inactive forms. A potent inhibitor would restore the original potency of these anticancer
compounds. Such an activity was determined for azepinomycin [Isshiki et al., 1987] and its
analog designed as transition state of this reaction (Fig. 27) [Chakraborty et al., 2011].
Figure 27. Apizenomycin as a template for guanine deaminase inhibitor.
11. Glycosidases and related enzymes
Glycoside hydrolases, the enzymes catalyzing hydrolysis of the glycosidic bond in di-, oligo-
and polysaccharides, and glycoconjugates, are ubiquitous in Nature and fundamental to ex‐
istence. The extreme stability of the glycosidic bond caused that they have evolved into
highly proficient catalysts, with an estimated 1017 fold rate enhancement over the uncata‐
lysed reaction. Such rate enhancements mean that enzymes bind the substrate at the transi‐
tion state with extraordinary affinity [Gloster & Davies, 2010].
In the most cases of glycoside hydrolysis, the short-lived transition state possesses substan‐
tial oxocarbenium character (Fig. 27) resembling classical SN1 reaction intermediate. Under
these conditions the anomeric carbon possesses trigonal character, which causes sp2 hybridi‐
sation predominantly along the bond between the anomeric carbon and endocyclic oxygen
and significant relative positive charge accumulation on the pyranose ring [Lee et al., 2004;
Biarnés et al., 2011; Davies at al., 2012].
The quest for potent and selective inhibitors of glycosidases is extremely active at present.
This results from the involvement of glycosidases in lysosomal storage disorders, cancer, vi‐
ral infections, diabetes and many others. Consequently a plethora of glycosidase inhibitors
have been already synthesized and evaluated. The number of them is continually growing.
It is outside the scope of this chapter to mention all of them in detail. One of the most ap‐
pealing ways to design a transition state analog would be to incorporate both the features of
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geometry and charge present at the transition state. Distortion of the ring to generate com‐
pounds which may resemble the geometry of the transition state can be done by introducing
a double bond in the pseudo-glycoside ring itself, whereas introduction of the charge might
be done by application of sulfonium or ammonium ions [Rempel & Withers, 2008; Gloster &
Davies, 2010; Sumida et al., 2012].
Figure 28. Mechanism of β-glucosidase action [after Vasella et al., 2002].
Some representatives, which fulfills these requirements are: salicinol, one of the active prin‐
ciples in the aqueous extracts of Salacia reticulata that is traditionally used in Sri Lanka and
India for the treatment of diabetes [Ghavami et al., 2001] and its structurally variable ana‐
logues [Liu et al., 2006; Bhat et al., 2007; Mohan & Pinto, 2008].
Figure 29. Salicinol and its analogs.
Sialic acids play an important role in a variety of biological processes. They are usually at‐
tached to the terminal positions of glycoproteins, glycolipids and oligosaccharides. From
more than 100 different sialic acids, N-acetylneuraminic acid (NeuAc) is the most abundant
one. Sialidases or neuraminidases are a family of exo-glycoside hydrolases that catalyze the
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cleavage of terminal sialic acid residues from sialylated oligosaccharides, glycoproteins, and
glycolipids. Aberrant expression of different human sialidases was found to associate with
various pathological conditions, including lysosomal storage diseases such as sialidosis and
galactosialidosis. Non-specific transition-state analog of sialidase, 2-deoxy-2,3-dehydro-N -
acetylneuraminic acid (DANA, Fig. 30) is a good starting point for the synthesis of specific
inhibitors of human enzymes [Streicher & Busse, 2006; Li et al., 2011].
Figure 30. Chemical structures of neuraminidaze inhibitors.
Influenza viruses, in particular those of type A that can infect animals and humans, continue
to represent a major threat to public health and animal health worldwide. The social and
economic burden associated with a pandemic is substantial. Two viral surface glycoproteins,
the sialoside-hydrolysing neuraminidase and the sialic acid-binding hemagglutinin, have
become important targets for such approach. Most likely, the function of flu virus neurami‐
nidase is to remove sialic acid receptors for the virus from the host cells, and also, perhaps
more importantly, from the newly formed virus particles themselves [Nelson & Holmes,
2007; Medina & Garcia-Sastre, 2011]. Three inhibitors of neuraminidase have been success‐
fully introduced as anti-influenza drugs, all of them being transition state analog inhibitors.
They were designed by systematic reduction of DANA structure using crystallographic data
and computer-aided methods [Wei, et al., 2006]. Relenza (zanamivir) was the first inhibitor
to be synthesized which specifically inhibited neuraminidases of both Type A and Type B
influenza viruses and is effective in controlling influenza infections. In people is given as a
powder by oral inhalation [Palese et al., 1974]. Interestingly, it is weaker inhibitor of neura‐
midase than DANA, however, DANA inhibited influenza virus replication in tissue culture
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but failed to prevent disease in flu-infected animals. In order to produce a neuraminidase
inhibitor, which was orally bioavailable and which was taken orally in capsules or as a sus‐
pension, Tamiflu (oseltavimir) was developed in 1997 [Kim et al.]. Third drug, which has
been authorized for the emergency use of treatment of certain hospitalized patients with
known or suspected 2009 H1N1 influenza, is permavir [Chand, et al., 2005]. Structures of
these drugs are presented in Figure 30.
All three drugs soon became lead structures for the design and preparation of new, presum‐
ably more effective ones. Syntheses and eveluation of phosphinic analogs and significantly
simplified analogs of permavir (Fig. 31) have been recently described [Kati et al., 2001; Bian‐
co et al., 2005; Shie et al., 2007; Udommaneethanakit et al., 2009].
Figure 31. Second generation of influenza neuraminidase inhibitors.
Modified phosphonic analogs of oseltamivir were used to functionalize gold nanoparticles
and were found to bind strongly and selectively to all seasonal and pandemic influenza vi‐
rus strains, and thus could serve as prototypes for novel virus sensors. This may be helpul in
fast influenza diagnosis [Stanley et al., 2012].
12. Transition state analogues of nucleic acids metabolism
N-Ribosyltransferases are a general class of enzymes that catalyze nucleophilic displacement
reactions by migration of the cationic ribooxacarbenium carbon from the fixed purine to
phosphate and water nucleophiles, respectively. Two major classes of these enzymes are hy‐
drolases and phosphorylases. Hydrolases, which release the heterocycle to generate a free
sugar ribosyl unit, include enzymes for DNA repair, RNA depurinations by plant toxins,
and purine and pyrimidine nucleoside and nucleotide metabolism. Phosphorylases, which
transfer ribosyl groups to phosphate, are also involved in the pathway for nucleoside sal‐
vage. Genetic defects in this pathway prevent normal purine catabolism in humans.
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The focus on transition states for a family of N-ribosyltransferases roots from physiologic
importance of these enzymes. Similarly as in the case of glycosidases, most sugar transferas‐
es form transition states with cationic charge at the anomeric carbon. The geometry is al‐
tered at this center from sp3 (tetrahedral geometry) in the reactant sugar to sp2 (trigonal
planargeometry) at the transition state (Fig. 32) [Schramm, 2002; Murkin et al., 2007; Silva et
al., 2011].
Figure 32. Course of reaction catalyzed by N-ribosyltransferases.
Newborns with a genetic deficiency of purine nucleoside phosphorylase are normal, but ex‐
hibit a specific T-cell immunodeficiency during the first years of development. All other cell
and organ systems remain functional. Human purine nucleoside phosphorylase degrades
deoxyguanosine, and apoptosis of T-cells occurs as a consequence of the accumulation of
deoxyguanosine in the circulation. Thus, control of T-cell proliferation is desirable in T-cell
cancers, autoimmune diseases, and tissue transplant rejection. The search for powerful in‐
hibitors of these enzymes as anti-T-cell agents has culminated in the discovery of immucil‐
lins. The atomic replacements between inosine and immunocilin H make an insignificant
change in atomic size, but a dramatic change in the molecular electrostatic potential surface
(Fig. 33). Thus, analysis of the molecular electrostatic potential surface similarity between
transition state and immucilin confirmed utility of this simple approach in helping to design
effective inhibitor [Schramm, 2002; Schramm, 2007].
Evolution of immucilin structure, performed using standard structural analogy techniques,
enabled to obtain new inhibitors of purine nucleotide phosphorylase of nano- to picomolar
affinities to the enzyme (Fig. 34) [Evans et al., 2008; Edwards et al., 2009; Ho et al. 2010; Rej‐
man et al., 2012].
Plasmodium parasites (causative agents of malaria) are purine auxotrophs and require pre‐
formed purine bases for synthesis of nucleotides, cofactors, and nucleic acids. The purine
phosphoribosyltransferases catalyze transfer the 5-phosphoribosyl group from 5-phospho-
α-D-ribofuranosyl-1-pyrophosphate to salvage hypoxanthine, guanine, or xanthine to form
intracellular nucleosides. Purine salvage in Plasmodium falciparum uses hypoxanthine formed
in erythrocytes or in parasites by the sequential actions of adenosine deaminase and purine
nucleoside phosphorylase
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but failed to prevent disease in flu-infected animals. In order to produce a neuraminidase
inhibitor, which was orally bioavailable and which was taken orally in capsules or as a sus‐
pension, Tamiflu (oseltavimir) was developed in 1997 [Kim et al.]. Third drug, which has
been authorized for the emergency use of treatment of certain hospitalized patients with
known or suspected 2009 H1N1 influenza, is permavir [Chand, et al., 2005]. Structures of
these drugs are presented in Figure 30.
All three drugs soon became lead structures for the design and preparation of new, presum‐
ably more effective ones. Syntheses and eveluation of phosphinic analogs and significantly
simplified analogs of permavir (Fig. 31) have been recently described [Kati et al., 2001; Bian‐
co et al., 2005; Shie et al., 2007; Udommaneethanakit et al., 2009].
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Figure 34. Effective inhibitors of purine nucleotide phosphorylase.
Therefore, effective inhibitors of both enzymes influence the life cycle of P. falciparum and
these pathways have been targets for antimalarials since the discovery that Plasmodium para‐
sites are purine auxotrophs.
Immunocillins HP and GP [Shi et al., 1999] and BCX4945 [Cassera et al., 2011] (Fig. 35) ap‐
pear to be effective inhibitors of phosphoribosyltransferases and are also able to influence
Figure 33. Molecular electrostatic potential surfaces for inosine, the transition state of purine nucleoside phosphory‐
lase and immucilin H.
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purine nucleoside phosphorylase, being dual inhibitor of the process. Especially the efficacy,
oral availability, chemical stability, unique mechanism of action and low toxicity of BCX4945
demonstrate potential for combination therapies with this novel antimalarial agent. Similar
studies have been also carried out for acyclic nucleoside phosphonates [Keough et al., 2009].
Figure 35. Antimalarial agents of dual inhibitory action.
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1. Introduction
The Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling
pathway play a fundamental role in regulating chronic systemic inflammatory responses in
rheumatoid arthritis (RA) [1-5], based on compelling evidence that JAK/STAT is activated
by many of the pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-2, IL-3, IL-6,
IL-12, IL-17, IL-18, IL-19/IL-20, interferon-α/γ (IFN-α/γ) and oncostatin M (OSM) which are
well-known to regulate, in part, immune-mediated inflammation in several autoimmune
diseases, including RA [6-10]. However, complicating matters is the fact that some of the an‐
ti-inflammatory cytokines, which are known to dampen inflammatory responses induced by
pro-inflammatory cytokines, including, IL-4, IL-10 and IL-13 also activate JAK/STAT [11-14].
In this regard, Müller-Ladner et al. [15] showed that synovial tissue obtained from RA pa‐
tients contained significant amounts of constitutively activated IL-4/STAT. Therefore it will
be necessary to understand more precisely the extent to which pro- and/or anti-inflammato‐
ry cytokine gene expression is deregulated in RA and which of the STAT-responsive genes
known to alter immune-mediated inflammation in response to these cytokines may be ame‐
nable to therapeutic intervention.
2. JAKs
JAKs are non-receptor tyrosine kinases that are pre-associated with the membrane-proximal
site of cytokine receptors [16]. Four mammalian JAK isoforms, JAK1, JAK2 and JAK3 and
TYK2 have been described to date mainly from the results of gene structural analysis [17].
All of the JAK isoforms share a common structure known as the JAK homology (JH) do‐
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main. Leonard and O’Shea [18] identified a proline-rich conserved region in the cytokine re‐
ceptors, called Box1, that associated with JH7 whereas the catalytic phosphotyrosine kinase
site, called YY was determined to correspond to the other JH domains (Figure 1).
Figure 1. JH domains and phosphorylation sites of JAK3: Structural analysis combined with functional studies of JAK3
showed that the JH4-JH7 region contained band 4.1 also known as the Four-point-one, Ezrin, Radixin, Moesin (FERM)
domain. Reprinted by permission from [16].
Additional structural analysis predicted that the JH2 domain was more than likely to be a
pseudosubstrate domain [19]. In view of this latter finding the structural requirements for
JAK activation was further clarified. Thus, the JH3-JH4 domain which shows a Src-homolo‐
gy-2-like structure had a shared homology with JH2. This finding indicated that the JH4-JH7
domains were, indeed, the critical regions required for regulating the interactions between
the various JAK isoforms and other protein kinases. JH4-JH7 were also found to be essential
for receptor binding, catalytic function, JAK autophosphorylation and even in some cases,
inhibition of JAK activity.
3. Stat proteins
Gene analysis has revealed the existence of at least 6 STAT protein isoforms, namely, JAK1,
JAK2, JAK3, JAK5A, JAK5B and JAK6 [20]. In normal homeostasis, phosphorylation of these
STAT proteins is achieved via phosphorylation (i.e. activation) of specific JAK isoforms fol‐
lowing the interaction of various cytokines and growth factors with their specific receptors
[16, 21]. In this manner, cytokine receptor-mediated JAK activation results in the conversion
of latent cytoplasmic un-phosphorylated STAT (U-STAT) proteins into phosphorylated
STAT (p-STAT) proteins which can form homo- or heterodimers and are then translocated
to the nucleus where these activated STAT protein dimers act as potent transcription factors
[17-20]. Although phosphorylation of specific STAT-tyrosine residues remains the primary
requisite mechanism for p-STAT protein dimer formation, a second phosphorylation site
was also recognized at a serine in the C-termini domain of the STAT protein [20, 22].
An amplification loop with potential major clinical significance in RA involves the transcrip‐
tional activity of p-STAT proteins which further regulate the expression of pro-inflammato‐
Drug Discovery374
ry and anti-inflammatory cytokine genes as well as other genes of significance in cancer and
autoimmune diseases [23-28]. In addition, p-STAT proteins can regulate other signaling
pathways necessary for lymphocyte development, as well as the aberrant survival of activat‐
ed dendritic cells, monocytes, lymphocytes and synoviocytes in disorders of the immune
system [29-33].
It is noteworthy that during normal homeostasis, activation of STAT proteins induced the
expression of Suppressor of Cytokine Signaling (SOCS) and Cytokine-Inducible SH-2 (CIS)
proteins and it has been concluded that this is the negative feedback loop that underlies one
of the mechanisms responsible for inhibiting JAK-mediated signaling by cytokines [34-38].
Thus, results of recently published experiments with human endothelial cells are germane to
this point since the data in this paper provided a direct connection between the silencing of
STAT3 with STAT3-specific silencing RNA and the suppression of SOCS3 [39].
The extent to which negative regulation of JAK-mediated signaling by SOCS/CIS may be in‐
activated in autoimmune diseases is a focus of current studies. In that regard, recent advan‐
ces in unraveling the details of mechanism(s) governing negative regulation of cytokine
signaling by SOCS/CIS proteins have shed additional light on the extent to which SOCS/CIS-
mediated down-regulation of pro- and/or anti-inflammatory cytokine JAK/STAT signaling
may be compromised in inflammatory arthritis [40]. However, the results of some recent
studies with osteoarthritic human cartilage have not clarified this issue. For example, one
study showed that the level of SOCS2 and CIS-1, but not SOCS1 and SOCS3, were reduced
in femoral head cartilages from subjects with osteoarthritis [41], whilst the results of another
study [42] indicated that SOCS3, but not SOCS1 expression, was elevated in chondrocytes
obtained from osteoarthritic cartilage compared to chondrocytes from cartilage obtained
from patients who had femoral neck fracture.
The status of the activity of certain other negative regulators such as protein tyrosine phos‐
phatases, including SHP-1,-2 [43] and CD45 [44] and the ‘Protein Inhibitor of Activated
STAT’ (PIAS) proteins [16, 45, 46] are also not precisely known in autoimmune diseases.
These proteins could very likely suppress the activity of phosphorylated JAKs and p-STAT
proteins by dephosphorylation or by interacting with p-STAT proteins in normal cells.
However, these pathways may be compromised or markedly suppressed in arthritis.
It is also critical for gaining a further understanding of what alterations may occur in cyto‐
kine signaling in RA to recognize the fact that activation of JAK/STAT by any of the relevant
cytokines can also activate other intracellular signaling pathways via the “cross-talk” mech‐
anism. Thus, “cross-talk” between JAK/STAT and other signaling pathways [16] can cause
activation of the Stress-Activated Protein Kinase/Mitogen-Activated Protein Kinase (SAPK/
MAPK) pathway, the Phosphatidylinositol-3-Kinase/Akt/mammalian Target of Rapamycin
(PI3K/Akt/mTOR) pathway [47], activation of signaling via Toll-like receptors [47, 48] and
immunoreceptor tyrosine-based activation motifs (ITAMs) [49] as well as the NF-κB path‐
way [50]. These alternative signaling pathways which are all connected to inflammation
have also been shown to significantly modulate many of the survival and/or apoptosis-sig‐
nals required to perpetuate abnormal proliferation and/or to cause the death of activated
dendritic cells, lymphocytes, macrophages, synoviocytes and chondrocytes.
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It is also critical for gaining a further understanding of what alterations may occur in cyto‐
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Evidence from a genome-wide analysis study (GWAS) of STAT-target genes showed that many
of these genes regulated cellular proliferation, angiogenesis and metastasis in cancer cells [51].
These results when coupled with the data from another recent study [52] which highlighted the
nature of the several forms of STAT-interacting proteins that bind to DNA suggested that GWAS
could be employed to identify pro-inflammatory and/or anti-inflammatory cytokine STAT-tar‐
get gene structures and potentially additional STAT-interacting proteins present in RA joint tis‐
sues. Thus GWAS may be considered the next step in the development of future therapies for RA
based on targeting STAT-responsive genes. This could be especially useful depending on the
status of the activity of the SOCS/CIS protein family acting on cytokine-receptor-mediated sig‐
naling. For example, if SOCS/CIS activity is dampened or deregulated in RA then it would be un‐
likely that this negative regulator pathway for controlling cytokine signaling would be able to
inhibit the amplification of pro-inflammatory cytokine-induced JAK/STAT signaling. To illus‐
trate this point, Isomäki et al. [40] showed that although SOCS-1 and SOCS-2 were up-regulated
in T-cells recovered from peripheral blood, that SOCS-3 was found in peripheral blood mono‐
cytes and a significant number of synovial tissue macrophages expressed SOCS-1 and SOCS-3
proteins, the majority of T-cells in RA synovium were ‘SOCS negative.’
For further discussion, this chapter will focus on the recent progress that has been made in
furthering our understanding of how cytokine gene expression is regulated by both U-STAT
and p-STAT proteins. The long-term prospect arising from the results of these studies would
be to exploit this new knowledge to reduce the level of pro-inflammatory cytokines or to
raise the level of anti-inflammatory cytokines in RA. By doing so this could potentially re‐
store the balance between these cytokine families and retard ongoing synovial joint damage
whilst also ameliorating RA clinical signs and symptoms.
4. Stat-DNA promoter-binding motifs
Defining transcription factor binding sites was critical for revealing the structure of cis-regu‐
latory motifs that regulated transcriptional activity [53]. However, microarray analysis using
different cell types determined that although several hundred genes were potential STAT3-
target gene sites, only a small fraction of those STAT3-target gene sites turned out to be true
direct STAT3-target genes [54].
As previously indicated, p-STAT proteins do not act independently of one another and U- and
p-STAT-protein interactions take various forms which enable them to bind efficiently to DNA
[55]. These activated STAT-protein interaction types include, 1) the direct binding of activated
STAT homodimers to DNA; 2) the interaction of activated STATs with non-STAT proteins to
form activated STAT/non-STAT protein complexes which bind to DNA; and 3) activated STAT
proteins interacting with other non-STAT transcription factors or co-activator proteins which
bind to DNA [16, 53]. In addition, several novel mechanisms were described for the binding of
U-STAT3 and U-STAT1 to DNA [54, 55]. In that regard, Cheon et al. [56] showed that U-STAT3
can drive expression of proteins not induced by p-STAT3, whereas U-STAT1 was shown to ex‐
tend and up-regulate the expression of a subset of genes initially responsive to p-STAT1 (e.g.,
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interferon, IL-6), that result in more prolonged antiviral and/or immune responses. Thus, the
results of these studies provided novel information regarding the functional significance for U-
STAT1 and U-STAT3 acting as transcriptional activators and organizers of chromatin. These
events have been shown to be important cellular mechanisms for regulating gene transcription
in the nuclei of cells of the immune system and cancer cells.
The results of DNA sequencing studies originally demonstrated specific DNA-binding sites for
STAT1 and STAT3 [57]. Boucheron et al. [58] then demonstrated that specific DNA binding
sites existed for STAT5A and STAT5B homodimers despite the fact that STAT5A and STAT5B
are evolutionarily conserved and encoded by 2 genes with a 91% homology in amino acid
structure [59]. Moreover, targeted gene deletion of STAT5A and STAT5B in mice resulted in
distinctive phenotypes [60]. This finding suggested a structural dissimilarity in the DNA-bind‐
ing motifs for these two STAT proteins. The results of studies reported in [60] were later con‐
firmed using the IL-3-dependent early pre-B cell line, Ba/F3 [61]. Here it was shown that both
STAT isoforms bound to all of the promoters tested, but STAT5A and STAT5B bound with dif‐
fering kinetics [62]. This result suggested that DNA binding activity was likely at the root of
any differences in the biological activity of these two STAT protein isoforms.
Ehret et al. [63] compared the specificity of STAT-DNA binding sites in specific STAT gene
knockout mice showing distinct phenotypes with the STAT-DNA binding sites in a variety
of cultured cells. From the in vitro analysis, Ehret et al. [63] also demonstrated that DNA
binding site motifs for STAT1, STAT5A, STAT5B and STAT6 were essentially the same with
only minor differences in DNA binding site specificity. However, STAT5A DNA-binding
specificity was much more similar to STAT6 than was the preferential DNA-binding site for
STAT1. Thus, the preferential DNA binding site for STAT6 contained a 4 base pair spacer
(i.e. TTCNNNNGAA) (N4) which was defined as the weak DNA binding site. However, ad‐
ditional analyses showed that STAT6 bound to TTCNNNG-AA (N3) sites (i.e. the strong
binding site) as well [63]. The binding of STAT1 and STAT5 to the N3 site was distinct from
STAT5A which preferred N4. Of note, most of the STAT6 binding sites were found in IL-4
responsive promoters in the N4 sites [64-67]. These results reported by Ehret et al. [63] were
extended by the findings of Moucadel and Constantinescu [64] who showed that STAT5B
bound to chromatin at both the N3 and the N4 site.
5. Stat-responsive cytokines genes
This overview covering the specificity of STAT-DNA binding becomes especially important
for improving our understanding of which cytokine gene expressional events are altered by
p-STAT and U-STAT proteins. This section analyzes our current interpretation of several cy‐
tokines relevant to RA and other autoimmune diseases, namely, IL-2, IL-3, IL-4, IL-6, IL-15,
IL-17, IL-19 and INF-γ, all of which have been shown to activate the JAK/STAT pathway
[16]. Moreover, activation of JAK/STAT signaling by these cytokines was shown to result in
altered patterns of transcriptional activity which lead to changes in the expression of the fol‐
lowing cytokine or cytokine-related genes, IL-2R, IL-3, IL-4, IL-6, IL-6ST (gp130), IL-10,
IL-18R1, INF-γ, oncostatin M (OSM) and TNF-α (Table 1).
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bound to chromatin at both the N3 and the N4 site.
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tokines relevant to RA and other autoimmune diseases, namely, IL-2, IL-3, IL-4, IL-6, IL-15,
IL-17, IL-19 and INF-γ, all of which have been shown to activate the JAK/STAT pathway
[16]. Moreover, activation of JAK/STAT signaling by these cytokines was shown to result in
altered patterns of transcriptional activity which lead to changes in the expression of the fol‐
lowing cytokine or cytokine-related genes, IL-2R, IL-3, IL-4, IL-6, IL-6ST (gp130), IL-10,
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1Cytokines that activate this STAT protein
2Activated STAT that becomes a transcription factor for the STAT-responsive cytokine/protein
3Function(s) of STAT-responsive cytokine/protein
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Table 1. STAT-Responsive Pro-Inflammatory Cytokine Gene Expression
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6. Th1/Th2 Cells, Treg Cells, IL-2R, and IL-15
Up-regulation of the Th1 and Th17 T-cell subsets and reduced levels of human T-regulatory
(Treg) cells are known to occur in autoimmune diseases [16, 68]. In addition, Treg cells are a
critical contributor to T-cell development in the thymus as well as being the T-cell subset
that regulates the genesis and maintenance of immune tolerance [16].
The IL-2Rα/IL-2Rβ subunits in complex with the common IL-2γ subunit make up the high-
affinity IL-2 receptor, whereas homodimeric IL-2Rα results in a low-affinity receptor [69].
The functional significance of blocking the high-affinity IL-2R with the small molecule inhib‐
itor (SMI), SP4206 (Kd ~70nM) in response to IL-2 (Kd~10nM) was that JAK/STAT activation
was inhibited [70]. This result could provide the impetus for development of the next gener‐
ation SMI designed to efficiently inhibit the IL-2/IL-2R pathway and this task should be fa‐
cilitated by employing recently developed technologies based on the principles of protein-
protein interactions [71].
As indicated previously, the interaction of IL-2 with the high-affinity IL-2R causes activation
of JAK/STAT with STAT5A and STAT5B, the principally activated STAT proteins. However,
the eventual change in STAT5-gene responsiveness following IL-2 activation of STAT5 was
shown to be dependent on the complexity of the promoter regions of those STAT5-target
genes [72]. Interestingly, Tsuji-Takayama et al. [73] showed that IL-2-mediated JAK/STAT
activation up-regulated the production of IL-10 by Treg cells. The production of IL-10 arose
from the interaction of STAT5 with a STAT5-responsive element within intron 4, designated
I-SRE-4 of the IL-10 locus which was considered to be an interspecies conserved enhancer
sequence (Table 1). Of note, the clustered CpG regions around I-SRE-4 were under-methy‐
lated in IL-10-producing Treg cells, but not in other T-cell subsets. This result confirmed pre‐
vious results which showed that expression of Foxp3, a member of the forkhead/winged-
helix family of transcription factors and a biomarker for the development and function of
Treg cells [47, 74] was also IL-2/STAT5-dependent [75]. Thus, development of Treg cells was
regulated by the methylation status of CpG residues because methylation of CpG residues
suppressed Foxp3 expression [76].
Chen et al. [77] identified a novel set of IL-4/STAT6-target genes in mice that regulated the
proliferation of activated T-cells. In addition, these genes were shown to regulate the pro‐
duction of the Th2 lineage as evinced by the finding that the cells isolated from wild-type
mice produced Th2 whereas cells from STAT6-/- mice did not. Later, Lund et al. [78] showed
that the IL-4/STAT6 pathway was also critical for the commitment of naïve T-cells to become
either the Th1 or Th2 subset. In that regard, the ratio of Th1 to Th2 produced from naïve T-
cells was found to be dependent on a set of STAT6-responsive genes which included the
transcription factors STATB1, Bcl-6, and TCF7 [78, 79]. Moreover, the IL-4/STAT6-mediated
pathway was also shown to be a strong modulator of human Treg cell production from either
Th1 or Th17 cells [80].
Wurster et al. [81] were among the first to demonstrate that IL-4-mediated activation of
STAT6 could also up-regulate IL-2Rα gene expression (Table 1). Because IL-2 is the major
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vious results which showed that expression of Foxp3, a member of the forkhead/winged-
helix family of transcription factors and a biomarker for the development and function of
Treg cells [47, 74] was also IL-2/STAT5-dependent [75]. Thus, development of Treg cells was
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suppressed Foxp3 expression [76].
Chen et al. [77] identified a novel set of IL-4/STAT6-target genes in mice that regulated the
proliferation of activated T-cells. In addition, these genes were shown to regulate the pro‐
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cells was found to be dependent on a set of STAT6-responsive genes which included the
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growth-promoting cytokine for T-cells [81], elevated production of IL-2Rα in response to ac‐
tivated STAT6 is considered instrumental in facilitating the proliferation of activated T-cells
in cancer as well as in several types of autoimmune diseases. In that regard, the high level of
expression of IL-2Rα in tumors correlated with a poor prognosis in cancer patients [82].
Thus, it will be interesting to determine if the same relationship holds true for RA patients
as well, including what role IL-2Rα polymorphisms [83, 84] might play in determining the
level of the expression of IL-2Rα. For example, IL-15, a pro-inflammatory cytokine which in‐
teracts with two receptor subunits similar to IL-2Rα/β drives the production of the memory
CD8+ T-cell phenotype [85]. Experimental therapies focusing on inhibiting the binding of
IL-15 to the IL-2Rα/β receptor complex were a decade ago considered to be a potential target
for autoimmune diseases [85]. However, since then considerable evidence has accumulated
showing a robust relationship between IL-15/IL-2Rα/β-mediated signaling, osteoclastogene‐
sis and boney erosions in RA joints [3]. In addition, González-Alvaro et al. [86] showed that
IL-15 stimulated production of TNF-α by monocytes derived from RA patients including,
the induction of the CD69 monocyte biomarker, and synthesis of IFN-γ protein by natural
killer (NK) cells. Of note, the results of a clinical study showed that IL-15 expression in RA
synovial tissue persisted even after TNF-α blockade, the latter treatment resulting in a posi‐
tive clinical response and reduced disease activity [87]. However, treating mononuclear cells
in vitro with HuMax-IL-15 f (ab’)2 neutralized the effect of IL-15 on these cells. Furthermore,
treatment with HuMax-IL-15 f(ab’)2 caused a significant improvement in RA disease activity
as measured by the American College of Rheumatology (ACR) clinical response criteria [88].
This finding may be particularly important for future drug development because the results
of a recently completed clinical trial showed that high levels of serum IL-15 in patients with
early arthritis predicted a more progressive and severe clinical course which may call for
early and aggressive drug therapy [89].
6.1. IL-6/gp130/IL-17
The IL-6/IL-6R/gp130 pathway is one of the strongest inducers of STAT3 activation [9] (Ta‐
ble 1) so much so that many studies have been devoted to the activation of the JAK/STAT
pathway by IL-6 because IL-6 is critical to the progression of joint damage in RA [16]. In fact,
the development of the anti-IL-6R monoclonal antibody, tocilizumab, appears to have been
predicated on this emerging evidence such that this drug is now considered useful in the
armamentarium of drug therapies for RA [90, 91]. Most compelling was recent evidence that
tocilizumab in conjunction with methotrexate retarded the progression of joint damage in
RA patients [92], an effect of this drug regimen that was apparently independent of the ca‐
pacity of tocilizumab to modify several clinical biomarkers of inflammation and concomi‐
tant RA disease activity.
Recent results have also emerged which have focused attention on the extent to which other
pro-inflammatory cytokines, such as IL-17, activate JAK/STAT and the mechanism by which
IL-17 modifies the production of IL-6 and other pro-inflammatory cytokines [9]. In that re‐
gard, the results of a study by Jovanovic et al. [93] was extremely informative because it pro‐
vided evidence that IL-17 was capable of activating additional signaling pathways other
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than JAK/STAT which resulted in elevated production of IL-1β and TNF-α. Therefore, it has
become obvious that suppressing the activity of IL-17 could bring about a reduction of these
pro-inflammatory cytokines as well, although this point must be rigorously reexamined in
view of the results from Dragon et al. [94] who showed that IL-17A significantly decreased
GM-CSF-induced neutrophil/granulocyte apoptosis by suppressing activation of p38 kinase,
extracellular-regulated kinase 1/2 and STAT5B.
Inhibiting aberrant T-cell survival in RA may ultimately hinge on the development of a ther‐
apeutic strategy directed specifically at STAT3 since STAT3 was shown to inhibit T-cell pro‐
liferation by up-regulating the Class O Forkhead transcriptions factors (Fox) via the binding
of STAT3 to FoxO1and FoxO3a promoters [95]. Potentially, STAT3 may also protect T-cells
from apoptosis [30, 96] in RA by suppressing IL-2 activity, although the results [95] indicat‐
ed that STAT3 increased T-cell proliferation and their survival through the up-regulation of
OX-40 (CD134), a member of the TNFR-superfamily of receptors and bcl-2 and by suppress‐
ing FasL and Bad expression.
Perhaps the most intriguing aspect of the clinical studies with tocilizumab performed in RA
patients is the extent to which neutralization of the IL-6/IL-6R/gp130 pathway using this
drug together with the putative suppression of IL-6 and gp130 gene expression in response
to inhibition of the STAT3 activation rebalances the skewed ratio of Th17/Treg in favor of Treg
[97, 98], the elevated serum levels of Th17-associated cytokines, IL-17, IL-23, IL-6 and TNF-α,
and the depressed level of Treg cells with its associated growth factor, transforming growth
factor-β (TGF-β) [99]. What is pertinent to these events are the results of a recent study
which showed that treatment of RA patients with tocilizumab in combination with metho‐
trexate resulted in a significant decrease in the percentage of Th17 cells (from 0.9% at base‐
line to 0.45%) and a significant increase in Treg cells (from 3.05% to 3.94%) whilst maintaining
their functional activity [98].
The  extent  to  which  gp130  gene  expression  is  altered  in  response  to  inhibition  of  the
JAK/STAT pathway activation is also an area of immense importance because deregulat‐
ed over-expression of gp130 in RA patients should not be neutralized by anti-IL-6R ther‐
apy. Importantly, O’Brien and Manolagas [100] showed that IL-6 or oncostatin M (OSM),
a member of the IL-6 protein superfamily, stimulated the activity of the gp130 (Table 1)
promoter in which the cytokine response element contained a cis-acting motif for activat‐
ed  STAT  complexes,  including  activated  STAT1  and  STAT3  homo-  and  heterodimers.
Furthermore, it can be conjectured that other pro-inflammatory cytokine members of the
IL-6 protein superfamily, such as ciliary neutrotrophic factor (CNTF), leukemia inhibitory
factor (LIF)  and cardiotropin-1 which use gp130 as their  primary signal  transducer pro‐
tein [9, 101] may provide an alternate mechanism resulting in constitutive JAK/STAT ac‐
tivation. Under those conditions STAT protein activation may not be inhibited any of the
anti-IL-6R agents which retain up-regulated gp130 gene expression. Of note, constitutive
activation of  STAT proteins is  one of  the signature events in the development and pro‐
gression of various cancers [102, 103] with a similar phenomenon having been described
in RA synovial  tissue [15].  Constitutively activated STAT proteins could also be predic‐
tive of a more aggressive form of RA [96].
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The interferon protein family in conjunction with the interferon-regulated gene (IRG) path‐
way plays an important role in RA, SLE and other autoimmune diseases because the IRG
pathway is a critical mediator of autoimmune-dependent inflammation [104-106]. INF-γ is
known to be one of the strongest activators of JAK/STAT and Tyk2 resulting in IRG-mediat‐
ed responses [16, 107, 108]. INF-γ has also been shown to play a role in the epigenetic regu‐
lation of specific gene activation as evinced by the finding of an association of pJAK2 and
IFN-γ receptor in the nucleus with histone H3 in IFN-γ-treated human amnionic (WISH;
American Tissue Culture Collection; CCL 25) cells in vitro [109]. AG-490 a JAK2 inhibitor,
also down-regulated STAT1 gene expression and AG-490 inhibited prolactin-induced IFN-γ,
TNF-α, IL-1β and IL-12p40 synthesis in mouse peritoneal macrophages in vitro [110]. Of
note, inhibition of JNK activity with the SMI, SP600125, also resulted in down-regulating
IFN-γ and TNF-α indicating that both the JAK/STAT and MAPK pathways contributed to
alterations in the expression of these cytokines. Although the importance of these results in
providing a rationale for manipulating signal transduction pathways in human RA remains
to be fully elucidated, the fact that the expression of several pro-inflammatory cytokines rel‐
evant to RA pathology are potentially controlled by cross-talk between JAK/STAT and
MAPK appears to be significant [47, 111, 112].
Three DNA-binding sites related to STAT protein-DNA binding have been recognized with‐
in the IFN-γ promoter. These DNA binding sites include an IL-12-mediated STAT4/DNA
binding site, an IL-2-induced STAT5/DNA binding site and a CD2-mediated STAT/IFN-γ
binding site [113]. Thus, CD2-mediated activation of human peripheral blood mononuclear
cells was shown to result in STAT/DNA binding to a 3.6kb DNA motif within the IFN-γ pro‐
moter which occurred principally via STAT5A binding and less so by STAT5B, with both be‐
ing independent of IL-2.
Induction of some of the IFN-regulatory factors (Irfs), including those gene responses brought
about by activation of irf9 via IFN-α were found to be STAT protein-independent [114]. In ad‐
dition, results from other studies showed that Akt activity was also involved in key IFN-α, -γ
gene responses [115]. Moreover, regulation of IFN-α, -γ-mediated responses required the di‐
rect control of mTOR [116] beginning with the initiation of protein translation [117].
In RA, the depressed level of IL-4 and IL-10 in mononuclear phagocytes is, in part, responsible
for the imbalance in Th1/Th2 cytokines [3, 16]. The primary model employed to describe the re‐
lationship between IFN-γ and IL-4/IL-10 is dependent on several factors. This view was origi‐
nally proposed by Hamilton et al. [118] as follows; IL-4 was shown to markedly suppress the
transcriptional activity of IFN-γ because the promoter sequence between IL-4 and IFN-γ were
essentially identical. Proof of this came from the results of experiments that showed that IFN-γ/
STAT1 and IL-4/STAT6 both formed complexes at the same regulatory sequence, but whereas
activated STAT1 promoted IFN-γ transcription, activated STAT6 did not. However, activated
STAT6 was required to suppress the transcriptional up-regulation of IL-4. Thus, in the model,
IL-4 appeared to be necessary to reduce IFN-γ gene expression (Table 1) and was related to a
competition between activated STAT1 and activated STAT6 for binding to the IFN-γ promoter.
In keeping with this model, the expression of IL-10 is also known to be suppressed by INF-γ
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[119]. Thus, it was shown that when transfected RPMI 8226.1 B-cells were incubated with IFN-
γ followed by lipopolysaccharide (LPS), IFN-γ reduced LPS-induced IL-10 promoter activity
which was independent of the irf, but dependent on an activated STAT-motif. Further analyses
indicated that IFN-γ down-regulated IL-10 gene expression via displacement of the trans-acti‐
vated STAT3 by STAT1 induced by IFN-γ.
Experimental strategies could be designed to increase the mononuclear cell expression of
IL-4/IL-10 by manipulating the ultra-sensitive INF-γ promoter region with various activated
STAT protein types. Another strategy for potentially improving the level of IL-10 in RA
would involve manipulating natural Treg cells in a cell-based therapy mode because Treg cells
are a rich source of IL-10 [120, 121]. However, as pointed out by Nandakumar et al. [121]
one must be mindful that the antigen specificity of natural Treg cells must be carefully regu‐
lated to protect against the development of self-reactive effector T-cells or for that matter,
Treg cells with inappropriate antigen specificity.
6.3. OSM
Recent advances have assigned OSM, a member of the IL-6 protein superfamily an impor‐
tant role in the pathogenesis and progression of RA and OA [101]. In that regard, one of the
more important experimental results involving OSM were reported by Hams et al. [122]
who compared the inflammatory responses in wild-type mice to IL-6-deficient and mice de‐
ficient in the OSM receptor β (OSMRβ). They showed that the OSMRβ knockout mice
showed enhanced trafficking of monocytes to sites of inflammation when these mice were
compared to the wild-type or IL-6-knockout mice. However, the OSMRβ knockout mice did
not demonstrate any differences in neutrophil or lymphocyte migration to inflamed tissue
when compared to their wild-type or IL-6-deficient counterparts. These results suggested
that the OSM/OSMRβ-pathway probably regulated chemokine production and chemokine
function. Indeed this proved to be the case when the up-regulated chemokine in response to
the activation of the OSMRβ-pathway was eventually identified as CCL5. CCL5 has been
shown to be a critical chemokine for regulating the recruitment and retention of monocytes
in inflamed RA synovial joints [3]. Although the evidence was indirect, these results sug‐
gested that a drug with the capacity to neutralize the interaction between IL-6 and IL6R in
arthritic joints would not alter OSM/OSMRβ-mediated STAT activation [9]. This view was
supported by the results from several previous studies which showed that 1) although the
OSMR consisted of a heterodimer of the LIF receptor and gp130, the alternative form of
OSMR, namely, OSMRβ, was activated only by OSM and not by LIF [123]; 2) OSM, but nei‐
ther IL-6 nor LIF induced tyrosine phosphorylation in the Shc adaptor protein p52 and p66
isoforms which in association with growth factor receptor-bound protein 2 (Grb2) were both
recruited to OSMR, but not to gp130 [124]; and 3) at least in human or canine osteosarcoma
cell lines, treatment with OSM phosphorylated JAK2/STAT3 and Src, each of which was
shown to be involved in an OSM dose-dependent-mediated increase in expression of the
MMP-2 gene (i.e. 72kDa gelatinase) and vascular endothelial growth factor (VEGF) gene
[125]. Of note, the STAT3 SMI, LLL3, inhibited MMP-2 and VEGF gene expression indicat‐
ing that MMP-2 and VEGF were genes targeted by activated STAT3. Importantly, Clarkson
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et al. [126] showed that another one of the activated STAT-responsive genes in mammary
epithelial cells was OSMR. This finding was critical for completing the circle which showed
that activation of OSMRβ was central to the upstream activation of the OSM-mediated path‐
way as well as to the downstream increase in the expression of the OSMRβ gene, both
events involving STAT proteins.
7. Other cytokines/cytokine receptors
The role played by activated STAT proteins in various aspects of autoimmune diseases and
in oncogenesis is best exemplified by the many genes and transcription factors that have
been shown to be STAT protein-responsive [51, 127]. Many of these STAT-regulated genes
include additional pro-inflammatory cytokine and cytokine receptor genes besides those
previously discussed. In this section we will analyze the contributions of these cytokine and
cytokine receptor genes to the pathology of RA.
7.1. IL-18
IL-18 is structurally similar to IL-1 and the IL-18 receptor is a member of the IL-1R/TLR pro‐
tein superfamily [128]. However, the function of IL-18 differs considerably from that of IL-1
and, in fact unlike IL-1, IL-18 is produced by a variety of immune as well as non-immune
cells. Although IL-18 in its role as a stimulator of Th1 responses is well known by its activity
as an immune defense cytokine against microbial infection, the over-production of IL-18 can
result in autoimmune disease via its capacity to modify and accentuate adaptive immuno‐
logical responses such as those seen in RA [129-132]. However, paradoxically IL-18 can also
stimulate Th2-related cytokine responses as well [128]. Thus, its putative role in altering the
Th1/Th2 cytokine repertoire cannot be dismissed.
Particularly important with regard to the role played by IL-18 in RA were results of a study
by Gracie et al. [133] who first identified abundant IL-18 in RA synovial tissue. These find‐
ings are relevant when coupled with those from other studies by Tanaka et al. [134] who al‐
so found elevated IL-18 and the IL-18 receptor α/β in RA synovial tissue. They also
demonstrated that IL-18 was a co-factor and regulatory cytokine in stimulating the synthesis
of IFN-γ by T-cells in RA synovial tissue, the latter also requiring IL-12, thus implicating the
up-regulation of IL-18 gene expression as an important component of RA disease progres‐
sion.
Activated STAT3 was identified as the JAK/STAT-related transcription factor responsible for
the increased synthesis of IL-18 [127]. In that regard, TNF-α was shown to increase IL-18
gene expression in RA synoviocyte cultures suggesting the possibility that TNF-α, a known
activator of p38 kinase and JNK may also activate STAT3 in synoviocyte and chondrocyte
cultures. Indeed, recent results from our laboratory showed that recombinant human TNF-α
activated STAT3 in normal human chondrocyte cultures and TNF-α activated STAT3, p38
kinase and JNK in cultured chondrocytes derived from human osteoarthritic knee cartilage
[Malemud et al. submitted]. Thus, it was instructive to learn that treating RA patients with
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the combination therapy of infliximab and methotrexate reduced the level of IL-18 in serum
whilst the level of the chemokine, CXCL12 was unaltered [135]. Moreover, synovial fluid
from these RA patients had higher levels of IL-18 (as well as TNF-α and IL-15) prior to be‐
ginning combination therapy with infliximab and methotrexate compared to the level of
these cytokines in a patient’s sera. In addition, the level of IL-18/TNF-α in synovial fluid was
strongly correlated with a patient’s high Disease Activity Score-28 [136]. Thus, it may be in‐
formative going forward to assess the level of activated STAT3 and IL-18 in the synovial flu‐
id and sera of RA patients before and after treatment with TNF antagonists or other
biological drugs that neutralize the activation of JAK/STAT and MAPK pathways to deter‐
mine the extent to which the level of activated STAT3, p38 kinase or JNK is correlated with
IL-18 gene expression by synovium and cartilage ex vivo.
7.2. IL-12
IL-12 is made up of 2 disulfide-linked protein subunits, termed IL-12p35 and IL-12p40
linked in a heterodimer configuration [137, 138]. Whilst the IL-12p40 subunit has structural
similarities with cytokine receptors, the IL-12p35 component is structurally similar to IL-6
and granulocyte-colony stimulating factor (G-CSF) [139]. Of note, if IL-12p35 and IL-12p40
are produced by the same cell, the bioactive heterodimer is termed, IL-12p70 [140].
IL-12 is synthesized by many cell types of the innate and adaptive immune systems, includ‐
ing, monocytes, macrophages, dendritic cells and neutrophils. IL-12 is a minor product of B-
cells [140]. Although IL-12p35 is constitutively expressed at low levels by many of these
cells, the expression of IL-12p40 is limited to those phagocytic cells that synthesize IL-12p70.
The connection between IL-12 and activation of the JAK/STAT pathway stems from the find‐
ing that IL-12 production was positively regulated by IFN-γ, the latter cytokine which is al‐
so induced by IL-12. Thus, IFN-γ regulates IL-12 gene expression and vice versa. By
contrast, two of the anti-inflammatory cytokines, namely, IL-10 and IL-13 which also acti‐
vate JAK/STAT, suppressed IL-12 production [140] (Table 1). In addition, the type I interfer‐
on proteins, exemplified by IFN-β, which activates STAT1 [141] was shown to inhibit IL-12
gene expression in mice [142].
The main immune functions of IL-12 involve the regulation of Th1 differentiation via the ac‐
tivation of STAT4 which induces the synthesis of the T-bet transcription factor [143]. T-bet
was shown to regulate IFN-γ expression and CD8+ suppressor T-cell development which
had been characterized as principally IFN-γ/STAT1-dependent, and IL-12/STAT4 independ‐
ent. In fact, expression of T-bet was shown to require activated STAT4 to achieve total IL-12-
dependent Th1 cell-fate determination [143]. However, Yang et al. [144] showed that the
effect of IL-12/STAT4 was more complex. Thus, IL-12 -induced activated STAT4 bound to a
distant but highly conserved STAT-responsive T-bet enhancer region where it induced IFN-
γ-activated STAT1 independent T-bet gene expression in CD8+ cells. Importantly, IL-4-in‐
duced STAT6 activation regulates the development and effector functions, not of Th1 cells,
but rather of Th2 cells in peripheral tissues such as skin, lung and gut [145]. However, Th2
cell produced in lymph nodes did not require IL-4-mediated activation of STAT6 [145].
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In summary, cell-fate determination induced by the IL-12-mediated activation of STAT4,
IL-4-mediated activation of STAT6, transforming growth factor-β (TGF-β), IL-6 plus TGF-β
and IL-27 activation of STAT3 profoundly influence the balance of Th1 and Th2 cells, Th17
cells and Treg cell production, respectively [80, 146-149]. This conclusion must, however, be
tempered by results of recent studies which also showed that formal interplays occurred be‐
tween IL-4-induced STAT6 phosphorylation, the GATA-binding protein-3 (GATA3) zinc-fin‐
ger transcription factor [150] and the Treg cell transcription factor, FoxP3 as well.
Importantly, GATA3 was revealed as the key transcription factor in this complex interplay
because GATA3 could 1) directly inhibit Th1 differentiation through its capacity to block up-
regulation of the IL-12β2 receptor; 2) inhibit the activity of STAT4; and 3) neutralize the ac‐
tivity of runt-related transcription factor 3 (runx3), via its capacity to induce protein-protein
interactions [150]. Thus, by modulating the activities of IL-4/STAT6, GATA3/STAT4 and
runx3 one could potentially alter the activity of pro-inflammatory and anti-inflammatory cy‐
tokines as well as overcome immune tolerance.
7.3. IL-21
IL-21 is a member of the Type I cytokine superfamily of cytokine receptors. In this group, the
common γ cytokine receptor complex is the functional component for receptor-mediated signal
transduction of IL-2, IL-4, IL-7, IL-9 and IL-15 [151-153]. Although IL-21 has strong structural ho‐
mology to IL-15, IL-21 interacts with a unique receptor, termed, IL-21Rα, which pairs with the γ-
common cytokine receptor chain (i.e. CD132) to form the active IL-21 receptor complex [154].
IL-21-mediated events affect the functions of NK cells, T-cells and B-cells. Although devel‐
opment of Treg cells from the Th17 lineage is generally considered to require IL-6 because
IL-6 reciprocally controls Th17 and Treg cell development through its ability to inhibit TGF-β-
induced FoxP3 and by inducing RORγ, in fact, IL-21 can also induce RORγ and Th17 devel‐
opment in the absence of IL-6. However, evidence also showed that the number of Th17
cells, the recruitment of Th17 cells to inflamed tissues and the development of autoimmune
encephalitis and myocarditis did not differ between IL-21R and IL-21 deficient mice com‐
pared to their wild-type counterparts [155, 156]. More importantly, IL-6 was the more potent
inducer of Th17 differentiation compared to IL-21 thus calling into question, whether IL-21
was even required for Th17 development.
Despite the emerging controversies regarding how important IL-21 is in T-cell development
and immune responses, a therapeutic intervention designed to limit the responses of im‐
mune cells to IL-21 has long been considered for treating cancer and autoimmune diseases
[157]. In addition, because the binding of IL-21R induces activation of several of the JAK iso‐
forms [153], it became apparent that it would be necessary to elucidate which cellular events
were controlled by STAT proteins activated by phosphorylated JAKs in response to IL-21/
IL-21R. Attempting to address this point, Habib et al. [151] found that IL-21 induced prolif‐
eration of pro-B-lymphoid cells in vitro which was dependent on both γc and the γc-associ‐
ated JAK3 complex. However, a monoclonal antibody reactive only with γc was effective in
limiting the proliferation of BaF3/IL21R α cells [151] indicating that neutralization of γc
alone could cause inhibition of JAK activation by IL-21/IL-21R.
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Implying a role for IL-21 in the development and progression of RA would also depend on
finding an elevated level of IL-21 in human RA tissues and by demonstrating an involve‐
ment of IL-21 in the pathogenesis of CIA or inflammatory arthritis in other animal models.
Thus the results of a study by Young et al. [158] were noteworthy in this regard for several
reasons. First and foremost, treating DBA mice with CIA with an antibody to IL-21R (i.e.
IL-21R.Fc) reduced the severity of arthritis. The reduction in hind paw swelling was accom‐
panied by lower levels of IL-6 in the hind paw but also in the sera of mice treated with
IL-21R.Fc suggesting that one of the downstream events regulated by IL-21 was IL-6 gene
expression. Of note, the level of INF-γ was increased in the hind paws of mice with CIA.
Furthermore, the cultured cells from the lymph nodes of mice with CIA treated with
IL-21R.Fc showed an increased level of IFN-γ ex vivo. These findings (i.e. reduced IFN-γ; in‐
creased IL-6) were mirrored ex vivo using Type II collagen-specific spleen cells from CIA
mice treated with IL-21R.Fc. Most importantly from the perspective of potentially using an
anti-IL-21R antibody as a therapeutic agent for RA was the finding that treating Lewis rats
with adjuvant –induced arthritis therapeutically with IL-21R.Fc “reversed” the swelling in
inflamed joints and tissues from these joints whilst the tissues showed improvement using a
well-validated histological scoring system. More recently, Yuan et al. [159] showed that
IL-21R mRNA was found in human RA synovial tissue samples. In addition, this group also
confirmed the results of the Young et al. study [158] since they showed that an anti-IL-21R
antibody ameliorated the severity of arthritis in CIA which was accompanied by reduced
cytokine levels in cells derived from the anti-IL-21R antibody-treated mice. Interestingly,
IL-21R-deficient K/BxN mice [160] failed to develop arthritis; a result which suggested that
IL-21R played a critical role in the pathogenesis of K/BxN serum-induced arthritis.
There now are several lines of evidence that showed that the IL-21/IL-21R pathway plays a
functional role in regulating inflammatory responses in autoimmune arthritis. In that re‐
gard, anti-IL-21 blockade should also be considered for future drug development for RA.
However, what would also be crucial to improving our understanding of the role of IL-21 in
RA would be to discover which pro-inflammatory cytokine levels are altered in response to
the JAK/STAT activation by IL-21/IL21R. This could provide a novel paradigm for reducing
pro-inflammatory cytokine levels in RA.
8. The extended IL-10 cytokine superfamily
IL-19, IL-20, IL-22, IL-24 (melanoma differentiation-associated gene 7; mda-7), and IL-26
(AK155) are all structurally similar to IL-10 and these interleukins constitute members of the
extended IL-10 cytokine superfamily [161-163]. Three additional members of the IL-10 cyto‐
kine superfamily have recently been added to this list, namely, IL-28A, IL-28B and IL-29
which now comprise the IFN-λ cytokine subfamily [164-166].
IL-19 and IL-20 are α-helical proteins. They have similar cysteine sites; their amino acid se‐
quences are approximately 30% identical. In the human genome, the genes encoding these
IL-10 superfamily members are located in two clusters; one cluster comprises the genes for
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IL-10, IL-19, IL-20, and IL-24/mda-7 which are located on chromosome 1q31-32 [167]. IL-19 and
IL-20 were predominately expressed in monocytes, as well as non-immune cells under inflam‐
matory conditions [168], whereas IL-22 and IL-26 was only produced by T-cells, especially Th1
cells and NK cells, whilst IL-24 synthesis was restricted to monocytes and T-cells [169].
Both IL-20 and IL-24 bind to the IL-20R complex which is made up of the cytokine receptor
family 2-8/IL-20Rα (IL-20R1) [170], although it was previously shown that IL-19/IL-19 recep‐
tor binding was similar to IL-20/IL-24 receptor binding [170]. IL-19 was also shown to inter‐
act with a DIRS1-like element which is composed of tyrosine recombinase-encoding
transposons/IL-20Rβ (IL-20R2) [170-172].
In all cases, the binding of IL-19, IL-20 or IL-24 to these receptors caused activation of STAT3
and activation of a minimal promoter region containing those sequences identified as STAT-
binding sites. Importantly, absent either of the R1 proteins in the two types of receptor com‐
plexes, IL-20R1/IL-20R2 and IL-22R1/IL-22R2 reduced the affinity of IL-19 or IL-24 for these
receptors. Furthermore, IL-20R2, and not IL-20R1, was identified as the high affinity recep‐
tor chain for these cytokines [173].
The functional significance of the IL-10-related cytokines, IL-19, IL-20, IL-21, IL-22 and IL-24
in terms of the pathophysiology of RA and other autoimmune diseases is systematically be‐
ing elucidated. In most cases, the role played by these cytokines has been inferred from
measurements in sera of RA patients before and/or after medical therapy.
8.1. IL-19
Sakurai et al. [174] showed that IL-19 was produced by cells of human RA synovial tissue.
The majority of IL-19 positive cells were vimentin- and CD68-positive, indicating that fibro‐
blasts and macrophages were the main sources of IL-19 in RA synovium. From a functional
perspective, synovial tissue lining and sublining layers were both identified with anti-
IL-20R1 and anti-IL-20R2 antibodies.
IL-19 activated synoviocyte STAT3 and, downstream, STAT3 activation caused up-regula‐
tion of IL-6 and IL-19 gene expression whilst decreasing synoviocyte apoptosis induced by
serum-starvation [174], a change which may predict the role of IL-19 in the development of
synovial hyperplasia [30, 96]. However, the role of IL-19 in RA relative to its activation of
signal transduction was further complicated by the findings of Alanärä et al. [175] who
showed that IL-1β, an activator of the MAPK pathway [176], also increased the level of IL-19
in peripheral blood mononuclear cells in vitro. Combined with other data this result showed
that in RA joints IL-19 expression was the highest of all of the IL-10 family cytokines. Fur‐
thermore, these results suggested that IL-19 played a significant role in synovial tissue in‐
flammation, with the caveat that further consideration of IL-19 as a target for intervention in
in RA must focus on the relative level of JAK/STAT activation of JAK/STAT versus activa‐
tion of the other signaling pathways.
IL-19 was highly expressed in synovial tissue and, in particular, expressed in fibroblasts iso‐
lated from rats with collagen-induced arthritis (CIA) [177]. Of note, treating these rats with a
anti-IL-19 antibody, 1BB1, reduced arthritis severity which was accompanied by the lower
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level of boney erosions and an improvement in the quality of subchondral bone. Moreover,
treatment of rats with CIA with 1BB1 reduced the expression of TNF-α, IL-1β, IL-6 and Re‐
ceptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) genes in synovial tissue and
also lowered IL-6 levels in serum. Synovial fibroblasts isolated from rats with CIA respond‐
ed to treatment with IL-19 in a similar fashion seen with synovial tissue in situ where in‐
creased synthesis of TNF-α, IL-1β, IL-6 and RANKL was detected.
There is now compelling evidence that IL-19-mediated activation of STAT3 was associated
with the development and progression of inflammatory arthritis which was characterized
by the elevated expression of many of the pro-inflammatory cytokines pertinent to human
RA joint destruction. These data also showed that the rat CIA model could be further ex‐
ploited to determine the extent to which specific dampening or up-regulation of STAT-re‐
sponsive cytokine genes would ameliorate inflammatory responses associated with CIA.
8.2. IL-20
IL-20 interacts with IL-20R1/IL-20R2 to activate the JAK/STAT pathway [166] and IL-20 has
been implicated in the pathogenesis of autoimmune diseases [178]. However, IL-20R2 sig‐
naling was shown to blunt mouse CD4 and CD8 T-cell responses to antigen in vitro and in
vivo [179]. Thus, it remains to be determined the extent to which IL-20 promotes or sup‐
presses immune-mediated inflammation.
In the CIA model in the rat, treatment with an anti-IL-20 antibody 7E, either alone, or in
combination with the TNF blocker, etanercept was compared to etanercept alone for their
capacity to 1) ameliorate cartilage damage; 2) stabilize bone mineral density; and 3) alter cy‐
tokine production [180]. In addition, the effect of antibody 7E on expression of various genes
implicated in the progression of CIA was evaluated on rat synovial fibroblasts in vitro. Treat‐
ment with 7E or etanercept or the combination of 7E and etanercept significantly reduced
the severity of arthritis as measured by rat hind paw thickness and swelling. These treat‐
ments also prevented cartilage degradation and bone loss whilst reducing the level of syno‐
vial tissue IL-20, IL-1β, IL-6, RANKL and MMPs. Of note, IL-20 induced the expression of
TNF-α in synovial fibroblasts isolated from rats with CIA. Moreover, IL-20 induced RANKL
production in synovial fibroblasts, osteoblasts and Th17 cells. In another study, antibody 7E
was shown to inhibit mouse osteoclast differentiation induced by macrophage-CSF and
RANKL [181]. These results [181] coupled with results from the CIA model [180] indicated
that IL-20 was likely to have promoted the increased bone loss in CIA by promoting osteo‐
clast differentiation and the activity of osteoclast-mediated bone resorption.
Correlative human studies of IL-20-mediated responses in RA are just emerging. However,
the results have differed somewhat from those seen in the CIA model. Thus, Kragstrup et al.
[182] showed that plasma IL-20 levels were increased in RA compared to OA patients with
the elevated level of IL-20 primarily localized to mononuclear cells and neutrophils. Stimu‐
lating mononuclear cells isolated from RA synovium with recombinant IL-20 resulted in the
increased secretion of the chemoattractant CCL2/MCP-1. However, at variance with find‐
ings in the CIA model, recombinant IL-20 did not alter the expression of TNF-α or IL-6 by
mononuclear cells in vitro.
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IL-10, IL-19, IL-20, and IL-24/mda-7 which are located on chromosome 1q31-32 [167]. IL-19 and
IL-20 were predominately expressed in monocytes, as well as non-immune cells under inflam‐
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tion of the other signaling pathways.
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anti-IL-19 antibody, 1BB1, reduced arthritis severity which was accompanied by the lower
Drug Discovery388
level of boney erosions and an improvement in the quality of subchondral bone. Moreover,
treatment of rats with CIA with 1BB1 reduced the expression of TNF-α, IL-1β, IL-6 and Re‐
ceptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) genes in synovial tissue and
also lowered IL-6 levels in serum. Synovial fibroblasts isolated from rats with CIA respond‐
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Correlative human studies of IL-20-mediated responses in RA are just emerging. However,
the results have differed somewhat from those seen in the CIA model. Thus, Kragstrup et al.
[182] showed that plasma IL-20 levels were increased in RA compared to OA patients with
the elevated level of IL-20 primarily localized to mononuclear cells and neutrophils. Stimu‐
lating mononuclear cells isolated from RA synovium with recombinant IL-20 resulted in the
increased secretion of the chemoattractant CCL2/MCP-1. However, at variance with find‐
ings in the CIA model, recombinant IL-20 did not alter the expression of TNF-α or IL-6 by
mononuclear cells in vitro.




IL-22 binds to the class II cytokine receptor family, IL-22R and IL-10Rβ [183]. IL-22 was
shown to activate STAT-1, -3 and -5 in H4IIE rat hepatoma cells by inducing the phosphory‐
lation of JAK1 and Tyk2, but not JAK1 [184]. However, H4IIE failed to respond to IL-10 via
activation of JAK1 and Tyk2 indicating a distinct signaling pathway for IL-22 versus IL-10.
IL-22 also failed to inhibit pro-inflammatory cytokine gene expression by monocytes in re‐
sponse to LPS although IL-22 did blunt the inhibitory effects of IL-4 produced from Th2 cells,
a finding distinct from the activity of IL-10.
A role for IL-22 in inflammation was inferred from its involvement as an inducer of pancrea‐
titis-associated protein by pancreatic acinar cells [185] and by the elevated serum levels of
IL-22 in patients with active Crohn’s disease [186]. With regard to activating various signal‐
ing mechanisms, Lejeune et al. [187] showed that IL-22 activated JAK/STAT. However, IL-22
also activated ERK, JNK and p38 kinase indicating that IL-22 could activate all of the 3 major
MAPK pathways. Brand et al. [186] then showed that treating intestinal epithelial cells with
TNF-α, IL-1β or LPS significantly increased IL-22R1 gene expression without altering
IL-10R2 mRNA. IL-22 also activated STAT1/STAT3, Akt, ERK 1/2 and JNK and, most impor‐
tantly IL-22 increased the expression of SOCS3, TNF-α, IL-8 and human-defensin-2 mRNAs.
Because IL-22 was shown to activate several disparate signaling pathways it is conjecture
that up-regulation of pro-inflammatory gene mRNAs by IL-22 involves ‘cross-talk’ between
all three pathways. Thus, experiments employing specific SMIs added either individually or
together to cells in culture will have to be performed to determine the extent to which any or
all of these signaling pathways are involved in regulating TNF-α, IL-8 or IL-1β gene expres‐
sion in response to IL-22.
IL-22 is elevated in RA synovial tissue with the lining and sublining layers of RA synovium
expressing the highest levels of IL-22R1 [188]. Recently, Leipe et al. [189] showed that about
50% of the RA patients studied had elevated serum IL-22 compared to a group of healthy
subjects. The level of serum IL-22 closely correlated with the extent of bone erosions as de‐
termined from radiographic analysis. However serum IL-22 did not correlate with the pres‐
ence or absence of either rheumatoid factor (RF) or anti-cyclic citrullinated peptide
antibodies nor was IL-22 associated with disease activity. CD4 T-cells were identified as the
main source of IL-22 in these RA patients. However, in another study, de Rocha Jr et al.
[190] showed that elevated serum IL-22 did correlate with the Disease Activity Score-28
(DAS-28) and the Clinical Disease Activity Index, a positive titer for RF and the extent to
which bone was eroded. The findings from this study [190] agreed with the results from an‐
other recently published study [191] the latter showing that plasma IL-22 was increased in
30 patients with established RA (i.e. mean disease duration of 10.7 years), even in those pa‐
tients receiving immunomodulatory therapy. Thus, any discrepancies between the results of
these various clinical studies relative to establishing a relationship between IL-22, RA dis‐
ease activity and RF levels may involve differences in terms of the types and duration of the
immunotherapies employed or in the proportion of RA patients who were in the early or
late stage of disease. The relationship between IL-22 and the presence of RF could also corre‐
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late with the immunological status of B-cells since, unlike IL-10, IL-22 does apparently not
regulate the induction of Ig by activated B-cells [192].
8.4. IL-24/mda-7
The apoptosis-inducing activity of IL-24/mda-7 has made this unique member of the extend‐
ed IL-10 cytokine family a target for cancer therapeutics [193-195] in view of the finding that
IL-24/mda-7 could kill cancer cells specifically without affecting the vitality off normal cells
or tissues [196]. Receptor binding of IL24/mda-7 to IL-20R activates STAT1 and STAT3 al‐
though additional signaling pathways have been shown to be modulated by cells over-ex‐
pressing IL-24/mda-7 which did not involve JAK/STAT activation [193]. Besides the interest
in IL-24/mda-7 as a tumor suppressor cytokine, mda-7/IL-24 has also been implicated in reg‐
ulating some of components of RA and psoriasis immunopathology [197]. However, some
of the details of the mechanism(s) by which IL-24/mda-7 could alter pro-inflammatory cyto‐
kine gene expression in RA via JAK/STAT have not been fully elucidated, although epige‐
netic and other transcriptional factor activity beyond activated STAT proteins have been
postulated to play critical roles. Thus, it is of interest that Sahoo et al. [198] recently showed
that STAT6 and c-Jun binding to the IL-24 promoter locus in Th2 cells caused trans-activa‐
tion of the IL-24 gene. Finding a relationship between the activators of STAT6 and c-Jun that
are relevant to RA which leads to IL-24 gene transcription may hold the key to increasing
local IL-24/mda-7 levels by Th2 cells. This, in turn, could help overcome the ‘apoptosis-resist‐
ance’ of RA synovium [96].
8.5. IL-3
IL-3 is one of several major cytokines that drive the differentiation of cells of the hemato‐
poietic lineage. The interaction between IL-3 and its cognate receptor activates several sig‐
naling pathways, including, JAK/STAT, PI3K/Akt/mTOR and the Ras/Raf/MAPK pathways
[199]. Downstream events that are regulated by IL-3 which are germane to RA and autoim‐
munity, in general, include the findings that depending on the conditions in the microenvir‐
onment, IL-3 can alter cell proliferation, survival or induce cell death by apoptosis [30].
IL-3 was identified as an activator of JAK2 and STAT5 [200] and the expression of the pro-
apoptotic protein, c-myc. This finding provided the initial evidence that cell proliferation
and apoptosis was regulated, in part, by activated STAT5. However, a subsequent study by
Chaturvedi et al. [201] provided evidence to the contrary in that the interaction of IL-3 with
its receptor activated STAT3 via the phosphorylation of tyr701. Moreover, the results of this
study [201] also showed that myeloid cell proliferation was regulated by IL-3-activated Src
kinase and not by IL-3-actiivated JAK3. This conclusion was based on the following results.
Inhibition of c-Src kinase activation using a dominant-negative (dn) Src mutant also blocked
STAT3 activation and, this in turn, inhibited proliferation of the 32Dcl3 myeloid cell line in
response to IL-3. Moreover, expression of a dn-JAK2 mutation increased apoptosis in 32Dcl3
cells in the absence of IL-3 which also involved the concomitant down-regulation of ERK-2.
Taken together these results indicated that Src kinase activation of STAT proteins regulated
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myeloid cell proliferation whereas JAKs controlled the activation of ERK-2 and associated
anti-apoptotic signals [202].
The results of another study [203] showed that IL-3 played an important role in regulating
SOCS3 and PIAS proteins [16, 20, 21] both of which are important in regulating cytokine sig‐
naling as well as the fine-tuning of the survival and/or cell death pathways for immune and
non-immune cells in general. IL-3 plays a particularly critical role in regulating these events
in mast cells [203], plasmacytoid dendritic cells [204], osteoclast-like cells, [205] and osteo‐
clasts [206, in particular. All of these cell types are involved in some aspect of RA pathology.
To further illustrate this point, Gupta et al. [206] showed that osteoclasts treated with IL-3
were diverted to the dendritic cell lineage which may also be related to the finding that that
IL-3 dampened human osteoclast-mediated bone resorption. Most recently, Srivastava et al.
[207] showed that IL-3 increased the number of functionally active Treg cells by stimulating
the production of IL-2 by non-Treg cells the latter being dependent on the dose of IL-3. Of
note, treating mice with CIA with IL-3 significantly reduced the severity of arthritis and also
increased the frequency of Treg cells found in the thymus, lymph nodes and spleen. Al‐
though this study [207] did not directly measure the status of activated STAT proteins in the
CIA mice treated with IL-3, these additional results showed that treatment of CIA with IL-3
decreased production of IL-6, IL-17A, TNF-α and IL-1 whilst increasing IFN-γ and IL-10
(Table 1).
8.6. IL-7
IL-7 was shown to be a fundamental contributor to thymocyte development as well as a regula‐
tor of T-cell homeostasis in peripheral blood. IL-7 activates both the PI3K/Akt/mTOR and JAK/
STAT pathways suggesting that IL-7 regulates the survival and/or death of T-cells [208].
The IL-7 receptor provides an indicator of the biological activity of IL-7. IL-7R is composed
of a γC and Rα polypeptide. JAK3 associates with γC. The binding of JAK3 to γC allows
IL-7 dimer formation to occur between γC and Rα so that JAK3 can phosphorylate Rα
and/or JAK1 [209]. In most cases, activation of JAK3 causes STAT5 to be phosphorylated.
With respect to relationship between IL-7 and RA, Kim et al. [210] showed that the levels of
IL-1β and TNF-α found in the synovial fluid of RA patients could typically increase IL-7
production by stromal cells in culture. In addition, IL-7 was also a strong inducer of RANKL
production by T-cells, independent of TNF-α [210]. Interestingly, van Roon et al. [211]
showed that TNF-α blockade in RA patients reduced IL-7 production. However, high levels
of IL-7 persisted in RA patients who failed to respond to antagonists of TNF-α.
Hartgring et al. [212] found significantly higher amounts of IL-7Rα in the synovial fluid of
RA patients as well as in synovial fluid from patients with undifferentiated arthritis. IL-7
level strongly correlated with the number of activated CD3+ T-cells. IL-7Rα was also identi‐
fied on B-cells and macrophages from RA patients, but importantly IL-7Rα-expressing T-
cells did not co-express, FoxP3. Ex vivo studies performed on monocytes collected from RA
patients revealed that recombinant human IL-7Rα inhibited IL-7 induced T-cell proliferation
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and IFN-γ production suggesting that blockade of IL-7Rα in RA patients reduced the ex‐
pression of the STAT-responsive gene, IFN-γ.
With respect to the putative role of IL-7 in regulating certain aspects of cartilage responses
in arthritis, Yammani et al. [213] reported that IL-7, IL-6 or IL-8 stimulated the production of
the Ca2+-binding protein, S100A4, by cultured human articular chondrocytes. Importantly,
IL-7 increased the synthesis of S100A4 to a greater extent than either IL-6 or IL-8 with IL-7-
stimulated S100A4 resulting from JAK3/STAT3 activation. In that regard, pre-treating chon‐
drocytes with the experimental JAK3, inhibitor, WHI-P154, or with cyclohexamide blocked
S100A4 synthesis which also inhibited the production of MMP-13. Because S100A4 has been
implicated as significantly contributing to pannus-mediated destruction of cartilage in RA
inflammation [214], blockade of IL-7R may be useful for down-regulating the expression of
S100A4 and MMP-13 with associated blunting of pannus invasion into cartilage.
The interaction between S100A4 and the tumor suppressor p53 protein was purported to be
related to the role of S100A4 as a promoter of cancer metastasis [215]. IL-7 via S100A4 was
also shown to induce the expression of MMP-13 as well as MMP-1, MMP-9 and S100A4 was
also shown to be involved in the neoangiogenesis and aberrant cell proliferation of rheuma‐
toid synovium [216]. Importantly a selective inhibitor of MMP-13 reduced the level of carti‐
lage destruction in 2 of 3 animal models of RA, including the SCID-mouse co-implantation
model and CIA, but not adjuvant arthritis. [217]. Thus, evidence has gradually accumulated
to show that up-regulation of S100A4 via activation of STAT3 significantly alters the pro‐
gression of inflammatory arthritis.
9. Experimental therapies that inhibit activated stat proteins: Is cytokine
gene expression altered?
The results  of  a  Phase 2B RA clinical  trial  have recently  been published which showed
that  the JAK3-specific  SMI,  tofacitinib (CP690,  550)  had clinical  efficacy as measured by
the  ACR  response  criteria  [218].  However,  there  has  been  less  progress  on  developing
novel  strategies  to  directly  inhibit  activated  STAT  proteins  or  dampen  STAT  gene  re‐
sponses.  Noteworthy  have  been  proof-of-principle  studies  that  activated  STAT  proteins
can be experimentally ‘deactivated’ which result in the inhibition of STAT/DNA binding.
Thus, JNK-mediated phosphorylation of the STAT6 ser707 decreased the DNA binding ca‐
pacity  of  IL-4-stimulated  STAT6  resulting  in  the  inhibition  of  STAT6-responsive  genes
[219].  Using immunosuppressive STAT oligodeoxynucleotides (ODN) to inhibit activated
STAT proteins have also been relatively successful.  These ODN have been shown to in‐
terfere  with  the  phosphorylation  of  STAT1  and  STAT4  [220]  and  STAT1  and  STAT3
[221].  Lastly,  administration  of  a  single  dose  of  a  STAT1  decoy  ODN  suppressed  joint
swelling  and the  histological  appearance  of  acute  and chronic  adjuvant-induced experi‐
mental arthritis in the mouse [222].  Electrophoretic mobility shift  analysis of the nuclear
extracts  from synoviocytes  from the  STAT1 decoy ODN-treated animals  incubated with
the STAT-1 decoy ODN inhibited STAT-1 binding to DNA. Of note, STAT-1 decoy ODN
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
393
myeloid cell proliferation whereas JAKs controlled the activation of ERK-2 and associated
anti-apoptotic signals [202].
The results of another study [203] showed that IL-3 played an important role in regulating
SOCS3 and PIAS proteins [16, 20, 21] both of which are important in regulating cytokine sig‐
naling as well as the fine-tuning of the survival and/or cell death pathways for immune and
non-immune cells in general. IL-3 plays a particularly critical role in regulating these events
in mast cells [203], plasmacytoid dendritic cells [204], osteoclast-like cells, [205] and osteo‐
clasts [206, in particular. All of these cell types are involved in some aspect of RA pathology.
To further illustrate this point, Gupta et al. [206] showed that osteoclasts treated with IL-3
were diverted to the dendritic cell lineage which may also be related to the finding that that
IL-3 dampened human osteoclast-mediated bone resorption. Most recently, Srivastava et al.
[207] showed that IL-3 increased the number of functionally active Treg cells by stimulating
the production of IL-2 by non-Treg cells the latter being dependent on the dose of IL-3. Of
note, treating mice with CIA with IL-3 significantly reduced the severity of arthritis and also
increased the frequency of Treg cells found in the thymus, lymph nodes and spleen. Al‐
though this study [207] did not directly measure the status of activated STAT proteins in the
CIA mice treated with IL-3, these additional results showed that treatment of CIA with IL-3
decreased production of IL-6, IL-17A, TNF-α and IL-1 whilst increasing IFN-γ and IL-10
(Table 1).
8.6. IL-7
IL-7 was shown to be a fundamental contributor to thymocyte development as well as a regula‐
tor of T-cell homeostasis in peripheral blood. IL-7 activates both the PI3K/Akt/mTOR and JAK/
STAT pathways suggesting that IL-7 regulates the survival and/or death of T-cells [208].
The IL-7 receptor provides an indicator of the biological activity of IL-7. IL-7R is composed
of a γC and Rα polypeptide. JAK3 associates with γC. The binding of JAK3 to γC allows
IL-7 dimer formation to occur between γC and Rα so that JAK3 can phosphorylate Rα
and/or JAK1 [209]. In most cases, activation of JAK3 causes STAT5 to be phosphorylated.
With respect to relationship between IL-7 and RA, Kim et al. [210] showed that the levels of
IL-1β and TNF-α found in the synovial fluid of RA patients could typically increase IL-7
production by stromal cells in culture. In addition, IL-7 was also a strong inducer of RANKL
production by T-cells, independent of TNF-α [210]. Interestingly, van Roon et al. [211]
showed that TNF-α blockade in RA patients reduced IL-7 production. However, high levels
of IL-7 persisted in RA patients who failed to respond to antagonists of TNF-α.
Hartgring et al. [212] found significantly higher amounts of IL-7Rα in the synovial fluid of
RA patients as well as in synovial fluid from patients with undifferentiated arthritis. IL-7
level strongly correlated with the number of activated CD3+ T-cells. IL-7Rα was also identi‐
fied on B-cells and macrophages from RA patients, but importantly IL-7Rα-expressing T-
cells did not co-express, FoxP3. Ex vivo studies performed on monocytes collected from RA
patients revealed that recombinant human IL-7Rα inhibited IL-7 induced T-cell proliferation
Drug Discovery392
and IFN-γ production suggesting that blockade of IL-7Rα in RA patients reduced the ex‐
pression of the STAT-responsive gene, IFN-γ.
With respect to the putative role of IL-7 in regulating certain aspects of cartilage responses
in arthritis, Yammani et al. [213] reported that IL-7, IL-6 or IL-8 stimulated the production of
the Ca2+-binding protein, S100A4, by cultured human articular chondrocytes. Importantly,
IL-7 increased the synthesis of S100A4 to a greater extent than either IL-6 or IL-8 with IL-7-
stimulated S100A4 resulting from JAK3/STAT3 activation. In that regard, pre-treating chon‐
drocytes with the experimental JAK3, inhibitor, WHI-P154, or with cyclohexamide blocked
S100A4 synthesis which also inhibited the production of MMP-13. Because S100A4 has been
implicated as significantly contributing to pannus-mediated destruction of cartilage in RA
inflammation [214], blockade of IL-7R may be useful for down-regulating the expression of
S100A4 and MMP-13 with associated blunting of pannus invasion into cartilage.
The interaction between S100A4 and the tumor suppressor p53 protein was purported to be
related to the role of S100A4 as a promoter of cancer metastasis [215]. IL-7 via S100A4 was
also shown to induce the expression of MMP-13 as well as MMP-1, MMP-9 and S100A4 was
also shown to be involved in the neoangiogenesis and aberrant cell proliferation of rheuma‐
toid synovium [216]. Importantly a selective inhibitor of MMP-13 reduced the level of carti‐
lage destruction in 2 of 3 animal models of RA, including the SCID-mouse co-implantation
model and CIA, but not adjuvant arthritis. [217]. Thus, evidence has gradually accumulated
to show that up-regulation of S100A4 via activation of STAT3 significantly alters the pro‐
gression of inflammatory arthritis.
9. Experimental therapies that inhibit activated stat proteins: Is cytokine
gene expression altered?
The results  of  a  Phase 2B RA clinical  trial  have recently  been published which showed
that  the JAK3-specific  SMI,  tofacitinib (CP690,  550)  had clinical  efficacy as measured by
the  ACR  response  criteria  [218].  However,  there  has  been  less  progress  on  developing
novel  strategies  to  directly  inhibit  activated  STAT  proteins  or  dampen  STAT  gene  re‐
sponses.  Noteworthy  have  been  proof-of-principle  studies  that  activated  STAT  proteins
can be experimentally ‘deactivated’ which result in the inhibition of STAT/DNA binding.
Thus, JNK-mediated phosphorylation of the STAT6 ser707 decreased the DNA binding ca‐
pacity  of  IL-4-stimulated  STAT6  resulting  in  the  inhibition  of  STAT6-responsive  genes
[219].  Using immunosuppressive STAT oligodeoxynucleotides (ODN) to inhibit activated
STAT proteins have also been relatively successful.  These ODN have been shown to in‐
terfere  with  the  phosphorylation  of  STAT1  and  STAT4  [220]  and  STAT1  and  STAT3
[221].  Lastly,  administration  of  a  single  dose  of  a  STAT1  decoy  ODN  suppressed  joint
swelling  and the  histological  appearance  of  acute  and chronic  adjuvant-induced experi‐
mental arthritis in the mouse [222].  Electrophoretic mobility shift  analysis of the nuclear
extracts  from synoviocytes  from the  STAT1 decoy ODN-treated animals  incubated with
the STAT-1 decoy ODN inhibited STAT-1 binding to DNA. Of note, STAT-1 decoy ODN
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also  inhibited  the  expression  of  macrophage  CD40  suggesting  that  interference  with
CD40-mediated signaling by macrophages may be the mechanism responsible for the at‐
tenuation of arthritis by the STAT-1 decoy ODN.
10. Conclusion
The medical therapy of RA was revolutionized with the introduction of biological drugs, in‐
cluding TNF antagonists, the IL-6R antagonist, tocilizumab, the T-cell co-stimulatory factor
inhibitor, abatacept, the B-cell inhibitor, rituximab and the IL-1 receptor antagonist, anakin‐
ra as well as the use of first-line therapy with disease-modifying anti-rheumatic drugs
(DMARDs) such as methotrexate and anti-malarial drugs [223]. Nevertheless, the long-term
and chronic use of these drugs for treating RA patients is not without potential deleterious
consequences for those RA patients who use them. Thus, RA patients prescribed DMARDs
and/or biological drugs need to be continuously monitored for changes in liver enzyme lev‐
els, ocular and/or kidney toxicities, infections and to a lesser extent malignancies such as
lymphoma [224]. Just as important is the fact that some RA patients fail to respond to one or
several of these biological drugs or become refractory to their action [225].
Development of JAK-specific SMIs was originally predicated on their use as a treatment for
suppressing organ transplant rejection. However, JAK-SMIs were also considered as a po‐
tential adjunctive therapy for overcoming issues of long-term use of biological drugs for the
therapy of RA [7, 11, 16, 17]. Now only time will tell whether or not the JAK-specific SMI,
tofacitinib [218, 225], will be aggressively employed in the treatment of RA, or whether tofa‐
citinib will be used in RA patients who only have exhibited a moderate or inadequate re‐
sponse to biological drugs or DMARDs.
Presently, there has been little attention paid, comparatively speaking, on acquiring data
from RA patients in the general population who have been treated over several years with
biological drugs to determine the extent to which the pro-inflammatory and/or anti-inflam‐
matory cytokine repertoires have been altered from baseline. In addition, there are hardly
any systematic studies, with the exception of some analyses conducted (often as a minor
component of an RA clinical trial) with respect to which of several biological drugs restore
the imbalance between Th1 and Th2 cytokines, suppress the activity of Th17-producing cyto‐
kines, or improve the biological activity of dysfunctional Treg cells [225]. Truly, the possibili‐
ty exists that treating RA patients with biological drugs only partially inhibit over-
expression of the pro-inflammatory cytokines that have been shown to mainly contribute to
the progression of RA, namely, IL-6, IFN-γ and TNF-α (Table 1). This ‘take-home’ point ap‐
pears to adequately justify a continual search for alternative cellular mechanisms that are ac‐
tive in determining whether clinical remission in RA patients is sustained or not. In
conclusion, determining how STAT-responsive cytokine genes are regulated at the molecu‐
lar and cellular level offers the potential going forward for developing yet another treatment
modality designed to suppress the clinical activity and progression of RA pathology.
Drug Discovery394
Acknowledgments
The Arthritis Research Laboratory at Case Western Reserve University School of Medicine
was supported by an investigator-initiated project grant from Takeda Pharmaceuticals of
North America (Deerfield, IL) and is presently supported by an investigator-initiated project
grant from Genentech/Roche Group, (South San Francisco, CA).
Author details
Charles J. Malemud*
Address all correspondence to: cjm4@cwru.edu
Arthritis  Research  Laboratory,  Division  of  Rheumatic  Diseases,  Case  Western  Reserve
University School of Medicine, Cleveland, Ohio, USA
The author declares no conflict of interest.
References
[1] Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Research & Therapy 2004; 6(4)
159-168.
[2] Walker JG, Ahern MJ, Coleman M et al. Expression of Jak3, STAT1, STAT4 and
STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic
cells in seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases 2006;
65(2) 149-156.
[3] Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in
rheumatoid arthritis. Current Rheumatology Reviews 2008; 4(4) 219-234.
[4] Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annual Review of
Pathology 2009; 4 417-434.
[5] Stritesky GL, Kaplan MH. Changing the STATus quo in T helper cells. Transcription
2011; 2(4) 179-182.
[6] Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cyto‐
kine & Growth Factor Reviews 2002; 13(4-5) 413-421.
[7] Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by
cytokines. Drug News Perspective 2005; 18(4) 243-249.
[8] Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Seminars in Cell
and Developmental Biology 2008; 19(4) 311-318.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
395
also  inhibited  the  expression  of  macrophage  CD40  suggesting  that  interference  with
CD40-mediated signaling by macrophages may be the mechanism responsible for the at‐
tenuation of arthritis by the STAT-1 decoy ODN.
10. Conclusion
The medical therapy of RA was revolutionized with the introduction of biological drugs, in‐
cluding TNF antagonists, the IL-6R antagonist, tocilizumab, the T-cell co-stimulatory factor
inhibitor, abatacept, the B-cell inhibitor, rituximab and the IL-1 receptor antagonist, anakin‐
ra as well as the use of first-line therapy with disease-modifying anti-rheumatic drugs
(DMARDs) such as methotrexate and anti-malarial drugs [223]. Nevertheless, the long-term
and chronic use of these drugs for treating RA patients is not without potential deleterious
consequences for those RA patients who use them. Thus, RA patients prescribed DMARDs
and/or biological drugs need to be continuously monitored for changes in liver enzyme lev‐
els, ocular and/or kidney toxicities, infections and to a lesser extent malignancies such as
lymphoma [224]. Just as important is the fact that some RA patients fail to respond to one or
several of these biological drugs or become refractory to their action [225].
Development of JAK-specific SMIs was originally predicated on their use as a treatment for
suppressing organ transplant rejection. However, JAK-SMIs were also considered as a po‐
tential adjunctive therapy for overcoming issues of long-term use of biological drugs for the
therapy of RA [7, 11, 16, 17]. Now only time will tell whether or not the JAK-specific SMI,
tofacitinib [218, 225], will be aggressively employed in the treatment of RA, or whether tofa‐
citinib will be used in RA patients who only have exhibited a moderate or inadequate re‐
sponse to biological drugs or DMARDs.
Presently, there has been little attention paid, comparatively speaking, on acquiring data
from RA patients in the general population who have been treated over several years with
biological drugs to determine the extent to which the pro-inflammatory and/or anti-inflam‐
matory cytokine repertoires have been altered from baseline. In addition, there are hardly
any systematic studies, with the exception of some analyses conducted (often as a minor
component of an RA clinical trial) with respect to which of several biological drugs restore
the imbalance between Th1 and Th2 cytokines, suppress the activity of Th17-producing cyto‐
kines, or improve the biological activity of dysfunctional Treg cells [225]. Truly, the possibili‐
ty exists that treating RA patients with biological drugs only partially inhibit over-
expression of the pro-inflammatory cytokines that have been shown to mainly contribute to
the progression of RA, namely, IL-6, IFN-γ and TNF-α (Table 1). This ‘take-home’ point ap‐
pears to adequately justify a continual search for alternative cellular mechanisms that are ac‐
tive in determining whether clinical remission in RA patients is sustained or not. In
conclusion, determining how STAT-responsive cytokine genes are regulated at the molecu‐
lar and cellular level offers the potential going forward for developing yet another treatment
modality designed to suppress the clinical activity and progression of RA pathology.
Drug Discovery394
Acknowledgments
The Arthritis Research Laboratory at Case Western Reserve University School of Medicine
was supported by an investigator-initiated project grant from Takeda Pharmaceuticals of
North America (Deerfield, IL) and is presently supported by an investigator-initiated project
grant from Genentech/Roche Group, (South San Francisco, CA).
Author details
Charles J. Malemud*
Address all correspondence to: cjm4@cwru.edu
Arthritis  Research  Laboratory,  Division  of  Rheumatic  Diseases,  Case  Western  Reserve
University School of Medicine, Cleveland, Ohio, USA
The author declares no conflict of interest.
References
[1] Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Research & Therapy 2004; 6(4)
159-168.
[2] Walker JG, Ahern MJ, Coleman M et al. Expression of Jak3, STAT1, STAT4 and
STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic
cells in seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases 2006;
65(2) 149-156.
[3] Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in
rheumatoid arthritis. Current Rheumatology Reviews 2008; 4(4) 219-234.
[4] Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annual Review of
Pathology 2009; 4 417-434.
[5] Stritesky GL, Kaplan MH. Changing the STATus quo in T helper cells. Transcription
2011; 2(4) 179-182.
[6] Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cyto‐
kine & Growth Factor Reviews 2002; 13(4-5) 413-421.
[7] Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by
cytokines. Drug News Perspective 2005; 18(4) 243-249.
[8] Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Seminars in Cell
and Developmental Biology 2008; 19(4) 311-318.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
395
[9] Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Ac‐
cess Rheumatology Research & Reviews 2009; 1: 133-150.
[10] Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunologic Research
2011; 50(1) 87-96.
[11] Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nu‐
cleus. Journal of Receptor Signal Transduction Research 1999; 19(1-4) 75-120.
[12] Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. Journal of
Allergy & Clinical Immunology 2000; 105(6 Pt 1) 1063-1070.
[13] Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, in‐
teraction partners, and target genes of STAT6. Cytokine & Growth Factor Reviews
2006; 17(3) 173-188.
[14] Tuomela S, Rautajoki KJ, Moulder R, Nyman TA, Lahesmaa R. Identification of novel
Stat6 regulated proteins in IL-4-treated mouse lymphocytes. Proteomics 2009; 9(4):
1087-1098.
[15] Müller-Ladner U, Judex M, Ballhorn W et al. Activation of the IL-4 STAT pathway in
rheumatoid synovium. Journal of Immunology 2000; 164(7) 3894-3901.
[16] Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory
diseases. Current Signal Transduction Research 2009; 4 201-221.
[17] Darnell JE Jr. STATS and gene regulation. Science 1997; 277(5332) 1630-1635.
[18] Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annual Review of
Immunology 1998; 16 293-322.
[19] Giordanetto P, Kroemer RT. Prediction of the structure of human Janus kinase2
(JAK2) comprising JAK homology domains 1 through 7. Protein Engineering 2002;
15(9) 727-737.
[20] Decker T, Korvarik P. Serine phosphorylation of STATs. Oncogene 2000; 19(21)
2628-2637.
[21] Malemud CJ. Differential activation of JAK enzymes in rheumatoid arthritis and au‐
toimmune disorders by pro-inflammatory cytokines: potential drug targets. Interna‐
tional Journal of Interferon, Cytokine & Mediator Research 2010; 2(1) 97-111.
[22] Zhu J, Cote-Sierra J, Guo L, Paul WE. Stat5 activation plays a critical role in Th2 dif‐
ferentiation. Immunity 2003; 19(5) 739-748.
[23] Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the
transcription factors STAT5A and STAT5B. Genes & Development 2008; 22(6)
711-721.
[24] Radtke S, Wüller S, Xang XP et al. Cross-regulation of cytokine signalling: pro-in‐
flammatory cytokines restrict IL-6 signalling through receptor internalisation and
degradation. Journal of Cell Science 2010; 123 (Pt 6) 947-959.
Drug Discovery396
[25] Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription-from
cytokine signaling to cancer biology. Biochimica et Biophysica Acta 2011; 1816(1)
38-49.
[26] Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36(4)
503-514.
[27] Wang X, Liu Q, Ihsan A et al. JAK/STAT pathway plays a critical role in the proin‐
flammatory gene expression and apoptosis of RAW264.7 cells induced by trichothe‐
cenes as DON and T-2 toxin. Toxicological Sciences 2012; 127(2) 412-424.
[28] Buitenhuis M, Coffer PJ, Koenderman L. Signal transducer and activator of transcrip‐
tion 5 (STAT5). International Journal of Biochemistry & Cell Biology 2004; 36(11)
2120-2124.
[29] Kasperkovitz PV, Verbeet NL, Smeets TJ et al. Activation of the STAT1 pathway in
rheumatoid arthritis. Annals of the Rheumatic Diseases 2004; 63(3) 233-239.
[30] Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. Current Rheumatology
Reviews 2005; 1(1) 131-142.
[31] Walker JG, Ahern MG, Coleman M et al. Changes in synovial tissue Jak-STAT ex‐
pression in rheumatoid arthritis in response to successful DMARD treatment. Annals
of the Rheumatic Diseases 2006; 65(12) 1558-1564.
[32] Walker JG, Ahern MG, Coleman M et al. Characterisation of a dendritic cell subset in
synovial tissue which strongly expresses Jak/STAT transcription factors from pa‐
tients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2007; 66 (8)
992-999.
[33] Stritesky GL, Muthukrishnan R, Sehra S et al. The transcription factor STAT3 is re‐
quired for T helper 2 cell development. Immunity 2011; 34(1) 39-49.
[34] Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem
Cells 2001; 19(5) 378-387.
[35] Giordanetto F, Kroemer RT. A three-dimensional model of Suppressor of Cytokine
Signaling 1 (SOCS-1). Protein Engineering 2003; 16(2) 115-124.
[36] Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune reg‐
ulation. Nature Reviews Immunology 2007; 7(6) 454-465.
[37] van de Geijn GJ, Gits J, Touw IP. Distinct activities of suppressor of cytokine signal‐
ing (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signal‐
ing. Journal of Leukocyte Biology 2004; 76(1) 237-244.
[38] Bruun C, Heding PE, Rønn SG et al. Suppressor of cytokine signalling-3 inhibits tu‐
mor necrosis factor-alpha induced apoptosis and signalling in beta cells. Molecular &
Cellular Endocrinology 2009; 311(1-2) 32-38.
[39] Pirvulescu M, Manduteanu I, Gan AM et al. A novel pro-inflammatory mechanism
of action of resistin in human endothelial cells: upregulation of SOCS3 expression
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
397
[9] Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Ac‐
cess Rheumatology Research & Reviews 2009; 1: 133-150.
[10] Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunologic Research
2011; 50(1) 87-96.
[11] Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nu‐
cleus. Journal of Receptor Signal Transduction Research 1999; 19(1-4) 75-120.
[12] Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. Journal of
Allergy & Clinical Immunology 2000; 105(6 Pt 1) 1063-1070.
[13] Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, in‐
teraction partners, and target genes of STAT6. Cytokine & Growth Factor Reviews
2006; 17(3) 173-188.
[14] Tuomela S, Rautajoki KJ, Moulder R, Nyman TA, Lahesmaa R. Identification of novel
Stat6 regulated proteins in IL-4-treated mouse lymphocytes. Proteomics 2009; 9(4):
1087-1098.
[15] Müller-Ladner U, Judex M, Ballhorn W et al. Activation of the IL-4 STAT pathway in
rheumatoid synovium. Journal of Immunology 2000; 164(7) 3894-3901.
[16] Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory
diseases. Current Signal Transduction Research 2009; 4 201-221.
[17] Darnell JE Jr. STATS and gene regulation. Science 1997; 277(5332) 1630-1635.
[18] Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annual Review of
Immunology 1998; 16 293-322.
[19] Giordanetto P, Kroemer RT. Prediction of the structure of human Janus kinase2
(JAK2) comprising JAK homology domains 1 through 7. Protein Engineering 2002;
15(9) 727-737.
[20] Decker T, Korvarik P. Serine phosphorylation of STATs. Oncogene 2000; 19(21)
2628-2637.
[21] Malemud CJ. Differential activation of JAK enzymes in rheumatoid arthritis and au‐
toimmune disorders by pro-inflammatory cytokines: potential drug targets. Interna‐
tional Journal of Interferon, Cytokine & Mediator Research 2010; 2(1) 97-111.
[22] Zhu J, Cote-Sierra J, Guo L, Paul WE. Stat5 activation plays a critical role in Th2 dif‐
ferentiation. Immunity 2003; 19(5) 739-748.
[23] Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the
transcription factors STAT5A and STAT5B. Genes & Development 2008; 22(6)
711-721.
[24] Radtke S, Wüller S, Xang XP et al. Cross-regulation of cytokine signalling: pro-in‐
flammatory cytokines restrict IL-6 signalling through receptor internalisation and
degradation. Journal of Cell Science 2010; 123 (Pt 6) 947-959.
Drug Discovery396
[25] Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription-from
cytokine signaling to cancer biology. Biochimica et Biophysica Acta 2011; 1816(1)
38-49.
[26] Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36(4)
503-514.
[27] Wang X, Liu Q, Ihsan A et al. JAK/STAT pathway plays a critical role in the proin‐
flammatory gene expression and apoptosis of RAW264.7 cells induced by trichothe‐
cenes as DON and T-2 toxin. Toxicological Sciences 2012; 127(2) 412-424.
[28] Buitenhuis M, Coffer PJ, Koenderman L. Signal transducer and activator of transcrip‐
tion 5 (STAT5). International Journal of Biochemistry & Cell Biology 2004; 36(11)
2120-2124.
[29] Kasperkovitz PV, Verbeet NL, Smeets TJ et al. Activation of the STAT1 pathway in
rheumatoid arthritis. Annals of the Rheumatic Diseases 2004; 63(3) 233-239.
[30] Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. Current Rheumatology
Reviews 2005; 1(1) 131-142.
[31] Walker JG, Ahern MG, Coleman M et al. Changes in synovial tissue Jak-STAT ex‐
pression in rheumatoid arthritis in response to successful DMARD treatment. Annals
of the Rheumatic Diseases 2006; 65(12) 1558-1564.
[32] Walker JG, Ahern MG, Coleman M et al. Characterisation of a dendritic cell subset in
synovial tissue which strongly expresses Jak/STAT transcription factors from pa‐
tients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2007; 66 (8)
992-999.
[33] Stritesky GL, Muthukrishnan R, Sehra S et al. The transcription factor STAT3 is re‐
quired for T helper 2 cell development. Immunity 2011; 34(1) 39-49.
[34] Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem
Cells 2001; 19(5) 378-387.
[35] Giordanetto F, Kroemer RT. A three-dimensional model of Suppressor of Cytokine
Signaling 1 (SOCS-1). Protein Engineering 2003; 16(2) 115-124.
[36] Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune reg‐
ulation. Nature Reviews Immunology 2007; 7(6) 454-465.
[37] van de Geijn GJ, Gits J, Touw IP. Distinct activities of suppressor of cytokine signal‐
ing (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signal‐
ing. Journal of Leukocyte Biology 2004; 76(1) 237-244.
[38] Bruun C, Heding PE, Rønn SG et al. Suppressor of cytokine signalling-3 inhibits tu‐
mor necrosis factor-alpha induced apoptosis and signalling in beta cells. Molecular &
Cellular Endocrinology 2009; 311(1-2) 32-38.
[39] Pirvulescu M, Manduteanu I, Gan AM et al. A novel pro-inflammatory mechanism
of action of resistin in human endothelial cells: upregulation of SOCS3 expression
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
397
through STAT3 activation. Biochemical & Biophysical Research Communications
2012; 422(2) 321-326.
[40] Isomäki P, Alanärä T, Isohanni P et al. The expression of SOCS is altered in rheuma‐
toid arthritis. Rheumatology (Oxford) 2007; 46(10) 1538-1546.
[41] de Andrés MC, Imagawa K, Hashimoto K et al. Suppressors of cytokine signaling
(SOCS) are reduced in osteoarthritis. Biochemical & Biophysical Research Communi‐
cations 2011; 407(1) 54-59.
[42] van de Loo FA, Veenbergen S, van den Brand B et al. Enhanced suppressor of cyto‐
kine signaling-3 in arthritic cartilage dysregulates human chondrocyte function. Ar‐
thritis & Rheumatism 2012; 64(10) 3313-3323.
[43] Zhang J, Somani AK, Siminovitch KA. Roles of SHP-1 tyrosine phosphatases in the
negative regulation of cell signaling. Seminars in Immunology 2000; 12 (4) 361-378.
[44] Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of
immune cell function. Seminars in Immunology 2000; 12(4) 349-359.
[45] Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Research
2006; 16(2) 196-202.
[46] Tahk S, Liu B, Chernishof V, Wong KA, Wu H, Shuai K. Control of specificity and
magnitude of NF-κB and STAT1-mediated gene activation through PIASy and PIAS1
cooperation. Proceedings of the National Academy of Sciences United States of
America 2007; 104(28) 11643-11648.
[47] Malemud CJ. Dsyfunctional immune-mediated inflammation in rheumatoid arthritis
dictates that development of anti-rheumatic drugs target multiple intracellular sig‐
naling pathways. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
2011; 10(1) 78-84.
[48] Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among JAK-STAT, Toll-like receptor,
and ITAM-dependent pathways in macrophage activation. Journal of Leukocyte Bi‐
ology 2007; 82(2) 237-243.
[49] Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nature Im‐
munology 2009; 10(4) 340-347.
[50] Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor
Perspectives in Biology 2009; 1(6) e001651.
[51] Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes. Elucidating the
mechanism of STAT-mediated oncogenesis. Cancer Biology & Therapy 2004; 3(11)
1045-1050.
[52] Oh YM, Kim JK, Choi S, Yoo JY. Identification of co-occurring transcription factor
binding sites from DNA sequence using clustered position weight matrices. Nucleic
Acids Research 2012; 40(5) e38.
Drug Discovery398
[53] Snyder M, Huang XY, Zhang JJ. Identification of novel direct Stat3 target genes for
control of growth and differentiation. Journal of Biological Chemistry 2008; 283(7)
3791-3798.
[54] Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene
2000; 19(21) 2638-2644.
[55] Timofeeva OA, Chasovskikh S, Lonskaya I et al. Mechanisms of unphosphorylated
STAT3 transcription factor binding to DNA. Journal of Biological Chemistry 2012;
287(17) 14192-14200.
[56] Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of
transcriptions 1 and 3 as cytokine-inducible proteins. Journal of Interferon & Cyto‐
kine Research 2011; 31(1) 33-40.
[57] Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA se‐
quence recognition suggests a novel DNA-binding domain. Genes & Development
1995; 9(8) 984-994.
[58] Boucheron C, Dumon S, Santos SC et al. A single amino acid in the DNA binding re‐
gions of STAT5A and STAT5B confers distinct DNA binding specificities. Journal of
Biological Chemistry 1998; 273(51) 33936-33941.
[59] Basham B, Sathe M, Grein J et al. In vivo identification of novel STAT5 target genes.
Nucleic Acids Research 2008; 36(11) 3802-3818.
[60] Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction
and transcription activation. Cytokine & Growth Factor Reviews 1999; 10(2) 131-157.
[61] Chang Y, Spicer DB, Sonenshein GE. Effects of IL-3 on promoter usage, attenuation
and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early
pre-B cell line. Oncogene 1991; 6(11) 1979-1982.
[62] Nelson EA, Walker SR, Alvarez JV, Frank DA. Isolation of unique STAT5 targets by
chromatin immunoprecipitation-based gene identification. Journal of Biological
Chemistry 2004; 279(52) 54724-54730.
[63] Ehret GB, Reichenbach P, Schindler U et al. DNA binding specificity of different
STAT proteins. Comparison of in vitro specificity with natural target sites. Journal of
Biological Chemistry 2001; 276(9) 6675-6688.
[64] Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent
and constitutively active cytokine receptors. Journal of Biological Chemistry 2005;
280(14) 13364-13373.
[65] Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of inter‐
leukin-2 complexed with its alpha receptor. Science 2005; 308(5727) 1477-1480.
[66] Kanai A, Suzuki K, Tanimoto K, Mizushima-Sugano J, Suzuki Y, Sugano S. Charac‐
terization of STAT6 target genes in human B cells and lung epithelial cells. DNA Re‐
search 2011; 18(5) 379-392.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
399
through STAT3 activation. Biochemical & Biophysical Research Communications
2012; 422(2) 321-326.
[40] Isomäki P, Alanärä T, Isohanni P et al. The expression of SOCS is altered in rheuma‐
toid arthritis. Rheumatology (Oxford) 2007; 46(10) 1538-1546.
[41] de Andrés MC, Imagawa K, Hashimoto K et al. Suppressors of cytokine signaling
(SOCS) are reduced in osteoarthritis. Biochemical & Biophysical Research Communi‐
cations 2011; 407(1) 54-59.
[42] van de Loo FA, Veenbergen S, van den Brand B et al. Enhanced suppressor of cyto‐
kine signaling-3 in arthritic cartilage dysregulates human chondrocyte function. Ar‐
thritis & Rheumatism 2012; 64(10) 3313-3323.
[43] Zhang J, Somani AK, Siminovitch KA. Roles of SHP-1 tyrosine phosphatases in the
negative regulation of cell signaling. Seminars in Immunology 2000; 12 (4) 361-378.
[44] Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of
immune cell function. Seminars in Immunology 2000; 12(4) 349-359.
[45] Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Research
2006; 16(2) 196-202.
[46] Tahk S, Liu B, Chernishof V, Wong KA, Wu H, Shuai K. Control of specificity and
magnitude of NF-κB and STAT1-mediated gene activation through PIASy and PIAS1
cooperation. Proceedings of the National Academy of Sciences United States of
America 2007; 104(28) 11643-11648.
[47] Malemud CJ. Dsyfunctional immune-mediated inflammation in rheumatoid arthritis
dictates that development of anti-rheumatic drugs target multiple intracellular sig‐
naling pathways. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
2011; 10(1) 78-84.
[48] Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among JAK-STAT, Toll-like receptor,
and ITAM-dependent pathways in macrophage activation. Journal of Leukocyte Bi‐
ology 2007; 82(2) 237-243.
[49] Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nature Im‐
munology 2009; 10(4) 340-347.
[50] Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor
Perspectives in Biology 2009; 1(6) e001651.
[51] Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes. Elucidating the
mechanism of STAT-mediated oncogenesis. Cancer Biology & Therapy 2004; 3(11)
1045-1050.
[52] Oh YM, Kim JK, Choi S, Yoo JY. Identification of co-occurring transcription factor
binding sites from DNA sequence using clustered position weight matrices. Nucleic
Acids Research 2012; 40(5) e38.
Drug Discovery398
[53] Snyder M, Huang XY, Zhang JJ. Identification of novel direct Stat3 target genes for
control of growth and differentiation. Journal of Biological Chemistry 2008; 283(7)
3791-3798.
[54] Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene
2000; 19(21) 2638-2644.
[55] Timofeeva OA, Chasovskikh S, Lonskaya I et al. Mechanisms of unphosphorylated
STAT3 transcription factor binding to DNA. Journal of Biological Chemistry 2012;
287(17) 14192-14200.
[56] Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of
transcriptions 1 and 3 as cytokine-inducible proteins. Journal of Interferon & Cyto‐
kine Research 2011; 31(1) 33-40.
[57] Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA se‐
quence recognition suggests a novel DNA-binding domain. Genes & Development
1995; 9(8) 984-994.
[58] Boucheron C, Dumon S, Santos SC et al. A single amino acid in the DNA binding re‐
gions of STAT5A and STAT5B confers distinct DNA binding specificities. Journal of
Biological Chemistry 1998; 273(51) 33936-33941.
[59] Basham B, Sathe M, Grein J et al. In vivo identification of novel STAT5 target genes.
Nucleic Acids Research 2008; 36(11) 3802-3818.
[60] Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction
and transcription activation. Cytokine & Growth Factor Reviews 1999; 10(2) 131-157.
[61] Chang Y, Spicer DB, Sonenshein GE. Effects of IL-3 on promoter usage, attenuation
and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early
pre-B cell line. Oncogene 1991; 6(11) 1979-1982.
[62] Nelson EA, Walker SR, Alvarez JV, Frank DA. Isolation of unique STAT5 targets by
chromatin immunoprecipitation-based gene identification. Journal of Biological
Chemistry 2004; 279(52) 54724-54730.
[63] Ehret GB, Reichenbach P, Schindler U et al. DNA binding specificity of different
STAT proteins. Comparison of in vitro specificity with natural target sites. Journal of
Biological Chemistry 2001; 276(9) 6675-6688.
[64] Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent
and constitutively active cytokine receptors. Journal of Biological Chemistry 2005;
280(14) 13364-13373.
[65] Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of inter‐
leukin-2 complexed with its alpha receptor. Science 2005; 308(5727) 1477-1480.
[66] Kanai A, Suzuki K, Tanimoto K, Mizushima-Sugano J, Suzuki Y, Sugano S. Charac‐
terization of STAT6 target genes in human B cells and lung epithelial cells. DNA Re‐
search 2011; 18(5) 379-392.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
399
[67] Thanos CD, DeLano WL, Wells JA. Hot-spot mimicry of a cytokine receptor by a
small molecule. Proceedings of the National Academy of Sciences of the United
States of America. 2006; 103(42) 15422-15427.
[68] Quaglino P, Bergallo M, Ponti R et al. Th1, Th2, Th17 and regulatory T cell patterns
in psoriatic patients: modulation of cytokines and gene targets induced by etanercept
treatment and correlation with clinical responses. Dermatology 2011; 223(1) 57-67.
[69] Delphin S, Stavnezer J. Characterization of an interleukin 4 (IL-4) responsive region
in the immunoglobulin heavy chain germline epsilon promoter: regulation by NF-
IL-4, a C/EBP family member and NF-kappa B/p50. Journal of Experimental Medi‐
cine 1995; 181(1) 181-192.
[70] Kotanides H, Reich NC. Interleukin-4-induced STAT6 recognizes and activates a tar‐
get site in the promoter of the interleukin-4 receptor gene. Journal of Biological
Chemistry 1996; 271(41) 25555-25561.
[71] Morelli X, Bourgeas R, Roche P. Chemical and structural lessons from recent success‐
es in protein-protein interaction inhibition (2P2I). Current Opinion in Chemical Biol‐
ogy 2011; 15(4) 475-481.
[72] Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cyto‐
kines. Oncogene 2000; 19(21) 2566-2576.
[73] Tsuji-Takayama K, Suzuki M, Yamamoto M et al. The production of IL-10 by human
regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer
in the IL-10 locus. Journal of Immunology 2008; 181(6) 3897-3905.
[74] Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model
for autoimmunity. Immunologic Research 2007; 38(1-3) 112-121.
[75] Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation
of Foxp3 expression in mouse and human Treg is IL-2/STAT dependent: implications
for the NOD STAT5B mutation in diabetes pathogenesis. Annals of the New York
Academy of Sciences 2006; 1079 198-204.
[76] Lai G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood
2009; 114(18) 3727-3735.
[77] Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R. Identifica‐
tion of novel IL-4/STAT6-regulated gene in T lymphocytes. Journal of Immunology
2003; 171(7) 3627-3635.
[78] Lund R, Ahlfors H, Kainonen E, Lahesmaa AM, Dixon C, Lahesmaa R. Identification
of genes involved in the initiation of human Th1 or Th2 cell commitment. European
Journal of Immunology 2005; 35(11) 3307-3319.
[79] Maier E, Hebenstreit D, Posselt G, Hammerl P, Duschl A, Horejs-Hoeck J. Inhibition
of suppressive T cell factor (TCF-1) isoforms in naïve CD4+ T cells is mediated by IL-4/
STAT6 signaling. Journal of Biological Chemistry 2011; 286(2) 919-928.
Drug Discovery400
[80] Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD. Regulation of the T helper cell type
2 (Th2/T regulatory cell (Treg) balance by IL-4 and STAT6. Journal of Leukocyte Biol‐
ogy 2010; 87(6) 1011-1018.
[81] Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000;
19(21) 2577-2584.
[82] Kuhn DJ, Dou QP. The role of interleukin-2 receptor alpha in cancer. Frontiers in Bio‐
science 2005; 10 1462-1474.
[83] Kurreeman FA, Daha NA, Chang M et al. Association of IL2RA and IL2RB with
rheumatoid arthritis: a replication study in a Dutch population. Annals of the Rheu‐
matic Diseases 2009; 68(11) 1789-1790.
[84] Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Current
Opinion in Rheumatology 2010; 22(2) 109-118.
[85] Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. Journal
of Clinical Immunology 2002; 22(2) 51-56.
[86] González-Álvaro I, Domínguez-Jiménez C, Ortiz AM et al. Interleukin-15 and inter‐
feron-γ participate in the cross-talk between natural killer and monocytic cells re‐
quired for tumor necrosis factor production. Arthritis Research & Therapy 2006; 8(4)
R88.
[87] Ernestam S, af Klint E, Catrina AI et al. Synovial expression of IL-15 in rheumatoid
arthritis is not influenced by blockade of tumor necrosis factor. Arthritis Research &
Therapy 2006; 8(1) R18.
[88] Baslund B, Tvede N, Danneskiold-Samsoe B et al. Targeting interleukin-15 in pa‐
tients with rheumatoid arthritis: a proof-of-concept study. Arthritis & Rheumatism
2005; 52(9) 2686-2692.
[89] González-Álvaro I, Ortiz AM, Álvaro-Gracia JM et al. Interleukin-15 levels in serum
may predict a severe disease course in patients with early arthritis. Public Library of
Science One 2011; 6(12) e29492.
[90] Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheuma‐
toid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clinical Ther‐
apy 2012; 34(4) 788-802.e3.
[91] Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the
treatment of rheumatoid arthritis. Clinical Medicine Insights in Arthritis & Muscu‐
loskeletal Disorders 2012; 5 27-42.
[92] Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits the progression of joint damage
in rheumatoid arthritis irrespective of its anti-inflammatory effects: dissociation of
the link between inflammation and destruction. Annals of the Rheumatic Diseases
2012; 71(5) 687-693.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
401
[67] Thanos CD, DeLano WL, Wells JA. Hot-spot mimicry of a cytokine receptor by a
small molecule. Proceedings of the National Academy of Sciences of the United
States of America. 2006; 103(42) 15422-15427.
[68] Quaglino P, Bergallo M, Ponti R et al. Th1, Th2, Th17 and regulatory T cell patterns
in psoriatic patients: modulation of cytokines and gene targets induced by etanercept
treatment and correlation with clinical responses. Dermatology 2011; 223(1) 57-67.
[69] Delphin S, Stavnezer J. Characterization of an interleukin 4 (IL-4) responsive region
in the immunoglobulin heavy chain germline epsilon promoter: regulation by NF-
IL-4, a C/EBP family member and NF-kappa B/p50. Journal of Experimental Medi‐
cine 1995; 181(1) 181-192.
[70] Kotanides H, Reich NC. Interleukin-4-induced STAT6 recognizes and activates a tar‐
get site in the promoter of the interleukin-4 receptor gene. Journal of Biological
Chemistry 1996; 271(41) 25555-25561.
[71] Morelli X, Bourgeas R, Roche P. Chemical and structural lessons from recent success‐
es in protein-protein interaction inhibition (2P2I). Current Opinion in Chemical Biol‐
ogy 2011; 15(4) 475-481.
[72] Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cyto‐
kines. Oncogene 2000; 19(21) 2566-2576.
[73] Tsuji-Takayama K, Suzuki M, Yamamoto M et al. The production of IL-10 by human
regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer
in the IL-10 locus. Journal of Immunology 2008; 181(6) 3897-3905.
[74] Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model
for autoimmunity. Immunologic Research 2007; 38(1-3) 112-121.
[75] Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation
of Foxp3 expression in mouse and human Treg is IL-2/STAT dependent: implications
for the NOD STAT5B mutation in diabetes pathogenesis. Annals of the New York
Academy of Sciences 2006; 1079 198-204.
[76] Lai G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood
2009; 114(18) 3727-3735.
[77] Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R. Identifica‐
tion of novel IL-4/STAT6-regulated gene in T lymphocytes. Journal of Immunology
2003; 171(7) 3627-3635.
[78] Lund R, Ahlfors H, Kainonen E, Lahesmaa AM, Dixon C, Lahesmaa R. Identification
of genes involved in the initiation of human Th1 or Th2 cell commitment. European
Journal of Immunology 2005; 35(11) 3307-3319.
[79] Maier E, Hebenstreit D, Posselt G, Hammerl P, Duschl A, Horejs-Hoeck J. Inhibition
of suppressive T cell factor (TCF-1) isoforms in naïve CD4+ T cells is mediated by IL-4/
STAT6 signaling. Journal of Biological Chemistry 2011; 286(2) 919-928.
Drug Discovery400
[80] Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD. Regulation of the T helper cell type
2 (Th2/T regulatory cell (Treg) balance by IL-4 and STAT6. Journal of Leukocyte Biol‐
ogy 2010; 87(6) 1011-1018.
[81] Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000;
19(21) 2577-2584.
[82] Kuhn DJ, Dou QP. The role of interleukin-2 receptor alpha in cancer. Frontiers in Bio‐
science 2005; 10 1462-1474.
[83] Kurreeman FA, Daha NA, Chang M et al. Association of IL2RA and IL2RB with
rheumatoid arthritis: a replication study in a Dutch population. Annals of the Rheu‐
matic Diseases 2009; 68(11) 1789-1790.
[84] Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Current
Opinion in Rheumatology 2010; 22(2) 109-118.
[85] Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. Journal
of Clinical Immunology 2002; 22(2) 51-56.
[86] González-Álvaro I, Domínguez-Jiménez C, Ortiz AM et al. Interleukin-15 and inter‐
feron-γ participate in the cross-talk between natural killer and monocytic cells re‐
quired for tumor necrosis factor production. Arthritis Research & Therapy 2006; 8(4)
R88.
[87] Ernestam S, af Klint E, Catrina AI et al. Synovial expression of IL-15 in rheumatoid
arthritis is not influenced by blockade of tumor necrosis factor. Arthritis Research &
Therapy 2006; 8(1) R18.
[88] Baslund B, Tvede N, Danneskiold-Samsoe B et al. Targeting interleukin-15 in pa‐
tients with rheumatoid arthritis: a proof-of-concept study. Arthritis & Rheumatism
2005; 52(9) 2686-2692.
[89] González-Álvaro I, Ortiz AM, Álvaro-Gracia JM et al. Interleukin-15 levels in serum
may predict a severe disease course in patients with early arthritis. Public Library of
Science One 2011; 6(12) e29492.
[90] Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheuma‐
toid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clinical Ther‐
apy 2012; 34(4) 788-802.e3.
[91] Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the
treatment of rheumatoid arthritis. Clinical Medicine Insights in Arthritis & Muscu‐
loskeletal Disorders 2012; 5 27-42.
[92] Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits the progression of joint damage
in rheumatoid arthritis irrespective of its anti-inflammatory effects: dissociation of
the link between inflammation and destruction. Annals of the Rheumatic Diseases
2012; 71(5) 687-693.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
401
[93] Jovanovic DV, Di Battista JA, Martel-Pelletier J et al. IL-17 stimulates the production
and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macro‐
phages. Journal of Immunology 1998; 160(7) 3513-3521.
[94] Dragon S, Saffar AS, Shan L, Gounni AS. IL-17 attenuates the anti-apoptotic effects of
GM-CSF in human neutrophils. Molecular Immunology 2008; 45(1) 160-168.
[95] Oh HM, Yu CR, Golestaneh N et al. STAT3 protein promotes T-cell survival and in‐
hibits interleukin-2 production through up-regulation of Class O Forkhead transcrip‐
tion factors. Journal of Biological Chemistry 2011; 286(35) 30888-30897.
[96] Malemud CJ. Apoptosis-resistance in rheumatoid arthritis synovial tissue. Journal of
Clinical & Cellular Immunology 2012; S3-006; doi: 10.4172/21559899.
[97] Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. European Journal of
Immunology 2010; 40(7) 1830-1835.
[98] Samson M, Audia S, Janikashvili N et al. Inhibition of IL-6 function corrects Th17/
Treg imbalance in patients with rheumatoid arthritis. Arthritis & Rheumatism 2012;
64(8) 2499-2503
[99] Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients
with rheumatoid arthritis. Rheumatology International 2012; 32(9) 2731-2736.
[100] O’Brien CA, Manolagas SC. Isolation and characterization of the human gp130 pro‐
moter. Regulation by STATs. Journal of Biological Chemistry 1997; 272(23)
15003-15010.
[101] Malemud CJ. Anticytokine therapy for osteoarthritis. Evidence to date. Drugs & Ag‐
ing 2010; 27(2) 95-115.
[102] Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune
responses by Stat-3 signaling in tumor cells. Nature Medicine 2004; 10(1) 48-54.
[103] Costa-Pereira AP, Bonito NA, Secki MJ. Dysregulation of janus kinases and signal
transducers and activators of transcription in cancer. American Journal of Cancer Re‐
search 2011; 1(6) 806-816.
[104] Sozzani D, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmun‐
ity. Autoimmunity 2010; 43(3) 196-203.
[105] Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: insights into the pathogene‐
sis of inflammatory arthritis? Immunologic Reviews 2010; 233(1) 79-96.
[106] Pramanik R, Jørgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces ex‐
pression of lfi202, an interferon-inducible candidate gene for lupus susceptibility.
Journal of Biological Chemistry 2004; 279(16) 16121-16127.
[107] Christova R, Jones T, Wu PJ et al. P-STAT1 mediates higher-order chromatin remod‐
eling of the human MHC response to IFNγ. Journal of Cell Science 2007; 120(Pt 18)
3262-3270.
Drug Discovery402
[108] Vogl C, Flatt T, Fuhrmann B et al. Transcriptosome analysis reveals a major impact of
JAK protein tyrosine kinase (Tyk2) on the expression of interferon-responsive and
metabolic genes. Biomedical Central Genomics 2010; 11 199.
[109] Noon-Song EN, Ahmed CM, Dabelic R, Canton J, Johnson HM. Controlling nuclear
JAKs and STATs for specific gene activation by IFNγ. Biochemical & Biophysical Re‐
search Communications 2011; 410(3) 648-653.
[110] Tripathi A, Sodhi A. Prolactin-induced production of cytokines in macrophages in
vitro involves JAK/STAT and JNK MAPK pathways. International Immunology
2008; 20(3) 327-336.
[111] David M, Petricoin E III, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement of
MAP kinase (ERK2) activity in interferon α and interferon β-stimulated gene expres‐
sion through STAT proteins. Science 1995; 269(5231) 1721-1723.
[112] Aznar S, Valéron PF, del Rincon SV, Peréz LF, Perona R, Lacal JC. Simultaneous tyro‐
sine and serine phosphorylation of STAT3 transcription factor is involved in Rho A
GTPase oncogenic transformation. Molecular & Cellular Biology 2001; 12(10)
3282-3294.
[113] Gonsky R, Deem RL, Bream J, Young HA, Targan SR. Enhancer role of STAT5 in CD2
activation of IFN-γ gene expression. Journal of Immunology 2004; 173(10) 6241-6247.
[114] Tsuno T, Mejido J, Zhao T, Schmeisser H, Morrow A, Zoon KC. IRF9 is a key factor
for eliciting the antiproliferative activity of IFN-α. Journal of Immunotherapy 2009;
32(8) 803-816.
[115] Kaur S, Uddin S, Platanias LC. The PI3’ kinase pathway in interferon signaling. Jour‐
nal of Interferon & Cytokine Research 2005; 25(12) 780-787.
[116] Kaur S, Sassano A, Dolniak B et al. Role of the Akt pathway in mRNA translation of
interferon-stimulated genes. Proceedings of the National Academy of Sciences of the
United States of America 2008; 105(12) 4808-4813.
[117] Kaur S, Katsoulidis E, Platanias LC. Akt and mRNA translation by interferons. Cell
Cycle 2008; 7(14) 2112-2116.
[118] Hamilton TA, Ohmori Y, Tebo JM, Kishore R. Regulation of macrophage gene ex‐
pression by pro- and anti-inflammatory cytokines. Pathobiology 199l; 67(5-6)
241-244.
[119] Schaefer A, Unterberger C, Frankenberger M et al. Mechanism of interferon-gamma
mediated down-regulation of interleukin-10 gene expression. Molecular Immunolo‐
gy 2009; 46(7) 1351-1359.
[120] Torgerson GR. Regulatory T cells in human autoimmune diseases. Springer Seminars
in Immunopathology 2006; 28(1) 63-76.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
403
[93] Jovanovic DV, Di Battista JA, Martel-Pelletier J et al. IL-17 stimulates the production
and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macro‐
phages. Journal of Immunology 1998; 160(7) 3513-3521.
[94] Dragon S, Saffar AS, Shan L, Gounni AS. IL-17 attenuates the anti-apoptotic effects of
GM-CSF in human neutrophils. Molecular Immunology 2008; 45(1) 160-168.
[95] Oh HM, Yu CR, Golestaneh N et al. STAT3 protein promotes T-cell survival and in‐
hibits interleukin-2 production through up-regulation of Class O Forkhead transcrip‐
tion factors. Journal of Biological Chemistry 2011; 286(35) 30888-30897.
[96] Malemud CJ. Apoptosis-resistance in rheumatoid arthritis synovial tissue. Journal of
Clinical & Cellular Immunology 2012; S3-006; doi: 10.4172/21559899.
[97] Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. European Journal of
Immunology 2010; 40(7) 1830-1835.
[98] Samson M, Audia S, Janikashvili N et al. Inhibition of IL-6 function corrects Th17/
Treg imbalance in patients with rheumatoid arthritis. Arthritis & Rheumatism 2012;
64(8) 2499-2503
[99] Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients
with rheumatoid arthritis. Rheumatology International 2012; 32(9) 2731-2736.
[100] O’Brien CA, Manolagas SC. Isolation and characterization of the human gp130 pro‐
moter. Regulation by STATs. Journal of Biological Chemistry 1997; 272(23)
15003-15010.
[101] Malemud CJ. Anticytokine therapy for osteoarthritis. Evidence to date. Drugs & Ag‐
ing 2010; 27(2) 95-115.
[102] Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune
responses by Stat-3 signaling in tumor cells. Nature Medicine 2004; 10(1) 48-54.
[103] Costa-Pereira AP, Bonito NA, Secki MJ. Dysregulation of janus kinases and signal
transducers and activators of transcription in cancer. American Journal of Cancer Re‐
search 2011; 1(6) 806-816.
[104] Sozzani D, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmun‐
ity. Autoimmunity 2010; 43(3) 196-203.
[105] Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: insights into the pathogene‐
sis of inflammatory arthritis? Immunologic Reviews 2010; 233(1) 79-96.
[106] Pramanik R, Jørgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces ex‐
pression of lfi202, an interferon-inducible candidate gene for lupus susceptibility.
Journal of Biological Chemistry 2004; 279(16) 16121-16127.
[107] Christova R, Jones T, Wu PJ et al. P-STAT1 mediates higher-order chromatin remod‐
eling of the human MHC response to IFNγ. Journal of Cell Science 2007; 120(Pt 18)
3262-3270.
Drug Discovery402
[108] Vogl C, Flatt T, Fuhrmann B et al. Transcriptosome analysis reveals a major impact of
JAK protein tyrosine kinase (Tyk2) on the expression of interferon-responsive and
metabolic genes. Biomedical Central Genomics 2010; 11 199.
[109] Noon-Song EN, Ahmed CM, Dabelic R, Canton J, Johnson HM. Controlling nuclear
JAKs and STATs for specific gene activation by IFNγ. Biochemical & Biophysical Re‐
search Communications 2011; 410(3) 648-653.
[110] Tripathi A, Sodhi A. Prolactin-induced production of cytokines in macrophages in
vitro involves JAK/STAT and JNK MAPK pathways. International Immunology
2008; 20(3) 327-336.
[111] David M, Petricoin E III, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement of
MAP kinase (ERK2) activity in interferon α and interferon β-stimulated gene expres‐
sion through STAT proteins. Science 1995; 269(5231) 1721-1723.
[112] Aznar S, Valéron PF, del Rincon SV, Peréz LF, Perona R, Lacal JC. Simultaneous tyro‐
sine and serine phosphorylation of STAT3 transcription factor is involved in Rho A
GTPase oncogenic transformation. Molecular & Cellular Biology 2001; 12(10)
3282-3294.
[113] Gonsky R, Deem RL, Bream J, Young HA, Targan SR. Enhancer role of STAT5 in CD2
activation of IFN-γ gene expression. Journal of Immunology 2004; 173(10) 6241-6247.
[114] Tsuno T, Mejido J, Zhao T, Schmeisser H, Morrow A, Zoon KC. IRF9 is a key factor
for eliciting the antiproliferative activity of IFN-α. Journal of Immunotherapy 2009;
32(8) 803-816.
[115] Kaur S, Uddin S, Platanias LC. The PI3’ kinase pathway in interferon signaling. Jour‐
nal of Interferon & Cytokine Research 2005; 25(12) 780-787.
[116] Kaur S, Sassano A, Dolniak B et al. Role of the Akt pathway in mRNA translation of
interferon-stimulated genes. Proceedings of the National Academy of Sciences of the
United States of America 2008; 105(12) 4808-4813.
[117] Kaur S, Katsoulidis E, Platanias LC. Akt and mRNA translation by interferons. Cell
Cycle 2008; 7(14) 2112-2116.
[118] Hamilton TA, Ohmori Y, Tebo JM, Kishore R. Regulation of macrophage gene ex‐
pression by pro- and anti-inflammatory cytokines. Pathobiology 199l; 67(5-6)
241-244.
[119] Schaefer A, Unterberger C, Frankenberger M et al. Mechanism of interferon-gamma
mediated down-regulation of interleukin-10 gene expression. Molecular Immunolo‐
gy 2009; 46(7) 1351-1359.
[120] Torgerson GR. Regulatory T cells in human autoimmune diseases. Springer Seminars
in Immunopathology 2006; 28(1) 63-76.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
403
[121] Nandakumar S, Miller CW, Kumaraguru U. T regulatory cells: an overview and in‐
tervention techniques to modulate allergy outcome. Clinical & Molecular Allergy
2009; 12(7) 5.
[122] Hams E, Colmont CS, Dioszeghy V et al. Oncostatin M receptor-β signaling limits
monocyte cell recruitment in acute inflammation. Journal of Immunology 2008;
181(3) 2174-2180.
[123] Mosley B, De Imus C, Friend D et al. Dual oncostatin M (OSM) receptors. Cloning
and characterization of an alternative signaling subunit conferring OSM-specific re‐
ceptor activation. Journal of Biological Chemistry 1996; 271(51) 32635-32643.
[124] Hermanns HM, Radkte S, Schaper F, Heinrich PC, Behrmann I. Non-redundant sig‐
nal transduction of interleukin-6-type cytokines. The adaptor protein Shc is specifi‐
cally recruited to the oncostatin M receptor. Journal of Biological Chemistry 2000;
275(52) 40742-40748.
[125] Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes
STAT3 activation, VEGF production and invasion of osteosarcoma cell lines. Biomed‐
ical Central Cancer 2011; 11 125.
[126] Clarkson RWE, Boland MP, Kritikou EA et al. The genes induced by signal transduc‐
ers and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells
define the roles of these STATs in mammary development. Molecular Endocrinology
2006; 20(3) 675-685.
[127] STAT Gene Regulatory Network. rulai/cshl.edu/TRED/GRN/STAT.htm
[128] Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1
and Th2 responses. Annual Review of Immunology 2001; 19 423-474.
[129] Liew FY, McInnes IB. Role of interleukin 15 and interleukin 18 in inflammatory re‐
sponse. Annals of the Rheumatic Diseases 2002; 61(Suppl 2) ii100-ii102.
[130] McInnes IB, Liew FY, Gracie JA. Interleukin-18: a therapeutic target in rheumatoid
arthritis? Arthritis Research & Therapy 2005; 7(1) 38-41.
[131] Matsui K, Tsutsui H, Nakanishi K. Pathophysiological roles for IL-18 in inflammato‐
ry arthritis. Expert Opinion on Therapeutic Targets 2003; 7(6) 701-724.
[132] Lotito AP, Silva CA, Mello SB. Interleukin-18 in chronic joint diseases. Autoimmuni‐
ty Reviews 2007; 6(4) 253-256.
[133] Gracie JA, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid
arthritis. Journal of Clinical Investigation 1999; 104(10) 1393-1401.
[134] Tanaka M, Harigai M, Kawaguchi Y et al. Mature form of interleukin-18 is expressed
in rheumatoid arthritis synovial tissue and contributes to interferon-gamma produc‐
tion by synovial T-cells. Journal of Rheumatology 2001; 28(8) 1779-1787.
[135] Van Oosterhout M, Levarht EWN, Sont JK, Huizinga TWJ, Toes REM, van Laar JM.
Clinical efficacy of infliximab plus methotrexate in DMARD naïve and DMARD re‐
Drug Discovery404
fractory rheumatoid arthritis is associated with decreased synovial expression of
TNFα and IL-18 but not CXCL12. Annals of the Rheumatic Diseases 2005; 64(4)
537-543.
[136] Petrovic-Rackov I, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α
measurement in rheumatoid arthritis. Clinical Rheumatology 2006; 25(4) 448-452.
[137] Trinchieri G, Scott P. Interleukin-12: a proinflammatory cytokine with immunoregu‐
latory functions. Research in Immunology 1995; 146(7–8) 423–431.
[138] Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Cur‐
rent Topics in Microbiology & Immunology 1999; 238 57–78.
[139] Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-
CSF family. Immunology Today 1992; 13(2) 77–78.
[140] Watford WT, Moriguchi M, Morinobu A, O’Shea JJ. Mini review. The biology of
IL-12: coordinating innate and adaptive immune responses. Cytokine & Growth Fac‐
tor Reviews 2003; 14 361–368.
[141] Yen JH, Kong W, Ganea D. IFN-β inhibits dendritic cell migration through STAT-1-
mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. Jour‐
nal of Immunology 2010; 187(7) 3478-3486.
[142] Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. Modulation of the
IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope
spreading and disease progression in murine autoimmune encephalomyelitis. Jour‐
nal of Neuroimmunology 2000; 111(1-2) 55-63.
[143] Thieu VT, Yu Q, Chang HC et al. Signal transducer and activator of transcription 4 is
required for the transcription factor T-bet to promote T helper 1 cell-fate determina‐
tion. Immunity 2008; 29(5) 679-690.
[144] Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a distant T-bet enhancer
responsive to IL-12/Stat4 and IFNγ/Stat1 signals. Blood 2007; 110(7) 2494-2500.
[145] Forbes E, van Panhuys N, Min B, Le Gros G. Differential requirements for IL-4/
STAT6 signalling in CD4 T-cell fate determination and the Th2-immune effector re‐
sponses. Immunology and Cell Biology 2010; 88(3) 240-243.
[146] Huber M, Steinwald V, Guralnik A et al. IL-27 inhibits the development of regulatory
T cells via STAT3. International Immunology 2008; 20(2) 223-234.
[147] Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regu‐
latory T cells (Treg) in human organ transplantation and autoimmune disease. Clini‐
cal & Experimental Immunology 2007; 148(1) 32-46.
[148] Peck A, Mellins ED. Plasticity of the T-cell phenotype and function: the T helper type
17 example. Immunology 2010; 129(2) 147-153.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
405
[121] Nandakumar S, Miller CW, Kumaraguru U. T regulatory cells: an overview and in‐
tervention techniques to modulate allergy outcome. Clinical & Molecular Allergy
2009; 12(7) 5.
[122] Hams E, Colmont CS, Dioszeghy V et al. Oncostatin M receptor-β signaling limits
monocyte cell recruitment in acute inflammation. Journal of Immunology 2008;
181(3) 2174-2180.
[123] Mosley B, De Imus C, Friend D et al. Dual oncostatin M (OSM) receptors. Cloning
and characterization of an alternative signaling subunit conferring OSM-specific re‐
ceptor activation. Journal of Biological Chemistry 1996; 271(51) 32635-32643.
[124] Hermanns HM, Radkte S, Schaper F, Heinrich PC, Behrmann I. Non-redundant sig‐
nal transduction of interleukin-6-type cytokines. The adaptor protein Shc is specifi‐
cally recruited to the oncostatin M receptor. Journal of Biological Chemistry 2000;
275(52) 40742-40748.
[125] Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes
STAT3 activation, VEGF production and invasion of osteosarcoma cell lines. Biomed‐
ical Central Cancer 2011; 11 125.
[126] Clarkson RWE, Boland MP, Kritikou EA et al. The genes induced by signal transduc‐
ers and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells
define the roles of these STATs in mammary development. Molecular Endocrinology
2006; 20(3) 675-685.
[127] STAT Gene Regulatory Network. rulai/cshl.edu/TRED/GRN/STAT.htm
[128] Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1
and Th2 responses. Annual Review of Immunology 2001; 19 423-474.
[129] Liew FY, McInnes IB. Role of interleukin 15 and interleukin 18 in inflammatory re‐
sponse. Annals of the Rheumatic Diseases 2002; 61(Suppl 2) ii100-ii102.
[130] McInnes IB, Liew FY, Gracie JA. Interleukin-18: a therapeutic target in rheumatoid
arthritis? Arthritis Research & Therapy 2005; 7(1) 38-41.
[131] Matsui K, Tsutsui H, Nakanishi K. Pathophysiological roles for IL-18 in inflammato‐
ry arthritis. Expert Opinion on Therapeutic Targets 2003; 7(6) 701-724.
[132] Lotito AP, Silva CA, Mello SB. Interleukin-18 in chronic joint diseases. Autoimmuni‐
ty Reviews 2007; 6(4) 253-256.
[133] Gracie JA, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid
arthritis. Journal of Clinical Investigation 1999; 104(10) 1393-1401.
[134] Tanaka M, Harigai M, Kawaguchi Y et al. Mature form of interleukin-18 is expressed
in rheumatoid arthritis synovial tissue and contributes to interferon-gamma produc‐
tion by synovial T-cells. Journal of Rheumatology 2001; 28(8) 1779-1787.
[135] Van Oosterhout M, Levarht EWN, Sont JK, Huizinga TWJ, Toes REM, van Laar JM.
Clinical efficacy of infliximab plus methotrexate in DMARD naïve and DMARD re‐
Drug Discovery404
fractory rheumatoid arthritis is associated with decreased synovial expression of
TNFα and IL-18 but not CXCL12. Annals of the Rheumatic Diseases 2005; 64(4)
537-543.
[136] Petrovic-Rackov I, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α
measurement in rheumatoid arthritis. Clinical Rheumatology 2006; 25(4) 448-452.
[137] Trinchieri G, Scott P. Interleukin-12: a proinflammatory cytokine with immunoregu‐
latory functions. Research in Immunology 1995; 146(7–8) 423–431.
[138] Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Cur‐
rent Topics in Microbiology & Immunology 1999; 238 57–78.
[139] Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-
CSF family. Immunology Today 1992; 13(2) 77–78.
[140] Watford WT, Moriguchi M, Morinobu A, O’Shea JJ. Mini review. The biology of
IL-12: coordinating innate and adaptive immune responses. Cytokine & Growth Fac‐
tor Reviews 2003; 14 361–368.
[141] Yen JH, Kong W, Ganea D. IFN-β inhibits dendritic cell migration through STAT-1-
mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. Jour‐
nal of Immunology 2010; 187(7) 3478-3486.
[142] Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. Modulation of the
IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope
spreading and disease progression in murine autoimmune encephalomyelitis. Jour‐
nal of Neuroimmunology 2000; 111(1-2) 55-63.
[143] Thieu VT, Yu Q, Chang HC et al. Signal transducer and activator of transcription 4 is
required for the transcription factor T-bet to promote T helper 1 cell-fate determina‐
tion. Immunity 2008; 29(5) 679-690.
[144] Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a distant T-bet enhancer
responsive to IL-12/Stat4 and IFNγ/Stat1 signals. Blood 2007; 110(7) 2494-2500.
[145] Forbes E, van Panhuys N, Min B, Le Gros G. Differential requirements for IL-4/
STAT6 signalling in CD4 T-cell fate determination and the Th2-immune effector re‐
sponses. Immunology and Cell Biology 2010; 88(3) 240-243.
[146] Huber M, Steinwald V, Guralnik A et al. IL-27 inhibits the development of regulatory
T cells via STAT3. International Immunology 2008; 20(2) 223-234.
[147] Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regu‐
latory T cells (Treg) in human organ transplantation and autoimmune disease. Clini‐
cal & Experimental Immunology 2007; 148(1) 32-46.
[148] Peck A, Mellins ED. Plasticity of the T-cell phenotype and function: the T helper type
17 example. Immunology 2010; 129(2) 147-153.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
405
[149] Chen Z, O’Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immuno‐
logic Research 2008; 41(2) 87-102.
[150] Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated
regulation of Th1 and Th2 cell differentiation. International Immunology 2011; 23(7)
415-420.
[151] Habib T, Senadheera S, Weinberg K, Kaushansky K. The common γ chain (γc) is a
required signaling component of the IL-21 receptor and supports IL-21-induced cell
proliferation via JAK3. Biochemistry 2002; 41(27) 8725-8731.
[152] Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immuno‐
logic Reviews 2004; 202 84-95.
[153] Ma J, Ma D, Ji C. The role of IL-21 in hematological malignancies. Cytokine 2011;
56(2) 133-139.
[154] Collins M, Whitters MJ, Young DA. IL-21 and IL-21 receptor: a new cytokine path‐
way modulates innate and adaptive immunity. Immunologic Reviews 2003; 28(2)
131-140.
[155] Sonderegger I, Kisielow J, Meier R, King C, Kopf M. IL-21 and IL-21R are not re‐
quired for development of Th17 cells and autoimmunity in vivo. European Journal of
Immunology 2008; 3897 1833-1838.
[156] Coquet JM, Chakravarti S, Smyth MJ, Godfrey DI. Cutting edge: IL-21 is not essential
for Th17 differentiation or experimental autoimmune encephalomyelitis. Journal of
Immunology 2008; 180(11) 7097-7101.
[157] Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleu‐
kin-21 signaling: functions in cancer and autoimmunity. Clinical Cancer Research
2007; 13(23) 6926-6932.
[158] Young DA, Hegen M, Ma HL et al. Blockade of the interleukin-21/interleukin-21 re‐
ceptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthri‐
tis & Rheumatism 2007; 56(4) 1152-1163.
[159] Yuan FL, Hu W, Lu WG et al. Targeting interleukin-21 in rheumatoid arthritis. Mo‐
lecular Biology Reports 2011; 38(3) 1717-1721.
[160] Wooley PA. What animal models are best to test novel rheumatoid arthritis thera‐
pies? Current Rheumatology Reviews 2008; 4(4) 277-287.
[161] Dumoutier L, Louahed J, and Renauld JC. Cloning and characterization of IL-10-re‐
lated T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to
IL-10 and inducible by IL-9. Journal of Immunology 2000; 164(4) 1814-1819.
[162] Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identifica‐
tion and role in epidermal function. Cell 2001; 104(1) 9-19.
Drug Discovery406
[163] Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. International Immunolo‐
gy 2011 23(3) 159-163.
[164] Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II
cytokines that share the IL-10 receptor-2 (IL-10R2) chain. Journal of Leukocyte Biolo‐
gy 2004; 76(2) 314-321.
[165] Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19,
IL-20, IL-22, IL-24, IL-26, IL-28 and IL-29. Journal of Allergy & Clinical immunology
2008; 121(5) 1108-1111.
[166] Trivella DB, Ferreira-Júnior JR, Dumoutier L, Renauld JC, Polikarpov I. Structure and
function of interleukin-22 and other members of the interleukin-10 family. Cellular &
Molecular Life Sciences 2010; 67(17) 2909-2935.
[167] Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy – review of a new approach.
Pharmacological Reviews 2003; 55(2) 241-269.
[168] Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with
importance in inflammatory diseases. Expert Opinion on Therapeutic Targets 2007;
11(5) 601-612.
[169] Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: Immune cells as sources and
targets of the IL-10 family members. Journal of Immunology 2002; 168(11) 5397-5402.
[170] Parrish-Novak J, Xu W, Brender T et al. Interleukins 19, 20, and 24 signal through
two distinct receptor complexes. Differences in receptor-ligand interactions mediate
unique biological functions. Journal of Biological Chemistry 2002; 277(49)
47517-47523.
[171] Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT
activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.
Journal of Immunology 2001; 167(7) 3545-3549.
[172] Kunz S, Wolk K, Witte E et al. Interleukin (IL)-19, IL-20 and IL-24 are produced and
act on keratinocytes and are distinct from classical ILs. Experimental Dermatology
2006; 15(12) 991-1004.
[173] Zdanov A. Structural features of the interleukin-10 family of cytokines. Current
Pharmaceutical Design 2004; 10(31) 3873-3884.
[174] Sakurai N, Kuroiwa T, Ikeuchi H et al. Expression of IL-19 and its receptors in RA:
potential role for synovial hyperplasia formation. Rheumatology (Oxford) 2008; 47(6)
815-820.
[175] Alanärä T, Karstila A, Moilanen T, Silvennoinen O, Isomäki P. Expression of IL-10
family cytokines in rheumatoid arthritis: elevated levels of IL-19 in joints. Scandina‐
vian Journal of Rheumatology 2010; 39(2) 118-126.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
407
[149] Chen Z, O’Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immuno‐
logic Research 2008; 41(2) 87-102.
[150] Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated
regulation of Th1 and Th2 cell differentiation. International Immunology 2011; 23(7)
415-420.
[151] Habib T, Senadheera S, Weinberg K, Kaushansky K. The common γ chain (γc) is a
required signaling component of the IL-21 receptor and supports IL-21-induced cell
proliferation via JAK3. Biochemistry 2002; 41(27) 8725-8731.
[152] Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immuno‐
logic Reviews 2004; 202 84-95.
[153] Ma J, Ma D, Ji C. The role of IL-21 in hematological malignancies. Cytokine 2011;
56(2) 133-139.
[154] Collins M, Whitters MJ, Young DA. IL-21 and IL-21 receptor: a new cytokine path‐
way modulates innate and adaptive immunity. Immunologic Reviews 2003; 28(2)
131-140.
[155] Sonderegger I, Kisielow J, Meier R, King C, Kopf M. IL-21 and IL-21R are not re‐
quired for development of Th17 cells and autoimmunity in vivo. European Journal of
Immunology 2008; 3897 1833-1838.
[156] Coquet JM, Chakravarti S, Smyth MJ, Godfrey DI. Cutting edge: IL-21 is not essential
for Th17 differentiation or experimental autoimmune encephalomyelitis. Journal of
Immunology 2008; 180(11) 7097-7101.
[157] Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleu‐
kin-21 signaling: functions in cancer and autoimmunity. Clinical Cancer Research
2007; 13(23) 6926-6932.
[158] Young DA, Hegen M, Ma HL et al. Blockade of the interleukin-21/interleukin-21 re‐
ceptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthri‐
tis & Rheumatism 2007; 56(4) 1152-1163.
[159] Yuan FL, Hu W, Lu WG et al. Targeting interleukin-21 in rheumatoid arthritis. Mo‐
lecular Biology Reports 2011; 38(3) 1717-1721.
[160] Wooley PA. What animal models are best to test novel rheumatoid arthritis thera‐
pies? Current Rheumatology Reviews 2008; 4(4) 277-287.
[161] Dumoutier L, Louahed J, and Renauld JC. Cloning and characterization of IL-10-re‐
lated T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to
IL-10 and inducible by IL-9. Journal of Immunology 2000; 164(4) 1814-1819.
[162] Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identifica‐
tion and role in epidermal function. Cell 2001; 104(1) 9-19.
Drug Discovery406
[163] Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. International Immunolo‐
gy 2011 23(3) 159-163.
[164] Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II
cytokines that share the IL-10 receptor-2 (IL-10R2) chain. Journal of Leukocyte Biolo‐
gy 2004; 76(2) 314-321.
[165] Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19,
IL-20, IL-22, IL-24, IL-26, IL-28 and IL-29. Journal of Allergy & Clinical immunology
2008; 121(5) 1108-1111.
[166] Trivella DB, Ferreira-Júnior JR, Dumoutier L, Renauld JC, Polikarpov I. Structure and
function of interleukin-22 and other members of the interleukin-10 family. Cellular &
Molecular Life Sciences 2010; 67(17) 2909-2935.
[167] Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy – review of a new approach.
Pharmacological Reviews 2003; 55(2) 241-269.
[168] Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with
importance in inflammatory diseases. Expert Opinion on Therapeutic Targets 2007;
11(5) 601-612.
[169] Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: Immune cells as sources and
targets of the IL-10 family members. Journal of Immunology 2002; 168(11) 5397-5402.
[170] Parrish-Novak J, Xu W, Brender T et al. Interleukins 19, 20, and 24 signal through
two distinct receptor complexes. Differences in receptor-ligand interactions mediate
unique biological functions. Journal of Biological Chemistry 2002; 277(49)
47517-47523.
[171] Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT
activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.
Journal of Immunology 2001; 167(7) 3545-3549.
[172] Kunz S, Wolk K, Witte E et al. Interleukin (IL)-19, IL-20 and IL-24 are produced and
act on keratinocytes and are distinct from classical ILs. Experimental Dermatology
2006; 15(12) 991-1004.
[173] Zdanov A. Structural features of the interleukin-10 family of cytokines. Current
Pharmaceutical Design 2004; 10(31) 3873-3884.
[174] Sakurai N, Kuroiwa T, Ikeuchi H et al. Expression of IL-19 and its receptors in RA:
potential role for synovial hyperplasia formation. Rheumatology (Oxford) 2008; 47(6)
815-820.
[175] Alanärä T, Karstila A, Moilanen T, Silvennoinen O, Isomäki P. Expression of IL-10
family cytokines in rheumatoid arthritis: elevated levels of IL-19 in joints. Scandina‐
vian Journal of Rheumatology 2010; 39(2) 118-126.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
407
[176] Malemud CJ. MAP kinases. In: OA, Inflammation and Degradation: A Continuum:
Biomedical and Health Research - Vol 70. Buckwalter J, Lotz M, Stoltz J-F. (eds). Am‐
sterdam: IOS Press; 2007. p 99-117.
[177] Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced
arthritis in rats. Rheumatology (Oxford) 2012; 51(3) 434-442.
[178] Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets
for autoimmune diseases. Expert Opinion on Therapeutic Targets 2011; 15(2) 119-126.
[179] Wahl C, Müller W, Leithäuser F et al. IL-20 receptor signaling down-regulates anti‐
gen-specific T cell responses. Journal of Immunology 2009; 182(2) 802-810.
[180] Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for ex‐
perimental arthritis. Arthritis & Rheumatism 2010; 62(11) 3311-3321.
[181] Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS. Anti-IL-20 monoclonal
antibody inhibits the differentiation of osteoclasts and protects against osteoporotic
bone loss. Journal of Experimental Medicine 2011; 208(9) 1849-1861.
[182] Kragstrup TW, Otkjaer K, Holm C et al. The expression of IL-20 and IL-24 and their
shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cy‐
tokine 2008; 41(1) 16-23.
[183] Kotenko SV, Izotova LS, Mirochnitchenko OV et al. Identification of the functional
Interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rβ) is a common
chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-
TIF) receptor complexes. Journal of Biological Chemistry 2001; 276(4) 2725-2732.
[184] Xie MH, Aggarwal S, Ho WH et al. Interleukin (IL)-22, a novel human cytokine that
signals through the interferon receptor-related proteins CRF2-4 and IL-22R. Journal
of Biological Chemistry 2000; 275(40) 31335-31339.
[185] Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas
are a target of interleukin-22. Journal of Interferon & Cytokine Research 2001; 21(12)
1047-1053.
[186] Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn’s disease and pro‐
motes proinflammatory gene expression and intestinal cell migration. American
Journal of Physiology-Gastrointestinal and Liver Physiology 2006; 290(4) G827-
G-838.
[187] Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. In‐
terleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase path‐
ways in a rat hepatoma cell line. Pathways that shared with and distinct from IL-10.
Journal of Biological Chemistry 2002; 277(37) 33676-33682.
[188] Ikeuchi H, Kuroiwa T, Hiramatsu N et al. Expression of interleukin-22 in rheumatoid
arthritis. Potential role as a proinflammatory cytokine. Arthritis & Rheumatism 2005;
52(4) 1037-1046.
Drug Discovery408
[189] Leipe J, Schramm MA, Grunke M et al. Interleukin 22 serum levels are associated
with radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Dis‐
eases 2011; 70(8) 1453-1457.
[190] da Rocha LF Jr, Duarte AL, Dantas AT et al. Increased serum interleukin-22 in pa‐
tients with rheumatoid arthritis and correlation with disease activity. Journal of
Rheumatology 2012; 39(7) 1320-1325.
[191] Zhang L, Li JM, Liu XG et al. Elevated Th22 cells correlated with Th17 cells in pa‐
tients with rheumatoid arthritis. Journal of Clinical Immunology 2011; 31(4) 606-614.
[192] Lécart S, Morel F, Noraz N et al. IL-22, in contrast to IL-10, does not induce Ig pro‐
duction, due to absence of a functional IL-22 receptor on activated human B cells. In‐
ternational Immunology 2002; 14(11) 1351-1356.
[193] Gopalkrishnan RV, Sauane M, Fisher PB. Cytokine and tumor cell apoptosis induc‐
ing activity of mda-7/IL-24. International Immunopharmacology 2004; 4(5) 635-647.
[194] Dent P, Yacoub A, Hamed HA et al. The development of MDA-7/IL-24 as a cancer
therapeutic. Pharmacology & Therapeutics 2010; 128(2) 375-384.
[195] Dent P, Yacoub A, Hamed A et al. MDA-7/IL-24 as a cancer therapeutic: from bench
to bedside. Anticancer Drugs 2010; 21(8) 725-731.
[196] Dash R, Bhutia SK, Azab B et al. mda-7/IL-24: a unique member of the IL-10 gene
family promoting cancer-targeted toxicity. Cytokine & Growth Factor Reviews 2010;
21(5) 381-391.
[197] Sahoo A, Sim SH. Molecular mechanism governing IL-24 gene expression. Immune
Network 2012; 12(1) 1-7.
[198] Sahoo A, Lee CG, Jash A et al. Stat6 and c-Jun mediate Th2 cell-specific IL-24 gene
expression. Journal of Immunology 2011; 186(7) 4098-4109.
[199] Yen JJ, Yang-Yen HF. Transcription factors mediating interleukin-3 survival signals.
Vitamins & Hormones 2006; 74 147-163.
[200] Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A. Suppression of interleu‐
kin-3-induced gene expression by a c-terminal Stat5. European Molecular Biology
Organization Journal 1996; 15(10) 2425-2433.
[201] Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activates STATs dur‐
ing IL-3-induced myeloid cell proliferation. Oncogene 1998; 16(13) 1749-1758.
[202] Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinas‐
es, JAKs and STATs: a covert liaison unveiled. Oncogene 2000; 19(21) 2532-2547.
[203] Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ. Mast cell homeostasis
and the JAK-STAT pathway. Genes & Immunity 2010; 11(8) 599-608.
[204] Cavanagh LL, Boyce A, Smith L et al. Rheumatoid arthritis synovium contains plas‐
macytoid dendritic cells. Arthritis Research & Therapy 2005; 7(2) R230-R240.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
409
[176] Malemud CJ. MAP kinases. In: OA, Inflammation and Degradation: A Continuum:
Biomedical and Health Research - Vol 70. Buckwalter J, Lotz M, Stoltz J-F. (eds). Am‐
sterdam: IOS Press; 2007. p 99-117.
[177] Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced
arthritis in rats. Rheumatology (Oxford) 2012; 51(3) 434-442.
[178] Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets
for autoimmune diseases. Expert Opinion on Therapeutic Targets 2011; 15(2) 119-126.
[179] Wahl C, Müller W, Leithäuser F et al. IL-20 receptor signaling down-regulates anti‐
gen-specific T cell responses. Journal of Immunology 2009; 182(2) 802-810.
[180] Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for ex‐
perimental arthritis. Arthritis & Rheumatism 2010; 62(11) 3311-3321.
[181] Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS. Anti-IL-20 monoclonal
antibody inhibits the differentiation of osteoclasts and protects against osteoporotic
bone loss. Journal of Experimental Medicine 2011; 208(9) 1849-1861.
[182] Kragstrup TW, Otkjaer K, Holm C et al. The expression of IL-20 and IL-24 and their
shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cy‐
tokine 2008; 41(1) 16-23.
[183] Kotenko SV, Izotova LS, Mirochnitchenko OV et al. Identification of the functional
Interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rβ) is a common
chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-
TIF) receptor complexes. Journal of Biological Chemistry 2001; 276(4) 2725-2732.
[184] Xie MH, Aggarwal S, Ho WH et al. Interleukin (IL)-22, a novel human cytokine that
signals through the interferon receptor-related proteins CRF2-4 and IL-22R. Journal
of Biological Chemistry 2000; 275(40) 31335-31339.
[185] Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas
are a target of interleukin-22. Journal of Interferon & Cytokine Research 2001; 21(12)
1047-1053.
[186] Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn’s disease and pro‐
motes proinflammatory gene expression and intestinal cell migration. American
Journal of Physiology-Gastrointestinal and Liver Physiology 2006; 290(4) G827-
G-838.
[187] Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. In‐
terleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase path‐
ways in a rat hepatoma cell line. Pathways that shared with and distinct from IL-10.
Journal of Biological Chemistry 2002; 277(37) 33676-33682.
[188] Ikeuchi H, Kuroiwa T, Hiramatsu N et al. Expression of interleukin-22 in rheumatoid
arthritis. Potential role as a proinflammatory cytokine. Arthritis & Rheumatism 2005;
52(4) 1037-1046.
Drug Discovery408
[189] Leipe J, Schramm MA, Grunke M et al. Interleukin 22 serum levels are associated
with radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Dis‐
eases 2011; 70(8) 1453-1457.
[190] da Rocha LF Jr, Duarte AL, Dantas AT et al. Increased serum interleukin-22 in pa‐
tients with rheumatoid arthritis and correlation with disease activity. Journal of
Rheumatology 2012; 39(7) 1320-1325.
[191] Zhang L, Li JM, Liu XG et al. Elevated Th22 cells correlated with Th17 cells in pa‐
tients with rheumatoid arthritis. Journal of Clinical Immunology 2011; 31(4) 606-614.
[192] Lécart S, Morel F, Noraz N et al. IL-22, in contrast to IL-10, does not induce Ig pro‐
duction, due to absence of a functional IL-22 receptor on activated human B cells. In‐
ternational Immunology 2002; 14(11) 1351-1356.
[193] Gopalkrishnan RV, Sauane M, Fisher PB. Cytokine and tumor cell apoptosis induc‐
ing activity of mda-7/IL-24. International Immunopharmacology 2004; 4(5) 635-647.
[194] Dent P, Yacoub A, Hamed HA et al. The development of MDA-7/IL-24 as a cancer
therapeutic. Pharmacology & Therapeutics 2010; 128(2) 375-384.
[195] Dent P, Yacoub A, Hamed A et al. MDA-7/IL-24 as a cancer therapeutic: from bench
to bedside. Anticancer Drugs 2010; 21(8) 725-731.
[196] Dash R, Bhutia SK, Azab B et al. mda-7/IL-24: a unique member of the IL-10 gene
family promoting cancer-targeted toxicity. Cytokine & Growth Factor Reviews 2010;
21(5) 381-391.
[197] Sahoo A, Sim SH. Molecular mechanism governing IL-24 gene expression. Immune
Network 2012; 12(1) 1-7.
[198] Sahoo A, Lee CG, Jash A et al. Stat6 and c-Jun mediate Th2 cell-specific IL-24 gene
expression. Journal of Immunology 2011; 186(7) 4098-4109.
[199] Yen JJ, Yang-Yen HF. Transcription factors mediating interleukin-3 survival signals.
Vitamins & Hormones 2006; 74 147-163.
[200] Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A. Suppression of interleu‐
kin-3-induced gene expression by a c-terminal Stat5. European Molecular Biology
Organization Journal 1996; 15(10) 2425-2433.
[201] Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activates STATs dur‐
ing IL-3-induced myeloid cell proliferation. Oncogene 1998; 16(13) 1749-1758.
[202] Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinas‐
es, JAKs and STATs: a covert liaison unveiled. Oncogene 2000; 19(21) 2532-2547.
[203] Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ. Mast cell homeostasis
and the JAK-STAT pathway. Genes & Immunity 2010; 11(8) 599-608.
[204] Cavanagh LL, Boyce A, Smith L et al. Rheumatoid arthritis synovium contains plas‐
macytoid dendritic cells. Arthritis Research & Therapy 2005; 7(2) R230-R240.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
409
[205] Barton BE, Mayer R. IL-3 induces differentiation of bone marrow precursor cells to
osteoclast-like cells. Journal of Immunology 1989; 143(10) 3211-3216.
[206] Gupta N, Barhanpurkar AP, Tomar GB et al. IL-3 inhibits human osteoclastogenesis
and bone resorption through downregulation of c-Fms and diverts the cells to den‐
dritic cell lineage. Journal of Immunology 2010; 185(4) 2261-2272.
[207] Srivastava RK, Tomar GB, Barhanpurkar AP et al. IL-3 attenuates collagen-induced
arthritis by modulating the development of Foxp3+ regulatory T cells. Journal of Im‐
munology 2011; 186(4) 2262-2267.
[208] Khaled AR, Durum SK. Death and Baxes: mechanism of lymphotropic cytokines. Im‐
munologic Review 2003; 193 48-57.
[209] Malemud CJ. The discovery of novel experimental therapies for inflammatory arthri‐
tis. Mediators of Inflammation doi: 10.1155/2009/698769.
[210] Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: Biology and roles in T-cell im‐
munity in health and disease. Critical Reviews in Immunology 2008; 28(4) 325-339.
[211] van Roon JA, Hartgring SA, Wenting van Wijk M. Persistence of interleukin-7 activi‐
ty and levels on tumour necrosis factor α blockade in patients with rheumatoid ar‐
thritis. Annals of the Rheumatic Diseases 2007; 66(5) 664-669.
[212] Hartgring SA, van Roon JA, Wenting van Wijk M. Elevated expression of interleu‐
kin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation
in rheumatoid arthritis. Arthritis & Rheumatism 2009; 60(9) 2595-2605.
[213] Yammani RR, Long D, Loeser RF. Interleukin-7 stimulates secretion of S100A4 by ac‐
tivating the JAK/STAT signaling pathway in human articular chondrocytes. Arthritis
& Rheumatism 2009; 60(3) 792-800.
[214] Senolt L, Grigorian M, Lukanidin E et al. S100A4 is expressed at site of invasion in
rheumatoid arthritis synovium and modulates production of matrix metalloprotei‐
nases. Annals of the Rheumatic Diseases 2006; 65(12) 1645-1648.
[215] Grigorian M, Andresen S, Tulchinsky E et al. Tumor suppressor p53 protein is a new
target for the metastasis-associated Mts1/S100A4 protein. Functional consequences of
their interaction. Journal of Biological Chemistry 2001; 276(25) 22699-22708.
[216] Senolt L, Grigorian M, Lukanidin E et al. S100A4 (Mts1): Is there any relation to the
pathogenesis of rheumatoid arthritis? Autoimmune Reviews 2006; 5(2) 129-131.
[217] Jüngel A, Ospelt C, Lesch M et al. Effect of oral application of a highly selective
MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Annals of
the Rheumatic Diseases 2010; 69(5) 898-902.
[218] Fleischmann R, Cutolo M, Genovese MC et al. Phase IIB dose-ranging study of the
oral JAK inhibitor tofacitinib (CP650,550) or adalimumab monotherapy versus place‐
bo in patients with active rheumatoid arthritis with an inadequate response to
DMARDs. Arthritis & Rheumatism 2012; 64(3) 617-629.
Drug Discovery410
[219] Shirakawa T, Kawazoe Y, Tsujikawa T, Jung D, Sato S, Uesugi M. Deactivation of
STAT6 through serine 707 phosphorylation by JNK. Journal of Biological Chemistry
2011; 286(5) 4003-4010.
[220] Klinman DM, Tross D, Klaschik S, Shirota H, Sato T. Therapeutic applications and
mechanisms underlying the activity of immunosuppressive oligonucleotides. Annals
of the New York Academy of Sciences 2009; 1175 80-88.
[221] Lührmann A, Tschernig T, von der Leyen H, Hecker M, Pabst R, Wagner AH. Decoy
oligodeoxynucleotides against STAT transcription factors decrease allergic inflam‐
mation in a rat asthma model. Experimental Lung Research 2010; 36(2) 85-93.
[222] Hückel M, Schurigt U, Wagner AH et al. Attenuation of murine antigen-induced ar‐
thritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer
and activator of transcription-1 (STAT-1). Arthritis Research & Therapy 2006; 8(1)
R17.
[223] Feely MG, Erickson A, O’Dell JR. Therapeutic options for rheumatoid arthritis. Ex‐
pert Opinion on Pharmacotherapy 2009; 10(13) 2095-2106.
[224] Malemud CJ. Inhibitors of JAK for the treatment of rheumatoid arthritis: rationale
and clinical data. Clinical Investigation 2012; 2(1) 39-47.
[225] Malemud CJ. Molecular mechanisms in rheumatic diseases: rationale for novel drug
development – Introduction. Anti-Inflammatory & Anti-Allergy Agents in Medicinal
Chemistry 2011; 10 73-77.
Suppression of Pro-Inflammatory Cytokines via Targeting of STAT-Responsive Genes
http://dx.doi.org/10.5772/52506
411
[205] Barton BE, Mayer R. IL-3 induces differentiation of bone marrow precursor cells to
osteoclast-like cells. Journal of Immunology 1989; 143(10) 3211-3216.
[206] Gupta N, Barhanpurkar AP, Tomar GB et al. IL-3 inhibits human osteoclastogenesis
and bone resorption through downregulation of c-Fms and diverts the cells to den‐
dritic cell lineage. Journal of Immunology 2010; 185(4) 2261-2272.
[207] Srivastava RK, Tomar GB, Barhanpurkar AP et al. IL-3 attenuates collagen-induced
arthritis by modulating the development of Foxp3+ regulatory T cells. Journal of Im‐
munology 2011; 186(4) 2262-2267.
[208] Khaled AR, Durum SK. Death and Baxes: mechanism of lymphotropic cytokines. Im‐
munologic Review 2003; 193 48-57.
[209] Malemud CJ. The discovery of novel experimental therapies for inflammatory arthri‐
tis. Mediators of Inflammation doi: 10.1155/2009/698769.
[210] Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: Biology and roles in T-cell im‐
munity in health and disease. Critical Reviews in Immunology 2008; 28(4) 325-339.
[211] van Roon JA, Hartgring SA, Wenting van Wijk M. Persistence of interleukin-7 activi‐
ty and levels on tumour necrosis factor α blockade in patients with rheumatoid ar‐
thritis. Annals of the Rheumatic Diseases 2007; 66(5) 664-669.
[212] Hartgring SA, van Roon JA, Wenting van Wijk M. Elevated expression of interleu‐
kin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation
in rheumatoid arthritis. Arthritis & Rheumatism 2009; 60(9) 2595-2605.
[213] Yammani RR, Long D, Loeser RF. Interleukin-7 stimulates secretion of S100A4 by ac‐
tivating the JAK/STAT signaling pathway in human articular chondrocytes. Arthritis
& Rheumatism 2009; 60(3) 792-800.
[214] Senolt L, Grigorian M, Lukanidin E et al. S100A4 is expressed at site of invasion in
rheumatoid arthritis synovium and modulates production of matrix metalloprotei‐
nases. Annals of the Rheumatic Diseases 2006; 65(12) 1645-1648.
[215] Grigorian M, Andresen S, Tulchinsky E et al. Tumor suppressor p53 protein is a new
target for the metastasis-associated Mts1/S100A4 protein. Functional consequences of
their interaction. Journal of Biological Chemistry 2001; 276(25) 22699-22708.
[216] Senolt L, Grigorian M, Lukanidin E et al. S100A4 (Mts1): Is there any relation to the
pathogenesis of rheumatoid arthritis? Autoimmune Reviews 2006; 5(2) 129-131.
[217] Jüngel A, Ospelt C, Lesch M et al. Effect of oral application of a highly selective
MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Annals of
the Rheumatic Diseases 2010; 69(5) 898-902.
[218] Fleischmann R, Cutolo M, Genovese MC et al. Phase IIB dose-ranging study of the
oral JAK inhibitor tofacitinib (CP650,550) or adalimumab monotherapy versus place‐
bo in patients with active rheumatoid arthritis with an inadequate response to
DMARDs. Arthritis & Rheumatism 2012; 64(3) 617-629.
Drug Discovery410
[219] Shirakawa T, Kawazoe Y, Tsujikawa T, Jung D, Sato S, Uesugi M. Deactivation of
STAT6 through serine 707 phosphorylation by JNK. Journal of Biological Chemistry
2011; 286(5) 4003-4010.
[220] Klinman DM, Tross D, Klaschik S, Shirota H, Sato T. Therapeutic applications and
mechanisms underlying the activity of immunosuppressive oligonucleotides. Annals
of the New York Academy of Sciences 2009; 1175 80-88.
[221] Lührmann A, Tschernig T, von der Leyen H, Hecker M, Pabst R, Wagner AH. Decoy
oligodeoxynucleotides against STAT transcription factors decrease allergic inflam‐
mation in a rat asthma model. Experimental Lung Research 2010; 36(2) 85-93.
[222] Hückel M, Schurigt U, Wagner AH et al. Attenuation of murine antigen-induced ar‐
thritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer
and activator of transcription-1 (STAT-1). Arthritis Research & Therapy 2006; 8(1)
R17.
[223] Feely MG, Erickson A, O’Dell JR. Therapeutic options for rheumatoid arthritis. Ex‐
pert Opinion on Pharmacotherapy 2009; 10(13) 2095-2106.
[224] Malemud CJ. Inhibitors of JAK for the treatment of rheumatoid arthritis: rationale
and clinical data. Clinical Investigation 2012; 2(1) 39-47.
[225] Malemud CJ. Molecular mechanisms in rheumatic diseases: rationale for novel drug
development – Introduction. Anti-Inflammatory & Anti-Allergy Agents in Medicinal
Chemistry 2011; 10 73-77.




Coupled Enzyme Activity and Thermal Shift Screening
of the Maybridge Rule of 3 Fragment Library Against
Trypanosoma brucei Choline Kinase; A Genetically
Validated Drug Target
Louise L. Major, Helen Denton and Terry K. Smith
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52668
1. Introduction
Infectious diseases caused by parasitic protozoa affect approximately 15% of the global pop‐
ulation, and more than 65% of the population in the Third and developing world, yet cur‐
rent drug therapies for protozoal infections are woefully inadequate. As protozoal infections
take their toll predominantly in the developing world, market forces are insufficient to pro‐
mote the development of novel anti-protozoal drugs. In 2000, only ca. 0.1% of global invest‐
ment in health research was spent on drug discovery for tropical diseases [1].
One such neglected parasitic disease is Human African Trypanosomiasis (HAT) or African
sleeping sickness, which is caused by the protozoan parasite Trypanosoma brucei and is trans‐
mitted by the bite of the Tsetse fly. The WHO estimates that HAT constitutes a serious
health risk to 60 million people in sub-Saharan Africa, 300,000-500,000 of whom become in‐
fected each year, with an estimated 10,000 fatalities. The related disease in cattle, Cattle Try‐
panosomiasis or Nagana, also represents a major health concern due to its devastating
economic, social and nutritional impact on African families, estimated by the WHO as an
annual economic loss of ~US$ 4 billion. As such, the total burden of Trypanosomiasis trans‐
lates into 1,598,000 Disability-Adjusted Life Years, this is on a par with big killers such as
Mycobacterium tuberculosis and Malaria [2, 3].
Treatment of HAT is dependent upon four drugs: suramin, melarsoprol, pentamidine and
eflornithine.These therapies are often toxic, difficult to administer and increasingly have an
acquired drug resistance [4, 5].Developed before the 1950s suramin and melarsoprol are
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used for chemotherapy of early stages of the disease, as is pentamidine. The arsenical melar‐
soprol is extremely toxic, with death for ~1 in 20 of cases and treatment failures as high as
30% in certain areas [4, 6]. Treatment of the second stage of the disease, where the parasites
cross the blood-brain barrier and invade the central nervous system, is limited to melarso‐
prol and eflornithine [7].The WHO as a desperate measure recently introduced nifurtimox-
eflornithine combination therapy for the treatment of HAT. This is despite nifurtimox, a
drug often used to treat Chagas' disease (caused by the related protozoan the South Ameri‐
can Trypanosoma cruzi), having low efficacy against HAT [8].
Hence there is an urgent need for new, more effective, less toxic, cheap and easy to adminis‐
ter therapeutic agents to treat African sleeping sickness and other closely related parasitic
diseases, e.g. Chagas’ disease and Leishmaniasis, whose current treatments suffer from simi‐
lar limitations.
T. brucei is able to survive and multiply in the harsh environment of a mammalian hosts’
bloodstream. This is due to the parasite’s dense cell-surface coat of the glycosylphosphatidy‐
linositol anchored variant surface glycoprotein (5 X 106 dimers/cell) [9-11], which protects
the parasite in two ways. Firstly by acting as a diffusion barrier, such that complement is
unable to reach and attack the plasma membrane of T. brucei. Secondly T. brucei is able to
undergo antigenic variation, where by it is able to express a new variant surface glycopro‐
tein from a repertoire of more than 1000 different genes, before the hosts’ innate immune
system is able to catch up [12, 13]. This antigenic variation is why a vaccine against this par‐
asite is not a viable option as a therapy.
Phospholipids account for ~80% of total lipids in T. brucei with a significant proportion of
these containing a choline-phosphate headgroup; phosphatidylcholine (PC) (~48%) and
sphingomyelin (~15%) [14,15]. Sphingomyelin is made from PC via the sphingomyelin syn‐
thases transferring the choline-phosphate headgroup from PC to a ceramide lipid moiety
[16]. These lipids contribute to the structural integrity of the membrane and in addition de‐
termine membrane fluidity and cell surface charge. Unsurprisingly, the biosynthesis and
utilisation of these choline-containing molecules are implicated in a variety of cellular proc‐
esses, including signaling, intracellular cellular protein sorting and transport [reviewed in
16]. Phosphocholine has been reported to be a required mitogen for DNA synthesis induced
by growth factors [17]. Recently we have shown that the essential T. brucei neutral sphingo‐
myelinase is actively involved in post Golgi sorting of the glycosylphosphatidylinositol
anchored variant surface glycoprotein mentioned earlier [18].
Most eukaryotes have three alternative pathways by which PC can be synthesised [19 and
reviewed in 20]. The first two pathways both involve three consecutive methylations of PE
by S-adenosyl-L-methionemethyltransferases [20]. The PE can be derived from two alterna‐
tive pathways, either from the concerted actions of the CDP-DAG dependantphosphatidyl‐
serine synthase and phosphatidylserine decarboxylase, or via the CDP-ethanolamine branch
of the Kennedy pathway. This involves phosphorylation of ethanolamine by an ethanola‐
mine kinase, its activation to CDP-ethanolamine by an ethanolamine-phosphate cytidyl‐
transferase and its transfer to diacylglycerol by an ethanolamine phosphotransferase. The
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presence of this branch of the Kennedy pathway was demonstrated in T. brucei [22], howev‐
er only recently have the constituent enzymes been characterized [23].
The trypanosomal genomes have revealed that T. brucei does not contain homologues for
any methyltransferase(s) required to convert PE to PC [24] (neither does T. cruzi, but Leish‐
mania do). Plasmodium falciparum have an alternative single plant-like S-adenosyl-L-methio‐
nemethyltransferase [25-27], responsible for phosphoethanolamine conversion to
phosphocholine, however there are no trypanosomatid homologues. This rather surprising
absence of PE to PC methylation has been confirmed by in vivo labellings by ourselves and
others [15, 22, 28].
The third alternative pathway for de novo synthesis of PC, and the only pathway by which T.
brucei can de novo synthesise PC, utilises the CDP-choline branch of the Kennedy pathway
[19, 29-33]. This involves the phosphorylation of choline by a choline kinase, its activation to
CDP-choline by a choline-phosphate cytidyltransferase and its transfer to diacylglycerol by
a choline phosphotransferase. Biochemical characterisation of the two choline/ethanolamine
kinases involved in the initial steps of the Kennedy pathway show that unusually amongst
eukaryotes only one of the kinases is able to phosphorylate choline [23].
Collectively this evidence of an absence of redundancy of de novo PC synthesis in T. brucei,
compared with other organisms (including humans), suggests T. brucei has a vulnerability to
inhibition of their only way to synthesise PC, i.e. the Kennedy pathway. Recently we have
exploited this fact by genetically validating the only T. brucei choline kinase (TbCK) as a
drug target both in culture and in an animal model [34]. Chemical intervention of the TbCK
enzyme activity is likely to interfere with the parasite’s biology in multiple ways and TbCK
is therefore of interest as a target for novel chemotherapeutics.
In this study we interrogate ~630 compounds of the Maybridge Rule of 3 Fragment Library
for compounds that interact with, and inhibit TbCK.The Maybridge Rule of 3 Fragment Li‐
brary is a small collection of quantifiable diverse [35, 36], pharmacophoric rich, chemical en‐
tities that comply with the following criteria; MW ≤ 300, cLogP ≤ 3, H-Bond Acceptors ≤ 3,
H-Bond Donors ≤ 3, Rotatable bonds (Flexibility Index) ≤ 3, Polar Surface Area ≤ 60 Å2 and
aqueous solubility ≥ 1 mM using LogS and high purity (≥ 95%). Comparisons between two
different screening methods, a coupled enzyme activity assay and differential scanning fluo‐
rimetry,has allowed identification of compounds that interact and inhibit the T. brucei chol‐
ine kinase, several of which possess selective trypanocidal activity.
2. Experimental
2.1. Materials
All materials unless stated were purchased either from Sigma/Aldrich or Invitrogen. An in
house Maybridge Rule of 3 Fragment Library kept in master plates at 200 mM in DMSO
(100%), was transferred into working plates with compounds occupying the central 80 wells
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used for chemotherapy of early stages of the disease, as is pentamidine. The arsenical melar‐
soprol is extremely toxic, with death for ~1 in 20 of cases and treatment failures as high as
30% in certain areas [4, 6]. Treatment of the second stage of the disease, where the parasites
cross the blood-brain barrier and invade the central nervous system, is limited to melarso‐
prol and eflornithine [7].The WHO as a desperate measure recently introduced nifurtimox-
eflornithine combination therapy for the treatment of HAT. This is despite nifurtimox, a
drug often used to treat Chagas' disease (caused by the related protozoan the South Ameri‐
can Trypanosoma cruzi), having low efficacy against HAT [8].
Hence there is an urgent need for new, more effective, less toxic, cheap and easy to adminis‐
ter therapeutic agents to treat African sleeping sickness and other closely related parasitic
diseases, e.g. Chagas’ disease and Leishmaniasis, whose current treatments suffer from simi‐
lar limitations.
T. brucei is able to survive and multiply in the harsh environment of a mammalian hosts’
bloodstream. This is due to the parasite’s dense cell-surface coat of the glycosylphosphatidy‐
linositol anchored variant surface glycoprotein (5 X 106 dimers/cell) [9-11], which protects
the parasite in two ways. Firstly by acting as a diffusion barrier, such that complement is
unable to reach and attack the plasma membrane of T. brucei. Secondly T. brucei is able to
undergo antigenic variation, where by it is able to express a new variant surface glycopro‐
tein from a repertoire of more than 1000 different genes, before the hosts’ innate immune
system is able to catch up [12, 13]. This antigenic variation is why a vaccine against this par‐
asite is not a viable option as a therapy.
Phospholipids account for ~80% of total lipids in T. brucei with a significant proportion of
these containing a choline-phosphate headgroup; phosphatidylcholine (PC) (~48%) and
sphingomyelin (~15%) [14,15]. Sphingomyelin is made from PC via the sphingomyelin syn‐
thases transferring the choline-phosphate headgroup from PC to a ceramide lipid moiety
[16]. These lipids contribute to the structural integrity of the membrane and in addition de‐
termine membrane fluidity and cell surface charge. Unsurprisingly, the biosynthesis and
utilisation of these choline-containing molecules are implicated in a variety of cellular proc‐
esses, including signaling, intracellular cellular protein sorting and transport [reviewed in
16]. Phosphocholine has been reported to be a required mitogen for DNA synthesis induced
by growth factors [17]. Recently we have shown that the essential T. brucei neutral sphingo‐
myelinase is actively involved in post Golgi sorting of the glycosylphosphatidylinositol
anchored variant surface glycoprotein mentioned earlier [18].
Most eukaryotes have three alternative pathways by which PC can be synthesised [19 and
reviewed in 20]. The first two pathways both involve three consecutive methylations of PE
by S-adenosyl-L-methionemethyltransferases [20]. The PE can be derived from two alterna‐
tive pathways, either from the concerted actions of the CDP-DAG dependantphosphatidyl‐
serine synthase and phosphatidylserine decarboxylase, or via the CDP-ethanolamine branch
of the Kennedy pathway. This involves phosphorylation of ethanolamine by an ethanola‐
mine kinase, its activation to CDP-ethanolamine by an ethanolamine-phosphate cytidyl‐
transferase and its transfer to diacylglycerol by an ethanolamine phosphotransferase. The
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presence of this branch of the Kennedy pathway was demonstrated in T. brucei [22], howev‐
er only recently have the constituent enzymes been characterized [23].
The trypanosomal genomes have revealed that T. brucei does not contain homologues for
any methyltransferase(s) required to convert PE to PC [24] (neither does T. cruzi, but Leish‐
mania do). Plasmodium falciparum have an alternative single plant-like S-adenosyl-L-methio‐
nemethyltransferase [25-27], responsible for phosphoethanolamine conversion to
phosphocholine, however there are no trypanosomatid homologues. This rather surprising
absence of PE to PC methylation has been confirmed by in vivo labellings by ourselves and
others [15, 22, 28].
The third alternative pathway for de novo synthesis of PC, and the only pathway by which T.
brucei can de novo synthesise PC, utilises the CDP-choline branch of the Kennedy pathway
[19, 29-33]. This involves the phosphorylation of choline by a choline kinase, its activation to
CDP-choline by a choline-phosphate cytidyltransferase and its transfer to diacylglycerol by
a choline phosphotransferase. Biochemical characterisation of the two choline/ethanolamine
kinases involved in the initial steps of the Kennedy pathway show that unusually amongst
eukaryotes only one of the kinases is able to phosphorylate choline [23].
Collectively this evidence of an absence of redundancy of de novo PC synthesis in T. brucei,
compared with other organisms (including humans), suggests T. brucei has a vulnerability to
inhibition of their only way to synthesise PC, i.e. the Kennedy pathway. Recently we have
exploited this fact by genetically validating the only T. brucei choline kinase (TbCK) as a
drug target both in culture and in an animal model [34]. Chemical intervention of the TbCK
enzyme activity is likely to interfere with the parasite’s biology in multiple ways and TbCK
is therefore of interest as a target for novel chemotherapeutics.
In this study we interrogate ~630 compounds of the Maybridge Rule of 3 Fragment Library
for compounds that interact with, and inhibit TbCK.The Maybridge Rule of 3 Fragment Li‐
brary is a small collection of quantifiable diverse [35, 36], pharmacophoric rich, chemical en‐
tities that comply with the following criteria; MW ≤ 300, cLogP ≤ 3, H-Bond Acceptors ≤ 3,
H-Bond Donors ≤ 3, Rotatable bonds (Flexibility Index) ≤ 3, Polar Surface Area ≤ 60 Å2 and
aqueous solubility ≥ 1 mM using LogS and high purity (≥ 95%). Comparisons between two
different screening methods, a coupled enzyme activity assay and differential scanning fluo‐
rimetry,has allowed identification of compounds that interact and inhibit the T. brucei chol‐
ine kinase, several of which possess selective trypanocidal activity.
2. Experimental
2.1. Materials
All materials unless stated were purchased either from Sigma/Aldrich or Invitrogen. An in
house Maybridge Rule of 3 Fragment Library kept in master plates at 200 mM in DMSO
(100%), was transferred into working plates with compounds occupying the central 80 wells
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of a 96-well plate, at 10 mM in 5% DMSO, allowing the two outside columns for positive
and negative controls.
2.2. Recombinant expression and purification of TbCK
Large-scale recombinant expression and purification of TbCK was conducted using the con‐
struct pET-15bTEV-TbCK in BL21 Rosetta (DE3) cells as described previously [23], except
the cells were grown in tryptone phosphate broth [37], harvested by centrifugation at 3500 g
for 20 min at 4°C and affinity purified with either a HisTrap™ FF crude column (enzyme
activity assay) or a HisTALON Cartridge (thermal shift analysis).
Briefly, pelleted cells were suspended in buffer A (50 mMTris/HCl, pH 8.0, 300 mMNaCl
and 10 mM imidazole) and lysed in the presence of DNase I by sonication. The lysate was
cleared by centrifugation at 35000 g for 30 min at 4°C and applied to a 1 ml HisTrap™ FF
crude column column (GE Healthcare) pre-loaded with Ni2+. Unbound proteins were re‐
moved by washing the column with 15 column volumes of buffer A containing 32.5 mM
imidazole and TbCK was eluted with 250 mM imidazole in the same buffer. Using a PD10
column, TbCK was buffer exchanged into 50 mMTris/HCl, pH 8.0, 300 mMNaCl, glycerol
(15% w/v) and stored at -80°C.
Alternatively, pelleted cells were suspended in 50 mMTris/HCl, pH 8.0, 300 mMNaCl and 5
mM imidazole and lysed by sonication. The lysate was cleared by centrifugation at 35000 g
for 30 min at 4°C and applied to a 1 ml HisTALON Cartridge (Clontech).Unbound proteins
were removed by washing the column with 10 column volumes of loading buffer, TbCK was
eluted with 15 mM imidazole and a final clearing wash of 250 mM imidazole in the same
buffer. Using a PD10 column, TbCK was buffer exchanged into 50 mM HEPES pH 8.0, 300
mMNaCl and 15% glycerol prior to storage at -80°C.
Typical yields were > 10 mg per litre of bacterial culture,TbCK was stable and freeze thaw‐
ing did not lead to any significant loss of activity.
2.3. T. brucei choline kinase activity assay
High throughput screening of the Maybridge Rule of 3 Fragment Library was carried out at
a final test concentration of 0.5 mM in 96-well plates (final assay volume 200 µl) using a
spectrophotometric assay that has been described previously [23]. The screened library
working plates consisted of compounds arrayed in 96 well plates at 10 mM in 5% DMSO;
columns 1 and 12 contained 5% DMSO only. For high throughput screening, 10 µl from each
well of the working plates was added to 110 µl of buffer containing 50 mM MOPS (pH 7.8),
150 mMKCl and 6 mM MgCl2. 3 µg of purified TbCK was added to each well in 30 µl of the
same buffer and the plates were mixed and incubated for 5 min at room temperature. A fur‐
ther 30 µl of buffer containing PEP (1 mM final), ATP (0.5 mM final), NADH (0.5 mM final)
and pyruvate kinase and lactate dehydrogenase(PK/LDH) (5 units/ml final) was added, and
the reaction was started by addition of 30 µl choline (0.5 mM final) to rows 1-11, 30 µl buffer
alone was added to row 12 (negative control) and this was used as an intra-plate control
(background rate) in conjunction with row 1 (maximal rate). Following mixing the change in
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absorbance at 341 nm was monitored for 10 min at room temperature. For testing inhibition
of the coupling enzymes (PK/LDH), standard buffer conditions were used but the assay con‐
tained 1 mM PEP, 0.1 mM ADP and 0.5 mM NADH. The PK/LDH was titrated to give a
change in absorbance of approximately 0.05 absorbance units/min in the absence of inhibi‐
tor.
2.4. Differential scanning fluorimetry with TbCK
Differential scanning fluorimetry was set up in 96 well PCR plates using a reaction volume
of 100 µL. Samples contained 2.1 µM TbCK, 6 mM MgCl2, 50 mM HEPES pH 8.0, 80
mMNaCl, 5.25% glycerol (v/v) and 1.4 x Sypro Orange (Invitrogen), Maybridge Ro3 com‐
pounds were screened at 1 mM concentration with a final DMSO concentration of 0.5% (v/
v).Two controls with eight repetitions per plate were used for the thermal shift experiments:
0.5% DMSO; 0.5 mM ATP, 0.5% DMSO.
Differential fluorimetric scans were performed in a realtime PCR machine (Stratagene
Mx3005P with software MxPro v 4.01) using a temperature scan from 25°C to 95°C at 0.5°C
min-1.Data were then exported to Excel for analysis using “DSF analysis” modified from the
template provided by Niesen et al. [38].Tm values were calculated by non-linear regression,
fitting the Boltzmann equation to the denaturation curves using GraFit. TbCK Tm, in the
presence of 6 mM MgCl2 and 0.5% DMSO, 41.21 ± 0.03°C (n > 60), Tm for TbCK and 0.5 mM
ATP = 44.46 ± 0.05°C (n > 60).
3. Results and discussion
Screening for inhibitors of the genetically validated drug target TbCK is problematic due to
the difficulty in following the reaction either continuously or directly. A direct choline kin‐
ase activity assay assessing the production of phosphocholine, utilising a modified method
of Kim et. al. [39], using TbCK and radiolabelled choline has been performed previously [23].
However this is not suitable for screening purposes, so choline kinase activity was measured
by a spectrophotometric coupled assay (Figure 1). This coupled enzyme assay utilises regen‐
eration of ATP from the ADP by-product of the choline kinase by pyruvate kinase, and sub‐
sequent oxidation of NADH as the resulting pyruvate is converted to lactate, by lactate
dehydrogenase. This assay using coupled enzymes is also problematic, as a compound
could potentially inhibit the coupled enzymes giving rise to a false positive.
An alternative approach for screening is differential scanning fluorimetry (Figure 2), allow‐
ing identification of compounds that interact with the TbCK protein, either to stabilise or de‐
stabilise it, therefore influencing the protein’s Tm (melting point) [38-40].
Initially TbCK was subjected to differential scanning fluorimetry to ascertain if this approach
was possible. Known components required for enzyme activity were tested to see if thermal
shifts were observed.In the presence of 6 mM MgCl2, a Tm of 41.2°C was obtained (Figure 1C,
solid dark line). The addition of 0.5 mM ATP resulted in a > 3°C Tm shift for TbCK(Figure 1C,
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of a 96-well plate, at 10 mM in 5% DMSO, allowing the two outside columns for positive
and negative controls.
2.2. Recombinant expression and purification of TbCK
Large-scale recombinant expression and purification of TbCK was conducted using the con‐
struct pET-15bTEV-TbCK in BL21 Rosetta (DE3) cells as described previously [23], except
the cells were grown in tryptone phosphate broth [37], harvested by centrifugation at 3500 g
for 20 min at 4°C and affinity purified with either a HisTrap™ FF crude column (enzyme
activity assay) or a HisTALON Cartridge (thermal shift analysis).
Briefly, pelleted cells were suspended in buffer A (50 mMTris/HCl, pH 8.0, 300 mMNaCl
and 10 mM imidazole) and lysed in the presence of DNase I by sonication. The lysate was
cleared by centrifugation at 35000 g for 30 min at 4°C and applied to a 1 ml HisTrap™ FF
crude column column (GE Healthcare) pre-loaded with Ni2+. Unbound proteins were re‐
moved by washing the column with 15 column volumes of buffer A containing 32.5 mM
imidazole and TbCK was eluted with 250 mM imidazole in the same buffer. Using a PD10
column, TbCK was buffer exchanged into 50 mMTris/HCl, pH 8.0, 300 mMNaCl, glycerol
(15% w/v) and stored at -80°C.
Alternatively, pelleted cells were suspended in 50 mMTris/HCl, pH 8.0, 300 mMNaCl and 5
mM imidazole and lysed by sonication. The lysate was cleared by centrifugation at 35000 g
for 30 min at 4°C and applied to a 1 ml HisTALON Cartridge (Clontech).Unbound proteins
were removed by washing the column with 10 column volumes of loading buffer, TbCK was
eluted with 15 mM imidazole and a final clearing wash of 250 mM imidazole in the same
buffer. Using a PD10 column, TbCK was buffer exchanged into 50 mM HEPES pH 8.0, 300
mMNaCl and 15% glycerol prior to storage at -80°C.
Typical yields were > 10 mg per litre of bacterial culture,TbCK was stable and freeze thaw‐
ing did not lead to any significant loss of activity.
2.3. T. brucei choline kinase activity assay
High throughput screening of the Maybridge Rule of 3 Fragment Library was carried out at
a final test concentration of 0.5 mM in 96-well plates (final assay volume 200 µl) using a
spectrophotometric assay that has been described previously [23]. The screened library
working plates consisted of compounds arrayed in 96 well plates at 10 mM in 5% DMSO;
columns 1 and 12 contained 5% DMSO only. For high throughput screening, 10 µl from each
well of the working plates was added to 110 µl of buffer containing 50 mM MOPS (pH 7.8),
150 mMKCl and 6 mM MgCl2. 3 µg of purified TbCK was added to each well in 30 µl of the
same buffer and the plates were mixed and incubated for 5 min at room temperature. A fur‐
ther 30 µl of buffer containing PEP (1 mM final), ATP (0.5 mM final), NADH (0.5 mM final)
and pyruvate kinase and lactate dehydrogenase(PK/LDH) (5 units/ml final) was added, and
the reaction was started by addition of 30 µl choline (0.5 mM final) to rows 1-11, 30 µl buffer
alone was added to row 12 (negative control) and this was used as an intra-plate control
(background rate) in conjunction with row 1 (maximal rate). Following mixing the change in
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absorbance at 341 nm was monitored for 10 min at room temperature. For testing inhibition
of the coupling enzymes (PK/LDH), standard buffer conditions were used but the assay con‐
tained 1 mM PEP, 0.1 mM ADP and 0.5 mM NADH. The PK/LDH was titrated to give a
change in absorbance of approximately 0.05 absorbance units/min in the absence of inhibi‐
tor.
2.4. Differential scanning fluorimetry with TbCK
Differential scanning fluorimetry was set up in 96 well PCR plates using a reaction volume
of 100 µL. Samples contained 2.1 µM TbCK, 6 mM MgCl2, 50 mM HEPES pH 8.0, 80
mMNaCl, 5.25% glycerol (v/v) and 1.4 x Sypro Orange (Invitrogen), Maybridge Ro3 com‐
pounds were screened at 1 mM concentration with a final DMSO concentration of 0.5% (v/
v).Two controls with eight repetitions per plate were used for the thermal shift experiments:
0.5% DMSO; 0.5 mM ATP, 0.5% DMSO.
Differential fluorimetric scans were performed in a realtime PCR machine (Stratagene
Mx3005P with software MxPro v 4.01) using a temperature scan from 25°C to 95°C at 0.5°C
min-1.Data were then exported to Excel for analysis using “DSF analysis” modified from the
template provided by Niesen et al. [38].Tm values were calculated by non-linear regression,
fitting the Boltzmann equation to the denaturation curves using GraFit. TbCK Tm, in the
presence of 6 mM MgCl2 and 0.5% DMSO, 41.21 ± 0.03°C (n > 60), Tm for TbCK and 0.5 mM
ATP = 44.46 ± 0.05°C (n > 60).
3. Results and discussion
Screening for inhibitors of the genetically validated drug target TbCK is problematic due to
the difficulty in following the reaction either continuously or directly. A direct choline kin‐
ase activity assay assessing the production of phosphocholine, utilising a modified method
of Kim et. al. [39], using TbCK and radiolabelled choline has been performed previously [23].
However this is not suitable for screening purposes, so choline kinase activity was measured
by a spectrophotometric coupled assay (Figure 1). This coupled enzyme assay utilises regen‐
eration of ATP from the ADP by-product of the choline kinase by pyruvate kinase, and sub‐
sequent oxidation of NADH as the resulting pyruvate is converted to lactate, by lactate
dehydrogenase. This assay using coupled enzymes is also problematic, as a compound
could potentially inhibit the coupled enzymes giving rise to a false positive.
An alternative approach for screening is differential scanning fluorimetry (Figure 2), allow‐
ing identification of compounds that interact with the TbCK protein, either to stabilise or de‐
stabilise it, therefore influencing the protein’s Tm (melting point) [38-40].
Initially TbCK was subjected to differential scanning fluorimetry to ascertain if this approach
was possible. Known components required for enzyme activity were tested to see if thermal
shifts were observed.In the presence of 6 mM MgCl2, a Tm of 41.2°C was obtained (Figure 1C,
solid dark line). The addition of 0.5 mM ATP resulted in a > 3°C Tm shift for TbCK(Figure 1C,
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dashed-line). These encouraging results showed TbCK was amenable to differential scanning
fluorimetry and allowed validation of this screening method.It is worth noting the surprising
low Tm of TbCK, considering that these parasites live within the bloodstream of a mammalian
host, i.e. 37°C, or higher with a fever. However, the presence of physiological
Figure 1. Schematic of the TbCK reaction and coupled assay.
T. brucei choline kinase (TbCK) catalyses the ATP dependent phosphorylation of choline, the
ADP is converted back to ATP by pyruvate kinase (PK), which converts phosphoenolpyru‐
vate (PEP) to pyruvate in the process. The resulting pyruvate is reduced to lactate by the
NADH dependent lactate dehydrogenase (LDH). The resulting conversion of NADH to
NAD+ is monitored, by measuring the reduction in absorbance at 341 nM.
Figure 2. Thermal shift assay; typical differential fluorimetry scans of TbCK.
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Differential fluorimetric scans were performed and analysed as described in Experimental.
TbCK + DMSO (control) solid dark line, TbCK + 0.5 µM ATP (positive control) dashed line,
TbCK + 1 mM compound 242, solid light line, TbCK + 1 mM compound 269, dotted line.Tm
of TbCK in the presence of 0.5%DMSO is 41.21 ± 0.03°C (control); Tm of TbCK and 0.5 mM
ATP is 44.46 ± 0.05°C (positive control). Insert: schematic representation of the thermal shift
assay.A protein will unfold exposing hydrophobic domains as it is denatured due to the in‐
creasing temperature. Dyes such as sypro orange (star) are able to bind to these exposed hy‐
drophobic areas giving rise to fluorescence. A plot of this increased fluorescence versus
temperature allows determination of Tm (melting point) of the protein. If a compound
(squares) is able to interact with the protein it may alter the protein’s Tm and thus a library of
compounds can be screened to see if they stabilise (increase in Tm) or destabilise (decrease in
Tm) the target protein.
An alternative approach for screening is differential scanning fluorimetry (Figure 2), allow‐
ing identification of compounds that interact with the TbCK protein, either to stabilise or de‐
stabilise it, therefore influencing the protein’s Tm (melting point) [38-40].
Initially TbCK was subjected to differential scanning fluorimetry to ascertain if this ap‐
proach was possible. Known components required for enzyme activity were tested to see if
thermal shifts were observed. In the presence of 6 mM MgCl2, a Tm of 41.2°C was obtained
(Figure 1C, solid dark line). The addition of 0.5 mM ATP resulted in a > 3°C Tm shift for
TbCK(Figure 1C, dashed-line). These encouraging results showed TbCK was amenable to
differential scanning fluorimetry and allowed validation of this screening method.It is worth
noting the surprising low Tm of TbCK, considering that these parasites live within the blood‐
stream of a mammalian host, i.e. 37°C, or higher with a fever. However, the presence of
physiological relevant levels of ATP does stabilize TbCK by > 3 °C, which may prolong the
half-life of the protein in the parasite.
The respective controls in both assay types allowed Z-factors to be determined for all of the
plates screened (Figure 3). Both the coupled enzyme activity assay and the thermal shift
analysis showed Z-factors to be above 0.5 for all plates, except for plate 5 for the thermal
shift assay (but still above 0.45), this is indicative of good reliable assays, with meaningful
results [41].
The MayBridge Rule of 3 Fragment Library was distributed over 9 plates (80 compounds per
plate) providing space for adequate positive and negative controls, allowing Z-factors to be
determined. This was done for each plate for both the choline kinase assay (+) and thermal
shift analysis (x). A Z-factor above 0.4 is acceptable and validates the data on that plate as
being reliable.
The ~630 compounds from the MayBridge Rule of 3 Fragment Library were assessed for
their ability to inhibit the TbCK coupled enzyme activity assay at a single concentration of
0.5 mM (Figure 4A). At this relative high concentration only 9 of the compounds (1.4%)
showed > 70% inhibition. These primary hits were retested in triplicate at 0.5 mM (Table 1),
2 of the 9(compounds 320 and 635) were confirmed as being false positives, while the re‐
maining 7 were confirmed to show good inhibition (80-100%) against the TbCK coupled en‐
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dashed-line). These encouraging results showed TbCK was amenable to differential scanning
fluorimetry and allowed validation of this screening method.It is worth noting the surprising
low Tm of TbCK, considering that these parasites live within the bloodstream of a mammalian
host, i.e. 37°C, or higher with a fever. However, the presence of physiological
Figure 1. Schematic of the TbCK reaction and coupled assay.
T. brucei choline kinase (TbCK) catalyses the ATP dependent phosphorylation of choline, the
ADP is converted back to ATP by pyruvate kinase (PK), which converts phosphoenolpyru‐
vate (PEP) to pyruvate in the process. The resulting pyruvate is reduced to lactate by the
NADH dependent lactate dehydrogenase (LDH). The resulting conversion of NADH to
NAD+ is monitored, by measuring the reduction in absorbance at 341 nM.
Figure 2. Thermal shift assay; typical differential fluorimetry scans of TbCK.
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Differential fluorimetric scans were performed and analysed as described in Experimental.
TbCK + DMSO (control) solid dark line, TbCK + 0.5 µM ATP (positive control) dashed line,
TbCK + 1 mM compound 242, solid light line, TbCK + 1 mM compound 269, dotted line.Tm
of TbCK in the presence of 0.5%DMSO is 41.21 ± 0.03°C (control); Tm of TbCK and 0.5 mM
ATP is 44.46 ± 0.05°C (positive control). Insert: schematic representation of the thermal shift
assay.A protein will unfold exposing hydrophobic domains as it is denatured due to the in‐
creasing temperature. Dyes such as sypro orange (star) are able to bind to these exposed hy‐
drophobic areas giving rise to fluorescence. A plot of this increased fluorescence versus
temperature allows determination of Tm (melting point) of the protein. If a compound
(squares) is able to interact with the protein it may alter the protein’s Tm and thus a library of
compounds can be screened to see if they stabilise (increase in Tm) or destabilise (decrease in
Tm) the target protein.
An alternative approach for screening is differential scanning fluorimetry (Figure 2), allow‐
ing identification of compounds that interact with the TbCK protein, either to stabilise or de‐
stabilise it, therefore influencing the protein’s Tm (melting point) [38-40].
Initially TbCK was subjected to differential scanning fluorimetry to ascertain if this ap‐
proach was possible. Known components required for enzyme activity were tested to see if
thermal shifts were observed. In the presence of 6 mM MgCl2, a Tm of 41.2°C was obtained
(Figure 1C, solid dark line). The addition of 0.5 mM ATP resulted in a > 3°C Tm shift for
TbCK(Figure 1C, dashed-line). These encouraging results showed TbCK was amenable to
differential scanning fluorimetry and allowed validation of this screening method.It is worth
noting the surprising low Tm of TbCK, considering that these parasites live within the blood‐
stream of a mammalian host, i.e. 37°C, or higher with a fever. However, the presence of
physiological relevant levels of ATP does stabilize TbCK by > 3 °C, which may prolong the
half-life of the protein in the parasite.
The respective controls in both assay types allowed Z-factors to be determined for all of the
plates screened (Figure 3). Both the coupled enzyme activity assay and the thermal shift
analysis showed Z-factors to be above 0.5 for all plates, except for plate 5 for the thermal
shift assay (but still above 0.45), this is indicative of good reliable assays, with meaningful
results [41].
The MayBridge Rule of 3 Fragment Library was distributed over 9 plates (80 compounds per
plate) providing space for adequate positive and negative controls, allowing Z-factors to be
determined. This was done for each plate for both the choline kinase assay (+) and thermal
shift analysis (x). A Z-factor above 0.4 is acceptable and validates the data on that plate as
being reliable.
The ~630 compounds from the MayBridge Rule of 3 Fragment Library were assessed for
their ability to inhibit the TbCK coupled enzyme activity assay at a single concentration of
0.5 mM (Figure 4A). At this relative high concentration only 9 of the compounds (1.4%)
showed > 70% inhibition. These primary hits were retested in triplicate at 0.5 mM (Table 1),
2 of the 9(compounds 320 and 635) were confirmed as being false positives, while the re‐
maining 7 were confirmed to show good inhibition (80-100%) against the TbCK coupled en‐
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zyme activity assay. These 7 compounds were then tested against just the coupled enzymes,
some inhibition was observed for some of the compounds, but this was insufficient to ac‐
count for the strong inhibition against the TbCK, thus these 7 compounds were believed to
show true TbCK inhibition.
Figure 3. Quality control (Z factors) for the TbCK thermal shift analysis and coupled enzyme activity assay.
It is worth noting the lack of false positives arising from significant inhibition of either of the
coupling enzymes, pyruvate kinase and lactate dehydrogenase this is encouraging when
screening other ATP utilizing enzymes.
Thermal shift analysis of TbCK with the ~630 compounds from the MayBridge Rule of 3
Fragment Library showed that the vast majority of compounds had little or no affect on the
Tm of TbCK (Figure 4B). Relatively few compounds showed an increase in Tm (stabilisation),
and only a handful of these showing an increase in Tm> 1°C, i.e. compound 269 (Figure 2,
dotted line), this was rather surprising given that ATP stabilises TbCK by > 3°C. Significant‐
ly more compounds showed a destabilisation affect, with 3 compounds having > 10°C de‐
crease in the Tm, i.e. compound 242 (Figure 2, solid light line). Most of the compounds
observed in this screen that show significant destabilisation of TbCK, do not cause similar
destabilisation affects with other enzymes that we have screened in a similar manner, the
only exceptions are compounds 68 (2-aminothiophene-3-carbonitrile) and 565 (4-(2-ami‐
no-1,3-thiazol-4-yl)phenol) (Table 1).
Several drug discovery style studies have shown that an increase in the thermal stability
of a protein is proportional to the concentration and affinity of the ligand to the protein
in  keeping  with  the  equilibrium  associated  with  ligand-protein  binding  [38,  41-44].  On
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those occasions where this  interaction destabilizes a  protein,  i.e.  lowering Tm,  a  thermo‐
dynamic model has been proposed which explains the how the same ligand can stabilise
and destabilise different proteins [42]. While the same protein may be stabilized and de‐
stabilized by very  similar  ligands,  this  was  exquisitely  demonstrated by the  changes  in
thermal stability of Acyl-CoA thioesterase, upon incubation with either CoA (destabilise)
or Acyl-CoA (stabilise) [45].
Figure 4. A) Percentage inhibition of TbCK enzyme activity assay for each of the compounds tested. B) Observed ther‐
mal shifts of TbCK for each of the compounds tested
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a Arbitrary library number
b CAS numbers are unique identifiers assigned by the "Chemical Abstracts Service" to describe every chemical descri‐
bed in open access scientific literature.
c Tm shift in °C, observed for TbCK in the presence of compound (1mM), value is mean ± SD from the Boltzman curve
fitting, see Experimental for details.
d Cytotoxicity studies, see Major and Smith 2011 for details, values are percentage of controls in the absence of com‐
pound, either mean ± SD (n=3) or mean ± SE (n=2), the latter being in bold.
Table 1. The compounds from the Maybridge Rule of 3 library that show >70% inhibition of TbCK.
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All of the compounds in the two data sets (the coupled enzyme activity assay and the ther‐
mal shift analysis), were compared to assess any correlation between the two very different
methods. In other words looking for compounds that showed a significant change in Tm and
a significant inhibition in TbCK enzyme activity (Figure 5A). The vast majority of com‐
pounds showed little or no inhibition and little or no shift in Tm. Compounds showing < 40%
inhibition of the enzyme activity were removed for clarification (Figure 5B), this highlighted
that the majority of compounds that show TbCK enzyme inhibition do not significantly alter
the Tm of TbCK. The exceptions are compound 565 with a decrease in Tm~9°C, and com‐
pound 68 and 95 with a decrease in Tm~2°C respectively, all show complete inhibition at 0.5
mM (Table 1). Twenty-one compounds showed > 40% enzyme inhibition, 9 of these (43%)
displayed > 1°C change in TbCK Tm. This is a substantial enrichment compared to the 7% of
compounds with Tm shifts > 1°C observed for the entire library.
Figure 5. Scatter graph representation showing the correlation between the observed thermal shifts and percentage
inhibition of TbCK enzyme activity. A) All of the compounds from the MayBridge Rule of 3 Fragment Library tested. B)
For those compounds with > 40% (dotted line) inhibition of TbCK enzyme activity.
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Of the compounds identified that  alter  the Tm  of  TbCK by >  1°C,  ~20% of  them inhibit
TbCK enzyme activity by > 40%. This suggests that for TbCK thermal shift analysis has al‐
lowed significant  enrichment,  but  not  total  capture  of  the  potential  inhibitors  of  TbCK.
However, if a direct assay for a potential drug target was very problematic, prior thermal
shift  analysis  could  significantly  streamline  the  number  of  compounds  to  be  screened,
thereby increasing the  potential  to  identify  lead compounds.  Thermal  shift  analysis  has
the disadvantage that good inhibitors could be missed if they do not significantly alter the
Tm of the protein.
This raises an interesting question, is it a viable option to target compounds that specifi‐
cally destabilise an enzyme, causing a decrease in enzyme activity? One could argue this
is  exactly  what  pharmaceutical  companies  are  focusing  their  research  efforts  upon,  but
with a slightly different approach. Some of their therapeutic targets rely on finding com‐
pounds  that  disrupt  various  interactions;  hetero-  or  homo-oligomeric  protein-protein,
DNA-binding protein and RNA polymerases, many of these are associated with signaling
events. Success stories include the identification of HDM2 antagonists associated with P53
activation [46], the identification of anti-cancer agent for the BCL-XL protein-protein com‐
plex  and several  others,  reviewed by  Wells  and McClendon [47]  and more  recently  by
Coyne and colleagues [48].
The techniques utilized to study the formation / disruption of protein-protein complexes are
driven by high throughput drug discovery, including fragment based approaches, these in‐
clude X-ray crystallography, NMR, dynamic light scattering, differential static light scatter‐
ing, differential scanning fluorimetry [42-50].
In summary, destabilisation by a ligand could affect the oligomeric state of a protein, or in
the case of a monomer disrupt intra-molecular interactions, i.e. between stacking α-helixes
or β-sheets, causing partial unfolding and thus destabilisation.In the case of TbCK, which we
know exists as a dimer, one of several potential mechanisms of destabilisation could be dis‐
ruption of the dimer interface, whereby a ligand is able to bind to freshly exposed hydro‐
phobic surfaces on the protein, and this interaction allows further destabilisation of the
monomer structure.
As  it  was  clear  that  compounds  that  inhibit  TbCK  enzyme  activity  do  not  necessarily
show a  significant  increase  or  decrease  in  Tm,  it  was  decided  to  compare  inhibition  of
TbCK  enzyme  activity  with  previously  determined  trypanocidal  activities  for  the  com‐
pounds [51]. From this comparison (Figure 6) a group of compounds above a threshold of
> 70% inhibition of TbCK showed significant trypanocidal activity (circled), suggesting a
direct correlation.
Compounds from the May Bridge Rule of 3 Fragment Library with greater than 70% inhibi‐
tion (dotted line) of the TbCK enzyme activity are circled and numbered. Numbers corre‐
spond to arbitrary compound library numbers; see Table 1 for chemical structures and extra
data. T. brucei survival data was previously determined [51].
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Figure 6. Correlation of the percentage inhibition of TbCK enzyme activity assay and T. brucei survival.
Figure 7. IC50 curves of the promising compounds (278 and 346) that show significant TbCK inhibition.
IC50 values were determined for these compounds (Table 1, Figure 7) ranging from 100s
of  µM to  low µM.  For  example,  compound 278  (1-methyl-(1H-indol-6-yl)methanol)  has
an IC50 value of 25.45 ± 1.16 µM however the selectivity index is  not very good, while
compound 346 (3-pyridin-3-ylaniline) has an IC50 value of 12.35 ± 0.64 µM with a high
selectivity index.
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IC50 values were determined for these compounds (Table 1, Figure 7) ranging from 100s
of  µM to  low µM.  For  example,  compound 278  (1-methyl-(1H-indol-6-yl)methanol)  has
an IC50 value of 25.45 ± 1.16 µM however the selectivity index is  not very good, while
compound 346 (3-pyridin-3-ylaniline) has an IC50 value of 12.35 ± 0.64 µM with a high
selectivity index.
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One of the strengths of the Maybridge Rule of 3 Fragment Library is the chemical diversity,
additionally a range of analogous structures can normally be found within it allowing initial
structure activity relationships to be formulated. There are several close analogues of com‐
pound 278 (1-methyl-(1H-indol-6-yl)methanol), which highlight that the N-methyl indole
moiety seems necessary to have any TbCK inhibition and the methanol portion of the mole‐
cule can not be replaced by a carboxylic acid. Investigation of the CHEMBL database for
similar compounds identified 1-Methyl-1H-pyrrolo[2,3-c]pyridine (CHEMBL594467) which
was screened as one of a library of tricyclic and bicyclic analogues of indoloquinoline alka‐
loids against a variety of protozoan parasites. The analogue mentioned here showed weak
trypanocidal activity (624 µM) against Trypanosoma brucei rhodesiense, but significantly better
(37 µM) against Plasmodium falciparum [52].
Another analogue, 1-Methyl-1H-indole (CHEMBL19912) has been shown to interact with
human intracellular adhesion molecules and highlights the importance of selectivity [53].
1H-indol-5-yl-methanol (CHEMBL1650258) has previously been screened against Leishmania
as a potential PTR1 inhibitor but was shown to be inactive at 500 µM [54]
For  the  relatively  simple  compound 346  (3-pyridin-3-ylaniline),  there  are  several  analo‐
gous  structures  in  the  library,  including  compound  262  (2-(1H-imidazo-1-yl)aniline)
which shows ~55% TbCK enzyme inhibition and is trypanocidal. Compound 347 (4-pyri‐
din-3-ylaniline) is  a structural  isomer of 346 but shows no TbCK enzyme inhibition and
is  not  trypanocidal.  The  only  related  structure  in  the  CHEMBL  database  was  3-(pyri‐
din-3-yl)benzenaminium (CHEMBL1778131)  which  was  shown to  be  a  weakinhibitor  of
metallo-β−lactamase IMP-1 [55].
4. Conclusions
In this study, screening of a comparatively small fragment library by two different screening
methods has allowed identification of several compounds that interact with and inhibit
TbCK, a genetically validated drug target against African sleeping sickness. Some of the in‐
hibitory fragments were also selectively trypanocidal, considering these are relatively sim‐
ple molecules with no optimization, finding low µΜ inhibitors is very encouraging.
Moreover some of the morphological phenotypes of these trypanocidal compounds include
cell-cycle arrests similar to those observed for the TbCK conditional knockout grown under
permissive conditions.
This study highlights that if faced with a drug target that is problematic to screen, prior ther‐
mal shift analysis could significantly triage the number of compounds to be screened, there‐
by significantly increasing the potential to identify lead compounds. This approach
obviously has the limitation that potential inhibitors could be missed if they do not signifi‐
cantly alter the Tm of the protein.
Future follow up work with TbCK will include expanding the structure activity relationship
of our most promising hits identified by this study. Their trypanocidal mode of action will
Drug Discovery426
be investigated by undertaking various in vivo biochemical phenotyping experiments to as‐
certain if they are inhibiting TbCK, thus causing a lack of de novo PC synthesis, known to be
essential for the parasite.
The ultimate goal is to identify new easy to make, affordable, easy to administer, drugs in
the fight against African sleeping sickness and other closely related protozoan transmitted
Third World diseases.
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1. Introduction
More than 10 years after the first sequencing of the human genome and despite major advan‐
ces in scientific and technological expertise into drug research and development processes
(R&D), the fact remains that we are facing a dearth of new drugs. Indeed, the number of drugs
approved by the US Food and Drug Administration (FDA) has roughly fallen to 50% over the
last ten years [1]. Unfortunately for pharmaceutical companies, at present this attrition in drug
discovery combined with the expiration of major product patents logically lead to the devel‐
opment of generics.  Facing both a major medical need and an obvious economical chal‐
lenge, there is an urgent need to make significant improvements in the research output.
Analyses of the clinical trials landscape reveal that a large number of promising drug leads
fail in late stages, mainly in phase II, with an overall failure rate of 67% (Fig. 1a). All studies
agree on the reasons by pinpointing either insufficient efficacy (~55%) or safety issues
(~20%) as major causes of human trials failure [2, 3]. Remarkably, the therapeutic area show‐
ing the largest number of failures is oncology, with only 29% of success rate in Phase II and
34% in Phase III (Fig.1b). Within oncology indications, the status of colorectal cancer (CRC)
is the most dramatic with an overall drug approval of only 3% (Fig.1c) over the last 10 years!
More surprisingly, more than half of the drugs currently approved to treat CRC work
through the general inhibition of DNA synthesis and cellular division, instead of targeting
molecular processes specifically involved in CRC progression (Table 1). These observations
highlight the necessity to both reduce failure rates in the clinic and shorten the time required
for developing innovative therapies.
© 2013 Constant et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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From this perspective, one of the obvious strategies would be:
1. to directly target the key regulators of CRC cancers
2. to streamline the critical Phase II and Phase III to obtain faster and more reliable re‐
sponses regarding the drug’s efficacy.
This strategy may save years of efforts and millions of dollars, giving that the average usual
time for developing a new drug is ten years and with a total cost amount to billions of dollars.
But in contrast, because a new drug has to show a benefit compared to an already approved
treatment, the number of patients involved in a pivotal trials is increasing more and more in
order to reach significance, and a similar trend is noted for the duration of the trial, that is
directly linked to safety. Therefore, regarding the constraints imposed by regulatory author‐
ities nowadays, it seems difficult to save on size and length of clinical trials.
In the mid-1990s, the pharmaceutical community has already attempted to increase R&D
productivity by embarking in a technological shift. That was the time of the inevitable high-
throughput screening, which combined with the “all-Omics” supposed to reduce costs and
blew up success rates [4]. As we have seen, this approach, maybe too reductionist in the
sense that it does not allow getting an idea of the full biological properties (ADME, toxici‐
ty,etc…) of a compound at an early stage, has favored the quantity instead of quality and
has not kept its promises [1].
Today, efforts have to be made to clearly address the early clinical discovery steps, with the
goal to better qualify “leads” to increase the signal-to-noise ratio of drugs entering into clini‐
cal trials. This point of view is supported by the important failure rate subsisting in Phases
III (Fig1b), suggesting an overestimation of the efficacy of candidate molecules during pre‐
clinical tests. One of the important reasons may be the use of irrelevant models or models
not predictive enough. Therefore, the development of relevant and predictive models is key
to increase the quality of preclinical researches and to increase the success rate of new drugs.
Consequently, the foundations of the drug discovery process have to be reconsidered by
giving definitively more emphasis to the quality of preclinical validations and by encourag‐
ing the design of new pertinent models, including human 3D (three dimensional) in vitro cell
models and tissue explants.
This article is intended to give an overview of the current knowledge about CRC and the
different models commonly used to study CRC, in order to identify the most suitable bio-
systems for optimal development of new CRC therapies. The first part will describe the
pathology and its molecular basis, and the various drugs that are currently in clinical use or
under development. Then, in the second part we will review and discuss the use of cancer
cell line collections, genetically engineered mouse models (GEM), primary human tumors
xenografts (PDX) and ex vivo organotypic cultures (EVOC) to identify and validate anticanc‐
er colon therapeutics.
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Figure 1. Success rate of drug development. Overall success rate of clinical trials for phases I-III from 2003 to 2010
corresponding to 4275 drugs and 7300 indications (a), success rate for phase II and III divided according to therapeu‐




Colorectal cancer is one of the major health concerns in the Western world. CRC is the sec‐
ond most frequently diagnosed cancer in men and women, right after lung cancer. It repre‐
sents the second leading cause of cancer-related deaths, both in the United States and in
Europe, with a significant rate of 9% and 13% of total cancer deaths, respectively (Fig.2). The
vast majority (~75%) of colon cancers are sporadic adenocarcinomas, arising from mutations
in the epithelial cells lining the wall of the intestine that is in continuous renewal. CRC often
begins as an adenomatous polyp, a benign growth on the interior surface of the organ. Most
of polyps remain benign, but over the years some of them become progressively more dys‐
plastic, accumulate mutations and progress to carcinoma and ultimately, to metastasis.
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From this perspective, one of the obvious strategies would be:
1. to directly target the key regulators of CRC cancers
2. to streamline the critical Phase II and Phase III to obtain faster and more reliable re‐
sponses regarding the drug’s efficacy.
This strategy may save years of efforts and millions of dollars, giving that the average usual
time for developing a new drug is ten years and with a total cost amount to billions of dollars.
But in contrast, because a new drug has to show a benefit compared to an already approved
treatment, the number of patients involved in a pivotal trials is increasing more and more in
order to reach significance, and a similar trend is noted for the duration of the trial, that is
directly linked to safety. Therefore, regarding the constraints imposed by regulatory author‐
ities nowadays, it seems difficult to save on size and length of clinical trials.
In the mid-1990s, the pharmaceutical community has already attempted to increase R&D
productivity by embarking in a technological shift. That was the time of the inevitable high-
throughput screening, which combined with the “all-Omics” supposed to reduce costs and
blew up success rates [4]. As we have seen, this approach, maybe too reductionist in the
sense that it does not allow getting an idea of the full biological properties (ADME, toxici‐
ty,etc…) of a compound at an early stage, has favored the quantity instead of quality and
has not kept its promises [1].
Today, efforts have to be made to clearly address the early clinical discovery steps, with the
goal to better qualify “leads” to increase the signal-to-noise ratio of drugs entering into clini‐
cal trials. This point of view is supported by the important failure rate subsisting in Phases
III (Fig1b), suggesting an overestimation of the efficacy of candidate molecules during pre‐
clinical tests. One of the important reasons may be the use of irrelevant models or models
not predictive enough. Therefore, the development of relevant and predictive models is key
to increase the quality of preclinical researches and to increase the success rate of new drugs.
Consequently, the foundations of the drug discovery process have to be reconsidered by
giving definitively more emphasis to the quality of preclinical validations and by encourag‐
ing the design of new pertinent models, including human 3D (three dimensional) in vitro cell
models and tissue explants.
This article is intended to give an overview of the current knowledge about CRC and the
different models commonly used to study CRC, in order to identify the most suitable bio-
systems for optimal development of new CRC therapies. The first part will describe the
pathology and its molecular basis, and the various drugs that are currently in clinical use or
under development. Then, in the second part we will review and discuss the use of cancer
cell line collections, genetically engineered mouse models (GEM), primary human tumors
xenografts (PDX) and ex vivo organotypic cultures (EVOC) to identify and validate anticanc‐
er colon therapeutics.
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Figure 1. Success rate of drug development. Overall success rate of clinical trials for phases I-III from 2003 to 2010
corresponding to 4275 drugs and 7300 indications (a), success rate for phase II and III divided according to therapeu‐




Colorectal cancer is one of the major health concerns in the Western world. CRC is the sec‐
ond most frequently diagnosed cancer in men and women, right after lung cancer. It repre‐
sents the second leading cause of cancer-related deaths, both in the United States and in
Europe, with a significant rate of 9% and 13% of total cancer deaths, respectively (Fig.2). The
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Figure 2. Cancer deaths anticipated in 2011. Estimated leading cancer sites mortality in US and in European Union
(EU-27) for the year 2011 expressed as percent of total cancer deaths. Column diagrams highlight the mortality rate
within the population specifically affected by colon cancer. Rates are standardized to the World Standard Population.




Loss of APC function is the initial molecular event that leads to adenoma formation. Indeed,
germline mutations in the gene APC have been identified as the cause of familial adenoma‐
tous polyposis (FAP), an inheritable intestinal cancer syndrome [5], and APC is mutated in
more than 80% of all sporadic cancers [6]. APC belongs to the WNT signaling pathway (Fig‐
ure 3) where it interacts with other proteins like AXINS and GSK3β to make a complex that
down-regulates the cellular levels of β-CATENIN (see [7] for review). Activating mutations
in β-CATENIN gene have also been observed in more than 10% of CRC [8]. When activated,
β-CATENIN interacts in the nucleus with the transcriptional complex LEF/TCF to induce
the expression of growth promoting genes, like MYC and CYCLIN D1. Additional waves of
genetic and epigenetic alterations (KRAS, P53, etc…) will follow this early set of molecular






Figure 3. Shematic representation of the WNT signaling pathway. WNT proteins bind to receptors of the Frizzled and
LRP families on the cell surface. Through several cytoplasmic components, the signal is transduced to β-CATENIN,
which enters the nucleus and forms a complex with LEF and TCF4 to activate transcription of WNT target genes. Muta‐
tions in APC, Axin and β-CATENIN genes lead to constitutive activation of WNT signaling and ultimately to cancer de‐
velopment.
2.2. Clinical management
It is commonly accepted that CRC results from complex interactions between inherited and
environmental factors, with a large contribution of dietary and life style factors as suggest‐
ed by wide geographical risk variations. However, the primary risk factor of CRC is age,
as 90% of the cases are diagnosed over the age of 50 years [9]. Surgical removal remains
the most efficient treatment for early stage colorectal cancer, and may be curative for can‐
cers that  have not spread.  Patients whose cancer is  detected at  an early,  localized stage
present a 5-year survival around 90% [9]. For these reasons, US and European Union have
implemented preventive screening programs that have contributed to slightly reduce mor‐
bidity and mortality [10].
Unfortunately, as in many other forms of cancer, colon cancer does not display too many
symptoms, develops slowly over a period of several years, and only manifests itself when
the disease begins to extend. Adjuvant chemotherapy in combination with surgery or radia‐
tion is then the usual treatment. However, 5 of the 9 anti-CRC drugs approved by the FDA
today are basic cytotoxic chemotherapeutics that attack cancer cells at a very fundamental
level (i.e. the cell division machinery) without specific targets, resulting in poor effectiveness
and strong side-effects (e.g., oxaliplatin; Table 1).
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Moreover, in more advanced cases, when CRC has spread to distant organs in the form of
metastasis and escape any surgical therapy, the 5-year survival dramatically drops to 12%
[9]. These figures underline the urgent need to expand the standard therapy options by
turning to more focused therapeutic strategies. In recent years, combination of basic chemo‐
therapies with targeted therapies, in the form of humanized monoclonal antibodies directed
against the vascular endothelial growth factor VEGF (Bevacizumab) to prevent the growth
of blood vessels to the tumor, or directed against the EGF receptor (Cetuximab, Panitumu‐
mab) to block mitogenic factors that promote cancer growth, have been introduced as possi‐
ble therapeutic protocol and used routinely to treat standard CRCs, as well as metastatic
CRCs (Table 1). During the preparation of this manuscript (August 2012), another recombi‐
nant protein active against angiogenesis, Aflibercept, has been approved by the FDA for the
treatment of metastatic CRC in second-line therapy (Table 1). This new VEGF inhibitor has
demonstrated a significant advance over currently available therapy in a Phase III study
(improvement in response rate and in overall survival; [11]).
Nonetheless, CRC remains a devastating disease since nearly 35-40% of all patients diag‐
nosed will die from the disease (Fig.2). Accordingly, the expansion and the development
of new path of therapy, like drugs specifically targeting the self-renewal of intestinal can‐
cer  stem cells  -  a  tumor cell  population from which CRC is  supposed to  relapse [12]  –
remains relevant.
Table 1. Anti-cancer colorectal drugs approved by the Food and Drug Administration. Drugs are presented sorted by
type, i.e. small molecule or biologics (including recombinant protein and monoclonal antibody, noted mAb). Source:
National Cancer Institute database, 2012.
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2.3. Designing new therapies
A classical approach of drug design in oncology is to identify modulators of specific signal
transduction pathways that are important for tumor growth, survival, invasion, and meta‐
stasis. Because aberrant WNT signaling has been shown to drive the earliest step of colorec‐
tal tumorigenesis (see before), the WNT/β-CATENIN pathway appears critical for CRC and
therefore represents a target of choice for the development of CRC therapeutics.
 
2.3.1. Oncogenic WNT/β-CATENIN pathway as a therapeutic target
Many experiments have demonstrated that disruption of the WNT signaling pathway lead
to consistent growth inhibition and apoptosis of CRC cell lines and effective inhibition of tu‐
mor growth in CRC animal models. These results can be achieved by modulating the path‐
way at different levels, from the membrane receptor to the final nuclear transcription factors
(Figure 3). A significant number of proof of principle studies have already been published,
including targeted inhibition of WNT1-2, FZD or LRP5/6 receptors by antibodies or inhibito‐
ry fusion proteins [13-15], inactivation of the pathway by re-expression of WIF1 (WNT-in‐
hibitory factor-1) or through restoration of tumor suppressors APC and Axin expression
[16], expression of a dominant-negative mutant to block the transcription factor TCF4 [17],
and finally direct inhibition of β-CATENIN using RNA interfering technologies in vitro and
in vivo [18, 19]. Taken together, these data provide a strong biological rationale for drugging
the WNT/β-CATENIN signaling pathway.
In addition, recent evidence also points to a role for WNT/β-CATENIN signaling in the
modulation of cancer stem cells. It is now well documented that a number of critical path‐
ways regulating stem cell maintenance and normal developmental processes (e.g. HEDGE‐
HOG-GLI, NOTCH, TGF) are also involved in the self-renewal and differentiation of cancer
stem cells whose tumors are initiated [20]. Consequently, in a way similar to the HEDGE‐
HOG-GLI pathway [21], a large number of high-throughput cell-based screening strategies,
mainly designed to disrupt TCF/β-CATENIN interaction, have led to the identification of
promising molecules as inhibitors of WNT/β-CATENIN pathway (reviewed by [22]).
However, currently few of these compounds have progressed beyond the preclinical stages.
To date, the only compound designed to specifically disrupt β-CATENIN is developed for
the treatment of Familial Adenomatous Polyposis (FAP), an inherited form of colon cancer.
This new RNAi-based therapeutic known as CEQ508 consists of a modified E.coli bacterium
that is able to express and deliver a shRNA to the epithelial cells of the gastrointestinal mu‐
cosa after ingestion by the patient [23]. CEQ508, which has shown efficiency in silencing β-
CATENIN and preventing polyp formation in the APCmin FAP mouse model, is now in a
Phase I clinical trial (Table 2).
Alternatively, a possible way of interfering with the WNT/β-CATENIN cascade, even if not
direct, may reside in the manipulation of KLF4 levels. KLF4 (Kruppel-like factor 4) is a tu‐
mor suppressor factor which is typically deficient in a variety of cancers, including colorec‐
tal cancer. In addition to controlling the cell cycle regulator cyclin D1, KLF4 has also been
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shown to inhibit the expression of β-CATENIN [24]. Therefore, the modulation of KLF4 ex‐
pression may represent a novel therapeutic approach for β-CATENIN-driven malignancies.
LOR-253 [25], a compound that stimulates KLF4 through the inhibition of the human metal-
regulatory transcription 1 (MTF1), is currently in a Phase I clinical study (Table 2).
It is noteworthy that despite the significance of this signaling axis for the treatment of spora‐
dic colorectal cancer, none of the therapies engaged to date in CRC clinical trials are directly
targeting WNT/β-CATENIN pathway members. Nonetheless, considering the huge effort
done at the research level to identify potential antagonists and the few candidate already en‐
gaged into preclinical studies, no doubt that innovative therapies will emerge from this
promising pathway in a near future.
 
2.3.2. Acquired tumor resistance and targeted therapies
In the recent years, a cohort of oncogenes, including BRAF, KRAS, NRAS, PI3K, PTEN and
SMAD4, have been found mutated in CRC with significant frequencies ranging from 6%
(NRAS) to 40% (KRAS) [26]. These observations pinpoint one of the most challenging as‐
pects of anticancer therapy that is intrinsic or acquired drug resistance. Indeed, several stud‐
ies have shown that these mutations are associated with the lack of response to Cetuximab
and Panitumumab (anti-EGFR therapies) observed in a subset of chemorefractory metastatic
CRCs, suggesting that the corresponding deregulated signaling pathways are responsible
for the occurrence of resistance of the tumor to the clinical treatment [27-28]. As a result,
downstream key components (mostly protein kinases) of these constitutively activated
growth-related signaling cascades have become targets for drug development. Small mole‐
cules inhibitors of BRAF (ARQ 736), MEK (Selumetinib, PD-0325901), PI3K (PX-866, BEZ235,
BKM120), and MET (Tivantinib) that were able to reverse resistance to EGFR inhibitor thera‐
py in pre-clinical studies [29-31] are currently in CRC Phase II clinical studies (Table 2). This
new class of drugs appears therefore as a promising third-line therapeutic strategy for colon
cancer patients, especially after recurrence of tumor resistance. However, a recent publica‐
tion reporting the apparition of resistance to PI3K and AKT inhibitors mediated by β-CATE‐
NIN overactivation, may temper this enthusiasm. Depending on the tumor status, from pro-
apoptotic tumor suppressor, PI3K or AKT inhibitors could become metastatic inducers [32].
Similar side effect induction mechanisms have also been reported in CRC for the
BRAF(V600E) inhibitor Vemurafenib that triggers paradoxical EGFR activation [33]. All to‐
gether, the complexity of these results supports the arrival of a personalized medicine,
where a careful profiling of tumors will be useful to stratify patient population in order to




2.3.3. New anti-angiogenesis therapies
As previously mentioned, until recently the humanized monoclonal antibody Bevacizumab
against VEGF was the only anti-angiogenesis agent approved by FDA. It is now completed
by Aflibercept, a recombinant protein consisting of the key domains of VEGF receptors 1
and 2. The compound captures and blocks all isoforms of VEGF-A and VEGF-B growth fac‐
tors, as well as placental growth factors [34]. Due to improvement in the understanding of
the critical role of angiogenesis in the maintenance of CRC tumors and the spread of their
metastasis, anti-angiogenesis has become an area of active investigation [35]. However, the
recent failure in Phase III first-line studies of two promising compounds (Sunitunib in 2009
and Cediranib in 2010) has cast serious doubt on that strategy. Therefore, the approval of
Aflibercept provides timely support to the further development of anti-angiogenics as treat‐
ment for metastatic CRC. Today, 4 additional therapeutic agents that target VEGF, Ramucir‐
umab [36], Icrucumab [37], Regorafenib [38] and Vatalanib [39-40] are under clinical
evaluation (Table 2). This battery of anti-angiogenics is supplemented by AMG386, a re‐
combinant peptide-antibody fusion protein (peptibody) which targets another signaling
pathway involved in tumoral angiogenesis, the angiopoietin axis [41]. AMG386, which in‐
hibits the interaction between the ligands ANGIOPOIETIN-1 and ANGIOPOIETIN-2 with
their TIE2 receptor, is currently in Phase II. Finally, a phase III trial was also recently initiat‐
ed (May 2012) to evaluate TAS-102, a combination agent composed of the cytotoxic pyrimi‐
dine analog TFT and a thymidine phosphorylase inhibitor (TPI) with antineoplastic activity
(Table 2). TAS-102 mechanism of action is based on the inhibition of the thymidine phos‐
phorylase (TYMP) also known as the platelet-derived endothelial cell growth factor, a po‐
tent angiogenic factor [42]. In this context, it is important to point out that differences in the
efficiency to block angiogenesis and tumor progression have been observed between pre‐
clinical models and clinical trials, when comparing antibodies with small molecules [35].
These discrepancies in clinical outcome underline the necessity to validate compounds on
relevant models, preferentially based on human tissues, very early during drug develop‐
ment process.
 
2.3.4. Other cellular mechanisms under target
Modifications in the epigenetic landscape are commonly associated with cancer, but on the
contrary to genetic mutations, these changes are potentially reversible and therefore drugga‐
ble. Most of the epigenetic drugs discovered to date modulate DNA methylation or histone
acetylation. Four epigenetic drugs have already been approved by FDA for use in clinic
against various cancers. An additional one, the histone deacetylase (HDAC) inhibitor Resmi‐
nostat [43] is currently being studied in patients with CRC, in a phase I/II trial (Table 2).
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Table 2. Anti-cancer drugs in colorectal clinical trials. This table gives an overview of the main colorectal cancer thera‐
pies being currently evaluated in clinical trials. Drugs are presented sorted by type, i.e. small molecule or biologics. For
each compound, the pathway target and clinical status is provided. Source: National Cancer Institute database, 2012
and the clinical database of the Journal of Gene Medicine (http://www.wiley.com/legacy/wileychi/genmed/clinical).
2.3.5. Unconventional approaches
Oncolytic viral therapy represents an appealing alternative therapeutic strategy for the treat‐
ment of CRC, both as single agent or in combination with existing clinical regimens. Onco‐
lytic viruses, like the vaccinia virus (a virus previously used for worldwide vaccination
against smallpox), have the property to selectively infect and destroy tumor cells with limit‐
ed or no toxicity to normal tissues. These viruses efficiently replicate in tumor tissue, cause
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tumor lyses and stimulate antitumor immune response. During the last decade, numerous
mutants have been engineered to improve their tumor specificity and antitumor efficacy,
and to allow tracking of viral delivering by non-invasive imaging [44]. No less than five on‐
colytic virotherapies are currently evaluated in clinical trials for metastatic CRC indication,
including ColoAd1, derived from an adenovirus [45], NV1020, derived from an Herpes sim‐
plex virus [46], Reolysin, a reovirus [47], and JX-594 [48] and GL-ONC1 [49] both derived
from vaccinia viruses, reflecting the many hopes carried by this emerging treatment modali‐
ty. However, it is noteworthy to mention that there are still some difficulties to viral infec‐
tion. Solid tumors have a complex microenvironment that includes disorganized
surrounding stroma, poor vascular network as well as high interstitial fluid pressure. All
these parameters will limit viral delivery since viral penetration directly depends on cellular
packing density and adhesion between cancer cells [50]. Moreover, hypoxia reduces viral
replication, and therefore oncolytic efficiency, without affecting tumoral cells viability [51].
These observations highlight how choosing the right experimental validation model, e.g. 3D
cell cultures or spheroids in vitro, or patient primary-derived xenografts that retain tumoral
architecture complexity in vivo, will be critical for future clinical success.
This inventory of new drugs for the treatment of colorectal cancer highlights the diversity of
approaches being considered to combat the disease. Whether based on small molecules,
humanized antibodies or modified viruses, their success in further clinical assessment is
largely related to the quality of their preclinical evaluation. This is why both the choice of
appropriate existing model systems and the development of more clinically relevant and
predictive pre-clinical models appear critical in overcoming the high attrition rates of com‐
pounds entering clinical trials.
Current research is also focusing on the development of biomarkers that will be useful for
the early detection of CRC, as well as for fine-tuning drug regimen and following efficacy
during trials and treatments. To date, only a few markers have been recommended for prac‐
tical use in clinic [52] but large-scale genomics technology combined with advanced statisti‐
cal analyses should generate soon new biomarker panels for CRC diagnosis [53]. Then, it
will be interesting to see how these biomarkers could be implemented in preclinical stages
to improve drug selection.
 
3. Preclinical models
3.1. Colon cancer cell lines
It is worth mentioning that most of our understanding of the molecular mechanisms in‐
volved in CRC come from studies done on mouse or human cell lines that represent only a
highly selected fraction of the original tumor and that may have acquired in vitro additional
genetic abnormalities. Moreover, isolated cells grown on plastic dish flooded with growth
factors appear retrospectively as a very poor model system to elucidate human CRC biolo‐
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gy, especially with regard to the importance of growth signaling pathways (EGF/FGF) and
tumor/stroma interactions in CRC progression. Clearly, the scientific community has taken
into account these limitations, as shown by the growing interest for more complex models
(e.g. 3D spheroids). However, although imperfect, colon cancer cell lines still represent a
unique resource that can be extremely valuable in term of genetic manipulation and high-
throughput screening, with cell viability, cell proliferation or promoter specific reporter ac‐
tivity being the usual endpoints followed. Several initiatives have been launched to
maximize their utility in large scale drug discovery programs.
3.1.1. NCI-60 cancer cell lines collection
The NCI60 is a collection of 59 human cancer cell lines derived from diverse tissues, includ‐
ing colon (HT-29, COLO-205, HCT-15), which was established in the early 1990s by the
Sanger institute (http://www.sanger.ac.uk/genetics/CGP/NCI). In an attempt to identify new
active molecules, over 100,000 chemical compounds were pharmacologically tested in this
cell line set. But disappointingly, most of the selected positive candidates were typical cyto‐
toxics, affecting cancer cells via general fundamental cellular processes, like cell cycle regu‐
lation. These cell lines are under further characterization by sequencing for mutations in
known human oncogenes. Interestingly, this resource can be screened on demand for any
chemical or biological agent. As an example, the NCI60 has been recently used to determine
the permissivity of standard cancer cell lines to VACV infection and replication, with the
aim to better characterize viral oncolytic therapeutic strategies [54].
3.1.2. The Cancer Genome Project
The emergence of tumor acquired resistance to pharmacological inhibitors linked to muta‐
tions in driver oncogenes has recently revived the interest for cancer cell lines. Indeed, an
extensive characterization of cell lines at the genomic and genetic levels will allow determin‐
ing a genetic profile predictive of drug sensitivity. Such a signature will help to stratify pa‐
tient population and identify efficient therapeutics combination, as long as cell lines reflect
real tumor biology. In this perspective, the Sanger Cancer Institute has started the genetic
characterization of a panel of 800 cancer cell lines (The Cancer Genome Project, http://
www.sanger.ac.uk/genetics/CGP). Using current high throughput techniques this program
intends to provide information on mutations, copy number variations, single nucleotide
polymorphisms (SNPs) and microsatellite instability of usual cancer cell lines.
3.1.3. The Cancer Cell Line Encyclopedia
Similarly, the cancer cell line encyclopedia project is a joint initiative between The Novartis
Institutes for Biomedical research and scientists from the Broad Institute (http://www.broad‐
institute.org/ccle/home) to provide a detailed genetic and pharmacologic characterization of
a panel of 1000 human cancer cell lines, including more than 60 CRC cell lines. Again, the
ultimate purpose of this project is to establish genetic maps that would predict anticancer
drug sensitivity [55].
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3.1.4. Biomimetic cell culture models
The derivation of a cancer cell line from the primary tumor is not an obvious process, and
for many cancers, few if any cell line can be obtained. A success rate of less than 10% has
been reported for the establishment of human colon cancer cell lines grew immediately in
vitro from fresh tumors [56]. Elasticity of the surrounding microenvironment has been point‐
ed out as a critical parameter of in vitro cell growth. Indeed, culture plastic dishes are much
more rigid than the epithelial wall of the intestine (10000 kPa vs 40 kPa). More importantly,
depending on the stiffness of the substrate, cells can be differentially sensitive to drugs in
term of spreading and apoptosis-induction, notably because of the expression and presenta‐
tion of surface receptors [57]. Therefore, the choice of an appropriate biomimetic substrate
that will preserve the in vivo phenotype appears decisive not only for cell survival but also
for clinical relevance. Soft polymer surface, with different degrees of stiffness reproducing
the original tumor environment have been engineered (ExCellness Biotech) and are now
available to improve 2D or 3D cultures.
3.1.5. Colon cancer stem cell models
Cancer stem cells (CSCs) are a discrete self-renewing tumor cell subpopulation that can dif‐
ferentiate into multiple lineages, drive tumor growth and metastasis. Moreover, CSCs are
thought to be responsible for tumor recurrence after chemotherapy and radiotherapy. One
of the characteristic of the CSCs is their ability to form spherical cell colonies when they are
cultured in chemically defined serum-free medium at a relative low density [58]. This mod‐
el, also called colonospheres, constitutes a unique in vitro system to elaborate therapeutic
strategies that specifically target colon CSCs, like oncolytic adenoviruses developed to target
specific CSCs antigens (e.g. CD44 or LGR5). In addition, sorting of CSCs based on specific
surface epitopes expression has also been used to enrich culture in tumor initiating cells in
order to increase the success rate of cell line establishment and therefore improve cell line
representation for CRC.
 
3.2. Multicellular Spheroid models
Early stage development of novel anti cancer treatment requires in vitro methods able to de‐
liver fast, reliable and predictive results. To select the most active molecule lead in a library,
pharmaceutical industry has turned its attention to High Throughput Screening (HTS) tests
which mimic human tissues. Furthermore, 3-Dimensional (3D) test system has been widely
accepted as being more informative and relevant than classical 2D cell systems. Combina‐
tion of HTS and 3D models such as the multicellular tumor spheroid model has been point‐
ed out having the potential to increase predictability of clinical efficacy from in vitro
validation therefore contributing savings in both development cost and time [59]. Advantag‐
es of spheroids compared to classical 2D cell line culture have been reported [60]. Indeed,
proteomic analysis of multicellular spheroids versus monolayers cultures identifies differen‐
tial protein expression relevant to tumor cell proliferation, survival, and chemoresistance.
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Consequently, spheroids strategy has been used for the screening of new anticancer agents,
like compounds that modulate apoptosis pathways [61].
Standardized spherical microtissue production in a 96 or 384-well hanging-drop multiwell
plate format on robotic platform has been successfully achieved by 3D Biomatrix and In‐
sphero AG. Formation of standardized spheroids rely on the use of A431.H9, a human epi‐
thelial carcinoma cells, [62] or the colon cancer cell line HCT116 [63]. Interestingly, loss of
cancer drug activity in HCT-116 cells during spheroid formation in a 3D spheroid cell cul‐
ture system has been reported [64]. Spheroid cell models also enable the study of colon can‐
cer chemoresistance and metastasis [65].
 
3.3. Colon cancer animal models
3.3.1. Chemically induced animal models
Colon cancer can be induced in mouse by specific carcinogens like 1,2-dimethylhydrazine
(DMH) and azoxymethane (AOM). Exposure of the mouse intestine to these chemicals trig‐
gers rapid and reproducible tumor induction which recapitulates the adenoma-carcinoma
sequence that occurs in human sporadic CRCs, with the notable exception however of the
invasive and metastatic stage. The application of colon carcinogenesis treatment to CRC
mouse model, like the Apcmin/+ animals, results in an increased tumor incidence by up to 6
fold. Interestingly, differences in genetic mutations that arise in chemically induced colon
tumor models are largely carcinogen specific. K-Ras mutations are predominant in the DMH
model, while AOM treated mice exhibit tumors with activating mutations in the β-catenin
gene [66]. These models could therefore be useful to assess therapies targeting specific CRC
signaling axis.
3.3.2. Apc min/+ mice
The multiple intestinal neoplasia (Min) mouse was identified following random mutagene‐
sis with ethylnitrosourea [67]. A mutation in the Apc gene was identified as the cause of the
disease, like in the human Familial Adenomatous Polyposys (FAP). However, Although
Apcmin/+ mice spontaneously form a large number of benign adenomas in the small intestine,
colon tumors develop in fewer than half of the animals, in contrast to human FAP patients
which routinely develop invasive carcinomas.
3.3.3. Genetically Engineered Mouse models (GEMs)
The main purpose for developing genetically engineered mice is to model the human dis‐
ease in order to first better understand the biological processes underlying normal and ma‐
lignant cell physiology, and second to establish a reliable preclinical model mimicking the
true biology of human cancer and useful for drug discovery. In an attempt to accurately
model the phenotype observed in FAP or sporadic CRC patients, a constellation of Apc ge‐
netically engineered mice, all based on the loss of the wild-type Apc allele, have been creat‐
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ed (see [68] for review). To date, GEMs have been extensively used to demonstrate the
function of candidate genes in CRC tumorigenesis, and the fact that tumors occur and devel‐
op naturally in the host constitutes undeniably an advantage of transgenic models compare
to xenograft models.
The main disadvantage, except the time and the cost required to generate and maintain such
animals, lies in the fact that none of these Apc mouse models consistently display metasta‐
sis, while treating metastasis is the current challenge.
 
3.4. Xenograft Models
The development of cancer xenograft models allows in vivo testing required for the predic‐
tive assessment of the clinical tolerability and efficacy of therapeutic agents. For decades,
xenografts have been generated from human tumor cell lines that have been selected by in
vitro culture.
3.4.1. Subcutaneous xenografts
As standard, tumor cells are implanted subcutaneous in the hindflank region of immunodefi‐
cient mice (e.g. Nude, NSG) to prevent rejection. Tumor growth during the treatment period
is monitored either by measuring the tumor mass on the animals using Vernier calipers or by
recording the activity of specific markers, like luminescent (Luciferase) or fluorescent (GFP)
reporters, using non invasive imaging. At the end of the experiment, animals are euthanized
and tumors are collected for histological or genetic analyses. Many applications are possible:
complex growth competition assays can be performed inside a same tumor by injecting a mix
of  genetically  modified tumor cell  population,  each expressing a  specific  reporter  (Red/
Green assay). These assays allow the identification of new oncogenic targets, revealed by growth
advantage, and therefore critical for tumor development [69]. Subcutaneous xenografts are
useful for the study of tumor / stroma / vascular network interactions, which is not possible in
cell lines. Nonetheless, this heterotypic human/mouse model has its limitations since some
murine ligands are not able to activate human receptors (e.g. HGF/MET, [70]). In addition,
some CRC cell lines, even if implanted subcutaneous, can produce distant metastasis to the
lung or the lymphatic nodes, allowing to study the effect of therapies specifically designed
against metastatic dissemination and growth (C. Mas, pers. comm.).
Here it is interesting to note that at the preclinical level, the in vivo antiangiogenic activity of
Sunitinib (see “New anti-angiogenesis therapies” section before) was evaluated in sub-cuta‐
neous xenograft tumor models derived from HT29 and Colo205 human colon carcinoma cell
lines implanted in athymic mice [71-72]. However, thereafter no advantage in anti-tumor ef‐
ficacy could be shown in Phase III trial. Although the reasons for this failure are not clearly
established, the genetic heterogeneity observed in primary CRC patient tumors could ex‐
plain this lack of efficacy: in vitro selected cell lines are not enough representative of CRC
patient’s tumors. This observation suggests that new models including large tumor panels
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able to recapitulate the biological heterogeneity of patient's populations appear necessary
for an accurate evaluation of molecular targeted agents.
3.4.2. Orthotopic xenografts
A number of observations suggest that the behavior of tumor cells can be significantly dif‐
ferent when implanted as a subcutaneous xenograft, compared to their behavior when
grown into the tissue of origin. For these reasons, orthotopic models are thought to be better
predictors of drug efficacy and are more clinically relevant. To this purpose, intracolonic
xenografts have been developed. Technically, a small incision is made in the abdomen of the
immunodeficient mouse, directly over the colon, and CRC cells are implanted under the se‐
rosa of the colon. Local tumor growth on the colon is then monitored. Although more realis‐
tic, the use of orthotopic xenograft models does not guarantee success. The efficacy of
Semaxanib, an antiangiogenic molecule, has been tested in preclinical stages using an intra‐
colonic Xenograft [73] but compound development was stopped after negative results from
Phase III. Again, representation of patient heterogeneity should be taken into account at the
preclinical level.
Finally, if the use of selected tumor lines and the value of the mouse as a host could be ques‐
tionable in xenograft models, the response end points, survival end points, and tumor cell
killing end points that are usually used during in vivo efficacy studies remain in line with
clinical investigations.
3.4.3. Patient-derived xenograft models (PDXs)
In order to circumvent the difficulties of establishing new cell lines, as well as to establish an
in vivo model preserving the histopathological characteristics of the original tumor, investi‐
gators have developed a new xenograft system based on the direct grafting of human tumor
fragment into immunodeficient mice (Figure 4). Several CRC patient-derived xenograft col‐
lections (PDX) have been reported, with an average tumor take rate of over 60% [56, 74-75].
They can be cryopreserved and re-established in mice as needed, or maintained as xeno‐
grafts from mice to mice. Intensive characterization has demonstrated that the architecture
of PDX tumors, their gene expression profile and their chromosomal instability remains
very similar to the parental tumor, even after successive passages [75-76]. Importantly, high
correlation between drug activity in PDX and clinical outcome has been reported, making
this model a valuable pharmacological tool for drug development [74-75]. Moreover, be‐
cause they are derived from tumor fragment, PDX tumors retains the genetic heterogeneity
existing in the original human tumor and are therefore useful for studies exploring acquired
drug resistance mechanisms [75, 77]. The use of PDX as a model for tumor-stroma interac‐
tion is however less obvious since by the fourth passages human tumor stroma is replaced
by the murine host [75]. All together, the above considerations highlight the potential of the
PDX model to accelerate drug development and predictive biomarker discovery in CRC.
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Figure 4. The PDX model. Sequential steps leading to the establishment of a CRC primary Patient-Derived Tumor Xen‐
ograft collection. Briefly, a CRC tumor fragment coming from surgical waste is directly xenografted in an immunodefi‐
cient mouse (Passage 0). After successful engraftment, new fragments are taken from the mouse hosted human
tumor and xenografted again in multiple immunodeficient mice (Passage 1). A collection of fragments from the re‐
sulting tumors can then be cryopreserved in a tissue bank for subsequent experiments or directly re-engrafted in mice
for expansion (P2, P3, etc…). At any step, tumor fragments can be analyzed and compared to the parental tumor in
terms of gene expression, genetic mutations, genomic stability or histopathological features.
 
3.5. Ex-Vivo Organotypic Culture models (EVOCs)
As previously mentionned, current 2D monolayer culture systems are not enough predictive
of in vivo tumor behavior. Indeed, 3D environement is required to provide essential signal‐
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able to recapitulate the biological heterogeneity of patient's populations appear necessary
for an accurate evaluation of molecular targeted agents.
3.4.2. Orthotopic xenografts
A number of observations suggest that the behavior of tumor cells can be significantly dif‐
ferent when implanted as a subcutaneous xenograft, compared to their behavior when
grown into the tissue of origin. For these reasons, orthotopic models are thought to be better
predictors of drug efficacy and are more clinically relevant. To this purpose, intracolonic
xenografts have been developed. Technically, a small incision is made in the abdomen of the
immunodeficient mouse, directly over the colon, and CRC cells are implanted under the se‐
rosa of the colon. Local tumor growth on the colon is then monitored. Although more realis‐
tic, the use of orthotopic xenograft models does not guarantee success. The efficacy of
Semaxanib, an antiangiogenic molecule, has been tested in preclinical stages using an intra‐
colonic Xenograft [73] but compound development was stopped after negative results from
Phase III. Again, representation of patient heterogeneity should be taken into account at the
preclinical level.
Finally, if the use of selected tumor lines and the value of the mouse as a host could be ques‐
tionable in xenograft models, the response end points, survival end points, and tumor cell
killing end points that are usually used during in vivo efficacy studies remain in line with
clinical investigations.
3.4.3. Patient-derived xenograft models (PDXs)
In order to circumvent the difficulties of establishing new cell lines, as well as to establish an
in vivo model preserving the histopathological characteristics of the original tumor, investi‐
gators have developed a new xenograft system based on the direct grafting of human tumor
fragment into immunodeficient mice (Figure 4). Several CRC patient-derived xenograft col‐
lections (PDX) have been reported, with an average tumor take rate of over 60% [56, 74-75].
They can be cryopreserved and re-established in mice as needed, or maintained as xeno‐
grafts from mice to mice. Intensive characterization has demonstrated that the architecture
of PDX tumors, their gene expression profile and their chromosomal instability remains
very similar to the parental tumor, even after successive passages [75-76]. Importantly, high
correlation between drug activity in PDX and clinical outcome has been reported, making
this model a valuable pharmacological tool for drug development [74-75]. Moreover, be‐
cause they are derived from tumor fragment, PDX tumors retains the genetic heterogeneity
existing in the original human tumor and are therefore useful for studies exploring acquired
drug resistance mechanisms [75, 77]. The use of PDX as a model for tumor-stroma interac‐
tion is however less obvious since by the fourth passages human tumor stroma is replaced
by the murine host [75]. All together, the above considerations highlight the potential of the
PDX model to accelerate drug development and predictive biomarker discovery in CRC.
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Figure 4. The PDX model. Sequential steps leading to the establishment of a CRC primary Patient-Derived Tumor Xen‐
ograft collection. Briefly, a CRC tumor fragment coming from surgical waste is directly xenografted in an immunodefi‐
cient mouse (Passage 0). After successful engraftment, new fragments are taken from the mouse hosted human
tumor and xenografted again in multiple immunodeficient mice (Passage 1). A collection of fragments from the re‐
sulting tumors can then be cryopreserved in a tissue bank for subsequent experiments or directly re-engrafted in mice
for expansion (P2, P3, etc…). At any step, tumor fragments can be analyzed and compared to the parental tumor in
terms of gene expression, genetic mutations, genomic stability or histopathological features.
 
3.5. Ex-Vivo Organotypic Culture models (EVOCs)
As previously mentionned, current 2D monolayer culture systems are not enough predictive
of in vivo tumor behavior. Indeed, 3D environement is required to provide essential signal‐
ing necessary for establishing and maintaining tumor specific morphogenic programs. Thus,
Colon Cancer: Current Treatments and Preclinical Models for the Discovery and Development of New Therapies
http://dx.doi.org/10.5772/53391
449
an ex vivo methodology which can recapitulate physiological processes and generate multi‐
ple experimental replicates from a single tumor, saving at the same time animals involved in
in vivo experiments will be of great benefit. Ex vivo organotypic cultures (EVOCs), by pre‐
serving the original cancer microenvironement (e.g. epithelial-stromal interaction) fulfill this
requirement. Recently, a number of culture methods have been perfected leading to the de‐
velopment of breast, lung, liver and colon EVOC tumor models [78-81]. EVOCs allow the
evaluation of tumor morphology, proliferation, viability and resistance to therapy in vitro.
Moreover, differential gene-expression profiling across tumor and stroma compartments
can be performed, without any contamination coming from a murine host as seen in xeno‐
graft models [78]. Recent observations have shown that CRC EVOCs mimic closely the in
vivo situation, at the immunohistochemical level [81], but also in term of oncogenic pathway
fonctionallity and pharmacodynamic properties [78]. Importantly, dose-response experi‐
ments with the PIK3 inhibitor LY294002 demonstrate that CRC EVOCs may be used to pre‐
dit tumor sensitivity to drugs in a patient-specific manner [78]. EVOCs represent therefore a
highly promising in vitro tumor model, when combined with automated medium-through‐
put analyses, has the potential to significantly enhance preclinical drug evaluation studies.
4. Conclusion
The development of relevant and predictive models is key to increase the quality of preclini‐
cal researches and to increase the success rate of new drugs. Many progresses have been
made in this area to get as closer as possible to in vivo situations of human CRC cancers.
Even though cell lines and animal models are still indispensable, the Xenograft Models,
EVOCs as well as the 3D culture of CRC cancer cells hold the promises for the development
of new, more efficient and safer drugs.
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1. Introduction
Snake venoms contain a complex mixture of proteins and biologically active peptides [1, 2].
Some of these bioactive peptides are derived from precursor proteins that through proteo‐
lytic processing generate mature active polypeptides [3]. As an example, the protein precur‐
sor of natriuretic peptide type-C (CNP) from the Brazilian pit viper Bothrops jararaca venom
and brain originates CNP, a hormone present in several animal species as well as various
isoforms of proline-rich oligopeptides (Bj-PROs) [4, 5]. Bj-PROs were the first natural inhibi‐
tors of angiotensin I-converting enzyme (ACE) described [6]. The metalloproteinase ACE,
the key enzyme of the renin-angiotensin system, displays two homologous active sites, one
at the C-terminal and the other at the N-terminal of the protein [7]. While both active sites
convert angiotensin I into angiotensin II and cleave bradykinin (BK) into BK1-5 and BK1-7,
the C-terminal is more effective in hydrolysis of these vasoactive peptides [8].
Bj-PROs are molecules of 5 to 14 amino acids residues with a pyroglutamyl residue (<E) at
the N-terminus and a proline residue at the C-terminus. Bj-PROs longer than seven amino
acids share similar features, including a high content of proline residues and a C-terminal
tripeptide sequence Ile–Pro–Pro [13]. Since Bj-PROs are ACE inhibitors, they potentiate
some pharmacological activities of BK, such as induction of contractile action of smooth
muscles of guinea-pig ileum in vitro as well as in vivo BK-induced effects on central nervous,
cardiovascular and anti-nociceptive systems [6, 9, 10]. For this reason, these peptides were
initially named bradykinin-potentiating peptides (BPPs). The ability of some Bj-PROs inhib‐
iting ACE turned them in structural models to develop the first non-peptide site directed in‐
hibitor of this enzyme. The development of Captopril in the early 1980s became a paradigm
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for “rational drug design”, a concept much heralded today and made possible by computer
imaging and genome science [11].
Many studies on structure–activity of Bj-PROs showed that a simple analogous structure to
Ala–Pro was optimal for binding to the active site of ACE. Replacement of the carboxyl by a
sulfhydryl group enhanced the inhibitory activity of the analogue by 1,000-fold. This com‐
pound proved to be one of the most potent competitive inhibitors of ACE and, therefore,
turned into a useful drug to treat human hypertension (reviewed by [12]). Captopril was a
blockbuster drug and inspired the creation of several generations of similar antihyperten‐
sive compounds.
However, due to structural diversity of Bj-PROs [13] other mechanisms besides inhibiting
ACE were proposed. In fact, some of these peptides augmenting argininosuccinate synthase
(AS) activity in vitro and in vivo, can also induce rises in free intracellular calcium concentra‐
tion ([Ca2+]i) by acting on muscarinic acetylcholine, BK or yet unidentified receptors [15-18]
or reversal inhibition of nicotinic acetylcholine receptor [19]. These novel mechanisms of ac‐
tion, recently identified for Bj-PROs explain their anti-hypertensive effects [14-17, 20, 21].
Therefore, investigation of Bj-PRO-induced effects through acting on different targets opens
possibilities of applications for these peptides in the treatment of several pathologies lacking
efficient treatment options.
Here, we describe the targets of various Bj-PROs and their potential use to treat different
target-related pathologies, as well as discuss chemical properties of these peptides for ob‐
taining an oral pharmaceutical formulation.
2. Targets of proline-rich oligopeptides from Bothrops jararaca
Recently, argininosuccinate synthase (AS) was identified as another target for the Bj-PROs,
which both in vitro and in vivo positively modulates the activity of this enzyme [14] which
leads to L-arginine synthesis [22]. L-arginine is a nonessential amino acid under normal con‐
ditions as it is obtained from the breakdown of proteins or synthesized de novo from citrul‐
line in the kidneys by AS (EC 6.3.4.5) and argininosuccinate lyase (ASL, EC 4.3.2.1). AS
catalyses the reversible condensation of citrulline with aspartate with consumption of ATP
to form argininosuccinate; ASL catalyzes the conversion of the argininosuccinate to fuma‐
rate and L-arginine, which is released into the circulation [22].
In the liver, enzymes involved in the anabolism of L-arginine, AS and ASL are present; how‐
ever, there is not a net production of L-arginine due to arginase activity (EC 3.5.3.1) as part
of the urea cycle, catalyzes the hydrolysis of L-arginine into L-ornithine and urea. The urea
is then excreted in the urine and L-ornithine is recycled back into the cycle [23]. Further‐
more, AS is the rate-limiting enzyme of the citrulline-nitric oxide (NO) cycle for the supply
of L-arginine which is then metabolized by NO synthase (NOS) to form NO and citrulline
[24-26]. Citrulline, through the reactions catalyzed by AS and ASL may cycle back to argi‐
nine, constituting the citrulline-NO cycle [27, 28]. In summary, AS activity contributes to
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three major different functions in the adult organism depending on the cell/tissue consid‐
ered: (i) ammonia detoxification in the liver, (ii) L-arginine production for the whole organ‐
ism by kidney and (iii) L-arginine synthesis for NO production in many other cells [22].
Three isoforms of NOS catalyze the reaction: the endothelial constitutive NOS (eNOS), the
neuronal constitutive NOS (nNOS) and the inducible NOS (iNOS), reviewed in [29, 30]. NO
is a gaseous molecule capable of interacting with many intracellular targets for triggering a
series of signal transduction pathways, resulting in a stimulatory and inhibitory signals. NO
plays roles in cardiovascular, immune and neuronal control. It is directly involved in arterial
tension control since it regulates the local and systemic resistance of vascular walls, as well
as the sodium balance [31]. The NO produced by endothelial cells reaches neighboring
smooth muscle cells where it activates two types of K+ channels, ATP-sensitive and Ca2+-de‐
pendent [32, 33], and thereby induces the relaxation of blood vessels and brings about vas‐
cular dilation leading direct consequences in processes like erection, arterial pressure
systemic or organ-specific [34].
Due to the great physiological importance of the NO, compounds revealing properties aspo‐
tential NO donors have been protected by patents. They are based on the fact that there are
many pathological states related to NO deficiency (reviewed by [35]). However, a major
problem of NO donors is to achieve a therapeutic dose without reaching a threshold of tox‐
icity. Mostly, if NO is produced in excess around of cells in a pro-oxidant state, NO could
react with reactive oxygen species (ROS) such as superoxide and hydrogen peroxide form‐
ing peroxynitrite and nitrogen oxide III, which has been linked to pathogenesis of neurode‐
generative disorders [35].
The superoxide anion is produced by uncoupling of NOS due to the lack of its natural sub‐
strate L-arginine or tetrahydrobiopterin (BH4) [36], an important cofactor for NOS. Excessive
production of superoxide is explained by increased activity and expression of the enzyme
arginase, which competes with eNOS for its substrate L-arginine [37]. Other possible sources
for elevated concentrations of ROS include increased expression and activity of NADPH
and reduced superoxide dismutase activity [38, 39].
In order to compensate for the deficiency of NO production without induction of toxicity,
addition of exogenous L-arginine in the maintenance of NO production has been investigat‐
ed. The inefficiency of swallowed L-arginine in promoting increase of NO can be explained
by its low availability, due to the first pass effect, since the viability of L-arginine as sub‐
strate for NOS is reduced by the activity of arginase in the liver. Several studies have shown
that induction or activation of arginase may lead to impaired NO production and endothe‐
lial dysfunction (reviewed by [35]).
Thus, NO presents challenges and opportunities to intervene and promote human health.
The study of regulation of NO production becomes important for understanding the mecha‐
nisms which maintain NO levels in a safe range and not injurious to the body.
An important mechanism for control and maintenance of NO levels is achieved by its recy‐
cling via the NO-citrulline cycle. The obtained L-arginine provided by the citrulline-NO cy‐
cle is then directed to sustain NO production, sparing bulk intracellular L-arginine for other
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ever, there is not a net production of L-arginine due to arginase activity (EC 3.5.3.1) as part
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is then excreted in the urine and L-ornithine is recycled back into the cycle [23]. Further‐
more, AS is the rate-limiting enzyme of the citrulline-nitric oxide (NO) cycle for the supply
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as the sodium balance [31]. The NO produced by endothelial cells reaches neighboring
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pendent [32, 33], and thereby induces the relaxation of blood vessels and brings about vas‐
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The superoxide anion is produced by uncoupling of NOS due to the lack of its natural sub‐
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production of superoxide is explained by increased activity and expression of the enzyme
arginase, which competes with eNOS for its substrate L-arginine [37]. Other possible sources
for elevated concentrations of ROS include increased expression and activity of NADPH
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In order to compensate for the deficiency of NO production without induction of toxicity,
addition of exogenous L-arginine in the maintenance of NO production has been investigat‐
ed. The inefficiency of swallowed L-arginine in promoting increase of NO can be explained
by its low availability, due to the first pass effect, since the viability of L-arginine as sub‐
strate for NOS is reduced by the activity of arginase in the liver. Several studies have shown
that induction or activation of arginase may lead to impaired NO production and endothe‐
lial dysfunction (reviewed by [35]).
Thus, NO presents challenges and opportunities to intervene and promote human health.
The study of regulation of NO production becomes important for understanding the mecha‐
nisms which maintain NO levels in a safe range and not injurious to the body.
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metabolic roles [24]. In view of that, compounds that increase AS activity and sustain tightly
NO production avoiding an excess production will ensure adequate bioavailability for prop‐
er physiological functioning. Guerreiro and colleagues demonstrated that a Bj-PRO pro‐
motes activation of AS, assayed in the presence of the substrates ATP, citrulline, and
aspartate, thus leading to NO production by endothelial cells [14]. More recently, we have
demonstrated that other Bj-PROs induce NO production by activation of AS or kinin-B2 re‐
ceptors as well as by M1 muscarinic acetylcholine activation, thereby inducing vasodilata‐
tion in vivo [16, 17].
The patent entitled “Proline-Rich Peptides, Pharmaceutical Composition, use of one or more
peptides and method of treatment” was deposited to protect the use and application of Bj-
PROs and analogous molecules [patent: BR2007/ 000003]. All applications contemplated by
patent BR2007/ 000003 are consistent with the use of PROs as prototype molecules for the
development of new drugs aiming to treat a range of pathological states related to deficien‐
cy in NO production and AS activity, e.g. lung hypertension, preeclampsia, essential hyper‐
tension, coagulopathies and citrullinemia. Some of these applications will be discussed
below.
3. Pulmonary hypertension
Pulmonary hypertension (PH) is an increase in blood pressure in the pulmonary artery, vein
or capillaries, together known as the lung vasculature. In fetus life, PH is a normal state es‐
sential for survival. Since the placenta, not the lung, serves as the organ of gas exchange dur‐
ing embryonic development, most of the right ventricular output crosses from the ductus
arteriosus to the aorta, and only 5–10% of the combined ventricular output is directed to the
pulmonary vascular bed. Pulmonary vascular constriction plays a key role in maintaining
high pulmonary vascular tone during fetal life. At the same time, the fetal lung and pulmo‐
nary vasculature must prepare for the dramatic adaptation to air breathing at the time of
birth [40].
However, PH can continue even after the birth, called persistent pulmonary hypertension
that develops when pulmonary vascular resistance remains elevated, resulting in right-to-
left shunting of blood through fetal circulatory pathways. The pulmonary vascular resist‐
ance may remain elevated due to pulmonary hypoplasia and cause disease states, like
congenital diaphragmatic hernia, as well as impaired development of the pulmonary arter‐
ies, resulting in the meconium aspiration syndrome, or failing adaption of the pulmonary
vascular bed as occurs with perinatal asphyxia [41]. Moreover, PH has more than one etio‐
logical factor, thus it can be classified as idiopathic PH when there is no identifiable cause of
this disease; familial PH with a previous disease history; and associated PH when an under‐
lying cause of PH such as connective tissue disease is present [42].
PH has been reported in patients with chronic hemolytic anemias, including sickle cell dis‐
ease, thalassemia, paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis, malaria,
among other disease states [43, 44]. The exact mechanism(s) involved in the development of
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PH in these patients is unclear. Hemolysis may result in a nitric oxide deficient state
through free hemoglobin scavenging of nitric oxide and release of erythrocyte arginase,
which limits L-arginine, a substrate for nitric oxide synthesis [45].
Nitric oxide is synthesized from terminal nitrogen of L-arginine by NOS. All three NOS iso‐
forms are expressed in the lung and are distinguished by regulation of their activities, as
well as by specific sites and developmental patterns of expression [46]. The isoform eNOS is
expressed in vascular endothelial cells and is believed to be the predominant source of NO
production in pulmonary circulation [40]. This hypothesis is corroborated by the fact that
NO inhalation in premature newborns with severe respiratory failure due to PH provides
improvement of symptoms, accompanied by marked increase in oxygenation [34].
Although large well-designed studies paved the way to Food and Drug Administration
(FDA) approval of therapeutic NO inhalation, it is equally important to note that inhaled
NO did not reduce the mortality, length of hospitalization, or the risk of significant neurode‐
velopmental impairment associated with persistent PH in newborn children [40]. It is
known that at excessive levels NO can react with reactive oxygen species (ROS) such as su‐
peroxide and hydrogen peroxide. Such increase in ROS was observed in the smooth muscle
and adventitia of pulmonary arteries from lambs with chronic intrauterine PH [47, 48],
forming peroxynitrite, an anion with deleterious tissue-oxidant effects [49].
Inhaled NO is usually delivered with high concentrations of oxygen. Whereas hyperoxic
ventilation continues to be a mainstay in the treatment of PH, little is  known about the
side effects of oxygen supply together with NO. The extreme hyperoxia routinely used in
PH management may in fact be toxic to the developing lung due to ROS formation [39, 50,
51]. Superoxide may react with arachidonic acid to increase concentrations of isoprostanes
and may also combine with NO to form peroxynitrite [52] with possible induction of vaso‐
constriction, cytotoxicity, and damage to surfactant proteins and lipids. Moreover, peroxy‐
nitrite has been shown to directly induce NOS uncoupling. New data indicate that even
brief (30 min) periods of exposure to 100% O2 are sufficient to increase reactivity of pulmo‐
nary vessels in healthy lambs [53, 54], to diminish the response of the pulmonary vascula‐
ture to endogenous and exogenous nitric oxide [54], and to increase the activity of cGMP-
specific  phosphodiesterases  [51].  Inhaled  NO  would  theoretically  benefit  patients  with
chronic primary or secondary pulmonary hypertension, but its therapeutic application in
this setting has been limited by the risk of causing rebound pulmonary hypertension, if it
is  inadvertently  discontinued,  and the lack of  practical  home-based continuous delivery
devices.
Therefore, we have proposed an alternative approach for controlled induction of NO pro‐
duction. We believe that cytosolic L-arginine provides a major NO donor. Arginine con‐
centrations subject to metabolic fine-tuning controls will assure that the amino acid is kept
in a homeostatic concentration range. These effects could be achieved by the action of Bj-
PRO on AS, a target unexplored by the pharmaceutical industry. Compounds inducing an
increase in AS expression and activity are promising for the treatment of diseases related
with deficient NO production.
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ance may remain elevated due to pulmonary hypoplasia and cause disease states, like
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vascular bed as occurs with perinatal asphyxia [41]. Moreover, PH has more than one etio‐
logical factor, thus it can be classified as idiopathic PH when there is no identifiable cause of
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Inhaled NO is usually delivered with high concentrations of oxygen. Whereas hyperoxic
ventilation continues to be a mainstay in the treatment of PH, little is  known about the
side effects of oxygen supply together with NO. The extreme hyperoxia routinely used in
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Preeclampsia, a pregnancy-specific syndrome characterized by hypertension, proteinuria
and edema, causes fetal and maternal morbidity and mortality with high incidence in devel‐
oping countries [55]. Symptoms of preeclampsia are currently combated by sodium restric‐
tion, rest and medication for blood pressure control to avoid complications for the mother
and prolong the pregnancy for fetal maturation [56-58]. However, this attempt is rather un‐
specific with possible side effects for the developing fetus [59, 60]. Currently, the only thera‐
py of preeclamsia involves placenta removal resulting in pre-term birth [61]. Therefore,
novel drug development for pregnancy-specific conditions remains a challenge [59].
The pathology of preeclampsia involves systemic inflammation, oxidative stress, alterations
in the levels of angiogenic factors, and vascular reactivity leading to hypertension of the
mother and metabolic alterations in the fetus [61, 62]. A number of evidence suggests that
clinical manifestations are caused by endothelial malfunction including insufficient produc‐
tion of NO [63, 64]. Levels of eNOS, the enzyme responsible for NO synthesis in the endo‐
thelium from L-arginine, are decreased in human umbilical vein endothelial cells from
pregnant women suffering from preeclampsia [62] together with impaired AS expression
[65]. The low availability of L-arginine uncouples eNOS activity, decreases NO production
and increases eNOS-dependent superoxide generation [62, 66], consequently resulting in re‐
duced vasodilatation or in inflammatory processes observed in preeclampsia [66, 67]. There‐
fore, it is expected that the sustained concentration of L-arginine in endothelial cells is likely
to play a critical role not only in the control of systemic blood pressure, but also in inhibition
of inflammatory processes [68].
Recently, we have reported that a Bj-PRO containing ten amino acid residues (Bj-PRO-10c),
activating AS, is able to correct dysfunction of human umbilical vein endothelial cells from
pregnant women suffering from preeclampsia [65] (Figure 1).
Bj-PRO-10c, besides augmenting the activity of AS both in vitro and in vivo [14] increases sig‐
nificantly eNOS expression of human umbilical vein endothelial cells obtained from preg‐
nant women suffering from preeclampsia [65]. It was observed that the increase in NO
levels induced by Bj-PRO-10c diminished the oxidative stress of the endothelial cells of pree‐
clamptic women, shown as a 50% reduction in superoxide levels [65] (Figure 1).
Most importantly, Bj-PRO-10c promoted NO production only in endothelial cells from pa‐
tients suffering from the disorder and not in normotensive pregnant women. In agreement,
Bj-PRO-10c is a molecule endowed with antihypertensive activity that reduced blood pres‐
sure in hypertensive but not in normotensive rats [69]. These observations led to suggest
that Bj-PRO-10c promotes its anti-hypertensive effect in mothers with preeclampsia without
any effect on the blood pressure of the fetus, a problem with drugs currently used for mini‐
mizing health problems arising from preeclampsia. Taken together, Bj-PRO-10c becomes a
potential tool for the development of an efficient drug for preeclampsia treatment.
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Figure 1. Bj-PRO-10c-induced effects on endothelial cell from healthy and pregnant women suffering from
preeclampsia. In endothelial cells from normotensive pregnant women (NORMAL), NO production is adequate to
maintain normal gestation. In cells from patients with the disease (PREECLAMPSIA) both decreased NO production
and increased superoxide (O
2
-) production are observed together with enhanced activity of the enzyme arginase, re‐
duced expression of eNOS and AS and uncoupled eNOS. When endothelial cells from pregnant women suffering from
preeclampsia are exposed to Bj-PRO-10c (PREECLAMPSIA + Bj-PRO-10c), production of NO and superoxide return to
normal ranges, since Bj-PRO-10c initiates a signaling cascade including increases of cytosolic calcium concentration ac‐
tivating eNOS and augmenting AS activity.
5. Citrullinemia
Citrullinemia, a disorder causing serious episodes of neurological symptoms associated
with hyperammonemia involving disorientation, abnormal behaviors (aggression, irritabili‐
ty, and hyperactivity), seizures, coma, and potentially death from brain edema [70], occurs
in two variants: CTLN1 (MIM#215700) or classical neonatal onset, and CTLN2
(MIM#603471) or adult-onset [71-74]. Classical citrullinemia in children is associated with a
mutation in the AS gene [75]. However, in CTLN2 the enzyme reveals normal kinetic prop‐
erties and is quantitatively deficient only in the liver of adult-onset citrullinemia patients
[71-74]. The most successful therapy of CTLN2 has been liver transplantation [76, 77] be‐
cause this treatment prevents hyperammonemic crises and corrects consequent metabolic
disturbances [70].
It has been reported that administration of L-arginine to CTLN2 patients is effective in de‐
creasing blood ammonia concentration [78, 79]. For ammonia detoxification, arginine needs
to enter the liver via the portal vein where is metabolized by mitochondrial arginase to pro‐
vide ornithine for citrulline and aspartate synthesis and for the priming of the urea cycle
[80]. However, care must be taken when administering L-arginine, as fatal cases caused by
L-arginine hydrochloride overdose have been reported [81]. In general, the dose of L-argi‐
nine supplementation used in the treatment of hyperammoaemia is in the high range be‐
tween 100 and 700 mg/kg body weight per day [82-85]. In animal models the effects of
hyperargininaemia can be observed, reflecting toxic effects of high L-arginine concentration
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and making it possible to predict side effects of L-arginine supplementation including cogni‐
tive deficits, epilepsy and a progressive spastic diplegia [86]. Therefore, drugs augmenting
AS activity, the step-limiting enzyme of urea cycle, may be a promising strategy for CTLN2
therapy, since AS is the step-limiting enzyme of the urea cycle. A consequence of increased
AS activity, a final common pathway is triggered resulting in the excretion of waste nitrogen
as urea [87].
As previously mentioned, CTLN2 is not associated with genetic mutation of the AS gene;
however, Saheki et al. identified the SLC25A13 gene as being defective in CTLN2 patients.
This gene encodes for a Ca2+-dependent mitochondrial solute carrier, designated citrin [88].
According to Saheki et al., it is difficult to predict disease-causing effects of citrin deficiency
in CTLN2, since children carrying citrin gene mutations may suffer from CTLN2 after more
than 10 years or several decades of being asymptomatic [70]. In view of that, an option to
prevent CLTN2 in infants with mutation of the citrin gen is being sought, having in mind
that the nutritional management with appropriate intake of proteins only avoids accumula‐
tion of nitrogen [70].
Based on information discussed here, the strategy to increase AS activity in the liver could
be an effective treatment for CTLN2 as well to prevent that children diagnosed as carrying
SLC25A13 mutations from developing CTLN2 in the future [89]. We believed that direct
pharmacological and clinical studies with Bj-PROs for these proposals, could turn them into
a powerful therapeutic tool. The efficiency of Bj-PRO action can yet be improved by the ra‐
tional design of a compound which in the liver accelerates the urea cycle for eliminating am‐
monia or even preventing its accumulation.
6. Conclusion
AS as molecular target for drug development will be important for the treatment of a wide
variety of diseases associated with deficiency of NO production, and also could transform
Bj-PROs or their synthetic analogous into blockbuster medicine, as happened in the 80s with
Captopril [90, 91]. The properties of Bj-PROs enhancing AS activity [14, 17], provides a pre‐
cise pharmacological tool for controlling pathophysiological mechanisms with advantages
of uncontrolled application of exogenous L-arginine or NO donors [92]. For instance, the ef‐
fect of exogenous NO donors is not subject to physiological control, thus being more suscep‐
tible of generating undesired ROS [93, 94]. For all these reasons, keeping NO production in a
safe level, so that a deleterious threshold would not be reached, is of particular interest. In
this way, Bj-PROs should serve as structural models for the development of therapeutic
agents for the treatment of various diseases related to NO deficiency, as cause or effect, as
well AS deficiency.
Chemical properties of Bj-PROs make these peptides even more attractive potential lead
compounds for drug development. For instance, Bj-PRO-10c is able to penetrate cells, where
it remains as an intact molecule for hours [14]. Moreover, Bj-PROs contain a notable high
proline content [13], which gives them some resistance to hydrolysis by aminopeptidases,
Drug Discovery466
carboxypeptidases and endopeptidases [95]. Nevertheless, cyclodextrins or nanocompounds
could provide carriers for Bj-PROs, since drug release could be controlled in accordance
with therapeutic propose [96, 97].
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1. Introduction
This chapter introduces biochemical pharmacology and highlights drug absorption and drug
transformation reactions and a general introduction to pharmacology, drug discovery and
clinical trials for new drug candidates. It also introduces the concept of individualization of
drug therapies. After studying this chapter, one is expected to demonstrate understanding the
following: (i) Linkage between the various pharmacological processes (ii) Routes of drug
administration, (iii) Mechanisms of drug absorption (iv) The kinetics of drug disposition and
concepts, such as volume of distribution, initial dose and half-life, (v) The biotransformation
and excretion of drugs.(vi) The role of biochemical knowledge in the discovery and develop‐
ment of candidate drug compounds into useful drugs (vii) Basic design of clinical trials of new
drugs and the drug approval process.(viii) The linkage between genetic variations and varied
drug responses in different individuals (ix) The various adverse drug reactions in different
patients (x) How different dosage regimens are calculated with respect to the prevailing health
status of individuals and how adjustments are carried out in old patients or geriatrics.
2. Pharmacology
Pharmacology is the science that deals with drugs, their properties, actions and fate in the
body. It embraces the sciences of pharmaceutics (preparation of drugs), therapeutics (treat‐
ment of diseases by use of drugs) and toxicosis or adverse side-effects that arise from the
therapeutic interventions. Pharmacology can be divided into the following processes:-
i. The pharmaceutical process of drugs; deals with chemical synthesis, formulation and
distribution of drugs.
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1. Introduction
This chapter introduces biochemical pharmacology and highlights drug absorption and drug
transformation reactions and a general introduction to pharmacology, drug discovery and
clinical trials for new drug candidates. It also introduces the concept of individualization of
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concepts, such as volume of distribution, initial dose and half-life, (v) The biotransformation
and excretion of drugs.(vi) The role of biochemical knowledge in the discovery and develop‐
ment of candidate drug compounds into useful drugs (vii) Basic design of clinical trials of new
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drug responses in different individuals (ix) The various adverse drug reactions in different
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body. It embraces the sciences of pharmaceutics (preparation of drugs), therapeutics (treat‐
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ii. Pharmacokinetic process; deals with the time course of drug concentration in the
body.This process can be further subdivided into; absorption, distribution, biotrans‐
formation and excretion of the drug.
iii. The pharmacodynamic process; deals with the mechanism of drug action: that is
interaction of drugs with the molecular structures in the body.
iv. The therapeutic process; deals with the clinical response arising from the pharmaco‐
dynamic process.
v. Toxicologic process; deals with adverse effects of drugs arising from either over
dosage or interference of biochemical pathways unrelated to the intended drug
target. The five processes are related as exemplified in Figure1.
3. Biochemical pharmacology
Biochemical pharmacology is concerned with the effects of drugs on biochemical pathways
underlying the pharmacokinetic and pharmacodynamic processes and the subsequent
therapeutic and the toxicological processes. The pharmaceutical process is, however, outside
the realms of biochemical pharmacology.
4. Routes of drug administration and systemic availability
This depends on the actual biochemical characteristics of the drug and the interaction of drug
molecules with body fluids and tissues. The main routes of drug administration are the topical
application, parenteral, and enteral routes.
The route of drug application determines how quickly the drug reaches its site of action. The
choice of the route of administration of a drug, therefore, depends on the therapeutic objectives
of the treatment. For instance, intravenous injection or inhalation may be selected to produce
intense, but rather short-lived effects, whereas oral dosing may be better and more convenient
for long lasting effects and even intensity. The various types of drug administration include;
4.1. Topical application
This is the most direct and easiest mode of drug administration. It involves local application
of a drug to the site of action e.g. eye drop solutions, sprays and lotions for oral, rectal, vaginal
and urethral use. These drugs are absorbed through the cell membranes. Absorption of drugs
through the skin is proportional to their lipid solubility since the epidermis behaves like a
hydrophilic barrier. Lipid insoluble drugs are therefore suspended in oily vehicles to enhance
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Figure 1. Relationships between the five pharmacological processes starting with the entry of the drug and ending
with the clinical response and/or the toxic effects
4.2. Oral administration
The drugs administered orally are absorbed at different sites along the gastrointestinal tract
(GIT):
4.2.1. Oral mucosal or sublingual
Drug absorption is generally rapid because of the rich vascular supply to the mucosa and the ab‐
sence of a stratum corneum. Drugs delivered using this route are not exposed to gastric and in‐
testinal digestive juices and are not subjected to immediate passage through the liver. Therefore
there is no prior biotransformation or first-effect before the drugs enter the systemic circulation.
4.2.2. Stomach and intestine
Absorption depends on different factors such as pH, gastric emptying, intestinal motility and
solubility of solid drugs. The rapidity with which a drug reaches the small intestine is enhanced
when a drug is taken with water and when the stomach is relatively empty. However drugs
absorbed in the stomach and intestine are subjected to first-pass effect.
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This is the preferred route when the oral route is unsuitable because of nausea or if the
drugs  have  objectionable  taste  or  odor.  This  route  also  protects  susceptible  drugs  from
the biotransformation reactions in the liver. However, absorption by this route is often ir‐
regular  and  incomplete.  Formulations  such  as  suppositories  or  enemas  are  applied  via
rectal route.
4.4. Parenteral administration
This mode of administration is also known as injection. It is generally more rapid and enables
more accurate dose selection and predictable absorption. Parenteral routes include;
4.4.1. Subcutaneous injection
This mode of administration is mainly used for non-irritating drugs. It provides even and slows
absorption producing sustained drug effects. Vasoconstrictor agents such as epinephrine can
be added to the drug solution to decrease the rate of absorption.
Large volumes of drugs may, however, be painful because of tissue distention.
4.4.2. Intramuscular injection
This method of drug delivery ensures rapid absorption of the drug in aqueous solutions. Slow
and even absorption is possible when drugs are suspended in oily vehicles.
4.4.3. Intravenous administration
This route ensures rapid delivery of the desired blood concentration of the drug to be obtained
accurately and immediately and is the preferred route of delivery in emergency situations.
Irritating drugs are delivered intravenously because the veins have low sensitivity to pain.
This mode of delivery is also preferred for drug such as the barbiturates and phenytoin, anti-
seizure drugs which dissolve only in rather strong alkaline solution and therefore need the
blood to buffer the pH of the drug solution for better solubility. Drugs such as ethylene di-
amine tetra acetic acid (EDTA) for treatment of heavy-metal poisoning are given by intrave‐
nous injection or through an infusion because they are poorly absorbed in the gut. The other
advantage of this mode of delivery is the avoidance of the hepatic and pulmonary first-pass
effect. Generally, the properties of the drug may determine the route that must be used for
reasonable efficacy.
5. Mechanisms of drug absorption across membranes
In order for drugs to elicit their pharmacological effects, they have to cross the biological
membranes into systemic circulation and reach the site of action. Therefore an insight into the
structure and function of the membrane leads to a better understanding of drug absorption.
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Membranes are phospholipid bi-layers with interspersed integral and peripheral proteins
which behave either as molecular ‘gates’ or ‘pumps’. Molecular gates are non-specific. The
intake of molecules into the cell depends on the charged groups in the pore and the size of
molecule to be transported across the membrane. Molecular pumps, however, are highly
specific and require energy for molecular transport. There are several mechanisms by which
drugs traverse membranes to reach their intended target site and they include the following:
5.1. Simple diffusion
This involves is the passage of polar but uncharged substances across water filled chan‐
nels  in  response  to  the  concentration  gradient.  Simple  diffusion  is  the  mechanism  of
choice for water soluble drugs and those with low molecular weight such as the an aes‐
thetic  nitrous  oxide  (44kD)  and  ethanol  (46  KDa).  The  majority  of  lipid-soluble  drugs
permeate cell  membranes by passive diffusion between the lipid molecules of the mem‐
brane.  The permeation rate of  a  lipid soluble drug depends on the concentration of  the
drug, its lipid/water partition coefficient concentration of protons and the surface area of
the absorbing membrane.  The lipid/water  partition coefficient  of  a  drug is  the principal
factor determining its absorption.
The  higher  the  value  of  lipid/water  partition  coefficient  of  a  drug,  the  more  rapidly  it
will  be  absorbed  and  vice  versa.  The  chemical  force  that  causes  lipid-soluble  drugs  to
move readily across  membranes is  termed the hydrophobic  force since water  molecules
repels  the  lipid-soluble  drugs.  In  most  cases,  drug  absorption  can  be  enhanced  by  ab‐
sorption  enhancers,  such  as  fatty  acids,  phospholipids  and  muco-adhesive  polymers.
These compounds disrupt the lipid bilayer making it  more permeable and also increase
the solubility of insoluble drugs.
5.2. Facilitated diffusion
This type of diffusion is achieved by carrier molecules which combine with the drug in question
to form complexes that can diffuse more rapidly across the membrane than free-drug could
do alone. An example is the transport of nucleotide antimetabolites used in viral or cancer
chemotherapy.
5.3. Active transport of drugs
This is the transport which is linked to a source of energy. Examples of specific active transport
systems are the sodium pump, which maintains high potassium and low sodium ions inside
the cell relative to the external medium and the calcium pump that maintains a high concen‐
tration of calcium inside the sarcoplasmic reticulum and a low concentration around the
myofibrils. Active transport of drugs across membranes have been discovered and an example
is the uptake of pentazocine (a narcotic antagonist) by leukocytes which is dependent upon
energy supply (glucose) and can be inhibited by cyclazocine, which competes for the same
transport mechanism.
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5.4. Pinocytosis and phagocytosis of drugs
Proteins, bacterial toxins and drugs with high molecular weights, (1000 KDa or more) en‐
ter cells by means of pinocytosis and endocytosis. These substances finally enter the lyso‐
somal system.
6. Factors affecting absorption of drugs
6.1. Surface area
For any substance that can penetrate the GIT in measurable amounts, the small intestine
represents the greatest area of absorption. For instance, ethanol can be absorbed by the
stomach, but it is absorbed eight times faster from the small intestine because of the large
surface area provided by the villi. The rate at which the stomach empties its contents into the
small intestine also markedly affects the overall rate at which drugs reach general circulation
after oral administration. For this reason many agents are administered on an empty stomach
with sufficient water to ensure their rapid passage to the small intestine.
6.2. Tissue pH
Drugs can be classified either as organic amines or organic acids and therefore their absorption
is markedly affected by pH. Tertiary amines are not charged at high pH and have a high lipid/
water partition coefficient and hence readily penetrate membranes.
At low pH, the tertiary amine is protonated and has low lipid/water partition coefficient thus

















In case of an organic acid, the same general principle applies. The unprotonated organic acid
at low pH permeates the tissues more readily as compared to the charged form of the drug
at high pH.
Low pH High pH
R-COOH ⇌ R – COO-+ H+
Stomach Intestine
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Therefore organic acids such as barbiturates and acetyl salicylic acid (aspirin) have a higher
absorption rate in the stomach.
The degree of ionization of the drug when in the GIT or other body fluids is the main deter‐
minant of the amount of the drug found in an uncharged form and this depends upon the










If the pH of the fluid is low, the ionization of acidic drugs is less while the ionization of basic
drugs will be high.When the pKa of a drug is equal to the pH of the surrounding fluid, there
is 50% ionization.
7. Types of tissue barriers to drugs
Most of these barriers are typically the same systems that animals use for defense against
invasion by foreign agents. These barriers include the skin, the GIT membranes, blood-brain
barrier and placenta.
7.1. Skin
The superficial layer of the skin, stratum corneum is particularly impermeable to most drugs.
The skin permeability for the drugs is enhanced by using a co-solvent system such as ethanol/
water which increases drug partition into the skin. The lipid domains of the buccal and nasal
mucosa also restrict drug entry and the drugs which permeate are able to do so through passive
diffusion using the hydrophilic trans-cellular spaces and direct permeation through the
membrane.
7.2. Tight junctions
The gap junctions between cells in different cell types within a tissue can form channels for
the passage of drugs between epithelial, endothelial, and mesothelial cells of the same tissue.
These channels comprise of a group of proteins known as connexin. Cells in different tissues
are however connected by tight junctions and these can impair transport between cells in
different tissues. The tight junctions are dynamic structures, which normally regulate the
trafficking of nutrients, medium sized compounds between cells, and form a regulated barrier
in spaces between cells. There is need therefore to use drug absorption enhancers such as bile
salts and long chain acyl-carnitines which act as Ca2+chelatorsand disrupt the tight junctions
thereby improving transport across the junctions. Tight junctions are shown in Figure 2.
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surface area provided by the villi. The rate at which the stomach empties its contents into the
small intestine also markedly affects the overall rate at which drugs reach general circulation
after oral administration. For this reason many agents are administered on an empty stomach
with sufficient water to ensure their rapid passage to the small intestine.
6.2. Tissue pH
Drugs can be classified either as organic amines or organic acids and therefore their absorption
is markedly affected by pH. Tertiary amines are not charged at high pH and have a high lipid/
water partition coefficient and hence readily penetrate membranes.
At low pH, the tertiary amine is protonated and has low lipid/water partition coefficient thus

















In case of an organic acid, the same general principle applies. The unprotonated organic acid
at low pH permeates the tissues more readily as compared to the charged form of the drug
at high pH.
Low pH High pH
R-COOH ⇌ R – COO-+ H+
Stomach Intestine
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Therefore organic acids such as barbiturates and acetyl salicylic acid (aspirin) have a higher
absorption rate in the stomach.
The degree of ionization of the drug when in the GIT or other body fluids is the main deter‐
minant of the amount of the drug found in an uncharged form and this depends upon the










If the pH of the fluid is low, the ionization of acidic drugs is less while the ionization of basic
drugs will be high.When the pKa of a drug is equal to the pH of the surrounding fluid, there
is 50% ionization.
7. Types of tissue barriers to drugs
Most of these barriers are typically the same systems that animals use for defense against
invasion by foreign agents. These barriers include the skin, the GIT membranes, blood-brain
barrier and placenta.
7.1. Skin
The superficial layer of the skin, stratum corneum is particularly impermeable to most drugs.
The skin permeability for the drugs is enhanced by using a co-solvent system such as ethanol/
water which increases drug partition into the skin. The lipid domains of the buccal and nasal
mucosa also restrict drug entry and the drugs which permeate are able to do so through passive
diffusion using the hydrophilic trans-cellular spaces and direct permeation through the
membrane.
7.2. Tight junctions
The gap junctions between cells in different cell types within a tissue can form channels for
the passage of drugs between epithelial, endothelial, and mesothelial cells of the same tissue.
These channels comprise of a group of proteins known as connexin. Cells in different tissues
are however connected by tight junctions and these can impair transport between cells in
different tissues. The tight junctions are dynamic structures, which normally regulate the
trafficking of nutrients, medium sized compounds between cells, and form a regulated barrier
in spaces between cells. There is need therefore to use drug absorption enhancers such as bile
salts and long chain acyl-carnitines which act as Ca2+chelatorsand disrupt the tight junctions
thereby improving transport across the junctions. Tight junctions are shown in Figure 2.
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stages of labour. 
8. Systemic availability of drugs 
A drug will reach systemic arterial circulation only if it is absorbed from the GIT and if it escapes metabolism in the gut, liver, and 
lungs. When the concentration of the drug in plasma is measured at specified time intervals, it is possible to construct 
concentration versus time graph and hence be able to determine the extent of drug availabilityas shown in Figure 4.  
The availability depends on both the extent of absorption and the extent of presystemic metabolism and comprises three aspects; 
Peak concentration (Cmax), Time taken to reach the peak (Tmax) and area under the curve (AUC)as shown in Figure 4. The Cmax and 
Tmax are measures of the rate of availability while AUC is a measure of the extent of availability (i.e. proportion of the administered 
Figure 2. Arrangement of epithelial cells with tight junctions
7.3. Cerebrospinal fluid barrier (CSF)
Epithelial cells which are in contact with the brain ventricular spaces form a barrier to the
movement of drugs. These epithelial cells are connected by occluding zonulae (blood- brain
barrier) as shown in Figure 3. The zonulae severely restrict the passage of most molecules
between the bloodstream and the parenchyma of the central nervous system. Drug entry across
this barrier is through either passive diffusion or carrier mediated transport. Only the lipid
soluble drugs cross into the CSF from blood.
Figur  3. Epithelial cells with tight junctions as part of the blood brain barrier
Epithelial cells that separate the CSF from the brain are connected with tight junctions and are
characterized by marked scarcity of pinocytic vesicles. However, the epithelial cells that lines
the brain are not connected by occluding zonulae and therefore, there is unrestricted passage
of drug molecules from CSF to th  brain. Drugs like penicillin wh ch are not much lipid-soluble
and required in high concentrations for the treatment of brain abscesses are administered
through i trathec l inj ctio s directly into the CFS.
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7.4. Placental barrier
The placental membrane limits the amount of maternal blood following through the placenta
to the foetus and passive diffusion is the main mechanism of drug entry from the maternal
blood to the foetus. The shortest time required for equilibration of a drug between mother and
foetus is about ten minutes and this delay is useful as it can allow a mother to be anaesthetized
during final stages of labour.
8. Systemic availability of drugs
A drug will reach systemic arterial circulation only if it is absorbed from the GIT and if it
escapes metabolism in the gut, liver, and lungs. When the concentration of the drug in plasma
is measured at specified time intervals, it is possible to construct concentration versus time
graph and hence be able to determine the extent of drug availability as shown in Figure 4.
The availability depends on both the extent of absorption and the extent of presystemic metabo‐
lism and comprises three aspects; Peak concentration (Cmax), Time taken to reach the peak (Tmax)
and area under the curve (AUC)as shown in Figure 4. The Cmax and Tmax are measures of the rate
of availability while AUC is a measure of the extent of availability (i.e. proportion of the admin‐
istered drug which reaches systemic circulation intact). For the three curves shown for the for‐
mulations a, b, and c; the AUC is the same, but the rate of availability is different in each case; a,

















Figure 4. Plasma concentration versus time curves for different drug formulations
The speed at which a particular drug is needed to reach the site of action will determine the type
of formulation to use. Drugs with the same relative bioavailability and can be used to treat the
same condition using either the same routes or dosages are known as bioequivalent drugs.
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The speed at which a particular drug is needed to reach the site of action will determine the type
of formulation to use. Drugs with the same relative bioavailability and can be used to treat the
same condition using either the same routes or dosages are known as bioequivalent drugs.
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9. Dosage and effect
A particular dose of an administered drug is subject to the biochemical processes in the body
as shown in Figure 5. The desired effect of a drug is proportional to the concentration of the
drug at its site of action which is described by the following kinetic parameters: (i) The apparent
volume of distribution (Vd) which is the volume of the hydrophilic and hydrophobic spaces
in the body that the drug is distributed in. It is obtained by dividing the injected dose (Do) by
the initial concentration (Co) in blood plasma. Drugs that bind to tissues extensively exhibit
low concentrations in the plasma and therefore, have higher a Vd compared to those that are
mainly bound by blood plasma proteins. An average 70kg person has a total body water

















Figure 5. Drug disposition routes from absorption to excretion
The apparent volume of distribution cannot tell us where in the body the drug really is. The
(Ctox) is the maximum drug concentration beyond which there would be toxic effects in the
body, while the (Cther) is the plasma concentration of a drug that would achieve a therapeutic
effect or effective clinical response. The steady state concentration (Css) is that concentration
that should be maintained between any two drug administration intervals. These pharmaco‐
kinetic data are important in that they characterize the fate of drugs in the body and are
required by pharmacologists to calculate doses and frequencies of drug administration.
However, in some clinical responses, the intensity of pharmacological action correlates better
with the concentration of free drug in plasma, while in other responses there is no direct
relationship between drug concentration and clinical response. The main variations of the drug
response effects include;
i. Drugs which combine with their receptors as quickly as they dissociate from them;
for this category of drugs, the pharmacological effect increases or reduces in tandem
with the plasma drug concentration.
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ii. Drugs which do not readily dissociate from their receptors. In this case the pharma‐
cological effect persists despite the falling plasma concentration.
iii. Drugs which combine with receptors and irrespective of their rates of association/
dissociation sets in motion a cascade of events which runs on despite falling plasma
concentrations.
10. Kinetics of drug disposition process
Drug disposition process most of the times follows the 1st order kinetics in which disposition
is proportional to the concentration of the drug at any given time. Therefore, the concentration
of a drug in plasma will decrease at a rate that is proportional at all times to the concentration
itself. Therefore;
-d C
dt  =  K C
∫ -d C
C












A more convenient form of this equation is obtained by taking log10
Since
ln x =  2.303log10 x (1)
It follows that;
2.303log10 C =  2.30.3log10 C0 - Kt
and log10 C=log10 C0 -  
Kt
2.303
A linear relationship is obtained when the logarithm of concentrations (log10C) is plotted
against (t), times of observation (Figure 6).
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Figure 6. Logarithmic time course of drug concentration
Half-life (t1/2) of a drug: this is the time period during which the concentration decreases to
one- half of its previous value. T 1/2 can be evaluated from the elimination rate constant.
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11. Drug biotransformation reactions
Drugs and other foreign substances (xenobiotics) undergo series of biotransformation reac‐
tions in the body. The biotransformation reactions act as first line defense strategy against these
xenobiotics. It is armed with a battery of enzymes which convert the lipid-soluble xenobiotics
into more water-soluble metabolites to allow more efficient excretion of the drugs in a limited
volume of water in urine or bile.
The enzymes involved in the biotransformation of endogenous chemicals are the same ones
that are used in the biotransformation of xenobiotics. There is, therefore, a close relationship
between drug biotransformation and fundamental homeostatic processes.
The drug biotransformation reaction may result in the following potential effects with respect
to pharmacological activity:
11.1. Activation
An inactive precursor may be converted into a pharmacologically active drug. For instance,
the nucleoside analogue used as an anti-HIV drug, have to undergo in vivo phosphorylation
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to form the active triphosphates which functions to inhibit the enzyme reverse transcriptase,
while L– dopa (inactive), which is used in the treatment of parkinsons disease, is converted
into dopamine (active) in the basal ganglia. Futamide, a drug used in the treatment of prostate
cancer, undergoes hydroxylation at the alkyl side chain to form hydroxyflutamide, a metab‐
olite that is more active and has a longer duration of action compared to the parent drug.
11.2. Maintenance of activity
An active drug is converted into another form which is also active, for instance diazepam, a
sedative hypnotic, is metabolized to an equally active metabolite, oxazepam.
11.3. Inactivation
An active drug is converted to inactive products, for example, pentobarbital is hydroxylated
to forminactive metabolites.
11.4. Phase I reactions
These include oxidation, reduction and hydrolytic reactions and such reactions generally
introduce or unmask a functional group (hydroxyl, amine, sulfhydryl etc) that make the drug
more polar.
11.5. Phase II reactions
Consist of synthetic/conjugation reactions in which an endogenous substance such as glucur‐
onic acid or glutathione combines with the functional group derived from phase I reactions to
produce a highly polar drug conjugate. All tissues have some ability to carry out drug
biotransformation reactions but the most important organs of biotransformation include; the
liver, GIT, lungs, skin, and kidneys in that order and most phase II reactions result in a decrease
in the pharmacological activity of the drug. The fact that the GIT and liver are the major sites
of drug biotransformation means that drugs which are administered orally will be extensively
bio-transformed before they eventually reach systemic circulation. This first-pass effect can
severely limit the oral bio- availability of some drugs. In addition, intestinal micro-organisms
are capable of catalyzing drug biotransformation reactions e.g. a glucuronide conjugate of a
drug may be excreted through the intestine via the bile where gut bacteria may convert the
conjugate back into free drug. The free drug is then reabsorbed and re-enters the liver via the
portal vein where the conjugation process is repeated. This leads to a phenomenon known as
entero-hepaticcirculation.
At sub-cellular level, enzymes of drug biotransformation are located in the endoplasmic
reticulum, mitochondria, cytosol and lysosome. The major site of drug biotransformation
within the hepatocytes and other cells is the membrane of the smooth endoplasmic reticulum.
The smooth endoplasmic reticulum constitutes the microsome fraction during differential
centrifugation of whole blood. The microsome fraction can be used to carry out many drug
biotransformation reactions in vitro.
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11.6. Mechanisms of phase I reactions
11.6.1. Oxidation
Is the most important category of the microsomal drug oxidizing systems and requires partici‐
pation of two distinct proteins in endoplasmic reticulum; cytochromes P450 (which functions as a
terminal oxidase) and cytochrome P450 reductase. The name Cyt450 is derived from the fact that
the reduced form of this hemoprotein complexes with carbon monoxide to form a complex that
has a unique absorption spectrum with a maximum at 450nm.Cytochrome P450 reductase serves
to transfer reducing equivalent from NADPH to the cytochrome P450 oxidase:
DrugRH + O2+ NADPH + H
+ → DrugROH (hydroxylated product) + H2O+ NADP
+
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ROH and restoration of 
the ferric form of cyt P450
Figure 7. Phase 1 drug biotransformation reactions in the liver microsomal fraction in which the drug is converted to a
more polar form.
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The phospholipids of the endoplasmic reticulum are required for substrate binding, electron
transfer, and facilitating the interaction between CytP450 and its reductase. However, cyto‐
chrome P450 does not catalyze all Oxidation reactions. The microsomal flavin– containing
monooxygenases (FMOs) catalyze NADPH – dependent oxygenation of nucleophilic phos‐
phorous, nitrogen and sulfur atoms. These atoms are present in a wide variety of xenobiotics
including the carbamate containing pesticides and therapeutic agents such as phenothiazines,






Many xenobiotics  including  phenytoin  can  be  co-oxidized  along  with  the  above  reduc‐
tion reaction.  This  pathway is  of  considerable  toxicological  importance  as  it  often leads
to  generation  of  toxic  reactive  metabolites.  Other  enzymes  that  catalyze  oxidation  of
xenobiotic  include  alcohol  dehydrogenase,  aldehyde  dehydrogenase,  xanthine  oxidase
and monoamine oxidase.
11.6.2. Reduction
Some drugs with azo-linkages (RN=NR, e.g. prontosil) and nitrogen groups (RNO2, such as
chloramphenicol) are transformed by reductive pathways. The Cyt P450 and NADPH–cyt
P450reductase enzymes that catalyze oxidation reactions are also involved in reduction
reactions for drugs containing quinine moieties. These transformation results in the formation
of semiquinone free radicals illustrated in Figure 8. The free radicals that are generated cause
oxidative stress, lipid peroxidation, DNA damage, and hence cytotoxicity. These effects are
particularly responsible for the antitumor property of a drug like doxorubicin.
11.6.3. Hydrolysis
Drugs containing ester functions (R1COOR2) such as procaine are hydrolyzed by a variety of
non-specific esterases in liver, and plasma while drugs with amide bonds are hydrolyzed by
amidases in the liver. The polypeptide drugs such as insulin and growth hormones are
hydrolyzed by peptidases in the plasma and erythrocytes. The metabolites resulting from
hydrolysis reactions are subjected to phase II biotransformation reactions before excretion in
the bile or urine.
11.7. Mechanisms of phase II reactions
The phase II reactions generally involve coupling of drug/drug metabolite with an endogenous
substance to enhance their removal from the body. They require participation of specific
transferase enzymes and high energy activated endogenous substances.
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11.7. Mechanisms of phase II reactions
The phase II reactions generally involve coupling of drug/drug metabolite with an endogenous
substance to enhance their removal from the body. They require participation of specific
transferase enzymes and high energy activated endogenous substances.
Introduction to Biochemical Pharmacology and Drug Discovery
http://dx.doi.org/10.5772/52014
489
Most of the conjugation reactions result in detoxification of the drug although in some cases
conjugation reactions result in bioactivation of drugs. The following is a summary of the





















Figure 8. The transformation pathways for drugs with quinine moieties to generate free radicals.
11.7.1. Glutathione conjugation
Glutathione-S-transferases catalyze the enzymatic conjugation of xenobiotics with the endog‐
enous tripeptide glutathione, glutamylcystenylglycine (GSH). The xenobiotics with suitable
electrophilic centres such as the epoxides and nitro groups can be subjected to nucleophilic
attack by glutathione (Figure 9). The final product, mercapturic acid is easily excreted from
the body.
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Figure 9. Glutathione conjugation reactions for a drug with a suitable nucleophilic centre leads to the formation of
mercapturic acid which is easily excreted from the body
11.7.2. Glucuronidation
This is the conjugation of a drug or xenobiotic with glucuronic acid. Many functional groups
are subject to glucuronidation. The benzoyl group in morphine, (an analgesic) and the amine
group in meprobamate (a sedative) can undergo glucuronidation. A drug with a benzoyl group
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A number of aromatic compounds are transformed by phase I reactions to form epoxide
intermediates. The epoxides are reactive electrophilic species that can bind covalently to
proteins and nucleic acids to bring about toxic effects. These epoxides are detoxified via the
nucleophilic attack of water molecule on one of the electron deficient carbon atoms of the
oxizane ring as shown below:
R2R1
CHCH













The glucuronide conjugates can be excreted via the bile or urine.
11.7.4. Acetylation
Acetylation  is  achieved  by  cytosolic  enzymes  known  as  N-acetyl  transferases  which
catalyze  transfer  of  acetate  from acetyl  co-enzyme A to  primary aromatic  amine or  hy‐
drazides (figure 10)























Figure 10. Acetylation reations leading to the formation of N– Acetylsulfanilamide, the final metabolite of the antimi‐
crobial agent sulfanilamide which is secreted from the body.
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11.7.5. Methylation
Most of the methyl transferases are cytosolic enzymes. They utilize S-adenosyl methionine
(SAM) as the methyl donor. The final metabolite, thiopurine, has antineoplastic properties and
is used as an anticancer agent (Figure 11)
Figure 11. Methylation reactions leading to the formation of methylthiopurine
12. Adverse drug reactions associated with drug biotransformation
reactions
Many adverse  drug  reactions  can  be  traced  to  an  improper  balance  between  bioactiva‐
tion and detoxification reactions. For example, when the analgesic acetaminophen is giv‐
en at normal therapeutic doses, it undergoes glucuronidation and sulfation reactions that
terminate the action of the drug and hasten its elimination. However,  some of the drug
is bioactivated via Cyt P450  to form N-acetylbenzoquinimine, a reactive intermediate that
can  be  detoxified  by  conjugation  with  glutathione  (GSH).  When  excessive  doses  of  the
drug are given, glucuronidation and sulfation reactions become saturated and more acet‐
aminophen is bioactivated via Cyt P450. This imbalance leads to high concentrations of N-
acetylbenzoqunonine  which  cannot  be  sufficiently  eliminated  by  the  limited
concentrations of gluthathione. This metabolite binds covalently to cellular protein thiols
and initiates hepatotoxicity leading to hepatic necrosis.
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12.1. Revision exercise 1
1. Discuss the absorption of ά-D- Ribose-5-phosphate, given that the two ionizable hydroxyl
groups of the monophosphate ester ribose have pKa values of 1.2. and 6.6. The fully











2. Using specific examples of drugs, justify their various routes of administration.
12.2. Revision exercise 2
If the concentration of a drug in plasma decreases at a rate that is proportional to its initial
concentration, give an expression that describes this relationship and hence show that [Ct] =
[Co].e-kt
12.3. Worked examples
Problem 1: Describe how you can determine the partition coefficient of a labeled drug
Solution: The partition coefficient of a drug is its differential distribution between the
hydrophobic and hydrophilic phases. The distribution of the drug between these two phases
can be determined by allowing equilibration of a radioactively labeled drug between aqueous
buffer containing the drug and a cell membrane preparation obtained by homogenization and
fractionation of a tissue sample. The ratio of drug concentration in the membrane to the
concentration in the aqueous phase gives the partition coefficient.
Problem 2: Describe how you can demonstrate transport across membranes
Solution: Erythrocyte ‘ghosts’ or self sealing micelles formed when the erythrocytes release
cytoplasmic contents upon exposure into a hypotonic solution can be used to study the uptake
or release of labeled molecules across erythrocytes. When the ghosts are prepared in 14C
glucose, it will be possible to monitor the rate of release or uptake of the labeled 14C glucose
from the membranes into the aqueous environment. These ‘ghosts’ can also be used to study
the uptake of various molecules at various concentrations under different conditions of
temperatures and the presence of inhibitors for specific molecular uptake.
Problem 3: A 120mg per kg dose of a drug was injected intravenously and its concentration
(mg/L) monitored regularly over time. When log 10 C was plotted vs time (h) a linear response
was obtained with a slope of – 0.08 and an extrapolated y-intercept of 1.3. Calculate the
following pharmacokinetic parameters;
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i. elimination rate constant (k)
ii. initial concentration of the drug in blood plasma (Co)
iii. volume of distribution (Vd)
iv. half-life of drug elimination (t ½).
Solution:
i. Slope = - k/2.303, therefore, k = -2.303x -0.08 = 0.184
ii. Co = Antilog of 1.3 = 10 1.3 = 20 mg/L
iii. Volume of distribution (Vd) = Do/Co = 120/20 = 6 L
iv. The half-life of elimination t1/2 = 0.693/k = 0.693/0.184 = 3.7 hours.
Once the apparent volume of distribution is known for a particular drug the amount of drug
that must be given to achieve a desired concentration can be determined from
Do = Co.Vd
Problem 4: You have been given the following data based on a 65 kg patient; t1/2 of drug X =
4.5hrs, Vd = 0.56L/kg, Cmin the = 5mg/L, C tox = 20mg/L and Css = 10mg/L; calculate:-
i. Drug clearance from the body
ii. Average rate of drug intake (Dosing rate)
iii. Maintenance dose
iv. Maintenance interval
v. Initial loading dose
vi. Loading dose at steady state concentration
Solution
Since t1/2 = 0.693/ k; k= 0.693/ t1/2 i.e. 0.693/4.5=0.154, and V= 0.56 x 65 = 36.4.
i. Total drug clearance = kV = 0.154 x 36.4 = 5.6L/h = 93.3ml/min.
ii. Average rate of drug intake = rate elimination constant
= kxVxCss
= 0.154 x 36.4 x 10
= 56 mg/h
iii. Maintenance dose
= (Ctox - Cther). V
= (20 – 5) x 36.4 = 546 mg
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iv. Maintenance interval = maintenance dose/ rate of elimination
= 546/56
= 9.75 hrs
For a practical loading schedule, the maintenance interval should be lowered to say 8.0 hrs
and the maintenance dose reduced proportionately: = 546 x 8/9.75 ~ 437 mg.
v. The initial loading dose
= Ctox.V
= 36.4 x 20
= 728 mg
vi. The loading dose at steady state
= Css x V
= 36.4 x 10 = 364 mg
Practical problem 1
The analytical method of assaying paracetamol relies on the introduction of a nitro group into
the molecule after the removal of plasma proteins through precipitation. The resultant
nitrophenol compound which is formed has a deep yellow colour in an alkaline medium and














Figure 12. Formation of a chromogenic nitro compound from an analgesic Acetaminophen





2. Design an experiment that would enable you to determine the t1/2 of paracetamol
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Practical problem 2
Liver damage can be induced by 20% w/v carbon tetrachloride. Given 10mg/ml pentobarbitone
and 10mg/ml Phenolbarbitone, design an experiment that demonstrates that the duration of
action of short acting barbiturates are dependent on the integrity of the liver.
13. Drug discovery and preclinical trials
The development of new drugs over the past 30 years has revolutionalized the practice of
medicine and has for instance seen the increased use of new anti-hypertensives and drugs that
reduce cholesterol synthesis or dissolve blood clots which led to a 50% reduction in the number
of deaths from cardio-vascular diseases and stroke among other diseases.
13.1. Conventional approaches to drug discovery
These are the classical approaches to drug discovery that do not initially involve detailed
scientific study they include the following;
Traditional knowledge approach
This is the discovery of drugs based on traditional medical knowledge. The best example is
the documented analgesic effects of extracts from opium poppy that led to the isolation of
morphine from the plant and the subsequent synthesis of related analgesics.
Discovery through serendipity
This is the accidental discovery of novel drugs based on the ingenuity of a scientist investi‐
gating a problem initially unrelated to the observed phenomenon; examples of such discov‐
eries include the observation by Alexander Flemmings that penicilliummould could inhibit
the growth of bacteria. This finding led to the discovery of antibiotics.
Discovery of therapeutic usefulness of a side effect e.g. clonidine originally used as a nasal
decongestant was found to have antihypertensive properties while, the hypoglycemic effects
of sulphonamides used in the treatment of typhoid fever led to the development of structurally
related sulphonylureas as oral hypoglycemic drugs.
Discovery from effects of endogenous agents in test animals
An example of discovery arising from studies of endogenous agents in test animals is the
anticoagulant action of the venom from the Malayan viper that led to the identification of the
anticoagulant ancrod.
Modern approaches to drug discovery
These are those approaches that form a basis for the rational design of drugs and include the
following;
Bioprospecting
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This is the screening of a large number of natural products, chemical entities, large libraries of
peptides, nucleic acids and other organic molecules for biological activity. This approach may
lead to identification and development of new drug molecules.
Metabolomics
This is the profiling of natural products of related plant species screening using either liquid
or gas chromatography mass spectrometry to determine active metabolites that may be present
in novel crude herbal medical preparations.
In silico screening
This is the most advanced technique for drug discovery. It entails virtual screening or docking
of compounds on the 3-D- structure of a known receptor based on homologies of the test drug
molecules with a known test parent drug. In silico screening can form a basis for the modifi‐
cation of a known drug molecule to determine possible therapeutic applications and may lead
to the development of putative drugs against new targets.
13.2. Screening of putative drug molecules
Selection of molecules for further study is usually conducted in animal models of human
disease and the pharmacological tests include both the in vitro and in vivo studies after the
initial screening for biological activity. For instance, antibacterial activity of drugs is assessed
by their ability to inhibit growth of a variety of micro-organisms, while hypoglycemic drugs
are tested for their ability to lower blood pressure.
The in vitro  methods include incubation of a parent compound with various subcellular
fractions  such as  microsomes,  individual  recombinant  drug metabolizing  enzymes  from
cells or tissue slices.  The in vivo  studies involve working on typical animal models such
as dogs or rats. Some of the invitro  and invivo studies that may be performed are shown
in tables 1 and 2 below;
Target Specific or tissue in vitro studies Biochemical measurement
a. (i) Receptor binding Cell membrane fraction / cloned
receptors
Receptor affinity
(ii) Receptor activity Sympathetic nerves Inhibition of nerve activity
(iii) Enzyme activity Purified enzymes from adrenal
glands
Inhibition of enzyme activity
e.g. tyrosine hydroxylase
b. Cellular function Cultured cells Cell viability
c. Isolated tissue Blood vessels, heart lung or ileum
from rat
Effects on vascular contraction and
relaxation
Table 1. Screening of drugs for specific inhibitory effects on enzymes and isolated tissues.
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Disease model Animal model Route of administration Physiological
measurements
a. Blood pressure Hypertensive rat
(conscious)
Parenteral Systolic/diastolic





c. CNS Mouse, rat Parenteral Degree of sedation
d. Respiratory
effects
Dog/guinea pig Parenteral Respiratory rate and
amplitude
e. GIT effects Rat Oral GIT motility and secretions
Table 2. Putative animal models used in studying effects of drugs
If an agent possesses useful activity it would be further studied for possible adverse effects on
other major organs. These studies might suggest the need for further chemical modification to
achieve desirable pharmacokinetic/pharmacodynamic properties.
13.3. Preclinical trials
The data from animal studies form a basis for the calculation of the initial or starting doses to
be used in the subsequent clinical studies. The human equivalent dose calculations for the
maximum recommended dose are normally based on either the body surface area or body
weight. The candidate drugs that survive initial screening and profiling must be carefully
evaluated for potential risks before and during clinical testing. The main types of evaluation
needed from safety and toxicity studies include:-
Acute toxicity
This involves looking at the effects of large single doses of therapeutic agent. Acute toxicity
studies are usually performed in animal models such as mice and rats. These studies enable
investigators to correlate any observed effects with the systemic level of the drug.
Sub-acute toxicity
This is similar to acute toxicity but measures the effects of multiple doses based on expected
duration of clinical usage. It entails haematological, histology and electron microscope studies
to identify organs which might be affected by toxicity. It usually lasts between one to three
months. This enables the selection of putative compounds for subsequent studies.
Chronic toxicity testing
These studies are required when the drug is intended to be used in humans for prolonged
periods. The goals of this investigation are mostly similar to those of sub-acute toxicity.
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These are measurements intended to determine the effects of the drug agents on; mating
behaviour, reproduction, parturition, progeny birth defects, and postnatal development.
Carcinogenicity studies
These studies are required to determine the effects of prolonged usage of the drug under
investigation. They involve hematological and histological autopsy analysis.
Mutagenicity studies
These studies look at the genetic stability and mutations of bacterial or mammalian cells in
culture. These studies are at the academic research level and are intended to provide data for
future research.
Investigative toxicology
The main purpose of toxicology is to discover the pathways that are involved in toxic action.
It includes studies on mechanisms of toxic action of drugs which may lead to the development
of safer drugs.
14. Evaluation of new drugs and drug approval process
Toxicity testing is time consuming and expensive and may require two to five years to collect
and analyze data before the drug can be considered ready for testing in humans.
Large numbers of animals are needed to obtain valid preclinical data.
Extrapolation of toxicity data from animals to humans may not be completely reliable.
The safety or  efficacy of  a  drug must  be thoroughly understood before  the drug is  ad‐
ministered  to  any  group  of  individuals.  Therefore  regulations  governing  the  develop‐
ment of new drugs have evolved to assure safety and efficacy of new medications.  The
clinical trials during drug development and post marketing experience form the scientific
basis of patient response to a drug.
Once a drug is judged ready to be studied in humans, a notice of clinical investigational
exemption for a new drug (IND) must be filled with the government body concerned with the
regulation and registration of drugs. The IND includes manufacturing information, all data
from animal studies, clinical plans and protocols and the names and credentials of physicians
who will conduct the clinical trials.
14.1. Phase I clinical trials
The main goal in phase I is to determine whether test animals and humans show signifi‐
cant  different  responses  to  the  drug  and  to  establish  limits  of  the  safe  clinical  dosage
range.  The measurements carried out in phase I  include,  the rate of  absorption,  t1/2  and
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metabolism of  the  candidate  drug  compound.  The  effects  of  the  drug  as  a  function  of
dosage are established in a small number 25 – 50 of healthy volunteers.  When the drug
is expected to have significant toxicity,  as often the case with cancer and AIDS therapy,
volunteer  patients  with  the  disease  are  used  instead  of  the  healthy  volunteers.  The  re‐
quirements of clinical trials include the following:
i. Homogenous populations of patients must be selected.
ii. Appropriate controls for the investigation must be included.
iii. Meaningful and sensitive indices for drug effects must be used i.e. well defined end-
points such as survival or pain relief should be used rather than surrogate or
intermediate markers e.g. levels of enzymes involved in the process of survival/pain
relief.
iv. The experimental observations must be converted to data and then into valid
conclusions.
v. The accuracy of diagnosis and severity of the disease must be comparable between
the groups being contrasted.
vi. The dosages of the drugs must be chosen and individualized in a manner that allows
relative efficacy to be compared at equivalent toxicities.
vii. Compliance with experimental regimens should be assessed before subjects are
assigned to experimental or control groups. Non-compliance may cause false
estimates of the true potential benefits or toxicity of a particular treatment.
viii. Ethical considerations. These may be the major determinants of the types of controls
that can be used e.g. for therapeutic trials that involve life threatening diseases for
which there is already in-effective therapy, the use of a placebo is considered
unethical. In such cases, new treatments must be compared with standard therapies.
14.2. Study design of phase I trials
For clinical trials to have validity they must be based on a sound statistical basis. Some of the
of the criteria that must be met include;
Randomization
Randomization is a design which ensures that there is no bias in allocation of treatments among
the different groups. The purpose of randomization is to minimize the possibility that an
observed treatment effect is due to inherent differences between groups. Randomization
eliminates bias by avoiding recruiting patients who have a particular characteristic to one
group and not the other e.g. only women/men and smokers/alcoholics. Randomization should
not be carried out until immediately before treatment. The delay allows a patient to have
second thoughts about taking part or the investigator to have to re-consider about admitting
patients to the study. Simple methods of randomization can be designed using published tables
of random numbers, where treatments are in a form of a square in which each treatment is




These are measurements intended to determine the effects of the drug agents on; mating
behaviour, reproduction, parturition, progeny birth defects, and postnatal development.
Carcinogenicity studies
These studies are required to determine the effects of prolonged usage of the drug under
investigation. They involve hematological and histological autopsy analysis.
Mutagenicity studies
These studies look at the genetic stability and mutations of bacterial or mammalian cells in
culture. These studies are at the academic research level and are intended to provide data for
future research.
Investigative toxicology
The main purpose of toxicology is to discover the pathways that are involved in toxic action.
It includes studies on mechanisms of toxic action of drugs which may lead to the development
of safer drugs.
14. Evaluation of new drugs and drug approval process
Toxicity testing is time consuming and expensive and may require two to five years to collect
and analyze data before the drug can be considered ready for testing in humans.
Large numbers of animals are needed to obtain valid preclinical data.
Extrapolation of toxicity data from animals to humans may not be completely reliable.
The safety or  efficacy of  a  drug must  be thoroughly understood before  the drug is  ad‐
ministered  to  any  group  of  individuals.  Therefore  regulations  governing  the  develop‐
ment of new drugs have evolved to assure safety and efficacy of new medications.  The
clinical trials during drug development and post marketing experience form the scientific
basis of patient response to a drug.
Once a drug is judged ready to be studied in humans, a notice of clinical investigational
exemption for a new drug (IND) must be filled with the government body concerned with the
regulation and registration of drugs. The IND includes manufacturing information, all data
from animal studies, clinical plans and protocols and the names and credentials of physicians
who will conduct the clinical trials.
14.1. Phase I clinical trials
The main goal in phase I is to determine whether test animals and humans show signifi‐
cant  different  responses  to  the  drug  and  to  establish  limits  of  the  safe  clinical  dosage
range.  The measurements carried out in phase I  include,  the rate of  absorption,  t1/2  and
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iii. Meaningful and sensitive indices for drug effects must be used i.e. well defined end-
points such as survival or pain relief should be used rather than surrogate or
intermediate markers e.g. levels of enzymes involved in the process of survival/pain
relief.
iv. The experimental observations must be converted to data and then into valid
conclusions.
v. The accuracy of diagnosis and severity of the disease must be comparable between
the groups being contrasted.
vi. The dosages of the drugs must be chosen and individualized in a manner that allows
relative efficacy to be compared at equivalent toxicities.
vii. Compliance with experimental regimens should be assessed before subjects are
assigned to experimental or control groups. Non-compliance may cause false
estimates of the true potential benefits or toxicity of a particular treatment.
viii. Ethical considerations. These may be the major determinants of the types of controls
that can be used e.g. for therapeutic trials that involve life threatening diseases for
which there is already in-effective therapy, the use of a placebo is considered
unethical. In such cases, new treatments must be compared with standard therapies.
14.2. Study design of phase I trials
For clinical trials to have validity they must be based on a sound statistical basis. Some of the
of the criteria that must be met include;
Randomization
Randomization is a design which ensures that there is no bias in allocation of treatments among
the different groups. The purpose of randomization is to minimize the possibility that an
observed treatment effect is due to inherent differences between groups. Randomization
eliminates bias by avoiding recruiting patients who have a particular characteristic to one
group and not the other e.g. only women/men and smokers/alcoholics. Randomization should
not be carried out until immediately before treatment. The delay allows a patient to have
second thoughts about taking part or the investigator to have to re-consider about admitting
patients to the study. Simple methods of randomization can be designed using published tables
of random numbers, where treatments are in a form of a square in which each treatment is
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contained only once in each row and column and the order of treatment is different in each
group (Table 3).The presence of other diseases or risk factors should be taken into consideration
i.e. need for careful selection and assignment of patients to each of the study groups.
Group Treatment
1 A B C D
2 C D A B
3 D C B A
4 B A D C
Table 3. A random number table array for assignment of various treatment regimes to various groups of patients in
clinical trials
This approach eliminates systematic variation between groups since the patients are allocated
at random order to group 1, 2, 3, or 4. A code list should be drawn up so that the main
investigators may be kept blind to the treatment an individual is receiving but also so that it
is possible to know the treatment by breaking the code. Coding should be such that when
broken, it does not yield information about the treatments other patients are getting. The
treatment information about all the patients should be left to one person preferably the
pharmacist or trial co-ordinator.
Blindness
Blinding is a design which does not allow the investigator to know what treatment the patient
is receiving. The purpose of blinding is to eliminate bias in reporting the outcome of the
treatment since if an investigator knows what treatment the patient is taking, he/she may in
some way influence a measurement or an outcome thus shifting the outcome in one direction
or another consciously or unconsciously. The ideal trial should be double blind where neither
the investigator nor the patient knows what treatment the patient is taking. Placebos or
dummies are used in order to achieve blindness. The placebos should match the active
treatment as closely as possible in terms of size, shape, color, texture, weight, taste and smell
with the active formulation.
Number of testing centers
Clinical trial should be carried out in a defined centre so as to minimize variations in the popula‐
tion and in the investigators techniques. This also avoids problems of data collection, communi‐
cation and follows up. Multi-centre trials may become necessary when studying a rare disease
hence scarcity of patients or when the effect being investigated is small one e.g. when one is
looking out for an interaction effect between a major condition and a minor condition.
Clinical trials designed to evaluate efficacy of new drugs should always be prospective i.e. the
characteristics of the population to be studied should be identified before the study begins.
For example, if one randomized all patients with heart failure to treatment with either digoxin
or a new drug X and then studied the outcome over six months that would be a prospective
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trial. In case of control study the outcome is first identified and then comparisons are made
retrospectively between the characteristics of patients who did or did not have the outcome.
Such a study for instance has shown that oral anticoagulants can reduce incidences of re-
infarction in patients who have already had a myocardial infarction. The case control studies
may be carried out some time, after the introduction of a drug therapy in order to get some
idea of its place in the overall management of the disease since the results of a case control
study may prompt formal prospective trials in order to confirm original findings.
14.3. Molecular markers in drug development
In vitro predictive efficacy and toxico-genomics should be carried out after phase 1 clinical
trials in order to validate the results of the phase 1 clinical trials. This is achieved by using
animal cell lines in which gene expression profiling and patterns of protein production are
used to identity candidate biomarkers for the disease. The utilization of markers that are
associated with the disease or those that indicate a known response to a therapeutic interven‐
tion or reflect a clinical outcome may yield information on efficacy or toxicity of a test drug.
An example of a biological readout that has traditionally been used to determine efficacy
during the treatment of diabetics is the determination of glucose in the urine of a diabetic
patient. Reliable and specific biomarkers that act as predictors of efficacy or long-term toxicity
are useful because they reduce the time, size and cost of clinical trials.
14.4. Phase II clinical trials
These are studies that recruit willing and informed patients and are designed to assess long
term safety, refine pharmacokinetic data, determine optimal dose. The purpose of phase II
studies is to determine efficacy. Typically, phase II trials require 100-150 subjects and take 9-12
months. An assessment of no effect or no worthwhile effect of a given drug demonstrates that
it is futile to proceed with further clinical testing of the drug. It is therefore important to
minimize type I errors or false negatives in the study design in order to minimize the risk of
discontinuing a potentially effective drug. The data from well designed phase I and phase II
trials are therefore critical in planning the subsequent trials. The phase III trials are large trials
intended to determine whether a treatment is effective and to establish safety data.
Phase II clinical trials include inert placebos as negative controls and older active drugs as
positive controls alongside the investigative compound. These studies are done in special
clinical centers such as University Hospitals. A broader range of toxicities may be detected at
this phase.
14.5. Phase III clinical trials
The drug is evaluated in a much larger number of patients (thousands) to further establish
safety and efficacy. Phase III trials are performed in settings similar to those anticipated for
the ultimate use of the drug. After successful phase III trials, the next step is the application
for review of the new drug to seek approval to use the drug for clinical management of the
disease condition.
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or another consciously or unconsciously. The ideal trial should be double blind where neither
the investigator nor the patient knows what treatment the patient is taking. Placebos or
dummies are used in order to achieve blindness. The placebos should match the active
treatment as closely as possible in terms of size, shape, color, texture, weight, taste and smell
with the active formulation.
Number of testing centers
Clinical trial should be carried out in a defined centre so as to minimize variations in the popula‐
tion and in the investigators techniques. This also avoids problems of data collection, communi‐
cation and follows up. Multi-centre trials may become necessary when studying a rare disease
hence scarcity of patients or when the effect being investigated is small one e.g. when one is
looking out for an interaction effect between a major condition and a minor condition.
Clinical trials designed to evaluate efficacy of new drugs should always be prospective i.e. the
characteristics of the population to be studied should be identified before the study begins.
For example, if one randomized all patients with heart failure to treatment with either digoxin
or a new drug X and then studied the outcome over six months that would be a prospective
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trial. In case of control study the outcome is first identified and then comparisons are made
retrospectively between the characteristics of patients who did or did not have the outcome.
Such a study for instance has shown that oral anticoagulants can reduce incidences of re-
infarction in patients who have already had a myocardial infarction. The case control studies
may be carried out some time, after the introduction of a drug therapy in order to get some
idea of its place in the overall management of the disease since the results of a case control
study may prompt formal prospective trials in order to confirm original findings.
14.3. Molecular markers in drug development
In vitro predictive efficacy and toxico-genomics should be carried out after phase 1 clinical
trials in order to validate the results of the phase 1 clinical trials. This is achieved by using
animal cell lines in which gene expression profiling and patterns of protein production are
used to identity candidate biomarkers for the disease. The utilization of markers that are
associated with the disease or those that indicate a known response to a therapeutic interven‐
tion or reflect a clinical outcome may yield information on efficacy or toxicity of a test drug.
An example of a biological readout that has traditionally been used to determine efficacy
during the treatment of diabetics is the determination of glucose in the urine of a diabetic
patient. Reliable and specific biomarkers that act as predictors of efficacy or long-term toxicity
are useful because they reduce the time, size and cost of clinical trials.
14.4. Phase II clinical trials
These are studies that recruit willing and informed patients and are designed to assess long
term safety, refine pharmacokinetic data, determine optimal dose. The purpose of phase II
studies is to determine efficacy. Typically, phase II trials require 100-150 subjects and take 9-12
months. An assessment of no effect or no worthwhile effect of a given drug demonstrates that
it is futile to proceed with further clinical testing of the drug. It is therefore important to
minimize type I errors or false negatives in the study design in order to minimize the risk of
discontinuing a potentially effective drug. The data from well designed phase I and phase II
trials are therefore critical in planning the subsequent trials. The phase III trials are large trials
intended to determine whether a treatment is effective and to establish safety data.
Phase II clinical trials include inert placebos as negative controls and older active drugs as
positive controls alongside the investigative compound. These studies are done in special
clinical centers such as University Hospitals. A broader range of toxicities may be detected at
this phase.
14.5. Phase III clinical trials
The drug is evaluated in a much larger number of patients (thousands) to further establish
safety and efficacy. Phase III trials are performed in settings similar to those anticipated for
the ultimate use of the drug. After successful phase III trials, the next step is the application
for review of the new drug to seek approval to use the drug for clinical management of the
disease condition.
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14.6. Phase IV clinical trials
This  phase  is  concerned  with  post-marketing  surveillance  and  the  main  goal  is  to  as‐
sess  adverse  reactions,  patterns  of  drug  utilization,  discovery  of  additional  indications.
The  interrelationships  between  the  various  studies  in  drug  development  are  illustrated
in Fig 13 below;
Phase II clinical trials include inert placebos as negative controls and older active drugs as 
positive controls alongside the investigative compound. These studies are done in special clinical 
centers such as University Hospitals.  A broader range of toxicities may be detected at this phase. 
Phase IIIclinical trials 
The drug is evaluated in a much larger number of patients (thousands) to further establish safety 
and efficacy.  Phase III trials are performed in settings similar to those anticipated for the 
ultimate use of the drug. After successful phase III trials, the next step is the application for 
review of the new drug to seek approval to use the drug for clinical management of the disease 
condition.
Phase IV clinical trials 
This phase is concerned withpost-marketing surveillance and the main goal is to assess adverse 
reactions, patterns of drug utilization, discovery of additional indications.The interrelationships 
between the various studies in drug development are illustrated in Fig 1.13 below; 
Figure 1.13Illustration of the key steps in the development of a drug from a putative drug 
candidate extract 
Crude drug preparation 
Biochemical profiling of 
crude drug product 
In vivo/in vitro 
therapeutic profile for 
test and control model 
In vivo toxicity profiles 










Figure 13. Illustration of the key steps in the development of a drug from a putative drug candidate extract
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14.7. Pharmacogenomics and drug development
The personalized medication which takes into account the genetic make-up of individu‐
als is known as pharmacogenomics. The pharmacogenomic differences that determine in‐
dividualized  therapy  include  genetic  polymorphisms  of  drug  transporters,  drug
receptors, and drug metabolizing enzymes. For example, genetic variation in Cyt P450 en‐
zymes that are largely responsible for drug metabolism shows that different individuals
respond differently  to  drug efficacy or  toxicity.  Genetic  variants  in  the  drug target,  the
disease pathway, genes or drug metabolizing enzymes could all be used as predictors of
drug  efficacy  or  toxicity.  For  example,  drug  monitoring  using  perpherazine,  a  Cyt  P450
substrate, shows that there are three main categories of individuals; the efficient metabo‐
lizers obtained from the heterozygotes, the poor metabolizers from the homozygotes and
the ultra-rapid metabolizers which carry two or more active genes in the same chromo‐
some, a phenomenon known as gene duplication.
The  information  obtained  from  pharmacogenetic  studies  can  be  used  to  design  new
drugs that take the persons’ genetic profile into consideration. The most common type of
genetic variation are single nucleotide polymorphisms, therefore, a high resolution of sin‐
gle  nucleotide  map  may  expedite  the  identification  of  genes  for  various  diseases.  The
molecular profiles of patients identified in phase I and II clinical trials as likely non-res‐
ponders  to  the  putative  drug  under  investigation  might  present  an  opportunity  to  ini‐
tiate new discovery programs for other pharmaceutical compounds.
14.8. Individualized drug therapy
Clinical usage of drugs requires a basic understanding of the pharmacokinetic and pharma‐
codynamic drug processes and an appreciation that a relationship does exist between the
pharmacological effect or toxic response to a drug and the concentration of the drug. The
interpatient and intrapatient variation in disposition of a drug must be taken into account in
choosing a drug regimen.
A drug dosage regimen therefore is a recipe for the administration of a drug so as to pro‐
duce a desired therapeutic effect with minimum toxic effects.
The regimen is described in terms of the following:
i. Dose of the drug to be used and the formulation.
ii. Frequency with which it is administered.
iii. Route of drug administration.
The factors that determine the relationship between the prescribed drug dosage and drug
effect operate at three levels; prescription level, drug administration level and at the physio‐
logical level of patient (Figure 14).
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review of the new drug to seek approval to use the drug for clinical management of the disease 
condition.
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14.7. Pharmacogenomics and drug development
The personalized medication which takes into account the genetic make-up of individu‐
als is known as pharmacogenomics. The pharmacogenomic differences that determine in‐
dividualized  therapy  include  genetic  polymorphisms  of  drug  transporters,  drug
receptors, and drug metabolizing enzymes. For example, genetic variation in Cyt P450 en‐
zymes that are largely responsible for drug metabolism shows that different individuals
respond differently  to  drug efficacy or  toxicity.  Genetic  variants  in  the  drug target,  the
disease pathway, genes or drug metabolizing enzymes could all be used as predictors of
drug  efficacy  or  toxicity.  For  example,  drug  monitoring  using  perpherazine,  a  Cyt  P450
substrate, shows that there are three main categories of individuals; the efficient metabo‐
lizers obtained from the heterozygotes, the poor metabolizers from the homozygotes and
the ultra-rapid metabolizers which carry two or more active genes in the same chromo‐
some, a phenomenon known as gene duplication.
The  information  obtained  from  pharmacogenetic  studies  can  be  used  to  design  new
drugs that take the persons’ genetic profile into consideration. The most common type of
genetic variation are single nucleotide polymorphisms, therefore, a high resolution of sin‐
gle  nucleotide  map  may  expedite  the  identification  of  genes  for  various  diseases.  The
molecular profiles of patients identified in phase I and II clinical trials as likely non-res‐
ponders  to  the  putative  drug  under  investigation  might  present  an  opportunity  to  ini‐
tiate new discovery programs for other pharmaceutical compounds.
14.8. Individualized drug therapy
Clinical usage of drugs requires a basic understanding of the pharmacokinetic and pharma‐
codynamic drug processes and an appreciation that a relationship does exist between the
pharmacological effect or toxic response to a drug and the concentration of the drug. The
interpatient and intrapatient variation in disposition of a drug must be taken into account in
choosing a drug regimen.
A drug dosage regimen therefore is a recipe for the administration of a drug so as to pro‐
duce a desired therapeutic effect with minimum toxic effects.
The regimen is described in terms of the following:
i. Dose of the drug to be used and the formulation.
ii. Frequency with which it is administered.
iii. Route of drug administration.
The factors that determine the relationship between the prescribed drug dosage and drug
effect operate at three levels; prescription level, drug administration level and at the physio‐
logical level of patient (Figure 14).
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Figure 1.14: The operational levels that determine the relationship between prescribed drug 
dosage and the drug effect.
Drugs that are excreted primarily unchanged by the kidneys tend to have low variation among 
patients with similar renal function than do drugs which are inactivated by metabolism. For the 
extensively metabolized drugs, those with high metabolic clearance and large first pass 
elimination have marked difference in bioavailability, whereas those with low biotransformation 
tend to have largest variation in elimination rates among individuals. 
Prescribed dose 
 Patience compliance 
 Medication errors 
Administered dose 
 Rate and extent of 
absorption
 Distribution and 
composition of body fluids 
and body size 
Concentration at site of action 
 Physiological variables 
 Pathological and Genetic 
factors 
 Interaction with other 
drugs
 Development of tolerance 
Intensity of effect 
 Drug - receptor 
interactions 
 Signal transduction 
Figure 14. The operational levels that determine the relationship between prescribed drug dosage and the drug effect.
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Drugs that are excreted primarily unchanged by the kidneys tend to have low variation among
patients with similar renal function than do drugs which are inactivated by metabolism. For
the extensively metabolized drugs, those with high metabolic clearance and large first pass
elimination have marked difference in bioavailability, whereas those with low biotransfor‐
mation tend to have largest variation in elimination rates among individuals.
14.9. Determination of drug dosage
The simplest  way of  determining a drug dosage regimen is  to base it  on the published
recommended dosage.  These are derived from the pharmacokinetics studies of the drug
and the general procedure in using the published recommendations is to start at the low‐
er end of  the recommended dosage range and monitor the therapeutic  effect.  If  the de‐
sired effect  does not occur,  the dosage can be increased gradually until  one reaches the
upper  limit  of  the  range.  In  certain  conditions  it  may  be  necessary  a  sufficiently  high
dose for the drug to accumulate in the body to a satisfactory degree. This dose is known
as the loading dose and is  equal  to  the volume of  distribution multiplied by the target
concentration in  the  plasma.  The reason for  giving a  loading dose  is  to  circumvent  the
sometimes unacceptable time lag preceding the steady state levels. Once the correct load‐
ing dose  is  given,  a  steady-state  concentration can be  achieved rapidly  and then main‐
tained by giving a smaller maintenance dose.
Adjustment  of  dosage  in  individual  patients  is  often  as  a  result  of  the  modification  of
pharmacokinetic parameters of which the three most important include; the bioavailabili‐
ty  or  the fraction of  a  drug that  is  absorbed into systemic circulation,  its  clearance and
the volume of distribution.
For drugs with a high toxicity to therapeutic ratio, the loading dose can be given as a single
dose and for drugs with a low toxicity: therapeutic ratio and a long half-life, the loading dose
can be divided into several portions and given at intervals long enough to allow detection of
adverse effects, but short enough to ensure that the loading dose is a true loading dose i.e.
relatively little amounts of the drug is eliminated from the body during the period of loading.
14.10. Systemic drug availability
The extent of availability of a drug after oral administration is expressed as a percentage of the
dose. The fractional availability (F) varies from 0 to 1. The extent of availability is more
important parameter to measure rather than the rate of availability.
A true decrease in bioavailability could be due to several reasons including, a poorly ad‐
ministered dosage form that fails to disintegrate or dissolve in the GIT, interaction with
other drugs in the GIT, metabolism of the drug in the GIT and/or first pass hepatic me‐
tabolism or biliary excretion.
Hepatic disease may in particular cause high availability because the metabolic capacity
decreases or development of vascular shunts in the liver. Significantly high availability
requires dosage adjustment by a factor of two, while significantly low in availability requires
dosage adjustment by a factor of half.
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Drugs that are excreted primarily unchanged by the kidneys tend to have low variation among
patients with similar renal function than do drugs which are inactivated by metabolism. For
the extensively metabolized drugs, those with high metabolic clearance and large first pass
elimination have marked difference in bioavailability, whereas those with low biotransfor‐
mation tend to have largest variation in elimination rates among individuals.
14.9. Determination of drug dosage
The simplest  way of  determining a drug dosage regimen is  to base it  on the published
recommended dosage.  These are derived from the pharmacokinetics studies of the drug
and the general procedure in using the published recommendations is to start at the low‐
er end of  the recommended dosage range and monitor the therapeutic  effect.  If  the de‐
sired effect  does not occur,  the dosage can be increased gradually until  one reaches the
upper  limit  of  the  range.  In  certain  conditions  it  may  be  necessary  a  sufficiently  high
dose for the drug to accumulate in the body to a satisfactory degree. This dose is known
as the loading dose and is  equal  to  the volume of  distribution multiplied by the target
concentration in  the  plasma.  The reason for  giving a  loading dose  is  to  circumvent  the
sometimes unacceptable time lag preceding the steady state levels. Once the correct load‐
ing dose  is  given,  a  steady-state  concentration can be  achieved rapidly  and then main‐
tained by giving a smaller maintenance dose.
Adjustment  of  dosage  in  individual  patients  is  often  as  a  result  of  the  modification  of
pharmacokinetic parameters of which the three most important include; the bioavailabili‐
ty  or  the fraction of  a  drug that  is  absorbed into systemic circulation,  its  clearance and
the volume of distribution.
For drugs with a high toxicity to therapeutic ratio, the loading dose can be given as a single
dose and for drugs with a low toxicity: therapeutic ratio and a long half-life, the loading dose
can be divided into several portions and given at intervals long enough to allow detection of
adverse effects, but short enough to ensure that the loading dose is a true loading dose i.e.
relatively little amounts of the drug is eliminated from the body during the period of loading.
14.10. Systemic drug availability
The extent of availability of a drug after oral administration is expressed as a percentage of the
dose. The fractional availability (F) varies from 0 to 1. The extent of availability is more
important parameter to measure rather than the rate of availability.
A true decrease in bioavailability could be due to several reasons including, a poorly ad‐
ministered dosage form that fails to disintegrate or dissolve in the GIT, interaction with
other drugs in the GIT, metabolism of the drug in the GIT and/or first pass hepatic me‐
tabolism or biliary excretion.
Hepatic disease may in particular cause high availability because the metabolic capacity
decreases or development of vascular shunts in the liver. Significantly high availability
requires dosage adjustment by a factor of two, while significantly low in availability requires
dosage adjustment by a factor of half.




In most clinical situations drugs are administered in such a way as to maintain a steady
concentration i.e. just enough drug is given in each dose to replace the drug eliminated since
the preceding dose. Therefore, clearance is the most important pharmacokinetic term to be
considered in defining a rational steady-state drug dosage regimen.
The rate of elimination = Cl x Tc
Where, Cl is the rate of clearance and Tc is the target concentration of the drug.
The Dosing rate = Rate of elimination = Cl x Tc.
Therefore, if the target concentration is known, the prevailing clearance in that patient will
determine the dosing rate and if the drug is given by a route that has a bio availability of less
than 100%, then the dosing rate above can be modified using the formula:
Dosing rate oral =  Dosing rateFractional availability
If intermitted doses are given, then maintenance dose = Dosing rate x Dosing interval.
14.12. Alteration of maintenance dose
The maintenance dose is usually altered when the clearance of the drug changes. For example,
during renal impairment, the clearance of drugs which are predominantly cleared by the
kidney is greatly reduced and therefore, the desired steady state concentration can only be
achieved either through altering the dose or altering the dosing interval. Therefore, when a
drug is cleared almost completely via kidneys, the dosage interval should be changed in
proportion to renal clearance as follows:
The % eliminated in dosing interval should be proportional to creatinine clearance by a
published constant to yield the percentage excreted in one dosage interval.
The quantities required for this adjustment are:
i. Fraction of normal function remaining, and the
ii. Fraction of drug usually excreted unchanged in urine.
The fraction of normal function remaining is equal to the ratio of patient’s creatinine clearance
to a normal value (120 ml/min/70kg).
The following equation is for adjustment of renal clearance
rfpt= 1 – fenl(1 – rfxpt) 
Where;
rfpt = the adjusted total clearance of the patient,
fenl = fraction of drug excreted unchanged in normal individuals,
rfxpt = fraction of renal clearance of the normal individual.
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Clearance should also be adjusted for the size of the patient and for convenience, the published
values are normalized to the metabolic rate = weight 0.75.
When clearance is low, t1/2 is similarly high and when the volume of distribution is high,
the t1/2 is also high. Therefore, by using parameters for the individual patient, the dosing
rate = Tc x Cl/F where, Tc = target concentration, Cl = clearance and F = fractional availa‐
bility of the drug.
If a drug is relatively non toxic then the maximum loading strategy can be employed so that
the dosing interval is much longer than t1/2.. For example t½, of penicillin is less than one hour
but it is usually given in very large doses every six to twelve hours since it is non-toxic. The







Where, Css, max and Css min are the maximum and minimum steady state concentrations,
T = dosage interval and K =
0.693
t½
14.13. Drug dosage adjustment in old patients (geriatrics)
Drug absorption in the elderly is slightly different from the normal patients and therefore
adjustment of the dosage should be taken into consideration during drug therapy. The rate of
transdermal drug absorption may be diminished in elderly because of reduced tissue blood
perfusion. Compounds that permeate the intestinal epithelium by carrier mediated transport
mechanisms may be absorbed at lower rates in the elderly.
14.14. Drug distribution
In geriatrics the ‘body mass’ declines with age and the total body water content falls by between
10 – 15%. The volume of distribution of hydrophilic drugs will therefore decrease while plasma
concentration will increase and the likelihood of toxic drug effects will also increase. When
geriatric patients use diuretics, the extracellular space reduces even further leading to a higher
likelihood of drug toxicity. The total body fat in the elderly increases by 12 – 18%, therefore,
for hydrophobic drugs, the higher volume of distribution implies an increase in half life of
distribution and the time needed to reach steady-state serum concentration. Therefore, for
geriatrics a once or twice daily drug administration is optimal. This can be achieved though
delayed release or fixed drug combinations.
14.15. Patient compliance and rational use of drugs
Drug treatment of any kind is often compromised by lack of full compliance by the patient.
The common errors of compliance to a regimen by a patient include; omission in taking the
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drug, wrong timing of dosages, premature termination of therapy or using additional
medications. In order to improve patient compliance, the patient should be made to under‐
stand the nature and prognosis of the illness and what to expect from the medication by
detailing both the acceptable and undesirable unwanted effects as well as signs of efficacy that
may help enforce compliances.
Patients frequently discontinue taking a medication such as septrin because they have not been
told the necessity of continuing with the drug after the acute symptoms have subsided.
The effectiveness of physician-patient communication is inversely related to the error rate in
the taking of drugs. A physician might prescribe a drug to be taken three times a day with
meals for a patient who either eats only twice a day or sleeps all day and works at night.
Therefore, an exploration of the patients eating, sleeping and working habits is necessary
before a prescription is given.
The educational level of a patient may also require that the prescription is carefully worded
and oral instructions given in the primary language of the patient since when such patients
take three or more medications they are less likely to use them properly. It is therefore
important to provide identifying symbols for each medication e.g. “Heart pill” or “sugar
pill”and to reduce the doses into once or twice daily regimens.
14.16. Adverse drug reactions
Pharmacological formulations are potentially harmful to the individuals taking the drugs.
There is need to ascertain the safety of new drugs before allowing them to be marketed.
The following figures  highlight  the  magnitude  of  the  problem:  ~  10  –  20% of  hospital‐
ized patients suffer adverse drug reactions, while 0.3 – 5.0% inpatients admissions and ~
0.3% deaths in hospital are due to adverse drug reactions. Adverse drug reactions can be
classified into two main categories:  They may be dose related or non dose related with
each being short-term or long-term.
14.17. Dose related adverse reactions
Adverse drug reactions can occur because of the changes in the systemic availability of a
formulation. For instance, the change of excipients in phenytoin capsules from CaSO4 to
lactose  leads to  high availability  and hence adverse  drug reactions.  Sometimes,  adverse
drug reactions can occur due to the presence of contaminants like bacteria if quality con‐
trol  breaks  down.  Out-of-date  formulations  may  also  cause  adverse  drug  reactions  be‐
cause of degradation products arising from the drug e.g. outdated tetracycline may cause
Faconis  Syndrome (a  type  of  rickets)  because  of  the  transformation  product,epiandrote‐
tracycline. Dose related adverse reactions may also arise from pharmacokinetic variations
in the individuals taking the drug. Pharmacokinetic variations may also arise due to hep‐
atic disease like advanced cirrhosis which lowers the clearance of drugs such as pheny‐
toin and morphine. The pharmacological variations could be environmental such as diet
or smoking, while others are genetic.
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14.18. Non-dose related adverse drug reactions
These include immunologic reactions and are related to the surface proteins present on β-
humans lymphocytes (HLA antigens) which are important in the function of T-lymphocytes.
The association of HLA antigens with foreign antigens stimulates T-lymphocytes. Some of
these antigens expressed by major histocompatibility complex (MHC) genes have been
associated with an increased risk of adverse drugs e.g. nephrotoxicity from penicillamine is
increased in patients with HLA types B8 and DR 3 while patients with HLA- DR, 7 are protected
against adverse drug effects.
14.19. Types of drug allergies
Drug allergies can be classified into five categories:
Type I
This anaphylaxis or immediate hypersensitivity reactions; the body reacts within five to thirty
minutes. The IgE molecules fixed to mast cells and basophil leucocytes release histamine and
other pharmacological mediators such as kinins. Drugs likely to cause are anaphylactic shock
include;-penicillins, streptomycin, local anaesthetics etc.
Type II
In these reactions, the circulating antibody of 1gG, 1gM or 1gA interacts with the drug
combined with a cell membrane protein to form a hapten-protein/antigen-Ab complex. This
leads to the activation of the complement leading to cell lysis of phagocytic attack of the cell
with the complex. Drugs such as the cephalosporins, penicillins, quinine and transfusion of
improperly matched blood can yield this type of reactions.
Type III
In this type of allergy, the immune complex reactions initiate an inflammatory response due
to the combination of the excess drug- protein complex with the IgG in circulation. The complex
thus formed is deposited in the tissues and causes activation of the complement and damage
of capillary endothelium. This type of reaction is manifested mostly as fever, arthritis, and/or
enlarged lymph nodes. Penicillins, sulphonamides and streptomycin may elicit type III allergic
reactions.
Type IV
This is the cell-mediated or delayed hypersensitivity reactions in which the T - lymphocytes
are sensitized by a hapten to form protein-antigenic complex such that when the lymphocytes
come into contact with the antigen, an inflammatory response ensues. Type IV reactions are
exemplified by contact dermatitis caused by local anaesthetic areas, antihistamine areas,
topical antibiotics and antifungal drugs.
Type V
These are pseudo allergic reactions, that resemble allergic reactions clinically, but for which
no immunological basis can be found, e.g. asthma and skin rashes caused by aspirin. Admin‐
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istration of ampicillin or amoxicillin causes a skin rash which resembles the one caused by
penicillin hypersensitivity. The ampicillin-caused rash can be distinguished from penicillin
hypersensitivity on the basis of two features; it has a later onset, typically ten to fourteen days,
compared to penicillin sensitivity which comes between seven to ten days. Furthermore, the
sensitivity does not recur following re-exposure to ampicillin and is not as serious as the one
caused by penicillin.
14.20. Clinical evaluation of adverse drug reactions
The two basic approaches for clinical evaluation of adverse drug reactions include the cohort
studies (or follow-up studies) of patients taking the drug and the case control studies which
record the incidences of adverse drug effects retrospectively.
Cohort or prospective studies
In cohort studies, drugs are identified and incidences of adverse effects recorded. The weak‐
nesses of these studies include; the relatively small number of patients likely to be recruited,
and lack of suitable control groups to assess the background incidence of any apparent adverse
reaction noted.
Case control or retrospective studies
The approach here is to start with the incidence of adverse reaction(s) and then look for the
drug and the individuals with symptoms which could be due to an adverse drug reaction.
These individuals are screened to see if they had taken the drug. The prevalence of drug taking
in the group is then compared with the prevalence in a reference population which did not
take the drug. This approach is excellent for validation and assessment of adverse drug effects,
but it may not detect new adverse effects. Furthermore, it requires a very large number of




Drug clearance must always be adjusted for alterations of renal function using the formula:
rfpt = 1 - fenl (1 - rfxpt),where fenl = fraction of the drug excreted unchanged in normal individuals,
rfpt = adjustment factor for total clearance in patient, rfxpt = patients’ clearance as a fraction of
normal clearance and Clnl= normal clearance.
Given that an asthmatic patient has a creatinine clearance of 40mlmin-1 70kg-1 and that the
fraction of terbutaline excreted unchanged, fenl= 0.56, the normal clearance,Clnl = 3.4
ml/min/kg, calculate the clearance of the drug in the patient.
Solution
The patient has depressed renal function: rfxpt = (40 ml/min)/ (120 ml/min) = 0.33
rfpt= 1 - fenl(1-rfxpt)
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inline formula rfpt= 1 - 0.56 (1 - 0.33) = 0.62
inline formula 
Clpt= Clnl.rfpt
 = 3.4ml.min-1kg-1x 0.62
 = 2.1ml.min-1kg-1
Problem 6
Given the following characteristics of drug A; t½ = 8h, given at a dosage of 450mg every 12h,
has Vss = 0.5 L/kg, effective concentration is 12mg/L and that
Cssmin =  
F  x dose / Vss(ex p −kt)  




Determine the Cssmin and Cssmax for a 60 kg patientif F = 1 and expKT = 0.35. Explain how
changing of the dosage interval to 6 hours would affect Cssmin.
Solution
The term exp(-KT) is the fraction of the last dose that remains in the body at the end of a dosing
interval and is equal to 0.35 and Css min = Css max.exp(-kt). Therefore,
Cssmin =
450/30 x 0.35
1- 0.35 =15/0.65 x 0.35 ~ 8.0 mg/L while Cssmax =15/0.65=23 mg/L
The predicted minimum of 8.0mg/L is below the effective concentration to achieve efficacy.
Therefore the dosing interval should be reduced. A reduction of the interval to, say, six hours,
increases denominator and therefore causes an increase of Cssmin. Since t1/2 = 0.693/K, K = 0.086
i.e. 1 - e-KT = 1 - 2.71-0.086 x 6 = 1 - 0.596 = 0.4.
The new Css minimum becomes; = 450/30 x 0.4 = 15 mg/L which is within the required thera‐
peutic concentration.
Review exercise
1. Write an essay on statistical considerations that guide clinical evaluation of new drug
agents
2. Write an essay on bioprospecting for new antimicrobial agents.
3. Drug clearance must always be adjusted for alterations of renal function using the
formula: rfpt = 1- fenl (1- rfxpt), explain what each term in the above equation represents.
Consequently, calculate the clearance of acetaminophen (panadol) in a 70 kg patient with
depressed renal function given the following; normal clearance = 350 ml min -170 kg; fenl
= 0.56. The patient creatinine clearance = 80 mlmin-1 70 kg. Normal creatinine clearance =
120 ml min-1 70 kg. What effect would the impaired renal function have on dosing interval?
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4. Given that fenl for drug X = 0.42, and the normal creatinine clearance is 120 ml/min/70 kg,
calculate the clearance rate of the drug by a patient with creatinine clearance of 75 ml/min/
70 kg.
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